TARGETED LIPID PARTICLES AND COMPOSITIONS AND USES THEREOF

Abstract

Provided herein are lipid particles containing a lipid bilayer enclosing a lumen or cavity, a henipavirus F protein molecule or biologically active portion thereof, and a targeted envelope protein containing a henipavirus envelope attachment glycoprotein G (G protein) or biologically active portion thereof and a binding domain, such as a single domain antibody (sdAb) variable domain. Also provided herein are targeted envelope proteins containing a G protein fused or linked to a binding domain, such as a sdAb variable domain, and polynucleotides encoding such proteins. Also provided are producer cells and compositions containing such targeted lipid particles and methods of making and using the targeted lipid particles.

Description

INCORPORATION BY REFERENCE OF SEQUENCE LISTING

The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled 186152003600SubSeqList.TXT, created Jun. 19, 2021, which is 2,076,399 bytes in size. The information in the electronic format of the Sequence Listing is incorporated by reference in its entirety

FIELD

The present disclosure relates to lipid particles containing a lipid bilayer enclosing a lumen or cavity, a henipavirus F protein molecule or biologically active portion thereof, and a targeted envelope protein containing a henipavirus envelope attachment glycoprotein G (G protein) or biologically active portion thereof and a binding domain, such as a single domain antibody (sdAb) variable domain. The present disclosure also provides a targeted envelope protein containing a G protein fused or linked to a binding domain, such as a sdAb variable domain, and polynucleotides encoding such proteins. Also disclosed are producer cells and compositions containing such targeted lipid particles and methods of making and using the targeted lipid particles.

BACKGROUND

Lipid particles, including virus-like particles and viral vectors, are commonly used for delivery of exogenous agents to cells. However, delivery of the lipid particles to certain target cells can be challenging. For lentivral vectors, the host range can be altered by pseudotyping with a heterologous envelope protein. Certain retargeted envelope proteins may not be sufficiently stable or expressed on the surface of the lipid particle. Improved lipid particles, including virus-like particles and viral vectors, for targeting desired cells are needed. The provided disclosure addresses this need.

SUMMARY

Provided herein is a targeted lipid particle which includes (a) a lipid bilayer enclosing a lumen, (b) a henipavirus F protein molecule or biologically active portion thereof; and (c) a targeted envelope protein comprising (i) a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and (ii) single domain antibody (sdAb) variable domain, wherein the sdAb variable domain is attached to the C-terminus of the G protein or the biologically active portion thereof, wherein the F protein molecule or the biologically active portion thereof and the targeted envelope protein are embedded in the lipid bilayer. In some embodiments, the the single domain antibody is attached to the G protein via a linker. In some embodiments, the linker is a peptide linker.

Provided herein is a targeted lipid particle which includes (a) a lipid bilayer enclosing a lumen, (b) a henipavirus F protein molecule or biologically active portion thereof; and (c) a targeted envelope protein comprising a henipavirus envelope attachment glycoprotein G (G protein) or biologically active portion thereof attached to a single domain antibody (sdAb) variable domain via a peptide linker, wherein the single domain antibody binds to a cell surface molecule of a target cell, wherein the F protein molecule or biologically active portion thereof and the targeted envelope protein are embedded in the lipid bilayer. In some embodiments, N-terminus of the F protein molecule or biologically active portion thereof is exposed on the outside of lipid bilayer. In some embodiments, the C-terminus of the G protein is exposed on the outside of the lipid bilayer.

In some embodiments, the single domain antibody binds a cell surface molecule present on a target cell. In some embodiments, the cell surface molecule is a protein, glycan, lipid or low molecular weight molecule. In some of any embodiments, the single domain antibody binds an antigen or portion thereof present on a target cell. In some embodiments, the antigen is the cell surface molecule or a portion of the cell surface molecule that contains an epitope recognized by the single domain antibody. In some of any embodiments, the target cell is selected from the group consisting of tumor-infiltrating lymphocytes, T cells, neoplastic or tumor cells, virus-infected cells, stem cells, central nervous system (CNS) cells, hematopoeietic stem cells (HSCs), liver cells or fully differentiated cells. In some embodiments, the target cell is selected from the group consisting of a CD3+ T cell, a CD4+ Tcell, a CD8+ T cell, a hepatocyte, a haematepoietic stem cell, a CD34+ haematepoietic stem cell, a CD105+ haematepoietic stem cell, a CD117+ haematepoietic stem cell, a CD105+ endothelial cell, a B cell, a CD20+ B cell, a CD19+ B cell, a cancer cell, a CD133+ cancer cell, an EpCAM+ cancer cell, a CD19+ cancer cell, a Her2/Neu+ cancer cell, a GluA2+ neuron, a GluA4+ neuron, a NKG2D+ natural killer cell, a SLC1A3+ astrocyte, a SLC7A10+ adipocyte, or a CD30+ lung epithelial cell. In some of any embodiments, the target cell is a hepatocyte. In some of any embodiments, the cell surface molecule or antigen is selected from the group consisting of ASGR1, ASGR2 and TM4SF5.

In some of any embodiments, the target cell is a T cell. In some of any embodiments, the cell surface molecule or antigen is CD8 or CD4.

In some of any embodiments, the cell surface molecule or antigen is LDL-R.

Provided herein are targeted lipid particles comprising (a) a lipid bilayer enclosing a lumen, (b) a henipavirus F protein molecule or biologically active portion thereof; and (c) a targeted envelope protein comprising (i) a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and (ii) a binding domain, wherein the binding domain is attached to the C-terminus of the G protein or the biologically active portion thereof, and wherein the binding domain binds a cell surface molecule selected from the group consisting of ASGR1, ASGR2, and TM4SF5, optionally human ASGR1, human ASGR2 and human ASGR2,

wherein the F protein molecule or the biologically active portion thereof and the targeted envelope protein are embedded in the lipid bilayer.

Provided herein are targeted lipid particles comprising (a) a lipid bilayer enclosing a lumen, (b) a henipavirus F protein molecule or biologically active portion thereof; and (c) a targeted envelope protein comprising (i) a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and (ii) a binding domain, wherein the binding domain is attached to the C-terminus of the G protein or the biologically active portion thereof, and wherein the binding domain binds a cell surface molecule selected from the group consisting of CD8 and CD4, optionally human CD8 or human CD4, wherein the F protein molecule or the biologically active portion thereof and the targeted envelope protein are embedded in the lipid bilayer.

Provided herein are targeted lipid particles comprising (a) a lipid bilayer enclosing a lumen, (b) a henipavirus F protein molecule or biologically active portion thereof; and (c) a targeted envelope protein comprising (i) a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and (ii) a binding domain, wherein the binding domain is attached to the C-terminus of the G protein or the biologically active portion thereof, and wherein the binding domain binds a cell surface molecule that is low density lipoprotein receptor (LDL-R), optionally human LDL-R, wherein the F protein molecule or the biologically active portion thereof and the targeted envelope protein are embedded in the lipid bilayer.

In some of any embodiments, the lipid particle is a lentiviral vector. In some of any embodiments, the binding domain is attached to the G protein via a linker. In some of any embodiments, the linker is a peptide linker.

Provided herein is a lentiviral vector, comprising a binding domain that targets a cell surface molecule selected from the group consisting of ASGR1, ASGR2 and TM4SF5, optionally human ASGR1, human ASGR2 and human TM4SF5, wherein the lentiviral vector is pseudotyped with a retargeted viral fusion protein, said retargeted viral fusion protein comprising: (a) a henipavirus F protein molecule or biologically active portion thereof; and (b) a targeted envelope protein comprising the binding domain attached to a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof.

Provided herein is a lentiviral vector, comprising a binding domain that targets a cell surface molecule selected from the group consisting of CD8 and CD4, optionally human CD8 and human CD4, wherein the lentiviral vector is pseudotyped with a retargeted viral fusion protein, said retargeted viral fusion protein comprising: (a) a henipavirus F protein molecule or biologically active portion thereof; and (b) a targeted envelope protein comprising the binding domain attached to a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof.

Provided herein is a lentiviral vector, comprising a binding domain that targets low density lipoprotein receptor (LDL-R), optionally wherein the LDL-R is human LDL-R, wherein the lentiviral vector is pseudotyped with a retargeted viral fusion protein comprising (a) a henipavirus F protein molecule or biologically active portion thereof; and (b) a targeted envelope protein comprising the binding domain attached to a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof.

In some of any embodiments, the binding domain is attached to the C-terminus of the G protein or the biologically active portion thereof.

Provided herein is a lentiviral vector, comprising (a) a henipavirus F protein molecule or biologically active portion thereof; and (b) a targeted envelope protein comprising (i) a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and (ii) a binding domain, wherein the binding domain is attached to the C-terminus of the G protein or the biologically active portion thereof, and wherein the binding domain binds CD4; and (c) a cargo comprising nucleic acid encoding a chimeric antigen receptor (CAR), wherein the CAR comprises (i) an extracellular antigen binding domain that binds an extracellular antigen (e.g., CD19 or BCMA) and (ii) an intracellular signaling region a CD3zeta signaling domain and, optionally a 4-1BB or CD28 co-stimulatory signaling domain. In some embodiments, the extracellular antigen binding domain of the CAR is an scFv.

In some of any embodiments, the lentiviral vector is capable of delivering the nucleic acid encoding the CAR to T cells. In some embodiments the T cells are in vivo in a subject.

Provided herein is a lentiviral vector, comprising:(a) a henipavirus F protein molecule or biologically active portion thereof; and (b) a targeted envelope protein comprising (i) a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and (ii) a binding domain, wherein the binding domain is attached to the C-terminus of the G protein or the biologically active portion thereof, and wherein the binding domain binds ASGR1; wherein the lentiviral vector is capable of targeting to hepatocytes. In some of any embodiments, the lentiviral vector further comprises an exogenous agent for delivery to hepatocytes.

In some of any embodiments, the lentiviral vector is capable of delivering the exogenous agent to hepatocytes, optionally wherein the hepatocytes are in vivo in a subject.

In some of any embodiments, the binding domain is attached to the G protein via a linker. In some of any embodiments, the linker is a peptide linker. In some of any embodiments, the binding domain is a single domain antibody. In some of any embodiments, the binding domain is a single chain variable fragment (scFv).

In some of any embodiments, the peptide linker comprises up to 65 amino acids in length. In some of any embodiments, the peptide linker comprises up to 50 amino acids in length. In some of any embodiments, the peptide linker comprises from or from about 2 to 65 amino acids, 2 to 60 amino acids, 2 to 56 amino acids, 2 to 52 amino acids, 2 to 48 amino acids, 2 to 44 amino acids, 2 to 40 amino acids, 2 to 36 amino acids, 2 to 32 amino acids, 2 to 28 amino acids, 2 to 24 amino acids, 2 to 20 amino acids, 2 to 18 amino acids, 2 to 14 amino acids, 2 to 12 amino acids, 2 to 10 amino acids, 2 to 8 amino acids, 2 to 6 amino acids, 6 to 65 amino acids, 6 to 60 amino acids, 6 to 56 amino acids, 6 to 52 amino acids, 6 to 48 amino acids, 6 to 44 amino acids, 6 to 40 amino acids, 6 to 36 amino acids, 6 to 32 amino acids, 6 to 28 amino acids, 6 to 24 amino acids, 6 to 20 amino acids, 6 to 18 amino acids, 6 to 14 amino acids, 6 to 12 amino acids, 6 to 10 amino acids, 6 to 8 amino acids, 8 to 65 amino acids, 8 to 60 amino acids, 8 to 56 amino acids, 8 to 52 amino acids, 8 to 48 amino acids, 8 to 44 amino acids, 8 to 40 amino acids, 8 to 36 amino acids, 8 to 32 amino acids, 8 to 28 amino acids, 8 to 24 amino acids, 8 to 20 amino acids, 8 to 18 amino acids, 8 to 14 amino acids, 8 to 12 amino acids, 8 to 10 amino acids, 10 to 65 amino acids, 10 to 60 amino acids, 10 to 56 amino acids, 10 to 52 amino acids, 10 to 48 amino acids, 10 to 44 amino acids, 10 to 40 amino acids, 10 to 36 amino acids, 10 to 32 amino acids, 10 to 28 amino acids, 10 to 24 amino acids, 10 to 20 amino acids, 10 to 18 amino acids, 10 to 14 amino acids, 10 to 12 amino acids, 12 to 65 amino acids, 12 to 60 amino acids, 12 to 56 amino acids, 12 to 52 amino acids, 12 to 48 amino acids, 12 to 44 amino acids, 12 to 40 amino acids, 12 to 36 amino acids, 12 to 32 amino acids, 12 to 28 amino acids, 12 to 24 amino acids, 12 to 20 amino acids, 12 to 18 amino acids, 12 to 14 amino acids, 14 to 65 amino acids, 14 to 60 amino acids, 14 to 56 amino acids, 14 to 52 amino acids, 14 to 48 amino acids, 14 to 44 amino acids, 14 to 40 amino acids, 14 to 36 amino acids, 14 to 32 amino acids, 14 to 28 amino acids, 14 to 24 amino acids, 14 to 20 amino acids, 14 to 18 amino acids, 18 to 65 amino acids, 18 to 60 amino acids, 18 to 56 amino acids, 18 to 52 amino acids, 18 to 48 amino acids, 18 to 44 amino acids, 18 to 40 amino acids, 18 to 36 amino acids, 18 to 32 amino acids, 18 to 28 amino acids, 18 to 24 amino acids, 18 to 20 amino acids, 20 to 65 amino acids, 20 to 60 amino acids, 20 to 56 amino acids, 20 to 52 amino acids, 20 to 48 amino acids, 20 to 44 amino acids, 20 to 40 amino acids, 20 to 36 amino acids, 20 to 32 amino acids, 20 to 28 amino acids, 20 to 26 amino acids, 20 to 24 amino acids, 24 to 65 amino acids, 24 to 60 amino acids, 24 to 56 amino acids, 24 to 52 amino acids, 24 to 48 amino acids, 24 to 44 amino acids, 24 to 40 amino acids, 24 to 36 amino acids, 24 to 32 amino acids, 24 to 30 amino acids, 24 to 28 amino acids, 28 to 65 amino acids, 28 to 60 amino acids, 28 to 56 amino acids, 28 to 52 amino acids, 28 to 48 amino acids, 28 to 44 amino acids, 28 to 40 amino acids, 28 to 36 amino acids, 28 to 34 amino acids, 28 to 32 amino acids, 32 to 65 amino acids, 32 to 60 amino acids, 32 to 56 amino acids, 32 to 52 amino acids, 32 to 48 amino acids, 32 to 44 amino acids, 32 to 40 amino acids, 32 to 38 amino acids, 32 to 36 amino acids, 36 to 65 amino acids, 36 to 60 amino acids, 36 to 56 amino acids, 36 to 52 amino acids, 36 to 48 amino acids, 36 to 44 amino acids, 36 to 40 amino acids, 40 to 65 amino acids, 40 to 60 amino acids, 40 to 56 amino acids, 40 to 52 amino acids, 40 to 48 amino acids, 40 to 44 amino acids, 44 to 65 amino acids, 44 to 60 amino acids, 44 to 56 amino acids, 44 to 52 amino acids, 44 to 48 amino acids, 48 to 65 amino acids, 48 to 60 amino acids, 48 to 56 amino acids, 48 to 52 amino acids, 50 to 65 amino acids, 50 to 60 amino acids, 50 to 56 amino acids, 50 to 52 amino acids, 54 to 65 amino acids, 54 to 60 amino acids, 54 to 56 amino acids, 58 to 65 amino acids, 58 to 60 amino acids, or 60 to 65 amino acids. In some of any embodiments, peptide linker comprises a polypeptide that is 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 or 65 amino acids in length. In some of any embodiments, wherein the peptide linker is a flexible linker that comprises GS, GGS, GGGGS (SEQ ID NO:43), GGGGGS (SEQ ID NO:41) or combinations thereof. In some of any embodiments, the peptide linker comprises (GGS)n, wherein n is 1 to 10. In some of any embodiments, the peptide linker comprises (GGGGS)n (SEQ ID NO: 42), wherein n is 1 to 10. In some of any embodiments, the peptide linker comprises (GGGGGS)n (SEQ ID NO:27), wherein n is 1 to 6.

In some of any embodiments, the G protein or the biologically active portion thereof is a wild-type Nipah virus G (NiV-G) protein or a Hendra virus G protein. In some of any embodiments, the G protein or the biologically active portion thereof is a wild-type NiV-G protein or a functionally active variant or biologically active portion thereof. In some of any embodiments, the mutant NiV-G protein or functionally active variant or biologically active portion thereof comprises an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at least at or about 84%, at least at or about 85%, at least at or about 86%, at least at or about 87%, at least at or about 88%, at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44.

In some of any embodiments, the NiV-G protein is a biologically active portion that is truncated and lacks up to 40 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44).

In some of any embodiments, the NiV-G protein is a biologically active portion that is truncated at the N-terminus of wild-type NiV-G and has the sequence set forth in any of SEQ ID NOS: 10-15, 35-40 or 45-50 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at least at or about 84%, at least at or about 85%, at least at or about 86%, at least at or about 87%, at least at or about 88%, at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NOs: 10-15, 35-40 or 45-50.

In some of any embodiments, the NiV-G protein is a biologically active portion that has a 5 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44). In some of any embodiments, the NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 10 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:10. In some of any embodiments, the NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 35 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:35. In some of any embodiments, the NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 45 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:45.

In some of any embodiments, the NiV-G protein is a biologically active portion that has a 10 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44). In some of any embodiments, the NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 36 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:36. In some of any embodiments, the NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 11 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:11. In some of any embodiments, the NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 46 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:46.

In some of any embodiments, the NiV-G protein or the biologically active portion has a 15 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44). In some of any embodiments, the NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 12 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:12. In some of any embodiments, the NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 37 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:37. In some of any embodiments, the NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 47 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:47.

In some of any embodiments, the NiV-G protein is a biologically active portion that has a 20 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44). In some of any embodiments, the NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 13 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:13. In some of any embodiments, the NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 38 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:38. In some of any embodiments, the NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 48 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:48.

In some of any embodiments, the NiV-G protein is a biologically active portion has a 25 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44). In some of any embodiments, the NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 14 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:14. In some of any embodiments, the NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 39 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:39. In some of any embodiments, the NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 49 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:49.

In some of any embodiments, the NiV-G protein is a biologically active portion has a 30 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44). In some of any embodiments, the NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 15 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:15. In some of any embodiments, the NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 40 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:40.

In some of any embodiments, the NiV-G protein is a biologically active portion that has a 34 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44). In some of any embodiments, the NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 22 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at least at or about 84%, at least at or about 85%, at least at or about 86%, at least at or about 87%, at least at or about 88%, at least at or about 89%, at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:22. In some of any embodiments, the NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 53 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at least at or about 84%, at least at or about 85%, at least at or about 86%, at least at or about 87%, at least at or about 88%, at least at or about 89%, at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:53.

In some of any embodiments, the G-protein, the biologically active portion thereof is a functionally active variant that is a mutant NiV-G protein that exhibits reduced binding to Ephrin B2 or Ephrin B3.

In some of any embodiments, the mutant NiV-G protein includes one or more amino acid substitutions corresponding to amino acid substitutions selected from the group consisting of E501A, W504A, Q530A and E533A with reference to numbering set forth in SEQ ID NO:28. In some of any embodiments, the mutant NiV-G protein includes the amino acid substitutions E501A, W504A, Q530A and E533A with reference to numbering set forth in SEQ ID NO:28.

In some of any embodiments, the mutant NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 16 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at least at or about 84%, at least at or about 85%, at least at or about 86%, at least at or about 87%, at least at or about 88%, at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:16. In some of any embodiments, the mutant NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 51 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at least at or about 84%, at least at or about 85%, at least at or about 86%, at least at or about 87%, at least at or about 88%, at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:51.

In some of any embodiments, the F protein or the biologically active portion thereof is a wild-type Nipah virus F (NiV-F) protein or a Hendra virus F protein or is a functionally active variant or biologically active portion thereof. In some of any embodiments, the F protein or the biologically active portion thereof is a wild-type NiV-F protein or a functionally active variant or a biologically active portion thereof. In some of any embodiments, the NiV-F-protein or the functionally active variant or biologically active portion thereof comprises the amino acid sequence set forth in SEQ ID NO: 2, or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at least at or about 84%, at least at or about 85%, at least at or about 86%, at least at or about 87%, at least at or about 88%, at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 2.

In some of any embodiments, the NiV-F protein is a biologically active portion thereof that has a 20 amino acid truncation at or near the C-terminus of the wild-type NiV-F protein (SEQ ID NO:2).

In some of any embodiments, the NiV-F protein or the biologically active portion has the sequence set forth in SEQ ID NO:5 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at least at or about 84%, at least at or about 85%, at least at or about 86%, at least at or about 87%, at least at or about 88%, at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 5.

In some of any embodiments, the NiV-F protein is a biologically active portion thereof that includes i) a 20 amino acid truncation at or near the C-terminus of the wild-type NiV-F protein (SEQ ID NO:2); and ii) a point mutation on an N-linked glycosylation site.

In some of any embodiments, the NiV-F protein or the biologically active portion has the sequence set forth in SEQ ID NO:7 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at least at or about 84%, at least at or about 85%, at least at or about 86%, at least at or about 87%, at least at or about 88%, at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 7.

In some of any embodiments, the NiV-F protein is a biologically active portion thereof that has a 22 amino acid truncation at or near the C-terminus of the wild-type NiV-F protein (SEQ ID NO:2).

In some of any embodiments, NiV-F protein or the biologically active portion has the sequence set forth in SEQ ID NO:8 or an amino acid sequence that is encoded by a sequence of nucleotides encoding a sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at least at or about 84%, at least at or about 85%, at least at or about 86%, at least at or about 87%, at least at or about 88%, at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 8.

In some of any embodiments, the NiV-F protein or the biologically active portion has the sequence set forth in SEQ ID NO:23 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at least at or about 84%, at least at or about 85%, at least at or about 86%, at least at or about 87%, at least at or about 88%, at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 23. In some of any embodiments, the F-protein or the biologically active portion thereof comprises an F1 subunit or a fusogenic portion thereof.

In some of any embodiments, the F protein comprises the sequence set forth in SEQ ID NO:23 and the G protein comprises the sequence set forth in SEQ ID NO:16.

In some of any embodiments, the F protein consists or consists essentially of the sequence set forth in SEQ ID NO:23 and/or the G protein consists or consists essentially of the sequence set forth in SEQ ID NO:16.

In some of any embodiments, the F1 subunit is a proteolytically cleaved portion of the F0 precursor. In some of any embodiments, the F1 subunit comprises the sequence set forth in SEQ ID NO: 4, or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at least at or about 84%, at least at or about 85%, at least at or about 86%, at least at or about 87%, at least at or about 88%, at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:4.

In some of any embodiments, the lipid bilayer is derived from a membrane of a host cell used for producing a retrovirus or retrovirus-like particle. In some of any embodiments, the host cell is selected from the group consisting of CHO cells, BHK cells, MDCK cells, C3H 10T1/2 cells, FLY cells, Psi-2 cells, BOSC 23 cells, PA317 cells, WEHI cells, COS cells, BSC 1 cells, BSC 40 cells, BMT 10 cells, VERO cells, W138 cells, MRCS cells, A549 cells, HT1080 cells, 293 cells, 293T cells, B-50 cells, 3T3 cells, NIH3T3 cells, HepG2 cells, Saos-2 cells, Huh7 cells, HeLa cells, W163 cells, 211 cells, and 211A cells. In some of any embodiments, the host cell comprises 293T cells. In some of any embodiments, the lipid bilayer is or comprises a viral envelope. In some of any embodiments, the retrovirus-like particle is replication defective.

In some of any embodiments, the targeted lipid particle comprises one or more viral components other than the F protein molecule and the G protein. In some of any embodiments, the one or more viral components are from a retrovirus. In some of any embodiments, the retrovirus is a lentivirus. In some of any embodiments, the one or more viral components comprise a viral packaging protein selected from one or more of Gag, Pol, Rev and Tat. In some of any embodiments, the one or more viral components comprises one or more of (e.g., all of) the following nucleic acid sequences: 5′ LTR (e.g., comprising U5 and lacking a functional U3 domain), Psi packaging element (Psi), Central polypurine tract (cPPT)/central termination sequence (CTS) (e.g. DNA flap), Poly A tail sequence, a posttranscriptional regulatory element (e.g. WPRE), a Rev response element (RRE), and 3′ LTR (e.g., comprising U5 and lacking a functional U3).

In some of any embodiments, the targeted lipid particle is a lentiviral vector.

In some of any embodiments, the targeted lipid particle or the lentiviral vector is replication defective.

In some of any embodiments, the targeted lipid particle or the lentiviral vector further comprises an exogenous agent. In some of any embodiments, the targeted lipid particle further comprises an exogenous agent. In some embodiments, the lentiviral vector further comprises an exogenous agent.

In some of any embodiments, the exogenous agent is present in the lumen. In some of any embodiments, the exogenous agent is a protein or a nucleic acid. In some embodiments, the nucleic acid is a DNA or RNA.

In some of any embodiments, the exogenous agent is a nucleic acid encoding a cargo for delivery to the target cell. In some of any embodiments, the exogenous agent encodes a therapeutic agent or a diagnostic agent.

In some of any embodiments, the exogenous agent encodes a membrane protein. In some embodiments, the membrane protein is an antigen receptor for targeting cells expressed by or associated with a disease or condition. In some embodiments, the membrane protein is a chimeric antigen receptor (CAR). In some embodiments, the CAR comprises (i) an extracellular antigen binding domain that binds an extracellular antigen (e.g., CD19 or BCMA), optionally wherein the extracellular antigen binding domain is an scFv, (ii) a transmembrane domain and (iii) an intracellular signaling region comprising a CD3zeta signaling domain and, optionally a co-stimulatory signaling domain, e.g., a 4-1BB or CD28 co-stimulatory signaling domain. In some embodiments, the target cell is a T cell. In some embodiments, the cell surface molecule on the target cell is CD4 or CD8. In some embodiments, the binding domain is an scFv that binds CD4 (e.g. human CD4). In some embodiments, the binding domain is a single domain antibody that binds CD4 (e.g. human CD4). In some embodiments, the binding domain is an scFv that binds CD8 (e.g. human CD8). In some embodiments, the binding domain is a single domain antibody that binds CD8 (e.g. human CD8).

In some of any embodiments, the exogenous agent is a nucleic acid comprising a payload gene for correcting a genetic deficiency, optionally a genetic deficiency in the target cell. In some embodiments, the genetic deficiency is associated with a liver cell or a hepatocyte. In some embodiments, the target cell is a hepatocyte. In some embodiments, the cell surface molecule is a molecule selected from the group consisting of ASGR1, ASGR2 and TM4SF5. In some embodiments, the binding domain is an scFv that binds ASGR1 (e.g. human ASGR1). In some embodiments, the binding domain is a single domain antibody that binds ASGR1 (e.g. human ASGR1). In some embodiments, the binding domain is an scFv that binds ASGR2 (e.g. human ASGR2). In some embodiments, the binding domain is a single domain antibody that binds ASGR2 (e.g. human ASGR2). In some embodiment, the binding domain is a scFv that binds TM4SF5 (e.g. human TM4SF5). In some embodiments, the binding domain is a single domain antibody that binds TM4SF5 (e.g. human TM4SF5).

In some of any embodiments, the single domain antibody binds a cell surface molecule present on a target cell. In some of any embodiments, the cell surface molecule is a protein, glycan, lipid or low molecular weight molecule. In some of any embodiments, the target cell is selected from the group consisting of tumor-infiltrating lymphocytes, T cells, neoplastic or tumor cells, virus-infected cells, stem cells, central nervous system (CNS) cells, hematopoeietic stem cells (HSCs), liver cells or fully differentiated cells. In some of any embodiments, the target cell is selected from the group consisting of a CD3+ T cell, a CD4+ Tcell, a CD8+ T cell, a hepatocyte, a haematepoietic stem cell, a CD34+ haematepoietic stem cell, a CD105+ haematepoietic stem cell, a CD117+ haematepoietic stem cell, a CD105+ endothelial cell, a B cell, a CD20+ B cell, a CD19+ B cell, a cancer cell, a CD133+ cancer cell, an EpCAM+ cancer cell, a CD19+ cancer cell, a Her2/Neu+ cancer cell, a GluA2+ neuron, a GluA4+ neuron, a NKG2D+ natural killer cell, a SLC1A3+ astrocyte, a SLC7A10+ adipocyte, or a CD30+ lung epithelial cell.

In some of any embodiments, the single domain antibody binds an antigen or portion thereof present on a target cell. In some of any embodiments, the cell surface molecule or antigen is selected from the group consisting of ASGR1, ASGR2 and TM4SF5. In some embodiments, the antigen or portion thereof is human ASGR1. In some embodiments, the antigen or portion thereof is human ASGR2. In some embodiments, the antigen or portion thereof is human TM4SF5.

Provided herein is a polynucleotide comprising a nucleic acid sequence encoding (i) a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and (ii) a binding domain that binds a cell surface molecule selected from the group consisting of ASGR1, ASGR2, and TM4SF5. In some embodiments, the cell surface molecule is human ASGR1. In some embodiments, the cell surface molecule is human ASGR2. In some embodiments, the cell surface molecule is human TM4SF5. In some of any embodiments, the cell surface molecule or antigen is CD8 or CD4.

Provided herein is a nucleic acid sequence encoding (i) a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and (ii) a binding domain that binds a cell surface molecule selected from the group consisting of CD4 and CD8. In some embodiments, the cell surface molecule is human CD4. In some embodiments, the cell surface molecule is human CD8. In some embodiments, the cell surface molecule or antigen is low density lipoprotein receptor (LDL-R). In some embodiments, the cell surface molecule or antigen is human LDL-R.

Provided herein is a polynucleotide comprising a nucleic acid sequence encoding (i) a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and (ii) a binding domain that binds low density lipoprotein receptor (LDL-R). In some embodiments, the binding domain binds human LDL-R. In some of any embodiments, the binding domain is a single domain antibody (sdAb). In some of any embodiments, the binding domain is a single chain variable fragment (scFv).

Provided herein is a polynucleotide comprising a nucleic acid sequence encoding (i) a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and (ii) a single domain antibody (sdAb) variable domain, wherein the sdAb variable domain is attached to the C-terminus of the G protein or the biologically active portion thereof. In some of any embodiments, the polynucleotide further comprises (iii) a nucleic acid sequence encoding a henipavirus F protein molecule or a biologically active portion thereof.

In some embodiments, the nucleic acid sequence is a first nucleic acid sequence and the polynucleotide further comprise a second nucleic acid sequence encoding a henipavirus F protein molecule or a biologically active portion thereof. In some embodiments, the polynucleotide comprise an IRES or a sequence encoding a linking peptide between the first and second nucleic acid sequence. In some embodiments, the linking peptide is a self-cleaving peptide or a peptide that causes ribosome skipping, optionally a T2A peptide.

In some of any embodiments, the polynucleotide includes at least one promoter that is operatively linked to control expression of the nucleic acid. In some of any embodiments, the promoter is operatively linked to control expression of the first nucleic acid sequence and the second nucleic acid sequence. In some of any embodiments, the promoter is a constitutive promoter. In some of any embodiments, the promoter is an inducible promoter.

In some of any embodiments, the sdAb variable domain is attached to the G protein via an encoded peptide linker. In some embodiments, the binding domain is attached to the G protein via an encoded peptide linker. In some of any embodiments, the encoded peptide linker comprises up to 25 amino acids in length. In some of any embodiments, the encoded peptide linker comprises up to 65 amino acids in length In some of any embodiments, the encoded peptide linker comprises from or from about 2 to 65 amino acids, 2 to 60 amino acids, 2 to 56 amino acids, 2 to 52 amino acids, 2 to 48 amino acids, 2 to 44 amino acids, 2 to 40 amino acids, 2 to 36 amino acids, 2 to 32 amino acids, 2 to 28 amino acids, 2 to 24 amino acids, 2 to 20 amino acids, 2 to 18 amino acids, 2 to 14 amino acids, 2 to 12 amino acids, 2 to 10 amino acids, 2 to 8 amino acids, 2 to 6 amino acids, 6 to 65 amino acids, 6 to 60 amino acids, 6 to 56 amino acids, 6 to 52 amino acids, 6 to 48 amino acids, 6 to 44 amino acids, 6 to 40 amino acids, 6 to 36 amino acids, 6 to 32 amino acids, 6 to 28 amino acids, 6 to 24 amino acids, 6 to 20 amino acids, 6 to 18 amino acids, 6 to 14 amino acids, 6 to 12 amino acids, 6 to 10 amino acids, 6 to 8 amino acids, 8 to 65 amino acids, 8 to 60 amino acids, 8 to 56 amino acids, 8 to 52 amino acids, 8 to 48 amino acids, 8 to 44 amino acids, 8 to 40 amino acids, 8 to 36 amino acids, 8 to 32 amino acids, 8 to 28 amino acids, 8 to 24 amino acids, 8 to 20 amino acids, 8 to 18 amino acids, 8 to 14 amino acids, 8 to 12 amino acids, 8 to 10 amino acids, 10 to 65 amino acids, 10 to 60 amino acids, 10 to 56 amino acids, 10 to 52 amino acids, 10 to 48 amino acids, 10 to 44 amino acids, 10 to 40 amino acids, 10 to 36 amino acids, 10 to 32 amino acids, 10 to 28 amino acids, 10 to 24 amino acids, 10 to 20 amino acids, 10 to 18 amino acids, 10 to 14 amino acids, 10 to 12 amino acids, 12 to 65 amino acids, 12 to 60 amino acids, 12 to 56 amino acids, 12 to 52 amino acids, 12 to 48 amino acids, 12 to 44 amino acids, 12 to 40 amino acids, 12 to 36 amino acids, 12 to 32 amino acids, 12 to 28 amino acids, 12 to 24 amino acids, 12 to 20 amino acids, 12 to 18 amino acids, 12 to 14 amino acids, 14 to 65 amino acids, 14 to 60 amino acids, 14 to 56 amino acids, 14 to 52 amino acids, 14 to 48 amino acids, 14 to 44 amino acids, 14 to 40 amino acids, 14 to 36 amino acids, 14 to 32 amino acids, 14 to 28 amino acids, 14 to 24 amino acids, 14 to 20 amino acids, 14 to 18 amino acids, 18 to 65 amino acids, 18 to 60 amino acids, 18 to 56 amino acids, 18 to 52 amino acids, 18 to 48 amino acids, 18 to 44 amino acids, 18 to 40 amino acids, 18 to 36 amino acids, 18 to 32 amino acids, 18 to 28 amino acids, 18 to 24 amino acids, 18 to 20 amino acids, 20 to 65 amino acids, 20 to 60 amino acids, 20 to 56 amino acids, 20 to 52 amino acids, 20 to 48 amino acids, 20 to 44 amino acids, 20 to 40 amino acids, 20 to 36 amino acids, 20 to 32 amino acids, 20 to 28 amino acids, 20 to 26 amino acids, 20 to 24 amino acids, 24 to 65 amino acids, 24 to 60 amino acids, 24 to 56 amino acids, 24 to 52 amino acids, 24 to 48 amino acids, 24 to 44 amino acids, 24 to 40 amino acids, 24 to 36 amino acids, 24 to 32 amino acids, 24 to 30 amino acids, 24 to 28 amino acids, 28 to 65 amino acids, 28 to 60 amino acids, 28 to 56 amino acids, 28 to 52 amino acids, 28 to 48 amino acids, 28 to 44 amino acids, 28 to 40 amino acids, 28 to 36 amino acids, 28 to 34 amino acids, 28 to 32 amino acids, 32 to 65 amino acids, 32 to 60 amino acids, 32 to 56 amino acids, 32 to 52 amino acids, 32 to 48 amino acids, 32 to 44 amino acids, 32 to 40 amino acids, 32 to 38 amino acids, 32 to 36 amino acids, 36 to 65 amino acids, 36 to 60 amino acids, 36 to 56 amino acids, 36 to 52 amino acids, 36 to 48 amino acids, 36 to 44 amino acids, 36 to 40 amino acids, 40 to 65 amino acids, 40 to 60 amino acids, 40 to 56 amino acids, 40 to 52 amino acids, 40 to 48 amino acids, 40 to 44 amino acids, 44 to 65 amino acids, 44 to 60 amino acids, 44 to 56 amino acids, 44 to 52 amino acids, 44 to 48 amino acids, 48 to 65 amino acids, 48 to 60 amino acids, 48 to 56 amino acids, 48 to 52 amino acids, 50 to 65 amino acids, 50 to 60 amino acids, 50 to 56 amino acids, 50 to 52 amino acids, 54 to 65 amino acids, 54 to 60 amino acids, 54 to 56 amino acids, 58 to 65 amino acids, 58 to 60 amino acids, or 60 to 65 amino acids.

In some of any embodiments, the encoded peptide linker comprises a polypeptide that is 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 or 65 amino acids in length. In some of any embodiments, the encoded peptide linker comprises GS, GGS, GGGGS (SEQ ID NO:43), GGGGGS (SEQ ID NO:41) and combinations thereof. In some of any embodiments, the encoded peptide linker comprises (GGS)n, wherein n is 1 to 10. In some of any embodiments, the encoded peptide linker comprises (GGGGS)n (SEQ ID NO:42), wherein n is 1 to 10. In some of any embodiments, the encoded peptide linker comprises (GGGGGS)n (SEQ ID NO:27), wherein n is 1 to 4. In some of any embodiments, the sequence encoding the G protein is a wild-type Nipah virus G (NiV-G) protein or a Hendra virus G protein or is a functionally active variant or a biologically active portion thereof. In some embodiments, the variant is a variant thereof that exhibits reduced binding for the native binding partner. In some of any embodiments, the nucleic acid sequence encoding the G protein is a wild-type Nipah virus G (NiV-G) protein or a Hendra virus G protein or is a variant thereof that exhibits reduced binding for the native binding partner. In some embodiments, the encoded G protein is a wild-type NiV-G protein or a functionally active variant or a biologically active portion thereof. In some of any embodiments, the nucleic acid sequence encoding the G protein is a wild-type NiV-G protein. In some of any embodiments, the nucleic acid sequence encoding the G-protein is a mutant NiV-G protein that exhibits reduced binding to Ephrin B2 or Ephrin B3.

In some of any embodiments, the NiV-G protein or functionally active variant or biologically active portion thereof comprises the amino acid sequence set forth in SEQ ID NO:9, SEQ ID NO: 28 or SEQ ID NO: 44 or comprises an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44. In some of any embodiments, the NiV-G protein is a biologically active portion that is truncated and lacks up to 40 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44). In some of any embodiments, the NiV-G protein is a biologically active portion that is truncated at the N-terminus of wild-type NiV-G and comprises the sequence set forth in any of SEQ ID NOS: 10-15, 35-40 or 45-50 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NOs: 10-15, 35-40 or 45-50.

In some of any embodiments, the NiV-G protein is a biologically active portion that comprises a 5 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44). In some of any embodiments, the NiV-G protein or the biologically active portion comprises the amino acid sequence set forth in SEQ ID NO: 10 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:10. In some of any embodiments, NiV-G protein or the biologically active portion comprises the amino acid sequence set forth in SEQ ID NO: 35 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:35. In some of any embodiments, the NiV-G protein or the biologically active portion comprises the amino acid sequence set forth in SEQ ID NO: 45 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:45.

In some of any embodiments, NiV-G protein is a biologically active portion that comprises a 10 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44). In some of any embodiments, the mutant NiV-G protein or the biologically active portion comprises the amino acid sequence set forth in SEQ ID NO: 11 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:11. In some of any embodiments, the NiV-G protein or the biologically active portion comprises the amino acid sequence set forth in SEQ ID NO: 36 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:36. In some of any embodiments, the NiV-G protein or the biologically active portion comprises the amino acid sequence set forth in SEQ ID NO: 46 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:46.

In some of any embodiments, the is a biologically active portion that NiV-G protein comprises a 15 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44). In some of any embodiments, the NiV-G protein or the biologically active portion comprises the amino acid sequence set forth in SEQ ID NO: 12 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:12. In some of any embodiments, the NiV-G protein or the biologically active portion comprises the amino acid sequence set forth in SEQ ID NO: 37 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:37. In some of any embodiments, the NiV-G protein or the biologically active portion comprises the amino acid sequence set forth in SEQ ID NO: 47 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:47.

In some of any embodiments, the NiV-G protein is a biologically active portion that comprises a 20 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44). In some of any embodiments, the NiV-G protein or the biologically active portion comprises the amino acid sequence set forth in SEQ ID NO: 13 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:13. In some of any embodiments, NiV-G protein or the biologically active portion comprises the amino acid sequence set forth in SEQ ID NO: 38 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:38. In some of any embodiments, the NiV-G protein or the biologically active portion comprises the amino acid sequence set forth in SEQ ID NO: 48 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:48.

In some of any embodiments, the NiV-G protein is a biologically active portion that comprises a 25 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44). In some of any embodiments, the NiV-G protein or the biologically active portion comprises the amino acid sequence set forth in SEQ ID NO: 14 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:14. In some of any embodiments, the NiV-G protein or the biologically active portion comprises the amino acid sequence set forth in SEQ ID NO: 39 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:39. In some of any embodiments, the NiV-G protein or the biologically active portion comprises the amino acid sequence set forth in SEQ ID NO: 49 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:49.

In some of any embodiments, the NiV-G protein is a biologically active portion that comprises a 30 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44). In some of any embodiments, the NiV-G protein or the biologically active portion comprises the amino acid sequence set forth in SEQ ID NO: 15 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:15. In some of any embodiments, the NiV-G protein or the biologically active portion comprises the amino acid sequence set forth in SEQ ID NO: 40 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:40. In some of any embodiments, the NiV-G protein or the biologically active portion comprises the amino acid sequence set forth in SEQ ID NO: 50 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 50.

In some of any embodiments, the NiV-G protein is a biologically active portion that has a 34 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44). In some of any embodiments, the NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 22 or an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:22. In some of any embodiments, the NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 53 or an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:53.

In some of any embodiments, the G-protein is a mutant NiV-G protein that exhibits reduced binding to Ephrin B2 or Ephrin B3. In some of any embodiments, the mutant NiV-G protein comprises: one or more amino acid substitutions corresponding to amino acid substitutions selected from the group consisting of E501A, W504A, Q530A and E533A with reference to numbering set forth in SEQ ID NO:28. In some of any embodiments, the mutant NiV-G protein comprises amino acid substitutions E501A, W504A, Q530A and E533A with reference to numbering set forth in SEQ ID NO:28.

In some of any embodiments, the mutant NiV-G protein comprises: i) a truncation at or near the N-terminus; and ii) point mutations selected from the group consisting of E501A, W504A, Q530A and E533A. In some of any embodiments, the mutant NiV-G protein comprises the amino acid sequence set forth in SEQ ID NO: 16 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:16. In some of any embodiments, the mutant NiV-G protein comprises the amino acid sequence set forth in SEQ ID NO: 51 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:51.

In some of any embodiments, the F protein or the biologically active portion thereof is a wild-type Nipah virus F (NiV-F) protein or a Hendra virus F protein or is a functionally active variant or biologically active portion thereof. In some of any embodiments, the F protein or the biologically active portion thereof is a wild-type NiV-F protein or a functionally active variant or a biologically active portion thereof. In some of any embodiments, the NiV-F-protein or the functionally active variant or biologically active portion thereof comprises the amino acid sequence set forth in SEQ ID NO: 2, or an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 2.

In some of any embodiments, the NiV-F protein is a is a biologically active portion thereof that has a 20 amino acid truncation at or near the C-terminus of the wild-type NiV-F protein (SEQ ID NO:2). In some of any embodiments, the NiV-F protein or the biologically active portion has the sequence set forth in SEQ ID NO:5 or an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 5. In some of any embodiments, the NiV-F protein is a biologically active portion thereof that comprises i) a 20 amino acid truncation at or near the C-terminus of the wild-type NiV-F protein (SEQ ID NO:2); and ii) a point mutation on an N-linked glycosylation site.

In some of any embodiments, the NiV-F protein or the biologically active portion has the sequence set forth in SEQ ID NO:7 or an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 7.

In some of any embodiments, the NiV-F protein is a biologically active portion thereof that has a 22 amino acid truncation at or near the C-terminus of the wild-type NiV-F protein (SEQ ID NO:2). In some of any embodiments, the NiV-F protein or the biologically active portion has the sequence set forth in SEQ ID NO:8 or an amino acid sequence that is encoded by a sequence of nucleotides encoding a sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 8.

In some of any embodiments, the NiV-F protein has the sequence set forth in SEQ ID NO:23 or an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 23. In some of any embodiments, the F protein comprises the sequence set forth in SEQ ID NO:23 and the G protein comprises the sequence set forth in SEQ ID NO:16. In some of any embodiments, the F protein consists or consists essentially of the sequence set forth in SEQ ID NO:23 and the G protein consists or consists essentially of the sequence set forth in SEQ ID NO:16.

Provided herein is a vector, comprising the polynucleotide of any of the embodiments described herein. In some of any embodiments, the vector is a mammalian vector, viral vector or artificial chromosome, optionally wherein the artificial chromosome is a bacterial artificial chromosome (BAC).

Provided herein is a plasmid, comprising the polynucleotide of any of the embodiments described herein. In some of any embodiments, the plasmid further comprises one or more nucleic acids encoding proteins for lentivirus production.

Provided herein is a cell comprising the polynucleotide of any of embodiments described herein or the vector of any of the embodiments described herein, or the plasmid of any of the embodiments described herein.

Provided herein is a method of making a targeted lipid particle comprising a henipavirus F protein molecule or biologically active portion thereof and a targeted envelope protein comprising a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and a single domain antibody (sdAb) variable domain, the method comprising a) providing a cell that comprises a nucleic acid encoding a henipavirus F protein molecule or biologically active portion thereof and a nucleic acid encoding a targeted envelope protein, the targeted envelope protein comprising a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and a single domain antibody (sdAb) variable domain; b) culturing the cell under conditions that allow for production of a targeted lipid particle, and c) separating, enriching, or purifying the targeted lipid particle from the cell, thereby making the targeted lipid particle.

Provided herein is a method of making a pseudotyped lentiviral vector, the method comprising a) providing a producer cell that comprises a lentiviral viral nucleic acid(s), a nucleic acid encoding a henipavirus F protein molecule or biologically active portion thereof, and a nucleic acid encoding a targeted envelope protein, said targeted envelope protein comprising a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and a single domain antibody; b) culturing the cell under conditions that allow for production of the lentiviral vector, and c) separating, enriching, or purifying the lentiviral vector from the cell, thereby making the pseudotyped lentiviral vector.

In some of any embodiments, the single domain antibody binds a cell surface molecule present on a target cell. In some of any embodiments, the cell surface molecule is a protein, glycan, lipid or low molecular weight molecule. In some of any embodiments, the target cell is selected from the group consisting of tumor-infiltrating lymphocytes, T cells, neoplastic or tumor cells, virus-infected cells, stem cells, central nervous system (CNS) cells, hematopoeietic stem cells (HSCs), liver cells or fully differentiated cells. In some of any embodiments, the target cell is selected from the group consisting of a CD3+ T cell, a CD4+ Tcell, a CD8+ T cell, a hepatocyte, a haematepoietic stem cell, a CD34+ haematepoietic stem cell, a CD105+ haematepoietic stem cell, a CD117+ haematepoietic stem cell, a CD105+ endothelial cell, a B cell, a CD20+ B cell, a CD19+ B cell, a cancer cell, a CD133+ cancer cell, an EpCAM+ cancer cell, a CD19+ cancer cell, a Her2/Neu+ cancer cell, a GluA2+ neuron, a GluA4+ neuron, a NKG2D+ natural killer cell, a SLC1A3+ astrocyte, a SLC7A10+ adipocyte, or a CD30+ lung epithelial cell. In some of any embodiments, the single domain antibody binds an antigen or portion thereof present on a target cell.

Provided herein is a method of making a targeted lipid particle comprising a henipavirus F protein molecule or biologically active portion thereof and a targeted envelope protein comprising a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and a binding domain, the method comprising a) providing a cell that comprises a nucleic acid encoding a henipavirus F protein molecule or biologically active portion thereof and a nucleic acid encoding a targeted envelope protein, the targeted envelope protein comprising a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and binding domain, wherein the binding domain (i) binds a cell surface molecule selected from the group consisting of ASGR1, ASGR2, and TM4SF5, optionally human ASGR1, human ASGR2 and human ASGR2; (ii) binds a cell surface molecule selected from the group consisting of CD4 or CD8, optionally human CD4 or human CD8; or (iii) binds a cell surface molecule that is low density lipoprotein receptor (LDL-R), optionally human LDL-R; b) culturing the cell under conditions that allow for production of a targeted lipid particle, and c) separating, enriching, or purifying the targeted lipid particle from the cell, thereby making the targeted lipid particle.

Provided herein is a method of making a pseudotyped lentiviral vector, the method comprising a) providing a producer cell that comprises a lentiviral viral nucleic acid(s), a nucleic acid encoding a henipavirus F protein molecule or biologically active portion thereof, and a nucleic acid encoding a targeted envelope protein, said targeted envelope protein comprising a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and binding domain, wherein the binding domain: (i) binds a cell surface molecule selected from the group consisting of ASGR1, ASGR2, and TM4SF5, optionally human ASGR1, human ASGR2 and human ASGR2; (ii) binds a cell surface molecule selected from the group consisting of CD4 or CD8, optionally human CD4 or human CD8; or (iii) binds a cell surface molecule that is low density lipoprotein receptor (LDL-R), optionally human LDL-R; b) culturing the producer cell under conditions that allow for production of a lentiviral vector, and c) separating, enriching, or purifying the lentiviral vector from the cell, thereby making the pseudotyped lentiviral vector.

In some of any embodiments, the binding domain is a single domain antibody. In some of any embodiments, the binding domain is a single chain variable fragment (scFv). In some of any embodiments, the cell surface molecule is selected from the group consisting of ASGR1, ASGR2 and TM4SF5. In some of any embodiments, the cell surface molecule is CD8 or CD4, In some of any embodiments, the cell surface molecule is LDL-R.

Provided herein is a method of making a targeted lipid particle comprising a henipavirus F protein molecule or biologically active portion thereof and a targeted envelope protein comprising a) providing a cell that comprises the polynucleotide of any of the embodiments provided herein the vector of any of the embodiments described herein, or the plasmid of any of the embodiments described herein; b) culturing the cell under conditions that allow for production of a targeted lipid particle, and c) separating, enriching, or purifying the targeted lipid particle particle from the cell, thereby making the targeted lipid particle.

Provided herein is a method of making a pseudotyped lentiviral vector, comprising: a) providing a producer cell that comprises a lentiviral viral nucleic acid(s), and the polynucleotide of any of the embodiments listed herein or the vector of any of the embodiments listed herein b) culturing the cell under conditions that allow for production of the lentiviral vector, and c) separating, enriching, or purifying the lentiviral vector from the cell, thereby making the pseudotyped lentiviral vector. In some of any embodiments, prior to step (b) the method further comprises providing the cell a polynucleotide encoding a henipavirus F protein molecule or biologically active portion thereof.

In some of any embodiments, the cell is a mammalian cell.

In some of any embodiments, the cell is a producer cell comprising viral nucleic acid. In some of any embodiments, the viral nucleic acid is a retroviral nucleic acid or lentiviral nucleic acid and the targeted lipid particle is a viral particle or a viral-like particle. In some of any embodiments, the viral particle or a viral-like particle is a retroviral particle or a retroviral-like particle. In some embodiments, the viral particle or a viral-like particle is a lentiviral particle or lentiviral-like particle.

In some of any embodiments, the viral nucleic acid(s) lacks one or more genes involved in viral replication. In some of any embodiments, the viral nucleic acid comprises a nucleic acid encoding a viral packaging protein selected from one or more of Gag, Pol, Rev and Tat. In some of any embodiments, the viral nucleic acid comprises:one or more of (e.g., all of) the following nucleic acid sequences: 5′ LTR (e.g., comprising U5 and lacking a functional U3 domain), Psi packaging element (Psi), Central polypurine tract (cPPT)/central termination sequence (CTS) (e.g. DNA flap), Poly A tail sequence, a posttranscriptional regulatory element (e.g. WPRE), a Rev response element (RRE), and 3′ LTR (e.g., comprising U5 and lacking a functional U3).

Provided herein is a producer cell comprising the polynucleotide of any of the embodiments listed herein or the vector of any of the embodiments listed herein, or the plasmid of any of the embodiments described herein.

In some of any embodiments, the producer cell further comprises a nucleic acid encoding a henipavirus F protein or a biologically active portion thereof.

In some of any embodiments, the cell further comprises a viral nucleic acid. In some of any embodiments, the viral nucleic acid is a lentiviral nucleic acid. Provided herein is a producer cell comprising (i) a viral nucleic acid(s) and (ii) nucleic acid encoding a henipavirus F protein molecule or biologically active portion thereof and (iii) a nucleic acid encoding a targeted envelope protein comprising a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and a single domain antibody (sdAb) variable domain, optionally wherein the viral nucleic acid(s) are lentiviral nucleic acids. In some of any embodiments the single domain antibody binds a cell surface molecule present on a target cell. In some of any embodiments the cell surface molecule is a protein, glycan, lipid or low molecular weight molecule.

In some of any embodiments the target cell is selected from the group consisting of tumor-infiltrating lymphocytes, T cells, neoplastic or tumor cells, virus-infected cells, stem cells, central nervous system (CNS) cells, hematopoeietic stem cells (HSCs), liver cells or fully differentiated cells. In some of any embodiments the target cell is selected from the group consisting of a CD3+ T cell, a CD4+ Tcell, a CD8+ T cell, a hepatocyte, a haematepoietic stem cell, a CD34+ haematepoietic stem cell, a CD105+ haematepoietic stem cell, a CD117+ haematepoietic stem cell, a CD105+ endothelial cell, a B cell, a CD20+ B cell, a CD19+ B cell, a cancer cell, a CD133+ cancer cell, an EpCAM+ cancer cell, a CD19+ cancer cell, a Her2/Neu+ cancer cell, a GluA2+ neuron, a GluA4+ neuron, a NKG2D+ natural killer cell, a SLC1A3+ astrocyte, a SLC7A10+ adipocyte, or a CD30+ lung epithelial cell. In some of any embodiments the single domain antibody binds an antigen or portion thereof present on a target cell.

Provided herein is a producer cell comprising (i) a viral nucleic acid(s) and (ii) nucleic acid encoding a henipavirus F protein molecule or biologically active portion thereof and (iii) a nucleic acid encoding a targeted envelope protein comprising a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and binding domain, wherein the binding domain (i) binds a cell surface molecule selected from the group consisting of ASGR1, ASGR2, and TM4SF5, optionally human ASGR1, human ASGR2 and human ASGR2; (ii) binds a cell surface molecule selected from the group consisting of CD4 or CD8, optionally human CD4 or human CD8; or (iii) binds a cell surface molecule that is low density lipoprotein receptor (LDL-R), optionally human LDL-R. In some of any embodiments the viral nucleic acid(s) are lentiviral nucleic acid.

In some of any embodiments the cell surface molecule or antigen is selected from the group consisting of ASGR1, ASGR2 and TM4SF5. In some of any embodiments, the cell surface molecule or antigen is CD8 or CD4. In some of any embodiments, the cell surface molecule or antigen is LDL-R.

In some of any embodiments, the viral nucleic acid(s) lacks one or more genes involved in viral replication. In some of any embodiments, the viral nucleic acid comprises a nucleic acid encoding a viral packaging protein selected from one or more of Gag, Pol, Rev and Tat.

In some of any embodiments, the viral nucleic acid comprises one or more of (e.g., all of) the following nucleic acid sequences: 5′ LTR (e.g., comprising U5 and lacking a functional U3 domain), Psi packaging element (Psi), Central polypurine tract (cPPT)/central termination sequence (CTS) (e.g. DNA flap), Poly A tail sequence, a posttranscriptional regulatory element (e.g. WPRE), a Rev response element (RRE), and 3′ LTR (e.g., comprising U5 and lacking a functional U3).

In some of any embodiments, the henipavirus F protein molecule or biologically active portion thereof comprises: (i) the sequence set forth in SEQ ID NO: 2; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:2. In some of any embodiments, the henipavirus F protein molecule or biologically active portion thereof comprises (i) the sequence set forth in SEQ ID NO: 5; (ii) an amino acid sequence having at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:5.

In some of any embodiments, the henipavirus F protein molecule or biologically active portion thereof comprises (i) the sequence set forth in SEQ ID NO: 7; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:7. In some of any embodiments, the henipavirus F protein molecule or biologically active portion thereof comprises (i) a sequence encoding by a nucleotide sequence encoding the sequence set forth in SEQ ID NO: 8; (ii) a amino acid sequence encoded by a nucleotide sequence encoding a sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:8.

In some of any embodiments, the henipavirus F protein molecule or biologically active portion thereof comprises: (i) the sequence set forth in SEQ ID NO: 23; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:23.

In some of any embodiments, the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises: (i) the sequence set forth in SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44.

In some of any embodiments, the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises: (i) the sequence set forth in SEQ ID NO: 10; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:10.

In some of any embodiments, the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises: (i) the sequence set forth in SEQ ID NO: 35; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:35.

In some of any embodiments, the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises: (i) the sequence set forth in SEQ ID NO: 45; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:45.

In some of any embodiments, the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises: (i) the sequence set forth in SEQ ID NO: 11; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:11.

In some of any embodiments, the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises: (i) the sequence set forth in SEQ ID NO: 36; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:36.

In some of any embodiments, the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises: (i) the sequence set forth in SEQ ID NO: 46; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:46.

In some of any embodiments, the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises: (i) the sequence set forth in SEQ ID NO: 12; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:12.

In some of any embodiments, the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises: (i) the sequence set forth in SEQ ID NO: 37; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:37.

In some of any embodiments, the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises: (i) the sequence set forth in SEQ ID NO: 47; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:47.

In some of any embodiments, the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises (i) the sequence set forth in SEQ ID NO: 13; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:13.

In some of any embodiments, the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises: (i) the sequence set forth in SEQ ID NO: 38; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:38.

In some of any embodiments, the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises: (i) the sequence set forth in SEQ ID NO: 48; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:48.

In some of any embodiments, the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises (i) the sequence set forth in SEQ ID NO: 14; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:14.

In some of any embodiments, the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises: (i) the sequence set forth in SEQ ID NO: 39; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:39.

In some of any embodiments, the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises: (i) the sequence set forth in SEQ ID NO: 49; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:49.

In some of any embodiments, the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises (i) the sequence set forth in SEQ ID NO: 15; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:15.

In some of any embodiments, the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises: (i) the sequence set forth in SEQ ID NO: 40; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:40.

In some of any embodiments, the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises: (i) the sequence set forth in SEQ ID NO: 50; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:50.

In some of any embodiments, the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises (i) the sequence set forth in SEQ ID NO: 16; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:16.

In some of any embodiments, the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises (i) the sequence set forth in SEQ ID NO: 51; (ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:51.

In some aspects of the provided embodiments, the targeted lipid particle has greater expression of the targeted envelope protein compared to a reference lipid particle that has incorporated into a similar lipid bilayer the same envelope protein but that is fused to an alternative targeting moiety, optionally wherein the alternative targeting moiety is a single chain variable fragment (scFv). In some of any embodiments, the expression is increased by at or greater than 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 125%, 150%, 200%, 300%, 400%, 500% or more. In some embodiments, the expression is increased by at or greater than 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 15-fold, 20-fold, 30-fold or more, preferably at or about or greater than 10-fold or more. In some of any embodiments, the titer in target cells following transduction is at or greater than 1×10⁶ transduction units (TU)/mL, at or greater than 2×10⁶ TU/mL, at or greater than 3×10⁶ TU/mL, at or greater than 4×10⁶ TU/mL, at or greater than 5×10⁶ TU/mL, at or greater than 6×10⁶ TU/mL, at or greater than 7×10⁶ TU/mL, at or greater than 8×10⁶ TU/mL, at or greater than 9×10⁶ TU/mL, or at or greater than 1×10⁷ TU/mL. Also provided herein is a composition wherein among the population of lipid particles, greater than at or about 50%, greater than at or about 55%, greater than at or about 60%, greater than at or about 65%, greater than at or about 70%, or greater than at or about 75% are surface positive for the targeted envelope protein. In some of any embodiments, the targeted envelope protein is present on the surface of the targeted lipid particle at a density of at least about (0.001, 0.002, 0.005, 0.01, 0.02, 0.05, 0.1, 0.2 or 0.5) targeted envelope proteins/nm².

Provided herein is a viral vector particle or viral-like particle produced from the producer cell of any of the embodiments provided herein.

Provided herein is a composition comprising a plurality of targeted lipid particles of any of the embodiments provided herein. In some embodiments, the composition further includes a pharmaceutically acceptable carrier. In some of any embodiments, the targeted lipid particles comprise an average diameter of less than 1 In some of any embodiments, the composition further includes a targeted envelope protein present on the surface of the targeted lipid particles at an average density of at least about (0.001, 0.002, 0.005, 0.01, 0.02, 0.05, 0.1, 0.2 or 0.5) targeted envelope proteins/nm².

Provided herein is a producer cell containing greater membrane (e.g., plasma membrane) expression of the targeted envelope protein compared to a reference producer cell that has incorporated into its membrane (e.g. plasma membrane) the same envelope protein but that is fused to an alternative targeting moiety, optionally wherein the alternative targeting moiety is a single chain variable fragment (scFv). In some embodiments, the expression is increased by at or greater than 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 125%, 150%, 200%, 300%, 400%, 500% or more. In some embodiments, the expression is increased by at or greater than 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 15-fold, 20-fold, 30-fold or more, preferably at or about or greater than 10-fold or more. In some embodiments, the producer cell has the expression of the targeted envelope protein on a membrane (e.g., plasma membrane) of the producer cell is at least 20 proteins (e.g., at least 50, 100, 200, 500, 1000, 2000, 5000, or 10,000 proteins) per square micron. In some of any embodiments, the targeted envelope protein comprises at least 0.1% (e.g., at least 0.2%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10%) of the total membrane (e.g., plasma membrane) proteins of the producer cell (e.g., by total protein weight).

Provided herein is a method of transducing a cell comprising transducing a cell with any of the viral vectors described herein or with any of the compositions described herein. In some of any embodiments, the targeted envelope protein of the lentiviral vector or targeted lipid particle targets CD4 and the cell is a CD4+ cell. In some of any embodiments, the targeted envelope protein of the lentiviral vector targets CD8 and the cell is a CD8+ cell. In some of any embodiments, the targeted envelope protein of the lentiviral vector targets ASGR1, ASGR2 or TM4SF5 and the cell is a hepatocyte.

Provided herein is a method of delivering an exogenous agent to a subject (e.g., a human subject), the method comprising administering to the subject the targeted lipid particle of any of the embodiments provided herein or the composition of any of the embodiments provided herein, wherein the targeted lipid particle or lentiviral vector comprise the exogenous agent.

Provided herein is a method of delivering an exogenous agent to a subject (e.g., a human subject), the method comprising administering to the subject any of the compositions described herein, wherein targeted lipid particle or lentiviral vectors of the plurality comprise the exogenous agent.

Provided herein is a method of delivering a chimeric antigen receptor (CAR) to a cell, comprising contacting a cell with any of the lentiviral vectors described herein or a targeted lipid particle of any of the embodiments described herein, wherein the lentiviral vector or targeted lipid particle comprise nucleic acid encoding the CAR.

Provided herein is a method of delivering a chimeric antigen receptor (CAR) to a cell, comprising contacting a cell with any of the compositions described herein, wherein lentiviral vectors or targeted lipid particles of the plurality comprise nucleic acid encoding the CAR.

Provided herein is a method of delivering an exogenous agent to a hepatocyte, comprising contacting a cell with any of the lentiviral vectors described herein, or a targeted lipid particle or lentiviral vector of any of the embodiments described herein.

Provided herein is a method of delivering an exogenous agent to a hepatocyte, comprising contacting a cell with any of the compositions described herein, wherein lentiviral vectors or targeted lipid particles of the plurality comprise an exogenous agent for delivery to the hepatocyte. In some of any embodiments, the contacting transduces the cell with lentiviral vector or the targeted lipid particle.

Provided herein is a method of treating a disease or disorder in a subject (e.g., a human subject), the method comprising administering to the subject the targeted lipid particle of any of the embodiments provided herein or the composition of any of the embodiments provided herein.

Provided herein is a method of fusing a mammalian cell to a targeted lipid particle, the method comprising administering to the subject the targeted lipid particle of any of the embodiments provided herein or the composition of any of the embodiments provided herein. In some of any embodiments, the fusing of the mammalian cell to the targeted lipid particle delivers an exogenous agent to a subject (e.g., a human subject). In some of any embodiments, the fusing of the mammalian cell to the targeted lipid particle treats a disease or disorder in a subject (e.g., a human subject). In some of any embodiments, the targeted envelope protein of the lentiviral vector or targeted lipid particle targets CD4 and the cell is a CD4+ cell. In some of any embodiments, the targeted envelope protein of the lentiviral vector targets CD8 and the cell is a CD8+ cell. In some of any embodiments, the targeted envelope protein of the lentiviral vector targets ASGR1, ASGR2 or TM4SF5 and the cell is a hepatocyte.

In some of any embodiments, the targeted lipid particle has greater expression of the targeted envelope protein compared to a reference lipid particle that has incorporated into a similar lipid bilayer the same envelope protein but that is fused to an alternative targeting moiety. In some embodiments, the alternative targeting moiety is a single chain variable fragment (scFv). In some of any embodiments, the expression is increased by at or greater than 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 125%, 150%, 200%, 300%, 400%, 500% or more. In some of any embodiments, the expression is increased by at or greater than 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 15-fold, 20-fold, 30-fold or more, preferably at or about or greater than 10-fold or more.

In some of any embodiments, the titer in target cells following transduction is at or greater than 1×10⁶ transduction units (TU)/mL, at or greater than 2×10⁶ TU/mL, at or greater than 3×10⁶ TU/mL, at or greater than 4×10⁶ TU/mL, at or greater than 5×10⁶ TU/mL, at or greater than 6×10⁶ TU/mL, at or greater than 7×10⁶ TU/mL, at or greater than 8×10⁶ TU/mL, at or greater than 9×10⁶ TU/mL, or at or greater than 1×10⁷ TU/mL.

In some of any embodiments, among the population of lipid particles or lentiviral vectors in the composition, greater than at or about 50%, greater than at or about 55%, greater than at or about 60%, greater than at or about 65%, greater than at or about 70%, or greater than at or about 75% are surface positive for the targeted envelope protein. In some of any embodiments, the targeted envelope protein is present on the surface of the targeted lipid particle at a density of at least about (0.001, 0.002, 0.005, 0.01, 0.02, 0.05, 0.1, 0.2 or 0.5) targeted envelope proteins/nm².

Provided herein is a composition comprising a plurality of the targeted lipid particles of any of the embodiments described herein or a plurality of lentiviral vectors of any of the embodiments described herein, wherein the targeted envelope protein is present on the surface of the targeted lipid particles at an average density of at least about (0.001, 0.002, 0.005, 0.01, 0.02, 0.05, 0.1, 0.2 or 0.5) targeted envelope proteins/nm².

In some of any embodiments, the producer cell has greater membrane (e.g., plasma membrane) expression of the targeted envelope protein compared to a reference producer cell that has incorporated into its membrane (e.g. plasma membrane) the same envelope protein but that is fused to an alternative targeting moiety, optionally wherein the alternative targeting moiety is a single chain variable fragment (scFv). In some of any embodiments, the expression is increased by at or greater than 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 125%, 150%, 200%, 300%, 400%, 500% or more. In some of any embodiments, the expression is increased by at or greater than 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 15-fold, 20-fold, 30-fold or more, preferably at or about or greater than 10-fold or more. In some of any embodiments, the producer cell has the expression of the targeted envelope protein on a membrane (e.g., plasma membrane) of the producer cell is at least 20 proteins (e.g., at least 50, 100, 200, 500, 1000, 2000, 5000, or 10,000 proteins) per square micron. In some of any embodiments, the targeted envelope protein comprises at least 0.1% (e.g., at least 0.2%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10%) of the total membrane (e.g., plasma membrane) proteins of the producer cell (e.g., by total protein weight).

DETAILED DESCRIPTION

Provided herein are targeted lipid particles containing a lipid bilayer enclosing a lumen or cavity and a targeted envelope protein containing (1) a henipavirus envelope attachment glycoprotein G (G protein) or biologically active portion thereof and (2) a binding domain, such as a a single domain antibody (sdAb) variable domain, in which the targeted envelope protein is embedded in the lipid bilayer of the lipid particles. In particular embodiments, the binding domain, such as a single domain antibody, is an antibody with the ability to bind, such as specifically bind, to a desired target molecule. Exemplary binding domains are described in Section II.A.2. In some embodiments, the targeted lipid particles also contains a henipavirus fusion (F) protein molecule or a biologically active portion thereof embedded in the lipid bilayer. In particular embodiments, the lipid particles can be a virus-like particle, a virus, or a viral vector, such as a lentiviral vector.

In some embodiments, one or both of the G protein and the F protein is from a Hendra (HeV) or a Nipah (NiV) virus, or is a biologically active portion thereof or is a variant or mutant thereof. In particular embodiments, both the G protein and the F protein is from a Hendra (HeV) or a Nipah (NiV) virus. In some embodiments, the fusion and attachment glycoproteins mediate cellular entry of Nipah virus.

The F protein, such as NiV-F, is a class I fusion protein that has structural and functional features in common with fusion proteins of many families (e.g., HIV-1 gp41 or influenza virus hemagglutinin [HA]), such as an ectodomain with a hydrophobic fusion peptide and two heptad repeat regions (White JM et al. 2008. Crit Rev Biochem Mol Biol 43:189-219). F proteins are synthesized as inactive precursors F₀ and are activated by proteolytic cleavage into the two disulfide-linked subunits F₁ and F₂ (Moll M. et al. 2004. J. Virol. 78(18): 9705-9712).

G proteins are attachment proteins of henipavirus (e.g. Nipah virus or Hendra virus) that are type II transmembrane glycoproteins containing an N-terminal cytoplasmic tail, a transmembrane domain, an extracellular stalk, and a globular head (Liu, Q. et al. 2015. Journal of Virology, 89(3):1838-1850). The attachment protein, NiV-G, recognizes the receptors EphrinB2 and EphrinB3. Binding of the receptor to NiV-G triggers a series of conformational changes that eventually lead to the triggering of NiV-F, which exposes the fusion peptide of NiV-F, allowing another series of conformational changes that lead to virus-cell membrane fusion (Stone J. A. et al. 2016. J Virol. 90(23): 10762-10773). EphrinB2 was previously identified as the primary NiV receptor (Negrete et al., 2005), as well as EphrinB3 as an alternate receptor (Negrete et al., 2006). In fact, NiV-G has a high affinity for EphrinB2 and B3, with affinity binding constants (Kd) in the picomolar range (Negrete et al., 2006) (Kd=0.06 nM and 0.58 nM for cell surface expressed ephrinB2 and B3, respectively).

The efficiency of transduction of targeted lipid particles can be improved by engineering hyperfusogenic mutations in one or both of NiV-F and NiV-G. Several such mutations have been previously described (see, e.g., Lee at al, 2011, Trends in Microbiology). This could be useful, for example, for maintaining the specificity and picomolar affinity of NiV-G for EphrinB2 and/or B3. Additionally, mutations in NiV-G that completely abrogate EphrinB2 and B3 binding, but that do not impact the association of this NiV-G with NiV-F, have been identified. Methods to improve targeting of lipid particles can be achieved by fusion of a binding molecule with a G protein (e.g. Niv-G, including a Niv-G with mutations to abrogate ephrin B2 and ephrin B3 binding). This could allow for altered G protein tropism allowing for targeting of other desired cell types that are not EphrinB2+ through the addition of the binding molecule molecule directed against a different cell surface molecule.

While retargeted lipid particles incorporating such binding molecules fused to a G protein have been generated, it is found herein that some some binding molecules when fused with a G protein (e.g. NiV-G) express better on the surface of lipid particles than others. For example, it is found that single domain antibodies (sdAbs), such as VHH, may express 10-fold better than a single chain variable fragment (scFv). Without wishing to be bound by theory, the increase in expression may be due to an increased stability of the retargeted G protein on the surface of the lipid particle. This greater expression can improve the ability of the lipid particle to target the target molecule (e.g. a cell surface molecule) compared to a similar lipid particle but containing an alternative binding domain, e.g. scFv, against the same target molecule.

Thus, provided herein are targeted lipid particles containing a G protein of a henipavirus (e.g. Hendra or Nipah, e.g. NiV-G) attached to a sdAb variable domain directed against or that is able to bind to a cell surface molecule on a target cell. sdAb variable domains can include those of a VL or VH only sdAb, nanobodies, camelid VHH domains, shark IgNAR or fragments thereof. In some embodiments, the sdAb is a VHH.

In aspects of the provided embodiments, a targeted lipid particle can be engineered to express a henipavirus F protein molecule or biologically active portion thereof; and a targeted envelope protein comprising (i) a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and (ii) single domain antibody (sdAb) variable domain, wherein the F protein molecule or the biologically active portion thereof and the targeted envelope protein are embedded in the lipid bilayer. In some embodiments, the sdAb variable domain is attached to the C-terminus of the G protein or the biologically active portion thereof. In some embodiments, the sdAb variable domain is attached to the G protein via a linker.

Also provided are targeted lipid particles additionally containing one or more exogenous agents, such as for delivery of a diagnostic or therapeutic agent to cells, including following in vivo administration to a subject. Also provided herein are methods and uses of the targeted lipid particles, such in diagnostic and therapeutic methods. Also provided are polynucleotides, methods for engineering, preparing, and producing the targeted lipid non-cell particles, compositions containing the particles, and kits and devices containing and for using, producing and administering the particles.

All publications, including patent documents, scientific articles and databases, referred to in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication were individually incorporated by reference. If a definition set forth herein is contrary to or otherwise inconsistent with a definition set forth in the patents, applications, published applications and other publications that are herein incorporated by reference, the definition set forth herein prevails over the definition that is incorporated herein by reference.

The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1C depict characterization of cells transfected with constructs containing scFv or VHH binding modalities. FIG. 1A depicts surface expression of cells transfected with constructs containing scFV or VHH binding modalities, analyzed by flow cytometry, and depicted as median fluorescence intensity (MFI), quantified by % of His+ cells. FIG. 1B depicts binding to soluble hCD4-Fc protein of cells transfected with constructs containing scFV of VHH binding modalities analyzed by flow cytometry, and depicted as median fluorescence intensity (MFI), quantified by % Fc+ cell. FIG. 1C depicts surface expression of targeted binding sequences on 293 cells for cells transfected with constructs containing VHH binding modalities, compared to the scFv binding modalities, analyzed by flow cytometry, and depicted as median fluorescence intensity (MFI), as quantified by % of His+ cells. Empty vector and the expression vector without the binder domain were used as negative controls.

FIG. 2 depicts transduction efficacy of four exemplary constructs containing scFV or VHH binding modalities on PanT cells from peripheral blood that were negatively selected to enrich for T cells were thawed and activated with anti CD3/anti-CD28. Cells were analyzed by flow cytometry, and titer determined by % of CD4-positive cells that were GFP+.

FIGS. 3A-3B depict transduction efficiency of CD8 retargeted pseudotyped lentiviruses in an in vivo model using activated PBMCs injected intraperitonally into NOD-scid-IL2rγ^null mice, as analyzed by flow cytometry. Transduciton efficiency of CD8 retargeted pseudotyped lentiviruses is depicted on CD8+ (FIG. 3A) or CD8− (FIG. 3B) T cells, and titer was determined by % of CD8 positive or negative cells that were GFP+.

FIGS. 4A-4B depict the ability of CD8 retargeted pseudotyped lentiviruses containing chimeric antigen receptors (CARs) to effect killing of leukemic cells in vitro. FIG. 4A shows the ability to detect CD19+ CAR expression on CD8+ cells at 4 days post transduction. FIG. 4B shows the elimination of Nalm6 cells evaluated at 18 hours post incubation, analyzed by flow cytometry

I. DEFINITIONS

Unless defined otherwise, all terms of art, notations and other technical and scientific terms or terminology used herein are intended to have the same meaning as is commonly understood by one of ordinary skill in the art to which the claimed subject matter pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art.

Unless defined otherwise, all technical and scientific terms, acronyms, and abbreviations used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Unless indicated otherwise, abbreviations and symbols for chemical and biochemical names is per IUPAC-IUB nomenclature. Unless indicated otherwise, all numerical ranges are inclusive of the values defining the range as well as all integer values in-between.

As used herein, the articles “a” and “an” refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

As used herein, the term “about” will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which it is used. As used herein, “about” when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ±20% or ±10%, more preferably ±5%, even more preferably ±1%, and still more preferably ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.

As used herein, “lipid particle” refers to any biological or synthetic particle that contains a bilayer of amphipathic lipids enclosing a lumen or cavity. Typically a lipid particle does not contain a nucleus. Examples of lipid particles include solid particles such as nanoparticles, viral-derived particles or cell-derived particles. Such lipid particles include, but are not limited to, viral particles (e.g. lentiviral particles), virus-like particles, viral vectors (e.g., lentiviral vectors) exosomes, enucleated cells, various vesicles, such as a microvesicle, a membrane vesicle, an extracellular membrane vesicle, a plasma membrane vesicle, a giant plasma membrane vesicle, an apoptotic body, a mitoparticle, a pyrenocyte, or a lysosome. In some embodiments, a lipid particle can be a fusosome. In some embodiments, the lipid particle is not a platelet.

As used herein a “biologically active portion,” such as with reference to a protein such as a G protein or an F protein, refers to a portion of the protein that exhibits or retains an activity or property of the full-length of the protein. For example, a biologically active portion of an F protein retains fusogenic activity in conjunction with the G protein when each are embedded in a lipid bilayer. A biologically active portion of the G protein retains fusogenic activity in conjunction with an F protein when each is embedded in a lipid bilayer. The retained activity and include 10%-150% or more of the activity of a full-length or wild-type F protein or G protein. Examples of biologically active portions of F and G proteins include truncations of the cytoplasmic domain, e.g. truncations of up to 1, 2, 3, 4, 5, 6, 7, 8 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35 or more contiguous amino acids, see e.g. Khetawat and Broder 2010 Virology Journal 7:312; Witting et al. 2013 Gene Therapy 20:997-1005; published international; patent application No. WO/2013/148327.

As used herein, “fusosome” refers to a particle containing a bilayer of amphipathic lipids enclosing a lumen or cavity and a fusogen that interacts with the amphipathic lipid bilayer. In embodiments, the fusosome comprises a nucleic acid. In some embodiments, the fusosome is a membrane enclosed preparation. In some embodiments, the fusosome is derived from a source cell.

As used herein, “fusosome composition” refers to a composition comprising one or more fusosomes.

As used herein, “fusogen” refers to an agent or molecule that creates an interaction between two membrane enclosed lumens. In embodiments, the fusogen facilitates fusion of the membranes. In other embodiments, the fusogen creates a connection, e.g., a pore, between two lumens (e.g., a lumen of a retroviral vector and a cytoplasm of a target cell). In some embodiments, the fusogen comprises a complex of two or more proteins, e.g., wherein neither protein has fusogenic activity alone. In some embodiments, the fusogen comprises a targeting domain.

As used herein, a “re-targeted fusogen” refers to a fusogen that comprises a targeting moiety having a sequence that is not part of the naturally-occurring form of the fusogen. In embodiments, the fusogen comprises a different targeting moiety relative to the targeting moiety in the naturally-occurring form of the fusogen. In embodiments, the naturally-occurring form of the fusogen lacks a targeting domain, and the re-targeted fusogen comprises a targeting moiety that is absent from the naturally-occurring form of the fusogen. In embodiments, the fusogen is modified to comprise a targeting moiety. In embodiments, the fusogen comprises one or more sequence alterations outside of the targeting moiety relative to the naturally-occurring form of the fusogen, e.g., in a transmembrane domain, fusogenically active domain, or cytoplasmic domain.

As used herein, a “targeted envelope protein” refers to a polypeptide that contains a henipavirus G protein attached to a single domain antibody (sdAb) variable domain, such as a VL or VH only sdAb, nanobodies, camelid VHH domains, shark IgNAR or fragments thereof, that targets a molecule on a desired cell type. In some such embodiments, the attachment may be directly or indirectly via a linker, such as a peptide linker.

As used herein, a “targeted lipid particle” refers to a lipid particle that contains a targeted envelope protein embedded in the lipid bilayer.

As used herein, a “retroviral nucleic acid” refers to a nucleic acid containing at least the minimal sequence requirements for packaging into a retrovirus or retroviral vector, alone or in combination with a helper cell, helper virus, or helper plasmid. In some embodiments, the retroviral nucleic acid further comprises or encodes an exogenous agent, a positive target cell-specific regulatory element, a non-target cell-specific regulatory element, or a negative TCSRE. In some embodiments, the retroviral nucleic acid comprises one or more of (e.g., all of) a 5′ LTR (e.g., to promote integration), U3 (e.g., to activate viral genomic RNA transcription), R (e.g., a Tat-binding region), U5, a 3′ LTR (e.g., to promote integration), a packaging site (e.g., psi (Ψ), RRE (e.g., to bind to Rev and promote nuclear export). The retroviral nucleic acid can comprise RNA (e.g., when part of a virion) or DNA (e.g., when being introduced into a source cell or after reverse transcription in a recipient cell). In some embodiments, the retroviral nucleic acid is packaged using a helper cell, helper virus, or helper plasmid which comprises one or more of (e.g., all of) gag, pol, and env.

As used herein, a “target cell” refers to a cell of a type to which it is desired that a targeted lipid particle delivers an exogenous agent. In embodiments, a target cell is a cell of a specific tissue type or class, e.g., an immune effector cell, e.g., a T cell. In some embodiments, a target cell is a diseased cell, e.g., a cancer cell. In some embodiments, the fusogen, e.g., re-targeted fusogen leads to preferential delivery of the exogenous agent to a target cell compared to a non-target cell.

As used herein a “non-target cell” refers to a cell of a type to which it is not desired that a targeted lipid particle delivers an exogenous agent. In some embodiments, a non-target cell is a cell of a specific tissue type or class. In some embodiments, a non-target cell is a non-diseased cell, e.g., a non-cancerous cell. In some embodiments, the fusogen, e.g., re-targeted fusogen leads to lower delivery of the exogenous agent to a non-target cell compared to a target cell.

As used herein, a “single domain antibody” or “sdAb” refers to an antibody having a single monomeric domain antigen binding/recognition domain. Such antibodies include nanobodies, camelid antibodies (e.g. VHH), or shark antibodies (e.g. IgNAR). In some embodiments, a variable domain of a sdAb comprises three CDRs and four framework regions, designated FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. In some embodiments, a sdAb variable domain may be truncated at the N-terminus or C-terminus such that it comprise only a partial FR1 and/or FR4, or lacks one or both of those framework regions, so long as the sdAb variable domain substantially maintains antigen binding and specificity.

The term “CDR” denotes a complementarity determining region as defined by at least one manner of identification to one of skill in the art. The precise amino acid sequence boundaries of a given CDR or FR can be readily determined using any of a number of well-known schemes, including those described by Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (“Kabat” numbering scheme); Al-Lazikani et al., (1997) JMB 273, 927-948 (“Chothia” numbering scheme); MacCallum et al., J. Mol. Biol. 262:732-745 (1996), “Antibody-antigen interactions: Contact analysis and binding site topography,” J. Mol. Biol. 262, 732-745.” (“Contact” numbering scheme); Lefranc M P et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Dev Comp Immunol, 2003 January; 27(1):55-77 (“IMGT” numbering scheme); Honegger A and Plückthun A, “Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool,” J Mol Biol, 2001 Jun. 8; 309(3):657-70, (“Aho” numbering scheme); and Martin et al., “Modeling antibody hypervariable loops: a combined algorithm,” PNAS, 1989, 86(23):9268-9272, (“AbM” numbering scheme).

The boundaries of a given CDR or FR may vary depending on the scheme used for identification. For example, the Kabat scheme is based on structural alignments, while the Chothia scheme is based on structural information. Numbering for both the Kabat and Chothia schemes is based upon the most common antibody region sequence lengths, with insertions accommodated by insertion letters, for example, “30a,” and deletions appearing in some antibodies. The two schemes place certain insertions and deletions (“indels”) at different positions, resulting in differential numbering. The Contact scheme is based on analysis of complex crystal structures and is similar in many respects to the Chothia numbering scheme. The AbM scheme is a compromise between Kabat and Chothia definitions based on that used by Oxford Molecular's AbM antibody modeling software.

In some embodiments, CDRs can be defined in accordance with any of the Chothia numbering schemes, the Kabat numbering scheme, a combination of Kabat and Chothia, the AbM definition, and/or the contact definition. A sdAb variable domain comprises three CDRs, designated CDR1, CDR2, and CDR3. Table 1, below, lists exemplary position boundaries of CDR-H1, CDR-H2, CDR-H3 as identified by Kabat, Chothia, AbM, and Contact schemes, respectively. For CDR-H1, residue numbering is listed using both the Kabat and Chothia numbering schemes. FRs are located between CDRs, for example, with FR-H1 located before CDR-H1, FR-H2 located between CDR-H1 and CDR-H2, FR-H3 located between CDR-H2 and CDR-H3 and so forth. It is noted that because the shown Kabat numbering scheme places insertions at H35A and H35B, the end of the Chothia CDR-H1 loop when numbered using the shown Kabat numbering convention varies between H32 and H34, depending on the length of the loop.

TABLE 1
Boundaries of CDRs according to various numbering schemes.
CDR	Kabat	Chothia	AbM	Contact
CDR-H1	H31--H35B	H26--H32 . . . 34	H26--H35B	H30--H35B
(Kabat
Num-
bering1)
CDR-H1	H31--H35	H26--H32	H26--H35	H30--H35
(Chothia
Num-
bering2)
CDR-H2	H50--H65	H52--H56	H50--H58	H47--H58
CDR-H3	H95--H102	H95--H102	H95--H102	H93--H101
1Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD
2Al-Lazikani et al., (1997) JMB 273, 927-948

Thus, unless otherwise specified, a “CDR” or “complementary determining region,” or individual specified CDRs (e.g., CDR-H1, CDR-H2, CDR-H3), of a given antibody or region thereof, such as a variable region thereof, should be understood to encompass a (or the specific) complementary determining region as defined by any of the aforementioned schemes. For example, where it is stated that a particular CDR (e.g., a CDR-H3) contains the amino acid sequence of a corresponding CDR in a given sdAb amino acid sequence, it is understood that such a CDR has a sequence of the corresponding CDR (e.g., CDR-H3) within the sdAb, as defined by any of the aforementioned schemes. It is understood that any antibody, such as a sdAb, includes CDRs and such can be identified according to any of the other aforementioned numbering schemes or other numbering schemes known to a skilled artisan.

As used herein, the term “specifically binds” to a target molecule, such as an antigen, means that a binding molecule, such as a single domain antibody, reacts or associates more frequently, more rapidly, with greater duration and/or with greater affinity with a particular target molecule than it does with alternative molecules. A binding molecule, such as a sdAb variable domain, “specifically binds” to a target molecule if it binds with greater affinity, avidity, more readily, and/or with greater duration than it binds to other molecules. It is understood that a binding molecule, such as a sdAb, that specifically binds to a first target may or may not specifically bind to a second target. As such, “specific binding” does not necessarily require (although it can include) exclusive binding.

As used herein, “percent (%) amino acid sequence identity” and “homology” with respect to a peptide, polypeptide or antibody sequence are defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific peptide or polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or MEGALIGN™ (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.

An amino acid substitution may include but are not limited to the replacement of one amino acid in a polypeptide with another amino acid. Exemplary substitutions are shown in Table 2 Amino acid substitutions may be introduced into an antibody of interest and the products screened for a desired activity, for example, retained/improved binding.

TABLE 2
Original Residue Exemplary Substitutions
Ala (A)          Val; Leu; Ile
Arg (R)          Lys; Gln; Asn
Asn (N)          Gln; His; Asp, Lys; Arg
Asp (D)          Glu; Asn
Cys (C)          Ser; Ala
Gln (Q)          Asn; Glu
Glu (E)          Asp; Gln
Gly (G)          Ala
His (H)          Asn; Gln; Lys; Arg
Ile (I)          Leu; Val; Met; Ala; Phe; Norleucine
Leu (L)          Norleucine; Ile; Val; Met; Ala; Phe
Lys (K)          Arg; Gln; Asn
Met (M)          Leu; Phe; Ile
Phe (F)          Trp; Leu; Val; Ile; Ala; Tyr
Pro (P)          Ala
Ser (S)          Thr
Thr (T)          Val; Ser
Trp (W)          Tyr; Phe
Tyr (Y)          Trp; Phe; Thr; Ser
Val (V)          Ile; Leu; Met; Phe; Ala; Norleucine

Amino acids may be grouped according to common side-chain properties:

• • (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile;
  • (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;
  • (3) acidic: Asp, Glu;
  • (4) basic: His, Lys, Arg;
  • (5) residues that influence chain orientation: Gly, Pro;
  • (6) aromatic: Trp, Tyr, Phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another class.

The term, “corresponding to” with reference to positions of a protein, such as recitation that nucleotides or amino acid positions “correspond to” nucleotides or amino acid positions in a disclosed sequence, such as set forth in the Sequence listing, refers to nucleotides or amino acid positions identified upon alignment with the disclosed sequence based on structural sequence alignment or using a standard alignment algorithm, such as the GAP algorithm. For example, corresponding residues of a similar sequence (e.g. fragment or species variant) can be determined by alignment to a reference sequence by structural alignment methods. By aligning the sequences, one skilled in the art can identify corresponding residues, for example, using conserved and identical amino acid residues as guides.

The term “isolated” as used herein refers to a molecule that has been separated from at least some of the components with which it is typically found in nature or produced. For example, a polypeptide is referred to as “isolated” when it is separated from at least some of the components of the cell in which it was produced. Where a polypeptide is secreted by a cell after expression, physically separating the supernatant containing the polypeptide from the cell that produced it is considered to be “isolating” the polypeptide. Similarly, a polynucleotide is referred to as “isolated” when it is not part of the larger polynucleotide (such as, for example, genomic DNA or mitochondrial DNA, in the case of a DNA polynucleotide) in which it is typically found in nature, or is separated from at least some of the components of the cell in which it was produced, for example, in the case of an RNA polynucleotide. Thus, a DNA polynucleotide that is contained in a vector inside a host cell may be referred to as “isolated”.

The term “effective amount” as used herein means an amount of a pharmaceutical composition which is sufficient enough to significantly and positively modify the symptoms and/or conditions to be treated (e.g., provide a positive clinical response). The effective amount of an active ingredient for use in a pharmaceutical composition will vary with the particular condition being treated, the severity of the condition, the duration of treatment, the nature of concurrent therapy, the particular active ingredient(s) being employed, the particular pharmaceutically-acceptable excipient(s) and/or carrier(s) utilized, and like factors with the knowledge and expertise of the attending physician.

An “exogenous agent” as used herein with reference to a targeted lipid particle, refers to an agent that is neither comprised by nor encoded in the corresponding wild-type virus or fusogen made from a corresponding wild-type source cell. In some embodiments, the exogenous agent does not naturally exist, such as a protein or nucleic acid that has a sequence that is altered (e.g., by insertion, deletion, or substitution) relative to a naturally occurring protein. In some embodiments, the exogenous agent does not naturally exist in the source cell. In some embodiments, the exogenous agent exists naturally in the source cell but is exogenous to the virus. In some embodiments, the exogenous agent does not naturally exist in the recipient cell. In some embodiments, the exogenous agent exists naturally in the recipient cell, but is not present at a desired level or at a desired time. In some embodiments, the exogenous agent comprises RNA or protein.

As used herein, a “promoter” refers to a cis-regulatory DNA sequence that, when operably linked to a gene coding sequence, drives transcription of the gene. The promoter may comprise a transcription factor binding sites. In some embodiments, a promoter works in concert with one or more enhancers which are distal to the gene.

As used herein, a composition refers to any mixture of two or more products, substances, or compounds, including cells. It may be a solution, a suspension, liquid, powder, a paste, aqueous, non-aqueous or any combination thereof.

As used herein, the term “pharmaceutically acceptable” refers to a material, such as carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively nontoxic, i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.

As used herein, the term “pharmaceutical. composition” refers to a mixture of at least one compound of the invention with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients. The pharmaceutical composition facilitates administration of the compound to an organism. Multiple techniques of administering a compound exist in the art including, but not limited to, intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary and topical administration.

A “disease” or “disorder” as used herein refers to a condition where treatment is needed and/or desired.

As used herein, the terms “treat,” “treating,” or “treatment” refer to ameliorating a disease or disorder, e.g., slowing or arresting or reducing the development of the disease or disorder or reducing at least one of the clinical symptoms thereof. For purposes of this disclosure, ameliorating a disease or disorder can include obtaining a beneficial or desired clinical result that includes, but is not limited to, any one or more of: alleviation of one or more symptoms, diminishment of extent of disease, preventing or delaying spread (for example, metastasis, for example metastasis to the lung or to the lymph node) of disease, preventing or delaying recurrence of disease, delay or slowing of disease progression, amelioration of the disease state, inhibiting the disease or progression of the disease, inhibiting or slowing the disease or its progression, arresting its development, and remission (whether partial or total).

The terms “individual” and “subject” are used interchangeably herein to refer to an animal; for example a mammal. The term patient includes human and veterinary subjects. In some embodiments, methods of treating mammals, including, but not limited to, humans, rodents, simians, felines, canines, equines, bovines, porcines, ovines, caprines, mammalian laboratory animals, mammalian farm animals, mammalian sport animals, and mammalian pets, are provided. The subject can be male or female and can be any suitable age, including infant, juvenile, adolescent, adult, and geriatric subjects. In some examples, an “individual” or “subject” refers to an individual or subject in need of treatment for a disease or disorder. In some embodiments, the subject to receive the treatment can be a patient, designating the fact that the subject has been identified as having a disorder of relevance to the treatment, or being at adequate risk of contracting the disorder. In particular embodiments, the subject is a human, such as a human patient.

II. TARGETED LIPID PARTICLES (E.G. LENTIVIRAL VECTORS)

Provided herein are targeted lipid particles that comprise a henipavirus F protein molecule or biologically active portion thereof, and a targeted envelope protein comprising (i) a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and (ii) binding domain, wherein the binding domain is attached to the C-terminus of the G protein or the biologically active portion, wherein each of (i) and (ii) is exposed on the outer surface of the targeted lipid particle. In some embodiments, the binding domain is a single domain antibody. In some embodiments, the binding domain is a single chain variable fragment. In particular embodiments, the provided lipid particles exhibit fusogenic activity, which is mediated by the targeted envelope protein that facilitates binding to a target cell and contains the G protein or biologically active portion thereof, and the F glycoprotein that is involved in facilitating the merger or fusion of the two lumens of the lipid particle and the target cell membranes.

Provided herein are targeted lipid particles that comprise a henipavirus F protein molecule or biologically active portion thereof, and a targeted envelope protein comprising (i) a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and (ii) a single domain antibody (sdAb) variable domain, wherein the single domain antibody is attached to the C-terminus of the G protein or the biologically active portion, wherein each of (i) and (ii) is exposed on the outer surface of the targeted lipid particle. In particular embodiments, the provided lipid particles exhibit fusogenic activity, which is mediated by the targeted envelope protein that facilitates binding to a target cell and contains the G protein or biologically active portion thereof, and the F glycoprotein that is involved in facilitating the merger or fusion of the two lumens of the lipid particle and the target cell membranes.

In some of any embodiment, the targeted lipid particles are viral particles or viral-like particles. In some aspects, such targeted lipid particles contain viral nucleic acid, such as retroviral nucleic acid, for example lentiviral nucleic acid. In particular embodiments, any provided targeted lipid particles, such as a viral particle or viral-like particle, is replication defective. In some embodiments, the targeted lipid particle is a lentiviral vector, in which the lentiviral vector is pseudotyped with the henipavirus F protein and the targeted envelope protein.

For instance, provided herein is a pseudotyped lentiviral vector that comprises a henipavirus F protein molecule or biologically active portion thereof, and a targeted envelope protein comprising (i) a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and (ii) binding domain, wherein the binding domain is attached to the C-terminus of the G protein or the biologically active portion, wherein each of (i) and (ii) is exposed on the outer surface of the targeted lipid particle. In some embodiments, the binding domain is a single domain antibody. In some embodiments, the binding domain is a single chain variable fragment.

In some embodiments, the targeted lipid particle provided herein (e.g. targeted lentiviral vector) has increased or greater expression of the targeted envelope protein compared to a reference lipid particle (e.g. reference lentiviral vector) that incorporates a similar envelope protein but that is fused to an alternative targeting moiety other than a sdAb variable domain, such as a single chain variable fragment (scFv). In some embodiments, such targeted lipid particles are produced by pseudotyping of lipid particles (e.g lentiviral particles) following co-transfection of the packaging cells with the transfer, envelope, and gag-pol plasmids.

In some embodiments, the expression is increased by at or greater than 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 125%, 150%, 200%, 300%, 400%, 500% or more, compared to a reference lipid particle (e.g. reference lentiviral vector), e.g. a reference lipid particle containing a similar envelope protein but that is fused to an scFv. In some examples, the expression is increased by at or greater than 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 15-fold, 20-fold, 30-fold or more, compared to a reference lipid particle (e.g. reference lentiviral vector), e.g. a reference lipid particle containing a similar envelope protein but that is fused to an scFv. In some embodiments, expression can be assayed in vitro using flow cytometry, e.g. FACs. In some embodiments, expression can be depicted as the number or density of targeted envelope protein on the surface of a targeted lipid particle (e.g. targeted lentiviral vector). In some embodiments, expression can be depicted as the mean fluorescent intensity (MFI) of surface expression of the targeted envelope protein on the surface of a targeted lipid particle (e.g. targeted lentiviral vector). In some embodiments, expression can be depicted as the percent of lipid particle (e.g. lentiviral vectors) in a population that are surface positive for the targeted envelope protein.

In some embodiments, in a population of targeted lipid particles (e.g. targeted lentiviral vectors) greater than at or about 50% of the lipid particles are surface positive for the targeted envelope protein. For example, in a population of provided targeted lipid particles (e.g. targeted lentiviral vectors) greater than at or about 55%, greater than at or about 60%, greater than at or about 65%, greater than at or about 70%, greater than at or about 75% of the cells in the population are surface positive for the targeted envelope protein.

In some embodiments, titer of the targeted lipid particles following introduction into target cells, such as by transduction (e.g. transduced cells), is increased compared to titer into the same target cells of reference lipid particles (e.g. reference lentiviral vector) that incorporate a similar envelope protein but fused to an alternative targeting moiety other than a sdAb variable domain, such as a single chain variable fragment (scFv). Typically, the alternative targeting moiety recognizes or binds the same target molecule as the sdAb variable domain of the targeted envelope protein of the targeted lipid particles. In some embodiments, the titer is increased by at or greater than 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 125%, 150%, 200%, 300%, 400%, 500% or more, compared to titer of a reference lipid particle (e.g. reference lentiviral vector), e.g. a reference lipid particle containing a similar envelope protein but that is fused to an scFv. In some examples, the titer is increased by at or greater than 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 15-fold, 20-fold, 30-fold or more, compared to the titer of a reference lipid particle (e.g. reference lentiviral vector), e.g. a reference lipid particle containing a similar envelope protein but that is fused to an scFv. In some embodiments, the titer of the targeted lipid particles in target cells (e.g. transduced cells) is greater than at or about 1×10⁶ transduction units (TU)/mL. For example, the titer of the targeted lipid particles in target cells (e.g. transduced cells) is greater than at or about 2×10⁶ TU/mL, greater than at or about 3×10⁶ TU/mL, greater than at or about 4×10⁶ TU/mL, greater than at or about 5×10⁶ TU/mL, greater than at or about 6×10⁶ TU/mL, greater than at or about 7×10⁶ TU/mL, greater than at or about 8×10⁶ TU/mL, greater than at or about 9×10⁶ TU/mL, or greater than at or about 1×10⁷ TU/mL.

A. Targeted Envelope Protein (e.g. Henipavirus Plus Binding Domain)

In some embodiments, the targeted lipid particle (e.g. lentiviral vector) includes a targeted envelope protein exposed on the surface of the targeted lipid particle (e.g. lentiviral vector).

In some embodiments, the targeted envelope protein contains a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and a binding domain that binds to a cell surface molecule on a target cell. In some embodiments, the binding domain is a single domain antibody (sdAb). In some embodiments, the binding domain is a single chain variable fragment (scFv). The binding domain can be linked directly or indirectly to the G protein. In particular embodiments, the binding domain is linked to the C-terminus (C-terminal amino acid) of the G protein or the biologically active portion thereof. The linkage can be via a peptide linker, such as a flexible peptide linker.

I. Protein

In some embodiments, the targeted envelope protein contains a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and a single domain antibody (sdAb) variable domain or biologically active portion thereof. In some embodiments, the sdAb binds to a cell surface molecule on a target cell. The sdAb variable domain can be linked directly or indirectly to the G protein. In particular embodiments, the sdAb variable domain is linked to the C-terminus (C-terminal amino acid) of the G protein or the biologically active portion thereof. The linkage can be via a peptide linker, such as a flexible peptide linker.

In some embodiments, an binding domain (e.g. sdAb) binds to a cell surface antigen of a cell. In some embodiments, a cell surface antigen is characteristic of one type of cell. In some embodiments, a cell surface antigen is characteristic of more than one type of cell.

In some embodiments, the binding domain (e.g. sdAb) variable domain binds a cell surface molecule or antigen. In some embodiments, the cell surface molecule is ASGR1, ASGR2, TM4SF5, CD8, CD4, or low density lipoprotein receptor (LDL-R). In some embodiments, the cell surface molecule is ASGR1. In some embodiments, the cell surface molecule is ASGR2. In some embodiments, the cell surface molecule is TM4SF5. In some embodiments, the cell surface molecule is CD8. In some embodiments, the cell surface molecule is CD4. In some embodiments, the cell surface molecule is LDL-R.

In some embodiments the G protein is a Henipavirus G protein or a biologically active portion thereof. In some embodiments, the Henipavirus G protein is a Hendra (HeV) virus G protein, a Nipah (NiV) virus G-protein (NiV-G), a Cedar (CedPV) virus G-protein, a Mojiang virus G-protein, a bat Paramyxovirus G-protein or a biologically active portion thereof. Table 3 provides non-limiting examples of G proteins.

The attachment G proteins are type II transmembrane glycoproteins containing an N-terminal cytoplasmic tail (e.g. corresponding to amino acids 1-49 of SEQ ID NO:9), a transmembrane domain (e.g. corresponding to amino acids 50-70 of SEQ ID NO:9), and an extracellular domain containing an extracellular stalk (e.g. corresponding to amino acids 71-187 of SEQ ID NO:9), and a globular head (corresponding to amino acids 188-602 of SEQ ID NO:9). The N-terminal cytoplasmic domain is within the inner lumen of the lipid bilayer and the C-terminal portion is the extracellular domain that is exposed on the outside of the lipid bilayer. Regions of the stalk in the C-terminal region (e.g. corresponding to amino acids 159-167 of NiV-G) have been shown to be involved in interactions with F protein and triggering of F protein fusion (Liu et al. 2015 J of Virology 89:1838). In wild-type G protein, the globular head mediates receptor binding to henipavirus entry receptors eprhin B2 and ephrin B3, but is dispensable for membrane fusion (Brandel-Tretheway et al. Journal of Virology. 2019. 93(13)e00577-19). In particular embodiments herein, tropism of the G protein is altered by linkage of the G protein or biologically active fragment thereof (e.g. cytoplasmic truncation) to a sdAb variable domain. Binding of the G protein to a binding partner can trigger fusion mediated by a compatible F protein or biologically active portion thereof. G protein sequences disclosed herein are predominantly disclosed as expressed sequences including an N-terminal methionine required for start of translation. As such N-terminal methionines are commonly cleaved co- or post-translationally, the mature protein sequences for all G protein sequences disclosed herein are also contemplated as lacking the N-terminal methionine.

G glycoproteins are highly conserved between henipavirus species. For example, the G protein of NiV and HeV viruses share 79% amino acids identity. Studies have shown a high degree of compatibility among G proteins with F proteins of different species as demonstrated by heterotypic fusion activation (Brandel-Tretheway et al. Journal of Virology. 2019). As described further below, a re-targeted lipid particle can contain heterologous G and F proteins from different species.

TABLE 3
Henipavirus protein G sequence clusters. Column 1, Genbank ID includes the
Genbank ID of the whole genome sequence of the virus that is the centroid sequence of the
cluster. Column 2, nucleotides of CDS provides the nucleotides corresponding to the CDS of
the gene in the whole genome. Column 3, Full Gene Name, provides the full name of the gene
including Genbank ID, virus species, strain, and protein name. Column 4, Sequence, provides
the amino acid sequence of the gene. Column 5, #Sequences/Cluster, provides the number of
sequences that cluster with this centroid sequence. Column 6 provides the SEQ ID numbers for
the described sequences.
						SEQ
						ID
						NO
						(without
	Nucleotides				SEQ	N-
Genbank	of	Full sequence		#Sequences/	ID	terminal
ID	CDS	ID	Sequence	Cluster	NO	methionine)
AF017	8913-	gb: AF017149|	MMADSKLVSLNNNLSGKIKDQGKVIKN	14	18	52
149	10727	Organism: Hen	YYGTMDIKKINDGLLDSKILGAFNTVIA
		dra	LLGSIIIIVMNIMIIQNYTRTTDNQALIKES
		virus|Strain	LQSVQQQIKALTDKIGFEIGPKVSLIDTSS
		Name: UNKN	TITIPANIGLLGSKISQSTSSINENVNDKC
		OWN-	KFTLPPLKIHECNISCPNPLPFREYRPISQ
		AF017149|Pro	GVSDLVGLPNQICLQKTTSTILKPRLISY
		tein	TLPINTREGVCITDPLLAVDNGFFAYSHL
		Name: glycopr	EKIGSCTRGIAKQRIIGVGEVLDRGDKVP
		otein|Gene	SMFMTNVWTPPNPSTIHHCSSTYHEDFY
		Symbol: G	YTLCAVSHVGDPILNSTSWTESLSLIRLA
			VRPKSDSGDYNQKYIAITKVERGKYDK
			VMPYGPSGIKQGDTLYFPAVGFLPRTEF
			QYNDSNCPIIHCKYSKAENCRLSMGVNS
			KSHYILRSGLLKYNLSLGGDIILQFIEIAD
			NRLTIGSPSKIYNSLGQPVFYQASYSWD
			TMIKLGDVDTVDPLRVQWRNNSVISRP
			GQSQCPRFNVCPEVCWEGTYNDAFLIDR
			LNWVSAGVYLNSNQTAENPVFAVFKDN
			EILYQVPLAEDDTNAQKTITDCFLLENVI
			WCISLVEIYDTGDSVIRPKLFAVKIPAQC
			SES
AF212	8943-	gb: AF2123021	MPAENKKVRFENTTSDKGKIPSKVIKSY	14	28	44
302	10751	Organism: Nip	YGTMDIKKINEGLLDSKILSAFNTVIALL
		ah virus|Strain	GSIVIIVMNIMIIQNYTRSTDNQAVIKDA
		Name: UNKN	LQGIQQQIKGLADKIGTEIGPKVSLIDTSS
		OWN-	TITIPANIGLLGSKISQSTASINENVNEKC
		AF212302|Pro	KFTLPPLKIHECNISCPNPLPFREYRPQTE
		tein	GVSNLVGLPNNICLQKTSNQILKPKLISY
		Name: attachm	TLPVVGQSGTCITDPLLAMDEGYFAYSH
		ent	LERIGSCSRGVSKQRIIGVGEVLDRGDEV
		glycoprotein|G	PSLFMTNVWTPPNPNTVYHCSAVYNNE
		ene Symbol: G	FYYVLCAVSTVGDPILNSTYWSGSLMM
			TRLAVKPKSNGGGYNQHQLALRSIEKG
			RYDKVMPYGPSGIKQGDTLYFPAVGFL
			VRTEFKYNDSNCPITKCQYSKPENCRLS
			MGIRPNSHYILRSGLLKYNLSDGENPKV
			VFIEISDQRLSIGSPSKIYDSLGQPVFYQA
			SFSWDTMIKFGDVLTVNPLVVNWRNNT
			VISRPGQSQCPRFNTCPEICWEGVYNDA
			FLIDRINWISAGVFLDSNQTAENPVFTVF
			KDNEILYRAQLASEDTNAQKTITNCFLL
			KNKIWCISLVEIYDTGDNVIRPKLFAVKI
			PEQCT
JQ001	8170-	gb: JQ001776:	MLSQLQKNYLDNSNQQGDKMNNPDKK	3	29	54
776	10275	8170-	LSVNFNPLELDKGQKDLNKSYYVKNKN
		10275|Organis	YNVSNLLNESLHDIKFCIYCIFSLLIIITIIN
		m: Cedar	IITISIVITRLKVHEENNGMESPNLQSIQD
		virus|S train	SLSSLTNMINTEITPRIGILVTATSVTLSSS
		Name: CG1a|Pr	INYVGTKTNQLVNELKDYITKSCGFKVP
		otein	ELKLHECNISCADPKISKSAMYSTNAYA
		Name: attachm	ELAGPPKIFCKSVSKDPDFRLKQIDYVIP
		ent	VQQDRSICMNNPLLDISDGFFTYIHYEGI
		glycoprotein|G	NSCKKSDSFKVLLSHGEIVDRGDYRPSL
		ene Symbol: G	YLLSSHYHPYSMQVINCVPVTCNQSSFV
			FCHISNNTKTLDNSDYSSDEYYITYFNGI
			DRPKTKKIPINNMTADNRYIHFTFSGGG
			GVCLGEEFIIPVTTVINTDVFTHDYCESF
			NCSVQTGKSLKEICSESLRSPTNSSRYNL
			NGIMIISQNNMTDFKIQLNGITYNKLSFG
			SPGRLSKTLGQVLYYQSSMSWDTYLKA
			GFVEKWKPFTPNWMNNTVISRPNQGNC
			PRYHKCPEICYGGTYNDIAPLDLGKDMY
			VSVILDSDQLAENPEITVFNSTTILYKER
			VSKDELNTRSTTTSCFLFLDEPWCISVLE
			TNRFNGKSIRPEIYSYKIPKYC
NC_02	9117-	gb: NC_02525	MPQKTVEFINMNSPLERGVSTLSDKKTL	2	30	55
5256	11015	6: 9117-	NQSKITKQGYFGLGSHSERNWKKQKNQ
		11015|Organis	NDHYMTVSTMILEILVVLGIMFNLIVLT
		m: Bat	MVYYQNDNINQRMAELTSNITVLNLNL
		Paramyxovirus	NQLTNKIQREIIPRITLIDTATTITIPSAITY
		Eid_he1/GH-	ILATLTTRISELLPSINQKCEFKTPTLVLN
		M74a/GHA/20	DCRINCTPPLNPSDGVKMSSLATNLVAH
		09|Strain	GPSPCRNFSSVPTIYYYRIPGLYNRTALD
		Name: BatPV/	ERCILNPRLTISSTKFAYVHSEYDKNCTR
		Eid_he1/GH-	GFKYYELMTFGEILEGPEKEPRMFSRSF
		M74a/GHA/20	YSPTNAVNYHSCTPIVTVNEGYFLCLEC
		09|Protein	TSSDPLYKANLSNSTFHLVILRHNKDEKI
		Name: glycopr	VSMPSFNLSTDQEYVQIIPAEGGGTAESG
		otein|Gene	NLYFPCIGRLLHKRVTHPLCKKSNCSRT
		Symbol: G	DDESCLKSYYNQGSPQHQVVNCLIRIRN
			AQRDNPTWDVITVDLTNTYPGSRSRIFG
			SFSKPMLYQSSVSWHTLLQVAEITDLDK
			YQLDWLDTPYISRPGGSECPFGNYCPTV
			CWEGTYNDVYSLTPNNDLFVTVYLKSE
			QVAENPYFAIFSRDQILKEFPLDAWISSA
			RTTTISCFMFNNEIWCIAALEITRLNDDII
			RPIYYSFWLPTDCRTPYPHTGKMTRVPL
			RSTYNY
NC_02	8716-	gb: NC_02535	MATNRDNTITSAEVSQEDKVKKYYGVE	2	31	56
5352	11257	2: 8716-	TAEKVADSISGNKVFILMNTLLILTGAIIT
		11257|Organis	ITLNITNLTAAKSQQNMLKIIQDDVNAK
		m: Mojiang	LEMFVNLDQLVKGEIKPKVSLINTAVSV
		virus|Strain	SIPGQISNLQTKFLQKYVYLEESITKQCT
		Name: Tonggu	CNPLSGIFPTSGPTYPPTDKPDDDTTDDD
		an1|Protein	KVDTTIKPIEYPKPDGCNRTGDHFTMEP
		Name: attachm	GANFYTVPNLGPASSNSDECYTNPSFSIG
		ent	SSIYMFSQEIRKTDCTAGEILSIQIVLGRI
		glycoprotein|G	VDKGQQGPQASPLLVWAVPNPKIINSCA
		ene Symbol: G	VAAGDEMGWVLCSVTLTAASGEPIPHM
			FDGFWLYKLEPDTEVVSYRITGYAYLLD
			KQYDSVFIGKGGGIQKGNDLYFQMYGL
			SRNRQSFKALCEHGSCLGTGGGGYQVL
			CDRAVMSFGSEESLITNAYLKVNDLASG
			KPVIIGQTFPPSDSYKGSNGRMYTIGDKY
			GLYLAPSSWNRYLRFGITPDISVRSTTWL
			KSQDPIMKILSTCTNTDRDMCPEICNTRG
			YQDIFPLSEDSEYYTYIGITPNNGGTKNF
			VAVRDSDGHIASIDILQNYYSITSATISCF
			MYKDEIWCIAITEGKKQKDNPQRIYAHS
			YKIRQMCYNMKSATVTVGNAKNITIRR
			Y

In some embodiments, the G protein has a sequence set forth in any of SEQ ID NOS: 9, 18, 28, 29, 30, 31, 44, 52, or 54-56 or is a functionally active variant or biologically active portion thereof that has a sequence that is at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at least at or about 84%, at least at or about 85%, at least at or about 86%, at least at or about 87%, at least at or about 88%, at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% identical to any one of SEQ ID NOS: 9, 18, 28, 29, 30, 31, 44, 52, or 54-56. In particular embodiments, the G protein or functionally active variant or biologically active portion is a protein that retains fusogenic activity in conjunction with a Henipavirus F protein, such as an F protein set forth in Section I.B (e.g. NiV-F or HeV-F). Fusogenic activity includes the activity of the G protein in conjunction with a Henipavirus F protein to promote or facilitate fusion of two membrane lumens, such as the lumen of the targeted lipid particle having embedded in its lipid bilayer a henipavirus F and G protein, and a cytoplasm of a target cell, e.g. a cell that contains a surface receptor or molecule that is recognized or bound by the targeted envelope protein. In some embodiments, the F protein and G protein are from the same Henipavirus species (e.g. NiV-G and NiV-F). In some embodiments, the F protein and G protein are from different Henipavirus species (e.g. NiV-G and HeV-F).

In particular embodiments, the G protein has the sequence of amino acids set forth in SEQ ID NO: 9, SEQ ID NO: 28, SEQ ID NO: 18, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 44, SEQ ID NO: 52 or SEQ ID NO: 54-56 or is a functionally active variant thereof or a biologically active portion thereof that retains fusogenic activity. In some embodiments, the functionally active variant comprises an amino acid sequence having at least at or about 80%, at least at or about 85%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:9, SEQ ID NO:28, SEQ ID NO: 18, SEQ ID NO:30, SEQ ID NO: 31, SEQ ID NO: 44, SEQ ID NO: 52 or SEQ ID NO: 54-56 and retains fusogenic activity in conjunction with a Henipavirus F protein (e.g., NiV-F or HeV-F). In some embodiments, the biologically active portion has an amino acid sequence having at least at or about 80%, at least at or about 85%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:9, SEQ ID NO:28, SEQ ID NO: 18, SEQ ID NO:30 SEQ ID NO: 31, SEQ ID NO: 44, SEQ ID NO: 52 or SEQ ID NO: 54-56 and retains fusogenic activity in conjunction with a Henipavirus F protein (e.g., NiV-F or HeV-F).

Reference to retaining fusogenic activity includes activity (in conjunction with a Henipavirus F protein) that is between at or about 10% and at or about 150% or more of the level or degree of binding of the corresponding wild-type G protein, such as set forth in SEQ ID NO:9, SEQ ID NO:28, SEQ ID NO: 18, SEQ ID NO:30, SEQ ID NO: 31, SEQ ID NO: 44, SEQ ID NO: 52 or SEQ ID NO: 54-56 such as at least or at least about 10% of the level or degree of fusogenic activity of the corresponding wild-type G protein, such as at least or at least about 15% of the level or degree of fusogenic activity of the corresponding wild-type G protein, such as at least or at least about 20% of the level or degree of fusogenic activity of the corresponding wild-type G protein, such as at least or at least about 25% of the level or degree of fusogenic activity of the corresponding wild-type G protein, such as at least or at least about 30% of the level or degree of fusogenic activity of the corresponding wild-type G protein, such as at least or at least about 35% of the level or degree of fusogenic activity of the corresponding wild-type G protein, such as at least or at least about 40% of the level or degree of fusogenic activity of the corresponding wild-type G protein, such as at least or at least about 45% of the level or degree of fusogenic activity of the corresponding wild-type G protein, such as at least or at least about 50% of the level or degree of fusogenic activity of the corresponding wild-type G protein, such as at least or at least about 55% of the level or degree of fusogenic activity of the corresponding wild-type G protein, such as at least or at least about 60% of the level or degree of fusogenic activity of the corresponding wild-type G protein, such as at least or at least about 65% of the level or degree of fusogenic activity of the corresponding wild-type G protein, such as at least or at least about 70% of the level or degree of fusogenic activity of the corresponding wild-type G protein, such as at least or at least about 75% of the level or degree of fusogenic activity of the corresponding wild-type G protein, such as at least or at least about 80% of the level or degree of fusogenic activity of the corresponding wild-type G protein, such as at least or at least about 85% of the level or degree of fusogenic activity of the corresponding wild-type G protein, such as at least or at least about 90% of the level or degree of fusogenic activity of the corresponding wild-type G protein, such as at least or at least about 95% of the level or degree of fusogenic activity of the corresponding wild-type G protein, such as at least or at least about 100% of the level or degree of fusogenic activity of the corresponding wild-type G protein, or such as at least or at least about 120% of the level or degree of fusogenic activity of the corresponding wild-type G protein.

In some embodiments the G protein is a mutant G protein that is a functionally active variant or biologically active portion containing one or more amino acid mutations, such as one or more amino acid insertions, deletions, substitutions or truncations. In some embodiments, the mutations described herein relate to amino acid insertions, deletions, substitutions or truncations of amino acids compared to a reference G protein sequence. In some embodiments, the reference G protein sequence is the wild-type sequence of a G protein or a biologically active portion thereof. In some embodiments, the functionally active variant or the biologically active portion thereof is a mutant of a wild-type Hendra (HeV) virus G protein, a wild-type Nipah (NiV) virus G-protein (NiV-G), a wild-type Cedar (CedPV) virus G-protein, a wild-type Mojiang virus G-protein, a wild-type bat Paramyxovirus G-protein or biologically active portion thereof. In some embodiments, the wild-type G protein has the sequence set forth in any one of SEQ ID NOS: 9, 18, 28, 29, 30, 31 SEQ ID NO: 44, SEQ ID NO: 52 or SEQ ID NO: 54-56.

In some embodiments, the G protein is a mutant G protein that is a biologically active portion that is an N-terminally and/or C-terminally truncated fragment of a wild-type Hendra (HeV) virus G protein, a wild-type Nipah (NiV) virus G-protein (NiV-G), a wild-type Cedar (CedPV) virus G-protein, a wild-type Mojiang virus G-protein, a wild-type bat Paramyxovirus G-protein. In particular embodiments, the truncation is an N-terminal truncation of all or a portion of the cytoplasmic domain. In some embodiments, the mutant G protein is a biologically active portion that is truncated and lacks up to 49 contiguous amino acid residues at or near the N-terminus of the wild-type G protein, such as a wild-type G protein set forth in any one of SEQ ID NOS: 9, 18, 28, 29, 30, 31, SEQ ID NO: 44, SEQ ID NO: 52 or SEQ ID NO: 54-56. In some embodiments, the mutant F protein is truncated and lacks up to 49 contiguous amino acids, such as up to 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 30, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 contiguous amino acids at the N-terminus of the wild-type G protein.

In some embodiments, the G protein is a wild-type Nipah virus G (NiV-G) protein or a Hendra virus G protein, or is a functionally active variant or biologically active portion thereof. In some embodiments, the G protein is a NiV-G protein that has the sequence set forth in SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44, or is a functional variant or a biologically active portion thereof that has an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at least at or about 84%, at least at or about 85%, at least at or about 86%, at least at or about 87%, at least at or about 88%, at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, at least at or about 99% sequence identity to SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44.

In some embodiments, the G protein is a mutant NiV-G protein that is a biologically active portion of a wild-type NiV-G. In some embodiments, the biologically active portion is an N-terminally truncated fragment. In some embodiments, the mutant NiV-G protein is truncated and lacks up to 5 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 6 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 7 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 8 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 9 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 10 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 11 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 12 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 13 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 14 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 15 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 16 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 17 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 18 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 19 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 20 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 21 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 22 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 23 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 24 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 25 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 26 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 27 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 28 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 29 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 30 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 31 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 32 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 33 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 34 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 35 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 36 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 37 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 38 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 39 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 40 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 41 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 42 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 43 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), up to 44 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), or up to 45 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44).

In some embodiments, the NiV-G protein is a biologically active portion that does not contain a cytoplasmic domain. In some embodiments, the NiV-G protein without the cytoplasmic domain is encoded by SEQ ID NO: 32.

In some embodiments, the mutant NiV-G protein comprises a sequence set forth in any of SEQ ID NOS: 10-15, 35-40, 45-50, 22, 53 or SEQ ID NO: 32, or is a functional variant thereof that has an amino acid sequence having at least at or 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NOs: 10-15, 35-40, 45-50, 22, 53 or SEQ ID NO:32.

In some embodiments, the mutant NiV-G protein has a 5 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), such as set forth in SEQ ID NO: 10 or a functional variant thereof having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:10 or such as set forth in SEQ ID NO: 35 or a functional variant thereof having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:35 or such as set forth in SEQ ID NO: 45 or a functional variant thereof having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:45. In some embodiments, the mutant NiV-G protein has a 10 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), such as set forth in SEQ ID NO: 11 or a functional variant thereof having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:11, or such as set forth in SEQ ID NO: 36 or a functional variant thereof having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:36 or such as set forth in SEQ ID NO: 46 or a functional variant thereof having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:46.

In some embodiments, the mutant NiV-G protein has a 15 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), such as set forth in SEQ ID NO: 12 or a functional variant thereof that has an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:12 or such as set forth in SEQ ID NO: 37 or a functional variant thereof having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:37 or such as set forth in SEQ ID NO: 47 or a functional variant thereof having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:47. In some embodiments, the mutant NiV-G protein has a 20 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44) such as set forth in SEQ ID NO: 13, or a functional variant thereof having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:13 or such as set forth in SEQ ID NO: 38 or a functional variant thereof having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:38 or such as set forth in SEQ ID NO: 48 or a functional variant thereof having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:48. In some embodiments, the mutant NiV-G protein has a 25 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), such as set forth in SEQ ID NO: 14 or a functional variant thereof having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:14 or such as set forth in SEQ ID NO: 39 or a functional variant thereof having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:39 or such as set forth in SEQ ID NO: 49 or a functional variant thereof having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:49. In some embodiments, the mutant NiV-G protein has a 30 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), such as set forth in SEQ ID NO: 15 or a functional variant thereof having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:15 or such as set forth in SEQ ID NO: 40 or a functional variant thereof having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:40, or such as set forth in SEQ ID NO: 50 or a functional variant thereof having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:50. In some embodiments, the mutant NiV-G protein has a 34 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), such as set forth in SEQ ID NO: 22 or a functional variant thereof having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:22 or such as set forth in SEQ ID NO: 53 or a functional variant thereof having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:53. In some embodiments, the mutant NiV-G protein lacks the N-terminal cytoplasmic domain of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44), such as set forth in SEQ ID NO:32 or a functional variant thereof having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:32.

In some embodiments, the mutant G protein is a mutant HeV-G protein that has the sequence set forth in SEQ ID NO:18 or 52, or is a functional variant or biologically active portion thereof that has an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at least at or about 84%, at or about 85%, at least at or about 86%, at least at or about 87%, at or about 88%, at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:18 or 52.

In some embodiments, the G protein is a mutant HeV-G protein that is a biologically active portion of a wild-type HeV-G. In some embodiments, the biologically active portion is an N-terminally truncated fragment. In some embodiments, the mutant HeV-G protein is truncated and lacks up to 5 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 6 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 7 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 8 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 9 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 10 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 11 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 12 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 13 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 14 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 15 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 16 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 17 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 18 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 19 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 20 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 21 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 22 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 23 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 24 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 25 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 26 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 27 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 28 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 29 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 30 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 31 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 32 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 33 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 34 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 35 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 36 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 37 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 38 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 39 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 40 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 41 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 42 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 43 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), up to 44 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52), or up to 45 contiguous amino acid residues at or near the N-terminus of the wild-type HeV-G protein (SEQ ID NO:18 or 52). In some embodiments, the HeV-G protein is a biologically active portion that does not contain a cytoplasmic domain. In some embodiments, the mutant HeV-G protein lacks the N-terminal cytoplasmic domain of the wild-type HeV-G protein (SEQ ID NO:18 or 52), such as set forth in SEQ ID NO:33 or a functional variant thereof having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:33.

In some embodiments, the G protein or the functionally active variant or biologically active portion thereof binds to Ephrin B2 or Ephrin B3. In some aspects, the G protein has the sequence of amino acids set forth in any one of SEQ ID NO:9, SEQ ID NO:18 or SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO: 44, SEQ ID NO:30 or SEQ ID NO:31, or is a functionally active variant thereof or a biologically active portion thereof that is able to bind to Ephrin B2 or Ephrin B3. In some embodiments, the functionally active variant or biologically active portion has an amino acid sequence having at least about 80%, at least about 85%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:9, SEQ ID NO:18 or SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO: 44, SEQ ID NO:30 or SEQ ID NO:31, or a functionally active variant or biologically active portion thereof, and retains binding to Ephrhin B2 or B3. Reference to retaining binding to Ephrin B2 or B3 includes binding that is at least or at least about 5% of the level or degree of binding of the corresponding wild-type G protein, such as set forth in SEQ ID NO:9, SEQ ID NO:18 or SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO: 44, SEQ ID NO:30 or SEQ ID NO:31, or a functionally active variant or biologically active portion thereof, 10% of the level or degree of binding of the corresponding wild-type G protein, such as set forth in SEQ ID NO:9, SEQ ID NO:18 or SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO: 44, SEQ ID NO:30 or SEQ ID NO:31, or a functionally active variant or biologically active portion thereof, 15% of the level or degree of binding of the corresponding wild-type G protein, such as set forth in SEQ ID NO:9, SEQ ID NO:18 or SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO: 44, SEQ ID NO:30 or SEQ ID NO:31, or a functionally active variant or biologically active portion thereof, 20% of the level or degree of binding of the corresponding wild-type G protein, such as set forth in SEQ ID NO:9, SEQ ID NO:18 or SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO: 44, SEQ ID NO:30 or SEQ ID NO:31, or a functionally active variant or biologically active portion thereof, 25% of the level or degree of binding of the corresponding wild-type G protein, such as set forth in SEQ ID NO:9, SEQ ID NO:18 or SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO: 44, SEQ ID NO:30 or SEQ ID NO:31, or a functionally active variant or biologically active portion, 30% of the level or degree of binding of the corresponding wild-type G protein, such as set forth in SEQ ID NO:9, SEQ ID NO:18 or SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO: 44, SEQ ID NO:30 or SEQ ID NO:31, or a functionally active variant or biologically active portion thereof, 35% of the level or degree of binding of the corresponding wild-type G protein, such as set forth in SEQ ID NO:9, SEQ ID NO:18 or SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO: 44, SEQ ID NO:30 or SEQ ID NO:31, or a functionally active variant or biologically active portion thereof, 40% of the level or degree of binding of the corresponding wild-type G protein, such as set forth in SEQ ID NO:9, SEQ ID NO:18 or SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO: 44, SEQ ID NO:30 or SEQ ID NO:31, or a functionally active variant or biologically active portion thereof, 45% of the level or degree of binding of the corresponding wild-type G protein, such as set forth in SEQ ID NO:9, SEQ ID NO:18 or SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO: 44, SEQ ID NO:30 or SEQ ID NO:31, or a functionally active variant or biologically active portion thereof, 50% of the level or degree of binding of the corresponding wild-type G protein, such as set forth in SEQ ID NO:9, SEQ ID NO:18 or SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO: 44, SEQ ID NO:30 or SEQ ID NO:31, or a functionally active variant or biologically active portion thereof, 55% of the level or degree of binding of the corresponding wild-type G protein, such as set forth in SEQ ID NO:9, SEQ ID NO:18 or SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO: 44, SEQ ID NO:30 or SEQ ID NO:31, or a functionally active variant or biologically active portion thereof, 60% of the level or degree of binding of the corresponding wild-type G protein, such as set forth in SEQ ID NO:9, SEQ ID NO:18 or SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO: 44, SEQ ID NO:30 or SEQ ID NO:31, or a functionally active variant or biologically active portion thereof, 65% of the level or degree of binding of the corresponding wild-type G protein, such as set forth in SEQ ID NO:9, SEQ ID NO:18 or SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO: 44, SEQ ID NO:30 or SEQ ID NO:31, or a functionally active variant or biologically active portion thereof, 70% of the level or degree of binding of the corresponding wild-type G protein, such as set forth in SEQ ID NO:9, SEQ ID NO:18 or SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO: 44, SEQ ID NO:30 or SEQ ID NO:31, or a functionally active variant or biologically active portion thereof, such as at least or at least about 75% of the level or degree of binding of the corresponding wild-type G protein, such as set forth in SEQ ID NO:9, SEQ ID NO:18 or SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO: 44, SEQ ID NO:30 or SEQ ID NO:31, or a functionally active variant or biologically active portion thereof, such as at least or at least about 80% of the level or degree of binding of the corresponding wild-type G protein, such as set forth in SEQ ID NO:9, SEQ ID NO:18 or SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO: 44, SEQ ID NO:30 or SEQ ID NO:31, or a functionally active variant or biologically active portion thereof, such as at least or at least about 85% of the level or degree of binding of the corresponding wild-type G protein, such as set forth in SEQ ID NO:9, SEQ ID NO:18 or SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO: 44, SEQ ID NO:30 or SEQ ID NO:31, or a functionally active variant or biologically active portion thereof, such as at least or at least about 90% of the level or degree of binding of the corresponding wild-type G protein, such as set forth in SEQ ID NO:9, SEQ ID NO:18 or SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO: 44, SEQ ID NO:30 or SEQ ID NO:31, or a functionally active variant or biologically active portion thereof, or such as at least or at least about 95% of the level or degree of binding of the corresponding wild-type protein, such as set forth in SEQ ID NO:9, SEQ ID NO:18 or SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO: 44, SEQ ID NO:30 or SEQ ID NO:31, or a functionally active variant or biologically active portion thereof. In some embodiments, the G protein is NiV-G or a functionally active variant or biologically active portion thereof and binds to Ephrin B2 or Ephrin B3. In some aspects, the NiV-G has the sequence of amino acids set forth in SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44, or is a functionally active variant thereof or a biologically active portion thereof that is able to bind to Ephrin B2 or Ephrin B3. In some embodiments, the functionally active variant or biologically active portion has an amino acid sequence having at least about 80%, at least about 85%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44 and retains binding to Eprhin B2 or B3. Exemplary biologically active portions include N-terminally truncated variants lacking all or a portion of the cytoplasmic domain, e.g. 1 or more, such as 1 to 49 contiguous N-terminal amino acid residues, e.g. set forth in any one of SEQ ID NOS: 10-15, 35-40, 45-50 and 32. Reference to retaining binding to Ephrin B2 or B3 includes binding that is at least or at least about 5% of the level or degree of binding of the corresponding wild-type NiV-G, such as set forth in SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44, 10% of the level or degree of binding of the corresponding wild-type NiV-G, such as set forth in SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44, 15% of the level or degree of binding of the corresponding wild-type NiV-G, such as set forth in SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44, 20% of the level or degree of binding of the corresponding wild-type NiV-G, such as set forth in SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44, 25% of the level or degree of binding of the corresponding wild-type NiV-G, such as set forth in SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44, 30% of the level or degree of binding of the corresponding wild-type NiV-G, such as set forth in SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44, 35% of the level or degree of binding of the corresponding wild-type NiV-G, such as set forth in SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44, 40% of the level or degree of binding of the corresponding wild-type NiV-G, such as set forth in SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44, 45% of the level or degree of binding of the corresponding wild-type NiV-G, such as set forth in SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44, 50% of the level or degree of binding of the corresponding wild-type NiV-G, such as set forth in SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44, 55% of the level or degree of binding of the corresponding wild-type NiV-G, such as set forth in SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44, 60% of the level or degree of binding of the corresponding wild-type NiV-G, such as set forth in SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44, 65% of the level or degree of binding of the corresponding wild-type NiV-G, such as set forth in SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44, 70% of the level or degree of binding of the corresponding wild-type NiV-G, such as set forth in SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44, such as at least or at least about 75% of the level or degree of binding of the corresponding wild-type NiV-G, such as set forth in SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44, such as at least or at least about 80% of the level or degree of binding of the corresponding wild-type NIV-G, such as set forth in SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44, such as at least or at least about 85% of the level or degree of binding of the corresponding wild-type NiV-G, such as set forth in SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44, such as at least or at least about 90% of the level or degree of binding of the corresponding wild-type NiV-G, such as set forth in SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44, or such as at least or at least about 95% of the level or degree of binding of the corresponding wild-type NiV-G, such as set forth in SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44.

In some embodiments, the G protein is HeV-G or a functionally active variant or biologically active portion thereof and binds to Ephrin B2 or Ephrin B3. In some aspects, the HeV-G has the sequence of amino acids set forth in SEQ ID NO:18 or 52, or is a functionally active variant thereof or a biologically active portion thereof that is able to bind to Ephrin B2 or Ephrin B3. In some embodiments, the functionally active variant or biologically active portion has an amino acid sequence having at least about 80%, at least about 85%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:18 or 52 and retains binding to Eprhin B2 or B3. Exemplary biologically active portions include N-terminally truncated variants lacking all or a portion of the cytoplasmic domain, e.g. 1 or more, such as 1 to 49 contiguous N-terminal amino acid residues, e.g. set forth in any one of SEQ ID NO:33. Reference to retaining binding to Ephrin B2 or B3 includes binding that is at least or at least about 5% of the level or degree of binding of the corresponding wild-type HeV-G, such as set forth in SEQ ID NO:18 or 52, 10% of the level or degree of binding of the corresponding wild-type HeV-G, such as set forth in SEQ ID NO:18 or 52, 15% of the level or degree of binding of the corresponding wild-type HeV-G, such as set forth in SEQ ID NO:18 or 52, 20% of the level or degree of binding of the corresponding wild-type HeV-G, such as set forth in SEQ ID NO:18 or 52, 25% of the level or degree of binding of the corresponding wild-type HeV-G, such as set forth in SEQ ID NO:18 or 52, 30% of the level or degree of binding of the corresponding wild-type HeV-G, such as set forth in SEQ ID NO:18 or 52, 35% of the level or degree of binding of the corresponding wild-type HeV-G, such as set forth in SEQ ID NO:18 or 52, 40% of the level or degree of binding of the corresponding wild-type HeV-G, such as set forth in SEQ ID NO:18 or 52, 45% of the level or degree of binding of the corresponding wild-type HeV-G, such as set forth in SEQ ID NO:18 or 52, 50% of the level or degree of binding of the corresponding wild-type HeV-G, such as set forth in SEQ ID NO:18 or 52, 55% of the level or degree of binding of the corresponding wild-type HeV-G, such as set forth in SEQ ID NO:18 or 52, 60% of the level or degree of binding of the corresponding wild-type HeV-G, such as set forth in SEQ ID NO:18 or 52, 65% of the level or degree of binding of the corresponding wild-type HeV-G, such as set forth in SEQ ID NO:18 or 52, 70% of the level or degree of binding of the corresponding wild-type HeV-G, such as set forth in SEQ ID NO:18 or 52, such as at least or at least about 75% of the level or degree of binding of the corresponding wild-type HeV-G, such as set forth in SEQ ID NO:18 or 52, such as at least or at least about 80% of the level or degree of binding of the corresponding wild-type NIV-G, such as set forth in SEQ ID NO:18 or 52, such as at least or at least about 85% of the level or degree of binding of the corresponding wild-type HeV-G, such as set forth in SEQ ID NO:18 or 52, such as at least or at least about 90% of the level or degree of binding of the corresponding wild-type HeV-G, such as set forth in SEQ ID NO:18 or 52, or such as at least or at least about 95% of the level or degree of binding of the corresponding wild-type HeV-G, such as set forth in SEQ ID NO:18 or 52.

In some embodiments, the G protein or the biologically thereof is a mutant G protein that exhibits reduced binding for the native binding partner of a wild-type G protein. In some embodiments, the mutant G protein or the biologically active portion thereof is a mutant of wild-type Niv-G and exhibits reduced binding to one or both of the native binding partners Ephrin B2 or Ephrin B3. In some embodiments, the mutant G-protein or the biologically active portion, such as a mutant NiV-G protein, exhibits reduced binding to the native binding partner. In some embodiments, the reduced binding to Ephrin B2 or Ephrin B3 is reduced by greater than at or about 5%, at or about 10%, at or about 15%, at or about 20%, at or about 25%, at or about 30%, at or about 40%, at or about 50%, at or about 60%, at or about 70%, at or about 80%, at or about 90%, or at or about 100%.

In some embodiments, the mutations described herein can improve transduction efficiency. In some embodiments, the mutations described herein allow for specific targeting of other desired cell types that are not Ephrin B2 or Ephrin B3. In some embodiments, the mutations described herein result in at least the partial inability to bind at least one natural receptor, such has reduce the binding to at least one of Ephrin B2 or Ephrin B3. In some embodiments, the mutations described herein interfere with natural receptor recognition.

In some embodiments, the G protein contains one or more amino acid substitutions in a residue that is involved in the interaction with one or both of Ephrin B2 and Ephrin B3. In some embodiments, the amino acid substitutions correspond to mutations E501A, W504A, Q530A and E533A with reference to numbering set forth in SEQ ID NO:28.

In some embodiments, the G protein is a mutant G protein containing one or more amino acid substitutions selected from the group consisting of E501A, W504A, Q530A and E533A with reference to numbering set forth in SEQ ID NO:28. In some embodiments, the G protein is a mutant G protein that contains one or more amino acid substitutions elected from the group consisting of E501A, W504A, Q530A and E533A with reference to SEQ ID NO:28 and is a biologically active portion thereof containing an N-terminal truncation. In some embodiments, the mutant NiV-G protein or the biologically active portion thereof is truncated and lacks up to 5 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 6 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 7 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 8 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 9 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), up to 10 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 11 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 12 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 13 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 14 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), up to 15 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 16 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 17 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 18 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 19 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), up to 20 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 21 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 22 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 23 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 24 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), up to 25 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 26 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 27 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 28 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 29 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), up to 30 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (EQ ID NO:28), up to 31 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 32 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 33 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 34 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), 35 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:28), up to 36 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (EQ ID NO:28), up to 37 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (EQ ID NO:28), up to 38 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (EQ ID NO:28), up to 39 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (EQ ID NO:28), or up to 40 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (EQ ID NO:28).

In some embodiments, the mutant NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 16 or 51 or an amino acid sequence having at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:16 or 51. In particular embodiments, the G protein has the sequence of amino acids set forth in SEQ ID NO: 16 or 51.

In some embodiments, the targeted envelope protein contains a G protein or a functionally active variant or biologically active portion and an sdAb variable domain, in which the targeted envelope protein exhibits increased binding for another molecule that is different from the native binding partner of a wild-type G protein. In some embodiments, the molecule can be a protein expressed on the surface of desired target cell. In some embodiments, the increased binding to the other molecule is increased by greater than at or about 25%, at or about 30%, at or about 40%, at or about 50%, at or about 60%, at or about 70%, at or about 80%, at or about 90%, or at or about 100%. In particular embodiments, the binding confers re-targeted binding compared to the binding of a wild-type G protein in which a new or different binding activity is conferred.

2. Binding Domain

In some embodiments, the binding domain can be any agent that binds to a cell surface molecule on a target cells. In some embodiments, the binding domain can be an antibody or an antibody portion or fragment.

The binding domain may be modulated to have different binding strengths. For example, scFvs and antibodies with various binding strengths may be used to alter the fusion activity of the chimeric attachment proteins towards cells that display high or low amounts of the target antigen. For example DARPins with different affinities may be used to alter the fusion activity towards cells that display high or low amounts of the target antigen. Binding domains may also be modulated to target different regions on the target ligand, which will affect the fusion rate with cells displaying the target.

The binding domain may comprise a humanized antibody molecule, intact IgA, IgG, IgE or IgM antibody; bi- or multi-specific antibody (e.g., Zybodies®, etc); antibody fragments such as Fab fragments, Fab′ fragments, F(ab′)2 fragments, Fd′ fragments, Fd fragments, and isolated CDRs or sets thereof; single chain Fvs; polypeptide-Fc fusions; single domain antibodies (e.g., shark single domain antibodies such as IgNAR or fragments thereof); cameloid antibodies; masked antibodies (e.g., Probodies®); Small Modular ImmunoPharmaceuticals (“SMIPsTM”); single chain or Tandem diabodies (TandAb®); VHHs; Anticalins®; Nanobodies®; minibodies; BiTE®s; ankyrin repeat proteins or DARPINs®; Avimers®; DARTs; TCR-like antibodies; Adnectins®; Affilins®; Trans-bodies®; Affibodies®; TrimerX®; MicroProteins; Fynomers®, Centyrins®; and KALBITOR®s. A targeting moiety can also include an antibody or an antigen-binding fragment thereof (e.g., Fab, Fab′, F(ab′)2, Fv fragments, scFv antibody fragments, disulfide-linked Fvs (sdFv), a Fd fragment consisting of the VH and CH1 domains, linear antibodies, single domain antibodies such as sdAb (either VL or VH), nanobodies, or camelid VHH domains), an antigen-binding fibronectin type III (Fn3) scaffold such as a fibronectin polypeptide minibody, a ligand, a cytokine, a chemokine, or a T cell receptor (TCRs).

In some embodiments, the binding domain is a single chain molecule. In some embodiments, the binding domain is a single domain antibody. In some embodiments, the binding domain is a single chain variable fragment. In particular embodiments, the binding domain contains an antibody variable sequence (s) that is human or humanized.

In some embodiments, the binding domain is a single domain antibody. In some embodiments, the single domain antibody can be human or humanized In some embodiments, the single domain antibody or portion thereof is naturally occurring. In some embodiments, the single domain antibody or portion thereof is synthetic.

In some embodiments, the single domain antibodies are antibodies whose complementary determining regions are part of a single domain polypeptide. In some embodiments, the single domain antibody is a heavy chain only antibody variable domain. In some embodiments, the single domain antibody does not include light chains.

In some embodiments, the heavy chain antibody devoid of light chains is referred to as VHH. In some embodiments, the single domain antibody antibodies have a molecular weight of 12-15 kDa. In some embodiments, the single domain antibody antibodies include camelid antibodies or shark antibodies. In some embodiments, the single domain antibody molecule is derived from antibodies raised in Camelidae species, for example in camel, llama, dromedary, alpaca, vicuna and guanaco. In some embodiments, the single domain antibody is referred to as immunoglobulin new antigen receptors (IgNARs) and is derived from cartilaginous fishes. In some embodiments, the single domain antibody is generated by splitting dimeric variable domains of human or mouse IgG into monomers and camelizing critical residues.

In some embodiments, the single domain antibody can be generated from phage display libraries. In some embodiments, the phage display libraries are generated from a VHH repertoire of camelids immunized with various antigens, as described in Arbabi et al., FEBS Letters, 414, 521-526 (1997); Lauwereys et al., EMBO J., 17, 3512-3520 (1998); Decanniere et al., Structure, 7, 361-370 (1999). In some embodiments, the phage display library is generated comprising antibody fragments of a non-immunized camelid. In some embodiments, single domain antibodies a library of human single domain antibodies is synthetically generated by introducing diversity into one or more scaffolds.

In some embodiments, the C-terminus of the single domain antibody is attached to the C-terminus of the G protein or biologically active portion thereof. In some embodiments, the N-terminus of the single domain antibody is exposed on the exterior surface of the lipid bilayer. In some embodiments, the N-terminus of the single domain antibody binds to a cell surface molecule of a target cell. In some embodiments, the single domain antibody specifically binds to a cell surface molecule present on a target cell. In some embodiments, the cell surface molecule is a protein, glycan, lipid or low molecular weight molecule.

In some embodiments, the cell surface molecule of a target cell is an antigen or portion thereof. In some embodiments, the single domain antibody or portion thereof is an antibody having a single monomeric domain antigen binding/recognition domain that is able to bind selectively to a specific antigen. In some embodiments, the single domain antibody binds an antigen present on a target cell.

Exemplary cells include polymorphonuclear cells (also known as PMN, PML, PMNL, or granulocytes), stem cells, embryonic stem cells, neural stem cells, mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), human myogenic stem cells, muscle-derived stem cells (MuStem), embryonic stem cells (ES or ESCs), limbal epithelial stem cells, cardio-myogenic stem cells, cardiomyocytes, progenitor cells, immune effector cells, lymphocytes, macrophages, dendritic cells, natural killer cells, T cells, cytotoxic T lymphocytes, allogenic cells, resident cardiac cells, induced pluripotent stem cells (iPS), adipose-derived or phenotypic modified stem or progenitor cells, CD133+ cells, aldehyde dehydrogenase-positive cells (ALDH+), umbilical cord blood (UCB) cells, peripheral blood stem cells (PBSCs), neurons, neural progenitor cells, pancreatic beta cells, glial cells, or hepatocytes,

In some embodiments, the target cell is a cell of a target tissue. The target tissue can include liver, lungs, heart, spleen, pancreas, gastrointestinal tract, kidney, testes, ovaries, brain, reproductive organs, central nervous system, peripheral nervous system, skeletal muscle, endothelium, inner ear, or eye.

In some embodiments, the target cell is a muscle cell (e.g., skeletal muscle cell), kidney cell, liver cell (e.g. hepatocyte), or a cadiac cell (e.g. cardiomyocyte). In some embodiments, the target cell is a cardiac cell, e.g., a cardiomyocyte (e.g., a quiescent cardiomyocyte), a hepatoblast (e.g., a bile duct hepatoblast), an epithelial cell, a T cell (e.g. a naive T cell), a macrophage (e.g., a tumor infiltrating macrophage), or a fibroblast (e.g., a cardiac fibroblast).

In some embodiments, the target cell is a tumor-infiltrating lymphocyte, a T cell, a neoplastic or tumor cell, a virus-infected cell, a stem cell, a central nervous system (CNS) cell, a hematopoeietic stem cell (HSC), a liver cell or a fully differentiated cell. In some embodiments, the target cell is a CD3+ T cell, a CD4+ Tcell, a CD8+ T cell, a hepatocyte, a haematepoietic stem cell, a CD34+ haematepoietic stem cell, a CD105+ haematepoietic stem cell, a CD117+ haematepoietic stem cell, a CD105+ endothelial cell, a B cell, a CD20+ B cell, a CD19+ B cell, a cancer cell, a CD133+ cancer cell, an EpCAM+ cancer cell, a CD19+ cancer cell, a Her2/Neu+ cancer cell, a GluA2+ neuron, a GluA4+ neuron, a NKG2D+ natural killer cell, a SLC1A3+ astrocyte, a SLC7A10+ adipocyte, or a CD30+ lung epithelial cell.

In some embodiments, the target cell is an antigen presenting cell, an MHC class II+ cell, a professional antigen presenting cell, an atypical antigen presenting cell, a macrophage, a dendritic cell, a myeloid dendritic cell, a plasmacyteoid dendritic cell, a CD11c+ cell, a CD11b+ cell, a splenocyte, a B cell, a hepatocyte, a endothelial cell, or a non-cancerous cell).

In some embodiments, the cell surface molecule is any one of CD8, CD4, asialoglycoprotein receptor 2 (ASGR2), transmembrane 4 L6 family member 5 (TM4SF5), low density lipoprotein receptor (LDLR) or asialoglycoprotein 1 (ASGR1).

In some embodiments, the G protein or functionally active variant or biologically active portion thereof is linked directly to the sdAb variable domain. In some embodiments, the targeted envelope protein is a fusion protein that has the following structure: (N′-single domain antibody-C′)-(C′-G protein-N′).

In some embodiments, the G protein or functionally active variant or biologically active portion thereof is linked indirectly via a linker to the the sdAb variable domain. In some embodiments, the linker is a peptide linker. In some embodiments, the linker is a chemical linker.

In some embodiments, the linker is a peptide linker and the targeted envelope protein is a fusion protein containing the G protein or functionally active variant or biologically active portion thereof linked via a peptide linker to the sdAb variable domain. In some embodiments, the targeted envelope protein is a fusion protein that has the following structure: (N′-single domain antibody-C′)-Linker-(C′-G protein-N′).

In some embodiments, the peptide linker is up to 65 amino acids in length. In some embodiments, the peptide linker comprises from or from about 2 to 65 amino acids, 2 to 60 amino acids, 2 to 56 amino acids, 2 to 52 amino acids, 2 to 48 amino acids, 2 to 44 amino acids, 2 to 40 amino acids, 2 to 36 amino acids, 2 to 32 amino acids, 2 to 28 amino acids, 2 to 24 amino acids, 2 to 20 amino acids, 2 to 18 amino acids, 2 to 14 amino acids, 2 to 12 amino acids, 2 to 10 amino acids, 2 to 8 amino acids, 2 to 6 amino acids, 6 to 65 amino acids, 6 to 60 amino acids, 6 to 56 amino acids, 6 to 52 amino acids, 6 to 48 amino acids, 6 to 44 amino acids, 6 to 40 amino acids, 6 to 36 amino acids, 6 to 32 amino acids, 6 to 28 amino acids, 6 to 24 amino acids, 6 to 20 amino acids, 6 to 18 amino acids, 6 to 14 amino acids, 6 to 12 amino acids, 6 to 10 amino acids, 6 to 8 amino acids, 8 to 65 amino acids, 8 to 60 amino acids, 8 to 56 amino acids, 8 to 52 amino acids, 8 to 48 amino acids, 8 to 44 amino acids, 8 to 40 amino acids, 8 to 36 amino acids, 8 to 32 amino acids, 8 to 28 amino acids, 8 to 24 amino acids, 8 to 20 amino acids, 8 to 18 amino acids, 8 to 14 amino acids, 8 to 12 amino acids, 8 to 10 amino acids, 10 to 65 amino acids, 10 to 60 amino acids, 10 to 56 amino acids, 10 to 52 amino acids, 10 to 48 amino acids, 10 to 44 amino acids, 10 to 40 amino acids, 10 to 36 amino acids, 10 to 32 amino acids, 10 to 28 amino acids, 10 to 24 amino acids, 10 to 20 amino acids, 10 to 18 amino acids, 10 to 14 amino acids, 10 to 12 amino acids, 12 to 65 amino acids, 12 to 60 amino acids, 12 to 56 amino acids, 12 to 52 amino acids, 12 to 48 amino acids, 12 to 44 amino acids, 12 to 40 amino acids, 12 to 36 amino acids, 12 to 32 amino acids, 12 to 28 amino acids, 12 to 24 amino acids, 12 to 20 amino acids, 12 to 18 amino acids, 12 to 14 amino acids, 14 to 65 amino acids, 14 to 60 amino acids, 14 to 56 amino acids, 14 to 52 amino acids, 14 to 48 amino acids, 14 to 44 amino acids, 14 to 40 amino acids, 14 to 36 amino acids, 14 to 32 amino acids, 14 to 28 amino acids, 14 to 24 amino acids, 14 to 20 amino acids, 14 to 18 amino acids, 18 to 65 amino acids, 18 to 60 amino acids, 18 to 56 amino acids, 18 to 52 amino acids, 18 to 48 amino acids, 18 to 44 amino acids, 18 to 40 amino acids, 18 to 36 amino acids, 18 to 32 amino acids, 18 to 28 amino acids, 18 to 24 amino acids, 18 to 20 amino acids, 20 to 65 amino acids, 20 to 60 amino acids, 20 to 56 amino acids, 20 to 52 amino acids, 20 to 48 amino acids, 20 to 44 amino acids, 20 to 40 amino acids, 20 to 36 amino acids, 20 to 32 amino acids, 20 to 28 amino acids, 20 to 26 amino acids, 20 to 24 amino acids, 24 to 65 amino acids, 24 to 60 amino acids, 24 to 56 amino acids, 24 to 52 amino acids, 24 to 48 amino acids, 24 to 44 amino acids, 24 to 40 amino acids, 24 to 36 amino acids, 24 to 32 amino acids, 24 to 30 amino acids, 24 to 28 amino acids, 28 to 65 amino acids, 28 to 60 amino acids, 28 to 56 amino acids, 28 to 52 amino acids, 28 to 48 amino acids, 28 to 44 amino acids, 28 to 40 amino acids, 28 to 36 amino acids, 28 to 34 amino acids, 28 to 32 amino acids, 32 to 65 amino acids, 32 to 60 amino acids, 32 to 56 amino acids, 32 to 52 amino acids, 32 to 48 amino acids, 32 to 44 amino acids, 32 to 40 amino acids, 32 to 38 amino acids, 32 to 36 amino acids, 36 to 65 amino acids, 36 to 60 amino acids, 36 to 56 amino acids, 36 to 52 amino acids, 36 to 48 amino acids, 36 to 44 amino acids, 36 to 40 amino acids, 40 to 65 amino acids, 40 to 60 amino acids, 40 to 56 amino acids, 40 to 52 amino acids, 40 to 48 amino acids, 40 to 44 amino acids, 44 to 65 amino acids, 44 to 60 amino acids, 44 to 56 amino acids, 44 to 52 amino acids, 44 to 48 amino acids, 48 to 65 amino acids, 48 to 60 amino acids, 48 to 56 amino acids, 48 to 52 amino acids, 50 to 65 amino acids, 50 to 60 amino acids, 50 to 56 amino acids, 50 to 52 amino acids, 54 to 65 amino acids, 54 to 60 amino acids, 54 to 56 amino acids, 58 to 65 amino acids, 58 to 60 amino acids, or 60 to 65 amino acids. In some embodiments, the peptide linker is a polypeptide that is 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, or 65 amino acids in length.

In particular embodiments, the linker is a flexible peptide linker. In some such embodiments, the linker is 1-20 amino acids, such as 1-20 amino acids predominantly composed of glycine. In some embodiments, the linker is 1-20 amino acids, such as 1-20 amino acids predominantly composed of glycine and serine. In some embodiments, the linker is a flexible peptide linker containing amino acids Glycine and Serine, referred to as GS-linkers. In some embodiments, the peptide linker includes the sequences GS, GGS, GGGGS (SEQ ID NO:43), GGGGGS (SEQ ID NO:41) or combinations thereof. In some embodiments, the polypeptide linker has the sequence (GGS)n, wherein n is 1 to 10. In some embodiments, the polypeptide linker has the sequence (GGGGS)n, (SEQ ID NO:42) wherein n is 1 to 10. In some embodiments, the polypeptide linker has the sequence (GGGGGS)n (SEQ ID NO:27), wherein n is 1 to 6.

3. Polynucleotides

Provided herein are polynucleotides comprising a nucleic acid sequence encoding a targeted envelope protein. In some embodiments, the polynucleotides comprise a nucleic acid sequence encoding a G protein or biologically active portion thereof. In some embodiments, the polynucleotides further comprise a nucleic acid sequence encoding a single domain antibody (sdAb) variable domain or biologically active portion thereof. The polynucleotides may include a sequence of nucleotides encoding any of the targeted envelope proteins described above. The polynucleotide can be a synthetic nucleic acid. Also provided are expression vector containing any of the provided polynucleotides.

In some of any embodiments, expression of natural or synthetic nucleic acids is typically achieved by operably linking a nucleic acid encoding the gene of interest to a promoter and incorporating the construct into an expression vector. In some embodiments, vectors can be suitable for replication and integration in eukaryotes. In some embodiments, cloning vectors contain transcription and translation terminators, initiation sequences, and promoters useful for expression of the desired nucleic acid sequence. In some of any embodiments, a plasmid comprises a promoter suitable for expression in a cell.

In some embodiments, the polynucleotides contain at least one promoter that is operatively linked to control expression of the targeted envelope protein containing the G protein and the single domain antibody (sdAb) variable domain. For expression of the targeted envelope protein, at least one module in each promoter functions to position the start site for RNA synthesis. The best known example of this is the TATA box, but in some promoters lacking a TATA box, such as the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the SV40 genes, a discrete element overlying the start site itself helps to fix the place of initiation.

In some embodiments, additional promoter elements, e.g., enhancers, regulate the frequency of transcriptional initiation. In some embodiments, additional promoter elements are located in the region 30-110 bp upstream of the start site, although a number of promoters have recently been shown to contain functional elements downstream of the start site as well. In some embodiments, spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In some embodiments, the thymidine kinase (tk) promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. In some embodiments, depending on the promoter, individual elements can function either cooperatively or independently to activate transcription.

A promoter may be one naturally associated with a gene or polynucleotide sequence, as may be obtained by isolating the 5′ non-coding sequences located upstream of the coding segment and/or exon. Such a promoter can be referred to as “endogenous.” Similarly, an enhancer may be one naturally associated with a polynucleotide sequence, located either downstream or upstream of that sequence. Alternatively, certain advantages will be gained by positioning the coding polynucleotide segment under the control of a recombinant or heterologous promoter, which refers to a promoter that is not normally associated with a polynucleotide sequence in its natural environment. A recombinant or heterologous enhancer refers also to an enhancer not normally associated with a polynucleotide sequence in its natural environment. Such promoters or enhancers may include promoters or enhancers of other genes, and promoters or enhancers isolated from any other prokaryotic, viral, or eukaryotic cell, and promoters or enhancers not “naturally occurring,” i.e., containing different elements of different transcriptional regulatory regions, and/or mutations that alter expression. In addition to producing nucleic acid sequences of promoters and enhancers synthetically, sequences may be produced using recombinant cloning and/or nucleic acid amplification technology, including PCR, in connection with the compositions disclosed herein (U.S. Pat. Nos. 4,683,202 and 5,928,906).

In some embodiments, a suitable promoter is the immediate early cytomegalovirus (CMV) promoter sequence. In some embodiments, the promoter sequence is a strong constitutive promoter sequence capable of driving high levels of expression of any polynucleotide sequence operatively linked thereto. In some embodiments, a suitable promoter is Elongation Growth Factor-la (EF-1 a). In some embodiments, other constitutive promoter sequences may also be used, including, but not limited to the simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, an avian leukemia virus promoter, an Epstein-Barr virus immediate early promoter, a Rous sarcoma virus promoter, as well as human gene promoters such as, but not limited to, the actin promoter, the myosin promoter, the hemoglobin promoter, and the creatine kinase promoter.

In some embodiments, the promoter is an inducible promoter. In some embodiments, the inducible promoter provides a molecular switch capable of turning on expression of the polynucleotide sequence which it is operatively linked when such expression is desired, or turning off the expression when expression is not desired. In some embodiments, inducible promoters comprise metallothionine promoter, a glucocorticoid promoter, a progesterone promoter, and a tetracycline promoter.

In some embodiments, exogenously controlled inducible promoters can be used to regulate expression of the G protein and single domain antibody (sdAb) variable domain. For example, radiation-inducible promoters, heat-inducible promoters, and/or drug-inducible promoters can be used to selectively drive transgene expression in, for example, targeted regions. In such embodiments, the location, duration, and level of transgene expression can be regulated by the administration of the exogenous source of induction.

In some embodiments, expression of the targeted envelope protein containing a G protein and single domain antibody (sdAb) variable domain is regulated using a drug-inducible promoter. For example, in some cases, the promoter, enhancer, or transactivator comprises a Lac operator sequence, a tetracycline operator sequence, a galactose operator sequence, a doxycycline operator sequence, a rapamycin operator sequence, a tamoxifen operator sequence, or a hormone-responsive operator sequence, or an analog thereof. In some instances, the inducible promoter comprises a tetracycline response element (TRE). In some embodiments, the inducible promoter comprises an estrogen response element (ERE), which can activate gene expression in the presence of tamoxifen. In some instances, a drug-inducible element, such as a TRE, can be combined with a selected promoter to enhance transcription in the presence of drug, such as doxycycline. In some embodiments, the drug-inducible promoter is a small molecule-inducible promoter.

Any of the provided polynucleotides can be modified to remove CpG motifs and/or to optimize codons for translation in a particular species, such as human, canine, feline, equine, ovine, bovine, etc. species. In some embodiments, the polynucleotides are optimized for human codon usage (i.e., human codon-optimized). In some embodiments, the polynucleotides are modified to remove CpG motifs. In other embodiments, the provided polynucleotides are modified to remove CpG motifs and are codon-optimized, such as human codon-optimized. Methods of codon optimization and CpG motif detection and modification are well-known. Typically, polynucleotide optimization enhances transgene expression, increases transgene stability and preserves the amino acid sequence of the encoded polypeptide.

In order to assess the expression of the targeted envelope protein, the expression vector to be introduced into a cell can also contain either a selectable marker gene or a reporter gene or both to facilitate identification and selection of expressing particles, e.g. viral particles. In other embodiments, the selectable marker may be carried on a separate piece of DNA and used in a co-transfection procedure. Both selectable markers and reporter genes may be flanked with appropriate regulatory sequences to enable expression in the host cells. Useful selectable markers are known in the art and include, for example, antibiotic-resistance genes, such as neo and the like.

Reporter genes are used for identifying potentially transfected cells and for evaluating the functionality of regulatory sequences. Reporter genes that encode for easily assayable proteins are well known in the art. In general, a reporter gene is a gene that is not present in or expressed by the recipient organism or tissue and that encodes a protein whose expression is manifested by some easily detectable property, e.g., enzymatic activity. Expression of the reporter gene is assayed at a suitable time after the DNA has been introduced into the recipient cells.

Suitable reporter genes may include genes encoding luciferase, beta-galactosidase, chloramphenicol acetyl transferase, secreted alkaline phosphatase, or the green fluorescent protein gene (see, e.g., Ui-Tei et al., 2000, FEBS Lett. 479:79-82). Suitable expression systems are well known and may be prepared using well known techniques or obtained commercially. Internal deletion constructs may be generated using unique internal restriction sites or by partial digestion of non-unique restriction sites. Constructs may then be transfected into cells that display high levels of the desired polynucleotide and/or polypeptide expression. In general, the construct with the minimal 5′ flanking region showing the highest level of expression of reporter gene is identified as the promoter. Such promoter regions may be linked to a reporter gene and used to evaluate agents for the ability to modulate promoter-driven transcription.

B. Fusogen (e.g. Henipavirus F Protein)

In some embodiments, the targeted lipid particle comprises one or more fusogens. In some embodiments, the targeted lipid particle contains an exogenous or overexpressed fusogen. In some embodiments, the fusogen is disposed in the lipid bilayer. In some embodiments, the fusogen facilitates the fusion of the targeted lipid particle to a membrane. In some embodiments, the membrane is a plasma cell membrane.

In some embodiments, fusogens comprise protein based, lipid based, and chemical based fusogens. In some embodiments, the targeted lipid particle comprises a first fusogen comprising a protein fusogen and a second fusogen comprising a lipid fusogen or chemical fusogen. In some embodiments, the fusogen binds fusogen binding partner on a target cell surface.

In some embodiments, the fusogen comprises a protein with a hydrophobic fusion peptide domain. In some embodiments, the fusogen comprises a henipavirus F protein molecule or biologically active portion thereof. In some embodiments, the Henipavirus F protein is a Hendra (Hey) virus F protein, a Nipah (NiV) virus F-protein, a Cedar (CedPV) virus F protein, a Mojiang virus F protein or a bat Paramyxovirus F protein or a biologically active portion thereof.

Table 4 provides non-limiting examples of F proteins. In some embodiments, the N-terminal hydrophobic fusion peptide domain of the F protein molecule or biologically active portion thereof is exposed on the outside of lipid bilayer.

F proteins of henipaviruses are encoded as F₀ precursors containing a signal peptide (e.g. corresponding to amino acid residues 1-26 of SEQ ID NO:1). Following cleavage of the signal peptide, the mature F₀ (e.g. SEQ ID NO:2) is transported to the cell surface, then endocytosed and cleaved by cathepsin L (e.g. between amino acids 109-110 of SEQ ID NO:1) into the mature fusogenic subunits F1 (e.g. corresponding to amino acids 110-546 of SEQ ID NO:1; set forth in SEQ ID NO:4) and F2 (e.g. corresponding to amino acid residues 27-109 of SEQ ID NO:1; set forth in SEQ ID NO:3). The F1 and F2 subunits are associated by a disulfide bond and recycled back to the cell surface. The F1 subunit contains the fusion peptide domain located at the N terminus of the F1 subunit (e.g. .g. corresponding to amino acids 110-129 of SEQ ID NO:1) where it is able to insert into a cell membrane to drive fusion. In particular cases, fusion activity is blocked by association of the F protein with G protein, until G engages with a target molecule resulting in its disassociation from F and exposure of the fusion peptide to mediate membrane fusion.

Among different henipavirus species, the sequence and activity of the F protein is highly conserved. For examples, the F protein of NiV and HeV viruses share 89% amino acid sequence identity. Further, in some cases, the henipavirus F proteins exhibit compatibility with G proteins from other species to trigger fusion (Brandel-Tretheway et al. Journal of Virology. 2019. 93(13):e00577-19). In some aspects or the provided re-targeted lipid particles, the F protein is heterologous to the G protein, i.e. the F and G protein or biologically active portions are from different henipavirus species. For example, the F protein is from Hendra virus and the G protein is from Nipah virus. In other aspects, the F protein can be a chimeric F protein containing regions of F proteins from different species of Henipavirus. In some embodiments, switching a region of amino acid residues of the F protein from one species of Henipavirus to another can result in fusion to the G protein of the species comprising the amino acid insertion. (Brandel-Tretheway et al. 2019). In some cases, the chimeric F protein contains an extracellular domain from one henipavirus species and a transmembrane and/or cytoplasmic domain from a different henipavirus species. For example, the F protein contains an extracellular domain of Hendra virus and a transmembrane/cytoplasmic domain of Nipah virus. F protein sequences disclosed herein are predominantly disclosed as expressed sequences including an N-terminal signal sequence. As such N-terminal signal sequences are commonly cleaved co- or post-translationally, the mature protein sequences for all F protein sequences disclosed herein are also contemplated as lacking the N-terminal signal sequence.

TABLE 4
Henipavirus F sequence clusters. Column 1, Genbank ID includes the Genbank ID of
the whole genome sequence of the virus that is the centroid sequence of the cluster. Column 2,
Nucleotides of CDS provides the nucleotides corresponding to the CDS of the gene in the whole
genome. Column 3, Full Gene Name, provides the full name of the gene including Genbank ID,
virus species, strain, and protein name. Nipah virus F protein is >80% identical to that of
Hendra virus and is found within the same sequence cluster. Column 4, Sequence, provides the
amino acid sequence of the gene. Column 5, #Sequences/Cluster, provides the number of
sequences that cluster with this centroid sequence. Column 6 provides the SEQ ID numbers for
the described sequences.
						SEQ
						ID
Gen-	Nucleotides				SEQ	(without
bank	of	Full Gene		#Sequences/	ID	signal
ID	CDS	Name	Sequence	Cluster	NO	sequence)
AF	6618	gb: AF017149|	MATQEVRLKCLLCGIIVLVLSLEGLGILHYEK	29	17	59
017	-	Organism: Hen	LSKIGLVKGITRKYKIKSNPLTKDIVIKMIPNVS
149	8258	dra virus|Strain	NVSKCTGTVMENYKSRLTGILSPIKGAIELYN
		Name: UNKN	NNTHDLVGDVKLAGVVMAGIAIGIATAAQIT
		OWN-	AGVALYEAMKNADNINKLKSSIESTNEAVVK
		AF017149|Prot	LQETAEKTVYVLTALQDYINTNLVPTIDQISC
		ein	KQTELALDLALSKYLSDLLFVFGPNLQDPVSN
		Name: fusion|G	SMTIQAISQAFGGNYETLLRTLGYATEDFDDL
		ene Symbol: F	LESDSIAGQIVYVDLSSYYIIVRVYFPILTEIQQ
			AYVQELLPVSENNDNSEWISIVPNEVLIRNTLI
			SNIEVKYCLITKKSVICNQDYATPMTASVREC
			LTGSTDKCPRELVVSSHVPRFALSGGVLFANC
			ISVTCQCQTTGRAISQSGEQTLLMIDNTTCTTV
			VLGNIIISLGKYLGSINYNSESIAVGPPVYTDK
			VDISSQISSMNQSLQQSKDYIKEAQKILDTVNP
			SLISMLSMIILYVLSIAALCIGLITFISFVIVEKK
			RGNYSRLDDRQVRPVSNGDLYYIGT
Q9I		Additional in	MVVILDKRCYCNLLILILMISECSVGILHYEKL	1	2
H6		cluster:	SKIGLVKGVTRKYKIKSNPLTKDIVIKMIPNVS
3		sp|Q9IH63|FU	NMSQCTGSVMENYKTRLNGILTPIKGALEIYK
		S_NIPAV	NNTHDLVGDVRLAGVIMAGVAIGIATAAQIT
		Fusion	AGVALYEAMKNADNINKLKSSIESTNEAVVK
		glycoprotein	LQETAEKTVYVLTALQDYINTNLVPTIDKISC
		F0 OS = Nipah	KQTELSLDLALSKYLSDLLFVFGPNLQDPVSN
		virus	SMTIQAISQAFGGNYETLLRTLGYATEDFDDL
			LESDSITGQIIYVDLSSYYIIVRVYFPILTEIQQA
			YIQELLPVSFNNDNSEWISIVPNFILVRNTLISN
			IEIGFCLITKRSVICNQDYATPMTNNMRECLTG
			STEKCPRELVVSSHVPRFALSNGVLFANCISVT
			CQCQTTGRAISQSGEQTLLMIDNTTCPTAVLG
			NVIISLGKYLGSVNYNSEGIAIGPPVFTDKVDI
			SSQISSMNQSLQQSKDYIKEAQRLLDTVNPSLI
			SMLSMIILYVLSIASLCIGLITFISFIIVEKKRNT
			YSRLEDRRVRPTSSGDLYYIGT
JQ	6129	gb: JQ001776: 6	MSNKRTTVLIIISYTLFYLNNAAIVGFDFDKLN	3	24	57
001	-	129-	KIGVVQGRVLNYKIKGDPMTKDLVLKFIPNIV
776	8166	8166|Organism:	NITECVREPLSRYNETVRRLLLPIHNMLGLYL
		Cedar	NNTNAKMTGLMIAGVIMGGIAIGIATAAQITA
		virus|Strain	GFALYEAKKNTENIQKLTDSIMKTQDSIDKLT
		Name: CG1a|Pr	DSVGTSILILNKLQTYINNQLVPNLELLSCRQN
		otein	KOEFDLMLTKYLVDLMTVIGPNINNPVNKDM
		Name: fusion	TIQSLSLLFDGNYDIMMSELGYTPQDFLDLIES
		glycoprotein|G	KSITGQIIYVDMENLYVVIRTYLPTHEVPDAQI
		ene Symbol: F	YEFNKITMSSNGGEYLSTIPNFILIRGNYMSNI
			DVATCYMTKASVICNQDYSLPMSQNLRSCYQ
			GETEYCPVEAVIASHSPRFALTNGVIFANCINT
			ICRCQDNGKTITQNINQFVSMIDNSTCNDVMV
			DKFTIKVGKYMGRKDINNINIQIGPQIIIDKVD
			LSNEINKMNQSLKDSIFYLREAKRILDSVNISLI
			SPSVQLFLIIISVLSFIILLIIIVYLYCKSKHSYKY
			NKFIDDPDYYNDYKRERINGKASKSNNIYYV
			GD
NC_	5950	gb: NC_025352:	MALNKNMFSSLFLGYLLVYATTVQSSIHYDS	2	25	60
02	-	5950-	LSKVGVIKGLTYNYKIKGSPSTKLMVVKLIPNI
535	8712	8712|Organism:	DSVKNCTQKQYDEYKNLVRKALEPVKMAID
2		Mojiang	TMLNNVKSGNNKYRFAGAIMAGVALGVATA
		virus|Strain	ATVTAGIALHRSNENAQAIANMKSAIQNTNE
		Name: Tonggua	AVKQLQLANKQTLAVIDTIRGEINNNIIPVINQ
		n1|Protein	LSCDTIGLSVGIRLTQYYSEIITAFGPALQNPV
		Name: fusion	NTRITIQAISSVFNGNFDELLKIMGYTSGDLYE
		protein|Gene	ILHSELIRGNIIDVDVDAGYIALEIEFPNLTLVP
		Symbol: F	NAVVQELMPISYNIDGDEWVTLVPRFVLTRTT
			LLSNIDTSRCTITDSSVICDNDYALPMSHELIG
			CLQGDTSKCAREKVVSSYVPKFALSDGLVYA
			NCLNTICRCMDTDTPISQSLGATVSLLDNKRC
			SVYQVGDVLISVGSYLGDGEYNADNVELGPPI
			VIDKIDIGNQLAGINQTLQEAEDYIEKSEEFLK
			GVNPSIITLGSMVVLYIFMILIAIVSVIALVLSIK
			LTVKGNVVRQQFTYTQHVPSMENINYVSH
NC_	6865	gb: NC_025256:	MKKKTDNPTISKRGHNHSRGIKSRALLRETDN	2	26	58
02	-	6865-	YSNGLIVENLVRNCHHPSKNNLNYTKTQKRD
525	8853	8853|Organism:	STIPYRVEERKGHYPKIKHLIDKSYKHIKRGKR
6		Bat	RNGHNGNIITIILLLILILKTQMSEGAIHYETLS
		Paramyxovirus	KIGLIKGITREYKVKGTPSSKDIVIKLIPNVTGL
		Eid_he1/GH-	NKCTNISMENYKEQLDKILIPIINNIIELYANSTK
		M74a/GHA/20	SAPGNARFAGVIIAGVALGVAAAAQITAGIAL
		09|Strain	HEARQNAERINLLKDSISATNNAVAELQEATG
		Name: BatPV/E	GIVNVITGMQDYINTNLVPQIDKLQCSQIKTA
		id_he1/GH-	LDISLSQYYSEILTVFGPNLQNPVTTSMSIQAIS
		M74a/GHA/20	QSFGGNIDLLLNLLGYTANDLLDLLESKSITG
		09|Protein	QITYINLEHYFMVIRVYYPIMTTISNAYVQELI
		Name: fusion	KISFNVDGSEWVSLVPSYILIRNSYLSNIDISEC
		protein|Gene	LITKNSVICRHDFAMPMSYTLKECLTGDTEKC
		Symbol: F	PREAVVTSYVPRFAISGGVIYANCLSTTCQCY
			QTGKVIAQDGSQTLMMIDNQTCSIVRIEEILIS
			TGKYLGSQEYNTMHVSVGNPVFTDKLDITSQI
			SNINQSIEQSKFYLDKSKAILDKINLNLIGSVPI
			SILFIIAILSLILSIITFVIVMIIVRRYNKYTPLINS
			DPSSRRSTIQDVYIIPNPGEHSIRSAARSIDRDR
			D

In some embodiments, the F protein is encoded by a nucleotide sequence that encodes the sequence set forth by any one of SEQ ID NOs: 1, 2, 17, 24, 25, 26 or 57-60 or is a functionally active variant or a biologically active portion thereof that has a sequence that is at least at or about 80%, at least at or about 85%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% identical to any one of SEQ ID NOS: 1, 2, 17, 24, 25, 26 or 57-60. In particular embodiments, the F protein or the functionally active variant or biologically active portion thereof retains fusogenic activity in conjunction with a Henipavirus G protein, such as a G protein set forth in Section I.A (e.g. NiV-G or HeV-G). Fusogenic activity includes the activity of the F protein in conjunction with a Henipavirus G protein to promote or facilitate fusion of two membrane lumens, such as the lumen of the targeted lipid particle having embedded in its lipid bilayer a henipavirus F and G protein, and a cytoplasm of a target cell, e.g. a cell that contains a surface receptor or molecule that is recognized or bound by the targeted envelope protein. In some embodiments, the F protein and G protein are from the same Henipavirus species (e.g. NiV-G and NiV-F). In some embodiments, the F protein and G protein are from different Henipavirus species (e.g. NiV-G and HeV-F). In particular embodiments, the F protein of the functionally active variant or biologically active portion retains the cleavage site cleaved by cathepsin L (e.g. corresponding to the cleavage site between amino acids 109-110 of SEQ ID NO:1).

In particular embodiments, the F protein has the sequence of amino acids set forth in SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:17, SEQ ID NO: 24, SEQ ID NO:25, SEQ ID NO: 26, SEQ ID NO: 57, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, or SEQ ID NO: 60 or is a functionally active variant thereof or a biologically active portion thereof that retains fusogenic activity. In some embodiments, the functionally active variant comprises an amino acid sequence having at least at or about 80%, at least at or about 85%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:17, SEQ ID NO: 24, SEQ ID NO:25, SEQ ID NO: 26, SEQ ID NO: 57, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, or SEQ ID NO: 60 and retains fusogenic activity in conjunction with a Henipavirus G protein (e.g., NiV-G or HeV-G). In some embodiments, the biologically active portion has an amino acid sequence having at least at or about 80%, at least at or about 85%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:17, SEQ ID NO: 24, SEQ ID NO:25, SEQ ID NO: 26, SEQ ID NO: 57, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, or SEQ ID NO: 60 and retains fusogenic activity in conjunction with a Henipavirus G protein (e.g., NiV-G or HeV-G).

Reference to retaining fusogenic activity includes activity (in conjunction with a Henipavirus G protein) that between at or about 10% and at or about 150% or more of the level or degree of binding of the corresponding wild-type F protein, such as set forth in SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:17, SEQ ID NO: 24, SEQ ID NO:25, SEQ ID NO: 26, SEQ ID NO: 57, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, or SEQ ID NO: 60, such as at least or at least about 10% of the level or degree of fusogenic activity of the corresponding wild-type F protein, such as at least or at least about 15% of the level or degree of fusogenic activity of the corresponding wild-type F protein, such as at least or at least about 20% of the level or degree of fusogenic activity of the corresponding wild-type F protein, such as at least or at least about 25% of the level or degree of fusogenic activity of the corresponding wild-type F protein, such as at least or at least about 30% of the level or degree of fusogenic activity of the corresponding wild-type F protein, such as at least or at least about 35% of the level or degree of fusogenic activity of the corresponding wild-type F protein, such as at least or at least about 40% of the level or degree of fusogenic activity of the corresponding wild-type F protein, such as at least or at least about 45% of the level or degree of fusogenic activity of the corresponding wild-type F protein, such as at least or at least about 50% of the level or degree of fusogenic activity of the corresponding wild-type F protein, such as at least or at least about 55% of the level or degree of fusogenic activity of the corresponding wild-type f protein, such as at least or at least about 60% of the level or degree of fusogenic activity of the corresponding wild-type F protein, such as at least or at least about 65% of the level or degree of fusogenic activity of the corresponding wild-type F protein, such as at least or at least about 70% of the level or degree of fusogenic activity of the corresponding wild-type F protein, such as at least or at least about 75% of the level or degree of fusogenic activity of the corresponding wild-type F protein, such as at least or at least about 80% of the level or degree of fusogenic activity of the corresponding wild-type F protein, such as at least or at least about 85% of the level or degree of fusogenic activity of the corresponding wild-type F protein, such as at least or at least about 90% of the level or degree of fusogenic activity of the corresponding wild-type F protein, such as at least or at least about 95% of the level or degree of fusogenic activity of the corresponding wild-type F protein, such as at least or at least about 100% of the level or degree of fusogenic activity of the corresponding wild-type F protein, or such as at least or at least about 120% of the level or degree of fusogenic activity of the corresponding wild-type F protein.

In some embodiments, the F protein is a mutant F protein that is a functionally active fragment or a biologically active portion containing one or more amino acid mutations, such as one or more amino acid insertions, deletions, substitutions or truncations. In some embodiments, the mutations described herein relate to amino acid insertions, deletions, substitutions or truncations of amino acids compared to a reference F protein sequence. In some embodiments, the reference F protein sequence is the wild-type sequence of an F protein or a biologically active portion thereof. In some embodiments, the mutant F protein or the biologically active portion thereof is a mutant of a wild-type Hendra (Hey) virus F protein, a Nipah (NiV) virus F-protein, a Cedar (CedPV) virus F protein, a Mojiang virus F protein or a bat Paramyxovirus F protein. In some embodiments, the wild-type F protein is encoded by a sequence of nucleotides that encodes any one of SEQ ID NO: 1, 2, 17, 24, 25, 26, or 57-60.

In some embodiments, the mutant F protein is a biologically active portion of a wild-type F protein that is an N-terminally and/or C-terminally truncated fragment. In some embodiments, the mutant F protein or the biologically active portion of a wild-type F protein thereof comprises one or more amino acid substitutions. In some embodiments, the mutations described herein can improve transduction efficiency. In some embodiments, the mutations described herein can increase fusogenic capacity. Exemplary mutations include any as described, see e.g. Khetawat and Broder 2010 Virology Journal 7:312; Witting et al. 2013 Gene Therapy 20:997-1005; published international; patent application No. WO/2013/148327.

In some embodiments, the mutant F protein is a biologically active portion that is truncated and lacks up to 20 contiguous amino acid residues at or near the C-terminus of the wild-type F protein, such as a wild-type F protein encoded by a sequence of nucleotides encoding the F protein set forth in any one of SEQ ID NOS: 1, 17, 24, 25 or 26. In some embodiments, the mutant F protein is truncated and lacks up to 19 contiguous amino acids, such as up to 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 contiguous amino acids at the C-terminus of the wild-type F protein.

In some embodiments, the F protein or the functionally active variant or biologically active portion thereof comprises an F1 subunit or a fusogenic portion thereof. In some embodiments, the F1 subunit is a proteolytically cleaved portion of the F0 precursor. In some embodiments, the F0 precursor is inactive. In some embodiments, the cleavage of the F0 precursor forms a disulfide-linked F1+F2 heterodimer. In some embodiments, the cleavage exposes the fusion peptide and produces a mature F protein. In some embodiments, the cleavage occurs at or around a single basic residue. In some embodiments, the cleavage occurs at Arginine 109 of NiV-F protein. In some embodiments, cleavage occurs at Lysine 109 of the Hendra virus F protein.

In some embodiments, the F protein is a wild-type Nipah virus F (NiV-F) protein or is a functionally active variant or biologically active portion thereof. In some embodiments, the F₀ precursor is encoded by a sequence of nucleotides encoding the sequence set forth in SEQ ID NO: 1. The encoding nucleic acid can encode a signal peptide sequence that has the sequence MVVILDKRCY CNLLILILMI SECSVG (SEQ ID NO: 34). In some embodiments, the F protein has the sequence set forth in SEQ ID NO:2. In some examples, the F protein is cleaved into an F1 subunit comprising the sequence set forth in SEQ ID NO:4 and an F2 subunit comprising the sequence set forth in SEQ ID NO: 3.

In some embodiments, the F protein is a NiV-F protein that is encoded by a sequence of nucleotides encoding the sequence set forth in SEQ ID NO:1, or is a functionally active variant or biologically active portion thereof that has an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at least at or about 84%, at least at or about 85%, at or about 86%, at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 1. In some embodiments, the NiV-F-protein has the sequence of set forth in SEQ ID NO: 2, or is a functionally active variant or a biologically active portion thereof that has an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at least at or about 84%, at least at or about 85%, at or about 86%, at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 2. In particular embodiments, the F protein or the functionally active variant or biologically active portion thereof retains the cleavage site cleaved by cathepsin L (e.g. corresponding to the cleavage site between amino acids 109-110 of SEQ ID NO:1).

In some embodiments, the F protein or the functionally active variant or the biologically active portion thereof includes an F1 subunit that has the sequence set forth in SEQ ID NO: 4, or an amino acid sequence having, at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at least at or about 84%, at least at or about 85%, at or about 86%, at least at or about 87%, at least at or about 88%, or at least at or about 89% at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:4.

In some embodiments, the F protein or the functionally active variant or biologically active portion thereof includes an F2 subunit that has the sequence set forth in SEQ ID NO: 3, or an amino acid sequence having, at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at least at or about 84%, at least at or about 85%, at or about 86%, at least at or about 87%, at least at or about 88%, or at least at or about 89% at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:3.

In some embodiments, the F protein is a mutant NiV-F protein that is a biologically active portion thereof that is truncated and lacks up to 20 contiguous amino acid residues at or near the C-terminus of the wild-type NiV-F protein (e.g. set forth SEQ ID NO:2). In some embodiments, the mutant NiV-F protein comprises an amino acid sequence set forth in SEQ ID NO:5. In some embodiments, the mutant NiV-F protein has a sequence that has at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 5. In some embodiments, the mutant F protein contains an F1 protein that has the sequence set forth in SEQ ID NO:6. In some embodiments, the mutant F protein has a sequence that has at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 6.

In some embodiments, the F protein is a mutant NiV-F protein that is a biologically active portion thereof that comprises a 20 amino acid truncation at or near the C-terminus of the wild-type NiV-F protein (SEQ ID NO:2); and a point mutation on an N-linked glycosylation site. In some embodiments, the mutant NiV-F protein comprises an amino acid sequence set forth in SEQ ID NO: 7. In some embodiments, the mutant NiV-F protein has a sequence that has at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 7.

In some embodiments, the F protein is a mutant NiV-F protein that is a biologically active portion thereof that comprises a 22 amino acid truncation at or near the C-terminus of the wild-type NiV-F protein (SEQ ID NO:2). In some embodiments, the NiV-F protein is encoded by a nucleotide sequence that encodes the sequence set forth in SEQ ID NO: 8. In some embodiments, the NiV-F proteins is encoded by a nucleotide sequence that encodes sequence having at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 8. In particular embodiments, the variant F protein is a mutant Niv-F protein that has the sequence of amino acids set forth in SEQ ID NO:23. In some embodiments, the NiV-F proteins is encoded by a a sequence having at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 23.

C. Lipid Bilayer

In some embodiments, the targeted lipid particle includes a naturally derived bilayer of amphipathic lipids that encloses lumen or cavity. In some embodiments, the targeted lipid particle comprises a lipid bilayer as the outermost surface. In some embodiments, the lipid bilayer encloses a lumen. In some embodiments, the lumen is aqueous. In some embodiments, the lumen is in contact with the hydrophilic head groups on the interior of the lipid bilayer. In some embodiments, the lumen is a cytosol. In some embodiments, the cytosol contains cellular components present in a source cell. In some embodiments, the cytosol does not contain components present in a source cell. In some embodiments, the lumen is a cavity. In some embodiments, the cavity contains an aqueous environment. In some embodiments, the cavity does not contain an aqueous environment.

In some aspects, the lipid bilayer is derived from a source cell during a process to produce a lipid-containing particle. Exemplary methods for producing lipid-containing particles are provided in Section I.E. In some embodiments, the lipid bilayer includes membrane components of the cell from which the lipid bilayer is produced, e.g., phospholipids, membrane proteins, etc. In some embodiments, the lipid bilayer includes a cytosol that includes components found in the cell from which the micro-vesicle is produced, e.g., solutes, proteins, nucleic acids, etc., but not all of the components of a cell, e.g., they lack a nucleus. In some embodiments, the lipid bilayer is considered to be exosome-like. The lipid bilayer may vary in size, and in some instances have a diameter ranging from 30 and 300 nm, such as from 30 and 150 nm, and including from 40 to 100 nm.

In some embodiments, the lipid bilayer is a viral envelope. In some embodiments, the viral envelope is obtained from a source cell. In some embodiments, the viral envelope is obtained by the viral capsid from the source cell plasma membrane. In some embodiments, the lipid bilayer is obtained from a membrane other than the plasma membrane of a host cell. In some embodiments, the viral envelope lipid bilayer is embedded with viral proteins, including viral glycoproteins.

In other aspects, the lipid bilayer includes synthetic lipid complex. In some embodiments, the synthetic lipid complex is a liposome. In some embodiments, the lipid bilayer is a vesicular structure characterized by a phospholipid bilayer membrane and an inner aqueous medium. In some embodiments, the lipid bilayer has multiple lipid layers separated by aqueous medium. In some embodiments, the lipid bilayer forms spontaneously when phospholipids are suspended in an excess of aqueous solution. In some examples, the lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers.

In some embodiments, a targeted envelope protein and fusogen, such as any described above including any that are exogenous or overexpressed relative to the source cell, is disposed in the lipid bilayer.

In some embodiments, the targeted lipid particle comprises several different types of lipids. In some embodiments, the lipids are amphipathic lipids. In some embodiments, the amphipathic lipids are phospholipids. In some embodiments, the phospholipids comprise phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, and phosphatidylserine. In some embodiments, the lipids comprise phospholipids such as phosphocholines and phosphoinositols. In some embodiments, the lipids comprise DMPC, DOPC, and DSPC.

In some embodiments, the bilayer may be comprised of one or more lipids of the same or different type. In some embodiments, the source cell comprises a cell selected from CHO cells, BHK cells, MDCK cells, C3H 10T1/2 cells, FLY cells, Psi-2 cells, BOSC 23 cells, PA317 cells, WEHI cells, COS cells, BSC 1 cells, BSC 40 cells, BMT 10 cells, VERO cells, W138 cells, MRCS cells, A549 cells, HT1080 cells, 293 cells, 293T cells, B-50 cells, 3T3 cells, NIH3T3 cells, HepG2 cells, Saos-2 cells, Huh7 cells, HeLa cells, W163 cells, 211 cells, and 211A cells.

D. Exogenous Agent

In embodiments, the targeted lipid particle, such as a lentiviral vector, further comprises an agent that is exogenous relative to the source cell (hereinafter also called “cargo” or “payload”). In some embodiments, the exogenous agent is a protein or a nucleic acid (e.g., a DNA, a chromosome (e.g. a human artificial chromosome), an RNA, e.g., an mRNA or miRNA). In some embodiments, the exogenous agent is a nucleic acid that encodes a protein. The protein can be any protein as is desired for targeted delivery to a target cell. In some embodiments, the protein is a therapeutic agent or a diagnostic agent. In some embodiments, the protein is an antigen receptor for targeting cells expressed by or associated with a disease or condition, for instance a chimeric antigen receptor (CAR) or a T cell receptor (TCR). Reference to the coding sequence of a nucleic acid encoding the protein also is referred to herein as a payload gene. In some embodiments, the exogenous agent or the nucleic acid encoding the exogenous agent are present in the lumen of the non-cell particle.

In some embodiments, the exogenous agent or cargo comprises or encodes a cytosolic protein. In some embodiments the exogenous agent or cargo comprises or encodes a membrane protein. In some embodiments, the exogenous agent or cargo comprises or encodes a therapeutic agent. In some embodiments, the therapeutic agent is chosen from one or more of a protein, e.g., an enzyme, a transmembrane protein, a receptor, an antibody; a nucleic acid, e.g., DNA, a chromosome (e.g. a human artificial chromosome), RNA, mRNA, siRNA, miRNA, or a small molecule.

In embodiments, the exogenous agent is present at least, or no more than, 10, 20, 50, 100, 200, 500, 1,000, 2,000, 5,000, 10,000, 20,000, 50,000, 100,000, 200,000, 500,000, 1,000,000, 5,000,000, 10,000,000, 50,000,000, 100,000,000, 500,000,000, or 1,000,000,000 copies. In embodiments, the targeted lipid particle has an altered, e.g., increased or decreased level of one or more endogenous molecule, e.g., protein or nucleic acid (e.g., in some embodiments, endogenous relative to the source cell, and in some embodiments, endogenous relative to the target cell), e.g., due to treatment of the source cell, e.g., mammalian source cell with a siRNA or gene editing enzyme. In embodiments, the endogenous molecule is present at least, or no more than, 10, 20, 50, 100, 200, 500, 1,000, 2,000, 5,000, 10,000, 20,000, 50,000, 100,000, 200,000, 500,000, 1,000,000, 5,000,000, 10,000,000, 50,000,000, 100,000,000, 500,000,000, or 1,000,000,000 copies. In embodiments, the endogenous molecule (e.g., an RNA or protein) is present at a concentration of at least 1, 2, 3, 4, 5, 10, 20, 50, 100, 500, 10³, 5.0×10³, 10⁴, 5.0×10⁴, 10⁵, 5.0×10⁵, 10⁶, 5.0×10⁶, 1.0×10⁷, 5.0×10⁷, or 1.0×10⁸, greater than its concentration in the source cell. In embodiments, the endogenous molecule (e.g., an RNA or protein) is present at a concentration of at least 1, 2, 3, 4, 5, 10, 20, 50, 100, 500, 10³, 5.0×10³, 10⁴, 5.0×10⁴, 10⁵, 5.0×10⁵, 10⁶, 5.0×10⁶, 1.0×10⁷, 5.0×10⁷, or 1.0×10⁸ less than its concentration in the source cell.

In some embodiments, the targeted lipid particle delivers to a target cell at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% of the cargo (e.g., a therapeutic agent, e.g., an exogenous therapeutic agent) comprised by the fusosome. In some embodiments, the targeted lipid particle that fuses with the target cell(s) delivers to the target cell an average of at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% of the cargo (e.g., a therapeutic agent, e.g., an exogenous therapeutic agent) comprised by the lipid particles that fuse with the target cell(s). In some embodiments, the targeted lipid particle composition delivers to a target tissue at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% of the cargo (e.g., a therapeutic agent, e.g., an exogenous therapeutic agent) comprised by the targeted lipid particle compositions.

In some embodiments, the exogenous agent or cargo is not expressed naturally in the cell from which the targeted lipid particle is derived. In some embodiments, the exogenous agent or cargo is expressed naturally in the cell from which the targeted lipid particle is derived. In some embodiments, the exogenous agent or cargo is loaded into the targeted lipid particle via expression in the cell from which the lipid particle is derived (e.g. expression from DNA or mRNA introduced via transfection, transduction, or electroporation). In some embodiments, the exogenous agent or cargo is expressed from DNA integrated into the genome or maintained episosomally. In some embodiments, expression of the exogenous agent or cargo is constitutive. In some embodiments, expression of the exogenous agent or cargo is induced. In some embodiments, expression of the exogenous agent or cargo is induced immediately prior to generating the targeted lipid particle. In some embodiments, expression of the exogenous agent or cargo is induced at the same time as expression of the fusogen.

In some embodiments, the exogenous agent or cargo is loaded into the lipid particle via electroporation into the lipid particle itself or into the cell from which the fusosome is derived. In some embodiments, the exogenous agent or cargo is loaded into the lipid particle via transfection (e.g., of a DNA or mRNA encoding the cargo) into the lipid particle itself or into the cell from which the lipid particle is derived.

In some embodiments, the exogenous agent or cargo may include one or more nucleic acid sequences, one or more polypeptides, a combination of nucleic acid sequences and/or polypeptides, one or more organelles, and any combination thereof. In some embodiments, the exogenous agent or cargo may include one or more cellular components. In some embodiments, the exogenous agent or cargo includes one or more cytosolic and/or nuclear components.

In some embodiments, the exogenous agent or cargo includes a nucleic acid, e.g., DNA, nDNA (nuclear DNA), mtDNA (mitochondrial DNA), protein coding DNA, gene, operon, chromosome, genome, transposon, retrotransposon, viral genome, intron, exon, modified DNA, mRNA (messenger RNA), tRNA (transfer RNA), modified RNA, microRNA, siRNA (small interfering RNA), tmRNA (transfer messenger RNA), rRNA (ribosomal RNA), mtRNA (mitochondrial RNA), snRNA (small nuclear RNA), small nucleolar RNA (snoRNA), SmY RNA (mRNA trans-splicing RNA), gRNA (guide RNA), TERC (telomerase RNA component), aRNA (antisense RNA), cis-NAT (Cis-natural antisense transcript), CRISPR RNA (crRNA), IncRNA (long noncoding RNA), piRNA (piwi-interacting RNA), shRNA (short hairpin RNA), tasiRNA (trans-acting siRNA), eRNA (enhancer RNA), satellite RNA, pcRNA (protein coding RNA), dsRNA (double stranded RNA), RNAi (interfering RNA), circRNA (circular RNA), reprogramming RNAs, aptamers, and any combination thereof. In some embodiments, the nucleic acid is a wild-type nucleic acid. In some embodiments, the protein is a mutant nucleic acid. In some embodiments the nucleic acid is a fusion or chimera of multiple nucleic acid sequences.

In some embodiments, the exogenous agent or cargo may include a nucleic acid. For example, the exogenous agent or cargo may comprise RNA to enhance expression of an endogenous protein, or a siRNA or miRNA that inhibits protein expression of an endogenous protein. For example, the endogenous protein may modulate structure or function in the target cells. In some embodiments, the cargo may include a nucleic acid encoding an engineered protein that modulates structure or function in the target cells. In some embodiments, the exogenous agent or cargo is a nucleic acid that targets a transcriptional activator that modulate structure or function in the target cells.

In some embodiments, the exogenous agent or cargo is or encodes a polypeptide, e.g., enzymes, structural polypeptides, signaling polypeptides, regulatory polypeptides, transport polypeptides, sensory polypeptides, motor polypeptides, defense polypeptides, storage polypeptides, transcription factors, antibodies, cytokines, hormones, catabolic polypeptides, anabolic polypeptides, proteolytic polypeptides, metabolic polypeptides, kinases, transferases, hydrolases, lyases, isomerases, ligases, enzyme modulator polypeptides, protein binding polypeptides, lipid binding polypeptides, membrane fusion polypeptides, cell differentiation polypeptides, epigenetic polypeptides, cell death polypeptides, nuclear transport polypeptides, nucleic acid binding polypeptides, reprogramming polypeptides, DNA editing polypeptides, DNA repair polypeptides, DNA recombination polypeptides, transposase polypeptides, DNA integration polypeptides, targeted endonucleases (e.g. Zinc-finger nucleases, transcription-activator-like nucleases (TALENs), cas9 and homologs thereof), recombinases, and any combination thereof. In some embodiments the protein targets a protein in the cell for degradation. In some embodiments the protein targets a protein in the cell for degradation by localizing the protein to the proteasome. In some embodiments, the protein is a wild-type protein. In some embodiments, the protein is a mutant protein. In some embodiments the protein is a fusion or chimeric protein.

In some embodiments, the exogenous agent or cargo is a small molecule, e.g., ions (e.g. Ca²⁺, Cl-, Fe²⁺), carbohydrates, lipids, reactive oxygen species, reactive nitrogen species, isoprenoids, signaling molecules, heme, polypeptide cofactors, electron accepting compounds, electron donating compounds, metabolites, ligands, and any combination thereof. In some embodiments the small molecule is a pharmaceutical that interacts with a target in the cell. In some embodiments the small molecule targets a protein in the cell for degradation. In some embodiments the small molecule targets a protein in the cell for degradation by localizing the protein to the proteasome. In some embodiments that small molecule is a proteolysis targeting chimera molecule (PROTAC).

In some embodiments, the exogenous agent or cargo includes a mixture of proteins, nucleic acids, or metabolites, e.g., multiple polypeptides, multiple nucleic acids, multiple small molecules; combinations of nucleic acids, polypeptides, and small molecules; ribonucleoprotein complexes (e.g. Cas9-gRNA complex); multiple transcription factors, multiple epigenetic factors, reprogramming factors (e.g. Oct4, Sox2, cMyc, and Klf4); multiple regulatory RNAs; and any combination thereof.

In some embodiments, the exogenous agent or cargo includes one or more organelles, e.g., chondrisomes, mitochondria, lysosomes, nucleus, cell membrane, cytoplasm, endoplasmic reticulum, ribosomes, vacuoles, endosomes, spliceosomes, polymerases, capsids, acrosome, autophagosome, centriole, glycosome, glyoxysome, hydrogenosome, melanosome, mitosome, myofibril, cnidocyst, peroxisome, proteasome, vesicle, stress granule, networks of organelles, and any combination thereof.

In some embodiments, the exogenous agent is or encodes a cytosolic protein, e.g., a protein that is produced in the recipient cell and localizes to the recipient cell cytoplasm. In some embodiments, the exogenous agent is or encodes a secreted protein, e.g., a protein that is produced and secreted by the recipient cell. In some embodiments, the exogenous agent is or encodes a nuclear protein, e.g., a protein that is produced in the recipient cell and is imported to the nucleus of the recipient cell. In some embodiments, the exogenous agent is or encodes an organellar protein (e.g., a mitochondrial protein), e.g., a protein that is produced in the recipient cell and is imported into an organelle (e.g., a mitochondrial) of the recipient cell. In some embodiments, the protein is a wild-type protein or a mutant protein. In some embodiments the protein is a fusion or chimeric protein.

In some embodiments, the exogenous agent is capable of being delivered to a hepatocyte or liver cell. In some embodiments, the exogenous agents or cargo can be delivered to treat a disease or disorder in a hepatocyte or liver cell.

In some embodiments, the exogenous agent is encoded by a gene from among OTC, CPS1, NAGS, BCKDHA, BCKDHB, DBT, DLD, MUT, MMAA, MMAB, MMACHC, MMADHC, MCEE, PCCA, PCCB, UGT1A1, ASS1, PAH, PAL, ATP8B1, ABCB11, ABCB4, TJP2, IVD, GCDH, ETFA, ETFB, ETFDH, ASL, D2HGDH, HMGCL, MCCC1, MCCC2, ABCD4, HCFC1, LNBRD1, ARG1, SLC25A15, SLC25A13, ALAD, CPDX, HMBS, PPDX, BTD, HLCS, PC, SLC7A7, CPT2, ACADM, ACADS, ACADVL, AGL, G6PC, GBE1, PHKA1, PHKA2, PHKB, PHKG2, SLC37A4, PMM2, CBS, FAH, TAT, GALT, GALK1, GALE, G6PD, SLC3A1, SLC7A9, MTHFR, MTR, MTRR, ATP7B, HPRT1, HJV, HAMP, JAG1, TTR, AGXT, LIPA, SERPING1, HSD17B4, UROD, HFE, LPL, GRHPR, HOGA1, LDLR, ACAD8, ACADSB, ACAT1, ACSF3, ASPA, AUH, DNAJC19, ETHE1, FBP1, FTCD, GSS, HIBCH, IDH2, L2HGDH, MLYCD, OPA3, OPLAH, OXCT1, POLG, PPM1K, SERAC1, SLC25A1, SUCLA2, SUCLG1, TAZ, AGK, CLPB, TMEM70, ALDH18A1, OAT, CASA, GLUD1, GLUL, UMPS, SLC22A5, CPT1A, HADHA, HADH, SLC52A1, SLC52A2, SLC52A3, HADHB, GYS2, PYGL, SLC2A2, ALG1, ALG2, ALG3, ALG6, ALG8, ALG9, ALG11, ALG12, ALG13, ATP6V0A2, B3GLCT, CHST14, COG1, COG2, COG4, COG5, COG6, COG7, COG8, DOLK, DHDDS, DPAGT1, DPM1, DPM2, DPM3, G6PC3, GFPT1, GMPPA, GMPPB, MAGT1, MAN1B1, MGAT2, MOGS, MPDU1, MPI, NGLY1, PGM1, PGM3, RFT1, SEC23B, SLC35A1, SLC35A2, SLC35C1, SSR4, SRD5A3, TMEM165, TRIP11, TUSC3, ALG14, B4GALT1, DDOST, NUS1, RPN2, SEC23A, SLC35A3, ST3GAL3, STT3A, STT3B, AGA, ARSA, ARSB, ASAH1, ATP13A2, CLN3, CLNS, CLN6, CLN8, CTNS, CTSA, CTSD, CTSF, CTSK, DNAJCS, FUCA1, GAA, GALC, GALNS, GLA, GLB1, GM2A, GNPTAB, GNPTG, GNS, GRN, GUSB, HEXA, HEXB, HGSNAT, HYAL1, IDS, IDUA, KCTD7, LAMP2, MAN2B1, MANBA, MCOLN1, MFSD8, NAGA, NAGLU, NEU1 NPC1, NPC2, SGSH, PPT1, PSAP, SLC17A5, SMPD1, SUMF1, TPP1, AHCY, GNMT, MAT1A, GCH1, PCBD1, PTS, QDPR, SPR, DNAJC12, ALDH4A1, PRODH, HPD, GBA, HGD, AMN, CD320, CUBN, GIF, TCN1, TCN2, PREPL, PHGDH, PSAT1, PSPH, AMT, GCSH, GLDC, LIAS, NFU1, SLC6A9, SLC2A1, ATP7A, AP1S1, CP, SLC33A1, PEX7 PHYH, AGPS, GNPAT, ABCD1, ACOX1, PEX1, PEX2, PEX3, PEXS, PEX6, PEX10, PEX12, PEX13, PEX14, PEX16, PEX19, PEX26, AMACR, ADA, ADSL, AMPD1, GPHN, MOCOS, MOCS1, PNP, XDH, SUOX, OGDH, SLC25A19, DHTKD1, SLC13A5, FH, DLAT, MPC1, PDHA1, PDHB, PDHX, PDP1, ABCC2, SLCO1B1, SLCO1B3, HFE2, ADAMTS13, PYGM, COL1A2, TNFRSF11B, TSC1, TSC2, DHCR7, PGK1, VLDLR, KYNU, F5, C3, COL4A1, CFH, SLC12A2, GK, SFTPC, CRTAP, P3H1, COL7A1, PKLR, TALDO1, TF, EPCAM, VHL, GC, SERPINA1, ABCC6, F8, F9, ApoB, PCSK9, LDLRAP1, ABCGS, ABCG8, LCAT, SPINKS, or GNE.

In some embodiments, the exogenous agent is encoded by a gene from among OTC, CPS1, NAGS, BCKDHA, BCKDHB, DBT, DLD, MUT, MMAA, MMAB, MMACHC, MMADHC, MCEE, PCCA, PCCB, UGT1A1, ASS1, PAL, PAH, ATP8B1, ABCB11, ABCB4, TJP2, IVD, GCDH, ETFA, ETFB, ETFDH, ASL, D2HGDH, HMGCL, MCCC1, MCCC2, ABCD4, HCFC1, LMBRD1, ARG1, SLC25A15, SLC25A13, ALAD, CPDX, HMBS, PPDX, BTD, HLCS, PC, SLC7A7, CPT2, ACADM, ACADS, ACADVL, AGL, G6PC, GBE1, PHKA1, PHKA2, PHKB, PHKG2, SLC37A4, PMM2, CBS, FAH, TAT, GALT, GALK1, GALE, G6PD, SLC3A1, SLC7A9, MTHFR, MTR, MTRR, ATP7B, HPRT1, HJV, HAMP, JAG1, TTR, AGXT, LIPA, SERPING1, HSD17B4, UROD, HFE, LPL, GRHPR, HOGA1, or LDLR. In some embodiments, the exogenous agent is the enzyme phenylalanine ammonia lyase (PAL).

In some embodiments, the exogenous agents or cargo can be delivered to treat and disease or indication listed in Table 5. In some embodiments, the indications are specific for a liver cell or hepatocyte.

In some embodiments, the exogenous agent comprises a protein of Table 5 below. In some embodiments, the exogenous agent comprises the wild-type human sequence of any of the proteins of Table 5, a functional fragment thereof (e.g., an enzymatically active fragment thereof), or a functional variant thereof. In some embodiments, the exogenous agent comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%, identity to an amino acid sequence of Table 5, e.g., a Uniprot Protein Accession Number sequence of column 4 of Table 5 or an amino acid sequence of column 5 of Table 5. In some embodiments, the payload gene encoding an exogenous agent encodes an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%, identity to an amino acid sequence of Table 5. In some embodiments, the payload gene encoding an exogenous agent has a nucleic acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%, identity to a nucleic acid sequence of Table 5, e.g., an Ensemble Gene Accession Number of column 3 of Table 5.

TABLE 5
The first column lists exogenous agents that can be delivered to treat the indications in the sixth column, according to the
methods and uses herein. Each Uniprot accession number of Table 5 is herein incorporated by reference in its entirety.
		Ensembl		Amino Acid
		Gene(s)		Sequence
		Accession	Uniprot	(first Uniprot
	Entrez	Number	Protein(s)	Accession
	Accession	(ENSG0000 +	Accession	Number)
Gene	Number	number shown)	Number	SEQ ID NO	Disease/Disorder	Category
OTC	5009	0036473	P00480	61	ornithine	Urea cycle disorder
					transcarbamylase
					(OTC) deficiency
CPS1	1373	0021826	P31327,	62	carbamoyl	Urea cycle disorder
			Q6PEK7,		phosphate
			B7ZAW0,		synthetase I
			A0A024R454		(CPSI) deficiency
NAGS	162417	0161653	Q8N159,	63	N-acetylglutamate	Urea cycle disorder
			Q2NKP2		synthase (NAGS)
					deficiency
BCKDHA	593	0248098	A0A024R0K3,	64	maple syrup urine	Organic acidemia
			P12694,		disease (MSUD);
			Q59EI3		Classic Maple
					Syrup Urine
					Disease (CMSUD)
BCKDHB	594	0083123	A0A140VKB3,	65	maple syrup urine	Organic acidemia
			P21953,		disease (MSUD);
			B4E2N3,		Classic Maple
			B7ZB80		Syrup Urine
					Disease (CMSUD)
DBT	1629	0137992	P11182	66	maple syrup urine	Organic acidemia
					disease (MSUD);
					Classic Maple
					Syrup Urine
					Disease (CMSUD)
DLD	1738	0091140	A0A024R713,	67	maple syrup urine	Urea cycle disorder
			P09622,		disease (MSUD)
			E9PEX6		Dihydrolipoamide
					dehydrogenase
					deficiency
MUT	4594	0146085	A0A024RD82,	68	methylmalonic	Organic acidemia
			B2R6K1,		acidemia due to
			P22033		methylmalonyl-
					CoA mutase
					deficiency
MMAA	166785	0151611	Q8IVH4	69	cobalamin A	Organic acidemia
					deficiency
					(methylmalonic
					acidemia)
MMAB	326625	0139428	Q96EY8	70	cobalamin B	Organic acidemia
					deficiency
					(methylmalonic
					acidemia)
MMACHC	25974	0132763	A0A0C4DGU2,	71	cobalamin C	Organic acidemia
			Q9Y4U1		deficiency
					(methylmalonic
					acidemia);
					Methylmalonic
					Acidemia with
					Homocystinuria
MMADHC	27249	0168288	Q9H3L0	72	cobalamin D	Organic acidemia
					deficiency
					(methylmalonic
					acidemia);
					Methylmalonic
					Acidemia with
					Homocystinuria;
					Homocystinuria;
					Cobalamin C
					Deficiency
MCEE	84693	0124370	Q96PE7	73	methylmalonic	Organic acidemia
					acidemia;
					Cobalamin D
					Deficiency
PCCA	5095	0175198	P05165	74	propionic acidemia	Organic acidemia
PCCB	5096	0114054	P05166	75	propionic acidemia	Organic acidemia
UGT1A1	54658	0241635	P22309,	76	Crigler-Najjar
			Q5DT03		syndrome type 1
					Crigler-Najjar
					syndrome type 2,
					Gilbert syndrome
ASS1	445	0130707	P00966,	77	citrullinemia type I	Urea cycle disorder
			Q5T6L4
PAH	5053	0171759	A0A024RBG4,	78	Phenylalanine	Aminoacidopathy
			P00439		hydroxylase
					deficiency
PAL				79	Phenylalanine	Aminoacidopathy
					hydroxylase
					deficiency
ATP8B1	5205	0081923	O43520	80	Progressive
					familial
					intrahepatic
					cholestasis Type 1
ABCB11	8647	0073734,	O95342	81	Progressive
		0276582			familial
					intrahepatic
					cholestasis Type 2;
					Progressive
					Familial
					Intrahepatic
					Cholestasis Type 3
ABCB4	5244	0005471	P21439	82	Progressive
					familial
					intrahepatic
					cholestasis Type 3;
					Progressive
					Familial
					Intrahepatic
					Cholestasis Type 2
TJP2	9414	0119139	B7Z2R3,	83	Progressive
			Q9UDY2,		familial
			B7Z954		intrahepatic
					cholestasis Type 4
IVD	3712	0128928	P26440,	84	isovaleric	Organic acidemia
			A0A0A0MT83		acidemia (IVD)
GCDH	2639	0105607	A0A024R7F9,	85	glutaric acidemia	Organic acidemia
			Q92947		type I
ETFA	2108	0140374	A0A0S2Z3L0,	86	multiple acyl-CoA	Organic acidemia
			P13804		dehydrogenase
					deficiency (a.k.a.
					glutaric aciduria
					type II)
ETFB	2109	0105379	P38117	87	multiple acyl-CoA	Organic acidemia
					dehydrogenase
					deficiency (a.k.a.
					glutaric aciduria
					type II)
ETFDH	2110	0171503	B4DEQ0,	88	multiple acyl-CoA	Organic acidemia
			Q16134		dehydrogenase
					deficiency (a.k.a.
					glutaric aciduria
					type II)
ASL	435	0126522	A0A024RDL8,	89	argininosuccinate	Urea cycle disorder
			P04424,		lyase (ASL)
			A0A0S2Z316		deficiency
D2HGDH	728294	0180902	B3KSR6,	90	D-2-	Organic acidemia
			B4E3K7,		hydroxyglutaric
			B5MCV2,		aciduria type I
			Q8N465
HMGCL	3155	0117305	P35914	91	3-hydroxy-3-	Organic academia
					methylglutaryl-	Urea cycle disorder
					CoA lyase
					(3HMG)
					deficiency
MCCC1	56922	0078070	Q68D27,	92	3-methylcrotonyl-	Organic acidemia
			Q96RQ3,		CoA carboxylase
			A0A0S2Z693,		(3MCC)
			E9PHF7		deficiency
MCCC2	64087	0131844,	A0A140VK29,	93	3-methylcrotonyl-	Organic acidemia
		0281742,	Q9HCC0		CoA carboxylase
		0275300			(3MCC)
					deficiency
ABCD4	5826	0119688	A0A024R6B9,	94	methylmalonic	Organic acidemia
			O14678,		acidemia with
			A0A024R6C8		homocystinuria
HCFC1	3054	0172534	P51610,	95	methylmalonic	Organic acidemia
			A6NEM2		acidemia with
					homocystinuria
LMBRD1	55788	0168216	Q9NUN5	96	methylmalonic	Organic acidemia
					acidemia with
					homocystinuria
ARG1	383	0118520	P05089	97	arginase (ARG1)	Urea cycle disorder
					deficiency
SLC25A15	10166	0102743	Q9Y619	98	hyperammonemia-	Urea cycle disorder
					hyperornithinemia-
					homocitrullinuria
					(HHH) syndrome
SLC25A13	10165	0004864	Q9UJS0	99	citrin deficiency	Urea cycle disorder
					citrullinemia type
					II
ALAD	210	0148218	P13716	100	Acute Hepatic	Porphyria
					porphyria
CPOX	1371	0080819	P36551	101	Acute Hepatic	Porphyria
					porphyria
HMBS	3145	0256269,	P08397	102	Acute Hepatic	Porphyria
		0281702			porphyria;
					Acute Intermittent
					Porphyria
PPOX	5498	0143224	P50336,	103	Acute Hepatic	Porphyria
			B4DY76		porphyria
BTD	686	0169814	P43251	104	Biotinidase	Organic acidemia
					Deficiency
HLCS	3141	0159267	P50747	105	Holocarboxylase	Organic acidemia
					Synthetase
					Deficiency
PC	5091	0173599	P11498	106	Pyruvate	Urea cycle disorder
			A0A024R5C5		Carboxylase
					Deficiency
SLC7A7	9056	0155465	Q9UM01	107	Lysinuric Protein	Urea cycle disorder
			A0A0S2Z502		Intolerance
CPT2	1376	0157184	P23786	108	Carnitine	Fatty Acid Oxidation
			A0A140VK13		Palmitoyltransferase
			A0A1B0GTB8		Type II (CPT II)
					Deficiency
ACADM	34	0117054	P11310	109	Medium Chain	Fatty Acid Oxidation
			A0A0S2Z366,		Acyl-CoA
			B7Z911,		Dehydrogenase
			Q5HYG7,		(MCAD)
			Q5T4U5,		Deficiency
			B4DJE7
ACADS	35	0122971	P16219	110	Short Chain Acyl-	Fatty acid oxidation
			E5KSD5,		CoA (SCAD)
			B4DUH1,		Dehydrogenase
			E9PE82		Deficiency
ACADVL	37	0072778	P49748	111	Very Long Chain	Fatty acid oxidation
			B3KPA6		Acyl-CoA
					Dehydrogenase
					(VLCAD)
					Deficiency
AGL	178	0162688	P35573	112	GSD III (Cori/	Liver glycogen storage
			A0A0S2A4E4		Forbe Disease or	disorder
					Debrancher)
G6PC	2538	0131482	P35575	113	GSDIa (Von	Liver glycogen storage
					Gierke Disease)	disorder
GBE1	2632	0114480	Q04446	114	GSD IV (Andersen	Liver glycogen storage
			Q59ET0		Disease, Brancher	disorder
					Enzyme)
PHKA1	5255	0067177	P46020	115	GSD IXa
PHKA2	0044446	5256	P46019	116	GSD IXa	Liver glycogen storage
	5256	0044446				disorder
PHKB	5257	0102893	Q93100	117	GSD IXb	Liver glycogen storage
						disorder
PHKG2	5261	0156873	P15735	118	GSD IXc	Liver glycogen storage
						disorder
SLC37A4	2542	0281500	O43826	119	GSDIb. c, d	Liver glycogen storage
		0137700	A0A024R3H9,			disorder
			A8K0S7,
			A0A024R3L1,
			B4DUH2
PMM2	5373	0140650	O15305,	120	PMM2-CDG	Glycosylation disorder
			A0A0S2Z4J6,
			Q59F02
CBS	102724560,	0160200	P35520,	121	Cystathionine	Aminoacidopathy
	875		P0DN79,		Beta-Synthase
			Q9NTF0,		Deficiency
			B7Z2D6		(Classic
					Homocystinuria);
					Homocystinuria
FAH	2184	0103876	P16930	122	Tyrosinemia Type	Aminoacidopathy
					I
TAT	6898	0198650	P17735,	123	Tyrosinemia Type	Aminoacidopathy
			A0A140VKB7		II
					Tyrosinemia Type
					III
GALT	2592	0213930	P07902,	124	Galactosemia	Carbohydrate disorder
			A0A0S2Z3Y7,		due to galactose-1-
			B2RAT6		phosphate
					uridylyltranserase
					(GALT)
					deficiency
GALK1	2584	0108479	P51570	125	Galactosemia	Carbohydrate disorder
GALE	2582	0117308	Q14376	126	Galactosemia	Carbohydrate disorder
G6PD	2539	0160211	P11413	127	Glucose-6-	Carbohydrate disorder
					Phosphate
					Dehydrogenase
					(G6PD)
					Deficiency
SLC3A1	6519	0138079	Q07837,	128	Cystinuria	Aminoacidopathy
			A0A0S2Z4E1,
			B8ZZK1
SLC7A9	11136	0021488	P82251	129	Cystinuria	Aminoacidopathy
MTHFR	4524	0177000	P42898,	130	Homocystinuria	Aminoacidopathy
			Q59GJ6,
			Q81U67
MTR	4548	0116984	Q99707	131	Homocystinuria	Aminoacidopathy
MTRR	4552	0124275	Q9UBK8	132	Homocystinuria	Aminoacidopathy
ATP7B	540	0123191	P35670,	133	Wilson Disease	Metal transport disorder
			A0A024RDX3,		Copper
			B7ZLR4,		Metabolism
			B7ZLR3,		Disorder
			E7ET55
HPRT1	3251	0165704	P00492,	134	Lesch-Nyhan	Purine Metabolism
			A0A140VJL3		Syndrome	Disorder
					Purine Metabolism
					Disorder
HJV	148738	0168509	Q6ZVN8	135	Hemochromatosis,
					Type 2A
HAMP	57817	0105697	P81172	136	Hemochromatosis
					Type 2B: Primary
					Hemochromatosis
JAG1	182	0101384	P78504,	137	Alagille Syndrome
			Q99740		1
TTR	7276	0118271	P02766,	138	Familial TTR
			E9KL36		Amyloidoisis;
					Familial amyloid
					polyneuropathy
AGXT	189	0172482	P21549	139	Primary
					Hyperoxaluria
					Type I
LIPA	3988	0107798	P38571	140	Lysosomal Acid	Lyososomal storage
			A0A0A0MT32		Lipase Deficiency	disorder
SERPING1	710	0149131	P05155,	141	Hereditary
			A0A0S2Z4J1,		Angioedma
			B2R659,
			E7EWE5,
			B3KSP2,
			G5E9S2
HSD17B4	3295	0133835	P51659	142	D-Bifunctional	Peroxisomal disorders
					Protein Deficiency
					X-linked
					Adrenoleukodystrophy
UROD	7389	0126088	P06132	143	Porphyria Cutanea
					Tarda
HFE	3077	0010704	Q30201	144	Porphyria Cutanea
					Tarda
LPL	4023	0175445	P06858,	145	Lipoprotein Lipase
			A0A1B1RVA9		Deficiency
					(“hyperlipoproteinemia
					type Ia;
					Buerger-Gruetz
					syndrome, or
					Familial
					hyperchylomicronemia)
GRHPR	9380	0137106	Q9UBQ7	146	Primary
					Hyperoxaluria
					Type II
HOGA1	112817	0241935	Q86XE5	147	Primary
					Hyperoxaluria
					Type III
LDLR	3949	0130164	P01130,	148	Homozygous
			A0A024R7D5		Familial
					Hypercholesterolemia
ACAD8	27034	0151498	Q9UKU7	149	isobutyryl-CoA	Organic acidemia
					dehydrogenase
					(IBD) deficiency
ACADSB	36	0196177	P45954,	150	short-branched	Organic acidemia
			A0A0S2Z3P9		chain acyl-CoA
					dehydrogenase
					(SBCAD)
					deficiency
ACAT1	38	0075239	A0A140VJX1,	151	beta-ketothiolase	Organic acidemia
			P24752		deficiency
ACSF3	197322	0176715	Q4G176,	152	combined malonic	Organic acidemia
			F5H5A1		and methylmalonic
					aciduria
ASPA	443	0108381	P45381,	153	Canavan disease	Organic acidemia
			Q6FH48
AUH	549	0148090	Q13825,	154	3-	Organic acidemia
			B4DYI6		methylglutaconic
					acidemia type I
DNAJC19	131118	0205981	Q96DA6,	155	dilated	Organic acidemia
			A0A0S2Z5X1		cardiomyopathy
					with ataxia
					syndrome (causes
					3-
					methylglutaconic
					aciduria)
ETHE1	23474	0105755	A0A0S2Z580,	156	ethylmalonic	Organic acidemia
			O95571,		encephalopathy
			A0A0S2Z5N8,
			A0A0S2Z5B3,
			B2RCZ7
FBP1	2203	0165140	P09467,	157	fructose 1,6-	Organic acidemia
			Q2TU34		Bisphosphatase
					deficiency
FTCD	10841	0160282,	O95954	158	glutamate	Organic acidemia
		0281775			formiminotransferase
					deficiency
					(FIGLU
GSS	2937	0100983	P48637,	159	glutathione	Organic acidemia
			V9HWJ1		synthetase
					deficiency
HIBCH	26275	0198130	A0A140VJL0,	160	3-	Organic acidemia
			Q6NVY1		hyroxyisobutyryl-
					CoA hydrolase
					deficiency
IDH2	3418	0182054	P48735,	161	D-2-	Organic acidemia
			B4DSZ6		hydroxyglutaric
					aciduria type II
L2HGDH	79944	0087299	Q9H9P8	162	L-2-	Organic acidemia
					hydroxyglutaric
					aciduria
MLYCD	23417	0103150	O95822	163	malonic acidemia	Organic acidemia
OPA3	80207	0125741	Q9H6K4,	164	Costeff syndrome/	Organic acidemia
			B4DK77		3-
					methylglutaconic
					aciduria type III
OPLAH	26873	0178814	O14841	165	5-oxoprolinase	Organic acidemia
					deficiency
OXCT1	5019	0083720	A0A024R040,	166	SCOT deficiency	Organic acidemia
			P55809
POLG	5428	0140521	E5KNU5,	167	3-	Organic acidemia
			P54098		methylglutaconic
					aciduria
PPM1K	152926	0163644	Q8N3J5	168	maple syrup urine	Organic acidemia
					disease (MSUD),
					variant type
SERAC1	84947	0122335	Q96JX3	169	Megdel Syndrome	Organic acidemia
SLC25A1	6576	0100075	D9HTE9,	170	D,L-2-	Organic acidemia
			B4DP62,		hydroxyglutaric
			P53007		aciduria
SUCLA2	8803	0136143	E5KS60,	171	succinate-CoA	Organic acidemia
			Q9P2R7,		ligase deficiency,
			Q9Y4T0		methylmalonic
					aciduria
SUCLG1	8802	0163541	P53597	172	succinate-CoA	Organic acidemia
					ligase deficiency,
					methylmalonic
					aciduria
TAZ	6901	0102125	A0A0S2Z4K0,	173	Barth syndrome	Organic acidemia
			Q16635,
			A6XNE1,
			A0A0S2Z4E6,
			A0A0S2Z4K9,
			A0A0S2Z4F4
AGK	55750	0006530,	A4D1U5,	174	3-	Organic acidemia
		0262327	Q53H12		methylglutaconic
					aciduria
CLPB	81570	0162129	Q9H078,	175	3-	Organic acidemia
			A0A140VK11		methylglutaconic
					aciduria
TMEM70	54968	0175606	Q9BUB7	176	3-	Organic acidemia
					methylglutaconic
					aciduria
ALDH18A1	5832	0059573	P54886	177	ALDH18A1-	Urea cycle disorder
					related cutis laxa
OAT	4942	0065154	A0A140VJQ4,	178	gyrate atrophy	Urea cycle disorder
			P04181		(OAT)
CA5A	763	0174990	P35218	179	carbonic	Urea cycle disorder
					anhydrase
					deficiency
GLUD1	2746	0148672	P00367,	180	glutamate	Urea cycle disorder
			E9KL48		dehydrogenase
					deficiency
GLUL	2752	0135821	A8YXX4,	181	glutamine	Urea cycle disorder
			P15104		synthetase
					deficienc
UMPS	7372	0114491	A8K5J1,	182	Orotic Aciduria	Urea cycle disorder
			P11172
SLC22A5	6584	0197375	O76082	183	carnitine-	Fatty acid oxidation
					acylcarnitine
					translocase
					(CACT)
					deficiency
CPT1A	1374	0110090	P50416,	184	carnitine	Fatty acid oxidation
			A0A024R5F4,		palmitoyltransferase
			B2RAQ8,		type I (CPT I)
			Q8WZ48		deficiency
HADHA	3030	0084754	E9KL44,	185	long chain 3-	Fatty acid oxidation
			P40939		hydroxyacyl-CoA
					dehydrogenase
					(LCHAD)
					deficiency
HADH	3033	0138796	Q16836,	186	medium/short	Fatty acid oxidation
			B3KTT6		chain acyl-CoA
					dehydrogenase
					(M/SCHAD)
					deficiency
SLC52A1	55065	0132517	Q9NWF4	187	Riboflavin	Fatty acid oxidation
					transporter
					deficiency
SLC52A2	79581	0185803	Q9HAB3	188	Riboflavin	Fatty acid oxidation
					transporter
					deficiency
SLC52A3	113278	0101276	K0A6P4,	189	Riboflavin	Fatty acid oxidation
			Q9NQ40		transporter
					deficiency
HADHB	3032	0138029	P55084,	190	Trifunctional	Fatty acid oxidation
			F5GZQ3		protein deficiency
GYS2	2998	0111713	P54840	191	GSD 0 (Glycogen	Liver glycogen storage
					synthase, liver	disorder
					isoform)
PYGL	5836	0100504	P06737	192	GSD VI (Hers	Liver glycogen storage
					disease)	disorder
SLC2A2	6514	0163581	P11168,	193	Fanconi-Bickel	Liver glycogen storage
			Q6PAU8		syndrome	disorder
ALG1	56052	0033011	Q9BT22	194	ALG1-CDG	Glycosylation disorder
ALG2	85365	0119523	A0A024R184,	195	ALG2-associated	Glycosylation disorder
			Q9H553		myasthenic
					syndrome
ALG3	10195	0214160	Q92685,	196	ALG3-CDG	Glycosylation disorder
			C9J7S5
ALG6	29929	0088035	Q9Y672	197	ALG6-CDG	Glycosylation disorder
ALG8	79053	0159063	Q9BVK2,	198	ALG8-CDG	Glycosylation disorder
			A0A024R5K5
ALG9	79796	0086848	Q9H6U8	199	ALG9-CDG	Glycosylation disorder
ALG11	440138	0253710	Q2TAA5	200	ALG11-CDG	Glycosylation disorder
ALG12	79087	0182858	A0A024R4V6,	201	ALG12-CDG	Glycosylation disorder
			Q9BV10
ALG13	79868	0101901	Q9NP73,	202	ALG13-CDG	Glycosylation disorder
			A0A087WX43,
			A0A087WT15
ATP6V0A2	23545	0185344	Q9Y487	203	ATP6V0A2-	Glycosylation disorder
					associated cutis
					laxa
B3GLCT	145173	0187676	Q6Y288	204	B3GLCT-CDG	Glycosylation disorder
CHST14	113189	0169105	Q8NCH0	205	CHST14-CDG	Glycosylation disorder
COG1	9382	0166685	Q8WTW3	206	COG1-CDG	Glycosylation disorder
COG2	22796	0135775	Q14746,	207	COG2-CDG	Glycosylation disorder
			B1ALW7
COG4	25839	0103051	A0A0A0MS45,	208	COG4-CDG	Glycosylation disorder
			Q8N8L9,
			Q9H9E3,
			J3KNI1
COG5	10466	0164597,	Q9UP83	209	COG5-CDG	Glycosylation disorder
		0284369
COG6	57511	0133103	A0A140VJG7,	210	COG6-CDG	Glycosylation disorder
			Q9Y2V7,
			A0A024RDW5
COG7	91949	0168434	A0A0S2Z652,	211	COG7-CDG	Glycosylation disorder
			P83436
COG8	84342	0272617	A0A024R6Z6,	212	COG8-CDG	Glycosylation disorder
			Q96MW5
DOLK	22845	0175283	A0A0S2Z597,	213	DOLK-CDG	Glycosylation disorder
			Q9UPQ8
DHDDS	79947	0117682	Q86SQ9	214	DHDDS-CDG	Glycosylation disorder
DPAGT1	1798	0172269	A0A024R3H8,	215	DPAGT1-CDG	Glycosylation disorder
			Q9H3H5
DPM1	8813	0000419	O60762,	216	DPM1-CDG	Glycosylation disorder
			Q5QPK2,
			A0A0S2Z4Y5
DPM2	8818	0136908	O94777	217	DPM2-CDG	Glycosylation disorder
DPM3	54344	0179085	A0A140VJI4,	218	DPM3-CDG	Glycosylation disorder
			Q9P2X0,
			Q86TM7
G6PC3	92579	0141349	Q9BUM1	219	Congenital	Glycosylation disorder
					neutropenia
GFPT1	2673	0198380	Q06210	220	Congenital	Glycosylation disorder
					myasthenic
					syndrome
GMPPA	29926	0144591	A0A024R482,	221	GMPPA-CDG	Glycosylation disorder
			Q96IJ6
GMPPB	29925	0173540	Q9Y5P6	222	Congenital	Glycosylation disorder
					muscular
					dystrophy,
					congenital
					myasthenic
					syndrome, and
					dystroglycanopathy
MAGT1	84061	0102158	A0A087WU53,	223	MAGT1-CDG; X-	Glycosylation disorder
			Q9H0U3		linked
					immunodeficiency
					with magnesium
					defect, Epstein-
					Barr virus
					infection and
					neoplasia (XMEN)
					syndrome
MAN1B1	11253	0177239	Q9UKM7	224	MAN1B1-CDG	Glycosylation disorder
MGAT2	4247	0168282	Q10469	225	MGAT2-CDG	Glycosylation disorder
MOGS	7841	0115275	Q13724,	226	MOGS-CDG	Glycosylation disorder
			Q58F09
MPDU1	9526	0129255	J3QW43,	227	MPDU1-CDG	Glycosylation disorder
			O75352,
			A0A0S2Z4W8,
			B4DLH7
MPI	4351	0178802	H3BPP3,	228	MPI-CDG	Glycosylation disorder
			Q8NHZ6,
			B4DW50,
			F5GX71,
			P34949,
			H3BPB8
NGLY1	55768	0151092	Q96IV0	229	NGLY1-CDG	Glycosylation disorder
PGM1	5236	0079739	B7Z6C2,	230	PGM1-CDG	Glycosylation disorder
			P36871,
			B4DDQ8
PGM3	5238	0013375	O95394,	231	PGM3-CDG	Glycosylation disorder
			A0A087WT27
RFT1	91869	0163933	Q96AA3	232	RFT1-CDG	Glycosylation disorder
SEC23B	10483	0101310	Q15437,	233	SEC23B-CDG	Glycosylation disorder
			B4DJW8
SLC35A1	10559	0164414	P78382	234	SLC35A1-CDG	Glycosylation disorder
SLC35A2	7355	0102100	P78381,	235	SLC35A2-CDG	Glycosylation disorder
			A6NFI1,
			A6NKM8,
			B4DE15
SLC35C1	55343	0181830	Q96A29,	236	SLC35C1-CDG	Glycosylation disorder
			B3KQH0
SSR4	6748	0180879	P51571	237	SSR4-CDG	Glycosylation disorder
SRD5A3	79644	0128039	Q9H8P0	238	SRD5A3-CDG	Glycosylation disorder
TMEM165	55858	0134851	Q9HC07	239	TMEM165-CDG	Glycosylation disorder
TRIP11	9321	0100815	Q15643	240	TRIP11-CDG	Glycosylation disorder
TUSC3	7991	0104723	Q13454	241	TUSC3-CDG	Glycosylation disorder
ALG14	199857	0172339	Q96F25	242	ALG14-CDG	Glycosylation disorder
B4GALT1	2683	0086062	P15291,	243	B4GALT1-CDG	Glycosylation disorder
			W6MEN3
DDOST	1650	0244038	A0A024RAD5,	244	DDOST-CDG	Glycosylation disorder
			P39656
NUS1	116150	0153989	Q96E22	245	NUS1-CDG	Glycosylation disorder
RPN2	6185	0118705	P04844	246	RPN2-CDG	Glycosylation disorder
SEC23A	10484	0100934	Q15436	247	SEC23A-CDG	Glycosylation disorder
SLC35A3	23443	0117620	Q9Y2D2,	248	SLC35A3-CDG	Glycosylation disorder
			A0A1W2PRT7,
			A0A1W2PSD1,
			A0A1W2PQL8
ST3GAL3	6487	0126091	Q11203	249	ST3GAL3-CDG	Glycosylation disorder
STT3A	3703	0134910	P46977	250	STT3A-CDG	Glycosylation disorder
STT3B	201595	0163527	Q8TCJ2	251	STT3B-CDG	Glycosylation disorder
AGA	175	0038002	P20933	252	Aspartylglucosaminuria	Lyososomal storage
						disorder
ARSA	410	0100299	A0A0C4DFZ2,	253	Metachromatic	Lyososomal storage
			B4DVI5,		leukodystrophy	disorder
			P15289
ARSB	411	0113273	A0A024RAJ9,	254	Mucopolysaccharidosis	Lyososomal storage
			P15848,		type VI	disorder
			A8K4A0
ASAH1	427	0104763	A8K0B6,	255	Farber disease	Lyososomal storage
			Q13510,			disorder
			Q53H01
ATP13A2	23400	0159363	Q8N4D4,	256	Neuronal ceroid	Lyososomal storage
			Q9NQ11,		lipofuscinosis 12	disorder
			Q8NBS1		(CLN12), Kufor-
					Rakeb syndrome
					(KRS)
CLN3	1201	0188603,	A0A024QZB8,	257	Neuronal ceroid	Lyososomal storage
		0261832	Q13286,		lipofuscinosis 3	disorder
			B4DMY6,		(CLN3)
			Q2TA70,
			B4DFF3
CLN5	1203	0102805	A0A024R644,	258	Neuronal ceroid	Lyososomal storage
			O75503		lipofuscinosis 5	disorder
					(CLN5)
CLN6	54982	0128973	A0A024R601,	259	Neuronal ceroid	Lyososomal storage
			Q9NWW5		lipofuscinosis 6	disorder
					(CLN6)
CLN8	2055	0182372,	A0A024QZ57,	260	Neuronal ceroid	Lyososomal storage
		0278220	Q9UBY8		lipofuscinosis 8	disorder
					(CLN8)
CTNS	1497	0040531	A0A0S2Z3I9,	261	cystinosis	Lyososomal storage
			O60931,			disorder
			A0A0S2Z3K3
CTSA	5476	0064601	P10619,	262	Galactosialidosis	Lyososomal storage
			X6R8A1,			disorder
			B4E324,
			X6R5C5
CTSD	1509	0117984	P07339,	263	Neuronal ceroid	Lyososomal storage
			V9HWI3		lipofuscinosis 10	disorder
					(CLN10)
CTSF	8722	0174080	Q9UBX1	264	Neuronal ceroid	Lyososomal storage
					lipofuscinosis 13	disorder
					(CLN13)
CTSK	1513	0143387	P43235	265	Pycnodysostosis	Lyososomal storage
						disorder
DNAJC5	80331	0101152	Q6AHX3,	266	Neuronal ceroid	Lyososomal storage
			Q9H3Z4		lipofuscinosis 4	disorder
					(CLN4)
FUCA1	2517	0179163	P04066,	267	Fucosidosis	Lyososomal storage
			B5MDC5			disorder
GAA	2548	0171298	P10253	268	Pompe disease	Lyososomal storage
						disorder
GALC	2581	0054983	A0A0A0MQV0,	269	Krabbe disease	Lyososomal storage
			P54803			disorder
GALNS	2588	0141012	P34059,	270	Mucopolysaccharidosis	Lyososomal storage
			Q96I49,		type IVa	disorder
			Q6YL38
GLA	2717	0102393	P06280,	271	Fabry disease	Lyososomal storage
			Q53Y83			disorder
GLB1	2720	0170266	P16278,	272	GM1	Lyososomal storage
			B7Z6Q5		gangliosidosis,	disorder
					Mucopolysaccharidosis
					IVb
GM2A	2760	0196743	P17900	273	GM2-	Lyososomal storage
					gangliosidosis, AB	disorder
					variant
GNPTAB	79158	0111670	Q3T906	274	Mucolipidosis type	Lyososomal storage
					II alpha/beta,	disorder
					Mucolipidosis III
					alpha/beta
GNPTG	84572	0090581	Q9UJJ9	275	Mucolipidosis III	Lyososomal storage
					gamma	disorder
GNS	2799	0135677	A0A024RBC5,	276	Mucopolysaccharidosis	Lyososomal storage
			P15586,		type IIID	disorder
			Q7Z3X3
GRN	2896	0030582	P28799	277	Neuronal ceroid	Lyososomal storage
					lipofuscinosis 11	disorder
					(CLN11),
					frontotemporal
					dementia
GUSB	2990	0169919	P08236	278	Mucopolysaccharidosis	Lyososomal storage
					type VII	disorder
HEXA	3073	0213614	A0A0S2Z3W3,	279	Tay-Sachs disease	Lyososomal storage
			P06865,			disorder
			B4DVA7,
			H3BP20
HEXB	3074	0049860	A0A024RAJ6,	280	Sandhoff diseaase	Lyososomal storage
			P07686,			disorder
			Q5URX0
HGSNAT	138050	0165102	Q68CP4,	281	Mucopolysaccharidosis	Lyososomal storage
			Q8IVU6		type IIIC	disorder
HYAL1	3373	0114378	A0A024R2X3,	282	Mucopolysaccharidosis	Lyososomal storage
			QI2794,		type IX	disorder
			B3KUI5,
			A0A0S2Z3Q0
IDS	3423	0010404	P22304,	283	Mucopolysaccharidosis	Lyososomal storage
			B4DGD7		type II	disorder
IDUA	3425	0127415	P35475	284	Mucopolysaccharidosis	Lyososomal storage
					type I	disorder
KCTD7	154881	0243335	Q96MP8,	285	Neuronal ceroid	Lyososomal storage
			A0A024RDN7		lipofuscinosis 14	disorder
					(CLN14)
LAMP2	3920	0005893	P13473	286	Danon disease	Lyososomal storage
						disorder
MAN2B1	4125	0104774	O00754,	287	alpha-	Lyososomal storage
			A8K6A7		mannosidosis	disorder
MANBA	4126	0109323	O00462	288	beta-mannosidosis	Lyososomal storage
						disorder
MCOLN1	57192	0090674	Q9GZU1	289	Mucolipidosis type	Lyososomal storage
					IV	disorder
MFSD8	256471	0164073	Q8NHS3	290	Neuronal ceroid	Lyososomal storage
					lipofuscinosis 7	disorder
					(CLN7)
NAGA	4668	0198951	A0A024R1Q5,	291	Schindler disease	Lyososomal storage
			P17050			disorder
NAGLU	4669	0108784	A0A140VJE4,	292	Mucopolysaccharidosis	Lyososomal storage
			P54802		IIIB	disorder
NEU1	4758	0204386,	Q5JQI0,	293	Mucolipidosis type	Lyososomal storage
		0227315,	Q99519		I, Sialidosis I	disorder
		0227129,
		0223957,
		0234846,
		0184494,
		0228691,
		0234343
NPC1	4864	0141458	O15118	294	Niemann-Pick	Lyososomal storage
					type C	disorder
NPC2	10577	0119655	A0A024R6C0,	295	Niemann-Pick	Lyososomal storage
			P61916,		type C	disorder
			G3V3E8
SGSH	6448	0181523	P51688	296	Mucopolysaccharidosis	Lyososomal storage
					IIIA	disorder
PPT1	5538	0131238	P50897	297	Neuronal ceroid	Lyososomal storage
					lipofuscinosis 1	disorder
					(CLN1)
PSAP	5660	0197746	P07602,	298	Prosaposin	Lyososomal storage
			A0A024QZQ2		deficiency, SapA	disorder
					deficiency (Krabbe
					variant), SapB
					deficiency
					(MLD variant),
					SapC deficiency
					(Gaucher variant)
SLC17A5	26503	0119899	Q9NRA2	299	Infantile sialic acid	Lyososomal storage
					storage disease,	disorder
					Salla disease
SMPD1	6609	0166311	P17405,	300	Niemann Pick	Lyososomal storage
			Q59EN6,		types A and B	disorder
			E9LUE8,
			Q8IUN0,
			E9LUE9
SUMF1	285362	0144455	Q8NBK3	301	Multiple sulfatase	Lyososomal storage
					deficiency	disorder
TPP1	1200	0166340	O14773	302	Neuronal ceroid	Lyososomal storage
					lipofuscinosis 2	disorder
					(CLN2)
AHCY	191	0101444	P23526,	303	Hypermethioninemia	Aminoacidophaty
			Q1RMG2
GNMT	27232	0124713	A0A0S2Z5F2,	304	Hypermethioninemia	Aminoacidophaty
			Q14749,
			V9HW60
MAT1A	4143	0151224	Q00266	305	Hypermethioninemia	Aminoacidophaty
GCH1	2643	0131979	A0A024R642,	306	BH4 cofactor	Aminoacidophaty
			P30793,		deficiency
			Q8IZH9
PCBD1	5092	0166228	P61457	307	BH4 cofactor	Aminoacidophaty
					deficiency
PTS	5805	0150787	Q03393	308	BH4 cofactor	Aminoacidophaty
					deficiency
QDPR	5860	0151552	A0A140VKA9,	309	BH4 cofactor	Aminoacidophaty
			P09417		deficiency
SPR	6697	0116096	P35270	310	BH4 cofactor	Aminoacidophaty
					deficiency
DNAJC12	56521	0108176	Q6IAH1,	311	Phenylalanine,	Aminoacidophaty
			Q9UKB3		tyrosine, and
					tryptophan
					hydroxylases heat
					shock
					co-chaperone
					deficiency
ALDH4A1	8659	0159423	P30038,	312	Hyperprolinemia	Aminoacidophaty
			A0A024RAD8
PRODH	5625	0100033	O43272	313	Hyperprolinemia	Aminoacidophaty
HPD	3242	0158104	P32754	314	Tyrosinemia type	Aminoacidophaty
					II
GBA	2629	0177628,	A0A068F658,	315	Gaucher disease
		0262446	P04062,
			B7Z6S9
HGD	3081	0113924	Q93099,	316	Alkaptonuria
			B3KW64
AMN	81693	0166126	Q9BXJ7,	317	Combined	Organic acidemia
			B3KP64		Methylmalonic
					Acidemia and
					Homocystinuria
CD320	51293	0167775	Q9NPF0	318	Combined	Organic acidemia
					Methylmalonic
					Acidemia and
					Homocystinuria
CUBN	8029	0107611	O60494	319	Combined	Organic acidemia
					Methylmalonic
					Acidemia and
					Homocystinuria
GIF	2694	0134812	P27352	320	Combined	Organic acidemia
					Methylmalonic
					Acidemia and
					Homocystinuria
TCN1	6947	0134827	P20061	321	Combined	Organic acidemia
					Methylmalonic
					Acidemia and
					Homocystinuria
TCN2	6948	0185339	P20062	322	Combined	Organic acidemia
					Methylmalonic
					Acidemia and
					Homocystinuria
PREPL	9581	0138078	Q4J6C6	323	Cystinuria	Aminoacidophaty
PHGDH	26227	0092621	O43175	324	Disorders of	Aminoacidophaty
					Serine
					Biosynthesis
PSAT1	29968	0135069	A0A024R280,	325	Disorders of	Aminoacidophaty
			Q9Y617,		Serine
			A0A024R222		Biosynthesis
PSPH	5723	0146733	A0A024RDL3,	326	Disorders of	Aminoacidophaty
			P78330		Serine
					Biosynthesis
AMT	275	0145020	A0A024R2U7,	327	Glycine	Aminoacidophaty
			P48728		Encephalopathy
GCSH	2653	0140905	P23434	328	Glycine	Aminoacidophaty
					Encephalopathy
GLDC	2731	0178445	P23378	329	Glycine	Aminoacidophaty
					Encephalopathy
LIAS	11019	0121897	O43766,	330	Glycine	Aminoacidophaty
			Q6P5Q6,		Encephalopathy
			B4E0L7,
			A0A024R9W0,
			A0A1W2PQE9,
			A0A1X7SBR7
NFU1	27247	0169599	Q9UMS0	331	Glycine	Aminoacidophaty
					Encephalopathy
SLC6A9	6536	0196517	P48067,	332	Glycine	Aminoacidophaty
			B7Z3W8,		Encephalopathy
			B7Z589
SLC2A1	6513	0117394	P11166,	333	Glucose	Carbohydrate disorder
			Q59GX2		Transporter Type 1
					Deficiency
ATP7A	538	0165240	B4DRW0,	334	ATP7A-Related	Metal transport disorder
			Q04656,		Disorders
			Q762B6		Copper
					Metabolism
					Disorder
AP1S1	1174	0106367	A0A024QYT6,	335	Copper	Metal transport disorder
			P61966		Metabolism
					Disorder
CP	1356	0047457	A5PL27,	336	Copper	Metal transport disorder
			P00450		Metabolism
					Disorder
SLC33A1	9197	0169359	O00400	337	Copper	Metal transport disorder
					Metabolism
					Disorder
PEX7	5191	0112357	O00628,	338	Adult Refsum	Peroxisomal disorders
			Q6FGN1		Disease
					Rhizomelic
					Chondrodysplasia
					Punctata Spectrum
PHYH	5264	0107537	O14832	339	Adult Refsum	Peroxisomal disorders
					Disease
AGPS	8540	0018510	O00116,	340	Rhizomelic	Peroxisomal disorders
			B7Z3Q4		Chondrodysplasia
					Punctata Spectrum
GNPAT	8443	0116906	O15228	341	Rhizomelic	Peroxisomal disorders
					Chondrodysplasia
					Punctata Spectrum
ABCD1	215	0101986	P33897	342	X-linked	Peroxisomal disorders
					Adrenoleukodystrophy
ACOX1	51	0161533	Q15067	343	X-linked	Peroxisomal disorders
					Adrenoleukodystrophy
PEX1	5189	0127980	O43933,	344	X-linked	Peroxisomal disorders
			A0A0C4DG33,		Adrenoleukodystrophy
			B4DER6
PEX2	5828	0164751	P28328	345	X-linked	Peroxisomal disorders
					Adrenoleukodystrophy
PEX3	8504	0034693	P56589	346	X-linked	Peroxisomal disorders
					Adrenoleukodystrophy
PEX5	5830	0139197	A0A0S2Z480,	347	X-linked	Peroxisomal disorders
			P50542,		Adrenoleukodystrophy
			B4DR50,
			A0A0S2Z4F3,
			A0A0S2Z4H1,
			B4E0T2
PEX6	5190	0124587	A0A024RD09,	348	X-linked	Peroxisomal disorders
			Q13608		Adrenoleukodystrophy
PEX10	5192	0157911	A0A024R068,	349	X-linked	Peroxisomal disorders
			O60683,		Adrenoleukodystrophy
			A0A024R0A4
PEX12	5193	0108733	O00623	350	X-linked	Peroxisomal disorders
					Adrenoleukodystrophy
PEX13	5194	0162928	Q92968	351	X-linked	Peroxisomal disorders
					Adrenoleukodystrophy
PEX14	5195	0142655	O75381	352	X-linked	Peroxisomal disorders
					Adrenoleukodystrophy
PEX16	9409	0121680	Q9Y5Y5	353	X-linked	Peroxisomal disorders
					Adrenoleukodystrophy
PEX19	5824	0162735	P40855,	354	X-linked	Peroxisomal disorders
			A0A0S2Z497		Adrenoleukodystrophy
PEX26	55670	0215193	A0A024R100,	355	X-linked	Peroxisomal disorders
			Q7Z412,		Adrenoleukodystrophy
			A0A0S2Z5M7,
			Q7Z2D7
AMACR	23600	0242110	Q9UHK6	356	Zellweger	Peroxisomal disorders
					Spectrum Disorder
ADA	100	0196839	A0A0S2Z381,	357	Purine Metabolism	Purine Metabolism
			P00813,		Disorder	Disorder
			F5GWI4
ADSL	158	0239900	P30566,	358	Purine Metabolism	Purine Metabolism
			X5D8S6,		Disorder	Disorder
			X5D7W4,
			A0A1B0GWJ0
AMPD1	270	0116748	P23109	359	Purine Metabolism	Purine Metabolism
					Disorder	Disorder
GPHN	10243	0171723	Q9NQX3	360	Purine Metabolism	Purine Metabolism
					Disorder	Disorder
MOCOS	55034	0075643	Q96EN8	361	Purine Metabolism	Purine Metabolism
					Disorder	Disorder
MOCS1	4337	0124615	A0A024RD17,	362	Purine Metabolism	Purine Metabolism
			Q9NZB8		Disorder	Disorder
PNP	4860	0198805	P00491,	363	Purine Metabolism	Purine Metabolism
			V9HWH6		Disorder	Disorder
XDH	7498	0158125	P47989	364	Purine Metabolism	Purine Metabolism
					Disorder	Disorder
SUOX	6821	0139531	A0A024RB79,	365	Purine Metabolism	Purine Metabolism
			P51687		Disorder	Disorder
OGDH	4967	0105953	A0A140VJQ5,	366	2-Ketoglutarate	PYRUVATE
			Q02218,		Dehydrogenase	METABOLISM AND
			B4E3E9,		Deficiency	TRICARBOXYLIC ACID
			E9PCR7,			CYCLE DEFECT
			E9PDF2
SLC25A19	60386	0125454	Q5JPC1,	367	2-Ketoglutarate	PYRUVATE
			Q9HC21		Dehydrogenase	METABOLISM AND
					Deficiency	TRICARBOXYLIC ACID
						CYCLE DEFECT
DHTKD1	55526	0181192	Q96HY7	368	2-Ketoglutarate	PYRUVATE
					Dehydrogenase	METABOLISM AND
					Deficiency	TRICARBOXYLIC ACID
						CYCLE DEFECT
SLC13A5	284111	0141485	Q68D44,	369	Citrate Transporter	PYRUVATE
			Q86YT5		Deficiency	METABOLISM AND
						TRICARBOXYLIC ACID
						CYCLE DEFECT
FH	2271	0091483	A0A0S2Z4C3,	370	Fumarase	PYRUVATE
			P07954		Deficiency	METABOLISM AND
						TRICARBOXYLIC ACID
						CYCLE DEFECT
DLAT	1737	0150768	P10515,	371	Pyruvate	PYRUVATE
			Q86YI5		Dehydrogenase	METABOLISM AND
					Deficiency	TRICARBOXYLIC ACID
						CYCLE DEFECT
MPC1	51660	0060762	Q5TI65,	372	Pyruvate	PYRUVATE
			Q9Y5U8		Dehydrogenase	METABOLISM AND
					Deficiency	TRICARBOXYLIC ACID
						CYCLE DEFECT
PDHA1	5160	0131828	A0A024RBX9,	373	Pyruvate	PYRUVATE
			P08559		Dehydrogenase	METABOLISM AND
					Deficiency	TRICARBOXYLIC ACID
						CYCLE DEFECT
PDHB	5162	0168291	P11177	374	Pyruvate	PYRUVATE
					Dehydrogenase	METABOLISM AND
					Deficiency	TRICARBOXYLIC ACID
						CYCLE DEFECT
PDHX	8050	0110435	O00330	375	Pyruvate	PYRUVATE
					Dehydrogenase	METABOLISM AND
					Deficiency	TRICARBOXYLIC ACID
						CYCLE DEFECT
PDP1	54704	0164951	Q9P0J1,	376	Pyruvate	PYRUVATE
			Q6P1N1,		Dehydrogenase	METABOLISM AND
			A0A024R9C0		Deficiency	TRICARBOXYLIC ACID
						CYCLE DEFECT
ABCC2	1244	0023839	Q92887	377	Dubin-Johnson
					syndrome
SLCO1B1	10599	0134538	A0A024RAU7,	378	Rotor Syndrome
			Q05CV5,
			Q9Y6L6
SLCO1B3	28234	0111700	B3KP78,	379	Rotor Syndrome
			Q9NPD5
HFE2	148738	0168509	Q6ZVN8,	380	Hemochromatosis,
			A8K466,		type 2A
			A0A024R4F5
ADAMTS13	11093	0160323,	Q76LX8	381	Congenital
		0281244			thrombotic
					thrombocytopenic
					purpura due to
					ADAMTS-13
					deficiency
PYGM	5837	0068976	P11217	382	McArdle's Disease
COL1A2	1278	0164692	A0A0S2Z3H5,	383	Ehlers-Danlos
			P08123		syndrome, cardiac
					valvular type
TNFRSF11B	4982	0164761	O00300	384	Juvenile Paget's
					disease
TSC1	7248	0165699	Q86WV8,	385	Tuberous sclerosis
			Q92574,
			X5D9D2,
			Q32NF0
TSC2	7249	0103197	P49815,	386	Tuberous sclerosis
			X5D7Q2,
			B3KWH7,
			Q5HYF7,
			H3BMQ0,
			X5D2U8
DHCR7	1717	0172893	A0A024R5F7,	387	Smith-Lemli-Opitz
			Q9UBM7		Syndrome
PGK1	5230	0102144	P00558,	388	D-
			V9HWF4		glycericacidemia
VLDLR	7436	0147852	P98155,	389	Dysequilibrium
			Q5VVF5		syndrome
KYNU	8942	0115919	Q16719	390	Encephalopathy
					due to
					hydroxykynureninuria
F5	2153	0198734	P12259	391	Factor V
					deficiency
C3	718	0125730	B4DR57,	392	Atypical hemolytic
			P01024,		uremic syndrome
			V9HWA9		with C3 anomaly
COL4A1	1282	0187498	A5PKV2,	393	Autosomal
			F5H5K0,		dominant familial
			P02462		hematuria - retinal
					arteriolar
					tortuosity -
					contractures
CFH	3075	0000971	A0A024R962,	394	Atypical hemolytic
			P08603,		uremic syndrome
			A0A0D9SG88
SLC12A2	6558	0064651	P55011,	395	Bartter syndrome
			Q53ZR1,		type I (neonatal)
			B7ZM24
GK	2710	0198814	B4DH54,	396	Glycerol kinase
			P32189		deficiency
SFTPC	6440	0168484	A0A0A0MTC9,	397	Chronic
			P11686,		respiratory distress
			A0A0S2Z4Q0,		with surfactant
			E5RI64		metabolism
					deficiency
CRTAP	10491	0170275	O75718	398	Osteogenesis
					Imperfecta VII
P3H1	64175	0117385	Q32P28	399	Osteogenesis
					Imperfecta VIII
COL7A1	1294	0114270	Q02388,	400	Autosomal
			Q59F16		recessive
					dystrophic
					epidermolysis
					bullosa
PKLR	5313	0143627	P30613	401	Pyruvate Kinase
					deficiency
TALDO1	6888	0177156	A0A140VK56,	402	Transaldolase
			P37837		deficiency
TF	7018	0091513	A0PJA6,	403	Atransferrinemia
			P02787,		(familial
			Q06AH7		hypotransferrinemia)
EPCAM	4072	0119888	P16422	404	Intestinal epithelial
					dysplasia
VHL	7428	0134086	A0A024R2F2,	405	Familial
			P40337,		erythrocytosis type
			A0A0S2Z4K1		2; von Hippel
					Lindau disease
GC	2638	0145321	P02774	406	Vitamin D
					deficiency
SERPINA1	5265	0197249,	E9KL23,	407	Alpha-1
		0277377	P01009		antitrypsin
					deficiency
ABCC6	368	0091262,	O95255	408	Pseudoxanthoma
		0275331			elasticum
F8	2157	0185010	P00451	409	Hemophilia A
F9	2158	0101981	P00740	410	Hemophilia B
ApoB	338	0084674	P04114	411	Familial
					hypercholesterolemia
PCSK9	255738	0169174	Q8NBP7	412	Familial
					hypercholesterolemia
LDLRAP1	26119	0157978	B3KR97,	413	Familial
			Q5SW96		hypercholesterolemia
ABCG5	64240	0138075	Q9H222	414	Sitosterolemia
ABCG8	64241	0143921	Q9H221	415	Sitosterolemia
LCAT	3931	0213398	A0A140VK24,	416	Lecithin
			P04180		cholesterol
					acyltransferase
					deficiency
SPINK5	11005	0133710	Q9NQ38	417	Netherton
					syndrome
GNE	10020	0159921	Q9Y223	418	Inclusion body
					myopathy 2

In some embodiments, the targeted lipid particle or lentiviral vector contains an exogenous agent that is capable of targeting a T cell. In some embodiments, the exogenous agent capable of targeting a T cell is a chimeric antigen receptor (CAR), a T cell receptor, an integrin, an ion channel, a pore forming protein, a Toll-Like Receptor, an interleukin receptor, a cell adhesion protein, or a transport protein.

In some embodiments, the CAR is or comprises a first generation CAR comprising an antigen binding domain, a transmembrane domain, and signaling domain (e.g., one, two or three signaling domains). In some embodiments, the CAR comprises a third generation CAR comprising an antigen binding domain, a transmembrane domain, and at least three signaling domains. In some embodiments, a fourth generation CAR comprising an antigen binding domain, a transmembrane domain, three or four signaling domains, and a domain which upon successful signaling of the CAR induces expression of a cytokine gene. In some embodiments, the antigen binding domain is or comprises an scFv or Fab.

In some embodiments, a CAR antigen binding domain is or comprises an antibody or antigen-binding portion thereof. In some embodiments, a CAR antigen binding domain is or comprises an scFv or Fab. In some embodiments a CAR antigen binding domain comprises an scFv or Fab fragment of a T-cell alpha chain antibody; T-cell β chain antibody; T-cell γ chain antibody; T-cell δ chain antibody; CCR7 antibody; CD3 antibody; CD4 antibody; CD5 antibody; CD7 antibody; CD8 antibody; CD11b antibody; CD11c antibody; CD16 antibody; CD19 antibody; CD20 antibody; CD21 antibody; CD22 antibody; CD25 antibody; CD28 antibody; CD34 antibody; CD35 antibody; CD40 antibody; CD45RA antibody; CD45RO antibody; CD52 antibody; CD56 antibody; CD62L antibody; CD68 antibody; CD80 antibody; CD95 antibody; CD117 antibody; CD127 antibody; CD133 antibody; CD137 (4-1 BB) antibody; CD163 antibody; F4/80 antibody; IL-4Ra antibody; Sca-1 antibody; CTLA-4 antibody; GITR antibody GARP antibody; LAP antibody; granzyme B antibody; LFA-1 antibody; MR1 antibody; uPAR antibody; or transferrin receptor antibody.

In some embodiments, a CAR binding domain binds to a cell surface antigen of a cell. In some embodiments, a cell surface antigen is characteristic of one type of cell. In some embodiments, a cell surface antigen is characteristic of more than one type of cell.

In some embodiments, the antigen binding domain of the CAR targets an antigen characteristic of a T cell. In some embodiments, the antigen characteristic of a T cell is selected from a cell surface receptor, a membrane transport protein (e.g., an active or passive transport protein such as, for example, an ion channel protein, a pore-forming protein, etc.), a transmembrane receptor, a membrane enzyme, and/or a cell adhesion protein characteristic of a T cell. In some embodiments, an antigen characteristic of a T cell may be a G protein-coupled receptor, receptor tyrosine kinase, tyrosine kinase associated receptor, receptor-like tyrosine phosphatase, receptor serine/threonine kinase, receptor guanylyl cyclase, histidine kinase associated receptor, AKT1; AKT2; AKT3; ATF2; BCL10; CALM1; CD3D (CD3δ); CD3E (CD3ε); CD3G (CD3γ); CD4; CD8; CD28; CD45; CD80 (B7-1); CD86 (B7-2); CD247 (CD3ζ); CTLA4 (CD152); ELK1; ERK1 (MAPK3); ERK2; FOS; FYN; GRAP2 (GADS); GRB2; HLA-DRA; HLA-DRB1; HLA-DRB3; HLA-DRB4; HLA-DRB5; HRAS; IKBKA (CHUK); IKBKB; IKBKE; IKBKG (NEMO); IL2; ITPR1; ITK; JUN; KRAS2; LAT; LCK; MAP2K1 (MEK1); MAP2K2 (MEK2); MAP2K3 (MKK3); MAP2K4 (MKK4); MAP2K6 (MKK6); MAP2K7 (MKK7); MAP3K1 (MEKK1); MAP3K3; MAP3K4; MAP3K5; MAP3K8; MAP3K14 (NIK); MAPK8 (JNK1); MAPK9 (JNK2); MAPK10 (JNK3); MAPK11 (p38β); MAPK12 (p38γ); MAPK13 (p38δ); MAPK14 (p38a); NCK; NFAT1; NFAT2; NFKB1; NFKB2; NFKBIA; NRAS; PAK1; PAK2; PAK3; PAK4; PIK3C2B; PIK3C3 (VPS34); PIK3CA; PIK3CB; PIK3CD; PIK3R1; PKCA; PKCB; PKCM; PKCQ; PLCY1; PRF1 (Perforin); PTEN; RAC1; RAF1; RELA; SDF1; SHP2; SLP76; SOS; SRC; TBK1; TCRA; TEC; TRAF6; VAV1; VAV2; or ZAP70.

In some embodiments, the antigen binding domain of the CAR targets an antigen characteristic of a disorder. In some embodiments, the disease or disorder is associates with CD4+ T cells. In some embodiments, the disease or disorder is associated with CD8+ T cells.

In some embodiments, the CAR transmembrane domain comprises at least a transmembrane region of the alpha, beta or zeta chain of a T cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, or functional variant thereof. In some embodiments, the transmembrane domain comprises at least a transmembrane region(s) of CD8α, CD8β, 4-1BB/CD137, CD28, CD34, CD4, FcεRIγ, CD16, OX40/CD134, CD3ζ, CD3ε, CD3γ, CD3δ, TCRα, TCRβ, TCRζ, CD32, CD64, CD64, CD45, CD5, CD9, CD22, CD37, CD80, CD86, CD40, CD40L/CD154, VEGFR2, FAS, and FGFR2B, or functional variant thereof.

In some embodiments, the CAR comprises at least one signaling domain selected from one or more of B7-1/CD80; B7-2/CD86; B7-H1/PD-L1; B7-H2; B7-H3; B7-H4; B7-H6; B7-H7; BTLA/CD272; CD28; CTLA-4; Gi24/VISTA/B7-H5; ICOS/CD278; PD-1; PD-L2/B7-DC; PDCD6); 4-1BB/TNFSF9/CD137; 4-1BB Ligand/TNFSF9; BAFF/BLyS/TNFSF13B; BAFF R/TNFRSF13C; CD27/TNFRSF7; CD27 Ligand/TNFSF7; CD30/TNFRSF8; CD30 Ligand/TNFSF8; CD40/TNFRSF5; CD40/TNFSF5; CD40 Ligand/TNFSF5; DR3/TNFRSF25; GITR/TNFRSF18; GITR Ligand/TNFSF18; HVEM/TNFRSF14; LIGHT/TNFSF14; Lymphotoxin-alpha/TNF-beta; OX40/TNFRSF4; OX40 Ligand/TNFSF4; RELT/TNFRSF19L; TACI/TNFRSF13B; TL1A/TNFSF15; TNF-alpha; TNF RII/TNFRSF1B); 2B4/CD244/SLAMF4; BLAME/SLAMF8; CD2; CD2F-10/SLAMF9; CD48/SLAMF2; CD58/LFA-3; CD84/SLAMF5; CD229/SLAMF3; CRACC/SLAMF7; NTB-A/SLAMF6; SLAM/CD150); CD2; CD7; CD53; CD82/Kai-1; CD90/Thy1; CD96; CD160; CD200; CD300a/LMIR1; HLA Class I; HLA-DR; Ikaros; Integrin alpha 4/CD49d; Integrin alpha 4 beta 1; Integrin alpha 4 beta 7/LPAM-1; LAG-3; TCL1A; TCL1B; CRTAM; DAP12; Dectin-1/CLEC7A; DPPIV/CD26; EphB6; TIM-1/KIM-1/HAVCR; TIM-4; TSLP; TSLP R; lymphocyte function associated antigen-1 (LFA-1); NKG2C, a CD3 zeta domain, an immunoreceptor tyrosine-based activation motif (ITAM), CD27, CD28, 4-1BB, CD134/OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83, or functional fragment thereof.

In some embodiments, the CAR comprises a CD3 zeta domain or an immunoreceptor tyrosine-based activation motif (ITAM), or functional variant thereof. In some embodiments, the CAR comprises (i) a CD3 zeta domain, or an immunoreceptor tyrosine-based activation motif (ITAM), or functional variant thereof; and (ii) a CD28 domain, or a 4-1BB domain, or functional variant thereof. In some embodiments, the CAR comprises a (i) a CD3 zeta domain, or an immunoreceptor tyrosine-based activation motif (ITAM), or functional variant thereof; (ii) a CD28 domain or functional variant thereof; and (iii) a 4-1BB domain, or a CD134 domain, or functional variant thereof. In some embodiments, the CAR comprises (i) a CD3 zeta domain, or an immunoreceptor tyrosine-based activation motif (ITAM), or functional variant thereof; (ii) a CD28 domain, or a 4-1BB domain, or functional variant thereof, and/or (iii) a 4-1BB domain, or a CD134 domain, or functional variant thereof. In some embodiments, the CAR comprises a (i) a CD3 zeta domain, or an immunoreceptor tyrosine-based activation motif (ITAM), or functional variant thereof; (ii) a CD28 domain or functional variant thereof; (iii) a 4-1BB domain, or a CD134 domain, or functional variant thereof; and (iv) a cytokine or costimulatory ligand transgene.

In certain embodiments, the intracellular signaling domain comprises a CD28 transmembrane and signaling domain linked to a CD3 (e.g., CD3-zeta) intracellular domain. In some embodiments, the intracellular signaling domain comprises a chimeric CD28 and CD137 (4-1BB, TNFRSF9) co-stimulatory domains, linked to a CD3 zeta intracellular domain

In some embodiments, the CAR encompasses one or more, e.g., two or more, costimulatory domains and an activation domain, e.g., primary activation domain, in the cytoplasmic portion. Exemplary CARs include intracellular components of CD3-zeta, CD28, and 4-1BB.

In some embodiments the intracellular signaling domain includes intracellular components of a 4-1BB signaling domain and a CD3-zeta signaling domain. In some embodiments, the intracellular signaling domain includes intracellular components of a CD28 signaling domain and a CD3zeta signaling domain.

In some embodiments, the CAR comprises an extracellular antigen binding domain (e.g., antibody or antibody fragment, such as an scFv) that binds to an antigen (e.g. tumor antigen), a spacer (e.g. containing a hinge domain, such as any as described herein), a transmembrane domain (e.g. any as described herein), and an intracellular signaling domain (e.g. any intracellular signaling domain, such as a primary signaling domain or costimulatory signaling domain as described herein). In some embodiments, the intracellular signaling domain is or includes a primary cytoplasmic signaling domain. In some embodiments, the intracellular signaling domain additionally includes an intracellular signaling domain of a costimulatory molecule (e.g., a costimulatory domain). Examples of exemplary components of a CAR are described in Table 6. In provided aspects, the sequences of each component in a CAR can include any combination listed in Table 6.

TABLE 6
CAR components and Exemplary Sequences
		SEQ
		ID
Component	Sequence	NO
Extracellular binding domain
Anti-CD19	DIQMTQTTSSLSASLGDRVTISCRASQDISKY	419
scFv (FMC63)	LNWYQQKPDGTVKLLIYHTSRLHSGVPSRFS
	GSGSGTDYSLTISNLEQEDIATYFCQQGNTLP
	YTFGGGTKLEITGSTSGSGKPGSGEGSTKGE
	VKLQESGPGLVAPSQSLSVTCTVSGVSLPDY
	GVSWIRQPPRKGLEWLGVIWGSETTYYNSA
	LKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYY
	CAKHYYYGGSYAMDYWGQGTSVTVSS
Anti-CD19	DIQMTQTTSSLSASLGDRVTISCRASQDISKY	420
scFv (FMC63)	LNWYQQKPDGTVKLLIYHTSRLHSGVPSRFS
	GSGSGTDYSLTISNLEQEDIATYFCQQGNTLP
	YTFGGGTKLEITGGGGSGGGGSGGGGSEVK
	LQESGPGLVAPSQSLSVTCTVSGVSLPDYGV
	SWIRQPPRKGLEWLGVIWGSETTYYNSALKS
	RLTIIKDNSKSQVFLKMNSLQTDDTAIYYCA
	KHYYYGGSYAMDYWGQGTSVTVSS
Spacer (e.g. hinge)
IgG4 Hinge	ESKYGPPCPPCP	421
CD8 Hinge	TTTPAPRPPTPAPTIASQPLSLRPE	422
CD28	IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPL	423
	FPGPSKP
Transmembrane
CD8	ACRPAAGGAVHTRGLDFACDIYIWAPLAGT	424
	CGVLLLSLVITLYC
CD28	FWVLVVVGGVLACYSLLVTVAFIIFWV	425
CD28	FWVLVVVGGVLACYSLLVTVAFIIFWV	426
Costimulatory domain
CD28	RSKRSRLLHSDYMNMTPRRPGPTRKHYQPY	427
	APPRDFAAYRS
4-1BB	KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCR	428
	FPEEEEGGCEL
Primary Signaling Domain
CD3zeta	RVKFSRSADAPAYQQGQNQLYNELNLGRRE	429
	EYDVLDKRRGRDPEMGGKPRRKNPQEGLY
	NELQKDKMAEAYSEIGMKGERRRGKGHDG
	LYQGLSTATKDTYDALHMQALPPR
CD3zeta	RVKFSRSADAPAYKQGQNQLYNELNLGRRE	430
	EYDVLDKRRGRDPEMGGKPRRKNPQEGLY
	NELQKDKMAEAYSEIGMKGERRRGKGHDG
	LYQGLSTATKDTYDALHMQALPPR

In some embodiments, the CAR further comprises one or more spacers, e.g., wherein the spacer is a first spacer between the antigen binding domain and the transmembrane domain. In some embodiments, the first spacer includes at least a portion of an immunoglobulin constant region or variant or modified version thereof. In some embodiments, the spacer is a second spacer between the transmembrane domain and a signaling domain. In some embodiments, the second spacer is an oligopeptide, e.g., wherein the oligopeptide comprises glycine-serine doublets.

In addition to the CARs described herein, various chimeric antigen receptors and nucleotide sequences encoding the same are known and would be suitable for fusosomal delivery and reprogramming of target cells in vivo and in vitro as described herein. See, e.g., WO2013040557; WO2012079000; WO2016030414; Smith T, et al., Nature Nanotechnology. 2017. (DOI: 10.1038/NNANO.2017.57), the disclosures of which are herein incorporated by reference in their entirety.

In some embodiments a targeted lipid particle comprising a CAR or a nucleic acid encoding a CAR (e.g., a DNA, a gDNA, a cDNA, an RNA, a pre-MRNA, an mRNA, an miRNA, an siRNA, etc.) is delivered to a target cell. In some embodiments the target cell is an effector cell, e.g., a cell of the immune system that expresses one or more Fc receptors and mediates one or more effector functions. In some embodiments, a target cell may include, but may not be limited to, one or more of a monocyte, macrophage, neutrophil, dendritic cell, eosinophil, mast cell, platelet, large granular lymphocyte, Langerhans' cell, natural killer (NK) cell, T lymphocyte (e.g., T cell), a Gamma delta T cell, B lymphocyte (e.g., B cell) and may be from any organism including but not limited to humans, mice, rats, rabbits, and monkeys.

E. Methods of Generating Targeted Lipid Particles

Provided herein is a targeted lipid particle comprising a lipid bilayer, a lumen surrounded by the lipid bilayer, a targeted envelope protein, and a fusogen, in which the targeted envelope protein and fusogen are embedded within the lipid bilayer. In some embodiments, the targeted lipid particle can be a viral particle, a virus-like particle, a nanoparticle, a vesicle, an exosome, a dendrimer, a lentivirus, a viral vector, an enucleated cell, a microvesicle, a membrane vesicle, an extracellular membrane vesicle, a plasma membrane vesicle, a giant plasma membrane vesicle, an apoptotic body, a mitoparticle, a pyrenocyte, a lysosome, another membrane enclosed vesicle, or a lentiviral vector, a viral based particle, a virus like particle (VLP) or a cell derived particle.

I. Virus-Like Particles

Provided herein are targeted lipid particles that are derived from virus, such as viral particles or virus-like particles, including those derived from retroviruses or lentiviruses. In some embodiments, the targeted lipid particle's bilayer of amphipathic lipids is or comprises the viral envelope. In some embodiments, the targeted lipid particle's bilayer of amphipathic lipids is or comprises lipids derived from a producer cell. In some embodiments, the viral envelope may comprise a fusogen, e.g., a fusogen that is endogenous to the virus or a pseudotyped fusogen. In some embodiments, the targeted lipid particle's lumen or cavity comprises a viral nucleic acid, e.g., a retroviral nucleic acid, e.g., a lentiviral nucleic acid. In some embodiments, the viral nucleic acid may be a viral genome. In some embodiments, the targeted lipid particle further comprises one or more viral non-structural proteins, e.g., in its cavity or lumen. In some embodiments, the targeted lipid particles is or comprises a virus-like particle (VLP). In some embodiments, the VLP does not comprise an envelope. In some embodiments, the VLP comprises an envelope.

In some embodiments, the viral particle or virus-like particle, such as retrovirus or retrovirus-like particle, comprises one or more of gag polyprotein, polymerase (e.g., pol), integrase (e.g., a functional or non-functional variant), protease, and a fusogen. In some embodiments, the targeted lipid particle further comprises rev. In some embodiments, one or more of the aforesaid proteins are encoded in the retroviral genome, and in some embodiments, one or more of the aforesaid proteins are provided in trans, e.g., by a helper cell, helper virus, or helper plasmid. In some embodiments, the targeted lipid particle nucleic acid (e.g., retroviral nucleic acid) comprises one or more of the following nucleic acid sequences: 5′ LTR (e.g., comprising U5 and lacking a functional U3 domain), Psi packaging element (Psi), Central polypurine tract (cPPT) Promoter operatively linked to the payload gene, payload gene (optionally comprising an intron before the open reading frame), Poly A tail sequence, WPRE, and 3′ LTR (e.g., comprising U5 and lacking a functional U3). In some embodiments the targeted lipid particle nucleic acid further comprises one or more insulator element. In some embodiments, the recognition sites are situated between the poly A tail sequence and the WPRE.

In some embodiments, the targeted lipid particle comprises supramolecular complexes formed by viral proteins that self-assemble into capsids. In some embodiments, the targeted lipid particle is a viral particle or virus-like particle derived from viral capsids. In some embodiments, the targeted lipid particle is a viral particle or virus-like particle derived from viral nucleocapsids. In some embodiments, the targeted lipid particle comprises nucleocapsid-derived that retain the property of packaging nucleic acids. In some embodiments, the viral particles or virus-like particles comprises only viral structural glycoproteins. In some embodiments, the targeted lipid particle does not contain a viral genome.

In some embodiments, the targeted lipid particle packages nucleic acids from host cells during the expression process. In some embodiments, the nucleic acids do not encode any genes involved in virus replication. In particular embodiments, the targeted lipid particle is a virus-like particle, e.g. retrovirus-like particle such as a lentivirus-like particle, that is replication defective.

In some cases, the targeted lipid particle is a viral particle that is morphologically indistinguishable from the wild type infectious virus. In some embodiments, the viral particle presents the entire viral proteome as an antigen. In some embodiments, the viral particle presents only a portion of the proteome as an antigen.

In some embodiments, the viral particle or virus-like particle is produced utilizing proteins (e.g., envelope proteins) from a virus within the Paramyxoviridae family In some embodiments, the Paramyxoviridae family comprises members within the Henipavirus genus. In some embodiments, the Henipavirus is or comprises a Hendra (HeV) or a Nipah (NiV) virus. In particular embodiments, the viral particles or virus-like particles incorporate a targeted envelope protein and fusogen as described in Section I.A. and 1.B.

In some embodiments, viral particles or virus-like particles may be produced in multiple cell culture systems including bacteria, mammalian cell lines, insect cell lines, yeast and plant cells.

In some embodiments, the assembly of a viral particle or virus-like particle is initiated by binding of the core protein to a unique encapsidation sequence within the viral genome (e.g. UTR with stem-loop structure). In some embodiments, the interaction of the core with the encapsidation sequence facilitates oligomerization.

In some embodiments, the targeted lipid particle is a virus-like particle which comprises a sequence that is devoid of or lacking viral RNA may be the result of removing or eliminating the viral RNA from the sequence. In some embodiments, this may be achieved by using an endogenous packaging signal binding site on gag. In some embodiments, the endogenous packaging signal binding site is on pol. In some embodiments, the RNA which is to be delivered will contain a cognate packaging signal. In some embodiments, a heterologous binding domain (which is heterologous to gag) located on the RNA to be delivered, and a cognate binding site located on gag or pol, can be used to ensure packaging of the RNA to be delivered. In some embodiments, the heterologous sequence could be non-viral or it could be viral, in which case it may be derived from a different virus. In some embodiments, the vector particles could be used to deliver therapeutic RNA, in which case functional integrase and/or reverse transcriptase is not required. In some embodiments, the vector particles could also be used to deliver a therapeutic gene of interest, in which case pol is typically included.

a. Transfer Vectors

In some embodiments, the retroviral nucleic acid comprises one or more of (e.g., all of): a 5′ promoter (e.g., to control expression of the entire packaged RNA), a 5′ LTR (e.g., that includes R (polyadenylation tail signal) and/or U5 which includes a primer activation signal), a primer binding site, a psi packaging signal, a RRE element for nuclear export, a promoter directly upstream of the transgene to control transgene expression, a transgene (or other exogenous agent element), a polypurine tract, and a 3′ LTR (e.g., that includes a mutated U3, a R, and U5). In some embodiments, the retroviral nucleic acid further comprises one or more of a cPPT, a WPRE, and/or an insulator element.

A retrovirus typically replicates by reverse transcription of its genomic RNA into a linear double-stranded DNA copy and subsequently covalently integrates its genomic DNA into a host genome. Illustrative retroviruses suitable for use in particular embodiments, include, but are not limited to: Moloney murine leukemia virus (M-MuLV), Moloney murine sarcoma virus (MoMSV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), gibbon ape leukemia virus (GaLV), feline leukemia virus (FLV), spumavirus, Friend murine leukemia virus, Murine Stem Cell Virus (MSCV) and Rous Sarcoma Virus (RSV), and lentivirus.

In some embodiments the retrovirus is a Gammaretrovirus. In some embodiments the retrovirus is an Epsilonretrovirus. In some embodiments the retrovirus is an Alpharetrovirus. In some embodiments the retrovirus is a Betaretrovirus. In some embodiments the retrovirus is a Deltaretrovirus. In some embodiments the retrovirus is a Lentivirus. In some embodiments the retrovirus is a Spumaretrovirus. In some embodiments the retrovirus is an endogenous retrovirus.

Illustrative lentiviruses include, but are not limited to: HIV (human immunodeficiency virus; including HIV type 1, and HIV type 2); visna-maedi virus (VMV) virus; the caprine arthritis-encephalitis virus (CAEV); equine infectious anemia virus (EIAV); feline immunodeficiency virus (FIV); bovine immune deficiency virus (BIV); and simian immunodeficiency virus (SIV). In some embodiments, HIV based vector backbones (i.e., HIV cis-acting sequence elements) are used.

In some embodiments, a vector herein is a nucleic acid molecule capable transferring or transporting another nucleic acid molecule. The transferred nucleic acid is generally linked to, e.g., inserted into, the vector nucleic acid molecule. A vector may include sequences that direct autonomous replication in a cell, or may include sequences sufficient to allow integration into host cell DNA. Useful vectors include, for example, plasmids (e.g., DNA plasmids or RNA plasmids), transposons, cosmids, bacterial artificial chromosomes, and viral vectors. Useful viral vectors include, e.g., replication defective retroviruses and lentiviruses.

In some embodiments, a viral vector comprises a nucleic acid molecule (e.g., a transfer plasmid) that includes virus-derived nucleic acid elements that typically facilitate transfer of the nucleic acid molecule or integration into the genome of a cell or to a viral particle that mediates nucleic acid transfer. Viral particles will typically include various viral components and sometimes also host cell components in addition to nucleic acid(s). In some embodiments, a viral vector comprises e.g., a virus or viral particle capable of transferring a nucleic acid into a cell, or to the transferred nucleic acid (e.g., as naked DNA). In some embodiments, a viral vectors and transfer plasmids comprise structural and/or functional genetic elements that are primarily derived from a virus. A retroviral vector can comprise a viral vector or plasmid containing structural and functional genetic elements, or portions thereof, that are primarily derived from a retrovirus. A lentiviral vector can comprise a viral vector or plasmid containing structural and functional genetic elements, or portions thereof, including LTRs that are primarily derived from a lentivirus.

In embodiments, a lentiviral vector (e.g., lentiviral expression vector) may comprise a lentiviral transfer plasmid (e.g., as naked DNA) or an infectious lentiviral particle. With respect to elements such as cloning sites, promoters, regulatory elements, heterologous nucleic acids, etc., it is to be understood that the sequences of these elements can be present in RNA form in lentiviral particles and can be present in DNA form in DNA plasmids.

In some embodiments, in the vectors described herein at least part of one or more protein coding regions that contribute to or are essential for replication may be absent compared to the corresponding wild-type virus. In some embodiments, the viral vector replication-defective. In some embodiments, the vector is capable of transducing a target non-dividing host cell and/or integrating its genome into a host genome.

In some embodiments, the structure of a wild-type retrovirus genome often comprises a 5′ long terminal repeat (LTR) and a 3′ LTR, between or within which are located a packaging signal to enable the genome to be packaged, a primer binding site, integration sites to enable integration into a host cell genome and gag, pol and env genes encoding the packaging components which promote the assembly of viral particles. More complex retroviruses have additional features, such as rev and RRE sequences in HIV, which enable the efficient export of RNA transcripts of the integrated provirus from the nucleus to the cytoplasm of an infected target cell. In the provirus, the viral genes are flanked at both ends by regions called long terminal repeats (LTRs). In some embodiments, the LTRs are involved in proviral integration and transcription. In some embodiments, LTRs serve as enhancer-promoter sequences and can control the expression of the viral genes. In some embodiments, encapsidation of the retroviral RNAs occurs by virtue of a psi sequence located at the 5′ end of the viral genome.

In some embodiments, LTRs are similar sequences that can be divided into three elements, which are called U3, R and U5. U3 is derived from the sequence unique to the 3′ end of the RNA. R is derived from a sequence repeated at both ends of the RNA and U5 is derived from the sequence unique to the 5′ end of the RNA. The sizes of the three elements can vary considerably among different retroviruses.

In some embodiments, for the viral genome, the site of transcription initiation is typically at the boundary between U3 and R in one LTR and the site of poly (A) addition (termination) is at the boundary between R and U5 in the other LTR. U3 contains most of the transcriptional control elements of the provirus, which include the promoter and multiple enhancer sequences responsive to cellular and in some cases, viral transcriptional activator proteins. In some embodiments, retroviruses comprise any one or more of the following genes that code for proteins that are involved in the regulation of gene expression: tat, rev, tax and rex.

In some embodiments, the structural genes gag, pol and env, gag encodes the internal structural protein of the virus. In some embodiments, Gag protein is proteolytically processed into the mature proteins MA (matrix), CA (capsid) and NC (nucleocapsid). In some embodiments, the pol gene encodes the reverse transcriptase (RT), which contains DNA polymerase, associated RNase H and integrase (IN), which mediate replication of the genome. In some embodiments, the env gene encodes the surface (SU) glycoprotein and the transmembrane (TM) protein of the virion, which form a complex that interacts specifically with cellular receptor proteins. In some embodiments, the interaction promotes infection by fusion of the viral membrane with the cell membrane.

In some embodiments, a replication-defective retroviral vector genome gag, pol and env may be absent or not functional. In some embodiments, the R regions at both ends of the RNA are typically repeated sequences. In some embodiments, U5 and U3 represent unique sequences at the 5′ and 3′ ends of the RNA genome respectively.

In some embodiments, retroviruses may also contain additional genes which code for proteins other than gag, pol and env. Examples of additional genes include (in HIV), one or more of vif, vpr, vpx, vpu, tat, rev and nef. EIAV has (amongst others) the additional gene S2. In some embodiments, proteins encoded by additional genes serve various functions, some of which may be duplicative of a function provided by a cellular protein. In EIAV, for example, tat acts as a transcriptional activator of the viral LTR (Derse and Newbold 1993 Virology 194:530-6; Maury et al. 1994 Virology 200:632-42). It binds to a stable, stem-loop RNA secondary structure referred to as TAR. Rev regulates and co-ordinates the expression of viral genes through rev-response elements (RRE) (Martarano et al. 1994 J. Virol. 68:3102-11).

In some embodiments, in addition to protease, reverse transcriptase and integrase, non-primate lentiviruses contain a fourth pol gene product which codes for a dUTPase. In some embodiments, this a role in the ability of these lentiviruses to infect certain non-dividing or slowly dividing cell types.

In embodiments, a recombinant lentiviral vector (RLV) is a vector with sufficient retroviral genetic information to allow packaging of an RNA genome, in the presence of packaging components, into a viral particle capable of infecting a target cell. In some embodiments, infection of the target cell can comprise reverse transcription and integration into the target cell genome. In some embodiments, the RLV typically carries non-viral coding sequences which are to be delivered by the vector to the target cell. In some embodiments, an RLV is incapable of independent replication to produce infectious retroviral particles within the target cell. In some embodiments, the RLV lacks a functional gag-pol and/or env gene and/or other genes involved in replication. In some embodiments, the vector may be configured as a split-intron vector, e.g., as described in PCT patent application WO 99/15683, which is herein incorporated by reference in its entirety.

In some embodiments, the lentiviral vector comprises a minimal viral genome, e.g., the viral vector has been manipulated so as to remove the non-essential elements and to retain the essential elements in order to provide the required functionality to infect, transduce and deliver a nucleotide sequence of interest to a target host cell, e.g., as described in WO 98/17815, which is herein incorporated by reference in its entirety.

In some embodiments, a minimal lentiviral genome may comprise, e.g., (5′)R-U5-one or more first nucleotide sequences-U3-R(3′). In some embodiments, the plasmid vector used to produce the lentiviral genome within a source cell can also include transcriptional regulatory control sequences operably linked to the lentiviral genome to direct transcription of the genome in a source cell. In some embodiments, the regulatory sequences may comprise the natural sequences associated with the transcribed retroviral sequence, e.g., the 5′ U3 region, or they may comprise a heterologous promoter such as another viral promoter, for example the CMV promoter. In some embodiments, lentiviral genomes comprise additional sequences to promote efficient virus production. In some embodiments, in the case of HIV, rev and RRE sequences may be included. In some embodiments, alternatively or combination, codon optimization may be used, e.g., the gene encoding the exogenous agent may be codon optimized, e.g., as described in WO 01/79518, which is herein incorporated by reference in its entirety. In some embodiments, alternative sequences which perform a similar or the same function as the rev/RRE system may also be used. In some embodiments, a functional analogue of the rev/RRE system is found in the Mason Pfizer monkey virus. In some embodiments, this is known as CTE and comprises an RRE-type sequence in the genome which is believed to interact with a factor in the infected cell. The cellular factor can be thought of as a rev analogue. In some embodiments, CTE may be used as an alternative to the rev/RRE system. In some embodiments, the Rex protein of HTLV-I can functionally replace the Rev protein of HIV-I. Rev and Rex have similar effects to IRE-BP.

In some embodiments, a retroviral nucleic acid (e.g., a lentiviral nucleic acid, e.g., a primate or non-primate lentiviral nucleic acid) (1) comprises a deleted gag gene wherein the deletion in gag removes one or more nucleotides downstream of about nucleotide 350 or 354 of the gag coding sequence; (2) has one or more accessory genes absent from the retroviral nucleic acid; (3) lacks the tat gene but includes the leader sequence between the end of the 5′ LTR and the ATG of gag; and (4) combinations of (1), (2) and (3). In an embodiment the lentiviral vector comprises all of features (1) and (2) and (3). This strategy is described in more detail in WO 99/32646, which is herein incorporated by reference in its entirety.

In some embodiments, a primate lentivirus minimal system requires none of the HIV/SIV additional genes vif, vpr, vpx, vpu, tat, rev and nef for either vector production or for transduction of dividing and non-dividing cells. In some embodiments, an EIAV minimal vector system does not require S2 for either vector production or for transduction of dividing and non-dividing cells.

In some embodiments, the deletion of additional genes may permit vectors to be produced without the genes associated with disease in lentiviral (e.g. HIV) infections. In some embodiments, tat is associated with disease. In some embodiments, the deletion of additional genes permits the vector to package more heterologous DNA. In some embodiments, genes whose function is unknown, such as S2, may be omitted, thus reducing the risk of causing undesired effects. Examples of minimal lentiviral vectors are disclosed in WO 99/32646 and in WO 98/17815.

In some embodiments, the retroviral nucleic acid is devoid of at least tat and S2 (if it is an EIAV vector system), and possibly also vif, vpr, vpx, vpu and nef. In some embodiments, the retroviral nucleic acid is also devoid of rev, RRE, or both.

In some embodiments the retroviral nucleic acid comprises vpx. The Vpx polypeptide binds to and induces the degradation of the SAMHD1 restriction factor, which degrades free dNTPs in the cytoplasm. In some embodiments, the concentration of free dNTPs in the cytoplasm increases as Vpx degrades SAMHD1 and reverse transcription activity is increased, thus facilitating reverse transcription of the retroviral genome and integration into the target cell genome.

In some embodiments, different cells differ in their usage of particular codons. In some embodiments, this codon bias corresponds to a bias in the relative abundance of particular tRNAs in the cell type. In some embodiments, by altering the codons in the sequence so that they are tailored to match with the relative abundance of corresponding tRNAs, it is possible to increase expression. In some embodiments, it is possible to decrease expression by deliberately choosing codons for which the corresponding tRNAs are known to be rare in the particular cell type. In some embodiments, an additional degree of translational control is available. An additional description of codon optimization is found, e.g., in WO 99/41397, which is herein incorporated by reference in its entirety.

In some embodiments viruses, including HIV and other lentiviruses, use a large number of rare codons and by changing these to correspond to commonly used mammalian codons, increased expression of the packaging components in mammalian producer cells can be achieved.

In some embodiments, codon optimization has a number of other advantages. In some embodiments, by virtue of alterations in their sequences, the nucleotide sequences encoding the packaging components may have RNA instability sequences (INS) reduced or eliminated from them. At the same time, the amino acid sequence coding sequence for the packaging components is retained so that the viral components encoded by the sequences remain the same, or at least sufficiently similar that the function of the packaging components is not compromised. In some embodiments, codon optimization also overcomes the Rev/RRE requirement for export, rendering optimized sequences Rev independent. In some embodiments, codon optimization also reduces homologous recombination between different constructs within the vector system (for example between the regions of overlap in the gag-pol and env open reading frames). In some embodiments, codon optimization leads to an increase in viral titer and/or improved safety.

In some embodiments, only codons relating to INS are codon optimized. In other embodiments, the sequences are codon optimized in their entirety, with the exception of the sequence encompassing the frameshift site of gag-pol.

The gag-pol gene comprises two overlapping reading frames encoding the gag-pol proteins. The expression of both proteins depends on a frameshift during translation. This frameshift occurs as a result of ribosome “slippage” during translation. This slippage is thought to be caused at least in part by ribosome-stalling RNA secondary structures. Such secondary structures exist downstream of the frameshift site in the gag-pol gene. For HIV, the region of overlap extends from nucleotide 1222 downstream of the beginning of gag (wherein nucleotide 1 is the A of the gag ATG) to the end of gag (nt 1503). Consequently, a 281 bp fragment spanning the frameshift site and the overlapping region of the two reading frames is preferably not codon optimized. In some embodiments, retaining this fragment will enable more efficient expression of the gag-pol proteins. For EIAV, the beginning of the overlap is at nt 1262 (where nucleotide 1 is the A of the gag ATG). The end of the overlap is at nt 1461. In order to ensure that the frameshift site and the gag-pol overlap are preserved, the wild type sequence may be retained from nt 1156 to 1465.

In some embodiments, derivations from optimal codon usage may be made, for example, in order to accommodate convenient restriction sites, and conservative amino acid changes may be introduced into the gag-pol proteins.

In some embodiments, codon optimization is based on codons with poor codon usage in mammalian systems. The third and sometimes the second and third base may be changed.

In some embodiments, due to the degenerate nature of the genetic code, it will be appreciated that numerous gag-pol sequences can be achieved by a skilled worker. Also, there are many retroviral variants described which can be used as a starting point for generating a codon optimized gag-pol sequence. Lentiviral genomes can be quite variable. For example there are many quasi-species of HIV-I which are still functional. This is also the case for EIAV. These variants may be used to enhance particular parts of the transduction process. Examples of HIV-I variants may be found in the HIV databases maintained by Los Alamos National Laboratory. Details of EIAV clones may be found at the NCBI database maintained by the National Institutes of Health.

In some embodiments, the strategy for codon optimized gag-pol sequences can be used in relation to any retrovirus, e.g., EIAV, FIV, BIV, CAEV, VMR, SIV, HIV-I and HIV-2. In addition this method could be used to increase expression of genes from HTLV-I, HTLV-2, HFV, HSRV and human endogenous retroviruses (HERV), MLV and other retroviruses.

In embodiments, the retroviral vector comprises a packaging signal that comprises from 255 to 360 nucleotides of gag in vectors that still retain env sequences, or about 40 nucleotides of gag in a particular combination of splice donor mutation, gag and env deletions. In some embodiments, the retroviral vector includes a gag sequence which comprises one or more deletions, e.g., the gag sequence comprises about 360 nucleotides derivable from the N-terminus.

In some embodiments, the retroviral vector, helper cell, helper virus, or helper plasmid may comprise retroviral structural and accessory proteins, for example gag, pol, env, tat, rev, vif, vpr, vpu, vpx, or nef proteins or other retroviral proteins. In some embodiments the retroviral proteins are derived from the same retrovirus. In some embodiments the retroviral proteins are derived from more than one retrovirus, e.g. 2, 3, 4, or more retroviruses.

In some embodiments, the gag and pol coding sequences are generally organized as the Gag-Pol Precursor in native lentivirus. The gag sequence codes for a 55-kD Gag precursor protein, also called p55. The p55 is cleaved by the virally encoded protease (a product of the pol gene) during the process of maturation into four smaller proteins designated MA (matrix [p17]), CA (capsid [p24]), NC (nucleocapsid [p9]), and p6. The pol precursor protein is cleaved away from Gag by a virally encoded protease, and further digested to separate the protease (p10), RT (p50), RNase H (p15), and integrase (p31) activities.

In some embodiments, the lentiviral vector is integration-deficient. In some embodiments, the pol is integrase deficient, such as by encoding due to mutations in the integrase gene. For example, the pol coding sequence can contain an inactivating mutation in the integrase, such as by mutation of one or more of amino acids involved in catalytic activity, i.e. mutation of one or more of aspartic 64, aspartic acid 116 and/or glutamic acid 152. In some embodiments, the integrase mutation is a D64V mutation. In some embodiments, the mutation in the integrase allows for packaging of viral RNA into a lentivirus. In some embodiments, the mutation in the integrase allows for packaging of viral proteins into a letivirus. In some embodiments, the mutation in the integrase reduces the possibility of insertional mutagenesis. In some embodiments, the mutation in the integrase decreases the possibility of generating replication-competent recombinants (RCRs) (Wanisch et al. 2009. Mol Ther. 1798):1316-1332). In some embodiments, native Gag-Pol sequences can be utilized in a helper vector (e.g., helper plasmid or helper virus), or modifications can be made. These modifications include, chimeric Gag-Pol, where the Gag and Pol sequences are obtained from different viruses (e.g., different species, subspecies, strains, clades, etc.), and/or where the sequences have been modified to improve transcription and/or translation, and/or reduce recombination.

In some embodiments, the retroviral nucleic acid includes a polynucleotide encoding a 150-250 (e.g., 168) nucleotide portion of a gag protein that (i) includes a mutated INS1 inhibitory sequence that reduces restriction of nuclear export of RNA relative to wild-type INS1, (ii) contains two nucleotide insertion that results in frame shift and premature termination, and/or (iii) does not include INS2, INS3, and INS4 inhibitory sequences of gag.

In some embodiments, a vector described herein is a hybrid vector that comprises both retroviral (e.g., lentiviral) sequences and non-lentiviral viral sequences. In some embodiments, a hybrid vector comprises retroviral e.g., lentiviral, sequences for reverse transcription, replication, integration and/or packaging.

In some embodiments, most or all of the viral vector backbone sequences are derived from a lentivirus, e.g., HIV-1. However, it is to be understood that many different sources of retroviral and/or lentiviral sequences can be used or combined and numerous substitutions and alterations in certain of the lentiviral sequences may be accommodated without impairing the ability of a transfer vector to perform the functions described herein. A variety of lentiviral vectors are described in Naldini et al., (1996a, 1996b, and 1998); Zufferey et al., (1997); Dull et al., 1998, U.S. Pat. Nos. 6,013,516; and 5,994,136, many of which may be adapted to produce a retroviral nucleic acid.

In some embodiments, at each end of the provirus, long terminal repeats (LTRs) are typically found. An LTR typically comprises a domain located at the ends of retroviral nucleic acid which, in their natural sequence context, are direct repeats and contain U3, R and U5 regions. LTRs generally promote the expression of retroviral genes (e.g., promotion, initiation and polyadenylation of gene transcripts) and viral replication. The LTR can comprise numerous regulatory signals including transcriptional control elements, polyadenylation signals and sequences for replication and integration of the viral genome. The viral LTR is typically divided into three regions called U3, R and U5. The U3 region typically contains the enhancer and promoter elements. The U5 region is typically the sequence between the primer binding site and the R region and can contain the polyadenylation sequence. The R (repeat) region can be flanked by the U3 and U5 regions. The LTR is typically composed of U3, R and U5 regions and can appear at both the 5′ and 3′ ends of the viral genome. In some embodiments, adjacent to the 5′ LTR are sequences for reverse transcription of the genome (the tRNA primer binding site) and for efficient packaging of viral RNA into particles (the Psi site).

In some embodiments, a packaging signal can comprise a sequence located within the retroviral genome which mediate insertion of the viral RNA into the viral capsid or particle, see e.g., Clever et al., 1995. J. of Virology, Vol. 69, No. 4; pp. 2101-2109. Several retroviral vectors use a minimal packaging signal (a psi NI sequence) for encapsidation of the viral genome.

In various embodiments, retroviral nucleic acids comprise modified 5′ LTR and/or 3′ LTRs. Either or both of the LTR may comprise one or more modifications including, but not limited to, one or more deletions, insertions, or substitutions. Modifications of the 3′ LTR are often made to improve the safety of lentiviral or retroviral systems by rendering viruses replication-defective, e.g., virus that is not capable of complete, effective replication such that infective virions are not produced (e.g., replication-defective lentiviral progeny).

In some embodiments, a vector is a self-inactivating (SIN) vector, e.g., replication-defective vector, e.g., retroviral or lentiviral vector, in which the right (3′) LTR enhancer-promoter region, known as the U3 region, has been modified (e.g., by deletion or substitution) to prevent viral transcription beyond the first round of viral replication. This is because the right (3′) LTR U3 region can be used as a template for the left (5′) LTR U3 region during viral replication and, thus, absence of the U3 enhancer-promoter inhibits viral replication. In embodiments, the 3′ LTR is modified such that the U5 region is removed, altered, or replaced, for example, with an exogenous poly(A) sequence The 3′ LTR, the 5′ LTR, or both 3′ and 5′ LTRs, may be modified LTRs.

In some embodiments, the U3 region of the 5′ LTR is replaced with a heterologous promoter to drive transcription of the viral genome during production of viral particles. Examples of heterologous promoters which can be used include, for example, viral simian virus 40 (SV40) (e.g., early or late), cytomegalovirus (CMV) (e.g., immediate early), Moloney murine leukemia virus (MoMLV), Rous sarcoma virus (RSV), and herpes simplex virus (HSV) (thymidine kinase) promoters. In some embodiments, promoters are able to drive high levels of transcription in a Tat-independent manner. In certain embodiments, the heterologous promoter has additional advantages in controlling the manner in which the viral genome is transcribed. For example, the heterologous promoter can be inducible, such that transcription of all or part of the viral genome will occur only when the induction factors are present. Induction factors include, but are not limited to, one or more chemical compounds or the physiological conditions such as temperature or pH, in which the host cells are cultured.

In some embodiments, viral vectors comprise a TAR (trans-activation response) element, e.g., located in the R region of lentiviral (e.g., HIV) LTRs. This element interacts with the lentiviral trans-activator (tat) genetic element to enhance viral replication. However, this element is not required, e.g., in embodiments wherein the U3 region of the 5′ LTR is replaced by a heterologous promoter.

In some embodiments, the R region, e.g., the region within retroviral LTRs beginning at the start of the capping group (i.e., the start of transcription) and ending immediately prior to the start of the poly A tract can be flanked by the U3 and U5 regions. The R region plays a role during reverse transcription in the transfer of nascent DNA from one end of the genome to the other.

In some embodiments, the retroviral nucleic acid can also comprise a FLAP element, e.g., a nucleic acid whose sequence includes the central polypurine tract and central termination sequences (cPPT and CTS) of a retrovirus, e.g., HIV-1 or HIV-2. Suitable FLAP elements are described in U.S. Pat. No. 6,682,907 and in Zennou, et al., 2000, Cell, 101:173, which are herein incorporated by reference in their entireties. During HIV-1 reverse transcription, central initiation of the plus-strand DNA at the central polypurine tract (cPPT) and central termination at the central termination sequence (CTS) can lead to the formation of a three-stranded DNA structure: the HIV-1 central DNA flap. In some embodiments, the retroviral or lentiviral vector backbones comprise one or more FLAP elements upstream or downstream of the gene encoding the exogenous agent. For example, in some embodiments a transfer plasmid includes a FLAP element, e.g., a FLAP element derived or isolated from HIV-1.

In embodiments, a retroviral or lentiviral nucleic acid comprises one or more export elements, e.g., a cis-acting post-transcriptional regulatory element which regulates the transport of an RNA transcript from the nucleus to the cytoplasm of a cell. Examples of RNA export elements include, but are not limited to, the human immunodeficiency virus (HIV) rev response element (RRE) (see e.g., Cullen et al., 1991. J. Virol. 65: 1053; and Cullen et al., 1991. Cell 58: 423), and the hepatitis B virus post-transcriptional regulatory element (HPRE), which are herein incorporated by reference in their entireties. Generally, the RNA export element is placed within the 3′ UTR of a gene, and can be inserted as one or multiple copies.

In some embodiments, expression of heterologous sequences in viral vectors is increased by incorporating one or more of, e.g., all of, posttranscriptional regulatory elements, polyadenylation sites, and transcription termination signals into the vectors. A variety of posttranscriptional regulatory elements can increase expression of a heterologous nucleic acid at the protein, e.g., woodchuck hepatitis virus posttranscriptional regulatory element (WPRE; Zufferey et al., 1999, J. Virol., 73:2886); the posttranscriptional regulatory element present in hepatitis B virus (HPRE) (Huang et al., Mol. Cell. Biol., 5:3864); and the like (Liu et al., 1995, Genes Dev., 9:1766), each of which is herein incorporated by reference in its entirety. In some embodiments, a retroviral nucleic acid described herein comprises a posttranscriptional regulatory element such as a WPRE or HPRE.

In some embodiments, a retroviral nucleic acid described herein lacks or does not comprise a posttranscriptional regulatory element such as a WPRE or HPRE.

In some embodiments, elements directing the termination and polyadenylation of the heterologous nucleic acid transcripts may be included, e.g., to increases expression of the exogenous agent. Transcription termination signals may be found downstream of the polyadenylation signal. In some embodiments, vectors comprise a polyadenylation sequence 3′ of a polynucleotide encoding the exogenous agent. A polyA site may comprise a DNA sequence which directs both the termination and polyadenylation of the nascent RNA transcript by RNA polymerase II. Polyadenylation sequences can promote mRNA stability by addition of a polyA tail to the 3′ end of the coding sequence and thus, contribute to increased translational efficiency. Illustrative examples of polyA signals that can be used in a retroviral nucleic acid, include AATAAA, ATTAAA, AGTAAA, a bovine growth hormone polyA sequence (BGHpA), a rabbit β-globin polyA sequence (rβgpA), or another suitable heterologous or endogenous polyA sequence.

In some embodiments, a retroviral or lentiviral vector further comprises one or more insulator elements, e.g., an insulator element described herein.

In various embodiments, the vectors comprise a promoter operably linked to a polynucleotide encoding an exogenous agent. The vectors may have one or more LTRs, wherein either LTR comprises one or more modifications, such as one or more nucleotide substitutions, additions, or deletions. The vectors may further comprise one of more accessory elements to increase transduction efficiency (e.g., a cPPT/FLAP), viral packaging (e.g., a Psi (Ψ) packaging signal, RRE), and/or other elements that increase exogenous gene expression (e.g., poly (A) sequences), and may optionally comprise a WPRE or HPRE.

In some embodiments, a lentiviral nucleic acid comprises one or more of, e.g., all of, e.g., from 5′ to 3′, a promoter (e.g., CMV), an R sequence (e.g., comprising TAR), a U5 sequence (e.g., for integration), a PBS sequence (e.g., for reverse transcription), a DIS sequence (e.g., for genome dimerization), a psi packaging signal, a partial gag sequence, an RRE sequence (e.g., for nuclear export), a cPPT sequence (e.g., for nuclear import), a promoter to drive expression of the exogenous agent, a gene encoding the exogenous agent, a WPRE sequence (e.g., for efficient transgene expression), a PPT sequence (e.g., for reverse transcription), an R sequence (e.g., for polyadenylation and termination), and a U5 signal (e.g., for integration).

b. Packaging Vectors and Producer Cells

Large scale viral particle production is often useful to achieve a desired viral titer. Viral particles can be produced by transfecting a transfer vector into a packaging cell line that comprises viral structural and/or accessory genes, e.g., gag, pol, env, tat, rev, vif, vpr, vpu, vpx, or nef genes or other retroviral genes.

In some embodiments, the packaging vector is an expression vector or viral vector that lacks a packaging signal and comprises a polynucleotide encoding one, two, three, four or more viral structural and/or accessory genes. Typically, the packaging vectors are included in a producer cell, and are introduced into the cell via transfection, transduction or infection. A retroviral, e.g., lentiviral, transfer vector can be introduced into a producer cell line, via transfection, transduction or infection, to generate a source cell or cell line. The packaging vectors can be introduced into human cells or cell lines by standard methods including, e.g., calcium phosphate transfection, lipofection or electroporation. In some embodiments, the packaging vectors are introduced into the cells together with a dominant selectable marker, such as neomycin, hygromycin, puromycin, blastocidin, zeocin, thymidine kinase, DHFR, Gln synthetase or ADA, followed by selection in the presence of the appropriate drug and isolation of clones. A selectable marker gene can be linked physically to genes encoding by the packaging vector, e.g., by IRES or self-cleaving viral peptides.

In some embodiments, producer cell lines include cell lines that do not contain a packaging signal, but do stably or transiently express viral structural proteins and replication enzymes (e.g., gag, pol and env) which can package viral particles. Any suitable cell line can be employed, e.g., mammalian cells, e.g., human cells. Suitable cell lines which can be used include, for example, CHO cells, BHK cells, MDCK cells, C3H 10T1/2 cells, FLY cells, Psi-2 cells, BOSC 23 cells, PA317 cells, WEHI cells, COS cells, BSC 1 cells, BSC 40 cells, BMT 10 cells, VERO cells, W138 cells, MRCS cells, A549 cells, HT1080 cells, 293 cells, 293T cells, B-50 cells, 3T3 cells, NIH3T3 cells, HepG2 cells, Saos-2 cells, Huh7 cells, HeLa cells, W163 cells, 211 cells, and 211A cells. In embodiments, the packaging cells are 293 cells, 293T cells, or A549 cells.

In some embodiments, a source cell line includes a cell line which is capable of producing recombinant retroviral particles, comprising a producer cell line and a transfer vector construct comprising a packaging signal. Methods of preparing viral stock solutions are illustrated by, e.g., Y. Soneoka et al. (1995) Nucl. Acids Res. 23:628-633, and N. R. Landau et al. (1992) J. Virol. 66:5110-5113, which are incorporated herein by reference. Infectious virus particles may be collected from the producer cells, e.g., by cell lysis, or collection of the supernatant of the cell culture. Optionally, the collected virus particles may be enriched or purified.

In some embodiments, the source cell comprises one or more plasmids coding for viral structural proteins and replication enzymes (e.g., gag, pol and env) which can package viral particles. In some embodiments, the sequences coding for at least two of the gag, pol, and env precursors are on the same plasmid. In some embodiments, the sequences coding for the gag, pol, and env precursors are on different plasmids. In some embodiments, the sequences coding for the gag, pol, and env precursors have the same expression signal, e.g., promoter. In some embodiments, the sequences coding for the gag, pol, and env precursors have a different expression signal, e.g., different promoters. In some embodiments, expression of the gag, pol, and env precursors is inducible. In some embodiments, the plasmids coding for viral structural proteins and replication enzymes are transfected at the same time or at different times. In some embodiments, the plasmids coding for viral structural proteins and replication enzymes are transfected at the same time or at a different time from the packaging vector.

In some embodiments, the source cell line comprises one or more stably integrated viral structural genes. In some embodiments expression of the stably integrated viral structural genes is inducible.

In some embodiments, expression of the viral structural genes is regulated at the transcriptional level. In some embodiments, expression of the viral structural genes is regulated at the translational level. In some embodiments, expression of the viral structural genes is regulated at the post-translational level.

In some embodiments, expression of the viral structural genes is regulated by a tetracycline (Tet)-dependent system, in which a Tet-regulated transcriptional repressor (Tet-R) binds to DNA sequences included in a promoter and represses transcription by steric hindrance (Yao et al, 1998; Jones et al, 2005). Upon addition of doxycycline (dox), Tet-R is released, allowing transcription. Multiple other suitable transcriptional regulatory promoters, transcription factors, and small molecule inducers are suitable to regulate transcription of viral structural genes.

In some embodiments, the third-generation lentivirus components, human immunodeficiency virus type 1 (HIV) Rev, Gag/Pol, and an envelope under the control of Tet-regulated promoters and coupled with antibiotic resistance cassettes are separately integrated into the source cell genome. In some embodiments the source cell only has one copy of each of Rev, Gag/Pol, and an envelope protein integrated into the genome.

In some embodiments a nucleic acid encoding the exogenous agent (e.g., a retroviral nucleic acid encoding the exogenous agent) is also integrated into the source cell genome.

In some embodiments, a retroviral nucleic acid described herein is unable to undergo reverse transcription. Such a nucleic acid, in embodiments, is able to transiently express an exogenous agent. The retrovirus or VLP, may comprise a disabled reverse transcriptase protein, or may not comprise a reverse transcriptase protein. In embodiments, the retroviral nucleic acid comprises a disabled primer binding site (PBS) and/or att site. In embodiments, one or more viral accessory genes, including rev, tat, vif, nef, vpr, vpu, vpx and S2 or functional equivalents thereof, are disabled or absent from the retroviral nucleic acid. In embodiments, one or more accessory genes selected from S2, rev and tat are disabled or absent from the retroviral nucleic acid.

2 Cell-Derived Particles

Provided herein are targeted lipid particles that comprise a naturally derived membrane. In some embodiments, the naturally derived membrane comprises membrane vesicles prepared from cells or tissues. In some embodiments, the targeted lipid particle comprises a vesicle that is obtainable from a cell. In some embodiments, the targeted lipid particle comprises a microvesicle, an exosome, a membrane enclosed body, an apoptotic body (from apoptotic cells), a particle (which may be derived from e.g. platelets), an ectosome (derivable from, e.g., neutrophiles and monocytes in serum), a prostatosome (obtainable from prostate cancer cells), or a cardiosome (derivable from cardiac cells).

In some embodiments, the source cell is an endothelial cell, a fibroblast, a blood cell (e.g., a macrophage, a neutrophil, a granulocyte, a leukocyte), a stem cell (e.g., a mesenchymal stem cell, an umbilical cord stem cell, bone marrow stem cell, a hematopoietic stem cell, an induced pluripotent stem cell e.g., an induced pluripotent stem cell derived from a subject's cells), an embryonic stem cell (e.g., a stem cell from embryonic yolk sac, placenta, umbilical cord, fetal skin, adolescent skin, blood, bone marrow, adipose tissue, erythropoietic tissue, hematopoietic tissue), a myoblast, a parenchymal cell (e.g., hepatocyte), an alveolar cell, a neuron (e.g., a retinal neuronal cell) a precursor cell (e.g., a retinal precursor cell, a myeloblast, myeloid precursor cells, a thymocyte, a meiocyte, a megakaryoblast, a promegakaryoblast, a melanoblast, a lymphoblast, a bone marrow precursor cell, a normoblast, or an angioblast), a progenitor cell (e.g., a cardiac progenitor cell, a satellite cell, a radial gial cell, a bone marrow stromal cell, a pancreatic progenitor cell, an endothelial progenitor cell, a blast cell), or an immortalized cell (e.g., HeEa, HEK293, MRC-5, WI-38, IMR 90, IMR 91, PER.C6, HT-1080, or BJ cell). In some embodiments, the source cell is other than a 293 cell, HEK cell, human endothelial cell, or a human epithelial cell, monocyte, macrophage, dendritic cell, or stem cell.

In some embodiments, the targeted lipid particle has a density of <1, 1-1.1, 1.05-1.15, 1.1-1.2, 1.15-1.25, 1.2-1.3, 1.25-1.35, or >1.35 g/ml. In some embodiments, the targeted lipid particle composition comprises less than 0.01%, 0.05%, 0.1%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 4%, 5%, or 10% source cells by protein mass or less than 0.01%, 0.05%, 0.1%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 4%, 5%, or 10% of cells having a functional nucleus.

In embodiments, the targeted lipid particle has a size, or the population of targeted lipid particles have an average size, that is less than about 0.01%, 0.05%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, of that of the source cell.

In some embodiments the targeted lipid particle comprises an extracellular vesicle, e.g., a cell-derived vesicle comprising a membrane that encloses an internal space and has a smaller diameter than the cell from which it is derived. In embodiments the extracellular vesicle has a diameter from 20 nm to 1000 nm. In embodiments the targeted lipid particle comprises an apoptotic body, a fragment of a cell, a vesicle derived from a cell by direct or indirect manipulation, a vesiculated organelle, and a vesicle produced by a living cell (e.g., by direct plasma membrane budding or fusion of the late endosome with the plasma membrane). In embodiments the extracellular vesicle is derived from a living or dead organism, explanted tissues or organs, or cultured cells.

In embodiments, the targeted lipid particle comprises a nanovesicle, e.g., a cell-derived small (e.g., between 20-250 nm in diameter, or 30-150 nm in diameter) vesicle comprising a membrane that encloses an internal space, and which is generated from said cell by direct or indirect manipulation. The production of nanovesicles can, in some instances, result in the destruction of the source cell. The nanovesicle may comprise a lipid or fatty acid and polypeptide.

In embodiments, the targeted lipid particle comprises an exosome. In embodiments, the exosome is a cell-derived small (e.g., between 20-300 nm in diameter, or 40-200 nm in diameter) vesicle comprising a membrane that encloses an internal space, and which is generated from said cell by direct plasma membrane budding or by fusion of the late endosome with the plasma membrane. In embodiments, production of exosomes does not result in the destruction of the source cell. In embodiments, the exosome comprises lipid or fatty acid and polypeptide. Exemplary exosomes and other membrane-enclosed bodies are also described in WO/2017/161010, WO/2016/077639, US20160168572, US20150290343, and US20070298118, each of which is incorporated by reference herein in its entirety.

In some embodiments, the targeted lipid particle is derived from a source cell with a genetic modification which results in increased expression of an immunomodulatory agent. In some embodiments, the immunosuppressive agent is on an exterior surface of the cell. In some embodiments, the immunosuppressive agent is incorporated into the exterior surface of the targeted lipid particle. In some embodiments, the targeted lipid particle comprises an immunomodulatory agent attached to the surface of the solid particle by a covalent or non-covalent bond.

c. A. Generation of Cell-Derived Particles

In some embodiments, targeted lipid particles are generated by inducing budding of an exosome, microvesicle, membrane vesicle, extracellular membrane vesicle, plasma membrane vesicle, giant plasma membrane vesicle, apoptotic body, mitoparticle, pyrenocyte, lysosome, or other membrane enclosed vesicle.

In some embodiments, targeted lipid particles are generated by inducing cell enucleation. Enucleation may be performed using assays such as genetic, chemical (e.g., using Actinomycin D, see Bayona-Bafaluyet al., “A chemical enucleation method for the transfer of mitochondrial DNA to p° cells” Nucleic Acids Res. 2003 Aug. 15; 31(16): e98), mechanical methods (e.g., squeezing or aspiration, see Lee et al., “A comparative study on the efficiency of two enucleation methods in pig somatic cell nuclear transfer: effects of the squeezing and the aspiration methods.” Anim Biotechnol. 2008; 19(2):71-9), or combinations thereof.

In some embodiments, the targeted lipid particles are generated by inducing cell fragmentation. In some embodiments, cell fragmentation can be performed using the following methods, including, but not limited to: chemical methods, mechanical methods (e.g., centrifugation (e.g., ultracentrifugation, or density centrifugation), freeze-thaw, or sonication), or combinations thereof.

In some embodiments, the targeted lipid particle is a microvesicle. In some embodiments the microvesicle has a diameter of about 100 nm to about 2000 nm. In some embodiments, a targeted lipid particle comprises a cell ghost. In some embodiments, a vesicle is a plasma membrane vesicle, e.g. a giant plasma membrane vesicle.

In some embodiments, the source cell used to make the targeted lipid particle will not be available for testing after the targeted lipid particle is made.

In some embodiments, a characteristic of a targeted lipid particle is described by comparison to a reference cell. In embodiments, the reference cell is the source cell. In embodiments, the reference cell is a HeLa, HEK293, HFF-1, MRC-5, WI-38, IMR 90, IMR 91, PER.C6, HT-1080, or BJ cell. In some embodiments, a characteristic of a population of targeted lipid particle is described by comparison to a population of reference cells, e.g., a population of source cells, or a population of HeLa, HEK293, MRC-5, WI-38, IMR 90, IMR 91, PER.C6, HT-1080, or BJ cells.

III. PHARMACEUTICAL COMPOSITIONS

The present disclosure also provides, in some aspects, a pharmaceutical composition comprising the targeted lipid particle composition described herein and pharmaceutically acceptable carrier. The pharmaceutical compositions can include any of the described targeted lipid particles.

In some embodiments, the targeted lipid particle meets a pharmaceutical or good manufacturing practices (GMP) standard. In some embodiments, the targeted lipid particle was made according to good manufacturing practices (GMP). In some embodiments, the targeted lipid particle has a pathogen level below a predetermined reference value, e.g., is substantially free of pathogens. In some embodiments, the targeted lipid particle has a contaminant level below a predetermined reference value, e.g., is substantially free of contaminants In some embodiments, the targeted lipid particle has low immunogenicity.

In some embodiments, provided herein are the use of pharmaceutical compositions of the invention or salts thereof to practice the methods of the invention. Such a pharmaceutical composition may consist of at least one compound or conjugate of the invention or a salt thereof in a form suitable for administration to a subject, or the pharmaceutical composition may comprise at least one compound or conjugate of the invention or a salt thereof, and one or more pharmaceutically acceptable carriers, one or more additional ingredients, or some combination of these. In some embodiments, the compound or conjugate of the invention may be present in the pharmaceutical composition in the form of a physiologically acceptable salt, such as in combination with a physiologically acceptable cation or anion, as is well known in the art.

In some embodiments, the pharmaceutical compositions useful for practicing the methods of the invention may be administered to deliver a dose of between 1 ng/kg/day and 100 mg/kg/day. In another embodiment, the pharmaceutical compositions useful for practicing the invention may be administered to deliver a dose of between 1 ng/kg/day and 500 mg/kg/day.

In some embodiments, the relative amounts of the active ingredient, the pharmaceutically acceptable carrier, and any additional ingredients in a pharmaceutical composition of the invention will vary, depending upon the identity, size, and condition of the subject treated and further depending upon the route by which the composition is to be administered. In some embodiments, the composition may comprise between 0.1% and 100% (w/w) active ingredient.

In some embodiments, pharmaceutical compositions that are useful in the methods of the invention may be suitably developed for oral, rectal, vaginal, parenteral, topical, pulmonary, intranasal, buccal, ophthalmic, or another route of administration. In some embodiments, a composition useful within the methods of the invention may be directly administered to the skin, vagina or any other tissue of a mammal. In some embodiments, formulations include liposomal preparations, resealed erythrocytes containing the active ingredient, and immunologically based formulations. In some embodiments, the route(s) of administration will be readily apparent to the skilled artisan and will depend upon any number of factors including the type and severity of the disease being treated, the type and age of the veterinary or human subject being treated, and the like.

In some embodiments, formulations of the pharmaceutical compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. In some embodiments, preparatory methods include the step of bringing the active ingredient into association with a carrier or one or more other accessory ingredients, and then, if necessary or desirable, shaping or packaging the product into a desired single- or multi-dose unit.

In some embodiments, a “unit dose” is a discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. In some embodiments, the amount of the active ingredient is generally equal to the dosage of the active ingredient that would be administered to a subject or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage. In some embodiments, the unit dosage form may be for a single daily dose or one of multiple daily doses (e.g., about 1 to 4 or more times per day). In some embodiments, when multiple daily doses are used, the unit dosage form may be the same or different for each dose.

In some embodiments, although the descriptions of pharmaceutical compositions provided herein are principally directed to pharmaceutical compositions that are suitable for ethical administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. In some embodiments, modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist may design and perform such modification with merely ordinary, if any, experimentation. In some embodiments, subjects to which administration of the pharmaceutical compositions of the invention is contemplated include humans and other primates, mammals including commercially relevant mammals such as cattle, pigs, horses, sheep, cats, and dogs.

In some of any embodiments, the compositions of the invention are formulated using one or more pharmaceutically acceptable excipients or carriers. In one embodiment, the pharmaceutical compositions of the invention comprise a therapeutically effective amount of a compound or conjugate of the invention and a pharmaceutically acceptable carrier. In some embodiments, pharmaceutically acceptable carriers that are useful, include, but are not limited to, glycerol, water, saline, ethanol and other pharmaceutically acceptable salt solutions such as phosphates and salts of organic acids. Examples of these and other pharmaceutically acceptable carriers are described in Remington's Pharmaceutical Sciences (1991, Mack Publication Co., New Jersey).

In some embodiments, the carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. In some embodiments, the proper fluidity may be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In some embodiments, prevention of the action of microorganisms may be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In some embodiments, it is preferable to include isotonic agents, for example, sugars, sodium chloride, or polyalcohols such as mannitol and sorbitol, in the composition. In some embodiments, prolonged absorption of the injectable compositions may be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate or gelatin. In one embodiment, the pharmaceutically acceptable carrier is not DMSO alone.

In some embodiments, formulations may be employed in admixtures with conventional excipients, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for oral, vaginal, parenteral, nasal, intravenous, subcutaneous, enteral, or any other suitable mode of administration, known to the art. In some embodiments, the pharmaceutical preparations may be sterilized and if desired mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure buffers, coloring, flavoring and/or aromatic substances and the like. In some embodiments, pharmaceutical preparations may also be combined where desired with other active agents, e.g., other analgesic agents.

In some embodiments, “additional ingredients” include, but are not limited to, one or more of the following: excipients; surface active agents; dispersing agents; inert diluents; granulating and disintegrating agents; binding agents; lubricating agents; sweetening agents; flavoring agents; coloring agents; preservatives; physiologically degradable compositions such as gelatin; aqueous vehicles and solvents; oily vehicles and solvents; suspending agents; dispersing or wetting agents; emulsifying agents, demulcents; buffers; salts; thickening agents; fillers; emulsifying agents; antioxidants; antibiotics; antifungal agents; stabilizing agents; and pharmaceutically acceptable polymeric or hydrophobic materials. In some embodiments, “additional ingredients” that may be included in the pharmaceutical compositions of the invention are known in the art and described, for example in Genaro, ed. (1985, Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa.), which is incorporated herein by reference.

In some embodiments, the composition of the invention may comprise a preservative from about 0.005% to 2.0% by total weight of the composition. In some embodiments, the preservative is used to prevent spoilage in the case of exposure to contaminants in the environment. In some embodiments, examples of preservatives useful in accordance with the invention included but are not limited to those selected from the group consisting of benzyl alcohol, sorbic acid, parabens, imidurea and combinations thereof. In some embodiments, a particularly preferred preservative is a combination of about 0.5% to 2.0% benzyl alcohol and 0.05% to 0.5% sorbic acid.

In some embodiments, the composition preferably includes an anti-oxidant and a chelating agent that inhibits the degradation of the compound. In some embodiments, antioxidants for some compounds are BHT, BHA, alpha-tocopherol and ascorbic acid in the preferred range of about 0.01% to 0.3% and more preferably BHT in the range of 0.03% to 0.1% by weight by total weight of the composition. In some embodiments, the chelating agent is present in an amount of from 0.01% to 0.5% by weight by total weight of the composition. Particularly preferred chelating agents include edetate salts (e.g. disodium edetate) and citric acid in the weight range of about 0.01% to 0.20% and more preferably in the range of 0.02% to 0.10% by weight by total weight of the composition. In some embodiments, the chelating agent is useful for chelating metal ions in the composition that may be detrimental to the shelf life of the formulation. In some embodiments, other suitable and equivalent antioxidants and chelating agents may be substituted therefore as would be known to those skilled in the art.

In some embodiments, liquid suspensions may be prepared using conventional methods to achieve suspension of the active ingredient in an aqueous or oily vehicle. In some embodiments, aqueous vehicles include, for example, water, and isotonic saline. In some embodiments, oily vehicles include, for example, almond oil, oily esters, ethyl alcohol, vegetable oils such as arachis, olive, sesame, or coconut oil, fractionated vegetable oils, and mineral oils such as liquid paraffin. In some embodiments, liquid suspensions may further comprise one or more additional ingredients including, but not limited to, suspending agents, dispersing or wetting agents, emulsifying agents, demulcents, preservatives, buffers, salts, flavorings, coloring agents, and sweetening agents. In some embodiments, oily suspensions may further comprise a thickening agent. In some embodiments, suspending agents include, but are not limited to, sorbitol syrup, hydrogenated edible fats, sodium alginate, polyvinylpyrrolidone, gum tragacanth, gum acacia, and cellulose derivatives such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose. In some embodiments, dispersing or wetting agents include, but are not limited to, naturally-occurring phosphatides such as lecithin, condensation products of an alkylene oxide with a fatty acid, with a long chain aliphatic alcohol, with a partial ester derived from a fatty acid and a hexitol, or with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene stearate, heptadecaethyleneoxycetanol, polyoxyethylene sorbitol monooleate, and polyoxyethylene sorbitan monooleate, respectively). Known emulsifying agents include, but are not limited to, lecithin, and acacia. Known preservatives include, but are not limited to, methyl, ethyl, or n-propyl-para-hydroxybenzoates, ascorbic acid, and sorbic acid. Known sweetening agents include, for example, glycerol, propylene glycol, sorbitol, sucrose, and saccharin. Known thickening agents for oily suspensions include, for example, beeswax, hard paraffin, and cetyl alcohol.

In some embodiments, liquid solutions of the active ingredient in aqueous or oily solvents may be prepared in substantially the same manner as liquid suspensions, the primary difference being that the active ingredient is dissolved, rather than suspended in the solvent. As used herein, an “oily” liquid is one which comprises a carbon-containing liquid molecule and which exhibits a less polar character than water. In some embodiments, liquid solutions of the pharmaceutical composition of the invention may comprise each of the components described with regard to liquid suspensions, it being understood that suspending agents will not necessarily aid dissolution of the active ingredient in the solvent. In some embodiments, aqueous solvents include, for example, water, and isotonic saline. In some embodiments, oily solvents include, for example, almond oil, oily esters, ethyl alcohol, vegetable oils such as arachis, olive, sesame, or coconut oil, fractionated vegetable oils, and mineral oils such as liquid paraffin.

In some embodiments, powdered and granular formulations of a pharmaceutical preparation of the invention may be prepared using known methods. In some embodiments, formulations may be administered directly to a subject, used, for example, to form tablets, to fill capsules, or to prepare an aqueous or oily suspension or solution by addition of an aqueous or oily vehicle thereto. In some of any embodiments, formulations may further comprise one or more of dispersing or wetting agent, a suspending agent, and a preservative. Additional excipients, such as fillers and sweetening, flavoring, or coloring agents, may also be included in these formulations.

In some embodiments, a pharmaceutical composition of the invention may also be prepared, packaged, or sold in the form of oil-in-water emulsion or a water-in-oil emulsion. In some embodiments, the oily phase may be a vegetable oil such as olive or arachis oil, a mineral oil such as liquid paraffin, or a combination of these. In some embodiments, compositions further comprise one or more emulsifying agents such as naturally occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soybean or lecithin phosphatide, esters or partial esters derived from combinations of fatty acids and hexitol anhydrides such as sorbitan monooleate, and condensation products of such partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. In some embodiments, emulsions may also contain additional ingredients including, for example, sweetening or flavoring agents.

IV. METHODS OF TREATMENT

In some embodiments, the targeted lipid particles provided herein, or pharmaceutical compositions thereof as described herein can be administered to a subject, e.g. a mammal, e.g. a human. In such embodiments, the subject may be at risk of, may have a symptom of, or may be diagnosed with or identified as having, a particular disease or condition. In one embodiment, the subject has cancer. In one embodiment, the subject has an infectious disease. In some embodiments, the targeted lipid particle contains nucleic acid sequences encoding an exogenous agent for treating the disease or condition in the subject. For example, the exogenous agent is one that targets or is specific for a protein of a neoplastic cells and the targeted lipid particle is administered to a subject for treating a tumor or cancer in the subject. In another example, the exogenous agent is an inflammatory mediator or immune molecule, such as a cytokine, and targeted lipid particle is administered to a subject for treating any condition in which it is desired to modulate (e.g. increase) the immune response, such as a cancer or infectious disease. In some embodiments, the targeted lipid particle is administered in an effective amount or dose to effect treatment of the disease, condition or disorder. Provided herein are uses of any of the provided targeted lipid particles in such methods and treatments, and in the preparation of a medicament in order to carry out such therapeutic methods. In some embodiments, the methods are carried out by administering the targeted lipid particle or compositions comprising the same, to the subject having, having had, or suspected of having the disease or condition or disorder. In some embodiments, the methods thereby treat the disease or condition or disorder in the subject. Also provided herein are uses of any of the compositions, such as pharmaceutical compositions provided herein, for the treatment of a disease, condition or disorder associated with a particular gene or protein targeted by or provided by the exogenous agent.

In some embodiments, the provided methods or uses involve administration of a pharmaceutical composition comprising oral, inhaled, transdermal or parenteral (including intravenous, intratumoral, intraperitoneal, intramuscular, intracavity, and subcutaneous) administration. In some embodiments, the targeted lipid particle may be administered alone or formulated as a pharmaceutical composition. In some embodiments, the targeted lipid particle or compositions described herein can be administered to a subject, e.g., a mammal, e.g., a human. In some of any embodiments, the subject may be at risk of, may have a symptom of, or may be diagnosed with or identified as having, a particular disease or condition (e.g., a disease or condition described herein). In some embodiments, the disease is a disease or disorder.

In some embodiments, the targeted lipid particles may be administered in the form of a unit-dose composition, such as a unit dose oral, parenteral, transdermal or inhaled composition. In some embodiments, the compositions are prepared by admixture and are adapted for oral, inhaled, transdermal or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories or aerosols.

In some embodiments, the regimen of administration may affect what constitutes an effective amount. In some embodiments, the therapeutic formulations may be administered to the subject either prior to or after a diagnosis of disease. In some embodiments, several divided dosages, as well as staggered dosages may be administered daily or sequentially, or the dose may be continuously infused, or may be a bolus injection. In some embodiments, the dosages of the therapeutic formulations may be proportionally increased or decreased as indicated by the exigencies of the therapeutic or prophylactic situation.

In some embodiments, the administration of the compositions of the present invention to a subject, preferably a mammal, more preferably a human, may be carried out using known procedures, at dosages and for periods of time effective to prevent or treat disease. In some embodiments, an effective amount of the therapeutic compound necessary to achieve a therapeutic effect may vary according to factors such as the activity of the particular compound employed; the time of administration; the rate of excretion of the compound; the duration of the treatment; other drugs, compounds or materials used in combination with the compound; the state of the disease or disorder, age, sex, weight, condition, general health and prior medical history of the subject being treated, and like factors well-known in the medical arts. In some embodiments, the dosage regimens may be adjusted to provide the optimum therapeutic response. In some embodiments, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. In some embodiments, the effective dose range for a therapeutic compound of the invention is from about 1 and 5,000 mg/kg of body weight/per day. One of ordinary skill in the art would be able to study the relevant factors and make the determination regarding the effective amount of the therapeutic compound without undue experimentation.

In some embodiments, the compound may be administered to a subject as frequently as several times daily, or it may be administered less frequently, such as once a day, once a week, once every two weeks, once a month, or even less frequently, such as once every several months or even once a year or less. In some embodiments, the amount of compound dosed per day may be administered, in non-limiting examples, every day, every other day, every 2 days, every 3 days, every 4 days, or every 5 days. In some embodiments, with every other day administration, a 5 mg per day dose may be initiated on Monday with a first subsequent 5 mg per day dose administered on Wednesday, a second subsequent 5 mg per day dose administered on Friday, and so on. The frequency of the dose will be readily apparent to the skilled artisan and will depend upon any number of factors, such as, but not limited to, the type and severity of the disease being treated, the type and age of the animal, etc.

In some embodiments, dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular subject, composition, and mode of administration, without being toxic to the subject.

A medical doctor, e.g., physician or veterinarian, having ordinary skill in the art may readily determine and prescribe the effective amount of the pharmaceutical composition required. In some embodiments, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

In some embodiments, it is especially advantageous to formulate the compound in dosage unit form for ease of administration and uniformity of dosage. In some embodiments, dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit containing a predetermined quantity of therapeutic compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical vehicle. In some embodiments, the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the therapeutic compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding/formulating such a therapeutic compound for the treatment of a disease in a subject.

In some embodiments, the term “container” includes any receptacle for holding the pharmaceutical composition. In some embodiments, the container is the packaging that contains the pharmaceutical composition. In other embodiments, the container is not the packaging that contains the pharmaceutical composition, i.e., the container is a receptacle, such as a box or vial that contains the packaged pharmaceutical composition or unpackaged pharmaceutical composition and the instructions for use of the pharmaceutical composition. It should be understood that the instructions for use of the pharmaceutical composition may be contained on the packaging containing the pharmaceutical composition, and as such the instructions form an increased functional relationship to the packaged product. In some embodiments, instructions may contain information pertaining to the compound's ability to perform its intended function, e.g., treating or preventing a disease in a subject, or delivering an imaging or diagnostic agent to a subject.

In some embodiments, routes of administration of any of the compositions disclosed herein include oral, nasal, rectal, parenteral, sublingual, transdermal, transmucosal (e.g., sublingual, lingual, (trans)buccal, (trans)urethral, vaginal (e.g., trans- and perivaginally), (intra)nasal, and (trans)rectal), intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical administration.

In some of any embodiments, suitable compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gel caps, troches, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays for nasal or oral administration, dry powder or aerosolized formulations for inhalation, compositions and formulations for intravesical administration and the like.

In some embodiments, the targeted lipid particle composition comprising an exogenous agent or cargo, may be used to deliver such exogenous agent or cargo to a cell tissue or subject. In some embodiments, delivery of a cargo by administration of a targeted lipid particle composition described herein may modify cellular protein expression levels. In certain embodiments, the administered composition directs upregulation of (via expression in the cell, delivery in the cell, or induction within the cell) of one or more cargo (e.g., a polypeptide or mRNA) that provide a functional activity which is substantially absent or reduced in the cell in which the polypeptide is delivered. In some embodiments, the missing functional activity may be enzymatic, structural, or regulatory in nature. In some embodiments, the administered composition directs up-regulation of one or more polypeptides that increases (e.g., synergistically) a functional activity which is present but substantially deficient in the cell in which the polypeptide is upregulated. In some of any embodiments, the administered composition directs downregulation of (via expression in the cell, delivery in the cell, or induction within the cell) of one or more cargo (e.g., a polypeptide, siRNA, or miRNA) that repress a functional activity which is present or upregulated in the cell in which the polypeptide, siRNA, or miRNA is delivered. In some of any embodiments, the upregulated functional activity may be enzymatic, structural, or regulatory in nature. In some embodiments, the administered composition directs down-regulation of one or more polypeptides that decreases (e.g., synergistically) a functional activity which is present or upregulated in the cell in which the polypeptide is downregulated. In some embodiments, the administered composition directs upregulation of certain functional activities and downregulation of other functional activities.

In some of any embodiments, the targeted lipid particle composition (e.g., one comprising mitochondria or DNA) mediates an effect on a target cell, and the effect lasts for at least 1, 2, 3, 4, 5, 6, or 7 days, 2, 3, or 4 weeks, or 1, 2, 3, 6, or 12 months. In some embodiments (e.g., wherein the targeted lipid particle composition comprises an exogenous protein), the effect lasts for less than 1, 2, 3, 4, 5, 6, or 7 days, 2, 3, or 4 weeks, or 1, 2, 3, 6, or 12 months.

In some of any embodiments, the targeted lipid particle composition described herein is delivered ex-vivo to a cell or tissue, e.g., a human cell or tissue. In embodiments, the composition improves function of a cell or tissue ex-vivo, e.g., improves cell viability, respiration, or other function (e.g., another function described herein).

In some embodiments, the composition is delivered to an ex vivo tissue that is in an injured state (e.g., from trauma, disease, hypoxia, ischemia or other damage).

In some embodiments, the composition is delivered to an ex-vivo transplant (e.g., a tissue explant or tissue for transplantation, e.g., a human vein, a musculoskeletal graft such as bone or tendon, cornea, skin, heart valves, nerves; or an isolated or cultured organ, e.g., an organ to be transplanted into a human, e.g., a human heart, liver, lung, kidney, pancreas, intestine, thymus, eye). In some embodiments, the composition is delivered to the tissue or organ before, during and/or after transplantation.

In some embodiments, the composition is delivered, administered or contacted with a cell, e.g., a cell preparation. In some embodiments, the cell preparation may be a cell therapy preparation (a cell preparation intended for administration to a human subject). In embodiments, the cell preparation comprises cells expressing a chimeric antigen receptor (CAR), e.g., expressing a recombinant CAR. The cells expressing the CAR may be, e.g., T cells, Natural Killer (NK) cells, cytotoxic T lymphocytes (CTL), regulatory T cells. In embodiments, the cell preparation is a neural stem cell preparation. In embodiments, the cell preparation is a mesenchymal stem cell (MSC) preparation. In embodiments, the cell preparation is a hematopoietic stem cell (HSC) preparation. In embodiments, the cell preparation is an islet cell preparation.

In some embodiments, the targeted lipid particle compositions described herein can be administered to a subject, e.g., a mammal, e.g., a human. In such embodiments, the subject may be at risk of, may have a symptom of, or may be diagnosed with or identified as having, a particular disease or condition (e.g., a disease or condition described herein).

In some embodiments, the source of targeted lipid particles are from the same subject that is administered a targeted lipid particle composition. In other embodiments, they are different. In some embodiments, the source of targeted lipid particles and recipient tissue may be autologous (from the same subject) or heterologous (from different subjects). In some embodiments, the donor tissue for targeted lipid particle compositions described herein may be a different tissue type than the recipient tissue. In some embodiments, the donor tissue may be muscular tissue and the recipient tissue may be connective tissue (e.g., adipose tissue). In other embodiments, the donor tissue and recipient tissue may be of the same or different type, but from different organ systems.

In some embodiments, the targeted lipid particle composition described herein may be administered to a subject having a cancer, an autoimmune disease, an infectious disease, a metabolic disease, a neurodegenerative disease, or a genetic disease (e.g., enzyme deficiency). In some embodiments, the subject is in need of regeneration.

In some embodiments, the targeted lipid particle is co-administered with an inhibitor of a protein that inhibits membrane fusion. For example, Suppressyn is a human protein that inhibits cell-cell fusion (Sugimoto et al., “A novel human endogenous retroviral protein inhibits cell-cell fusion” Scientific Reports 3: 1462 (DOI: 10.1038/srep01462)). In some embodiments, the targeted lipid particle particles is co-administered with an inhibitor of sypressyn, e.g., a siRNA or inhibitory antibody.

V. EXEMPLARY EMBODIMENTS

Among the provided embodiments are:

1. A targeted lipid particle, comprising:

(a) a lipid bilayer enclosing a lumen,

(b) a henipavirus F protein molecule or biologically active portion thereof; and

(c) a targeted envelope protein comprising (i) a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and (ii) single domain antibody (sdAb) variable domain, wherein the sdAb variable domain is attached to the C-terminus of the G protein or the biologically active portion thereof, wherein the F protein molecule or the biologically active portion thereof and the targeted envelope protein are embedded in the lipid bilayer.

2. The targeted lipid particle of embodiment 1, wherein the single domain antibody is attached to the G protein via a linker.

3. The targeted lipid particle of embodiment 2, wherein the linker is a peptide linker.

4. A targeted lipid particle, comprising:

(a) a lipid bilayer enclosing a lumen,

(b) a henipavirus F protein molecule or biologically active portion thereof; and

(c) a targeted envelope protein comprising a henipavirus envelope attachment glycoprotein G (G protein) or biologically active portion thereof attached to a single domain antibody (sdAb) variable domain via a peptide linker, wherein the single domain antibody binds to a cell surface molecule of a target cell,

wherein the F protein molecule or biologically active portion thereof and the targeted envelope protein are embedded in the lipid bilayer.

5. The targeted lipid particle of any of embodiments 1-4, wherein N-terminus of the F protein molecule or biologically active portion thereof is exposed on the outside of lipid bilayer.

6. The targeted lipid particle of any of embodiments 1-5, wherein the C-terminus of the G protein is exposed on the outside of the lipid bilayer.

7. The targeted lipid particle of any of embodiments 1-6, wherein the single domain antibody binds a cell surface molecule present on a target cell.

8. The targeted lipid particle of embodiment 7, wherein the cell surface molecule is a protein, glycan, lipid or low molecular weight molecule.

9. The targeted lipid particle of embodiment 7, wherein the target cell is selected from the group consisting of tumor-infiltrating lymphocytes, T cells, neoplastic or tumor cells, virus-infected cells, stem cells, central nervous system (CNS) cells, hematopoeietic stem cells (HSCs), liver cells or fully differentiated cells.

10. The targeted lipid particle of embodiment 9, wherein the target cell is selected from the group consisting of a CD3+ T cell, a CD4+ Tcell, a CD8+ T cell, a hepatocyte, a haematepoietic stem cell, a CD34+ haematepoietic stem cell, a CD105+ haematepoietic stem cell, a CD117+ haematepoietic stem cell, a CD105+ endothelial cell, a B cell, a CD20+ B cell, a CD19+ B cell, a cancer cell, a CD133+ cancer cell, an EpCAM+ cancer cell, a CD19+ cancer cell, a Her2/Neu+ cancer cell, a GluA2+ neuron, a GluA4+ neuron, a NKG2D+ natural killer cell, a SLC1A3+ astrocyte, a SLC7A10+ adipocyte, or a CD30+ lung epithelial cell.

11. The targeted lipid particle of any of the preceding embodiments, wherein the single domain antibody binds an antigen or portion thereof present on a target cell.

12. The targeted lipid particle of any of embodiments 3-11, wherein the peptide linker comprises up to 65 amino acids in length.

13. The targeted lipid particle of any of embodiments 3-11, wherein the peptide linker comprises from or from about 2 to 65 amino acids, 2 to 60 amino acids, 2 to 56 amino acids, 2 to 52 amino acids, 2 to 48 amino acids, 2 to 44 amino acids, 2 to 40 amino acids, 2 to 36 amino acids, 2 to 32 amino acids, 2 to 28 amino acids, 2 to 24 amino acids, 2 to 20 amino acids, 2 to 18 amino acids, 2 to 14 amino acids, 2 to 12 amino acids, 2 to 10 amino acids, 2 to 8 amino acids, 2 to 6 amino acids, 6 to 65 amino acids, 6 to 60 amino acids, 6 to 56 amino acids, 6 to 52 amino acids, 6 to 48 amino acids, 6 to 44 amino acids, 6 to 40 amino acids, 6 to 36 amino acids, 6 to 32 amino acids, 6 to 28 amino acids, 6 to 24 amino acids, 6 to 20 amino acids, 6 to 18 amino acids, 6 to 14 amino acids, 6 to 12 amino acids, 6 to 10 amino acids, 6 to 8 amino acids, 8 to 65 amino acids, 8 to 60 amino acids, 8 to 56 amino acids, 8 to 52 amino acids, 8 to 48 amino acids, 8 to 44 amino acids, 8 to 40 amino acids, 8 to 36 amino acids, 8 to 32 amino acids, 8 to 28 amino acids, 8 to 24 amino acids, 8 to 20 amino acids, 8 to 18 amino acids, 8 to 14 amino acids, 8 to 12 amino acids, 8 to 10 amino acids, 10 to 65 amino acids, 10 to 60 amino acids, 10 to 56 amino acids, 10 to 52 amino acids, 10 to 48 amino acids, 10 to 44 amino acids, 10 to 40 amino acids, 10 to 36 amino acids, 10 to 32 amino acids, 10 to 28 amino acids, 10 to 24 amino acids, 10 to 20 amino acids, 10 to 18 amino acids, 10 to 14 amino acids, 10 to 12 amino acids, 12 to 65 amino acids, 12 to 60 amino acids, 12 to 56 amino acids, 12 to 52 amino acids, 12 to 48 amino acids, 12 to 44 amino acids, 12 to 40 amino acids, 12 to 36 amino acids, 12 to 32 amino acids, 12 to 28 amino acids, 12 to 24 amino acids, 12 to 20 amino acids, 12 to 18 amino acids, 12 to 14 amino acids, 14 to 65 amino acids, 14 to 60 amino acids, 14 to 56 amino acids, 14 to 52 amino acids, 14 to 48 amino acids, 14 to 44 amino acids, 14 to 40 amino acids, 14 to 36 amino acids, 14 to 32 amino acids, 14 to 28 amino acids, 14 to 24 amino acids, 14 to 20 amino acids, 14 to 18 amino acids, 18 to 65 amino acids, 18 to 60 amino acids, 18 to 56 amino acids, 18 to 52 amino acids, 18 to 48 amino acids, 18 to 44 amino acids, 18 to 40 amino acids, 18 to 36 amino acids, 18 to 32 amino acids, 18 to 28 amino acids, 18 to 24 amino acids, 18 to 20 amino acids, 20 to 65 amino acids, 20 to 60 amino acids, 20 to 56 amino acids, 20 to 52 amino acids, 20 to 48 amino acids, 20 to 44 amino acids, 20 to 40 amino acids, 20 to 36 amino acids, 20 to 32 amino acids, 20 to 28 amino acids, 20 to 26 amino acids, 20 to 24 amino acids, 24 to 65 amino acids, 24 to 60 amino acids, 24 to 56 amino acids, 24 to 52 amino acids, 24 to 48 amino acids, 24 to 44 amino acids, 24 to 40 amino acids, 24 to 36 amino acids, 24 to 32 amino acids, 24 to 30 amino acids, 24 to 28 amino acids, 28 to 65 amino acids, 28 to 60 amino acids, 28 to 56 amino acids, 28 to 52 amino acids, 28 to 48 amino acids, 28 to 44 amino acids, 28 to 40 amino acids, 28 to 36 amino acids, 28 to 34 amino acids, 28 to 32 amino acids, 32 to 65 amino acids, 32 to 60 amino acids, 32 to 56 amino acids, 32 to 52 amino acids, 32 to 48 amino acids, 32 to 44 amino acids, 32 to 40 amino acids, 32 to 38 amino acids, 32 to 36 amino acids, 36 to 65 amino acids, 36 to 60 amino acids, 36 to 56 amino acids, 36 to 52 amino acids, 36 to 48 amino acids, 36 to 44 amino acids, 36 to 40 amino acids, 40 to 65 amino acids, 40 to 60 amino acids, 40 to 56 amino acids, 40 to 52 amino acids, 40 to 48 amino acids, 40 to 44 amino acids, 44 to 65 amino acids, 44 to 60 amino acids, 44 to 56 amino acids, 44 to 52 amino acids, 44 to 48 amino acids, 48 to 65 amino acids, 48 to 60 amino acids, 48 to 56 amino acids, 48 to 52 amino acids, 50 to 65 amino acids, 50 to 60 amino acids, 50 to 56 amino acids, 50 to 52 amino acids, 54 to 65 amino acids, 54 to 60 amino acids, 54 to 56 amino acids, 58 to 65 amino acids, 58 to 60 amino acids, or 60 to 65 amino acids.

14. The targeted lipid particle of any of embodiments 3-1 1, wherein peptide linker comprises a polypeptide that is 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 or 65 amino acids in length.

15. The targeted lipid particle of any of embodiments 3-14, wherein the peptide linker is a flexible linker that comprises GS, GGS, GGGGS (SEQ ID NO:43), GGGGGS (SEQ ID NO:41) or combinations thereof.

16. The targeted lipid particle of any of embodiments 3-15, wherein the peptide linker comprises (GGS)n, wherein n is 1 to 10.

17. The targeted lipid particle of any of embodiments 3-15, wherein the peptide linker comprises (GGGGS)n (SEQ ID NO:42), wherein n is 1 to 10.

18. The targeted lipid particle of any of embodiments 3-15, wherein the peptide linker comprises (GGGGGS)n (SEQ ID NO:27), wherein n is 1 to 6.

19. The targeted lipid particle of any of embodiments 1-18, wherein the G protein or the biologically active portion thereof is a wild-type Nipah virus G (NiV-G) protein or a Hendra virus G protein.

20. The targeted lipid particle of any of embodiments 1-19, wherein the G protein or the biologically active portion thereof is a wild-type NiV-G protein or a functionally active variant or biologically active portion thereof.

21. The targeted lipid particle of embodiment 20, wherein the mutant NiV-G protein or functionally active variant or biologically active portion thereof comprises an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at least at or about 84%, at least at or about 85%, at least at or about 86%, at least at or about 87%, at least at or about 88%, at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44.

22. The targeted lipid particle of embodiment 21, wherein the NiV-G protein is a biologically active portion that is truncated and lacks up to 40 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44).

23. The targeted lipid particle of any of embodiments 1-18, wherein the NiV-G protein is a biologically active portion that is truncated at the N-terminus of wild-type NiV-G and has the sequence set forth in any of SEQ ID NOS: 10-15, 35-40 or 45-50 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at least at or about 84%, at least at or about 85%, at least at or about 86%, at least at or about 87%, at least at or about 88%, at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NOs: 10-15, 35-40 or 45-50.

24. The targeted lipid particle of any of embodiments 21-23, wherein the NiV-G protein has a 5 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44).

25. The targeted lipid particle of embodiment 24, wherein the NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 10 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:10.

26. The targeted lipid particle of embodiment 24, wherein the NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 35 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:35.

27. The targeted lipid particle of embodiment 24, wherein the NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 45 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:45.

28. The targeted lipid particle of any of embodiments 21-23, wherein the NiV-G protein has a 10 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44).

29. The targeted lipid particle of embodiment 28, wherein the NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 11 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:11.

30. The targeted lipid particle of embodiment 28, wherein the NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 36 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:36.

31. The targeted lipid particle of embodiment 28, wherein the NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 46 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:46.

32. The targeted lipid particle of any of embodiments 21-23, wherein the NiV-G protein has a 15 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44).

33. The targeted lipid particle of embodiment 32, wherein the NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 12 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:12.

34. The targeted lipid particle of embodiment 32, wherein the NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 37 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:37.

35. The targeted lipid particle of embodiment 32, wherein the NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 47 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:47.

36. The targeted lipid particle of any of embodiments 21-23, wherein the NiV-G protein has a 20 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44).

37. The targeted lipid particle of embodiment 36, wherein the NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 13 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:13.

38. The targeted lipid particle of embodiment 36, wherein the NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 38 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:38.

39. The targeted lipid particle of embodiment 36, wherein the NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 48 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:48.

40. The targeted lipid particle of any of embodiments 21-23, wherein the NiV-G protein has a 25 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44).

41. The targeted lipid particle of embodiment 40, wherein the NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 14 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:14.

42. The targeted lipid particle of embodiment 40, wherein the NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 39 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:39.

43. The targeted lipid particle of embodiment 40, wherein the NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 49 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:49.

44. The targeted lipid particle of any of embodiments 21-23, wherein the NiV-G protein has a 30 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44).

45. The targeted lipid particle of embodiment 44, wherein the NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 15 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:15.

46. The targeted lipid particle of embodiment 44, wherein the NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 40 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:40.

47. The targeted lipid particle of embodiment 44, wherein the NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 50 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:50.

48. The targeted lipid particle of any of embodiments 21-23, wherein the NiV-G protein has a 34 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO:9, SEQ ID NO:28 or SEQ ID NO:44).

49. The targeted lipid particle of embodiment 48, wherein the NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 22 or an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:22.

50. The targeted lipid particle of embodiment 48, wherein the NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 53 or an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:53.

51. The targeted lipid particle any of embodiments 1-48, wherein the G-protein or the biologically active portion thereof is a mutant NiV-G protein that exhibits reduced binding to Ephrin B2 or Ephrin B3.

52. The targeted lipid particle of embodiment 51, wherein the mutant NiV-G protein comprises:

one or more amino acid substitutions corresponding to amino acid substitutions selected from the group consisting of E501A, W504A, Q530A and E533A with reference to numbering set forth in SEQ ID NO:28.

53. The targeted lipid particle of embodiment 51 or embodiment 52, wherein the mutant NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 16 or an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:16.

54. The targeted lipid particle of embodiment 51 or embodiment 52, wherein the mutant NiV-G protein has the amino acid sequence set forth in SEQ ID NO: 51 or an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:51.

55. The targeted lipid particle of any of embodiments 1-54, wherein the F protein or the biologically active portion thereof is a wild-type Nipah virus F (NiV-F) protein or a Hendra virus F protein or is a functionally active variant or biologically active portion thereof.

56. The targeted lipid particle of any of embodiments 1-55, wherein the F protein or the biologically active portion thereof is a wild-type NiV-F protein or a functionally active variant or a biologically active portion thereof.

57. The targeted lipid particle of any of embodiments 1-56, wherein the NiV-F-protein or the functionally active variant or biologically active portion thereof comprises the amino acid sequence set forth in SEQ ID NO: 2, or an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 2.

58. The targeted lipid particle of any of embodiments 1-57, wherein the NiV-F protein is a is a biologically active portion thereof that has a 20 amino acid truncation at or near the C-terminus of the wild-type NiV-F protein (SEQ ID NO:2).

59. The targeted lipid particle of embodiment 58, wherein the NiV-F protein has an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 5.

60. The targeted lipid particle of any of embodiments 1-57, wherein the NiV-F protein is a biologically active portion thereof that comprises:

i) a 20 amino acid truncation at or near the C-terminus of the wild-type NiV-F protein (SEQ ID NO:2); and

ii) a point mutation on an N-linked glycosylation site.

61. The targeted lipid particle of embodiment 60, wherein the NiV-F protein has an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 7.

62. The targeted lipid particle of any of embodiments 1-57, wherein the NiV-F protein is a biologically active portion thereof that has a 22 amino acid truncation at or near the C-terminus of the wild-type NiV-F protein (SEQ ID NO:2).

63. The targeted lipid particle of embodiment 62, wherein the NiV-F protein has an amino acid sequence that is encoded by a sequence of nucleotides encoding a sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 8.

64. The targeted lipid particle of embodiment 63, wherein the NiV-F protein has an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 23.

65. The targeted lipid particle of any of embodiments 1-57, wherein the F-protein or the biologically active portion thereof comprises an F1 subunit or a fusogenic portion thereof.

66. The targeted lipid particle of embodiment 65, wherein the F1 subunit is a proteolytically cleaved portion of the F0 precursor.

67. The targeted lipid particle of embodiment 66, wherein the F1 subunit comprises the sequence set forth in SEQ ID NO: 4, or an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 4.

68. The targeted lipid particle of any of embodiments 1-67, wherein the lipid bilayer is derived from a membrane of a host cell used for producing a retrovirus or retrovirus-like particle.

69. The targeted lipid particle of any of embodiments 1-60, wherein the lipid bilayer is or comprises a viral envelope.

70. The targeted lipid particle of embodiment 68, wherein the retrovirus-like particle is replication defective.

71. The targeted lipid particle of any of embodiments 1-70, wherein the targeted lipid particle comprises one or more viral components other than the F protein molecule and the G protein.

72. The targeted lipid particle of embodiment 71, wherein the one or more viral components are from a retrovirus.

73. The targeted lipid particle of embodiment 72, wherein the retrovirus is a lentivirus.

74. The targeted lipid particle of any of embodiments 71-73, wherein the one or more viral components comprise a viral packaging protein selected from one or more of Gag, Pol, Rev and Tat.

75. The targeted lipid particle of any of embodiments 71-74, wherein the one or more viral components comprises one or more of (e.g., all of) the following nucleic acid sequences: 5′ LTR (e.g., comprising U5 and lacking a functional U3 domain), Psi packaging element (Psi), Central polypurine tract (cPPT)/central termination sequence (CTS) (e.g. DNA flap), Poly A tail sequence, a posttranscriptional regulatory element (e.g. WPRE), a Rev response element (RRE), and 3′ LTR (e.g., comprising U5 and lacking a functional U3).

76. The targeted lipid particle of any of embodiments 1-75, wherein the lipid particle further comprises an exogenous agent.

77. The targeted lipid particle of embodiment 76, wherein the exogenous agent is present in the lumen.

78. The targeted lipid particle of embodiment 77, wherein the exogenous agent is a protein or a nucleic acid, optionally wherein the nucleic acid is a DNA or RNA.

79. The targeted lipid particle of any of embodiments 76-78, wherein the exogenous agent encodes a therapeutic agent or a diagnostic agent.

80. The targeted lipid particle of any of embodiments 68-79, wherein the host cell is selected from the group consisting of CHO cells, BHK cells, MDCK cells, C3H 10T1/2 cells, FLY cells, Psi-2 cells, BOSC 23 cells, PA317 cells, WEHI cells, COS cells, BSC 1 cells, BSC 40 cells, BMT 10 cells, VERO cells, W138 cells, MRCS cells, A549 cells, HT1080 cells, 293 cells, 293T cells, B-50 cells, 3T3 cells, NIH3T3 cells, HepG2 cells, Saos-2 cells, Huh7 cells, HeLa cells, W163 cells, 211 cells, and 211A cells.

81. The targeted lipid particle of any of embodiments 68-80, wherein the host cell comprises 293T cells.

82. A polynucleotide comprising a nucleic acid sequence encoding (i) a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and (ii) a single domain antibody (sdAb) variable domain, wherein the sdAb variable domain is attached to the C-terminus of the G protein or the biologically active portion thereof.

83. The polynucleotide of embodiment 82, further comprising (iii) a nucleic acid sequence encoding a henipavirus F protein molecule or a biologically active portion thereof.

84. The polynucleotide of embodiment 82 or embodiment 83, further comprising at least one promoter that is operatively linked to control expression of the nucleic acid.

85. The polynucleotide of any of embodiments 83-84, wherein the promoter is a constitutive promoter.

86. The polynucleotide of any of embodiments 83-85, wherein the promoter is an inducible promoter.

87. The polynucleotide of any of embodiments 82-86, wherein the sdAb variable domain is attached to the G protein via an encoded peptide linker.

88. The polynucleotide of any of embodiments 86-87, wherein the encoded peptide linker comprises up to 65 amino acids in length.

89. The polynucleotide of any of embodiments 86-87, wherein the encoded peptide linker comprises from or from about 2 to 65 amino acids, 2 to 60 amino acids, 2 to 56 amino acids, 2 to 52 amino acids, 2 to 48 amino acids, 2 to 44 amino acids, 2 to 40 amino acids, 2 to 36 amino acids, 2 to 32 amino acids, 2 to 28 amino acids, 2 to 24 amino acids, 2 to 20 amino acids, 2 to 18 amino acids, 2 to 14 amino acids, 2 to 12 amino acids, 2 to 10 amino acids, 2 to 8 amino acids, 2 to 6 amino acids, 6 to 65 amino acids, 6 to 60 amino acids, 6 to 56 amino acids, 6 to 52 amino acids, 6 to 48 amino acids, 6 to 44 amino acids, 6 to 40 amino acids, 6 to 36 amino acids, 6 to 32 amino acids, 6 to 28 amino acids, 6 to 24 amino acids, 6 to 20 amino acids, 6 to 18 amino acids, 6 to 14 amino acids, 6 to 12 amino acids, 6 to 10 amino acids, 6 to 8 amino acids, 8 to 65 amino acids, 8 to 60 amino acids, 8 to 56 amino acids, 8 to 52 amino acids, 8 to 48 amino acids, 8 to 44 amino acids, 8 to 40 amino acids, 8 to 36 amino acids, 8 to 32 amino acids, 8 to 28 amino acids, 8 to 24 amino acids, 8 to 20 amino acids, 8 to 18 amino acids, 8 to 14 amino acids, 8 to 12 amino acids, 8 to 10 amino acids, 10 to 65 amino acids, 10 to 60 amino acids, 10 to 56 amino acids, 10 to 52 amino acids, 10 to 48 amino acids, 10 to 44 amino acids, 10 to 40 amino acids, 10 to 36 amino acids, 10 to 32 amino acids, 10 to 28 amino acids, 10 to 24 amino acids, 10 to 20 amino acids, 10 to 18 amino acids, 10 to 14 amino acids, 10 to 12 amino acids, 12 to 65 amino acids, 12 to 60 amino acids, 12 to 56 amino acids, 12 to 52 amino acids, 12 to 48 amino acids, 12 to 44 amino acids, 12 to 40 amino acids, 12 to 36 amino acids, 12 to 32 amino acids, 12 to 28 amino acids, 12 to 24 amino acids, 12 to 20 amino acids, 12 to 18 amino acids, 12 to 14 amino acids, 14 to 65 amino acids, 14 to 60 amino acids, 14 to 56 amino acids, 14 to 52 amino acids, 14 to 48 amino acids, 14 to 44 amino acids, 14 to 40 amino acids, 14 to 36 amino acids, 14 to 32 amino acids, 14 to 28 amino acids, 14 to 24 amino acids, 14 to 20 amino acids, 14 to 18 amino acids, 18 to 65 amino acids, 18 to 60 amino acids, 18 to 56 amino acids, 18 to 52 amino acids, 18 to 48 amino acids, 18 to 44 amino acids, 18 to 40 amino acids, 18 to 36 amino acids, 18 to 32 amino acids, 18 to 28 amino acids, 18 to 24 amino acids, 18 to 20 amino acids, 20 to 65 amino acids, 20 to 60 amino acids, 20 to 56 amino acids, 20 to 52 amino acids, 20 to 48 amino acids, 20 to 44 amino acids, 20 to 40 amino acids, 20 to 36 amino acids, 20 to 32 amino acids, 20 to 28 amino acids, 20 to 26 amino acids, 20 to 24 amino acids, 24 to 65 amino acids, 24 to 60 amino acids, 24 to 56 amino acids, 24 to 52 amino acids, 24 to 48 amino acids, 24 to 44 amino acids, 24 to 40 amino acids, 24 to 36 amino acids, 24 to 32 amino acids, 24 to 30 amino acids, 24 to 28 amino acids, 28 to 65 amino acids, 28 to 60 amino acids, 28 to 56 amino acids, 28 to 52 amino acids, 28 to 48 amino acids, 28 to 44 amino acids, 28 to 40 amino acids, 28 to 36 amino acids, 28 to 34 amino acids, 28 to 32 amino acids, 32 to 65 amino acids, 32 to 60 amino acids, 32 to 56 amino acids, 32 to 52 amino acids, 32 to 48 amino acids, 32 to 44 amino acids, 32 to 40 amino acids, 32 to 38 amino acids, 32 to 36 amino acids, 36 to 65 amino acids, 36 to 60 amino acids, 36 to 56 amino acids, 36 to 52 amino acids, 36 to 48 amino acids, 36 to 44 amino acids, 36 to 40 amino acids, 40 to 65 amino acids, 40 to 60 amino acids, 40 to 56 amino acids, 40 to 52 amino acids, 40 to 48 amino acids, 40 to 44 amino acids, 44 to 65 amino acids, 44 to 60 amino acids, 44 to 56 amino acids, 44 to 52 amino acids, 44 to 48 amino acids, 48 to 65 amino acids, 48 to 60 amino acids, 48 to 56 amino acids, 48 to 52 amino acids, 50 to 65 amino acids, 50 to 60 amino acids, 50 to 56 amino acids, 50 to 52 amino acids, 54 to 65 amino acids, 54 to 60 amino acids, 54 to 56 amino acids, 58 to 65 amino acids, 58 to 60 amino acids, or 60 to 65 amino acids.

90. The polynucleotide of any of embodiments 86-87, wherein the encoded peptide linker comprises a polypeptide that is 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 or 65 amino acids in length.

91. The polynucleotide of any of embodiments 86-87, wherein the encoded peptide linker comprises GS, GGS, GGGGS (SEQ ID NO:43), GGGGGS (SEQ ID NO:41) and combinations thereof.

92. The polynucleotide of any of embodiments 86-87, wherein the encoded peptide linker comprises (GGS)n, wherein n is 1 to 10.

93. The polynucleotide of any of embodiments 86-87, wherein the encoded peptide linker comprises (GGGGS)n (SEQ ID NO:42), wherein n is 1 to 10. 94. The polynucleotide of any of embodiments 86-87, wherein the encoded peptide linker comprises (GGGGGS)n (SEQ ID NO:27), wherein n is 1 to 4.

95. The polynucleotide of any of embodiments 86-87, wherein the nucleic acid sequence encoding the G protein is a wild-type Nipah virus G (NiV-G) protein or a Hendra virus G protein or is a variant thereof that exhibits reduced binding for the native binding partner.

96. The polynucleotide of any of embodiments 82-95, wherein the nucleic acid sequence encoding the G protein is a wild-type NiV-G protein.

97. The polynucleotide of any of embodiments 82-95, wherein the nucleic acid sequence encoding the G-protein is a mutant NiV-G protein that exhibits reduced binding to Ephrin B2 or Ephrin B3.

98. The polynucleotide of embodiment 97, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 9, SEQ ID NO:28 or SEQ ID NO: 44.

99. The polynucleotide of any of embodiments 82-95 and 97, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises the sequence set forth in any of SEQ ID NOS: 10-15, 35-40 or 45-50 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NOs: 10-15, 35-40 or 45-50.

100. The polynucleotide of any of embodiments 97-99, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises a 5 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO: 9, SEQ ID NO:28 or SEQ ID NO: 44).

101. The polynucleotide of embodiment 100, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises the amino acid sequence set forth in SEQ ID NO: 10 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:10.

102. The polynucleotide of embodiment 100, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises the amino acid sequence set forth in SEQ ID NO: 35 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:35.

103. The polynucleotide of embodiment 100, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises the amino acid sequence set forth in SEQ ID NO: 45 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:45.

104. The polynucleotide of any of embodiments 97-99, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises a 10 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO: 9, SEQ ID NO:28 or SEQ ID NO: 44).

105. The polynucleotide of embodiment 104, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises the amino acid sequence set forth in SEQ ID NO: 11 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:11.

106. The polynucleotide of embodiment 104, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises the amino acid sequence set forth in SEQ ID NO: 36 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:36.

107. The polynucleotide of embodiment 104, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises the amino acid sequence set forth in SEQ ID NO: 46 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:46.

108. The polynucleotide of any of embodiments 97-99, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises a 15 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO: 9, SEQ ID NO:28 or SEQ ID NO: 44).

109. The polynucleotide of embodiment 108, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises the amino acid sequence set forth in SEQ ID NO: 12 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:12.

110. The polynucleotide of embodiment 108, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises the amino acid sequence set forth in SEQ ID NO: 37 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:37.

111. The polynucleotide of embodiment 108, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises the amino acid sequence set forth in SEQ ID NO: 47 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:47.

112. The polynucleotide of any of embodiments 97-99, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises a 20 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO: 9, SEQ ID NO:28 or SEQ ID NO: 44).

113. The polynucleotide of embodiment 112, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises the amino acid sequence set forth in SEQ ID NO: 13 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:13.

114. The polynucleotide of embodiment 112, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises the amino acid sequence set forth in SEQ ID NO: 38 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:38.

115. The polynucleotide of embodiment 112, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises the amino acid sequence set forth in SEQ ID NO: 48 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:48.

116. The polynucleotide of any of embodiments 97-99, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises a 25 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO: 9, SEQ ID NO:28 or SEQ ID NO: 44).

117. The polynucleotide of embodiment 116, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises the amino acid sequence set forth in SEQ ID NO: 14 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:14.

118. The polynucleotide of embodiment 116, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises the amino acid sequence set forth in SEQ ID NO: 39 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:39.

119. The polynucleotide of embodiment 116, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises the amino acid sequence set forth in SEQ ID NO: 49 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:49.

120. The polynucleotide of any of embodiments 97-99, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises a 30 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein (SEQ ID NO: 9, SEQ ID NO:28 or SEQ ID NO: 44).

121. The polynucleotide of embodiment 120, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises the amino acid sequence set forth in SEQ ID NO: 15 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:15.

122. The polynucleotide of embodiment 120, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises the amino acid sequence set forth in SEQ ID NO: 40 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:40.

123. The polynucleotide of embodiment 120, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises the amino acid sequence set forth in SEQ ID NO: 50 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 50.

124. The polynucleotide of any of embodiments 97-99, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises:

i) a truncation at or near the N-terminus; and

ii) point mutations selected from the group consisting of E501A, W504A, Q530A and E533A.

125. The polynucleotide of embodiment 124, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises the amino acid sequence set forth in SEQ ID NO: 16 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:16.

126. The polynucleotide of embodiment 124, wherein the nucleic acid sequence encoding the mutant NiV-G protein comprises the amino acid sequence set forth in SEQ ID NO: 51 or an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:51.

127. A vector, comprising the polynucleotide of any of embodiments 82-126.

128. The vector of embodiment 127, wherein the vector is a mammalian vector, viral vector or artificial chromosome, optionally wherein the artificial chromosome is a bacterial artificial chromosome (BAC).

129. A cell comprising the polynucleotide of any of embodiments 82-126 or the vector of embodiment 127 or embodiment 128.

130. A method of making a targeted lipid particle comprising a henipavirus F protein molecule or biologically active portion thereof and a targeted envelope protein comprising a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and a single domain antibody (sdAb) variable domain comprising:

a) providing a cell that comprises a nucleic acid encoding a henipavirus F protein molecule or biologically active portion thereof and a nucleic acid encoding a targeted envelope protein comprising a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and a single domain antibody (sdAb) variable domain;

b) culturing the cell under conditions that allow for production of a targeted lipid particle, and

c) separating, enriching, or purifying the targeted lipid particle from the cell, thereby making the targeted lipid particle.

131. A method of making a targeted lipid particle comprising a henipavirus F protein molecule or biologically active portion thereof and a targeted envelope protein comprising a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and a single domain antibody (sdAb) variable domain, comprising:

a) providing a cell that comprises the polynucleotide of any of embodiments 82-126 or the vector of embodiment 127 or embodiment 128;

b) providing the cell a polynucleotide encoding a henipavirus F protein molecule or biologically active portion thereof;

c) culturing the cell under conditions that allow for production of a targeted lipid particle, and

d) separating, enriching, or purifying the targeted lipid particle particle from the cell, thereby making the targeted lipid particle.

132. The method of embodiment 130 or embodiment 131, wherein the cell is a mammalian cell.

133. The method of any of embodiments 130-131, wherein the cell is a producer cell and the targeted lipid particle is a viral particle or a viral-like particle, optionally a retroviral particle or a retroviral-like particle, optionally a lentiviral particle or lentiviral-like particle.

134. A producer cell comprising (i) a viral nucleic acid(s) and (ii) nucleic acid encoding a henipavirus F protein molecule or biologically active portion thereof and (iii) a nucleic acid encoding a targeted envelope protein comprising a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and a single domain antibody (sdAb) variable domain, optionally wherein the viral nucleic acid(s) are lentiviral nucleic acids.

135. The producer cell of embodiment 134, wherein the viral nucleic acid(s) lacks one or more genes involved in viral replication.

136. The producer cell of embodiment 134 or embodiment 135, wherein the viral nucleic acid comprises a nucleic acid encoding a viral packaging protein selected from one or more of Gag, Pol, Rev and Tat.

137. The producer cell of any of embodiments 134-136, wherein the viral nucleic acid comprises:

one or more of (e.g., all of) the following nucleic acid sequences: 5′ LTR (e.g., comprising U5 and lacking a functional U3 domain), Psi packaging element (Psi), Central polypurine tract (cPPT)/central termination sequence (CTS) (e.g. DNA flap), Poly A tail sequence, a posttranscriptional regulatory element (e.g. WPRE), a Rev response element (RRE), and 3′ LTR (e.g., comprising U5 and lacking a functional U3);

138. The producer cell of any of embodiments 134-137, wherein the henipavirus F protein molecule or biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 2;

(ii) an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:2.

139. The producer cell of any of embodiments 134-137, wherein the henipavirus F protein molecule or biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 5;

(ii) an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:5.

140. The producer cell of any of embodiments 134-137, wherein the henipavirus F protein molecule or biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 7;

(ii) an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:7.

141. The producer cell of any of embodiments 134-137, wherein the henipavirus F protein molecule or biologically active portion thereof comprises:

(i) a sequence encoding by a nucleotide sequence encoding the sequence set forth in SEQ ID NO: 8;

(ii) a amino acid sequence encoded by a nucleotide sequence encoding a sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:8.

142. The producer cell of any of embodiments 134-137, wherein the henipavirus F protein molecule or biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 23;

(ii) an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:23.

143. The producer cell of any of embodiments 134-142, wherein the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 9, SEQ ID NO:28 or SEQ ID NO:44;

(ii) an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 9, SEQ ID NO:28 or SEQ ID NO:44.

144. The producer cell of any of embodiments 134-142, wherein the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 10;

(ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:10.

145. The producer cell of any of embodiments 134-142, wherein the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 35;

(ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:35.

146. The producer cell of any of embodiments 134-142, wherein the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 45;

(ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:45.

147. The producer cell of any of embodiments 134-142, wherein the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 11;

(ii) an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:11.

148. The producer cell of any of embodiments 134-142, wherein the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 36;

(ii) an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:36.

149. The producer cell of any of embodiments 134-142, wherein the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 46;

(ii) an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:46.

150. The producer cell of any of embodiments 134-142, wherein the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 12;

(ii) an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:12.

151. The producer cell of any of embodiments 134-142, wherein the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 37;

(ii) an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:37.

152. The producer cell of any of embodiments 134-142, wherein the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 47;

(ii) an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:47.

153. The producer cell of any of embodiments 134-142, wherein the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 13;

(ii) an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:13.

154. The producer cell of any of embodiments 134-142, wherein the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 38;

(ii) an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:38.

155. The producer cell of any of embodiments 134-142, wherein the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 48;

(ii) an amino acid sequence having at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:48.

156. The producer cell of any of embodiments 134-142, wherein the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 14;

(ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:14.

157. The producer cell of any of embodiments 134-142, wherein the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 39;

(ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:39.

158. The producer cell of any of embodiments 134-142, wherein the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 49;

(ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:49.

159. The producer cell of any of embodiments 134-142, wherein the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 15;

(ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:15.

160. The producer cell of any of embodiments 134-142, wherein the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 40;

(ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:40.

161. The producer cell of any of embodiments 134-142, wherein the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 50;

(ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:50.

162. The producer cell of any of embodiments 134-142, wherein the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 16;

(ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:16.

163. The producer cell of any of embodiments 134-142, wherein the henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof comprises:

(i) the sequence set forth in SEQ ID NO: 51;

(ii) an amino acid sequence having at least at or about 80%, at least at or about 81%, at least at or about 82%, at least at or about 83%, at or about 84%, at least at or about 85%, at least at or about 86%, or at least at or about 87%, at least at or about 88%, or at least at or about 89%, at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:51.

164. A viral vector particle or viral-like particle produced from the producer cell of any of embodiments 134-163.

165. A composition comprising a plurality of targeted lipid particles of any of embodiments 1-81 and 173-176.

166. The composition of embodiment 165 further comprising a pharmaceutically acceptable carrier.

167. The pharmaceutical composition of embodiment 165 or embodiment 166, wherein the targeted lipid particles comprise an average diameter of less than 1 μm.

168. A method of delivering an exogenous agent to a subject (e.g., a human subject), the method comprising administering to the subject the targeted lipid particle of any of embodiments 1-81 and 173-176 or the composition of any of embodiments 165-167 and 177.

169. A method of treating a disease or disorder in a subject (e.g., a human subject), the method comprising administering to the subject a targeted lipid particle of any of embodiments 1-81 and 173-176 or the composition of any of embodiments 165-167 and 177.

170. A method of fusing a mammalian cell to a targeted lipid particle, the method comprising administering to the subject a targeted lipid particle of any of embodiments 1-81 and 173-176 or the composition of any of embodiments 165-167 and 177.

171. The method of embodiment 170, wherein the fusing of the mammalian cell to the targeted lipid particle delivers an exogenous agent to a subject (e.g., a human subject).

172. The method of embodiment 170 or embodiment 171, wherein the fusing of the mammalian cell to the targeted lipid particle treats a disease or disorder in a subject (e.g., a human subject).

173. The targeted lipid particle of any of embodiments 1-81, wherein the targeted lipid particle has greater expression of the targeted envelope protein compared to a reference lipid particle that has incorporated into a similar lipid bilayer the same envelope protein but that is fused to an alternative targeting moiety, optionally wherein the alternative targeting moiety is a single chain variable fragment (scFv).

174. The targeted lipid particle of embodiment 173, wherein the expression is increased by at or greater than 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 125%, 150%, 200%, 300%, 400%, 500% or more.

175. The targeted lipid particle of embodiment 173, wherein the expression is increased by at or greater than 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 15-fold, 20-fold, 30-fold or more, preferably at or about or greater than 10-fold or more.

176. The targeted lipid particle of any of embodiments 1-81 and 173-175 or the viral vector particle or viral-like particle of embodiment 164, wherein the titer in target cells following transduction is at or greater than 1×10⁶ transduction units (TU)/mL, at or greater than 2×10⁶ TU/mL, at or greater than 3×10⁶ TU/mL, at or greater than 4×10⁶ TU/mL, at or greater than 5×10⁶ TU/mL, at or greater than 6×10⁶ TU/mL, at or greater than 7×10⁶ TU/mL, at or greater than 8×10⁶ TU/mL, at or greater than 9×10⁶ TU/mL, or at or greater than 1×10⁷ TU/mL.

177. The composition of any of embodiments 165-167, wherein among the population of lipid particles in the composition, greater than at or about 50%, greater than at or about 55%, greater than at or about 60%, greater than at or about 65%, greater than at or about 70%, or greater than at or about 75% are surface positive for the targeted envelope protein.

178. The targeted lipid particle of any of embodiments 1-81 and 173-176, wherein the targeted envelope protein is present on the surface of the targeted lipid particle at a density of at least about (0.001, 0.002, 0.005, 0.01, 0.02, 0.05, 0.1, 0.2 or 0.5) targeted envelope proteins/nm².

179. A composition comprising a plurality of the targeted lipid particles of any of embodiments 1-81, 173-176 and 178, wherein the targeted envelope protein is present on the surface of the targeted lipid particles at an average density of at least about (0.001, 0.002, 0.005, 0.01, 0.02, 0.05, 0.1, 0.2 or 0.5) targeted envelope proteins/nm².

180. The producer cell of any one of embodiments 134-163, wherein the producer cell has greater membrane (e.g., plasma membrane) expression of the targeted envelope protein compared to a reference producer cell that has incorporated into its membrane (e.g. plasma membrane) the same envelope protein but that is fused to an alternative targeting moiety, optionally wherein the alternative targeting moiety is a single chain variable fragment (scFv).

181. The producer cell of embodiment 180, wherein the expression is increased by at or greater than 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 125%, 150%, 200%, 300%, 400%, 500% or more.

182. The producer cell of embodiment 180, wherein the expression is increased by at or greater than 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 15-fold, 20-fold, 30-fold or more, preferably at or about or greater than 10-fold or more.

183. The producer cell of any one of embodiments 134-163 and 180-182, wherein the producer cell has the expression of the targeted envelope protein on a membrane (e.g., plasma membrane) of the producer cell is at least 20 proteins (e.g., at least 50, 100, 200, 500, 1000, 2000, 5000, or 10,000 proteins) per square micron.

184. The producer cell of any one of embodiments 134-163 and 180-183, wherein the targeted envelope protein comprises at least 0.1% (e.g., at least 0.2%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10%) of the total membrane (e.g., plasma membrane) proteins of the producer cell (e.g., by total protein weight).

EXAMPLES

The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.

Example 1: Generation and Characterization of Producer Cells Containing Targeted Binders

This Example describes generation and assessment of NiVG targeted binding sequences in which NiVG was linked to scFv or VHH binding modalities.

A. Binding Modalities Directed to CD4.

Exemplary retargeted NivG fusogen constructs were generated containing an scFv or VHH binding modality against human cellular receptor CD4. For each binding modality, four different sequences that contained a unique CDR3 were assessed. Each exemplary binder sequence was codon optimized and cloned into an expression vector as a fusion with a sequence encoding NiVG (GcΔ34; Bender et al. 2016 PLoS Pathol 12(6):e1005641). The resulting vectors encoded a NivG targeting domain containing NiVG (SEQ ID NO:16) a flexible linker and the binding domain, followed by a 6xHis-tag for detection (NivG-linker-scFv-6xHis).

After subcloning, 5 μg of each exemplary construct was transfected into HEK 293 cells using a transfection reagent. A pcDNA3.1 plasmid (empty vector) and the expression vector without the binder domain (NiVG-linker-NoBinder) were used as negative controls.

At 48 hours post-transfection, cells were harvested and 100,000 cells were incubated for 1 hour at 4° C. with either 50 nM or 300 nM of soluble human CD4 protein with a human Fc tag (hCD4-Fc). After incubation, cells were washed and co-stained with an anti-His antibody conjugated to Alexa-647 to detect surface expression of NivG-binders and an anti-human Fc antibody conjugated to Alexa-488 to detect binding to soluble hCD4-Fc protein.

Cells were analyzed by flow cytometry, and gates for His (surface expression) and Fc (CD4-protein binding) were set based on the negative control empty vector (pcDNA3.1). Evaluation of median fluorescence intensity (MFI) of cells transfected with constructs containing VHH binding modalities demonstrated higher surface expression as quantified by % of His+ cells (FIG. 1A) and higher binding to soluble hCD4-Fc protein as quantified by % Fc+ cell (FIG. 1B), than cells transfected with constructs containing scFv binding modalities.

B. Binding Modalities Directed to Multiple Cellular Receptors

Exemplary constructs were generated containing scFv and VHH binding modalities generally as described above, but containing unique sequences directed against other cellular receptors hCD8, CD4, ASGR2, TM4SF5, LDLR or ASGR1. Multiple sequences, each containing a unique CDR3, were assessed for each binding modality containing distinct cellular receptors. After subcloning into the NivG-linker-6xHis expression vector as described above, 5 μg of each exemplary construct was transfected into about HEK 293 cells. The pcDNA3.1 plasmid (empty vector) and the expression vector without the binding domain (NiVG-linker-NoBinder) were used as negative controls.

At 48 hours post-transfection, cells were harvested and 100,000 cells were washed and stained with an anti-His antibody conjugated to Alexa-647 to detect surface expression of NivG-binders. Cells were analyzed by flow cytometry, and gates for His (surface expression) were set based on the negative control empty vector (pcDNA3.1). Median fluorescence intensity (MFI) was normalized to that of the NivG-NoBinder control set to 100. Cells transfected with constructs containing VHH binding modalities, compared to the scFv binding modalities, demonstrated higher surface expression of targeted binding sequences on 293 cells as quantified by % of His+ cells (FIG. 1C).

Example 2: Generation and Characterization of Lentiviruses Pseudotyped with Targeted Binders

This Example describes generation of lentiviruses pseudotyped with NivG retargeted fusogens and assessment of transduction of primary human T cells.

A. Generation of NivG Pseudotyped Lentiviruses.

293 cells were plated at 5.4×10⁶ into 10 cm dishes and allowed to rest for 24 hours. At 24 hours after plating, cells were transfected using polyethylenimine (PEI) with the following plasmids: NivG pseudotyped vector containing hCD4 targeted binding sequences linked to scFv or VHH binding modalities (NivG-linker-hCD4-binding modality), vector containing a nucleotide sequence encoding the NivF sequence NivFde122 (SEQ ID NO:8; or SEQ ID NO:23 without a signal sequence; Bender et al. 2016 PLoS), a packaging plasmid containing an empty backbone, an HIV-1 pol, HIV-1 gag, HIV-1 Rev, HIV-1 Tat, an AmpR promoter and an SV40 promoter and a lentiviral reporter plasmid encoding an enhanced green fluorescent protein (eGFP) under the control of a SFFV promoter pLenti-SFFV-eGFP. Positive control cells were generated using the plasmids described above along with 4 μg of VSV-G.

B. NivG Pseudotyped Lentiviral Transduction Efficiency of Primary Human T Cells.

PanT cells from peripheral blood (StemCellTech, Vancouver, Canada) that were negatively selected to enrich for T cells were thawed and activated with anti CD3/anti-CD28 for 2 days. Concentrated lentiviruses generated generally as described above were serially diluted 6-fold starting at 0.05 dilution with a total of 4 points in the dilution series. Lentiviruses were added to 100,000 PanT cells and transduced by spinfection for 90 minutes at 1000 g at 25C. Transduced PanT cells were split on days 2 and 5 post-transduction, and on day 7 post-transduction, cells were harvested and stained with an Alexa-647 conjugated anti-human CD4 antibody. Cells were analyzed by flow cytometry, and titer was determined by % of CD4-positive cells that were GFP+. Cells transfected with constructs containing VHH binding modalities demonstrated a 10-fold increased titer over constructs containing scFv binding modalities on primary human T cells (FIG. 2).

Example 3. In Vivo Delivery of Lentiviruses Pseudotyped with CD8 Targeted Binders

This Example describes generation of lentiviruses pseudotyped with a CD8 NivG retargeted fusogen and in vivo assessment of transduction of primary human T cells.

CD8 retargeted NivG fusogens were generated essentially as described in Example 2. The retargeted NivG pseudotyped fusogen contained a NivG targeting domain containing NiVG (SEQ ID NO:16) a flexible linker and an exemplary CD8 binding domain, either a VHH or scFv binding modality.

T cells from human peripheral blood mononuclear cells (PBMCs) were activated with anti CD3/anti-CD28 for 3 days. After 3 days of incubation, 1×10⁷ cells were injected intraperitoneally into NOD-scid-IL2rγ^null mice. One day post-injection, mice received 1×10⁷ transducing units (TU) of CD8 NivG pseudotyped lentiviruses generated as described above, or no lenti-viral vector (LVV) control, through intraperitoneal injection. On day 7 post-CD8 NivG psedudotyped lentivirus injection, peritoneal cells were harvested and analyzed by flow cytometry, and titer was determined by % of CD8 positive or negative cells that were GFP+. The CD8 retargeted pseudotyped lentiviruses demonstrated significant in vivo transduction of CD8+ T cells (FIG. 3A) and minimal transduction of CD8− T cells (FIG. 3B). These results indicate that CD8 targeted pseudotyped lentiviral-mediated delivery permits specific delivery of a transgene to the intended cell type (e.g. CD8+ T cells).

Example 4. In Vitro Assessment of Chimeric Antigen Receptor (Car) Containing Pseudotyped Lentiviruses with CD8 Targeted Binders

This Example describes the in vitro tumor killing activity of lentivirus pseudotyped with a CD8 retargeted fusogen and expressing a CD19-directed chimeric antigen receptor (CD19CAR). The lentiviruses were generated substantially as described in Example 3, except that a plasmid encoding either the eGFP or the CD19CAR were transfected into the 293 producer cells. The CD19CAR contained an anti-scFv directed against CD19 and an intracellular signaling domain containing intracellular components of 4-1BB and CD3-zeta.

Human peripheral blood mononuclear cells (PBMCs) were activated with anti CD3/anti-CD28reagent and were transduced with CD8 retargeted NivG lentiviruses expressing CD19+CAR or GFP at various concentration ranges (10-10,000 transducing units/well). RFP+Nalm6 leukemia cells were added to cultures on day 3, and elimination of Nalm6 cells was evaluated at 18 hours by flow cytometry.

As shown in FIG. 4A, CD19+CAR expression was detected specifically in CD8+ cells with both CD8 retargeted fusogens at 4 days after transduction. Transduced CD8+ T cells expressing the CD19CAR also mediated a potent and lentivirus dose-dependent increase in killing of CD19+ Nalm6 leukemia cells, while in contrast, cells transduced to express GFP did not exhibit target cell killing (FIG. 4B).

These results demonstrate that CD8-retargeted pseudotyped lentiviruses with a transgene encoding a CD19CAR deliver CD19CAR to human CD8+ T cells to mediate a specific transduction of CD8+ T cells in a complex mixture of PBMCs and showed a dose-dependent anti-tumor response by killing of leukemic cells in vitro.

The present invention is not intended to be limited in scope to the particular disclosed embodiments, which are provided, for example, to illustrate various aspects of the invention. Various modifications to the compositions and methods described will become apparent from the description and teachings herein. Such variations may be practiced without departing from the true scope and spirit of the disclosure and are intended to fall within the scope of the present disclosure.

SEQUENCES
#	SEQUENCE	ANNOTATION
1	MVVILDKRCY CNLLILILMI SECSVGILHY EKLSKIGLVK	Nipah virus
	GVTRKYKIKS NPLTKDIVIK MIPNVSNMSQ CTGSVMENYK	NiV-F with
	TRLNGILTPI KGALEIYKNN THDLVGDVRL AGVIMAGVAI	signal sequence
	GIATAAQITA GVALYEAMKN ADNINKLKSS IESTNEAVVK	(aa 1-546)
	LQETAEKTVY VLTALQDYIN TNLVPTIDKI SCKQTELSLD	Uniprot Q9IH63
	LALSKYLSDL LFVFGPNLQD PVSNSMTIQA ISQAFGGNYE
	TLLRTLGYAT EDFDDLLESD SITGQIIYVD LSSYYIIVRV
	YFPILTEIQQ AYIQELLPVS FNNDNSEWIS IVPNFILVRN
	TLISNIEIGF CLITKRSVIC NQDYATPMTN NMRECLTGST
	EKCPRELVVS SHVPRFALSN GVLFANCISV TCQCQTTGRA
	ISQSGEQTLL MIDNTTCPTA VLGNVIISLG KYLGSVNYNS
	EGIAIGPPVF TDKVDISSQI SSMNQSLQQS KDYIKEAQRL
	LDTVNPSLIS MLSMIILYVL SIASLCIGLI TFISFIIVEK
	KRNTYSRLED RRVRPTSSGD LYYIGT
2	ILHY EKLSKIGLVK GVTRKYKIKS NPLTKDIVIK MIPNVSNMSQ	Nipah virus
	CTGSVMENYK TRLNGILTPI KGALEIYKNN THDLVGDVRL	NiV-F F0 (aa 27-
	AGVIMAGVAI GIATAAQITA GVALYEAMKN ADNINKLKSS	546)
	IESTNEAVVK LQETAEKTVY VLTALQDYIN TNLVPTIDKI
	SCKQTELSLD LALSKYLSDL LFVFGPNLQD PVSNSMTIQA
	ISQAFGGNYE TLLRTLGYAT EDFDDLLESD SITGQIIYVD
	LSSYYIIVRV YFPILTEIQQ AYIQELLPVS FNNDNSEWIS
	IVPNFILVRN TLISNIEIGF CLITKRSVIC NQDYATPMTN
	NMRECLTGST EKCPRELVVS SHVPRFALSN GVLFANCISV
	TCQCQTTGRA ISQSGEQTLL MIDNTTCPTA VLGNVIISLG
	KYLGSVNYNS EGIAIGPPVF TDKVDISSQI SSMNQSLQQS
	KDYIKEAQRL LDTVNPSLIS MLSMIILYVL SIASLCIGLI
	TFISFIIVEK KRNTYSRLED RRVRPTSSGD LYYIGT
3	ILHYEKLSKIGLVKGVTRKYKIKSNPLIKDIVIKMIPNVSNMSQCTGSVME	Nipah virus
	NYKTRLNGILTPIKGALEIYKNNTHDLVGDVR	NiV-F F2 (aa 27-
		109)
4	LAGVIMAGVAIGIATAAQITAGVALYEAMKNADNINKLKSSIESTNEAVVK	Nipah virus NiV
	LQETAEKTVYVLTALQDYINTNLVPTIDKISCKQTELSLDLALSKYLSDLL	F F1 (aa 110-
	FVFGPNLQDPVSNSMTIQAISQAFGGNYETLLRTLGYATEDFDDLLESDSI	546)
	TGQIIYVDLSSYYIIVRVYFPILTEIQQAYIQELLPVSFNNDNSEWISIVP
	NFILVRNTLISNIEIGFCLITKRSVICNQDYATPMTNNMRECLTGSTEKCP
	RELVVSSHVPRFALSNGVLFANCISVTCQCQTTGRAISQSGEQTLLMIDNT
	TCPTAVLGNVIISLGKYLGSVNYNSEGIAIGPPVFTDKVDISSQISSMNQS
	LQQSKDYIKEAQRLLDTVNPSLISMLSMIILYVLSIASLCIGLITFISFII
	VEKKRNTYSRLEDRRVRPTSSGDLYYIGT
5	ILHY EKLSKIGLVK GVTRKYKIKS NPLTKDIVIK MIPNVSNMSQ	Nipah virus
	CTGSVMENYK TRLNGILTPI KGALEIYKNN THDLVGDVRL	NiV-F F0 T234
	AGVIMAGVAI GIATAAQITA GVALYEAMKN ADNINKLKSS	truncation (aa
	IESTNEAVVK LQETAEKTVY VLTALQDYIN TNLVPTIDKI	525-544)
	SCKQTELSLD LALSKYLSDL LFVFGPNLQD PVSNSMTIQA
	ISQAFGGNYE TLLRTLGYAT EDFDDLLESD SITGQIIYVD
	LSSYYIIVRV YFPILTEIQQ AYIQELLPVS FNNDNSEWIS
	IVPNFILVRN TLISNIEIGF CLITKRSVIC NQDYATPMTN
	NMRECLTGST EKCPRELVVS SHVPRFALSN GVLFANCISV
	TCQCQTTGRA ISQSGEQTLL MIDNTTCPTA VLGNVIISLG
	KYLGSVNYNS EGIAIGPPVF TDKVDISSQI SSMNQSLQQS
	KDYIKEAQRL LDTVNPSLIS MLSMIILYVL SIASLCIGLI
	TFISFIIVEK KRNTGT
6	LAGVIMAGVAIGIATAAQITAGVALYEAMKNADNINKLKSSIESTNEAVVK	Nipah virus NiV
	LQETAEKTVYVLTALQDYINTNLVPTIDKISCKQTELSLDLALSKYLSDLL	F F1 (aa 110-
	FVFGPNLQDPVSNSMTIQAISQAFGGNYETLLRTLGYATEDFDDLLESDSI	546) truncation
	TGQIIYVDLSSYYIIVRVYFPILTEIQQAYIQELLPVSFNNDNSEWISIVP	(aa 525-544)
	NFILVRNTLISNIEIGFCLITKRSVICNQDYATPMTNNMRECLTGSTEKCP
	RELVVSSHVPRFALSNGVLFANCISVTCQCQTTGRAISQSGEQTLLMIDNT
	TCPTAVLGNVIISLGKYLGSVNYNSEGIAIGPPVFTDKVDISSQISSMNQS
	LQQSKDYIKEAQRLLDTVNPSLISMLSMIILYVLSIASLCIGLITFISFII
	VEKKRNTGT
7	ILHY EKLSKIGLVK GVTRKYKIKS NPLTKDIVIK MIPNVSNMSQ	Nipah virus
	CTGSVMENYK TRLNGILTPI KGALEIYKNQ THDLVGDVRL	NiV-F F0 T234
	AGVIMAGVAI GIATAAQITA GVALYEAMKN ADNINKLKSS	truncation (aa
	IESTNEAVVK LQETAEKTVY VLTALQDYIN TNLVPTIDKI	525-544) AND
	SCKQTELSLD LALSKYLSDL LFVFGPNLQD PVSNSMTIQA	mutation on N-
	ISQAFGGNYE TLLRTLGYAT EDFDDLLESD SITGQIIYVD	linked
	LSSYYIIVRV YFPILTEIQQ AYIQELLPVS FNNDNSEWIS	glycosylation
	IVPNFILVRN TLISNIEIGF CLITKRSVIC NQDYATPMTN	site
	NMRECLTGST EKCPRELVVS SHVPRFALSN GVLFANCISV
	TCQCQTTGRA ISQSGEQTLL MIDNTTCPTA VLGNVIISLG
	KYLGSVNYNS EGIAIGPPVF TDKVDISSQI SSMNQSLQQS
	KDYIKEAQRL LDTVNPSLIS MLSMIILYVL SIASLCIGLI
	TFISFIIVEK KRNTGT
8	MVVILDKRCY CNLLILILMI SECSVGILHY EKLSKIGLVK	Truncated NiV
	GVTRKYKIKS NPLTKDIVIK MIPNVSNMSQ CTGSVMENYK	fusion
	TRLNGILTPI KGALEIYKNN THDLVGDVRL AGVIMAGVAI	glycoprotein
	GIATAAQITA GVALYEAMKN ADNINKLKSS IESTNEAVVK	(FcDelta22) at
	LQETAEKTVY VLTALQDYIN TNLVPTIDKI SCKQTELSLD	cytoplasmic tail
	LALSKYLSDL LFVFGPNLQD PVSNSMTIQA ISQAFGGNYE	(with signal
	TLLRTLGYAT EDFDDLLESD SITGQIIYVD LSSYYIIVRV	sequence)
	YFPILTEIQQ AYIQELLPVS FNNDNSEWIS IVPNFILVRN
	TLISNIEIGF CLITKRSVIC NQDYATPMTN NMRECLTGST
	EKCPRELVVS SHVPRFALSN GVLFANCISV TCQCQTTGRA
	ISQSGEQTLL MIDNTTCPTA VLGNVIISLG KYLGSVNYNS
	EGIAIGPPVF TDKVDISSQI SSMNQSLQQS KDYIKEAQRL
	LDTVNPSLIS MLSMIILYVL SIASLCIGLI TFISFIIVEK KRNT
9	MGPAENKKVR FENTTSDKGK IPSKVIKSYY GTMDIKKINE	NiVG protein
	GLLDSKILSA FNTVIALLGS IVIIVMNIMI IQNYTRSTDN	attachment
	QAVIKDALQG IQQQIKGLAD KIGTEIGPKV SLIDTSSTIT	glycoprotein
	IPANIGLLGS KISQSTASIN ENVNEKCKFT LPPLKIHECN	(602 aa)
	ISCPNPLPFR EYRPQTEGVS NLVGLPNNIC LQKTSNQILK
	PKLISYTLPV VGQSGTCITD PLLAMDEGYF AYSHLERIGS
	CSRGVSKQRI IGVGEVLDRG DEVPSLFMTN VWTPPNPNTV
	YHCSAVYNNE FYYVLCAVST VGDPILNSTY WSGSLMMTRL
	AVKPKSNGGG YNQHQLALRS IEKGRYDKVM PYGPSGIKQG
	DTLYFPAVGF LVRTEFKYND SNCPITKCQY SKPENCRLSM
	GIRPNSHYIL RSGLLKYNLS DGENPKVVFI EISDQRLSIG
	SPSKIYDSLG QPVFYQASFS WDTMIKFGDV LTVNPLVVNW
	RNNTVISRPG QSQCPRFNTC PEICWEGVYN DAFLIDRINW
	ISAGVFLDSN QTAENPVFTV FKDNEILYRA QLASEDTNAQ
	KTITNCFLLK NKIWCISLVE IYDTGDNVIR PKLFAVKIPE QC
10	MGKVR FENTTSDKGK IPSKVIKSYY GTMDIKKINE GLLDSKILSA	NiVG protein
	FNTVIALLGS IVIIVMNIMI IQNYTRSTDN QAVIKDALQG	attachment
	IQQQIKGLAD KIGTEIGPKV SLIDTSSTIT IPANIGLLGS	glycoprotein
	KISQSTASIN ENVNEKCKFT LPPLKIHECN ISCPNPLPFR	Truncated Δ5
	EYRPQTEGVS NLVGLPNNIC LQKTSNQILK PKLISYTLPV
	VGQSGTCITD PLLAMDEGYF AYSHLERIGS CSRGVSKQRI
	IGVGEVLDRG DEVPSLFMTN VWTPPNPNTV YHCSAVYNNE
	FYYVLCAVST VGDPILNSTY WSGSLMMTRL AVKPKSNGGG
	YNQHQLALRS IEKGRYDKVM PYGPSGIKQG DTLYFPAVGF
	LVRTEFKYND SNCPITKCQY SKPENCRLSM GIRPNSHYIL
	RSGLLKYNLS DGENPKVVFI EISDQRLSIG SPSKIYDSLG
	QPVFYQASFS WDTMIKFGDV LTVNPLVVNW RNNTVISRPG
	QSQCPRFNTC PEICWEGVYN DAFLIDRINW ISAGVFLDSN
	QTAENPVFTV FKDNEILYRA QLASEDTNAQ KTITNCFLLK
	NKIWCISLVE IYDTGDNVIR PKLFAVKIPE QC
11	MGNTTSDKGK IPSKVIKSYY GTMDIKKINE GLLDSKILSA	NiVG protein
	FNTVIALLGS IVIIVMNIMI IQNYTRSTDN QAVIKDALQG	attachment
	IQQQIKGLAD KIGTEIGPKV SLIDTSSTIT IPANIGLLGS	glycoprotein
	KISQSTASIN ENVNEKCKFT LPPLKIHECN ISCPNPLPFR	Truncated Δ10
	EYRPQTEGVS NLVGLPNNIC LQKTSNQILK PKLISYTLPV
	VGQSGTCITD PLLAMDEGYF AYSHLERIGS CSRGVSKQRI
	IGVGEVLDRG DEVPSLFMTN VWTPPNPNTV YHCSAVYNNE
	FYYVLCAVST VGDPILNSTY WSGSLMMTRL AVKPKSNGGG
	YNQHQLALRS IEKGRYDKVM PYGPSGIKQG DTLYFPAVGF
	LVRTEFKYND SNCPITKCQY SKPENCRLSM GIRPNSHYIL
	RSGLLKYNLS DGENPKVVFI EISDQRLSIG SPSKIYDSLG
	QPVFYQASFS WDTMIKFGDV LTVNPLVVNW RNNTVISRPG
	QSQCPRFNTC PEICWEGVYN DAFLIDRINW ISAGVFLDSN
	QTAENPVFTV FKDNEILYRA QLASEDTNAQ KTITNCFLLK
	NKIWCISLVE IYDTGDNVIR PKLFAVKIPE QC
12	MGKGK IPSKVIKSYY GTMDIKKINE GLLDSKILSA FNTVIALLGS	NiVG protein
	IVIIVMNIMI IQNYTRSTDN QAVIKDALQG IQQQIKGLAD	attachment
	KIGTEIGPKV SLIDTSSTIT IPANIGLLGS KISQSTASIN	glycoprotein
	ENVNEKCKFT LPPLKIHECN ISCPNPLPFR EYRPQTEGVS	Truncated Δ15
	NLVGLPNNIC LQKTSNQILK PKLISYTLPV VGQSGTCITD
	PLLAMDEGYF AYSHLERIGS CSRGVSKQRI IGVGEVLDRG
	DEVPSLFMTN VWTPPNPNTV YHCSAVYNNE FYYVLCAVST
	VGDPILNSTY WSGSLMMTRL AVKPKSNGGG YNQHQLALRS
	IEKGRYDKVM PYGPSGIKQG DTLYFPAVGF LVRTEFKYND
	SNCPITKCQY SKPENCRLSM GIRPNSHYIL RSGLLKYNLS
	DGENPKVVFI EISDQRLSIG SPSKIYDSLG QPVFYQASFS
	WDTMIKFGDV LTVNPLVVNW RNNTVISRPG QSQCPRFNTC
	PEICWEGVYN DAFLIDRINW ISAGVFLDSN QTAENPVFTV
	FKDNEILYRA QLASEDTNAQ KTITNCFLLK NKIWCISLVE
	IYDTGDNVIR PKLFAVKIPE QC
13	MGSKVIKSYY GTMDIKKINE GLLDSKILSA FNTVIALLGS	NiVG protein
	IVIIVMNIMI IQNYTRSTDN QAVIKDALQG IQQQIKGLAD	attachment
	KIGTEIGPKV SLIDTSSTIT IPANIGLLGS KISQSTASIN	glycoprotein
	ENVNEKCKFT LPPLKIHECN ISCPNPLPFR EYRPQTEGVS	Truncated Δ20
	NLVGLPNNIC LQKTSNQILK PKLISYTLPV VGQSGTCITD
	PLLAMDEGYF AYSHLERIGS CSRGVSKQRI IGVGEVLDRG
	DEVPSLFMTN VWTPPNPNTV YHCSAVYNNE FYYVLCAVST
	VGDPILNSTY WSGSLMMTRL AVKPKSNGGG YNQHQLALRS
	IEKGRYDKVM PYGPSGIKQG DTLYFPAVGF LVRTEFKYND
	SNCPITKCQY SKPENCRLSM GIRPNSHYIL RSGLLKYNLS
	DGENPKVVFI EISDQRLSIG SPSKIYDSLG QPVFYQASFS
	WDTMIKFGDV LTVNPLVVNW RNNTVISRPG QSQCPRFNTC
	PEICWEGVYN DAFLIDRINW ISAGVFLDSN QTAENPVFTV
	FKDNEILYRA QLASEDTNAQ KTITNCFLLK NKIWCISLVE
	IYDTGDNVIR PKLFAVKIPE QC
14	MGSYY GTMDIKKINE GLLDSKILSA FNTVIALLGS IVIIVMNIMI	NiVG protein
	IQNYTRSTDN QAVIKDALQG IQQQIKGLAD KIGTEIGPKV	attachment
	SLIDTSSTIT IPANIGLLGS KISQSTASIN ENVNEKCKFT	glycoprotein
	LPPLKIHECN ISCPNPLPFR EYRPQTEGVS NLVGLPNNIC	Truncated Δ25
	LQKTSNQILK PKLISYTLPV VGQSGTCITD PLLAMDEGYF
	AYSHLERIGS CSRGVSKQRI IGVGEVLDRG DEVPSLFMTN
	VWTPPNPNTV YHCSAVYNNE FYYVLCAVST VGDPILNSTY
	WSGSLMMTRL AVKPKSNGGG YNQHQLALRS IEKGRYDKVM
	PYGPSGIKQG DTLYFPAVGF LVRTEFKYND SNCPITKCQY
	SKPENCRLSM GIRPNSHYIL RSGLLKYNLS DGENPKVVFI
	EISDQRLSIG SPSKIYDSLG QPVFYQASFS WDTMIKFGDV
	LTVNPLVVNW RNNTVISRPG QSQCPRFNTC PEICWEGVYN
	DAFLIDRINW ISAGVFLDSN QTAENPVFTV FKDNEILYRA
	QLASEDTNAQ KTITNCFLLK NKIWCISLVE IYDTGDNVIR
	PKLFAVKIPE QC
15	MGTMDIKKINE GLLDSKILSA FNTVIALLGS IVIIVMNIMI	NiVG protein
	IQNYTRSTDN QAVIKDALQG IQQQIKGLAD KIGTEIGPKV	attachment
	SLIDTSSTIT IPANIGLLGS KISQSTASIN ENVNEKCKFT	glycoprotein
	LPPLKIHECN ISCPNPLPFR EYRPQTEGVS NLVGLPNNIC	Truncated Δ30
	LQKTSNQILK PKLISYTLPV VGQSGTCITD PLLAMDEGYF
	AYSHLERIGS CSRGVSKQRI IGVGEVLDRG DEVPSLFMTN
	VWTPPNPNTV YHCSAVYNNE FYYVLCAVST VGDPILNSTY
	WSGSLMMTRL AVKPKSNGGG YNQHQLALRS IEKGRYDKVM
	PYGPSGIKQG DTLYFPAVGF LVRTEFKYND SNCPITKCQY
	SKPENCRLSM GIRPNSHYIL RSGLLKYNLS DGENPKVVFI
	EISDQRLSIG SPSKIYDSLG QPVFYQASFS WDTMIKFGDV
	LTVNPLVVNW RNNTVISRPG QSQCPRFNTC PEICWEGVYN
	DAFLIDRINW ISAGVFLDSN QTAENPVFTV FKDNEILYRA
	QLASEDTNAQ KTITNCFLLK NKIWCISLVE IYDTGDNVIR
	PKLFAVKIPE QC
16	MKKINEGLLDSKILSA FNTVIALLGS IVIIVMNIMI IQNYTRSTDN	NiVG protein
	QAVIKDALQG IQQQIKGLAD KIGTEIGPKV SLIDTSSTIT	attachment
	IPANIGLLGS KISQSTASIN ENVNEKCKFT LPPLKIHECN	glycoprotein
	ISCPNPLPFR EYRPQTEGVS NLVGLPNNIC LQKTSNQILK	Truncated and
	PKLISYTLPV VGQSGTCITD PLLAMDEGYF AYSHLERIGS	mutated
	CSRGVSKQRI IGVGEVLDRG DEVPSLFMTN VWTPPNPNTV	(E501 A,
	YHCSAVYNNE FYYVLCAVST VGDPILNSTY WSGSLMMTRL	W504A, Q530A,
	AVKPKSNGGG YNQHQLALRS IEKGRYDKVM PYGPSGIKQG	E533A) NiV G
	DTLYFPAVGF LVRTEFKYND SNCPITKCQY SKPENCRLSM	protein (Gc Δ
	GIRPNSHYIL RSGLLKYNLS DGENPKVVFI EISDQRLSIG	34)
	SPSKIYDSLG QPVFYQASFS WDTMIKFGDV LTVNPLVVNW
	RNNTVISRPG QSQCPRFNTC PAICAEGVYN DAFLIDRINW
	ISAGVFLDSN ATAANPVFTV FKDNEILYRA QLASEDTNAQ
	KTITNCFLLK NKIWCISLVE IYDTGDNVIR PKLFAVKIPE QCT
17	MATQEVRLKC LLCGIIVLVL SLEGLGILHY EKLSKIGLVK	Hendra virus F
	GITRKYKIKS	protein
	NPLTKDIVIK MIPNVSNVSK CTGTVMENYK SRLTGILSPI	Uniprot O89342
	KGAIELYNNN	(with signal
	THDLVGDVKL AGVVMAGIAI GIATAAQITA GVALYEAMKN	sequence)
	ADNINKLKSS
	IESTNEAVVK LQETAEKTVY VLTALQDYIN TNLVPTIDQI
	SCKQTELALD
	LALSKYLSDL LFVFGPNLQD PVSNSMTIQA ISQAFGGNYE
	TLLRTLGYAT EDFDDLLESD SIAGQIVYVD LSSYYIIVRV
	YFPILTEIQQ AYVQELLPVS
	FNNDNSEWIS IVPNFVLIRN TLISNIEVKY CLITKKSVIC
	NQDYATPMTA
	SVRECLTGST DKCPRELVVS SHVPRFALSG GVLFANCISV
	TCQCQTTGRA ISQSGEQTLL MIDNTTCTTV VLGNIIISLG
	KYLGSINYNS ESIAVGPPVY
	TDKVDISSQI SSMNQSLQQS KDYIKEAQKI LDTVNPSLIS
	MLSMIILYVL
	SIAALCIGLI TFISFVIVEK KRGNYSRLDD RQVRPVSNGD LYYIGT
18	MMADSKLVSL NNNLSGKIKD QGKVIKNYYG TMDIKKINDG	Hendra virus G
	LLDSKILGAF	protein Uniprot
	NTVIALLGSI IIIVMNIMII QNYTRTTDNQ ALIKESLQSV	O89343
	QQQIKALTDK IGTEIGPKVS LIDTSSTITI PANIGLLGSK
	ISQSTSSINE NVNDKCKFTL
	PPLKIHECNI SCPNPLPFRE YRPISQGVSD LVGLPNQICL
	QKTTSTILKP RLISYTLPIN TREGVCITDP LLAVDNGFFA
	YSHLEKIGSC TRGIAKQRII GVGEVLDRGD KVPSMFMTNV
	WTPPNPSTIH HCSSTYHEDF YYTLCAVSHV
	GDPILNSTSW TESLSLIRLA VRPKSDSGDY NQKYIAITKV
	ERGKYDKVMP
	YGPSGIKQGD TLYFPAVGFL PRTEFQYNDS NCPIIHCKYS
	KAENCRLSMG
	VNSKSHYILR SGLLKYNLSL GGDIILQFIE IADNRLTIGS
	PSKIYNSLGQ PVFYQASYSW DTMIKLGDVD TVDPLRVQWR
	NNSVISRPGQ SQCPRFNVCP
	EVCWEGTYND AFLIDRLNWV SAGVYLNSNQ TAENPVFAVF
	KDNEILYQVP LAEDDTNAQK TITDCFLLEN VIWCISLVEI
	YDTGDSVIRP KLFAVKIPAQ CSES
19	MVVILDKRCY CNLLILILMI SECSVGILHY EKLSKIGLVK	Nipah virus
	GVTRKYKIKS NPLTKDIVIK MIPNVSNMSQ CTGSVMENYK	NiV-F F0 T234
	TRLNGILTPI KGALEIYKNN THDLVGDVRL AGVIMAGVAI	truncation (aa
	GIATAAQITA GVALYEAMKN ADNINKLKSS IESTNEAVVK	525-544)(with
	LQETAEKTVY VLTALQDYIN TNLVPTIDKI SCKQTELSLD	signal sequence)
	LALSKYLSDL LFVFGPNLQD PVSNSMTIQA ISQAFGGNYE
	TLLRTLGYAT EDFDDLLESD SITGQIIYVD LSSYYIIVRV
	YFPILTEIQQ AYIQELLPVS FNNDNSEWIS IVPNFILVRN
	TLISNIEIGF CLITKRSVIC NQDYATPMTN NMRECLTGST
	EKCPRELVVS SHVPRFALSN GVLFANCISV TCQCQTTGRA
	ISQSGEQTLL MIDNTTCPTA VLGNVIISLG KYLGSVNYNS
	EGIAIGPPVF TDKVDISSQI SSMNQSLQQS KDYIKEAQRL
	LDTVNPSLIS MLSMIILYVL SIASLCIGLI TFISFIIVEK KRNTGT
20	MVVILDKRCY CNLLILILMI SECSVGILHY EKLSKIGLVK	Nipah virus
	GVTRKYKIKS NPLTKDIVIK MIPNVSNMSQ CTGSVMENYK	NiV-F F0 T234
	TRLNGILTPI KGALEIYKNQ THDLVGDVRL AGVIMAGVAI	truncation (aa
	GIATAAQITA GVALYEAMKN ADNINKLKSS IESTNEAVVK	525-544) AND
	LQETAEKTVY VLTALQDYIN TNLVPTIDKI SCKQTELSLD	mutation on N-
	LALSKYLSDL LFVFGPNLQD PVSNSMTIQA ISQAFGGNYE	linked
	TLLRTLGYAT EDFDDLLESD SITGQIIYVD LSSYYIIVRV	glycosylation
	YFPILTEIQQ AYIQELLPVS FNNDNSEWIS IVPNFILVRN	site (with signal
	TLISNIEIGF CLITKRSVIC NQDYATPMTN NMRECLTGST	sequence)
	EKCPRELVVS SHVPRFALSN GVLFANCISV TCQCQTTGRA
	ISQSGEQTLL MIDNTTCPTA VLGNVIISLG KYLGSVNYNS
	EGIAIGPPVF TDKVDISSQI SSMNQSLQQS KDYIKEAQRL
	LDTVNPSLIS MLSMIILYVL SIASLCIGLI TFISFIIVEK KRNTGT
21	MVVILDKRCY CNLLILILMI SECSVGILHY EKLSKIGLVK	Truncated NiV
	GVTRKYKIKS NPLTKDIVIK MIPNVSNMSQ CTGSVMENYK	fusion
	TRLNGILTPI KGALEIYKNN THDLVGDVRL AGVIMAGVAI	glycoprotein
	GIATAAQITA GVALYEAMKN ADNINKLKSS IESTNEAVVK	(FcDelta22) at
	LQETAEKTVY VLTALQDYIN TNLVPTIDKI SCKQTELSLD	cytoplasmic tail
	LALSKYLSDL LFVFGPNLQD PVSNSMTIQA ISQAFGGNYE	(with signal
	TLLRTLGYAT EDFDDLLESD SITGQIIYVD LSSYYIIVRV	sequence)
	YFPILTEIQQ AYIQELLPVS FNNDNSEWIS IVPNFILVRN
	TLISNIEIGF CLITKRSVIC NQDYATPMTN NMRECLTGST
	EKCPRELVVS SHVPRFALSN GVLFANCISV TCQCQTTGRA
	ISQSGEQTLL MIDNTTCPTA VLGNVIISLG KYLGSVNYNS
	EGIAIGPPVF TDKVDISSQI SSMNQSLQQS KDYIKEAQRL
	LDTVNPSLIS MLSMIILYVL SIASLCIGLI TFISFIIVEK KRNT
22	MKKINEGLLDSKILSA FNTVIALLGS IVIIVMNIMI IQNYTRSTDN	NiVG protein
	QAVIKDALQG IQQQIKGLAD KIGTEIGPKV SLIDTSSTIT	attachment
	IPANIGLLGS KISQSTASIN ENVNEKCKFT LPPLKIHECN	glycoprotein
	ISCPNPLPFR EYRPQTEGVS NLVGLPNNIC LQKTSNQILK	Truncated (Gc Δ
	PKLISYTLPV VGQSGTCITD PLLAMDEGYF AYSHLERIGS	34)
	CSRGVSKQRI IGVGEVLDRG DEVPSLFMTN VWTPPNPNTV
	YHCSAVYNNE FYYVLCAVST VGDPILNSTY WSGSLMMTRL
	AVKPKSNGGG YNQHQLALRS IEKGRYDKVM PYGPSGIKQG
	DTLYFPAVGF LVRTEFKYND SNCPITKCQY SKPENCRLSM
	GIRPNSHYIL RSGLLKYNLS DGENPKVVFI EISDQRLSIG
	SPSKIYDSLG QPVFYQASFS WDTMIKFGDV LTVNPLVVNW
	RNNTVISRPG QSQCPRFNTC PEICWEGVYN DAFLIDRINW
	ISAGVFLDSN QTAENPVFTV FKDNEILYRA QLASEDTNAQ
	KTITNCFLLK NKIWCISLVE IYDTGDNVIR PKLFAVKIPE QCT
23	ILHY EKLSKIGLVK GVTRKYKIKS NPLTKDIVIK MIPNVSNMSQ	Truncated
	CTGSVMENYK TRLNGILTPI KGALEIYKNN THDLVGDVRL	mature NiV
	AGVIMAGVAI GIATAAQITA GVALYEAMKN ADNINKLKSS	fusion
	IESTNEAVVK LQETAEKTVY VLTALQDYIN TNLVPTIDKI	glycoprotein
	SCKQTELSLD LALSKYLSDL LFVFGPNLQD PVSNSMTIQA	(FcDelta22) at
	ISQAFGGNYE TLLRTLGYAT EDFDDLLESD SITGQIIYVD	cytoplasmic tail
	LSSYYIIVRV YFPILTEIQQ AYIQELLPVS FNNDNSEWIS
	IVPNFILVRN TLISNIEIGF CLITKRSVIC NQDYATPMTN
	NMRECLTGST EKCPRELVVS SHVPRFALSN GVLFANCISV
	TCQCQTTGRA ISQSGEQTLL MIDNTTCPTA VLGNVIISLG
	KYLGSVNYNS EGIAIGPPVF TDKVDISSQI SSMNQSLQQS
	KDYIKEAQRL LDTVNPSLIS MLSMIILYVL SIASLCIGLI
	TFISFIIVEK KRNT
24	MSNKRTTVLIIISYTLFYLNNAAIVGFDFDKLNKIGVVQGRVLNYKIKGDP	gb: JQ001776: 61
	MTKDLVLKFIPNIVNITECVREPLSRYNETVRRLLLPIHNMLGLYLNNTNA	29-
	KMTGLMIAGVIMGGIAIGIATAAQITAGFALYEAKKNTENIQKLTDSIMKT	8166|Organism:
	QDSIDKLTDSVGTSILILNKLQTYINNQLVPNLELLSCRQNKIEFDLMLTK	Cedar
	YLVDLMTVIGPNINNPVNKDMTIQSLSLLFDGNYDIMMSELGYTPQDFLDL	virus|Strain
	IESKSITGQIIYVDMENLYVVIRTYLPTLIEVPDAQIYEFNKITMSSNGGE	Name: CG1a|Prot
	YLSTIPNFILIRGNYMSNIDVATCYMTKASVICNQDYSLPMSQNLRSCYQG	ein Name: fusion
	ETEYCPVEAVIASHSPRFALTNGVIFANCINTICRCQDNGKTITQNINQFV	glycoprotein|Gen
	SMIDNSTCNDVMVDKFTIKVGKYMGRKDINNINIQIGPQIIIDKVDLSNEI	e Symbol: F
	NKMNQSLKDSIFYLREAKRILDSVNISLISPSVQLFLIIISVLSFIILLII	(with signal
	IVYLYCKSKHSYKYNKFIDDPDYYNDYKRERINGKASKSNNIYYVGD	sequence)
25	MALNKNMFSSLFLGYLLVYATTVQSSIHYDSLSKVGVIKGLTYNYKIKGSP	gb: NC_025352: 5
	STKLMVVKLIPNIDSVKNCTQKQYDEYKNLVRKALEPVKMAIDTMLNNVKS	950-
	GNNKYRFAGAIMAGVALGVATAATVTAGIALHRSNENAQAIANMKSAIQNT	8712|Organism:
	NEAVKQLQLANKQTLAVIDTIRGEINNNIIPVINQLSCDTIGLSVGIRLTQ	Mojiang
	YYSEIITAFGPALQNPVNTRITIQAISSVFNGNFDELLKIMGYTSGDLYEI	virus|Strain
	LHSELIRGNIIDVDVDAGYIALEIEFPNLTLVPNAVVQELMPISYNIDGDE	Name: Tongguan
	WVTLVPRFVLTRTTLLSNIDTSRCTITDSSVICDNDYALPMSHELIGCLQG	1|Protein
	DISKCAREKVVSSYVPKFALSDGLVYANCLNTICRCMDTDTPISQSLGATV	Name: fusion
	SLLDNKRCSVYQVGDVLISVGSYLGDGEYNADNVELGPPIVIDKIDIGNQL	protein|lGene
	AGINQTLQEAEDYIEKSEEFLKGVNPSIITLGSMVVLYIFMILIAIVSVIA	Symbol: F (with
	LVLSIKLTVKGNVVRQQFTYTQHVPSMENINYVSH	signal sequence)
26	MKKKTDNPTISKRGHNHSRGIKSRALLRETDNYSNGLIVENLVRNCHHPSK	gb: NC_025256: 6
	NNLNYTKTQKRDSTIPYRVEERKGHYPKIKHLIDKSYKHIKRGKRRNGHNG	865-
	NIITIILLLILILKTQMSEGAIHYETLSKIGLIKGITREYKVKGTPSSKDI	8853|Organism:
	VIKLIPNVTGLNKCTNISMENYKEQLDKILIPINNIIELYANSTKSAPGNA	Bat
	RFAGVIIAGVALGVAAAAQITAGIALHEARQNAERINLLKDSISATNNAVA	Paramyxovirus
	ELQEATGGIVNVITGMQDYINTNLVPQIDKLQCSQIKTALDISLSQYYSEI	Eid_hel/GH-
	LTVFGPNLQNPVTTSMSIQAISQSFGGNIDLLLNLLGYTANDLLDLLESKS	M74a/GHA/200
	ITGQITYINLEHYFMVIRVYYPIMTTISNAYVQELIKISFNVDGSEWVSLV	9|Strain
	PSYILIRNSYLSNIDISECLITKNSVICRHDFAMPMSYTLKECLTGDTEKC	Name: BatPV/Ei
	PREAVVTSYVPRFAISGGVIYANCLSTTCQCYQTGKVIAQDGSQTLMMIDN	d_hel/GH-
	QTCSIVRIEEILISTGKYLGSQEYNTMHVSVGNPVFTDKLDITSQISNINQ	M74a/GHA/200
	SIEQSKFYLDKSKAILDKINLNLIGSVPISILFIIAILSLILSIITFVIVM	9|Protein
	IIVRRYNKYTPLINSDPSSRRSTIQDVYIIPNPGEHSIRSAARSIDRDRD	Name: fusion
		protein|Gene
		Symbol: F (with
		signal sequence)
27	(GGGGGS)n wherein n is 1 to 6	Peptide Linker
28	MPAENKKVRFENTTSDKGKIPSKVIKSYYGTMDIKKINEGLLDSKILSAFN	gb: AF212302|Or
	TVIALLGSIVIIVMNIMIIQNYTRSTDNQAVIKDALQGIQQQIKGLADKIG	ganism: Nipah
	TEIGPKVSLIDTSSTITIPANIGLLGSKISQSTASINENVNEKCKFTLPPL	virus|Strain
	KIHECNISCPNPLPFREYRPQTEGVSNLVGLPNNICLQKTSNQILKPKLIS	Name: UNKNO
	YTLPVVGQSGTCITDPLLAMDEGYFAYSHLERIGSCSRGVSKQRIIGVGEV	WN-
	LDRGDEVPSLFMTNVWTPPNPNTVYHCSAVYNNEFYYVLCAVSTVGDPILN	AF212302|Protei
	STYWSGSLMMTRLAVKPKSNGGGYNQHQLALRSIEKGRYDKVMPYGPSGIK	n
	QGDTLYFPAVGFLVRTEFKYNDSNCPITKCQYSKPENCRLSMGIRPNSHYI	Name: attachmen
	LRSGLLKYNLSDGENPKVVFIEISDQRLSIGSPSKIYDSLGQPVFYQASFS	t
	WDTMIKFGDVLTVNPLVVNWRNNTVISRPGQSQCPRFNTCPEICWEGVYND	glycoprotein|Gen
	AFLIDRINWISAGVFLDSNQTAENPVFTVFKDNEILYRAQLASEDTNAQKT	e Symbol: G
	ITNCFLLKNKIWCISLVEIYDTGDNVIRPKLFAVKIPEQCT	(Uniprot
		Q9IH62)
29	MLSQLQKNYLDNSNQQGDKMNNPDKKLSVNFNPLELDKGQKDLNKSYYVKN	gb: JQ001776: 81
	KNYNVSNLLNESLHDIKFCIYCIFSLLIIITIINIITISIVITRLKVHEEN	70-
	NGMESPNLQSIQDSLSSLTNMINTEITPRIGILVTATSVILSSSINYVGTK	10275|Organism:
	TNQLVNELKDYITKSCGFKVPELKLHECNISCADPKISKSAMYSTNAYAEL	Cedar
	AGPPKIFCKSVSKDPDFRLKQIDYVIPVQQDRSICMNNPLLDISDGFFTYI	virus|Strain
	HYEGINSCKKSDSFKVLLSHGEIVDRGDYRPSLYLLSSHYHPYSMQVINCV	Name: CG1a|Prot
	PVTCNQSSFVFCHISNNTKTLDNSDYSSDEYYITYFNGIDRPKTKKIPINN	ein
	MTADNRYIHFTFSGGGGVCLGEEFIIPVTTVINTDVFTHDYCESFNCSVQT	Name: attachmen
	GKSLKEICSESLRSPTNSSRYNLNGIMIISQNNMTDFKIQLNGITYNKLSF	t
	GSPGRLSKTLGQVLYYQSSMSWDTYLKAGFVEKWKPFTPNWMNNTVISRPN	glycoprotein|Gen
	QGNCPRYHKCPEICYGGTYNDIAPLDLGKDMYVSVILDSDQLAENPEITVF	e Symbol: G
	NSTTILYKERVSKDELNTRSTTTSCFLFLDEPWCISVLETNRFNGKSIRPE
	IYSYKIPKYC
30	MPQKTVEFINMNSPLERGVSTLSDKKTLNQSKITKQGYFGLGSHSERNWKK	gb: NC_025256: 9
	QKNQNDHYMTVSTMILEILVVLGIMFNLIVLTMVYYQNDNINQRMAELTSN	117-
	ITVLNLNLNQLINKIQREIIPRITLIDTATTITIPSAITYILATLTTRISE	11015|Organism:
	LLPSINQKCEFKTPTLVLNDCRINCTPPLNPSDGVKMSSLATNLVAHGPSP	Bat
	CRNFSSVPTIYYYRIPGLYNRTALDERCILNPRLTISSTKFAYVHSEYDKN	Paramyxovirus
	CTRGFKYYELMTFGEILEGPEKEPRMFSRSFYSPTNAVNYHSCTPIVTVNE	Eid_hel/GH-
	GYFLCLECTSSDPLYKANLSNSTFHLVILRHNKDEKIVSMPSFNLSTDQEY	M74a/GHA/200
	VQIIPAEGGGTAESGNLYFPCIGRLLHKRVTHPLCKKSNCSRTDDESCLKS	9|Strain
	YYNQGSPQHQVVNCLIRIRNAQRDNPTWDVITVDLTNTYPGSRSRIFGSFS	Name: BatPV/Ei
	KPMLYQSSVSWHTLLQVAEITDLDKYQLDWLDTPYISRPGGSECPFGNYCP	d_hel/GH-
	TVCWEGTYNDVYSLTPNNDLFVTVYLKSEQVAENPYFAIFSRDQILKEFPL	M74a/GHA/200
	DAWISSARTTTISCFMFNNEIWCIAALEITRLNDDIIRPIYYSFWLPTDCR	9|Protein
	TPYPHTGKMTRVPLRSTYNY	Name: glycoprote
		in|Gene
		Symbol: G
31	MATNRDNTITSAEVSQEDKVKKYYGVETAEKVADSISGNKVFILMNTLLIL	gb: NC_025352: 8
	TGAIITITLNITNLTAAKSQQNMLKIIQDDVNAKLEMFVNLDQLVKGEIKP	716-
	KVSLINTAVSVSIPGQISNLQTKFLQKYVYLEESITKQCTCNPLSGIFPTS	11257}Organtsm:
	GPTYPPTDKPDDDTTDDDKVDTTIKPIEYPKPDGCNRTGDHFTMEPGANFY	Mojiang
	TVPNLGPASSNSDECYTNPSFSIGSSIYMFSQEIRKTDCTAGEILSIQIVL	virus|Strain
	GRIVDKGQQGPQASPLLVWAVPNPKIINSCAVAAGDEMGWVLCSVTLTAAS	Name: Tongguan
	GEPIPHMFDGFWLYKLEPDTEVVSYRITGYAYLLDKQYDSVFIGKGGGIQK	1|Protein
	GNDLYFQMYGLSRNRQSFKALCEHGSCLGTGGGGYQVLCDRAVMSFGSEES	Name: attachmen
	LITNAYLKVNDLASGKPVIIGQTFPPSDSYKGSNGRMYTIGDKYGLYLAPS	t
	SWNRYLRFGITPDISVRSTTWLKSQDPIMKILSTCTNTDRDMCPEICNTRG	glycoprotein|Gen
	YQDIFPLSEDSEYYTYIGITPNNGGTKNFVAVRDSDGHIASIDILQNYYSI	e Symbol: G
	TSATISCFMYKDEIWCIAITEGKKQKDNPQRIYAHSYKIRQMCYNMKSATV
	TVGNAKNITIRRY
32	FNTVIALLGS IVIIVMNIMI IQNYTRSTDN QAVIKDALQG	NivG protein
	IQQQIKGLAD KIGTEIGPKV SLIDTSSTIT IPANIGLLGS	attachment
	KISQSTASIN ENVNEKCKFT LPPLKIHECN ISCPNPLPFR	glycoprotein
	EYRPQTEGVS NLVGLPNNIC LQKTSNQILK PKLISYTLPV	Without
	VGQSGTCITD PLLAMDEGYF AYSHLERIGS CSRGVSKQRI	cytoplasmic tail
	IGVGEVLDRG DEVPSLFMTN VWTPPNPNTV YHCSAVYNNE	Uniprot Q9IH62
	FYYVLCAVST VGDPILNSTY WSGSLMMTRL AVKPKSNGGG
	YNQHQLALRS IEKGRYDKVM PYGPSGIKQG DTLYFPAVGF
	LVRTEFKYND SNCPITKCQY SKPENCRLSM GIRPNSHYIL
	RSGLLKYNLS DGENPKVVFI EISDQRLSIG SPSKIYDSLG
	QPVFYQASFS WDTMIKFGDV LTVNPLVVNW RNNTVISRPG
	QSQCPRFNTC PEICWEGVYN DAFLIDRINW ISAGVFLDSN
	QTAENPVFTV FKDNEILYRA QLASEDTNAQ KTITNCFLLK
	NKIWCISLVE IYDTGDNVIR PKLFAVKIPE QC
33	FNTVIALLGSI IIIVMNIMII QNYTRTTDNQ ALIKESLQSV	Hendra virus G
	QQQIKALTDK	protein Uniprot
	IGTEIGPKVS LIDTSSTITI PANIGLLGSK ISQSTSSINE	O89343
	NVNDKCKFTL	Without
	PPLKIHECNI SCPNPLPFRE YRPISQGVSD LVGLPNQICL	cytoplasmic tail
	QKTTSTILKP
	RLISYTLPIN TREGVCITDP LLAVDNGFFA YSHLEKIGSC
	TRGIAKQRII
	GVGEVLDRGD KVPSMFMTNV WTPPNPSTIH HCSSTYHEDF
	YYTLCAVSHV
	GDPILNSTSW TESLSLIRLA VRPKSDSGDY NQKYIAITKV
	ERGKYDKVMP
	YGPSGIKQGD TLYFPAVGFL PRTEFQYNDS NCPIIHCKYS
	KAENCRLSMG
	VNSKSHYILR SGLLKYNLSL GGDIILQFIE IADNRLTIGS
	PSKIYNSLGQ
	PVFYQASYSW DTMIKLGDVD TVDPLRVQWR NNSVISRPGQ
	SQCPRFNVCP EVCWEGTYND AFLIDRLNWV SAGVYLNSNQ
	TAENPVFAVF KDNEILYQVP LAEDDTNAQK TITDCFLLEN
	VIWCISLVEI YDTGDSVIRP KLFAVKIPAQ CSES
34	MVVILDKRCY CNLLILILMI SECSVG	signal sequence
35	MKVR FENTTSDKGK IPSKVIKSYY GTMDIKKINE GLLDSKILSA	NiVG protein
	FNTVIALLGS IVIIVMNIMI IQNYTRSTDN QAVIKDALQG	attachment
	IQQQIKGLAD KIGTEIGPKV SLIDTSSTIT IPANIGLLGS	glycoprotein
	KISQSTASIN ENVNEKCKFT LPPLKIHECN ISCPNPLPFR	Truncated 45
	EYRPQTEGVS NLVGLPNNIC LQKTSNQILK PKLISYTLPV
	VGQSGTCITD PLLAMDEGYF AYSHLERIGS CSRGVSKQRI
	IGVGEVLDRG DEVPSLFMTN VWTPPNPNTV YHCSAVYNNE
	FYYVLCAVST VGDPILNSTY WSGSLMMTRL AVKPKSNGGG
	YNQHQLALRS IEKGRYDKVM PYGPSGIKQG DTLYFPAVGF
	LVRTEFKYND SNCPITKCQY SKPENCRLSM GIRPNSHYIL
	RSGLLKYNLS DGENPKVVFI EISDQRLSIG SPSKIYDSLG
	QPVFYQASFS WDTMIKFGDV LTVNPLVVNW RNNTVISRPG
	QSQCPRFNTC PEICWEGVYN DAFLIDRINW ISAGVFLDSN
	QTAENPVFTV FKDNEILYRA QLASEDTNAQ KTITNCFLLK
	NKIWCISLVE IYDTGDNVIR PKLFAVKIPE QCT
36	MNTTSDKGK IPSKVIKSYY GTMDIKKINE GLLDSKILSA	NiVG protein
	FNTVIALLGS IVIIVMNIMI IQNYTRSTDN QAVIKDALQG	attachment
	IQQQIKGLAD KIGTEIGPKV SLIDTSSTIT IPANIGLLGS	glycoprotein
	KISQSTASIN ENVNEKCKFT LPPLKIHECN ISCPNPLPFR	Truncated Δ10
	EYRPQTEGVS NLVGLPNNIC LQKTSNQILK PKLISYTLPV
	VGQSGTCITD PLLAMDEGYF AYSHLERIGS CSRGVSKQRI
	IGVGEVLDRG DEVPSLFMTN VWTPPNPNTV YHCSAVYNNE
	FYYVLCAVST VGDPILNSTY WSGSLMMTRL AVKPKSNGGG
	YNQHQLALRS IEKGRYDKVM PYGPSGIKQG DTLYFPAVGF
	LVRTEFKYND SNCPITKCQY SKPENCRLSM GIRPNSHYIL
	RSGLLKYNLS DGENPKVVFI EISDQRLSIG SPSKIYDSLG
	QPVFYQASFS WDTMIKFGDV LTVNPLVVNW RNNTVISRPG
	QSQCPRFNTC PEICWEGVYN DAFLIDRINW ISAGVFLDSN
	QTAENPVFTV FKDNEILYRA QLASEDTNAQ KTITNCFLLK
	NKIWCISLVE IYDTGDNVIR PKLFAVKIPE QCT
37	MKGK IPSKVIKSYY GTMDIKKINE GLLDSKILSA FNTVIALLGS	NiVG protein
	IVIIVMNIMI IQNYTRSTDN QAVIKDALQG IQQQIKGLAD	attachment
	KIGTEIGPKV SLIDTSSTIT IPANIGLLGS KISQSTASIN	glycoprotein
	ENVNEKCKFT LPPLKIHECN ISCPNPLPFR EYRPQTEGVS	Truncated Δ15
	NLVGLPNNIC LQKTSNQILK PKLISYTLPV VGQSGTCITD
	PLLAMDEGYF AYSHLERIGS CSRGVSKQRI IGVGEVLDRG
	DEVPSLFMTN VWTPPNPNTV YHCSAVYNNE FYYVLCAVST
	VGDPILNSTY WSGSLMMTRL AVKPKSNGGG YNQHQLALRS
	IEKGRYDKVM PYGPSGIKQG DTLYFPAVGF LVRTEFKYND
	SNCPITKCQY SKPENCRLSM GIRPNSHYIL RSGLLKYNLS
	DGENPKVVFI EISDQRLSIG SPSKIYDSLG QPVFYQASFS
	WDTMIKFGDV LTVNPLVVNW RNNTVISRPG QSQCPRFNTC
	PEICWEGVYN DAFLIDRINW ISAGVFLDSN QTAENPVFTV
	FKDNEILYRA QLASEDTNAQ KTITNCFLLK NKIWCISLVE
	IYDTGDNVIR PKLFAVKIPE QCT
38	MSKVIKSYY GTMDIKKINE GLLDSKILSA FNTVIALLGS	NiVG protein
	IVIIVMNIMI IQNYTRSTDN QAVIKDALQG IQQQIKGLAD	attachment
	KIGTEIGPKV SLIDTSSTIT IPANIGLLGS KISQSTASIN	glycoprotein
	ENVNEKCKFT LPPLKIHECN ISCPNPLPFR EYRPQTEGVS	Truncated Δ20
	NLVGLPNNIC LQKTSNQILK PKLISYTLPV VGQSGTCITD
	PLLAMDEGYF AYSHLERIGS CSRGVSKQRI IGVGEVLDRG
	DEVPSLFMTN VWTPPNPNTV YHCSAVYNNE FYYVLCAVST
	VGDPILNSTY WSGSLMMTRL AVKPKSNGGG YNQHQLALRS
	IEKGRYDKVM PYGPSGIKQG DTLYFPAVGF LVRTEFKYND
	SNCPITKCQY SKPENCRLSM GIRPNSHYIL RSGLLKYNLS
	DGENPKVVFI EISDQRLSIG SPSKIYDSLG QPVFYQASFS
	WDTMIKFGDV LTVNPLVVNW RNNTVISRPG QSQCPRFNTC
	PEICWEGVYN DAFLIDRINW ISAGVFLDSN QTAENPVFTV
	FKDNEILYRA QLASEDTNAQ KTITNCFLLK NKIWCISLVE
	IYDTGDNVIR PKLFAVKIPE QCT
39	MSYY GTMDIKKINE GLLDSKILSA FNTVIALLGS IVIIVMNIMI	NiVG protein
	IQNYTRSTDN QAVIKDALQG IQQQIKGLAD KIGTEIGPKV	attachment
	SLIDTSSTIT IPANIGLLGS KISQSTASIN ENVNEKCKFT	glycoprotein
	LPPLKIHECN ISCPNPLPFR EYRPQTEGVS NLVGLPNNIC	Truncated Δ25
	LQKTSNQILK PKLISYTLPV VGQSGTCITD PLLAMDEGYF
	AYSHLERIGS CSRGVSKQRI IGVGEVLDRG DEVPSLFMTN
	VWTPPNPNTV YHCSAVYNNE FYYVLCAVST VGDPILNSTY
	WSGSLMMTRL AVKPKSNGGG YNQHQLALRS IEKGRYDKVM
	PYGPSGIKQG DTLYFPAVGF LVRTEFKYND SNCPITKCQY
	SKPENCRLSM GIRPNSHYIL RSGLLKYNLS DGENPKVVFI
	EISDQRLSIG SPSKIYDSLG QPVFYQASFS WDTMIKFGDV
	LTVNPLVVNW RNNTVISRPG QSQCPRFNTC PEICWEGVYN
	DAFLIDRINW ISAGVFLDSN QTAENPVFTV FKDNEILYRA
	QLASEDTNAQ KTITNCFLLK NKIWCISLVE IYDTGDNVIR
	PKLFAVKIPE QCT
40	MTMDIKKINE GLLDSKILSA FNTVIALLGS IVIIVMNIMI	NiVG protein
	IQNYTRSTDN QAVIKDALQG IQQQIKGLAD KIGTEIGPKV	attachment
	SLIDTSSTIT IPANIGLLGS KISQSTASIN ENVNEKCKFT	glycoprotein
	LPPLKIHECN ISCPNPLPFR EYRPQTEGVS NLVGLPNNIC	Truncated Δ30
	LQKTSNQILK PKLISYTLPV VGQSGTCITD PLLAMDEGYF
	AYSHLERIGS CSRGVSKQRI IGVGEVLDRG DEVPSLFMTN
	VWTPPNPNTV YHCSAVYNNE FYYVLCAVST VGDPILNSTY
	WSGSLMMTRL AVKPKSNGGG YNQHQLALRS IEKGRYDKVM
	PYGPSGIKQG DTLYFPAVGF LVRTEFKYND SNCPITKCQY
	SKPENCRLSM GIRPNSHYIL RSGLLKYNLS DGENPKVVFI
	EISDQRLSIG SPSKIYDSLG QPVFYQASFS WDTMIKFGDV
	LTVNPLVVNW RNNTVISRPG QSQCPRFNTC PEICWEGVYN
	DAFLIDRINW ISAGVFLDSN QTAENPVFTV FKDNEILYRA
	QLASEDTNAQ KTITNCFLLK NKIWCISLVE IYDTGDNVIR
	PKLFAVKIPE QCT
41	GGGGGS	Peptide linker
42	(GGGGS)n wherein n is 1 to 10	Peptide linker
43	GGGGS	Peptide linker
44	PAENKKVR FENTTSDKGK IPSKVIKSYY GTMDIKKINE	NiVG protein
	GLLDSKILSA FNTVIALLGS IVIIVMNIMI IQNYTRSTDN	attachment
	QAVIKDALQG IQQQIKGLAD KIGTEIGPKV SLIDTSSTIT	glycoprotein
	IPANIGLLGS KISQSTASIN ENVNEKCKFT LPPLKIHECN	(602 aa)
	ISCPNPLPFR EYRPQTEGVS NLVGLPNNIC LQKTSNQILK	Without N-
	PKLISYTLPV VGQSGTCITD PLLAMDEGYF AYSHLERIGS	terminal
	CSRGVSKQRI IGVGEVLDRG DEVPSLFMTN VWTPPNPNTV	methionine
	YHCSAVYNNE FYYVLCAVST VGDPILNSTY WSGSLMMTRL
	AVKPKSNGGG YNQHQLALRS IEKGRYDKVM PYGPSGIKQG
	DTLYFPAVGF LVRTEFKYND SNCPITKCQY SKPENCRLSM
	GIRPNSHYIL RSGLLKYNLS DGENPKVVFI EISDQRLSIG
	SPSKIYDSLG QPVFYQASFS WDTMIKFGDV LTVNPLVVNW
	RNNTVISRPG QSQCPRFNTC PEICWEGVYN DAFLIDRINW
	ISAGVFLDSN QTAENPVFTV FKDNEILYRA QLASEDTNAQ
	KTITNCFLLK NKIWCISLVE IYDTGDNVIR PKLFAVKIPE QC
45	KVR FENTTSDKGK IPSKVIKSYY GTMDIKKINE GLLDSKILSA	NiVG protein
	FNTVIALLGS IVIIVMNIMI IQNYTRSTDN QAVIKDALQG	attachment
	IQQQIKGLAD KIGTEIGPKV SLIDTSSTIT IPANIGLLGS	glycoprotein
	KISQSTASIN ENVNEKCKFT LPPLKIHECN ISCPNPLPFR	Truncated Δ5
	EYRPQTEGVS NLVGLPNNIC LQKTSNQILK PKLISYTLPV	Without N-
	VGQSGTCITD PLLAMDEGYF AYSHLERIGS CSRGVSKQRI	terminal
	IGVGEVLDRG DEVPSLFMTN VWTPPNPNTV YHCSAVYNNE	methionine
	FYYVLCAVST VGDPILNSTY WSGSLMMTRL AVKPKSNGGG
	YNQHQLALRS IEKGRYDKVM PYGPSGIKQG DTLYFPAVGF
	LVRTEFKYND SNCPITKCQY SKPENCRLSM GIRPNSHYIL
	RSGLLKYNLS DGENPKVVFI EISDQRLSIG SPSKIYDSLG
	QPVFYQASFS WDTMIKFGDV LTVNPLVVNW RNNTVISRPG
	QSQCPRFNTC PEICWEGVYN DAFLIDRINW ISAGVFLDSN
	QTAENPVFTV FKDNEILYRA QLASEDTNAQ KTITNCFLLK
	NKIWCISLVE IYDTGDNVIR PKLFAVKIPE QC
46	NTTSDKGK IPSKVIKSYY GTMDIKKINE GLLDSKILSA	NiVG protein
	FNTVIALLGS IVIIVMNIMI IQNYTRSTDN QAVIKDALQG	attachment
	IQQQIKGLAD KIGTEIGPKV SLIDTSSTIT IPANIGLLGS	glycoprotein
	KISQSTASIN ENVNEKCKFT LPPLKIHECN ISCPNPLPFR	Truncated Δ10
	EYRPQTEGVS NLVGLPNNIC LQKTSNQILK PKLISYTLPV	Without N-
	VGQSGTCITD PLLAMDEGYF AYSHLERIGS CSRGVSKQRI	terminal
	IGVGEVLDRG DEVPSLFMTN VWTPPNPNTV YHCSAVYNNE	methionine
	FYYVLCAVST VGDPILNSTY WSGSLMMTRL AVKPKSNGGG
	YNQHQLALRS IEKGRYDKVM PYGPSGIKQG DTLYFPAVGF
	LVRTEFKYND SNCPITKCQY SKPENCRLSM GIRPNSHYIL
	RSGLLKYNLS DGENPKVVFI EISDQRLSIG SPSKIYDSLG
	QPVFYQASFS WDTMIKFGDV LTVNPLVVNW RNNTVISRPG
	QSQCPRFNTC PEICWEGVYN DAFLIDRINW ISAGVFLDSN
	QTAENPVFTV FKDNEILYRA QLASEDTNAQ KTITNCFLLK
	NKIWCISLVE IYDTGDNVIR PKLFAVKIPE QC
47	KGK IPSKVIKSYY GTMDIKKINE GLLDSKILSA FNTVIALLGS	NiVG protein
	IVIIVMNIMI IQNYTRSTDN QAVIKDALQG IQQQIKGLAD	attachment
	KIGTEIGPKV SLIDTSSTIT IPANIGLLGS KISQSTASIN	glycoprotein
	ENVNEKCKFT LPPLKIHECN ISCPNPLPFR EYRPQTEGVS	Truncated 4 5
	NLVGLPNNIC LQKTSNQILK PKLISYTLPV VGQSGTCITD	Without N-
	PLLAMDEGYF AYSHLERIGS CSRGVSKQRI IGVGEVLDRG	terminal
	DEVPSLFMTN VWTPPNPNTV YHCSAVYNNE FYYVLCAVST	methionine
	VGDPILNSTY WSGSLMMTRL AVKPKSNGGG YNQHQLALRS
	IEKGRYDKVM PYGPSGIKQG DTLYFPAVGF LVRTEFKYND
	SNCPITKCQY SKPENCRLSM GIRPNSHYIL RSGLLKYNLS
	DGENPKVVFI EISDQRLSIG SPSKIYDSLG QPVFYQASFS
	WDTMIKFGDV LTVNPLVVNW RNNTVISRPG QSQCPRFNTC
	PEICWEGVYN DAFLIDRINW ISAGVFLDSN QTAENPVFTV
	FKDNEILYRA QLASEDTNAQ KTITNCFLLK NKIWCISLVE
	IYDTGDNVIR PKLFAVKIPE QC
48	SKVIKSYY GTMDIKKINE GLLDSKILSA FNTVIALLGS	NiVG protein
	IVIIVMNIMI IQNYTRSTDN QAVIKDALQG IQQQIKGLAD	attachment
	KIGTEIGPKV SLIDTSSTIT IPANIGLLGS KISQSTASIN	glycoprotein
	ENVNEKCKFT LPPLKIHECN ISCPNPLPFR EYRPQTEGVS	Truncated Δ20
	NLVGLPNNIC LQKTSNQILK PKLISYTLPV VGQSGTCITD	Without N-
	PLLAMDEGYF AYSHLERIGS CSRGVSKQRI IGVGEVLDRG	terminal
	DEVPSLFMTN VWTPPNPNTV YHCSAVYNNE FYYVLCAVST	methionine
	VGDPILNSTY WSGSLMMTRL AVKPKSNGGG YNQHQLALRS
	IEKGRYDKVM PYGPSGIKQG DTLYFPAVGF LVRTEFKYND
	SNCPITKCQY SKPENCRLSM GIRPNSHYIL RSGLLKYNLS
	DGENPKVVFI EISDQRLSIG SPSKIYDSLG QPVFYQASFS
	WDTMIKFGDV LTVNPLVVNW RNNTVISRPG QSQCPRFNTC
	PEICWEGVYN DAFLIDRINW ISAGVFLDSN QTAENPVFTV
	FKDNEILYRA QLASEDTNAQ KTITNCFLLK NKIWCISLVE
	IYDTGDNVIR PKLFAVKIPE QC
49	SYY GTMDIKKINE GLLDSKILSA FNTVIALLGS IVIIVMNIMI	NiVG protein
	IQNYTRSTDN QAVIKDALQG IQQQIKGLAD KIGTEIGPKV	attachment
	SLIDTSSTIT IPANIGLLGS KISQSTASIN ENVNEKCKFT	glycoprotein
	LPPLKIHECN ISCPNPLPFR EYRPQTEGVS NLVGLPNNIC	Truncated Δ25
	LQKTSNQILK PKLISYTLPV VGQSGTCITD PLLAMDEGYF	Without N-
	AYSHLERIGS CSRGVSKQRI IGVGEVLDRG DEVPSLFMTN	terminal
	VWTPPNPNTV YHCSAVYNNE FYYVLCAVST VGDPILNSTY	methionine
	WSGSLMMTRL AVKPKSNGGG YNQHQLALRS IEKGRYDKVM
	PYGPSGIKQG DTLYFPAVGF LVRTEFKYND SNCPITKCQY
	SKPENCRLSM GIRPNSHYIL RSGLLKYNLS DGENPKVVFI
	EISDQRLSIG SPSKIYDSLG QPVFYQASFS WDTMIKFGDV
	LTVNPLVVNW RNNTVISRPG QSQCPRFNTC PEICWEGVYN
	DAFLIDRINW ISAGVFLDSN QTAENPVFTV FKDNEILYRA
	QLASEDTNAQ KTITNCFLLK NKIWCISLVE IYDTGDNVIR
	PKLFAVKIPE QC
50	TMDIKKINE GLLDSKILSA FNTVIALLGS IVIIVMNIMI	NiVG protein
	IQNYTRSTDN QAVIKDALQG IQQQIKGLAD KIGTEIGPKV	attachment
	SLIDTSSTIT IPANIGLLGS KISQSTASIN ENVNEKCKFT	glycoprotein
	LPPLKIHECN ISCPNPLPFR EYRPQTEGVS NLVGLPNNIC	Truncated Δ30
	LQKTSNQILK PKLISYTLPV VGQSGTCITD PLLAMDEGYF	Without N-
	AYSHLERIGS CSRGVSKQRI IGVGEVLDRG DEVPSLFMTN	terminal
	VWTPPNPNTV YHCSAVYNNE FYYVLCAVST VGDPILNSTY	methionine
	WSGSLMMTRL AVKPKSNGGG YNQHQLALRS IEKGRYDKVM
	PYGPSGIKQG DTLYFPAVGF LVRTEFKYND SNCPITKCQY
	SKPENCRLSM GIRPNSHYIL RSGLLKYNLS DGENPKVVFI
	EISDQRLSIG SPSKIYDSLG QPVFYQASFS WDTMIKFGDV
	LTVNPLVVNW RNNTVISRPG QSQCPRFNTC PEICWEGVYN
	DAFLIDRINW ISAGVFLDSN QTAENPVFTV FKDNEILYRA
	QLASEDTNAQ KTITNCFLLK NKIWCISLVE IYDTGDNVIR
	PKLFAVKIPE QC
51	KKINEGLLDSKILSA FNTVIALLGS IVIIVMNIMI IQNYTRSTDN	NiVG protein
	QAVIKDALQG IQQQIKGLAD KIGTEIGPKV SLIDTSSTIT	attachment
	IPANIGLLGS KISQSTASIN ENVNEKCKFT LPPLKIHECN	glycoprotein
	ISCPNPLPFR EYRPQTEGVS NLVGLPNNIC LQKTSNQILK	Truncated and
	PKLISYTLPV VGQSGTCITD PLLAMDEGYF AYSHLERIGS	mutated
	CSRGVSKQRI IGVGEVLDRG DEVPSLFMTN VWTPPNPNTV	(E501 A,
	YHCSAVYNNE FYYVLCAVST VGDPILNSTY WSGSLMMTRL	W504A, Q530A,
	AVKPKSNGGG YNQHQLALRS IEKGRYDKVM PYGPSGIKQG	E533A) NiV G
	DTLYFPAVGF LVRTEFKYND SNCPITKCQY SKPENCRLSM	protein (Gc Δ
	GIRPNSHYIL RSGLLKYNLS DGENPKVVFI EISDQRLSIG	34) Without N-
	SPSKIYDSLG QPVFYQASFS WDTMIKFGDV LTVNPLVVNW	terminal
	RNNTVISRPG QSQCPRFNTC PAICAEGVYN DAFLIDRINW	methionine
	ISAGVFLDSN ATAANPVFTV FKDNEILYRA QLASEDTNAQ
	KTITNCFLLK NKIWCISLVE IYDTGDNVIR PKLFAVKIPE QCT
52	MADSKLVSL NNNLSGKIKD QGKVIKNYYG TMDIKKINDG	Hendra virus G
	LLDSKILGAF	protein Uniprot
	NTVIALLGSI IIIVMNIMII QNYTRTTDNQ ALIKESLQSV	O89343 Without
	QQQIKALTDK IGTEIGPKVS LIDTSSTITI PANIGLLGSK	N-terminal
	ISQSTSSINE NVNDKCKFTL	methionine
	PPLKIHECNI SCPNPLPFRE YRPISQGVSD LVGLPNQICL
	QKTTSTILKP RLISYTLPIN TREGVCITDP LLAVDNGFFA
	YSHLEKIGSC TRGIAKQRII GVGEVLDRGD KVPSMFMTNV
	WTPPNPSTIH HCSSTYHEDF YYTLCAVSHV
	GDPILNSTSW TESLSLIRLA VRPKSDSGDY NQKYIAITKV
	ERGKYDKVMP
	YGPSGIKQGD TLYFPAVGFL PRTEFQYNDS NCPIIHCKYS
	KAENCRLSMG
	VNSKSHYILR SGLLKYNLSL GGDIILQFIE IADNRLTIGS
	PSKIYNSLGQ PVFYQASYSW DTMIKLGDVD TVDPLRVQWR
	NNSVISRPGQ SQCPRFNVCP
	EVCWEGTYND AFLIDRLNWV SAGVYLNSNQ TAENPVFAVF
	KDNEILYQVP LAEDDTNAQK TITDCFLLEN VIWCISLVEI
	YDTGDSVIRP KLFAVKIPAQ CSES
53	KKINEGLLDSKILSA FNTVIALLGS IVIIVMNIMI IQNYTRSTDN	NiVG protein
	QAVIKDALQG IQQQIKGLAD KIGTEIGPKV SLIDTSSTIT	attachment
	IPANIGLLGS KISQSTASIN ENVNEKCKFT LPPLKIHECN	glycoprotein
	ISCPNPLPFR EYRPQTEGVS NLVGLPNNIC LQKTSNQILK	Truncated (Gc Δ
	PKLISYTLPV VGQSGTCITD PLLAMDEGYF AYSHLERIGS	34) Without N-
	CSRGVSKQRI IGVGEVLDRG DEVPSLFMTN VWTPPNPNTV	terminal
	YHCSAVYNNE FYYVLCAVST VGDPILNSTY WSGSLMMTRL	methionine
	AVKPKSNGGG YNQHQLALRS IEKGRYDKVM PYGPSGIKQG
	DTLYFPAVGF LVRTEFKYND SNCPITKCQY SKPENCRLSM
	GIRPNSHYIL RSGLLKYNLS DGENPKVVFI EISDQRLSIG
	SPSKIYDSLG QPVFYQASFS WDTMIKFGDV LTVNPLVVNW
	RNNTVISRPG QSQCPRFNTC PEICWEGVYN DAFLIDRINW
	ISAGVFLDSN QTAENPVFTV FKDNEILYRA QLASEDTNAQ
	KTITNCFLLK NKIWCISLVE IYDTGDNVIR PKLFAVKIPE QCT
54	LSQLQKNYLDNSNQQGDKMNNPDKKLSVNFNPLELDKGQKDLNKSYYVKNK	gb: JQ001776: 81
	NYNVSNLLNESLHDIKFCIYCIFSLLIIITIINIITISIVITRLKVHEENN	70-
	GMESPNLQSIQDSLSSLTNMINTEITPRIGILVTATSVTLSSSINYVGTKT	10275|Organism:
	NQLVNELKDYITKSCGFKVPELKLHECNISCADPKISKSAMYSTNAYAELA	Cedar
	GPPKIFCKSVSKDPDFRLKQIDYVIPVQQDRSICMNNPLLDISDGFFTYIH	virus|Strain
	YEGINSCKKSDSFKVLLSHGEIVDRGDYRPSLYLLSSHYHPYSMQVINCVP	Name: CG1a|Prot
	VTCNQSSFVFCHISNNTKTLDNSDYSSDEYYITYFNGIDRPKTKKIPINNM	ein
	TADNRYIHFTFSGGGGVCLGEEFIIPVTTVINTDVFTHDYCESFNCSVQTG	Name: attachmen
	KSLKEICSESLRSPTNSSRYNLNGIMIISQNNMTDFKIQLNGITYNKLSFG	t
	SPGRLSKTLGQVLYYQSSMSWDTYLKAGFVEKWKPFTPNWMNNTVISRPNQ	glycoprotein|Gen
	GNCPRYHKCPEICYGGTYNDIAPLDLGKDMYVSVILDSDQLAENPEITVFN	e Symbol: G
	STTILYKERVSKDELNTRSTTTSCFLFLDEPWCISVLETNRFNGKSIRPEI	Without N-
	YSYKIPKYC	terminal
		methionine
55	PQKTVEFINMNSPLERGVSTLSDKKTLNQSKITKQGYFGLGSHSERNWKKQ	gb: NC_025256: 9
	KNQNDHYMTVSTMILEILVVLGIMFNLIVLTMVYYQNDNINQRMAELTSNI	117-
	TVLNLNLNQLTNKIQREIIPRITLIDTATTITIPSAITYILATLTTRISEL	11015|Organism:
	LPSINQKCEFKTPTLVLNDCRINCTPPLNPSDGVKMSSLATNLVAHGPSPC	Bat
	RNFSSVPTIYYYRIPGLYNRTALDERCILNPRLTISSTKFAYVHSEYDKNC	Paramyxovirus
	TRGFKYYELMTFGEILEGPEKEPRMFSRSFYSPTNAVNYHSCTPIVTVNEG	Eid_hel/GH-
	YFLCLECTSSDPLYKANLSNSTFHLVILRHNKDEKIVSMPSFNLSTDQEYV	M74a/GHA/200
	QIIPAEGGGTAESGNLYFPCIGRLLHKRVTHPLCKKSNCSRTDDESCLKSY	9|Strain
	YNQGSPQHQVVNCLIRIRNAQRDNPTWDVITVDLTNTYPGSRSRIFGSFSK	Name: BatPV/Ei
	PMLYQSSVSWHTLLQVAEITDLDKYQLDWLDTPYISRPGGSECPFGNYCPT	d_hel/GH-
	VCWEGTYNDVYSLTPNNDLFVTVYLKSEQVAENPYFAIFSRDQILKEFPLD	M74a/GHA/200
	AWISSARTTTISCFMFNNEIWCIAALEITRLNDDIIRPIYYSFWLPTDCRT	9|Protein
	PYPHTGKMTRVPLRSTYNY	Name: glycoprote
		in|Gene
		Symbol: G
		Without N-
		terminal
		methionine
56	ATNRDNTITSAEVSQEDKVKKYYGVETAEKVADSISGNKVFILMNTLLILT	gb: NC_025352: 8
	GAIITITLNITNLTAAKSQQNMLKIIQDDVNAKLEMFVNLDQLVKGEIKPK	716-
	VSLINTAVSVSIPGQISNLQTKFLQKYVYLEESITKQCTCNPLSGIFPTSG	11257|Organism:
	PTYPPTDKPDDDTTDDDKVDTTIKPIEYPKPDGCNRTGDHFTMEPGANFYT	Mojiang
	VPNLGPASSNSDECYTNPSFSIGSSIYMFSQEIRKTDCTAGEILSIQIVLG	virus|Strain
	RIVDKGQQGPQASPLLVWAVPNPKIINSCAVAAGDEMGWVLCSVTLTAASG	Name: Tongguan
	EPIPHMFDGFWLYKLEPDTEVVSYRITGYAYLLDKQYDSVFIGKGGGIQKG	1|Protein
	NDLYFQMYGLSRNRQSFKALCEHGSCLGTGGGGYQVLCDRAVMSFGSEESL	Name: attachmen
	ITNAYLKVNDLASGKPVIIGQTFPPSDSYKGSNGRMYTIGDKYGLYLAPSS	t
	WNRYLRFGITPDISVRSTTWLKSQDPIMKILSTCTNTDRDMCPEICNTRGY	glycoprotein|lGen
	QDIFPLSEDSEYYTYIGITPNNGGTKNFVAVRDSDGHIASIDILQNYYSIT	e Symbol: G
	SATISCFMYKDEIWCIAITEGKKQKDNPQRIYAHSYKIRQMCYNMKSATVT	Without N-
	VGNAKNITIRRY	terminal
		methionine
57	DFDKLNKIGVVQGRVLNYKIKGDPMTKDLVLKFIPNIVNITECVREPLSRY	gb: JQ001776: 61
	NETVRRLLLPIHNMLGLYLNNTNAKMTGLMIAGVIMGGIAIGIATAAQITA	29-
	GFALYEAKKNTENIQKLTDSIMKTQDSIDKLTDSVGTSILILNKLQTYINN	8166|Organism:
	QLVPNLELLSCRQNKIEFDLMLTKYLVDLMTVIGPNINNPVNKDMTIQSLS	Cedar
	LLFDGNYDIMMSELGYTPQDFLDLIESKSITGQIIYVDMENLYVVIRTYLP	virus|Strain
	TLIEVPDAQIYEFNKITMSSNGGEYLSTIPNFILIRGNYMSNIDVATCYMT	Name: CG1a|Prot
	KASVICNQDYSLPMSQNLRSCYQGETEYCPVEAVIASHSPRFALTNGVIFA	ein Name: fusion
	NCINTICRCQDNGKTITQNINQFVSMIDNSTCNDVMVDKFTIKVGKYMGRK	glycoprotein|Gen
	DINNINIQIGPQIIIDKVDLSNEINKMNQSLKDSIFYLREAKRILDSVNIS	e Symbol: F
	LISPSVQLFLIIISVLSFIILLIIIVYLYCKSKHSYKYNKFIDDPDYYNDY	(without signal
	KRERINGKASKSNNIYYVGD	sequence)
58	SRALLRETDNYSNGLIVENLVRNCHHPSKNNLNYTKTQKRDSTIPYRVEER	gb: NC_025256: 6
	KGHYPKIKHLIDKSYKHIKRGKRRNGHNGNIITIILLLILILKTQMSEGAI	865-
	HYETLSKIGLIKGITREYKVKGTPSSKDIVIKLIPNVTGLNKCTNISMENY	8853|Organism:
	KEQLDKILIPINNIIELYANSTKSAPGNARFAGVIIAGVALGVAAAAQITA	Bat
	GIALHEARQNAERINLLKDSISATNNAVAELQEATGGIVNVITGMQDYINT	Paramyxovirus
	NLVPQIDKLQCSQIKTALDISLSQYYSEILTVFGPNLQNPVTTSMSIQAIS	Eid_hel/GH-
	QSFGGNIDLLLNLLGYTANDLLDLLESKSITGQITYINLEHYFMVIRVYYP	M74a/GHA/200
	IMTTISNAYVQELIKISFNVDGSEWVSLVPSYILIRNSYLSNIDISECLIT	9|Strain
	KNSVICRHDFAMPMSYTLKECLTGDTEKCPREAVVTSYVPRFAISGGVIYA	Name: BatPV/Ei
	NCLSTTCQCYQTGKVIAQDGSQTLMMIDNQTCSIVRIEEILISTGKYLGSQ	d_hel/GH-
	EYNTMHVSVGNPVFTDKLDITSQISNINQSIEQSKFYLDKSKAILDKINLN	M74a/GHA/200
	LIGSVPISILFIIAILSLILSIITFVIVMIIVRRYNKYTPLINSDPSSRRS	9|Protein
	TIQDVYIIPNPGEHSIRSAARSIDRDRD	Name: fusion
		proteinlGene
		Symbol: F
		(without signal
		sequence)
59	ILHY EKLSKIGLVK GITRKYKIKS	Hendra virus F
	NPLTKDIVIK MIPNVSNVSK CTGTVMENYK SRLTGILSPI	protein
	KGAIELYNNN	Uniprot O89342
	THDLVGDVKL AGVVMAGIAI GIATAAQITA GVALYEAMKN	(without signal
	ADNINKLKSS	sequence)
	IESTNEAVVK LQETAEKTVY VLTALQDYIN TNLVPTIDQI
	SCKQTELALD
	LALSKYLSDL LFVFGPNLQD PVSNSMTIQA ISQAFGGNYE
	TLLRTLGYAT EDFDDLLESD SIAGQIVYVD LSSYYIIVRV
	YFPILTEIQQ AYVQELLPVS
	FNNDNSEWIS IVPNFVLIRN TLISNIEVKY CLITKKSVIC
	NQDYATPMTA
	SVRECLTGST DKCPRELVVS SHVPRFALSG GVLFANCISV
	TCQCQTTGRA ISQSGEQTLL MIDNTTCTTV VLGNIIISLG
	KYLGSINYNS ESIAVGPPVY
	TDKVDISSQI SSMNQSLQQS KDYIKEAQKI LDTVNPSLIS
	MLSMIILYVL
	SIAALCIGLI TFISFVIVEK KRGNYSRLDD RQVRPVSNGD LYYIGT
60	IHYDSLSKVGVIKGLTYNYKIKGSPSTKLMVVKLIPNIDSVKNCTQKQYDE	gb: NC_025352: 5
	YKNLVRKALEPVKMAIDTMLNNVKSGNNKYRFAGAIMAGVALGVATAATVT	950-
	AGIALHRSNENAQAIANMKSAIQNTNEAVKQLQLANKQTLAVIDTIRGEIN	8712|Organism:
	NNIIPVINQLSCDTIGLSVGIRLTQYYSEIITAFGPALQNPVNTRITIQAI	Mojiang
	SSVFNGNFDELLKIMGYTSGDLYEILHSELIRGNIIDVDVDAGYIALEIEF	virus|Strain
	PNLTLVPNAVVQELMPISYNIDGDEWVILVPRFVLTRTTLLSNIDTSRCTI	Name: Tongguan
	TDSSVICDNDYALPMSHELIGCLQGDTSKCAREKVVSSYVPKFALSDGLVY	1|Protein
	ANCLNTICRCMDTDTPISQSLGATVSLLDNKRCSVYQVGDVLISVGSYLGD	Name: fusion
	GEYNADNVELGPPIVIDKIDIGNQLAGINQTLQEAEDYIEKSEEFLKGVNP	protein|Gene
	SIITLGSMVVLYIFMILIAIVSVIALVLSIKLTVKGNVVRQQFTYTQHVPS	Symbol: F
	MENINYVSH	(without signal
		sequence)
61	MLFNLRILLNNAAFRNGHNFMVRNFRCGQPLQNKVQLKGRDLLTL	OTC
	KNFTGEEIKYMLWLSADLKFRIKQKGEYLPLLQGKSLGMIFEKRSTR
	TRLSTETGFALLGGHPCFLTTQDIHLGVNESLTDTARVLSSMADAVL
	ARVYKQSDLDTLAKEASIPIINGLSDLYHPIQILADYLTLQEHYSSLK
	GLTLSWIGDGNNILHSIMMSAAKFGMHLQAATPKGYEPDASVTKL
	AEQYAKENGTKLLLTNDPLEAAHGGNVLITDTWISMGQEEEKKKR
	LQAFQGYQVTMKTAKVAASDWTFLHCLPRKPEEVDDEVFYSPRSL
	VFPEAENRKWTIMAVMVSLLTDYSPQLQKPKF
62	MTRILTAFKVVRTLKTGFGFTNVTAHQKWKFSRPGIRLLSVKAQTA	CPS1
	HIVLEDGTKMKGYSFGHPSSVAGEVVFNTGLGGYPEAITDPAYKGQ
	ILTMANPIIGNGGAPDTTALDELGLSKYLESNGIKVSGLLVLDYSKD
	YNHWLATKSLGQWLQEEKVPAIYGVDTRMLTKIIRDKGTMLGKIEF
	EGQPVDFVDPNKQNLIAEVSTKDVKVYGKGNPTKVVAVDCGIKNN
	VIRLLVKRGAEVHLVPWNHDFTKMEYDGILIAGGPGNPALAEPLIQ
	NVRKILESDRKEPLFGISTGNLITGLAAGAKTYKMSMANRGQNQPV
	LNITNKQAFITAQNHGYALDNTLPAGWKPLFVNVNDQTNEGIMHES
	KPFFAVQFHPEVTPGPIDTEYLFDSFFSLIKKGKATTITSVLPKPALVA
	SRVEVSKVLILGSGGLSIGQAGEFDYSGSQAVKAMKEENVKTVLMN
	PNIASVQTNEVGLKQADTVYFLPITPQFVTEVIKAEQPDGLILGMGG
	QTALNCGVELFKRGVLKEYGVKVLGTSVESIMATEDRQLFSDKLNE
	INEKIAPSFAVESIEDALKAADTIGYPVMIRSAYALGGLGSGICPNRE
	TLMDLSTKAFAMTNQILVEKSVTGWKEIEYEVVRDADDNCVTVCN
	MENVDAMGVHTGDSVVVAPAQTLSNAEFQMLRRTSINVVRHLGIV
	GECNIQFALHPTSMEYCIIEVNARLSRSSALASKATGYPLAFIAAKIA
	LGIPLPEIKNVVSGKTSACFEPSLDYMVTKIPRWDLDRFHGTSSRIGS
	SMKSVGEVMAIGRTFEESFQKALRMCHPSIEGFTPRLPMNKEWPSN
	LDLRKELSEPSSTRIYAIAKAIDDNMSLDEIEKLTYIDKWFLYKMRDI
	LNMEKTLKGLNSESMTEETLKRAKEIGFSDKQISKCLGLTEAQTREL
	RLKKNIHPWVKQIDTLAAEYPSVTNYLYVTYNGQEHDVNFDDHGM
	MVLGCGPYHIGSSVEFDWCAVSSIRTLRQLGKKTVVVNCNPETVST
	DFDECDKLYFEELSLERILDIYHQEACGGCIISVGGQIPNNLAVPLYK
	NGVKIMGTSPLQIDRAEDRSIFSAVLDELKVAQAPWKAVNTLNEAL
	EFAKSVDYPCLLRPSYVLSGSAMNVVFSEDEMKKFLEEATRVSQEH
	PVVLTKFVEGAREVEMDAVGKDGRVISHAISEHVEDAGVHSGDAT
	LMLPTQTISQGAIEKVKDATRKIAKAFAISGPFNVQFLVKGNDVLVI
	ECNLRASRSFPFVSKTLGVDFIDVATKVMIGENVDEKHLPTLDHPIIP
	ADYVAIKAPMFSWPRLRDADPILRCEMASTGEVACFGEGIHTAFLK
	AMLSTGFKIPQKGILIGIQQSFRPRFLGVAEQLHNEGFKLFATEATSD
	WLNANNVPATPVAWPSQEGQNPSLSSIRKLIRDGSIDLVINLPNNNT
	KFVHDNYVIRRTAVDSGIPLLTNFQVTKLFAEAVQKSRKVDSKSLF
	HYRQYSAGKAA
63	MATALMAVVLRAAAVAPRLRGRGGTGGARRLSCGARRRAARGTS	NAGS
	PGRRLSTAWSQPQPPPEEYAGADDVSQSPVAEEPSWVPSPRPPVPHE
	SPEPPSGRSLVQRDIQAFLNQCGASPGEARHWLTQFQTCHHSADKPF
	AVIEVDEEVLKCQQGVSSLAFALAFLQRMDMKPLVVLGLPAPTAPS
	GCLSFWEAKAQLAKSCKVLVDALRHNAAAAVPFFGGGSVLRAAEP
	APHASYGGIVSVETDLLQWCLESGSIPILCPIGETAARRSVLLDSLEV
	TASLAKALRPTKIIFLNNTGGLRDSSHKVLSNVNLPADLDLVCNAE
	WVSTKERQQMRLIVDVLSRLPHHSSAVITAASTLLTELFSNKGSGTL
	FKNAERMLRVRSLDKLDQGRLVDLVNASFGKKLRDDYLASLRPRL
	HSIYVSEGYNAAAILTMEPVLGGTPYLDKFVVSSSRQGQGSGQMLW
	ECLRRDLQTLFWRSRVTNPINPWYFKHSDGSFSNKQWIFFWFGLAD
	IRDSYELVNHAKGLPDSFHKPASDPGS
64	MAVAIAAARVWRLNRGLSQAALLLLRQPGARGLARSHPPRQQQQF	BCKDHA
	SSLDDKPQFPGASAEFIDKLEFIQPNVISGIPIYRVMDRQGQIINPSEDP
	HLPKEKVLKLYKSMTLLNTMDRILYESQRQGRISFYMTNYGEEGTH
	VGSAAALDNTDLVFGQYREAGVLMYRDYPLELFMAQCYGNISDLG
	KGRQMPVHYGCKERHFVTISSPLATQIPQAVGAAYAAKRANANRV
	VICYFGEGAASEGDAHAGFNFAATLECPIIFFCRNNGYAISTPTSEQY
	RGDGIAARGPGYGIMSIRVDGNDVFAVYNATKEARRRAVAENQPF
	LIEAMTYRIGHHSTSDDSSAYRSVDEVNYWDKQDHPISRLRHYLLS
	QGWWDEEQEKAWRKQSRRKVMEAFEQAERKPKPNPNLLFSDVYQ
	EMPAQLRKQQESLARHLQTYGEHYPLDHFDK
65	MAVVAAAAGWLLRLRAAGAEGHWRRLPGAGLARGFLHPAATVE	BCKDHB
	DAAQRRQVAHFTFQPDPEPREYGQTQKMNLFQSVTSALDNSLAKD
	PTAVIFGEDVAFGGVFRCTVGLRDKYGKDRVFNTPLCEQGIVGFGIG
	IAVTGATAIAEIQFADYIFPAFDQIVNEAAKYRYRSGDLFNCGSLTIR
	SPWGCVGHGALYHSQSPEAFFAHCPGIKVVIPRSPFQAKGLLLSCIE
	DKNPCIFFEPKILYRAAAEEVPIEPYNIPLSQAEVIQEGSDVTLVAWG
	TQVHVIREVASMAKEKLGVSCEVIDLRTIIPWDVDTICKSVIKTGRLL
	ISHEAPLTGGFASEISSTVQEECFLNLEAPISRVCGYDTPFPHIFEPFYI
	PDKWKCYDALRKMINY
66	MAAVRMLRTWSRNAGKLICVRYFQTCGNVHVLKPNYVCFFGYPSF	DBT
	KYSHPHHFLKTTAALRGQVVQFKLSDIGEGIREVTVKEWYVKEGDT
	VSQFDSICEVQSDKASVTITSRYDGVIKKLYYNLDDIAYVGKPLVDI
	ETEALKDSEEDVVETPAVSHDEHTHQEIKGRKTLATPAVRRLAMEN
	NIKLSEVVGSGKDGRILKEDILNYLEKQTGAILPPSPKVEIMPPPPKP
	KDMTVPILVSKPPVFTGKDKTEPIKGFQKAMVKTMSAALKIPHFGY
	CDEIDLTELVKLREELKPIAFARGIKLSFMPFFLKAASLGLLQFPILNA
	SVDENCQNITYKASHNIGIAMDTEQGLIVPNVKNVQICSIFDIATELN
	RLQKLGSVGQLSTTDLTGGTFTLSNIGSIGGTFAKPVIMPPEVAIGAL
	GSIKAIPRFNQKGEVYKAQIMNVSWSADHRVIDGATMSRFSNLWKS
	YLENPAFMLLDLK
67	MQSWSRVYCSLAKRGHFNRISHGLQGLSAVPLRTYADQPIDADVTV	DLD
	IGSGPGGYVAAIKAAQLGFKTVCIEKNETLGGTCLNVGCIPSKALLN
	NSHYYHMAHGKDFASRGIEMSEVRLNLDKMMEQKSTAVKALTGGI
	AHLFKQNKVVHVNGYGKITGKNQVTATKADGGTQVIDTKNILIATG
	SEVTPFPGITIDEDTIVSSTGALSLKKVPEKMVVIGAGVIGVELGSVW
	QRLGADVTAVEFLGHVGGVGIDMEISKNFQRILQKQGFKFKLNTKV
	TGATKKSDGKIDVSIEAASGGKAEVITCDVLLVCIGRRPFTKNLGLE
	ELGIELDPRGRIPVNTRFQTKIPNIYAIGDVVAGPMLAHKAEDEGIIC
	VEGMAGGAVHIDYNCVPSVIYTHPEVAWVGKSEEQLKEEGIEYKV
	GKFPFAANSRAKTNADTDGMVKILGQKSTDRVLGAHILGPGAGEM
	VNEAALALEYGASCEDIARVCHAHPTLSEAFREANLAASFGKSINF
68	MLRAKNQLFLLSPHYLRQVKESSGSRLIQQRLLHQQQPLHPEWAAL	MUT
	AKKQLKGKNPEDLIWHTPEGISIKPLYSKRDTMDLPEELPGVKPFTR
	GPYPTMYTFRPWTIRQYAGFSTVEESNKFYKDNIKAGQQGLSVAFD
	LATHRGYDSDNPRVRGDVGMAGVAIDTVEDTKILFDGIPLEKMSVS
	MTMNGAVIPVLANFIVTGEEQGVPKEKLTGTIQNDILKEFMVRNTYI
	FPPEPSMKIIADIFEYTAKHMPKFNSISISGYHMQEAGADAILELAYT
	LADGLEYSRTGLQAGLTIDEFAPRLSFFWGIGMNFYMEIAKMRAGR
	RLWAHLIEKMFQPKNSKSLLLRAHCQTSGWSLTEQDPYNNIVRTAI
	EAMAAVFGGTQSLHTNSFDEALGLPTVKSARIARNTQIIIQEESGIPK
	VADPWGGSYMMECLTNDVYDAALKLINEIEEMGGMAKAVAEGIP
	KLRIEECAARRQARIDSGSEVIVGVNKYQLEKEDAVEVLAIDNTSVR
	NRQIEKLKKIKSSRDQALAERCLAALTECAASGDGNILALAVDASR
	ARCTVGEITDALKKVFGEHKANDRMVSGAYRQEFGESKEITSAIKR
	VHKFMEREGRRPRLLVAKMGQDGHDRGAKVIATGFADLGFDVDIG
	PLFQTPREVAQQAVDADVHAVGISTLAAGHKTLVPELIKELNSLGRP
	DILVMCGGVIPPQDYEFLFEVGVSNVFGPGTRIPKAAVQVLDDIEKC
	LEKKQQSV
69	MPMLLPHPHQHFLKGLLRAPFRCYHFIFHSSTHLGSGIPCAQPFNSL	MMAA
	GLHCTKWMLLSDGLKRKLCVQTTLKDHTEGLSDKEQRFVDKLYTG
	LIQGQRACLAEAITLVESTHSRKKELAQVLLQKVLLYHREQEQSNK
	GKPLAFRVGLSGPPGAGKSTFIEYFGKMLTERGHKLSVLAVDPSSCT
	SGGSLLGDKTRMTELSRDMNAYIRPSPTRGTLGGVTRTTNEAILLCE
	GAGYDIILIETVGVGQSEFAVADMVDMFVLLLPPAGGDELQGIKRGI
	IEMADLVAVTKSDGDLIVPARRIQAEYVSALKLLRKRSQVWKPKVI
	RISARSGEGISEMWDKMKDFQDLMLASGELTAKRRKQQKVWMWN
	LIQESVLEHFRTHPTVREQIPLLEQKVLIGALSPGLAADFLLKAFKSR
	D
70	MAVCGLGSRLGLGSRLGLRGCFGAARLLYPRFQSRGPQGVEDGDR	MMAB
	PQPSSKTPRIPKIYTKTGDKGFSSTFTGERRPKDDQVFEAVGTTDELS
	SAIGFALELVTEKGHTFAEELQKIQCTLQDVGSALATPCSSAREAHL
	KYTTFKAGPILELEQWIDKYTSQLPPLTAFILPSGGKISSALHFCRAV
	CRRAERRVVPLVQMGETDANVAKFLNRLSDYLFTLARYAAMKEG
	NQEKIYMKNDPSAESEGL
71	MFDRALKPFLQSCHLRMLTDPVDQCVAYHLGRVRESLPELQIEIIAD	MMACHC
	YEVHPNRRPKILAQTAAHVAGAAYYYQRQDVEADPWGNQRISGVC
	IHPRFGGWFAIRGVVLLPGIEVPDLPPRKPHDCVPTRADRIALLEGFN
	FHWRDWTYRDAVTPQERYSEEQKAYFSTPPAQRLALLGLAQPSEKP
	SSPSPDLPFTTPAPKKPGNPSRARSWLSPRVSPPASPGP
72	MANVLCNRARLVSYLPGFCSLVKRVVNPKAFSTAGSSGSDESHVA	MMADHC
	AAPPDICSRTVWPDETMGPFGPQDQRFQLPGNIGFDCHLNGTASQK
	KSLVHKTLPDVLAEPLSSERHEFVMAQYVNEFQGNDAPVEQEINSA
	ETYFESARVECAIQTCPELLRKDFESLFPEVANGKLMILTVTQKTKN
	DMTVWSEEVEIEREVLLEKFINGAKEICYALRAEGYWADFIDPSSGL
	AFFGPYTNNTLFETDERYRHLGFSVDDLGCCKVIRHSLWGTHVVVG
	SIFTNATPDSHIMKKLSGN
73	MARVLKAAAANAVGLFSRLQAPIPTVRASSTSQPLDQVTGSVWNL	MCEE
	GRLNHVAIAVPDLEKAAAFYKNILGAQVSEAVPLPEHGVSVVFVNL
	GNTKMELLHPLGRDSPIAGFLQKNKAGGMHHICIEVDNINAAVMDL
	KKKKIRSLSEEVKIGAHGKPVIFLHPKDCGGVLVELEQA
74	MAGFWVGTAPLVAAGRRGRWPPQQLMLSAALRTLKHVLYYSRQC	PCCA
	LMVSRNLGSVGYDPNEKTFDKILVANRGEIACRVIRTCKKMGIKTV
	AIHSDVDASSVHVKMADEAVCVGPAPTSKSYLNMDAIMEAIKKTR
	AQAVHPGYGFLSENKEFARCLAAEDVVFIGPDTHAIQAMGDKIESK
	LLAKKAEVNTIPGFDGVVKDAEEAVRIAREIGYPVMIKASAGGGGK
	GMRIAWDDEETRDGFRLSSQEAASSFGDDRLLIEKFIDNPRHIEIQVL
	GDKHGNALWLNERECSIQRRNQKVVEEAPSIFLDAETRRAMGEQA
	VALARAVKYSSAGTVEFLVDSKKNFYFLEMNTRLQVEHPVTECITG
	LDLVQEMIRVAKGYPLRHKQADIRINGWAVECRVYAEDPYKSFGLP
	SIGRLSQYQEPLHLPGVRVDSGIQPGSDISIYYDPMISKLITYGSDRTE
	ALKRMADALDNYVIRGVTHNIALLREVIINSRFVKGDISTKFLSDVY
	PDGFKGHMLTKSEKNQLLAIASSLFVAFQLRAQHFQENSRMPVIKP
	DIANWELSVKLHDKVHTVVASNNGSVFSVEVDGSKLNVTSTWNLA
	SPLLSVSVDGTQRTVQCLSREAGGNMSIQFLGTVYKVNILTRLAAEL
	NKFMLEKVTEDTSSVLRSPMPGVVVAVSVKPGDAVAEGQEICVIEA
	MKMQNSMTAGKTGTVKSVHCQAGDTVGEGDLLVELE
75	MAAALRVAAVGARLSVLASGLRAAVRSLCSQATSVNERIENKRRT	PCCB
	ALLGGGQRRIDAQHKRGKLTARERISLLLDPGSFVESDMFVEHRCA
	DFGMAADKNKFPGDSVVTGRGRINGRLVYVFSQDFTVFGGSLSGA
	HAQKICKIMDQAITVGAPVIGLNDSGGARIQEGVESLAGYADIFLRN
	VTASGVIPQISLIMGPCAGGAVYSPALTDFTFMVKDTSYLFITGPDV
	VKSVTNEDVTQEELGGAKTHTTMSGVAHRAFENDVDALCNLRDFF
	NYLPLSSQDPAPVRECHDPSDRLVPELDTIVPLESTKAYNMVDIIHSV
	VDEREFFEIMPNYAKNIIVGFARMNGRTVGIVGNQPKVASGCLDINS
	SVKGARFVRFCDAFNIPLITFVDVPGFLPGTAQEYGGIIRHGAKLLY
	AFAEATVPKVTVITRKAYGGAYDVMSSKHLCGDTNYAWPTAEIAV
	MGAKGAVEIIFKGHENVEAAQAEYIEKFANPFPAAVRGFVDDIIQPS
	STRARICCDLDVLASKKVQRPWRKHANIPL
76	MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGA	UGT1A1
	IQQLQQRGHEIVVLAPDASLYIRDGAFYTLKTYPVPFQREDVKESFV
	SLGHNVFENDSFLQRVIKTYKKIKKDSAMLLSGCSHLLHNKELMAS
	LAESSFDVMLTDPFLPCSPIVAQYLSLPTVFFLHALPCSLEFEATQCP
	NPFSYVPRPLSSHSDHMTFLQRVKNMLIAFSQNFLCDVVYSPYATL
	ASEFLQREVTVQDLLSSASVWLFRSDFVKDYPRPIMPNMVFVGGIN
	CLHQNPLSQEFEAYINASGEHGIVVFSLGSMVSEIPEKKAMAIADAL
	GKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGHPMTRAFITH
	AGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVL
	EMTSEDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWV
	EFVMRHKGAPHLRPAAHDLTWYQYHSLDVIGFLLAVVLTVAFITFK
	CCAYGYRKCLGKKGRVKKAHKSKTH
77	MSSKGSVVLAYSGGLDTSCILVWLKEQGYDVIAYLANIGQKEDFEE	ASS1
	ARKKALKLGAKKVFIEDVSREFVEEFIWPAIQSSALYEDRYLLGTSL
	ARPCIARKQVEIAQREGAKYVSHGATGKGNDQVRFELSCYSLAPQI
	KVIAPWRMPEFYNRFKGRNDLMEYAKQHGIPIPVTPKNPWSMDEN
	LMHISYEAGILENPKNQAPPGLYTKTQDPAKAPNTPDILEIEFKKGVP
	VKVTNVKDGTTHQTSLELFMYLNEVAGKHGVGRIDIVENRFIGMKS
	RGIYETPAGTILYHAHLDIEAFTMDREVRKIKQGLGLKFAELVYTGF
	WHSPECEFVRHCIAKSQERVEGKVQVSVLKGQVYILGRESPLSLYN
	EELVSMNVQGDYEPTDATGFININSLRLKEYHRLQSKVTAK
78	MSTAVLENPGLGRKLSDFGQETSYIEDNCNQNGAISLIFSLKEEVGA	PAH
	LAKVLRLFEENDVNLTHIESRPSRLKKDEYEFFTHLDKRSLPALTNII
	KILRHDIGATVHELSRDKKKDTVPWFPRTIQELDRFANQILSYGAEL
	DADHPGFKDPVYRARRKQFADIAYNYRHGQPIPRVEYMEEEKKTW
	GTVFKTLKSLYKTHACYEYNHIFPLLEKYCGFHEDNIPQLEDVSQFL
	QTCTGFRLRPVAGLLSSRDFLGGLAFRVFHCTQYIRHGSKPMYTPEP
	DICHELLGHVPLFSDRSFAQFSQEIGLASLGAPDEYIEKLATIYWFTV
	EFGLCKQGDSIKAYGAGLLSSFGELQYCLSEKPKLLPLELEKTAIQN
	YTVTEFQPLYYVAESFNDAKEKVRNFAATIPRPFSVRYDPYTQRIEV
	LDNTQQLKILADSINSEIGILCSALQKIK
79	MAKTLSQAQSKTSSQQFSFTGNSSANVIIGNQKLTINDVARVARNGT	PAL
	LVSLTNNTDILQGIQASCDYINNAVESGEPIYGVTSGFGGMANVAIS
	REQASELQTNLVWFLKTGAGNKLPLADVRAAMLLRANSHMRGAS
	GIRLELIKRMEIFLNAGVTPYVYEFGSIGASGDLVPLSYITGSLIGLDP
	SFKVDFNGKEMDAPTALRQLNLSPLTLLPKEGLAMMNGTSVMTGI
	AANCVYDTQILTAIAMGVHALDIQALNGTNQSFHPFIHNSKPHPGQL
	WAADQMISLLANS
	QLVRDELDGKHDYRDHELIQDRYSLRCLPQYLGPIVDGISQIAKQIEI
	EINSVTDNPLIDVDNQASYHGGNFLGQYVGMGMDHLRYYIGLLAK
	HLDVQIALLASPEFSNGLPPSLLGNRERKVNMGLKGLQICGNSIMPL
	LTFYGNSIADRFPTHAEQFNQNINSQGYTSATLARRSVDIFQNYVAI
	ALMFGVQAVDLRTYKKTGHYDARASLSPATERLYSAVRHVVGQKP
	TSDRPYIWNDNEQGLDEHIARISADIAAGGVIVQAVQDILPSLH
80	MSTERDSETTFDEDSQPNDEVVPYSDDETEDELDDQGSAVEPEQNR	ATP8B1
	VNREAEENREPFRKECTWQVKANDRKYHEQPHFMNTKFLCIKESK
	YANNAIKTYKYNAFTFIPMNLFEQFKRAANLYFLALLILQAVPQIST
	LAWYTTLVPLLVVLGVTAIKDLVDDVARHKMDKEINNRTCEVIKD
	GRFKVAKWKEIQVGDVIRLKKNDFVPADILLLSSSEPNSLCYVETAE
	LDGETNLKFKMSLEITDQYLQREDTLATFDGFIECEEPNNRLDKFTG
	TLFWRNTSFPLDADKILLRGCVIRNTDFCHGLVIFAGADTKIMKNSG
	KTRFKRTKIDYLMNYMVYTIFVVLILLSAGLAIGHAYWEAQVGNSS
	WYLYDGEDDTPSYRGFLIFWGYIIVLNTMVPISLYVSVEVIRLGQSH
	FINWDLQMYYAEKDTPAKARTTTLNEQLGQIHYIFSDKTGTLTQNI
	MTFKKCCINGQIYGDHRDASQHNHNKIEQVDFSWNTYADGKLAFY
	DHYLIEQIQSGKEPEVRQFFFLLAVCHTVMVDRTDGQLNYQAASPD
	EGALVNAARNFGFAFLARTQNTITISELGTERTYNVLAILDFNSDRK
	RMSIIVRTPEGNIKLYCKGADTVIYERLHRMNPTKQETQDALDIFAN
	ETLRTLCLCYKEIEEKEFTEWNKKFMAASVASTNRDEALDKVYEEI
	EKDLILLGATAIEDKLQDGVPETISKLAKADIKIWVLTGDKKETAENI
	GFACELLTEDTTICYGEDINSLLHARMENQRNRGGVYAKFAPPVQE
	SFFPPGGNRALIITGSWLNEILLEKKTKRNKILKLKFPRTEEERRMRT
	QSKRRLEAKKEQRQKNFVDLACECSAVICCRVTPKQKAMVVDLVK
	RYKKAITLAIGDGANDVNMIKTAHIGVGISGQEGMQAVMSSDYSFA
	QFRYLQRLLLVHGRWSYIRMCKFLRYFFYKNFAFTLVHFWYSFFNG
	YSAQTAYEDWFITLYNVLYTSLPVLLMGLLDQDVSDKLSLRFPGLY
	IVGQRDLLFNYKRFFVSLLHGVLTSMILFFIPLGAYLQTVGQDGEAP
	SDYQSFAVTIASALVITVNFQIGLDTSYWTFVNAFSIFGSIALYFGIMF
	DFHSAGIHVLFPSAFQFTGTASNALRQPYIWLTIILAVAVCLLPVVAI
	RFLSMTIWPSESDKIQKHRKRLKAEEQWQRRQQVFRRGVSTRRSAY
	AFSHQRGYADLISSGRSIRKKRSPLDAIVADGTAEYRRTGDS
81	MSDSVILRSIKKFGEENDGFESDKSYNNDKKSRLQDEKKGDGVRVG	ABCB11
	FFQLFRFSSSTDIWLMFVGSLCAFLHGIAQPGVLLIFGTMTDVFIDYD
	VELQELQIPGKACVNNTIVWTNSSLNQNMTNGTRCGLLNIESEMIKF
	ASYYAGIAVAVLITGYIQICFWVIAAARQIQKMRKFYFRRIMRMEIG
	WFDCNSVGELNTRFSDDINKINDAIADQMALFIQRMTSTICGFLLGF
	FRGWKLTLVIISVSPLIGIGAATIGLSVSKFTDYELKAYAKAGVVAD
	EVISSMRTVAAFGGEKREVERYEKNLVFAQRWGIRKGIVMGFFTGF
	VWCLIFLCYALAFWYGSTLVLDEGEYTPGTLVQIFLSVIVGALNLGN
	ASPCLEAFATGRAAATSIFETIDRKPIIDCMSEDGYKLDRIKGEIEFHN
	VTFHYPSRPEVKILNDLNMVIKPGEMTALVGPSGAGKSTALQLIQRF
	YDPCEGMVTVDGHDIRSLNIQWLRDQIGIVEQEPVLFSTTIAENIRYG
	REDATMEDIVQAAKEANAYNFIMDLPQQFDTLVGEGGGQMSGGQ
	KQRVAIARALIRNPKILLLDMATSALDNESEAMVQEVLSKIQHGHTII
	SVAHRLSTVRAADTIIGFEHGTAVERGTHEELLERKGVYFTLVTLQS
	QGNQALNEEDIKDATEDDMLARTFSRGSYQDSLRASIRQRSKSQLS
	YLVHEPPLAVVDHKSTYEEDRKDKDIPVQEEVEPAPVRRILKFSAPE
	WPYMLVGSVGAAVNGTVTPLYAFLFSQILGTFSIPDKEEQRSQINGV
	CLLFVAMGCVSLFTQFLQGYAFAKSGELLTKRLRKFGFRAMLGQDI
	AWFDDLRNSPGALTTRLATDASQVQGAAGSQIGMIVNSFTNVTVA
	MIIAFSFSWKLSLVILCFFPFLALSGATQTRMLTGFASRDKQALEMV
	GQITNEALSNIRTVAGIGKERRHEALETELEKPFKTAIQKANIYGFCF
	AFAQCIMFIANSASYRYGGYLISNEGLHFSYVFRVISAVVLSATALG
	RAFSYTPSYAKAKISAARFFQLLDRQPPISVYNTAGEKWDNFQGKID
	FVDCKFTYPSRPDSQVLNGLSVSISPGQTLAFVGSSGCGKSTSIQLLE
	RFYDPDQGKVMIDGHDSKKVNVQFLRSNIGIVSQEPVLFACSIMDNI
	KYGDNTKEIPMERVIAAAKQAQLHDFVMSLPEKYETNVGSQGSQLS
	RGEKQRIAIARAIVRDPKILLLDEATSALDTESEKTVQVALDKAREG
	RTCIVIAHRLSTIQNADIIAVMAQGVVIEKGTHEELMAQKGAYYKLV
	TTGSPIS
82	MDLEAAKNGTAWRPTSAEGDFELGISSKQKRKKTKTVKMIGVLTLF	ABCB4
	RYSDWQDKLFMSLGTIMAIAHGSGLPLMMIVFGEMTDKFVDTAGN
	FSFPVNFSLSLLNPGKILEEEMTRYAYYYSGLGAGVLVAAYIQVSFW
	TLAAGRQIRKIRQKFFHAILRQEIGWFDINDTTELNTRLTDDISKISEG
	IGDKVGMFFQAVATFFAGFIVGFIRGWKLTLVIMAISPILGLSAAVW
	AKILSAFSDKELAAYAKAGAVAEEALGAIRTVIAFGGQNKELERYQ
	KHLENAKEIGIKKAISANISMGIAFLLIYASYALAFWYGSTLVISKEY
	TIGNAMTVFFSILIGAFSVGQAAPCIDAFANARGAAYVIFDIIDNNPKI
	DSFSERGHKPDSIKGNLEFNDVHFSYPSRANVKILKGLNLKVQSGQT
	VALVGSSGCGKSTTVQLIQRLYDPDEGTINIDGQDIRNFNVNYLREII
	GVVSQEPVLFSTTIAENICYGRGNVTMDEIKKAVKEANAYEFIMKLP
	QKFDTLVGERGAQLSGGQKQRIAIARALVRNPKILLLDEATSALDTE
	SEAEVQAALDKAREGRTTIVIAHRLSTVRNADVIAGFEDGVIVEQGS
	HSELMKKEGVYFKLVNMQTSGSQIQSEEFELNDEKAATRMAPNGW
	KSRLFRHSTQKNLKNSQMCQKSLDVETDGLEANVPPVSFLKVLKLN
	KTEWPYFVVGTVCAIANGGLQPAFSVIFSEIIAIFGPGDDAVKQQKC
	NIFSLIFLFLGIISFFTFFLQGFTFGKAGEILTRRLRSMAFKAMLRQDM
	SWFDDHKNSTGALSTRLATDAAQVQGATGTRLALIAQNIANLGTGII
	ISFIYGWQLTLLLLAVVPIIAVSGIVEMKLLAGNAKRDKKELEAAGK
	IATEAIENIRTVVSLTQERKFESMYVEKLYGPYRNSVQKAHIYGITFS
	ISQAFMYFSYAGCFRFGAYLIVNGHMRFRDVILVFSAIVFGAVALGH
	ASSFAPDYAKAKLSAAHLFMLFERQPLIDSYSEEGLKPDKFEGNITF
	NEVVFNYPTRANVPVLQGLSLEVKKGQTLALVGSSGCGKSTVVQL
	LERFYDPLAGTVFVDFGFQLLDGQEAKKLNVQWLRAQLGIVSQEPI
	LFDCSIAENIAYGDNSRVVSQDEIVSAAKAANIHPFIETLPHKYETRV
	GDKGTQLSGGQKQRIAIARALIRQPQILLLDEATSALDTESEKVVQE
	ALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQLLA
	QKGIYFSMVSVQAGTQNL
83	MPVRGDRGFPPRRELSGWLRAPGMEELIWEQYTVTLQKDSKRGFGI	TJP2
	AVSGGRDNPHFENGETSIVISDVLPGGPADGLLQENDRVVMVNGTP
	MEDVLHSFAVQQLRKSGKVAAIVVKRPRKVQVAALQASPPLDQDD
	RAFEVMDEFDGRSFRSGYSERSRLNSHGGRSRSWEDSPERGRPHER
	ARSRERDLSRDRSRGRSLERGLDQDHARTRDRSRGRSLERGLDHDF
	GPSRDRDRDRSRGRSIDQDYERAYHRAYDPDYERAYSPEYRRGAR
	HDARSRGPRSRSREHPHSRSPSPEPRGRPGPIGVLLMKSRANEEYGL
	RLGSQIFVKEMTRTGLATKDGNLHEGDIILKINGTVTENMSLTDARK
	LIEKSRGKLQLVVLRDSQQTLINIPSLNDSDSEIEDISEIESNRSFSPEE
	RRHQYSDYDYHSSSEKLKERPSSREDTPSRLSRMGATPTPFKSTGDI
	AGTVVPETNKEPRYQEDPPAPQPKAAPRTFLRPSPEDEAIYGPNTKM
	VRFKKGDSVGLRLAGGNDVGIFVAGIQEGTSAEQEGLQEGDQILKV
	NTQDFRGLVREDAVLYLLEIPKGEMVTILAQSRADVYRDILACGRG
	DSFFIRSHFECEKETPQSLAFTRGEVFRVVDTLYDGKLGNWLAVRIG
	NELEKGLIPNKSRAEQMASVQNAQRDNAGDRADFWRMRGQRSGV
	KKNLRKSREDLTAVVSVSTKFPAYERVLLREAGFKRPVVLFGPIADI
	AMEKLANELPDWFQTAKTEPKDAGSEKSTGVVRLNTVRQIIEQDKH
	ALLDVTPKAVDLLNYTQWFPIVIFFNPDSRQGVKTMRQRLNPTSNK
	SSRKLFDQANKLKKTCAHLFTATINLNSANDSWFGSLKDTIQHQQG
	EAVWVSEGKMEGMDDDPEDRMSYLTAMGADYLSCDSRLISDFEDT
	DGEGGAYTDNELDEPAEEPLVSSITRSSEPVQHEESIRKPSPEPRAQM
	RRAASSDQLRDNSPPPAFKPEPPKAKTQNKEESYDFSKSYEYKSNPS
	AVAGNETPGASTKGYPPPVAAKPTFGRSILKPSTPIPPQEGEEVGESS
	EEQDNAPKSVLGKVKIFEKMDHKARLQRMQELQEAQNARIEIAQK
	HPDIYAVPIKTHKPDPGTPQHTSSRPPEPQKAPSRPYQDTRGSYGSD
	AEEEEYRQQLSEHSKRGYYGQSARYRDTEL
84	MATATRLLGWRVASWRLRPPLAGFVSQRAHSLLPVDDAINGLSEE	IVD
	QRQLRQTMAKFLQEHLAPKAQEIDRSNEFKNLREFWKQLGNLGVL
	GITAPVQYGGSGLGYLEHVLVMEEISRASGAVGLSYGAHSNLCINQ
	LVRNGNEAQKEKYLPKLISGEYIGALAMSEPNAGSDVVSMKLKAE
	KKGNHYILNGNKFWITNGPDADVLIVYAKTDLAAVPASRGITAFIVE
	KGMPGFSTSKKLDKLGMRGSNTCELIFEDCKIPAANILGHENKGVY
	VLMSGLDLERLVLAGGPLGLMQAVLDHTIPYLHVREAFGQKIGHFQ
	LMQGKMADMYTRLMACRQYVYNVAKACDEGHCTAKDCAGVILY
	SAECATQVALDGIQCFGGNGYINDFPMGRFLRDAKLYEIGAGTSEV
	RRLVIGRAFNADFH
85	MALRGVSVRLLSRGPGLHVLRTWVSSAAQTEKGGRTQSQLAKSSR	GCDH
	PEFDWQDPLVLEEQLTTDEILIRDTFRTYCQERLMPRILLANRNEVF
	HREIISEMGELGVLGPTIKGYGCAGVSSVAYGLLARELERVDSGYRS
	AMSVQSSLVMHPIYAYGSEEQRQKYLPQLAKGELLGCFGLTEPNSG
	SDPSSMETRAHYNSSNKSYTLNGTKTWITNSPMADLFVVWARCED
	GCIRGFLLEKGMRGLSAPRIQGKFSLRASATGMIIMDGVEVPEENVL
	PGASSLGGPFGCLNNARYGIAWGVLGASEFCLHTARQYALDRMQF
	GVPLARNQLIQKKLADMLTEITLGLHACLQLGRLKDQDKAAPEMV
	SLLKRNNCGKALDIARQARDMLGGNGISDEYHVIRHAMNLEAVNT
	YEGTHDIHALILGRAITGIQAFTASK
86	MFRAAAPGQLRRAASLLRFQSTLVIAEHANDSLAPITLNTITAATRL	ETFA
	GGEVSCLVAGTKCDKVAQDLCKVAGIAKVLVAQHDVYKGLLPEEL
	TPLILATQKQFNYTHICAGASAFGKNLLPRVAAKLEVAPISDHAIKSP
	DTFVRTIYAGNALCTVKCDEKVKVFSVRGTSFDAAATSGGSASSEK
	ASSTSPVEISEWLDQKLTKSDRPELTGAKVVVSGGRGLKSGENFKLL
	YDLADQLHAAVGASRAAVDAGFVPNDMQVGQTGKIVAPELYIAV
	GISGAIQHLAGMKDSKTIVAINKDPEAPIFQVADYGIVADLFKVVPE
	MTEILKKK
87	MAELRVLVAVKRVIDYAVKIRVKPDRTGVVTDGVKHSMNPFCEIA	ETFB
	VEEAVRLKEKKLVKEVIAVSCGPAQCQETIRTALAMGADRGIHVEV
	PPAEAERLGPLQVARVLAKLAEKEKVDLVLLGKQAIDDDCNQTGQ
	MTAGFLDWPQGTFASQVTLEGDKLKVEREIDGGLETLRLKLPAVVT
	ADLRLNEPRYATLPNIMKAKKKKIEVIKPGDLGVDLTSKLSVISVED
	PPQRTAGVKVETTEDLVAKLKEIGRI
88	MLVPLAKLSCLAYQCFHALKIKKNYLPLCATRWSSTSTVPRITTHYT	ETFDH
	IYPRDKDKRWEGVNMERFAEEADVVIVGAGPAGLSAAVRLKQLAV
	AHEKDIRVCLVEKAAQIGAHTLSGACLDPGAFKELFPDWKEKGAPL
	NTPVTEDRFGILTEKYRIPVPILPGLPMNNHGNYIVRLGHLVSWMGE
	QAEALGVEVYPGYAAAEVLFHDDGSVKGIATNDVGIQKDGAPKAT
	FERGLELHAKVTIFAEGCHGHLAKQLYKKFDLRANCEPQTYGIGLK
	ELWVIDEKNWKPGRVDHTVGWPLDRHTYGGSFLYHLNEGEPLVAL
	GLVVGLDYQNPYLSPFREFQRWKHHPSIRPTLEGGKRIAYGARALN
	EGGFQSIPKLTFPGGLLIGCSPGFMNVPKIKGTHTAMKSGILAAESIF
	NQLTSENLQSKTIGLHVTEYEDNLKNSWVWKELYSVRNIRPSCHGV
	LGVYGGMIYTGIFYWILRGMEPWTLKHKGSDFERLKPAKDCTPIEY
	PKPDGQISFDLLSSVALSGTNHEHDQPAHLTLRDDSIPVNRNLSIYDG
	PEQRFCPAGVYEFVPVEQGDGFRLQINAQNCVHCKTCDIKDPSQNIN
	WVVPEGGGGPAYNGM
89	MASESGKLWGGRFVGAVDPIMEKFNASIAYDRHLWEVDVQGSKA	ASL
	YSRGLEKAGLLTKAEMDQILHGLDKVAEEWAQGTFKLNSNDEDIH
	TANERRLKELIGATAGKLHTGRSRNDQVVTDLRLWMRQTCSTLSG
	LLWELIRTMVDRAEAERDVLFPGYTHLQRAQPIRWSHWILSHAVAL
	TRDSERLLEVRKRINVLPLGSGAIAGNPLGVDRELLRAELNFGAITL
	NSMDATSERDFVAEFLFWASLCMTHLSRMAEDLILYCTKEFSFVQL
	SDAYSTGSSLMPQKKNPDSLELIRSKAGRVFGRCAGLLMTLKGLPS
	TYNKDLQEDKEAVFEVSDTMSAVLQVATGVISTLQIHQENMGQAL
	SPDMLATDLAYYLVRKGMPFRQAHEASGKAVFMAETKGVALNQL
	SLQELQTISPLFSGDVICVWDYGHSVEQYGALGGTARSSVDWQIRQ
	VRALLQAQQA
90	MVGGSVPVFDEIILSTARMNRVLSFHSVSGILVCQAGCVLEELSRYV	D2HGDH
	EERDFIMPLDLGAKGSCHIGGNVATNAGGLRFLRYGSLHGTVLGLE
	VVLADGTVLDCLTSLRKDNTGYDLKQLFIGSEGTLGIITTVSILCPPK
	PRAVNVAFLGCPGFAEVLQTFSTCKGMLGEILSAFEFMDAVCMQLV
	GRHLHLASPVQESPFYVLIETSGSNAGHDAEKLGHFLEHALGSGLVT
	DGTMATDQRKVKMLWALRERITEALSRDGYVYKYDLSLPVERLYD
	IVTDLRARLGPHAKHVVGYGHLGDGNLHLNVTAEAFSPSLLAALEP
	HVYEWTAGQQGSVSAEHGVGFRKRDVLGYSKPPGALQLMQQLKA
	LLDPKGILNPYKTLPSQA
91	MAAMRKALPRRLVGLASLRAVSTSSMGTLPKRVKIVEVGPRDGLQ	HMGCL
	NEKNIVSTPVKIKLIDMLSEAGLSVIETTSFVSPKWVPQMGDHTEVL
	KGIQKFPGINYPVLTPNLKGFEAAVAAGAKEVVIFGAASELFTKKNI
	NCSIEESFQRFDAILKAAQSANISVRGYVSCALGCPYEGKISPAKVAE
	VTKKFYSMGCYEISLGDTIGVGTPGIMKDMLSAVMQEVPLAALAV
	HCHDTYGQALANTLMALQMGVSVVDSSVAGLGGCPYAQGASGNL
	ATEDLVYMLEGLGIHTGVNLQKLLEAGNFICQALNRKTSSKVAQAT
	CKL
92	MAAASAVSVLLVAAERNRWHRLPSLLLPPRTWVWRQRTMKYTTA	MCCC1
	TGRNITKVLIANRGEIACRVMRTAKKLGVQTVAVYSEADRNSMHV
	DMADEAYSIGPAPSQQSYLSMEKIIQVAKTSAAQAIHPGCGFLSENM
	EFAELCKQEGIIFIGPPPSAIRDMGIKSTSKSIMAAAGVPVVEGYHGE
	DQSDQCLKEHARRIGYPVMIKAVRGGGGKGMRIVRSEQEFQEQLES
	ARREAKKSFNDDAMLIEKFVDTPRHVEVQVFGDHHGNAVYLFERD
	CSVQRRHQKIIEEAPAPGIKSEVRKKLGEAAVRAAKAVNYVGAGTV
	EFIMDSKHNFCFMEMNTRLQVEHPVTEMITGTDLVEWQLRIAAGEK
	IPLSQEEITLQGHAFEARIYAEDPSNNFMPVAGPLVHLSTPRADPSTR
	IETGVRQGDEVSVHYDPMIAKLVVWAADRQAALTKLRYSLRQYNI
	VGLHTNIDFLLNLSGHPEFEAGNVHTDFIPQHHKQLLLSRKAAAKES
	LCQAALGLILKEKAMTDTFTLQAHDQFSPFSSSSGRRLNISYTRNMT
	LKDGKNNVAIAVTYNHDGSYSMQIEDKTFQVLGNLYSEGDCTYLK
	CSVNGVASKAKLIILENTIYLFSKEGSIEIDIPVPKYLSSVSSQETQGG
	PLAPMTGTIEKVFVKAGDKVKAGDSLMVMIAMKMEHTIKSPKDGT
	VKKVFYREGAQANRHTPLVEFEEEESDKRESE
93	MWAVLRLALRPCARASPAGPRAYHGDSVASLGTQPDLGSALYQEN	MCCC2
	YKQMKALVNQLHERVEHIKLGGGEKARALHISRGKLLPRERIDNLI
	DPGSPFLELSQFAGYQLYDNEEVPGGGIITGIGRVSGVECMIIANDAT
	VKGGAYYPVTVKKQLRAQEIAMQNRLPCIYLVDSGGAYLPRQADV
	FPDRDHFGRTFYNQAIMSSKNIAQIAVVMGSCTAGGAYVPAMADE
	NIIVRKQGTIFLAGPPLVKAATGEEVSAEDLGGADLHCRKSGVSDH
	WALDDHHALHLTRKVVRNLNYQKKLDVTIEPSEEPLFPADELYGIV
	GANLKRSFDVREVIARIVDGSRFTEFKAFYGDTLVTGFARIFGYPVGI
	VGNNGVLFSESAKKGTHFVQLCCQRNIPLLFLQNITGFMVGREYEA
	EGIAKDGAKMVAAVACAQVPKITLIIGGSYGAGNYGMCGRAYSPR
	FLYIWPNARISVMGGEQAANVLATITKDQRAREGKQFSSADEAALK
	EPIIKKFEEEGNPYYSSARVWDDGIIDPADTRLVLGLSFSAALNAPIE
	KTDFGIFRM
94	MAVAGPAPGAGARPRLDLQFLQRFLQILKVLFPSWSSQNALMFLTL	ABCD4
	LCLTLLEQFVIYQVGLIPSQYYGVLGNKDLEGFKTLTFLAVMLIVLN
	STLKSFDQFTCNLLYVSWRKDLTEHLHRLYFRGRAYYTLNVLRDDI
	DNPDQRISQDVERFCRQLSSMASKLIISPFTLVYYTYQCFQSTGWLG
	PVSIFGYFILGTVVNKTLMGPIVMKLVHQEKLEGDFRFKHMQIRVN
	AEPAAFYRAGHVEHMRTDRRLQRLLQTQRELMSKELWLYIGINTFD
	YLGSILSYVVIAIPIFSGVYGDLSPAELSTLVSKNAFVCIYLISCFTQLI
	DLSTTLSDVAGYTHRIGQLRETLLDMSLKSQDCEILGESEWGLDTPP
	GWPAAEPADTAFLLERVSISAPSSDKPLIKDLSLKISEGQSLLITGNTG
	TGKTSLLRVLGGLWTSTRGSVQMLTDFGPHGVLFLPQKPFFTDGTL
	REQVIYPLKEVYPDSGSADDERILRFLELAGLSNLVARTEGLDQQVD
	WNWYDVLSPGEMQRLSFARLFYLQPKYAVLDEATSALTEEVESEL
	YRIGQQLGMTFISVGHRQSLEKFHSLVLKLCGGGRWELMRIKVE
95	MASAVSPANLPAVLLQPRWKRVVGWSGPVPRPRHGHRAVAIKELI	HCFC1
	VVFGGGNEGIVDELHVYNTATNQWFIPAVRGDIPPGCAAYGFVCDG
	TRLLVFGGMVEYGKYSNDLYELQASRWEWKRLKAKTPKNGPPPCP
	RLGHSFSLVGNKCYLFGGLANDSEDPKNNIPRYLNDLYILELRPGSG
	VVAWDIPITYGVLPPPRESHTAVVYTEKDNKKSKLVIYGGMSGCRL
	GDLWTLDIDTLTWNKPSLSGVAPLPRSLHSATTIGNKMYVFGGWVP
	LVMDDVKVATHEKEWKCTNTLACLNLDTMAWETILMDTLEDNIPR
	ARAGHCAVAINTRLYIWSGRDGYRKAWNNQVCCKDLWYLETEKP
	PPPARVQLVRANTNSLEVSWGAVATADSYLLQLQKYDIPATAATAT
	SPTPNPVPSVPANPPKSPAPAAAAPAVQPLTQVGITLLPQAAPAPPTT
	TTIQVLPTVPGSSISVPTAARTQGVPAVLKVTGPQATTGTPLVTMRP
	ASQAGKAPVTVTSLPAGVRMVVPTQSAQGTVIGSSPQMSGMAALA
	AAAAATQKIPPSSAPTVLSVPAGTTIVKTMAVTPGTTTLPATVKVAS
	SPVMVSNPATRMLKTAAAQVGTSVSSATNTSTRPIITVHKSGTVTV
	AQQAQVVTTVVGGVTKTITLVKSPISVPGGSALISNLGKVMSVVQT
	KPVQTSAVTGQASTGPVTQIIQTKGPLPAGTILKLVTSADGKPTTIITT
	TQASGAGTKPTILGISSVSPSTTKPGTTTIIKTIPMSAIITQAGATGVTS
	SPGIKSPITIITTKVMTSGTGAPAKIITAVPKIATGHGQQGVTQVVLK
	GAPGQPGTILRTVPMGGVRLVTPVTVSAVKPAVTTLVVKGTTGVTT
	LGTVTGTVSTSLAGAGGHSTSASLATPITTLGTIATLSSQVINPTAITV
	SAAQTTLTAAGGLTTPTITMQPVSQPTQVTLITAPSGVEAQPVHDLP
	VSILASPTTEQPTATVTIADSGQGDVQPGTVTLVCSNPPCETHETGTT
	NTATTTVVANLGGHPQPTQVQFVCDRQEAAASLVTSTVGQQNGSV
	VRVCSNPPCETHETGTTNTATTATSNMAGQHGCSNPPCETHETGTT
	NTATTAMSSVGANHQRDARRACAAGTPAVIRISVATGALEAAQGS
	KSQCQTRQTSATSTTMTVMATGAPCSAGPLLGPSMAREPGGRSPAF
	VQLAPLSSKVRLSSPSIKDLPAGRHSHAVSTAAMTRSSVGAGEPRM
	APVCESLQGGSPSTTVTVTALEALLCPSATVTQVCSNPPCETHETGT
	TNTATTSNAGSAQRVCSNPPCETHETGTTHTATTATSNGGTGQPEG
	GQQPPAGRPCETHQTTSTGTTMSVSVGALLPDATSSHRTVESGLEV
	AAAPSVTPQAGTALLAPFPTQRVCSNPPCETHETGTTHTATTVTSN
	MSSNQDPPPAASDQGEVESTQGDSVNITSSSAITTTVSSTLTRAVTTV
	TQSTPVPGPSVPPPEELQVSPGPRQQLPPRQLLQSASTALMGESAEV
	LSASQTPELPAAVDLSSTGEPSSGQESAGSAVVATVVVQPPPPTQSE
	VDQLSLPQELMAEAQAGTTTLMVTGLTPEELAVTAAAEAAAQAAA
	TEEAQALAIQAVLQAAQQAVMGTGEPMDTSEAAATVTQAELGHLS
	AEGQEGQATTIPIVLTQQELAALVQQQQLQEAQAQQQHHHLPTEAL
	APADSLNDPAIESNCLNELAGTVPSTVALLPSTATESLAPSNTFVAPQ
	PVVVASPAKLQAAATLTEVANGIESLGVKPDLPPPPSKAPMKKENQ
	WFDVGVIKGTNVMVTHYFLPPDDAVPSDDDLGTVPDYNQLKKQEL
	QPGTAYKFRVAGINACGRGPFSEISAFKTCLPGFPGAPCAIKISKSPD
	GAHLTWEPPSVTSGKIIEYSVYLAIQSSQAGGELKSSTPAQLAFMRV
	YCGPSPSCLVQSSSLSNAHIDYTTKPAIIFRIAARNEKGYGPATQVRW
	LQETSKDSSGTKPANKRPMSSPEMKSAPKKSKADGQ
96	MATSGAASAELVIGWCIFGLLLLAILAFCWIYVRKYQSRRESEVVST	LMBRD1
	ITAIFSLAIALITSALLPVDIFLVSYMKNQNGTFKDWANANVSRQIED
	TVLYGYYTLYSVILFCVFFWIPFVYFYYEEKDDDDTSKCTQIKTALK
	YTLGFVVICALLLLVGAFVPLNVPNNKNSTEWEKVKSLFEELGSSH
	GLAALSFSISSLTLIGMLAAITYTAYGMSALPLNLIKGTRSAAYERLE
	NTEDIEEVEQHIQTIKSKSKDGRPLPARDKRALKQFEERLRTLKKRE
	RHLEFIENSWWTKFCGALRPLKIVWGIFFILVALLFVISLFLSNLDKA
	LHSAGIDSGFIIFGANLSNPLNMLLPLLQTVFPLDYILITIIIMYFIFTSM
	AGIRNIGIWFFWIRLYKIRRGRTRPQALLFLCMILLLIVLHTSYMIYSL
	APQYVMYGSQNYLIETNITSDNHKGNSTLSVPKRCDADAPEDQCTV
	TRTYLFLHKFWFFSAAYYFGNWAFLGVFLIGLIVSCCKGKKSVIEGV
	DEDSDISDDEPSVYSA
97	MSAKSRTIGIIGAPFSKGQPRGGVEEGPTVLRKAGLLEKLKEQECDV	ARG1
	KDYGDLPFADIPNDSPFQIVKNPRSVGKASEQLAGKVAEVKKNGRIS
	LVLGGDHSLAIGSISGHARVHPDLGVIWVDAHTDINTPLTTTSGNLH
	GQPVSFLLKELKGKIPDVPGFSWVTPCISAKDIVYIGLRDVDPGEHYI
	LKTLGIKYFSMTEVDRLGIGKVMEETLSYLLGRKKRPIHLSFDVDGL
	DPSFTPATGTPVVGGLTYREGLYITEEIYKTGLLSGLDIMEVNPSLGK
	TPEEVTRTVNTAVAITLACFGLAREGNHKPIDYLNPPK
98	MKSNPAIQAAIDLTAGAAGGTACVLTGQPFDTMKVKMQTFPDLYR	SLC25A15
	GLTDCCLKTYSQVGFRGFYKGTSPALIANIAENSVLFMCYGFCQQV
	VRKVAGLDKQAKLSDLQNAAAGSFASAFAALVLCPTELVKCRLQT
	MYEMETSGKIAKSQNTVWSVIKSILRKDGPLGFYHGLSSTLLREVPG
	YFFFFGGYELSRSFFASGRSKDELGPVPLMLSGGVGGICLWLAVYPV
	DCIKSRIQVLSMSGKQAGFIRTFINVVKNEGITALYSGLKPTMIRAFP
	ANGALFLAYEYSRKLMMNQLEAY
99	MAAAKVALTKRADPAELRTIFLKYASIEKNGEFFMSPNDFVTRYLNI	SLC25A13
	FGESQPNPKTVELLSGVVDQTKDGLISFQEFVAFESVLCAPDALFMV
	AFQLFDKAGKGEVTFEDVKQVFGQTTIHQHIPFNWDSEFVQLHFGK
	ERKRHLTYAEFTQFLLEIQLEHAKQAFVQRDNARTGRVTAIDFRDI
	MVTIRPHVLTPFVEECLVAAAGGTTSHQVSFSYFNGFNSLLNNMELI
	RKIYSTLAGTRKDVEVTKEEFVLAAQKFGQVTPMEVDILFQLADLY
	EPRGRMTLADIERIAPLEEGTLPFNLAEAQRQKASGDSARPVLLQVA
	ESAYRFGLGSVAGAVGATAVYPIDLVKTRMQNQRSTGSFVGELMY
	KNSFDCFKKVLRYEGFFGLYRGLLPQLLGVAPEKAIKLTVNDFVRD
	KFMHKDGSVPLAAEILAGGCAGGSQVIFTNPLEIVKIRLQVAGEITT
	GPRVSALSVVRDLGFFGIYKGAKACFLRDIPFSAIYFPCYAHVKASF
	ANEDGQVSPGSLLLAGAIAGMPAASLVTPADVIKTRLQVAARAGQT
	TYSGVIDCFRKILREEGPKALWKGAGARVFRSSPQFGVTLLTYELLQ
	RWFYIDFGGVKPMGSEPVPKSRINLPAPNPDHVGGYKLAVATFAGI
	ENKFGLYLPLFKPSVSTSKAIGGGP
100	MQPQSVLHSGYFHPLLRAWQTATTTLNASNLIYPIFVTDVPDDIQPIT	ALAD
	SLPGVARYGVKRLEEMLRPLVEEGLRCVLIFGVPSRVPKDERGSAA
	DSEESPAIEAIHLLRKTFPNLLVACDVCLCPYTSHGHCGLLSENGAF
	RAEESRQRLAEVALAYAKAGCQVVAPSDMMDGRVEAIKEALMAH
	GLGNRVSVMSYSAKFASCFYGPFRDAAKSSPAFGDRRCYQLPPGAR
	GLALRAVDRDVREGADMLMVKPGMPYLDIVREVKDKHPDLPLAV
	YHVSGEFAMLWHGAQAGAFDLKAAVLEAMTAFRRAGADIIITYYT
	PQLLQWLKEE
101	MALQLGRLSSGPCWLVARGGCGGPRAWSQCGGGGLRAWSQRSAA	CPOX
	GRVCRPPGPAGTEQSRGLGHGSTSRGGPWVGTGLAAALAGLVGLA
	TAAFGHVQRAEMLPKTSGTRATSLGRPEEEEDELAHRCSSFMAPPV
	TDLGELRRRPGDMKTKMELLILETQAQVCQALAQVDGGANFSVDR
	WERKEGGGGISCVLQDGCVFEKAGVSISVVHGNLSEEAAKQMRSR
	GKVLKTKDGKLPFCAMGVSSVIHPKNPHAPTIHFNYRYFEVEEADG
	NKQWWFGGGCDLTPTYLNQEDAVHFHRTLKEACDQHGPDLYPKF
	KKWCDDYFFIAHRGERRGIGGIFFDDLDSPSKEEVFRFVQSCARAVV
	PSYIPLVKKHCDDSFTPQEKLWQQLRRGRYVEFNLLYDRGTKFGLF
	TPGSRIESILMSLPLTARWEYMHSPSENSKEAEILEVLRHPRDWVR
102	MSGNGNAAATAEENSPKMRVIRVGTRKSQLARIQTDSVVATLKAS	HMBS
	YPGLQFEIIAMSTTGDKILDTALSKIGEKSLFTKELEHALEKNEVDLV
	VHSLKDLPTVLPPGFTIGAICKRENPHDAVVFHPKFVGKTLETLPEK
	SVVGTSSLRRAAQLQRKFPHLEFRSIRGNLNTRLRKLDEQQEFSAIIL
	ATAGLQRMGWHNRVGQILHPEECMYAVGQGALGVEVRAKDQDIL
	DLVGVLHDPETLLRCIAERAFLRHLEGGCSVPVAVHTAMKDGQLY
	LTGGVWSLDGSDSIQETMQATIHVPAQHEDGPEDDPQLVGITARNIP
	RGPQLAAQNLGISLANLLLSKGAKNILDVARQLNDAH
103	MGRTVVVLGGGISGLAASYHLSRAPCPPKVVLVESSERLGGWIRSV	PPOX
	RGPNGAIFELGPRGIRPAGALGARTLLLVSELGLDSEVLPVRGDHPA
	AQNRFLYVGGALHALPTGLRGLLRPSPPFSKPLFWAGLRELTKPRG
	KEPDETVHSFAQRRLGPEVASLAMDSLCRGVFAGNSRELSIRSCFPS
	LFQAEQTHRSILLGLLLGAGRTPQPDSALIRQALAERWSQWSLRGG
	LEMLPQALETHLTSRGVSVLRGQPVCGLSLQAEGRWKVSLRDSSLE
	ADHVISAIPASVLSELLPAEAAPLARALSAITAVSVAVVNLQYQGAH
	LPVQGFGHLVPSSEDPGVLGIVYDSVAFPEQDGSPPGLRVTVMLGG
	SWLQTLEASGCVLSQELFQQRAQEAAATQLGLKEMPSHCLVHLHK
	NCIPQYTLGHWQKLESARQFLTAHRLPLTLAGASYEGVAVNDCIES
	GRQAAVSVLGTEPNS
104	MAHAHIQGGRRAKSRFVVCIMSGARSKLALFLCGCYVVALGAHTG	BTD
	EESVADHHEAEYYVAAVYEHPSILSLNPLALISRQEALELMNQNLDI
	YEQQVMTAAQKDVQIIVFPEDGIHGFNFTRTSIYPFLDFMPSPQVVR
	WNPCLEPHRFNDTEVLQRLSCMAIRGDMFLVANLGTKEPCHSSDPR
	CPKDGRYQFNTNVVFSNNGTLVDRYRKHNLYFEAAFDVPLKVDLIT
	FDTPFAGRFGIFTCFDILFFDPAIRVLRDYKVKHVVYPTAWMNQLPL
	LAAIEIQKAFAVAFGINVLAANVHHPVLGMTGSGIHTPLESFWYHD
	MENPKSHLIIAQVAKNPVGLIGAENATGETDPSHSKFLKILSGDPYC
	EKDAQEVHCDEATKWNVNAPPTFHSEMMYDNFTLVPVWGKEGYL
	HVCSNGLCCYLLYERPTLSKELYALGVFDGLHTVHGTYYIQVCALV
	RCGGLGFDTCGQEITEATGIFEFHLWGNFSTSYIFPLFLTSGMTLEVP
	DQLGWENDHYFLRKSRLSSGLVTAALYGRLYERD
105	MEDRLHMDNGLVPQKIVSVHLQDSTLKEVKDQVSNKQAQILEPKP	HLCS
	EPSLEIKPEQDGMEHVGRDDPKALGEEPKQRRGSASGSEPAGDSDR
	GGGPVEHYHLHLSSCHECLELENSTIESVKFASAENIPDLPYDYSSSL
	ESVADETSPEREGRRVNLTGKAPNILLYVGSDSQEALGRFHEVRSVL
	ADCVDIDSYILYHLLEDSALRDPWTDNCLLLVIATRESIPEDLYQKF
	MAYLSQGGKVLGLSSSFTFGGFQVTSKGALHKTVQNLVFSKADQSE
	VKLSVLSSGCRYQEGPVRLSPGRLQGHLENEDKDRMIVHVPFGTRG
	GEAVLCQVHLELPPSSNIVQTPEDFNLLKSSNFRRYEVLREILTTLGL
	SCDMKQVPALTPLYLLSAAEEIRDPLMQWLGKHVDSEGEIKSGQLS
	LRFVSSYVSEVEITPSCIPVVTNMEAFSSEHFNLEIYRQNLQTKQLGK
	VILFAEVTPTTMRLLDGLMFQTPQEMGLIVIAARQTEGKGRGGNVW
	LSPVGCALSTLLISIPLRSQLGQRIPFVQHLMSVAVVEAVRSIPEYQDI
	NLRVKWPNDIYYSDLMKIGGVLVNSTLMGETFYILIGCGFNVTNSN
	PTICINDLITEYNKQHKAELKPLRADYLIARVVTVLEKLIKEFQDKGP
	NSVLPLYYRYWVHSGQQVHLGSAEGPKVSIVGLDDSGFLQVHQEG
	GEVVTVHPDGNSFDMLRNLILPKRR
106	MLKFRTVHGGLRLLGIRRTSTAPAASPNVRRLEYKPIKKVMVANRG	PC
	EIAIRVFRACTELGIRTVAIYSEQDTGQMHRQKADEAYLIGRGLAPV
	QAYLHIPDIIKVAKENNVDAVHPGYGFLSERADFAQACQDAGVRFI
	GPSPEVVRKMGDKVEARAIAIAAGVPVVPGTDAPITSLHEAHEFSNT
	YGFPIIFKAAYGGGGRGMRVVHSYEELEENYTRAYSEALAAFGNGA
	LFVEKFIEKPRHIEVQILGDQYGNILHLYERDCSIQRRHQKVVEIAPA
	AHLDPQLRTRLTSDSVKLAKQVGYENAGTVEFLVDRHGKHYFIEV
	NSRLQVEHTVTEEITDVDLVHAQIHVAEGRSLPDLGLRQENIRINGC
	AIQCRVTTEDPARSFQPDTGRIEVFRSGEGMGIRLDNASAFQGAVISP
	HYDSLLVKVIAHGKDHPTAATKMSRALAEFRVRGVKTNIAFLQNV
	LNNQQFLAGTVDTQFIDENPELFQLRPAQNRAQKLLHYLGHVMVN
	GPTTPIPVKASPSPTDPVVPAVPIGPPPAGFRDILLREGPEGFARAVRN
	HPGLLLMDTTFRDAHQSLLATRVRTHDLKKIAPYVAHNFSKLFSME
	NWGGATFDVAMRFLYECPWRRLQELRELIPNIPFQMLLRGANAVG
	YTNYPDNVVFKFCEVAKENGMDVFRVFDSLNYLPNMLLGMEAAG
	SAGGVVEAAISYTGDVADPSRTKYSLQYYMGLAEELVRAGTHILCI
	KDMAGLLKPTACTMLVSSLRDRFPDLPLHIHTHDTSGAGVAAMLA
	CAQAGADVVDVAADSMSGMTSQPSMGALVACTRGTPLDTEVPME
	RVFDYSEYWEGARGLYAAFDCTATMKSGNSDVYENEIPGGQYTNL
	HFQAHSMGLGSKFKEVKKAYVEANQMLGDLIKVTPSSKIVGDLAQ
	FMVQNGLSRAEAEAQAEELSFPRSVVEFLQGYIGVPHGGFPEPFRSK
	VLKDLPRVEGRPGASLPPLDLQALEKELVDRHGEEVTPEDVLSAAM
	YPDVFAHFKDFTATFGPLDSLNTRLFLQGPKIAEEFEVELERGKTLHI
	KALAVSDLNRAGQRQVFFELNGQLRSILVKDTQAMKEMHFHPKAL
	KDVKGQIGAPMPGKVIDIKVVAGAKVAKGQPLCVLSAMKMETVVT
	SPMEGTVRKVHVTKDMTLEGDDLILEIE
107	MVDSTEYEVASQPEVETSPLGDGASPGPEQVKLKKEISLLNGVCLIV	SLC7A7
	GNMIGSGIFVSPKGVLIYSASFGLSLVIWAVGGLFSVFGALCYAELG
	TTIKKSGASYAYILEAFGGFLAFIRLWTSLLIIEPTSQAIIAITFANYMV
	QPLFPSCFAPYAASRLLAAACICLLTFINCAYVKWGTLVQDIFTYAK
	VLALIAVIVAGIVRLGQGASTHFENSFEGSSFAVGDIALALYSALFSY
	SGWDTLNYVTEEIKNPERNLPLSIGISMPIVTIIYILTNVAYYTVLDM
	RDILASDAVAVTFADQIFGIFNWIIPLSVALSCFGGLNASIVAASRLFF
	VGSREGHLPDAICMIHVERFTPVPSLLFNGIMALIYLCVEDIFQLINY
	YSFSYWFFVGLSIVGQLYLRWKEPDRPRPLKLSVFFPIVFCLCTIFLV
	AVPLYSDTINSLIGIAIALSGLPFYFLIIRVPEHKRPLYLRRIVGSATRY
	LQVLCMSVAAEMDLEDGGEMPKQRDPKSN
108	MVPRLLLRAWPRGPAVGPGAPSRPLSAGSGPGQYLQRSIVPTMHYQ	CPT2
	DSLPRLPIPKLEDTIRRYLSAQKPLLNDGQFRKTEQFCKSFENGIGKE
	LHEQLVALDKQNKHTSYISGPWFDMYLSARDSVVLNFNPFMAFNP
	DPKSEYNDQLTRATNMTVSAIRFLKTLRAGLLEPEVFHLNPAKSDTI
	TFKRLIRFVPSSLSWYGAYLVNAYPLDMSQYFRLFNSTRLPKPSRDE
	LFTDDKARHLLVLRKGNFYIFDVLDQDGNIVSPSEIQAHLKYILSDSS
	PAPEFPLAYLTSENRDIWAELRQKLMSSGNEESLRKVDSAVFCLCLD
	DFPIKDLVHLSHNMLHGDGTNRWFDKSFNLIIAKDGSTAVHFEHSW
	GDGVAVLRFFNEVFKDSTQTPAVTPQSQPATTDSTVTVQKLNFELT
	DALKTGITAAKEKFDATMKTLTIDCVQFQRGGKEFLKKQKLSPDAV
	AQLAFQMAFLRQYGQTVATYESCSTAAFKHGRTETIRPASVYTKRC
	SEAFVREPSRHSAGELQQMMVECSKYHGQLTKEAAMGQGFDRHLF
	ALRHLAAAKGIILPELYLDPAYGQINHNVLSTSTLSSPAVNLGGFAP
	VVSDGFGVGYAVHDNWIGCNVSSYPGRNAREFLQCVEKALEDMFD
	ALEGKSIKS
109	MAAGFGRCCRVLRSISRFHWRSQHTKANRQREPGLGFSFEFTEQQK	ACADM
	EFQATARKFAREEIIPVAAEYDKTGEYPVPLIRRAWELGLMNTHIPE
	NCGGLGLGTFDACLISEELAYGCTGVQTAIEGNSLGQMPIIIAGNDQ
	QKKKYLGRMTEEPLMCAYCVTEPGAGSDVAGIKTKAEKKGDEYII
	NGQKMWITNGGKANWYFLLARSDPDPKAPANKAFTGFIVEADTPG
	IQIGRKELNMGQRCSDTRGIVFEDVKVPKENVLIGDGAGFKVAMGA
	FDKTRPVVAAGAVGLAQRALDEATKYALERKTFGKLLVEHQAISF
	MLAEMAMKVELARMSYQRAAWEVDSGRRNTYYASIAKAFAGDIA
	NQLATDAVQILGGNGFNTEYPVEKLMRDAKIYQIYEGTSQIQRLIVA
	REHIDKYKN
110	MAAALLARASGPARRALCPRAWRQLHTIYQSVELPETHQMLLQTC	ACADS
	RDFAEKELFPIAAQVDKEHLFPAAQVKKMGGLGLLAMDVPEELGG
	AGLDYLAYAIAMEEISRGCASTGVIMSVNNSLYLGPILKFGSKEQKQ
	AWVTPFTSGDKIGCFALSEPGNGSDAGAASTTARAEGDSWVLNGT
	KAWITNAWEASAAVVFASTDRALQNKGISAFLVPMPTPGLTLGKKE
	DKLGIRGSSTANLIFEDCRIPKDSILGEPGMGFKIAMQTLDMGRIGIA
	SQALGIAQTALDCAVNYAENRMAFGAPLTKLQVIQFKLADMALAL
	ESARLLTWRAAMLKDNKKPFIKEAAMAKLAASEAATAISHQAIQIL
	GGMGYVTEMPAERHYRDARITEIYEGTSEIQRLVIAGHLLRSYRS
111	MQAARMAASLGRQLLRLGGGSSRLTALLGQPRPGPARRPYAGGAA	ACADVL
	QLALDKSDSHPSDALTRKKPAKAESKSFAVGMFKGQLTTDQVFPYP
	SVLNEEQTQFLKELVEPVSRFFEEVNDPAKNDALEMVEETTWQGLK
	ELGAFGLQVPSELGGVGLCNTQYARLVEIVGMHDLGVGITLGAHQS
	IGFKGILLFGTKAQKEKYLPKLASGETVAAFCLTEPSSGSDAASIRTS
	AVPSPCGKYYTLNGSKLWISNGGLADIFTVFAKTPVTDPATGAVKE
	KITAFVVERGFGGITHGPPEKKMGIKASNTAEVFFDGVRVPSENVLG
	EVGSGFKVAMHILNNGRFGMAAALAGTMRGIIAKAVDHATNRTQF
	GEKIHNFGLIQEKLARMVMLQYVTESMAYMVSANMDQGATDFQIE
	AAISKIFGSEAAWKVTDECIQIMGGMGFMKEPGVERVLRDLRIFRIF
	EGTNDILRLFVALQGCMDKGKELSGLGSALKNPFGNAGLLLGEAG
	KQLRRRAGLGSGLSLSGLVHPELSRSGELAVRALEQFATVVEAKLIK
	HKKGIVNEQFLLQRLADGAIDLYAMVVVLSRASRSLSEGHPTAQHE
	KMLCDTWCIEAAARIREGMAALQSDPWQQELYRNFKSISKALVER
	GGVVTSNPLGF
112	MGHSKQIRILLLNEMEKLEKTLFRLEQGYELQFRLGPTLQGKAVTV	AGL
	YTNYPFPGETFNREKFRSLDWENPTEREDDSDKYCKLNLQQSGSFQ
	YYFLQGNEKSGGGYIVVDPILRVGADNHVLPLDCVTLQTFLAKCLG
	PFDEWESRLRVAKESGYNMIHFTPLQTLGLSRSCYSLANQLELNPDF
	SRPNRKYTWNDVGQLVEKLKKEWNVICITDVVYNHTAANSKWIQE
	HPECAYNLVNSPHLKPAWVLDRALWRFSCDVAEGKYKEKGIPALIE
	NDHHMNSIRKIIWEDIFPKLKLWEFFQVDVNKAVEQFRRLLTQENR
	RVTKSDPNQHLTIIQDPEYRRFGCTVDMNIALTTFIPHDKGPAAIEEC
	CNWFHKRMEELNSEKHRLINYHQEQAVNCLLGNVFYERLAGHGPK
	LGPVTRKHPLVTRYFTFPFEEIDFSMEESMIHLPNKACFLMAHNGW
	VMGDDPLRNFAEPGSEVYLRRELICWGDSVKLRYGNKPEDCPYLW
	AHMKKYTEITATYFQGVRLDNCHSTPLHVAEYMLDAARNLQPNLY
	VVAELFTGSEDLDNVFVTRLGISSLIREAMSAYNSHEEGRLVYRYG
	GEPVGSFVQPCLRPLMPAIAHALFMDITHDNECPIVHRSAYDALPST
	TIVSMACCASGSTRGYDELVPHQISVVSEERFYTKWNPEALPSNTGE
	VNFQSGIIAARCAISKLHQELGAKGFIQVYVDQVDEDIVAVTRHSPSI
	HQSVVAVSRTAFRNPKTSFYSKEVPQMCIPGKIEEVVLEARTIERNT
	KPYRKDENSINGTPDITVEIREHIQLNESKIVKQAGVATKGPNEYIQEI
	EFENLSPGSVIIFRVSLDPHAQVAVGILRNHLTQFSPHFKSGSLAVDN
	ADPILKIPFASLASRLTLAELNQILYRCESEEKEDGGGCYDIPNWSAL
	KYAGLQGLMSVLAEIRPKNDLGHPFCNNLRSGDWMIDYVSNRLISR
	SGTIAEVGKWLQAMFFYLKQIPRYLIPCYFDAILIGAYTTLLDTAWK
	QMSSFVQNGSTFVKHLSLGSVQLCGVGKFPSLPILSPALMDVPYRLN
	EITKEKEQCCVSLAAGLPHFSSGIFRCWGRDTFIALRGILLITGRYVE
	ARNIILAFAGTLRHGLIPNLLGEGIYARYNCRDAVWWWLQCIQDYC
	KMVPNGLDILKCPVSRMYPTDDSAPLPAGTLDQPLFEVIQEAMQKH
	MQGIQFRERNAGPQIDRNMKDEGFNITAGVDEETGFVYGGNRFNC
	GTWMDKMGESDRARNRGIPATPRDGSAVEIVGLSKSAVRWLLELS
	KKNIFPYHEVTVKRHGKAIKVSYDEWNRKIQDNFEKLFHVSEDPSD
	LNEKHPNLVHKRGIYKDSYGASSPWCDYQLRPNFTIAMVVAPELFT
	TEKAWKALEIAEKKLLGPLGMKTLDPDDMVYCGIYDNALDNDNY
	NLAKGFNYHQGPEWLWPIGYFLRAKLYFSRLMGPETTAKTIVLVKN
	VLSRHYVHLERSPWKGLPELTNENAQYCPFSCETQAWSIATILETLY
	DL
113	MEEGMNVLHDFGIQSTHYLQVNYQDSQDWFILVSVIADLRNAFYV	G6PC
	LFPIWFHLQEAVGIKLLWVAVIGDWLNLVFKWILFGQRPYWWVLD
	TDYYSNTSVPLIKQFPVTCETGPGSPSGHAMGTAGVYYVMVTSTLSI
	FQGKIKPTYRFRCLNVILWLGFWAVQLNVCLSRIYLAAHFPHQVVA
	GVLSGIAVAETFSHIHSIYNASLKKYFLITFFLFSFAIGFYLLLKGLGV
	DLLWTLEKAQRWCEQPEWVHIDTTPFASLLKNLGTLFGLGLALNSS
	MYRESCKGKLSKWLPFRLSSIVASLVLLHVFDSLKPPSQVELVFYVL
	SFCKSAVVPLASVSVIPYCLAQVLGQPHKKSL
114	MAAPMTPAARPEDYEAALNAALADVPELARLLEIDPYLKPYAVDF	GBE1
	QRRYKQFSQILKNIGENEGGIDKFSRGYESFGVHRCADGGLYCKEW
	APGAEGVFLTGDFNGWNPFSYPYKKLDYGKWELYIPPKQNKSVLV
	PHGSKLKVVITSKSGEILYRISPWAKYVVREGDNVNYDWIHWDPEH
	SYEFKHSRPKKPRSLRIYESHVGISSHEGKVASYKHFTCNVLPRIKGL
	GYNCIQLMAIMEHAYYASFGYQITSFFAASSRYGTPEELQELVDTAH
	SMGIIVLLDVVHSHASKNSADGLNMFDGTDSCYFHSGPRGTHDLW
	DSRLFAYSSWEILRFLLSNIRWWLEEYRFDGFRFDGVTSMLYHHHG
	VGQGFSGDYSEYFGLQVDEDALTYLMLANHLVHTLCPDSITIAEDV
	SGMPALCSPISQGGGGFDYRLAMAIPDKWIQLLKEFKDEDWNMGDI
	VYTLTNRRYLEKCIAYAESHDQALVGDKSLAFWLMDAEMYTNMS
	VLTPFTPVIDRGIQLHKMIRLITHGLGGEGYLNFMGNEFGHPEWLDF
	PRKGNNESYHYARRQFHLTDDDLLRYKFLNNFDRDMNRLEERYG
	WLAAPQAYVSEKHEGNKIIAFERAGLLFIFNFHPSKSYTDYRVGTAL
	PGKFKIVLDSDAAEYGGHQRLDHSTDFFSEAFEHNGRPYSLLVYIPS
	RVALILQNVDLPN
115	MRSRSNSGVRLDGYARLVQQTILCHQNPVTGLLPASYDQKDAWVR	PHKA1
	DNVYSILAVWGLGLAYRKNADRDEDKAKAYELEQSVVKLMRGLL
	HCMIRQVDKVESFKYSQSTKDSLHAKYNTKTCATVVGDDQWGHL
	QLDATSVYLLFLAQMTASGLHIIHSLDEVNFIQNLVFYIEAAYKTAD
	FGIWERGDKTNQGISELNASSVGMAKAALEALDELDLFGVKGGPQS
	VIHVLADEVQHCQSILNSLLPRASTSKEVDASLLSVVSFPAFAVEDS
	QLVELTKQEIITKLQGRYGCCRFLRDGYKTPKEDPNRLYYEPAELKL
	FENIECEWPLFWTYFILDGVFSGNAEQVQEYKEALEAVLIKGKNGV
	PLLPELYSVPPDRVDEEYQNPHTVDRVPMGKLPHMWGQSLYILGSL
	MAEGFLAPGEIDPLNRRFSTVPKPDVVVQVSILAETEEIKTILKDKGI
	YVETIAEVYPIRVQPARILSHIYSSLGCNNRMKLSGRPYRHMGVLGT
	SKLYDIRKTIFTFTPQFIDQQQFYLALDNKMIVEMLRTDLSYLCSRW
	RMTGQPTITFPISHSMLDEDGTSLNSSILAALRKMQDGYFGGARVQT
	GKLSEFLTTSCCTHLSFMDPGPEGKLYSEDYDDNYDYLESGNWMN
	DYDSTSHARCGDEVARYLDHLLAHTAPHPKLAPTSQKGGLDRFQA
	AVQTTCDLMSLVTKAKELHVQNVHMYLPTKLFQASRPSFNLLDSP
	HPRQENQVPSVRVEIHLPRDQSGEVDFKALVLQLKETSSLQEQADIL
	YMLYTMKGPDWNTELYNERSATVRELLTELYGKVGEIRHWGLIRYI
	SGILRKKVEALDEACTDLLSHQKHLTVGLPPEPREKTISAPLPYEALT
	QLIDEASEGDMSISILTQEIMVYLAMYMRTQPGLFAEMFRLRIGLIIQ
	VMATELAHSLRCSAEEATEGLMNLSPSAMKNLLHHILSGKEFGVER
	SVRPTDSNVSPAISIHEIGAVGATKTERTGIMQLKSEIKQVEFRRLSIS
	AESQSPGTSMTPSSGSFPSAYDQQSSKDSRQGQWQRRRRLDGALNR
	VPVGFYQKVWKVLQKCHGLSVEGFVLPSSTTREMTPGEIKFSVHVE
	SVLNRVPQPEYRQLLVEAILVLTMLADIEIHSIGSIIAVEKIVHIANDL
	FLQEQKTLGADDTMLAKDPASGICTLLYDSAPSGRFGTMTYLSKAA
	ATYVQEFLPHSICAMQ
116	MRSRSNSGVRLDGYARLVQQTILCYQNPVTGLLSASHEQKDAWVR	PHKA2
	DNIYSILAVWGLGMAYRKNADRDEDKAKAYELEQNVVKLMRGLL
	QCMMRQVAKVEKFKHTQSTKDSLHAKYNTATCGTVVGDDQWGH
	LQVDATSLFLLFLAQMTASGLRIIFTLDEVAFIQNLVFYIEAAYKVA
	DYGMWERGDKTNQGIPELNASSVGMAKAALEAIDELDLFGAHGGR
	KSVIHVLPDEVEHCQSILFSMLPRASTSKEIDAGLLSIISFPAFAVEDV
	NLVNVTKNEIISKLQGRYGCCRFLRDGYKTPREDPNRLHYDPAELK
	LFENIECEWPVFWTYFIIDGVFSGDAVQVQEYREALEGILIRGKNGIR
	LVPELYAVPPNKVDEEYKNPHTVDRVPMGKVPHLWGQSLYILSSLL
	AEGFLAAGEIDPLNRRFSTSVKPDVVVQVTVLAENNHIKDLLRKHG
	VNVQSIADIHPIQVQPGRILSHIYAKLGRNKNMNLSGRPYRHIGVLG
	TSKLYVIRNQIFTFTPQFTDQHHFYLALDNEMIVEMLRIELAYLCTC
	WRMTGRPTLTFPISRTMLTNDGSDIHSAVLSTIRKLEDGYFGGARVK
	LGNLSEFLTTSFYTYLTFLDPDCDEKLFDNASEGTFSPDSDSDLVGY
	LEDTCNQESQDELDHYINHLLQSTSLRSYLPPLCKNTEDRHVFSAIH
	STRDILSVMAKAKGLEVPFVPMTLPTKVLSAHRKSLNLVDSPQPLLE
	KVPESDFQWPRDDHGDVDCEKLVEQLKDCSNLQDQADILYILYVIK
	GPSWDTNLSGQHGVTVQNLLGELYGKAGLNQEWGLIRYISGLLRK
	KVEVLAEACTDLLSHQKQLTVGLPPEPREKIISAPLPPEELTKLIYEA
	SGQDISIAVLTQEIVVYLAMYVRAQPSLFVEMLRLRIGLIIQVMATEL
	ARSLNCSGEEASESLMNLSPFDMKNLLHHILSGKEFGVERSVRPIHS
	STSSPTISIHEVGHTGVTKTERSGINRLRSEMKQMTRRFSADEQFFSV
	GQAASSSAHSSKSARSSTPSSPTGTSSSDSGGHHIGWGERQGQWLRR
	RRLDGAINRVPVGFYQRVWKILQKCHGLSIDGYVLPSSTTREMTPH
	EIKFAVHVESVLNRVPQPEYRQLLVEAIMVLTLLSDTEMTSIGGIIHV
	DQIVQMASQLFLQDQVSIGAMDTLEKDQATGICHFFYDSAPSGAYG
	TMTYLTRAVASYLQELLPNSGCQMQ
117	MAGAAGLTAEVSWKVLERRARTKRSGSVYEPLKSINLPRPDNETL	PHKB
	WDKLDHYYRIVKSTLLLYQSPTTGLFPTKTCGGDQKAKIQDSLYCA
	AGAWALALAYRRIDDDKGRTHELEHSAIKCMRGILYCYMRQADKV
	QQFKQDPRPTTCLHSVFNVHTGDELLSYEEYGHLQINAVSLYLLYL
	VEMISSGLQIIYNTDEVSFIQNLVFCVERVYRVPDFGVWERGSKYNN
	GSTELHSSSVGLAKAALEAINGFNLFGNQGCSWSVIFVDLDAHNRN
	RQTLCSLLPRESRSHNTDAALLPCISYPAFALDDEVLFSQTLDKVVR
	KLKGKYGFKRFLRDGYRTSLEDPNRCYYKPAEIKLFDGIECEFPIFFL
	YMMIDGVFRGNPKQVQEYQDLLTPVLHHTTEGYPVVPKYYYVPAD
	FVEYEKNNPGSQKRFPSNCGRDGKLFLWGQALYIIAKLLADELISPK
	DIDPVQRYVPLKDQRNVSMRFSNQGPLENDLVVHVALIAESQRLQV
	FLNTYGIQTQTPQQVEPIQIWPQQELVKAYLQLGINEKLGLSGRPDR
	PIGCLGTSKIYRILGKTVVCYPIIFDLSDFYMSQDVFLLIDDIKNALQF
	IKQYWKMHGRPLFLVLIREDNIRGSRFNPILDMLAALKKGIIGGVKV
	HVDRLQTLISGAVVEQLDFLRISDTEELPEFKSFEELEPPKHSKVKRQ
	SSTPSAPELGQQPDVNISEWKDKPTHEILQKLNDCSCLASQAILLGIL
	LKREGPNFITKEGTVSDHIERVYRRAGSQKLWLAVRYGAAFTQKFS
	SSIAPHITTFLVHGKQVTLGAFGHEEEVISNPLSPRVIQNIIYYKCNTH
	DEREAVIQQELVIHIGWIISNNPELFSGMLKIRIGWIIHAMEYELQIRG
	GDKPALDLYQLSPSEVKQLLLDILQPQQNGRCWLNRRQIDGSLNRT
	PTGFYDRVWQILERTPNGIIVAGKHLPQQPTLSDMTMYEMNFSLLV
	EDTLGNIDQPQYRQIVVELLMVVSIVLERNPELEFQDKVDLDRLVKE
	AFNEFQKDQSRLKEIEKQDDMTSFYNTPPLGKRGTCSYLTKAVMNL
	LLEGEVKPNNDDPCLIS
118	MTLDVGPEDELPDWAAAKEFYQKYDPKDVIGRGVSSVVRRCVHRA	PHKG2
	TGHEFAVKIMEVTAERLSPEQLEEVREATRRETHILRQVAGHPHIITL
	IDSYESSSFMFLVFDLMRKGELFDYLTEKVALSEKETRSIMRSLLEA
	VSFLHANNIVHRDLKPENILLDDNMQIRLSDFGFSCHLEPGEKLREL
	CGTPGYLAPEILKCSMDETHPGYGKEVDLWACGVILFTLLAGSPPF
	WHRRQILMLRMIMEGQYQFSSPEWDDRSSTVKDLISRLLQVDPEAR
	LTAEQALQHPFFERCEGSQPWNLTPRQRFRVAVWTVLAAGRVALS
	THRVRPLTKNALLRDPYALRSVRHLIDNCAFRLYGHWVKKGEQQN
	RAALFQHRPPGPFPIMGPEEEGDSAAITEDEAVLVLG
119	MAAQGYGYYRTVIFSAMFGGYSLYYFNRKTFSFVMPSLVEEIPLDK	SLC37A4
	DDLGFITSSQSAAYAISKFVSGVLSDQMSARWLFSSGLLLVGLVNIF
	FAWSSTVPVFAALWFLNGLAQGLGWPPCGKVLRKWFEPSQFGTW
	WAILSTSMNLAGGLGPILATILAQSYSWRSTLALSGALCVVVSFLCL
	LLIHNEPADVGLRNLDPMPSEGKKGSLKEESTLQELLLSPYLWVLST
	GYLVVFGVKTCCTDWGQFFLIQEKGQSALVGSSYMSALEVGGLVG
	SIAAGYLSDRAMAKAGLSNYGNPRHGLLLFMMAGMTVSMYLFRV
	TVTSDSPKLWILVLGAVFGFSSYGPIALFGVIANESAPPNLCGTSHAI
	VGLMANVGGFLAGLPFSTIAKHYSWSTAFWVAEVICAASTAAFFLL
	RNIRTKMGRVSKKAE
120	MAAPGPALCLFDVDGTLTAPRQKITKEMDDFLQKLRQKIKIGVVGG	PMM2
	SDFEKVQEQLGNDVVEKYDYVFPENGLVAYKDGKLLCRQNIQSHL
	GEALIQDLINYCLSYIAKIKLPKKRGTFIEFRNGMLNVSPIGRSCSQEE
	RIEFYELDKKENIRQKFVADLRKEFAGKGLTFSIGGQISFDVFPDGW
	DKRYCLRHVENDGYKTIYFFGDKTMPGGNDHEIFTDPRTMGYSVT
	APEDTRRICELLFS
121	MPSETPQAEVGPTGCPHRSGPHSAKGSLEKGSPEDKEAKEPLWIRPD	CBS
	APSRCTWQLGRPASESPHHHTAPAKSPKILPDILKKIGDTPMVRINKI
	GKKFGLKCELLAKCEFFNAGGSVKDRISLRMIEDAERDGTLKPGDTI
	IEPTSGNTGIGLALAAAVRGYRCIIVMPEKMSSEKVDVLRALGAEIV
	RTPTNARFDSPESHVGVAWRLKNEIPNSHILDQYRNASNPLAHYDT
	TADEILQQCDGKLDMLVASVGTGGTITGIARKLKEKCPGCRIIGVDP
	EGSILAEPEELNQTEQTTYEVEGIGYDFIPTVLDRTVVDKWFKSNDE
	EAFTFARMLIAQEGLLCGGSAGSTVAVAVKAAQELQEGQRCVVILP
	DSVRNYMTKFLSDRWMLQKGFLKEEDLTEKKPWWWHLRVQELGL
	SAPLTVLPTITCGHTIEILREKGFDQAPVVDEAGVILGMVTLGNMLS
	SLLAGKVQPSDQVGKVIYKQFKQIRLTDTLGRLSHILEMDHFALVV
	HEQIQYHSTGKSSQRQMVFGVVTAIDLLNFVAAQERDQK
122	MSFIPVAEDSDFPIHNLPYGVFSTRGDPRPRIGVAIGDQILDLSIIKHLF	FAH
	TGPVLSKHQDVFNQPTLNSFMGLGQAAWKEARVFLQNLLSVSQAR
	LRDDTELRKCAFISQASATMHLPATIGDYTDFYSSRQHATNVGIMFR
	DKENALMPNWLHLPVGYHGRASSVVVSGTPIRRPMGQMKPDDSKP
	PVYGACKLLDMELEMAFFVGPGNRLGEPIPISKAHEHIFGMVLMND
	WSARDIQKWEYVPLGPFLGKSFGTTVSPWVVPMDALMPFAVPNPK
	QDPRPLPYLCHDEPYTFDINLSVNLKGEGMSQAATICKSNFKYMYW
	TMLQQLTHHSVNGCNLRPGDLLASGTISGPEPENFGSMLELSWKGT
	KPIDLGNGQTRKFLLDGDEVIITGYCQGDGYRIGFGQCAGKVLPALL
	PS
123	MDPYMIQMSSKGNLPSILDVHVNVGGRSSVPGKMKGRKARWSVRP	TAT
	SDMAKKTFNPIRAIVDNMKVKPNPNKTMISLSIGDPTVFGNLPTDPE
	VTQAMKDALDSGKYNGYAPSIGFLSSREEIASYYHCPEAPLEAKDVI
	LTSGCSQAIDLCLAVLANPGQNILVPRPGFSLYKTLAESMGIEVKLY
	NLLPEKSWEIDLKQLEYLIDEKTACLIVNNPSNPCGSVFSKRHLQKIL
	AVAARQCVPILADEIYGDMVFSDCKYEPLATLSTDVPILSCGGLAKR
	WLVPGWRLGWILIHDRRDIFGNEIRDGLVKLSQRILGPCTIVQGALK
	SILCRTPGEFYHNTLSFLKSNADLCYGALAAIPGLRPVRPSGAMYLM
	VGIEMEHFPEFENDVEFTERLVAEQSVHCLPATCFEYPNFIRVVITVP
	EVMMLEACSRIQEFCEQHYHCAEGSQEECDK
124	MSRSGTDPQQRQQASEADAAAATFRANDHQHIRYNPLQDEWVLVS	GALT
	AHRMKRPWQGQVEPQLLKTVPRHDPLNPLCPGAIRANGEVNPQYD
	STFLFDNDFPALQPDAPSPGPSDHPLFQAKSARGVCKVMCFHPWSD
	VTLPLMSVPEIRAVVDAWASVTEELGAQYPWVQIFENKGAMMGCS
	NPHPHCQVWASSFLPDIAQREERSQQAYKSQHGEPLLMEYSRQELL
	RKERLVLTSEHWLVLVPFWATWPYQTLLLPRRHVRRLPELTPAERD
	DLASIMKKLLTKYDNLFETSFPYSMGWHGAPTGSEAGANWNHWQ
	LHAHYYPPLLRSATVRKFMVGYEMLAQAQRDLTPEQAAERLRALP
	EVHYHLGQKDRETATIA
125	MAALRQPQVAELLAEARRAFREEFGAEPELAVSAPGRVNLIGEHTD	GALK1
	YNQGLVLPMALELMTVLVGSPRKDGLVSLLTTSEGADEPQRLQFPL
	PTAQRSLEPGTPRWANYVKGVIQYYPAAPLPGFSAVVVSSVPLGGG
	LSSSASLEVATYTFLQQLCPDSGTIAARAQVCQQAEHSFAGMPCGI
	MDQFISLMGQKGHALLIDCRSLETSLVPLSDPKLAVLITNSNVRHSL
	ASSEYPVRRRQCEEVARALGKESLREVQLEELEAARDLVSKEGFRR
	ARHVVGEIRRTAQAAAALRRGDYRAFGRLMVESHRSLRDDYEVSC
	PELDQLVEAALAVPGVYGSRMTGGGFGGCTVTLLEASAAPHAMRH
	IQEHYGGTATFYLSQAADGAKVLCL
126	MAEKVLVTGGAGYIGSHTVLELLEAGYLPVVIDNFHNAFRGGGSLP	GALE
	ESLRRVQELTGRSVEFEEMDILDQGALQRLFKKYSFMAVIHFAGLK
	AVGESVQKPLDYYRVNLTGTIQLLEIMKAHGVKNLVFSSSATVYGN
	PQYLPLDEAHPTGGCTNPYGKSKFFIEEMIRDLCQADKTWNAVLLR
	YFNPTGAHASGCIGEDPQGIPNNLMPYVSQVAIGRREALNVFGNDY
	DTEDGTGVRDYIHVVDLAKGHIAALRKLKEQCGCRIYNLGTGTGYS
	VLQMVQAMEKASGKKIPYKVVARREGDVAACYANPSLAQEELGW
	TAALGLDRMCEDLWRWQKQNPSGFGTQA
127	MAEQVALSRTQVCGILREELFQGDAFHQSDTHIFIIMGASGDLAKKK	G6PD
	IYPTIWWLFRDGLLPENTFIVGYARSRLTVADIRKQSEPFFKATPEEK
	LKLEDFFARNSYVAGQYDDAASYQRLNSHMNALHLGSQANRLFYL
	ALPPTVYEAVTKNIHESCMSQIGWNRIIVEKPFGRDLQSSDRLSNHIS
	SLFREDQIYRIDHYLGKEMVQNLMVLRFANRIFGPIWNRDNIACVIL
	TFKEPFGTEGRGGYFDEFGIIRDVMQNHLLQMLCLVAMEKPASTNS
	DDVRDEKVKVLKCISEVQANNVVLGQYVGNPDGEGEATKGYLDD
	PTVPRGSTTATFAAVVLYVENERWDGVPFILRCGKALNERKAEVRL
	QFHDVAGDIFHQQCKRNELVIRVQPNEAVYTKMMTKKPGMFFNPE
	ESELDLTYGNRYKNVKLPDAYERLILDVFCGSQMHFVRSDELREA
	WRIFTPLLHQIELEKPKPIPYIYGSRGPTEADELMKRVGFQYEGTYK
	WVNPHKL
128	MAEDKSKRDSIEMSMKGCQTNNGFVHNEDILEQTPDPGSSTDNLKH	SLC3A1
	STRGILGSQEPDFKGVQPYAGMPKEVLFQFSGQARYRIPREILFWLT
	VASVLVLIAATIAIIALSPKCLDWWQEGPMYQIYPRSFKDSNKDGNG
	DLKGIQDKLDYITALNIKTVWITSFYKSSLKDFRYGVEDFREVDPIFG
	TMEDFENLVAAIHDKGLKLIIDFIPNHTSDKHIWFQLSRTRTGKYTD
	YYIWHDCTHENGKTIPPNNWLSVYGNSSWHFDEVRNQCYFHQFMK
	EQPDLNFRNPDVQEEIKEILRFWLTKGVDGFSLDAVKFLLEAKHLR
	DEIQVNKTQIPDTVTQYSELYHDFTTTQVGMHDIVRSFRQTMDQYS
	TEPGRYRFMGTEAYAESIDRTVMYYGLPFIQEADFPFNNYLSMLDT
	VSGNSVYEVITSWMENMPEGKWPNWMIGGPDSSRLTSRLGNQYVN
	VMNMLLFTLPGTPITYYGEEIGMGNIVAANLNESYDINTLRSKSPMQ
	WDNSSNAGFSEASNTWLPTNSDYHTVNVDVQKTQPRSALKLYQDL
	SLLHANELLLNRGWFCHLRNDSHYVVYTRELDGIDRIFIVVLNFGES
	TLLNLHNMISGLPAKMRIRLSTNSADKGSKVDTSGIFLDKGEGLIFE
	HNTKNLLHRQTAFRDRCFVSNRACYSSVLNILYTSC
129	MGDTGLRKRREDEKSIQSQEPKTTSLQKELGLISGISIIVGTIIGSGIFV	SLC7A9
	SPKSVLSNTEAVGPCLIIWAACGVLATLGALCFAELGTMITKSGGEY
	PYLMEAYGPIPAYLFSWASLIVIKPTSFAIICLSFSEYVCAPFYVGCKP
	PQIVVKCLAAAAILFISTVNSLSVRLGSYVQNIFTAAKLVIVAIIIISGL
	VLLAQGNTKNFDNSFEGAQLSVGAISLAFYNGLWAYDGWNQLNYI
	TEELRNPYRNLPLAIIIGIPLVTACYILMNVSYFTVMTATELLQSQAV
	AVTFGDRVLYPASWIVPLFVAFSTIGAANGTCFTAGRLIYVAGREGH
	MLKVLSYISVRRLTPAPAIIFYGIIATIYIIPGDINSLVNYFSFAAWLFY
	GLTILGLIVMRFTRKELERPIKVPVVIPVLMTLISVFLVLAPIISKPTW
	EYLYCVLFILSGLLFYFLFVHYKFGWAQKISKPITMHLQMLMEVVPP
	EEDPE
130	MVNEARGNSSLNPCLEGSASSGSESSKDSSRCSTPGLDPERHERLRE	MTHFR
	KMRRRLESGDKWFSLEFFPPRTAEGAVNLISRFDRMAAGGPLYIDV
	TWHPAGDPGSDKETSSMMIASTAVNYCGLETILHMTCCRQRLEEIT
	GHLHKAKQLGLKNIMALRGDPIGDQWEEEEGGFNYAVDLVKHIRS
	EFGDYFDICVAGYPKGHPEAGSFEADLKHLKEKVSAGADFIITQLFF
	EADTFFRFVKACTDMGITCPIVPGIFPIQGYHSLRQLVKLSKLEVPQE
	IKDVIEPIKDNDAAIRNYGIELAVSLCQELLASGLVPGLHFYTLNREM
	ATTEVLKRLGMWTEDPRRPLPWALSAHPKRREEDVRPIFWASRPKS
	YIYRTQEWDEFPNGRWGNSSSPAFGELKDYYLFYLKSKSPKEELLK
	MWGEELTSEESVFEVFVLYLSGEPNRNGHKVTCLPWNDEPLAAETS
	LLKEELLRVNRQGILTINSQPNINGKPSSDPIVGWGPSGGYVFQKAY
	LEFFTSRETAEALLQVLKKYELRVNYHLVNVKGENITNAPELQPNA
	VTWGIFPGREIIQPTVVDPVSFMFWKDEAFALWIERWGKLYEEESPS
	RTIIQYIHDNYFLVNLVDNDFPLDNCLWQVVEDTLELLNRPTQNAR
	ETEAP
131	MSPALQDLSQPEGLKKTLRDEINAILQKRIMVLDGGMGTMIQREKL	MTR
	NEEHFRGQEFKDHARPLKGNNDILSITQPDVIYQIHKEYLLAGADIIE
	TNTFSSTSIAQADYGLEHLAYRMNMCSAGVARKAAEEVTLQTGIKR
	FVAGALGPTNKTLSVSPSVERPDYRNITFDELVEAYQEQAKGLLDG
	GVDILLIETIFDTANAKAALFALQNLFEEKYAPRPIFISGTIVDKSGRT
	LSGQTGEGFVISVSHGEPLCIGLNCALGAAEMRPFIEIIGKCTTAYVL
	CYPNAGLPNTFGDYDETPSMMAKHLKDFAMDGLVNIVGGCCGSTP
	DHIREIAEAVKNCKPRVPPATAFEGHMLLSGLEPFRIGPYTNFVNIGE
	RCNVAGSRKFAKLIMAGNYEEALCVAKVQVEMGAQVLDVNMDD
	GMLDGPSAMTRFCNLIASEPDIAKVPLCIDSSNFAVIEAGLKCCQGK
	CIVNSISLKEGEDDFLEKARKIKKYGAAMVVMAFDEEGQATETDTK
	IRVCTRAYHLLVKKLGFNPNDIIFDPNILTIGTGMEEHNLYAINFIHAT
	KVIKETLPGARISGGLSNLSFSFRGMEAIREAMHGVFLYHAIKSGMD
	MGIVNAGNLPVYDDIHKELLQLCEDLIWNKDPEATEKLLRYAQTQG
	TGGKKVIQTDEWRNGPVEERLEYALVKGIEKHIIEDTEEARLNQKK
	YPRPLNIIEGPLMNGMKIVGDLFGAGKMFLPQVIKSARVMKKAVGH
	LIPFMEKEREETRVLNGTVEEEDPYQGTIVLATVKGDVHDIGKNIVG
	VVLGCNNFRVIDLGVMTPCDKILKAALDHKADIIGLSGLITPSLDEMI
	FVAKEMERLAIRIPLLIGGATTSKTHTAVKIAPRYSAPVIHVLDASKS
	VVVCSQLLDENLKDEYFEEIMEEYEDIRQDHYESLKERRYLPLSQAR
	KSGFQMDWLSEPHPVKPTFIGTQVFEDYDLQKLVDYIDWKPFFDV
	WQLRGKYPNRGFPKIFNDKTVGGEARKVYDDAHNMLNTLISQKKL
	RARGVVGFWPAQSIQDDIHLYAEAAVPQAAEPIATFYGLRQQAEKD
	SASTEPYYCLSDFIAPLHSGIRDYLGLFAVACFGVEELSKAYEDDGD
	DYSSIMVKALGDRLAEAFAEELHERVRRELWAYCGSEQLDVADLR
	RLRYKGIRPAPGYPSQPDHTEKLTMWRLADIEQSTGIRLTESLAMAP
	ASAVSGLYFSNLKSKYFAVGKISKDQVEDYALRKNISVAEVEKWLG
	PILGYDTD
132	MGAASVRAGARLVEVALCSFTVTCLEVMRRFLLLYATQQGQAKAI	MTRR
	AEEICEQAVVHGFSADLHCISESDKYDLKTETAPLVVVVSTTGTGDP
	PDTARKFVKEIQNQTLPVDFFAHLRYGLLGLGDSEYTYFCNGGKIID
	KRLQELGARHFYDTGHADDCVGLELVVEPWIAGLWPALRKHFRSS
	RGQEEISGALPVASPASSRTDLVKSELLHIESQVELLRFDDSGRKDSE
	VLKQNAVNSNQSNVVIEDFESSLTRSVPPLSQASLNIPGLPPEYLQVH
	LQESLGQEESQVSVTSADPVFQVPISKAVQLTTNDAIKTTLLVELDIS
	NTDFSYQPGDAFSVICPNSDSEVQSLLQRLQLEDKREHCVLLKIKAD
	TKKKGATLPQHIPAGCSLQFIFTWCLEIRAIPKKAFLRALVDYTSDSA
	EKRRLQELCSKQGAADYSRFVRDACACLLDLLLAFPSCQPPLSLLLE
	HLPKLQPRPYSCASSSLFHPGKLHFVFNIVEFLSTATTEVLRKGVCTG
	WLALLVASVLQPNIHASHEDSGKALAPKISISPRTTNSFHLPDDPSIPI
	IMVGPGTGIAPFIGFLQHREKLQEQHPDGNFGAMWLFFGCRHKDRD
	YLFRKELRHFLKHGILTHLKVSFSRDAPVGEEEAPAKYVQDNIQLH
	GQQVARILLQENGHIYVCGDAKNMAKDVHDALVQIISKEVGVEKL
	EAMKTLATLKEEKRYLQDIWS
133	MPEQERQITAREGASRKILSKLSLPTRAWEPAMKKSFAFDNVGYEG	ATP7B
	GLDGLGPSSQVATSTVRILGMTCQSCVKSIEDRISNLKGIISMKVSLE
	QGSATVKYVPSVVCLQQVCHQIGDMGFEASIAEGKAASWPSRSLPA
	QEAVVKLRVEGMTCQSCVSSIEGKVRKLQGVVRVKVSLSNQEAVIT
	YQPYLIQPEDLRDHVNDMGFEAAIKSKVAPLSLGPIDIERLQSTNPK
	RPLSSANQNFNNSETLGHQGSHVVTLQLRIDGMHCKSCVLNIEENIG
	QLLGVQSIQVSLENKTAQVKYDPSCTSPVALQRAIEALPPGNFKVSL
	PDGAEGSGTDHRSSSSHSPGSPPRNQVQGTCSTTLIAIAGMTCASCV
	HSIEGMISQLEGVQQISVSLAEGTATVLYNPSVISPEELRAAIEDMGF
	EASVVSESCSTNPLGNHSAGNSMVQTTDGTPTSVQEVAPHTGRLPA
	NHAPDILAKSPQSTRAVAPQKCFLQIKGMTCASCVSNIERNLQKEAG
	VLSVLVALMAGKAEIKYDPEVIQPLEIAQFIQDLGFEAAVMEDYAG
	SDGNIELTITGMTCASCVHNIESKLTRTNGITYASVALATSKALVKF
	DPEIIGPRDIIKIIEEIGFHASLAQRNPNAHHLDHKMEIKQWKKSFLCS
	LVFGIPVMALMIYMLIPSNEPHQSMVLDHNIIPGLSILNLIFFILCTFV
	QLLGGWYFYVQAYKSLRHRSANMDVLIVLATSIAYVYSLVILVVA
	VAEKAERSPVTFFDTPPMLFVFIALGRWLEHLAKSKTSEALAKLMS
	LQATEATVVTLGEDNLIIREEQVPMELVQRGDIVKVVPGGKFPVDG
	KVLEGNTMADESLITGEAMPVTKKPGSTVIAGSINAHGSVLIKATHV
	GNDTTLAQIVKLVEEAQMSKAPIQQLADRFSGYFVPFIIIMSTLTLVV
	WIVIGFIDFGVVQRYFPNPNKHISQTEVIIRFAFQTSITVLCIACPCSLG
	LATPTAVMVGTGVAAQNGILIKGGKPLEMAHKIKTVMFDKTGTITH
	GVPRVMRVLLLGDVATLPLRKVLAVVGTAEASSEHPLGVAVTKYC
	KEELGTETLGYCTDFQAVPGCGIGCKVSNVEGILAHSERPLSAPASH
	LNEAGSLPAEKDAVPQTFSVLIGNREWLRRNGLTISSDVSDAMTDH
	EMKGQTAILVAIDGVLCGMIAIADAVKQEAALAVHTLQSMGVDVV
	LITGDNRKTARAIATQVGINKVFAEVLPSHKVAKVQELQNKGKKVA
	MVGDGVNDSPALAQADMGVAIGTGTDVAIEAADVVLIRNDLLDVV
	ASIHLSKRTVRRIRINLVLALIYNLVGIPIAAGVFMPIGIVLQPWMGS
	AAMAASSVSVVLSSLQLKCYKKPDLERYEAQAHGHMKPLTASQVS
	VHIGMDDRWRDSPRATPWDQVSYVSQVSLSSLTSDKPSRHSAAAD
	DDGDKWSLLLNGRDEEQYI
134	MATRSPGVVISDDEPGYDLDLFCIPNHYAEDLERVFIPHGLIMDRTE	HPRT1
	RLARDVMKEMGGHHIVALCVLKGGYKFFADLLDYIKALNRNSDRS
	IPMTVDFIRLKSYCNDQSTGDIKVIGGDDLSTLTGKNVLIVEDIIDTG
	KTMQTLLSLVRQYNPKMVKVASLLVKRTPRSVGYKPDFVGFEIPDK
	FVVGYALDYNEYFRDLNHVCVISETGKAKYKA
135	MGEPGQSPSPRSSHGSPPTLSTLTLLLLLCGHAHSQCKILRCNAEYVS	HJV
	STLSLRGGGSSGALRGGGGGGRGGGVGSGGLCRALRSYALCTRRT
	ARTCRGDLAFHSAVHGIEDLMIQHNCSRQGPTAPPPPRGPALPGAGS
	GLPAPDPCDYEGRFSRLHGRPPGFLHCASFGDPHVRSFHHHFHTCR
	VQGAWPLLDNDFLFVQATSSPMALGANATATRKLTIIFKNMQECID
	QKVYQAEVDNLPVAFEDGSINGGDRPGGSSLSIQTANPGNHVEIQA
	AYIGTTIIIRQTAGQLSFSIKVAEDVAMAFSAEQDLQLCVGGCPPSQR
	LSRSERNRRGAITIDTARRLCKEGLPVEDAYFHSCVFDVLISGDPNFT
	VAAQAALEDARAFLPDLEKLHLFPSDAGVPLSSATLLAPLLSGLFVL
	WLCIQ
136	MALSSQIWAACLLLLLLLASLTSGSVFPQQTGQLAELQPQDRAGAR	HAMP
	ASWMPMFQRRRRRDTHFPICIFCCGCCHRSKCGMCCKT
137	MRSPRTRGRSGRPLSLLLALLCALRAKVCGASGQFELEILSMQNVN	JAG1
	GELQNGNCCGGARNPGDRKCTRDECDTYFKVCLKEYQSRVTAGGP
	CSFGSGSTPVIGGNTFNLKASRGNDRNRIVLPFSFAWPRSYTLLVEA
	WDSSNDTVQPDSIIEKASHSGMINPSRQWQTLKQNTGVAHFEYQIR
	VTCDDYYYGFGCNKFCRPRDDFFGHYACDQNGNKTCMEGWMGPE
	CNRAICRQGCSPKHGSCKLPGDCRCQYGWQGLYCDKCIPHPGCVH
	GICNEPWQCLCETNWGGQLCDKDLNYCGTHQPCLNGGTCSNTGPD
	KYQCSCPEGYSGPNCEIAEHACLSDPCHNRGSCKETSLGFECECSPG
	WTGPTCSTNIDDCSPNNCSHGGTCQDLVNGFKCVCPPQWTGKTCQ
	LDANECEAKPCVNAKSCKNLIASYYCDCLPGWMGQNCDININDCL
	GQCQNDASCRDLVNGYRCICPPGYAGDHCERDIDECASNPCLNGG
	HCQNEINRFQCLCPTGFSGNLCQLDIDYCEPNPCQNGAQCYNRASD
	YFCKCPEDYEGKNCSHLKDHCRTTPCEVIDSCTVAMASNDTPEGVR
	YISSNVCGPHGKCKSQSGGKFTCDCNKGFTGTYCHENINDCESNPC
	RNGGTCIDGVNSYKCICSDGWEGAYCETNINDCSQNPCHNGGTCRD
	LVNDFYCDCKNGWKGKTCHSRDSQCDEATCNNGGTCYDEGDAFK
	CMCPGGWEGTTCNIARNSSCLPNPCHNGGTCVVNGESFTCVCKEG
	WEGPICAQNTNDCSPHPCYNSGTCVDGDNWYRCECAPGFAGPDCR
	ININECQSSPCAFGATCVDEINGYRCVCPPGHSGAKCQEVSGRPCIT
	MGSVIPDGAKWDDDCNTCQCLNGRIACSKVWCGPRPCLLHKGHSE
	CPSGQSCIPILDDQCFVHPCTGVGECRSSSLQPVKTKCTSDSYYQDN
	CANITFTFNKEMMSPGLTTEHICSELRNLNILKNVSAEYSIYIACEPSP
	SANNEIHVAISAEDIRDDGNPIKEITDKIIDLVSKRDGNSSLIAAVAEV
	RVQRRPLKNRTDFLVPLLSSVLTVAWICCLVTAFYWCLRKRRKPGS
	HTHSASEDNTTNNVREQLNQIKNPIEKHGANTVPIKDYENKNSKMS
	KIRTHNSEVEEDDMDKHQQKARFAKQPAYTLVDREEKPPNGTPTK
	HPNWTNKQDNRDLESAQSLNRMEYIV
138	MASHRLLLLCLAGLVFVSEAGPTGTGESKCPLMVKVLDAVRGSPAI	TTR
	NVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVE
	IDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTT
	AVVTNPKE
139	MASHKLLVTPPKALLKPLSIPNQLLLGPGPSNLPPRIMAAGGLQMIG	AGXT
	SMSKDMYQIMDEIKEGIQYVFQTRNPLTLVISGSGHCALEAALVNV
	LEPGDSFLVGANGIWGQRAVDIGERIGARVHPMTKDPGGHYTLQEV
	EEGLAQHKPVLLFLTHGESSTGVLQPLDGFGELCHRYKCLLLVDSV
	ASLGGTPLYMDRQGIDILYSGSQKALNAPPGTSLISFSDKAKKKMYS
	RKTKPFSFYLDIKWLANFWGCDDQPRMYHHTIPVISLYSLRESLALI
	AEQGLENSWRQHREAAAYLHGRLQALGLQLFVKDPALRLPTVTTV
	AVPAGYDWRDIVSYVIDHFDIEIMGGLGPSTGKVLRIGLLGCNATRE
	NVDRVTEALRAALQHCPKKKL
140	MKMRFLGLVVCLVLWTLHSEGSGGKLTAVDPETNMNVSEIISYWG	LIPA
	FPSEEYLVETEDGYILCLNRIPHGRKNHSDKGPKPVVFLQHGLLADS
	SNWVTNLANSSLGFILADAGFDVWMGNSRGNTWSRKHKTLSVSQD
	EFWAFSYDEMAKYDLPASINFILNKTGQEQVYYVGHSQGTTIGFIAF
	SQIPELAKRIKMFFALGPVASVAFCTSPMAKLGRLPDHLIKDLFGDK
	EFLPQSAFLKWLGTHVCTHVILKELCGNLCFLLCGFNERNLNMSRV
	DVYTTHSPAGTSVQNMLHWSQAVKFQKFQAFDWGSSAKNYFHYN
	QSYPPTYNVKDMLVPTAVWSGGHDWLADVYDVNILLTQITNLVFH
	ESIPEWEHLDFIWGLDAPWRLYNKIINLMRKYQ
141	MASRLTLLTLLLLLLAGDRASSNPNATSSSSQDPESLQDRGEGKVAT	SERPING1
	TVISKMLFVEPILEVSSLPTTNSTTNSATKITANTTDEPTTQPTTEPTT
	QPTIQPTQPTTQLPTDSPTQPTTGSFCPGPVTLCSDLESHSTEAVLGD
	ALVDFSLKLYHAFSAMKKVETNMAFSPFSIASLLTQVLLGAGENTK
	TNLESILSYPKDFTCVHQALKGFTTKGVTSVSQIFHSPDLAIRDTFVN
	ASRTLYSSSPRVLSNNSDANLELINTWVAKNTNNKISRLLDSLPSDT
	RLVLLNAIYLSAKWKTTFDPKKTRMEPFHFKNSVIKVPMMNSKKYP
	VAHFIDQTLKAKVGQLQLSHNLSLVILVPQNLKHRLEDMEQALSPS
	VFKAIMEKLEMSKFQPTLLTLPRIKVTTSQDMLSIMEKLEFFDFSYD
	LNLCGLTEDPDLQVSAMQHQTVLELTETGVEAAAASAISVARTLLV
	FEVQQPFLFVLWDQQHKFPVFMGRVYDPRA
142	MGSPLRFDGRVVLVTGAGAGLGRAYALAFAERGALVVVNDLGGD	HSD17B4
	FKGVGKGSLAADKVVEEIRRRGGKAVANYDSVEEGEKVVKTALDA
	FGRIDVVVNNAGILRDRSFARISDEDWDIIHRVHLRGSFQVTRAAWE
	HMKKQKYGRIIMTSSASGIYGNFGQANYSAAKLGLLGLANSLAIEG
	RKSNIHCNTIAPNAGSRMTQTVMPEDLVEALKPEYVAPLVLWLCHE
	SCEENGGLFEVGAGWIGKLRWERTLGAIVRQKNHPMTPEAVKANW
	KKICDFENASKPQSIQESTGSIIEVLSKIDSEGGVSANHTSRATSTATS
	GFAGAIGQKLPPFSYAYTELEAIMYALGVGASIKDPKDLKFIYEGSS
	DFSCLPTFGVIIGQKSMMGGGLAEIPGLSINFAKVLHGEQYLELYKP
	LPRAGKLKCEAVVADVLDKGSGVVIIMDVYSYSEKELICHNQFSLF
	LVGSGGFGGKRTSDKVKVAVAIPNRPPDAVLTDTTSLNQAALYRLS
	GDWNPLHIDPNFASLAGFDKPILHGLCTFGFSARRVLQQFADNDVS
	RFKAIKARFAKPVYPGQTLQTEMWKEGNRIHFQTKVQETGDIVISN
	AYVDLAPTSGTSAKTPSEGGKLQSTFVFEEIGRRLKDIGPEVVKKVN
	AVFEWHITKGGNIGAKWTIDLKSGSGKVYQGPAKGAADTTIILSDE
	DFMEVVLGKLDPQKAFFSGRLKARGNIMLSQKLQMILKDYAKL
143	MEANGLGPQGFPELKNDTFLRAAWGEETDYTPVWCMRQAGRYLP	UROD
	EFRETRAAQDFFSTCRSPEACCELTLQPLRRFPLDAAIIFSDILVVPQA
	LGMEVTMVPGKGPSFPEPLREEQDLERLRDPEVVASELGYVFQAITL
	TRQRLAGRVPLIGFAGAPWTLMTYMVEGGGSSTMAQAKRWLYQR
	PQASHQLLRILTDALVPYLVGQVVAGAQALQLFESHAGHLGPQLFN
	KFALPYIRDVAKQVKARLREAGLAPVPMIIFAKDGHFALEELAQAG
	YEVVGLDWTVAPKKARECVGKTVTLQGNLDPCALYASEEEIGQLV
	KQMLDDFGPHRYIANLGHGLYPDMDPEHVGAFVDAVHKHSRLLR
	QN
144	MGPRARPALLLLMLLQTAVLQGRLLRSHSLHYLFMGASEQDLGLSL	HFE
	FEALGYVDDQLFVFYDHESRRVEPRTPWVSSRISSQMWLQLSQSLK
	GWDHMFTVDFWTIMENHNHSKESHTLQVILGCEMQEDNSTEGYW
	KYGYDGQDHLEFCPDTLDWRAAEPRAWPTKLEWERHKIRARQNR
	AYLERDCPAQLQQLLELGRGVLDQQVPPLVKVTHHVTSSVTTLRCR
	ALNYYPQNITMKWLKDKQPMDAKEFEPKDVLPNGDGTYQGWITL
	AVPPGEEQRYTCQVEHPGLDQPLIVIWEPSPSGTLVIGVISGIAVFVVI
	LFIGILFIILRKRQGSRGAMGHYVLAERE
145	MESKALLVLTLAVWLQSLTASRGGVAAADQRRDFIDIESKFALRTP	LPL
	EDTAEDTCHLIPGVAESVATCHFNHSSKTFMVIHGWTVTGMYESW
	VPKLVAALYKREPDSNVIVVDWLSRAQEHYPVSAGYTKLVGQDVA
	RFINWMEEEFNYPLDNVHLLGYSLGAHAAGIAGSLTNKKVNRITGL
	DPAGPNFEYAEAPSRLSPDDADFVDVLHTFTRGSPGRSIGIQKPVGH
	VDIYPNGGTFQPGCNIGEAIRVIAERGLGDVDQLVKCSHERSIHLFID
	SLLNEENPSKAYRCSSKEAFEKGLCLSCRKNRCNNLGYEINKVRAK
	RSSKMYLKTRSQMPYKVFHYQVKIHFSGTESETHTNQAFEISLYGT
	VAESENIPFTLPEVSTNKTYSFLIYTEVDIGELLMLKLKWKSDSYFS
	WSDWWSSPGFAIQKIRVKAGETQKKVIFCSREKVSHLQKGKAPAVF
	VKCHDKSLNKKSG
146	MRPVRLMKVFVTRRIPAEGRVALARAADCEVEQWDSDEPIPAKELE	GRHPR
	RGVAGAHGLLCLLSDHVDKRILDAAGANLKVISTMSVGIDHLALDE
	IKKRGIRVGYTPDVLTDTTAELAVSLLLTTCRRLPEAIEEVKNGGWT
	SWKPLWLCGYGLTQSTVGIIGLGRIGQAIARRLKPFGVQRFLYTGRQ
	PRPEEAAEFQAEFVSTPELAAQSDFIVVACSLTPATEGLCNKDFFQK
	MKETAVFINISRGDVVNQDDLYQALASGKIAAAGLDVTSPEPLPTN
	HPLLTLKNCVILPHIGSATHRTRNTMSLLAANNLLAGLRGEPMPSEL
	KL
147	MLGPQVWSSVRQGLSRSLSRNVGVWASGEGKKVDIAGIYPPVTTPF	HOGA1
	TATAEVDYGKLEENLHKLGTFPFRGFVVQGSNGEFPFLTSSERLEVV
	SRVRQAMPKNRLLLAGSGCESTQATVEMTVSMAQVGADAAMVVT
	PCYYRGRMSSAALIHHYTKVADLSPIPVVLYSVPANTGLDLPVDAV
	VTLSQHPNIVGMKDSGGDVTRIGLIVHKTRKQDFQVLAGSAGFLMA
	SYALGAVGGVCALANVLGAQVCQLERLCCTGQWEDAQKLQHRLIE
	PNAAVTRRFGIPGLKKIMDWFGYYGGPCRAPLQELSPAEEEALRMD
	FTSNGWL
148	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYK	LDLR
	WVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRC
	DGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCL
	DGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWP
	QRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSD
	EENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVN
	VTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNEC
	LDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTC
	SQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVR
	KMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLD
	RAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADT
	KGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLN
	GVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNR
	KTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLA
	ENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINP
	HSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTA
	VRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNE
	KKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVY
	QKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA
149	MLWSGCRRFGARLGCLPGGLRVLVQTGHRS	ACAD8
	LTSCIDPSMGLNEEQKEFQKVAFDFAAREM
	APNMAEWDQKELFPVDVMRKAAQLGFGGVY
	IQTDVGGSGLSRLDTSVIFEALATGCTSTT
	AYISIHNMCAWMIDSFGNEE
	QRHKFCPPLCTMEKFASYCLTEPGSGSDAA
	SLLTSAKKQGDHYILNGSKAFISGAGESDI
	YVVMCRTGGPGPKGISCIVVEKGTPGLSFG
	KKEKKVGWNSQPTRAVIFEDCAVPVANRIG
	SEGQGFLIAVRGLNGGRINIASCSLGAAHA
	SVILTRDHLNVRKQFGEPLASNQYLQFTLADMATRLVAARLMVRN
	AAVALQEERKDAVALCSMAKLFATDECFAICNQALQMHGGYGYL
	KDYAVQQYVRDSRVHQILEGSNEVMRILISRSLLQE
150	MEGLAVRLLRGSRLLRRNFLTCLSSWKIPPHVSKSSQSEALLNITNN	ACADSB
	GIHFAPLQTFTDEEMMIKSSVKKFAQEQIAPLVSTMDENSKMEKSVI
	QGLFQQGLMGIEVDPEYGGTGASFLSTVLVIEELAKVDASVAVFCEI
	QNTLINTLIRKHGTEEQKATYLPQLTTEKVGSFCLSEAGAGSDSFAL
	KTRADKEGDYYVLNGSKMWISSAEHAGLFLVMANVDPTIGYKGIT
	SFLVDRDTPGLHIGKPENKLGLRASSTCPLTFENVKVPEANILGQIGH
	GYKYAIGSLNEGRIGIAAQMLGLAQGCFDYTIPYIKERIQFGKRLFDF
	QGLQHQVAHVATQLEAARLLTYNAARLLEAGKPFIKEASMAKYYA
	SEIAGQTTSKCIEWMGGVGYTKDYPVEKYFRDAKIGTIYEGASNIQL
	NTIAKHIDAEY
151	MAVLAALLRSGARSRSPLLRRLVQEIRYVERSYVSKPTLKEVVIVSA	ACAT1
	TRTPIGSFLGSLSLLPATKLGSIAIQGAIEKAGIPKEEVKEAYMGNVL
	QGGEGQAPTRQAVLGAGLPISTPCTTINKVCASGMKAIMMASQSLM
	CGHQDVMVAGGMESMSNVPYVMNRGSTPYGGVKLEDLIVKDGLT
	DVYNKIHMGSCAENTAKKLNIARNEQDAYAINSYTRSKAAWEAGK
	FGNEVIPVTVTVKGQPDVVVKEDEEYKRVDFSKVPKLKTVFQKEN
	GTVTAANASTLNDGAAALVLMTADAAKRLNVTPLARIVAFADAAV
	EPIDFPIAPVYAASMVLKDVGLKKEDIAMWEVNEAFSLVVLANIKM
	LEIDPQKVNINGGAVSLGHPIGMSGARIVGHLTHALKQGEYGLASIC
	NGGGGASAMLIQKL
152	MLPHVVLTFRRLGCALASCRLAPARHRGSGLLHTAPVARSDRSAPV	ACSF3
	FTRALAFGDRIALDQHGRHTYRELYSRSLRLSQEICRLCGCVGGDLR
	EERVSFLCANDASYVVAQWASWMSGGVAVPLYRKHPAAQLEYVI
	CDSQSSVVLASQEYLELLSPVVRKLGVPLLPLTPAIYTGAVEEPAEV
	PVPEQGWRNKGAMIIYTSGTTGRPKGVLSTHQNIRAVVTGLVHKW
	AWTKDDVILHVLPLHHVHGVVNALLCPLWVGATCVMMPEFSPQQ
	VWEKFLSSETPRINVFMAVPTIYTKLMEYYDRHFTQPHAQDFLRAV
	CEEKIRLMVSGSAALPLPVLEKWKNITGHTLLERYGMTEIGMALSG
	PLTTAVRLPGSVGTPLPGVQVRIVSENPQREACSYTIHAEGDERGTK
	VTPGFEEKEGELLVRGPSVFREYWNKPEETKSAFTLDGWFKTGDTV
	VFKDGQYWIRGRTSVDIIKTGGYKVSALEVEWHLLAHPSITDVAVIG
	VPDMTWGQRVTAVVTLREGHSLSHRELKEWARNVLAPYAVPSELV
	LVEEIPRNQMGKIDKKALIRHFHPS
153	MTSCHIAEEHIQKVAIFGGTHGNELTGVFLVKHWLENGAEIQRTGLE	ASPA
	VKPFITNPRAVKKCTRYIDCDLNRIFDLENLGKKMSEDLPYEVRRAQ
	EINHLFGPKDSEDSYDIIFDLHNTTSNMGCTLILEDSRNNFLIQMFHYI
	KTSLAPLPCYVYLIEHPSLKYATTRSIAKYPVGIEVGPQPQGVLRADI
	LDQMRKMIKHALDFIHHFNEGKEFPPCAIEVYKIIEKVDYPRDENGE
	IA
	AIIHPNLQDQDWKPLHPGDPMFLTLDGKTIPLGGDCTVYPVFVNEA
	AYYEKKEAFAKTTKLTLNAKSIRCCLH
154	MAAAVAAAPGALGSLHAGGARLVAACSAWLCPGLRLPGSLAGRR	AUH
	AGPAIWAQGWVPAAGGPAPKRGYSSEMKTEDELRVRHLEEENRGI
	VVLGINRAYGKNSLSKNLIKMLSKAVDALKSDKKVRTIIIRSEVPGIF
	CAGADLKERAKMSSSEVGPFVSKIRAVINDIANLPVPTIAAIDGLAL
	GGGLELALACDIRVAASSAKMGLVETKLAIIPGGGGTQRLPRAIGMS
	LAKELIFSARVLDGKEAKAVGLISHVLEQNQEGDAAYRKALDLARE
	FLPQGPVAMRVAKLAINQGMEVDLVTGLAIEEACYAQTIPTKDRLE
	GLLAFKEKRPPRYKGE
155	MASTVVAVGLTIAAAGFAGRYVLQAMKHMEPQVKQVFQSLPKSAF	DNAJC19
	SGGYYRGGFEPKMTKREAALILGVSPTANKGKIRDAHRRIMLLNHP
	DKGGSPYIAAKINEAKDLLEGQAKK
156	MAEAVLRVARRQLSQRGGSGAPILLRQMFEPVSCTFTYLLGDRESR	ETHE1
	EAVLIDPVLETAPRDAQLIKELGLRLLYAVNTHCHADHITGSGLLRS
	LLPGCQSVISRLSGAQADLHIEDGDSIRFGRFALETRASPGHTPGCVT
	FVLNDHSMAFTGDALLIRGCGRTDFQQGCAKTLYHSVHEKIFTLPG
	DCLIYPAHDYHGFTVSTVEEERTLNPRLTLSCEEFVKIMGNLNLPKP
	QQIDFAVPANMRCGVQTPTA
157	MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAIS	FBP1
	SAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFA
	TCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGI
	YRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVN
	CFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYARDFDPAVTEYIQR
	KKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGK
	LRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGS
	PDDVLEFLKVYEKHSAQ
158	MSQLVECVPNFSEGKNQEVIDAISGAITQTPGCVLLDVDAGPSTNRT	FTCD
	VYTFVGPPECVVEGALNAARVASRLIDMSRHQGEHPRMGALDVCP
	FIPVRGVSVDECVLCAQAFGQRLAEELDVPVYLYGEAARMDSRRTL
	PAIRAGEYEALPKKLQQADWAPDFGPSSFVPSWGATATGARKFLIA
	FNINLLGTKEQAHRIALNLREQGRGKDQPGRLKKVQGIGWYLDEKN
	LAQVSTNLLDFEVTALHTVYEETCREAQELSLPVVGSQLVGLVPLK
	ALLDAAAFYCEKENLFILEEEQRI
	RLVVSRLGLDSLCPFSPKERIIEYLVPERGPERGLGSKSLRAFVGEVG
	ARSAAPGGGSVAAAAAAMGAALGSMVGLMTYGRRQFQSLDTTMR
	RLIPPFREASAKLTTLVDADAEAFTAYLEAMRLPKNTPEEKDRRTA
	ALQEGLRRAVSVPLTLAETVASLWPALQELARCGNLACRSDLQVA
	AKALEMGVFGAYFNVLINLRDITDEAFKDQIHHRVSSLLQEAKTQA
	ALVLDCLETRQE
159	MATNWGSLLQDKQQLEELARQAVDRALAEGVLLRTSQEPTSSEVV	GSS
	SYAPFTLFPSLVPSALLEQAYAVQMDFNLLVDAVSQNAAFLEQTLS
	STIKQDDFTARLFDIHKQVLKEGIAQTVFLGLNRSDYMFQRSADGSP
	ALKQIEINTISASFGGLASRTPAVHRHVLSVLSKTKEAGKILSNNPSK
	GLALGIAKAWELYGSPNALVLLIAQEKERNIFDQRAIENELLARNIH
	VIRRTFEDISEKGSLDQDRRLFVDGQEIAVVYFRDGYMPRQYSLQN
	WEARLLLERSHAAKCPDIATQLAGTKKVQQELSRPGMLEMLLPGQ
	PEAVARLRATFAGLYSLDVGEEGDQAIAEALAAPSRFVLKPQREGG
	GNNLYGEEMVQALKQLKDSEERASYILMEKIEPEPFENCLLRPGSPA
	RVVQCISELGIFGVYVRQEKTLVMNKHVGHLLRTKAIEHADGGVA
	AGVAVLDNPYPV
160	MGQREMWRLMSRFNAFKRTNTILHHLRMSKHTDAAEEVLLEKKG	HIBCH
	CTGVITLNRPKFLNALTLNMIRQIYPQLKKWEQDPETFLIIIKGAGGK
	AFCAGGDIRVISEAEKAKQKIAPVFFREEYMLNNAVGSCQKPYVALI
	HGITMGGGVGLSVHGQFRVATEKCLFAMPETAIGLFPDVGGGYFLP
	RLQGKLGYFLALTGFRLKGRDVYRAGIATHFVDSEKLAMLEEDLLA
	LKSPSKENIASVLENYHTESKIDRDKSFILEEHMDKINSCFSANTVEEI
	IENLQQDGSSFALEQLKVINKMSPTSLKITLRQLMEGSSKTLQEVLT
	MEYRLSQACMRGHDFHEGVRAVLIDKDQSPKWKPADLKEVTEEDL
	NNHFKSLGSSDLKF
161	MAGYLRVVRSLCRASGSRPAWAPAALTAPTSQEQPRRHYADKRIK	IDH2
	VAKPVVEMDGDEMTRIIWQFIKEKLILPHVDIQLKYFDLGLPNRDQT
	DDQVTIDSALATQKYSVAVKCATITPDEARVEEFKLKKMWKSPNG
	TIRNILGGTVFREPIICKNIPRLVPGWTKPITIGRHAHGDQYKATDFV
	ADRAGTFKMVFTPKDGSGVKEWEVYNFPAGGVGMGMYNTDESIS
	GFAHSCFQYAIQKKWPLYMSTKNTILKAYDGRFKDIFQEIFDKHYK
	TDFDKNKIWYEHRLIDDMVAQVLKSSGGFVWACKNYDGDVQSDIL
	AQGFGSLGLMTSVLVCPDGKTIEAEAAHGTVTRHYREHQKGRPTST
	NPIASIFAWTRGLEHRGKLDGNQDLIRFAQMLEKVCVETVESGAMT
	KDLAGCIHGLSNVKLNEHFLNTTDFLDTIKSNLDRALGRQ
162	MVPALRYLVGACGRARGLFAGGSPGACGFASGRPRPLCGGSRSAST	L2HGDH
	SSFDIVIVGGGIVGLASARALILRHPSLSIGVLEKEKDLAVHQTGHNS
	GVIHSGIYYKPESLKAKLCVQGAALLYEYCQQKGISYKQCGKLIVA
	VEQEEIPRLQALYEKGLQNGVPGLRLIQQEDIKKKEPYCRGLMAIDC
	PHTGIVDYRQVALSFAQDFQEAGGSVLTNFEVKGIEMAKESPSRSID
	GMQYPIVIKNTKGEEIRCQYVVTCAGLYSDRISELSGCTPDPRIVPFR
	GDYLLLKPEKCYLVKGNIYPVPDSRFPFLGVHFTPRMDGSIWLGPN
	AVLAFKREGYRPFDFSATDVMDIIINSGLIKLASQNFSYGVTEMYKA
	CFLGATVKYLQKFIPEITISDILRGPAGVRAQALDRDGNLVEDFVFD
	AGVGDIGNRILHVRNAPSPAATSSIAISGMIADEVQQRFEL
163	MRGFGPGLTARRLLPLRLPPRPPGPRLASGQAAGALERAMDELLRR	MLYCD
	AVPPTPAYELREKTPAPAEGQCADFVSFYGGLAETAQRAELLGRLA
	RGFGVDHGQVAEQSAGVLHLRQQQREAAVLLQAEDRLRYALVPR
	YRGLFHHISKLDGGVRFLVQLRADLLEAQALKLVEGPDVREMNGV
	LKGMLSEWFSSGFLNLERVTWHSPCEVLQKISEAEAVHPVKNWMD
	MKRRVGPYRRCYFFSHCSTPGEPLVVLHVALTGDISSNIQAIVKEHP
	PSETEEKNKITAAIFYSISLTQQGLQG
	VELGTFLIKRVVKELQREFPHLGVFSSLSPIPGFTKWLLGLLNSQTKE
	HGRNELFTDSECKEISEITGGPINETLKLLLSSSEWVQSEKLVRALQT
	PLMRLCAWYLYGEKHRGYALNPVANFHLQNGAVLWRINWMADV
	SLRGITGSCGLMANYRYFLEETGPNSTSYLGSKIIKASEQVLSLVAQF
	QKNSKL
164	MVVGAFPMAKLLYLGIRQVSKPLANRIKEAARRSEFFKTYICLPPAQ	OPA3
	LYHWVEMRTKMRIMGFRGTVIKPLNEEAAAELGAELLGEATIFIVG
	GGCLVLEYWRHQAQQRHKEEEQRAAWNALRDEVGHLALALEALQ
	AQVQAAPPQGALEELRTELQEVRAQLCNPGRSASHAVPASKK
165	MGSPEGRFHFAIDRGGTFTDVFAQCPGGHVRVLKLLSEDPANYADA	OPLAH
	PTEGIRRILEQEAGMLLPRDQPLDSSHIASIRMGTTVATNALLERKGE
	RVALLVTRGFRDLLHIGTQARGDLFDLAVPMPEVLYEEVLEVDERV
	VLHRGEAGTGTPVKGRTGDLLEVQQPVDLGALRGKLEGLLSRGIRS
	LAVVLMHSYTWAQHEQQVGVLARELGFTHVSLSSEAMPMVRIVPR
	GHTACADAYLTPAIQRYVQGFCRGFQGQLKDVQVLFMRSDGGLAP
	MDTFSGSSAVLSGPAGGVVGYSATTYQQEGGQPVIGFDMGGTSTD
	VSRYAGEFEHVFEASTAGVTLQAPQLDINTVAAGGGSRLFFRSGLF
	VVGPESAGAHPGPACYRKGGPVTVTDANLVLGRLLPASFPCIFGPG
	ENQPLSPEASRKALEAVATEVNSFLTNGPCPASPLSLEEVAMGFVRV
	ANEAMCRPIRALTQARGHDPSAHVLACFGGAGGQHACAIARALGM
	DTVHIHRHSGLLSALGLALADVVHEAQEPCSLLYAPETFVQLDQRL
	SRLEEQCVDALQAQGFPRSQISTESFLHLRYQGTDCALMVSAHQHP
	ATA
	RSPRAGDFGAAFVERYMREFGFVIPERPVVVDDVRVRGTGRSGLRL
	EDAPKAQTGPPRVDKMTQCYFEGGYQETPVYLLAELGYGHKLHGP
	CLIIDSNSTILVEPGCQAEVTKTGDICISVGAEVPGTVGPQLDPIQLSIF
	SHRFMSIAEQMGRILQRTAISTNIKERLDFSCALFGPDGGLVSNAPHI
	PVHLGAMQETVQFQIQHLGADLHPGDVLLSNHPSAGGSHLPDLTVI
	TPVFWPGQTRPVFYVASRGHHADIGGITPGSMPPHSTMLQQEGAVF
	LSFKLVQGGVFQEEAVTEALRAPGKVPNCSGTRNLHDNLSDLRAQ
	VAANQKGIQLVGELIGQYGLDVVQAYMGHIQANAELAVRDMLRAF
	GTSRQARGLPLEVSSEDHMDDGSPIRLRVQISLSQGSAVFDFSGTGP
	EVFGNLNAPRAVTLSALIYCLRCLVGRDIPLNQGCLAPVRVVIPRGSI
	LDPSPEAAVVGGNVLTSQRVVDVILGAFGACAASQGCMNNVTLGN
	AHMGYYETVAGGAGAGPSWHGRSGVHSHMTNTRITDPEILESRYP
	VILRRFELRRGSGGRGRFRGGDGVTRELLFREEALLSVLTERRAFRP
	YGLHGGEPGARGLNLLIRKNGRTVNLGGKTSVTVYPGDVFCLHTPG
	GGGYGDPEDPAPPPGSPPQALAFPEHGSVYEYRRAQEAV
166	MAALKLLSSGLRLCASARGSGATWYKGCVCSFSTSAHRHTKFYTD	OXCT1
	PVEAVKDIPDGATVLVGGFGLCGIPENLIDALLKTGVKGLTAVSNN
	AGVDNFGLGLLLRSKQIKRMVSSYVGENAEFERQYLSGELEVELTP
	QGTLAERIRAGGAGVPAFYTPTGYGTLVQEGGSPIKYNKDGSVAIA
	SKPREVREFNGQHFILEEAITGDFALVKAWKADRAGNVIFRKSARN
	FNLPMCKAAETTVVEVEEIVDIGAFAPEDIHIPQIYVHRLIKGEKYEK
	RIERLSIRKEGDGEAKSAKPGDDVRERIIKRAALEFEDGMYANLGIGI
	PLLASNFISPNITVHLQSENGVLGLGPYPRQHEADADLINAGKETVTI
	LPGASFFSSDESFAMIRGGHVDLTMLGAMQVSKYGDLANWMIPGK
	MVKGMGGAMDLVSSAKTKVVVTMEHSAKGNAHKIMEKCTLPLTG
	KQCVNRIITEKAVFDVDKKKGLTLIELWEGLTVDDVQKSTGCDFAV
	SPKLMPMQQIAN
167	MSRLLWRKVAGATVGPGPVPAPGRWVSSSVPASDPSDGQRRRQQQ	POLG
	QQQQQQQQQQPQQPQVLSSEGGQLRHNPLDIQMLSRGLHEQIFGQG
	GEMPGEAAVRRSVEHLQKHGLWGQPAVPLPDVELRLPPLYGDNLD
	QHFRLLAQKQSLPYLEAANLLLQAQLPPKPPAWAWAEGWTRYGPE
	GEAVPVAIPEERALVFDVEVCLAEGTCPTLAVAISPSAWYSWCSQR
	LVEERYSWTSQLSPADLIPLEVPTGASSPTQRDWQEQLVVGHNVSF
	DRAHIREQYLIQGSRMRFLDTMSMHMAISGLSSFQRSLWIAAKQGK
	HKVQPPTKQGQKSQRKARRGPAISSWDWLDISSVNSLAEVHRLYV
	GGPPLEKEPRELFVKGTMKDIRENFQDLMQYCAQDVWATHEVFQQ
	QLPLFLERCPHPVTLAGMLEMGVSYLPVNQNWERYLAEAQGTYEE
	LQREMKKSLMDLANDACQLLSGERYKEDPWLWDLEWDLQEFKQK
	KAKKVKKEPATASKLPIEGAGAPGDPMDQEDLGPCSEEEEFQQDV
	MARACLQKLKGTTELLPKRPQHLPGHPGWYRKLCPRLDDPAWTPG
	PSLLSLQMRVTPKLMALTWDGFPLHYSERHGWGYLVPGRRDNLAK
	LPTGTTLESAGVVCPYRAIESLYRKHCLEQGKQQLMPQEAGLAEEF
	LLTDNSAIWQTVEELDYLEVEAEAKMENLRAAVPGQPLALTARGG
	PKDTQPSYHHGNGPYNDVDIPGCWFFKLPHKDGNSCNVGSPFAKDF
	LPKMEDGTLQAGPGGASGPRALEINKMISFWRNAHKRISSQMVVW
	LPRSALPRAVIRHPDYDEEGLYGAILPQVVTAGTITRRAVEPTWLTA
	SNARPDRVGSELKAMVQAPPGYTLVGADVDSQELWIAAVLGDAHF
	AGMHGCTAFGWMTLQGRKSRGTDLHSKTATTVGISREHAKIFNYG
	RIYGAGQPFAERLLMQFNHRLTQQEAAEKAQQMYAATKGLRWYR
	LSDEGEWLVRELNLPVDRTEGGWISLQDLRKVQRETARKSQWKKW
	EVVAERAWKGGTESEMFNKLESIATSDIPRTPVLGCCISRALEPSAV
	QEEFMTSRVNWVVQSSAVDYLHLMLVAMKWLFEEFAIDGRFCISIH
	DEVRYLVREEDRYRAALALQITNLLTRCMFAYKLGLNDLPQSVAFF
	SAVDIDRCLRKEVTMDCKTPSNPTGMERRYGIPQGEALDIYQIIELT
	KGSLEKRSQPGP
168	MSTAALITLVRSGGNQVRRRVLLSSRLLQDDRRVTPTCHSSTSEPRC	PPM1K
	SRFDPDGSGSPATWDNFGIWDNRIDEPILLPPSIKYGKPIPKISLENVG
	CASQIGKRKENEDRFDFAQLTDEVLYFAVYDGHGGPAAADFCHTH
	MEKCIMDLLPKEKNLETLLTLAFLEIDKAFSSHARLSADATLLTSGT
	TATVALLRDGIELVVASVGDSRAILCRKGKPMKLTIDHTPERKDEKE
	RIKKCGGFVAWNSLGQPHVNGRLAMTRSIGDLDLKTSGVIAEPETK
	RIKLHHADDSFLVLTTDGINFMVNSQEICDFVNQCHDPNEAAHAVT
	EQAIQYGTEDNSTAVVVPFGAWGKYKNSEINFSFSRSFASSGRWA
169	MSLAAYCVICCRRIGTSTSPPKSGTHWRDIRNIIKFTGSLILGGSLFLT	SERAC1
	YEVLALKKAVTLDTQVVEREKMKSYIYVHTVSLDKGENHGIAWQA
	RKELHKAVRKVLATSAKILRNPFADPFSTVDIEDHECAVWLLLRKS
	KSDDKTTRLEAVREMSETHHWHDYQYRIIAQACDPKTLIGLARSEE
	SDLRFFLLPPPLPSLKEDSSTEEELRQLLASLPQTELDECIQYFTSLAL
	SESSQ
	SLAAQKGGLWCFGGNGLPYAESFGEVPSATVEMFCLEAIVKHSEIST
	HCDKIEANGGLQLLQRLYRLHKDCPKVQRNIMRVIGNMALNEHLH
	SSIVRSGWVSIMAEAMKSPHIMESSHAARILANLDRETVQEKYQDG
	VYVLHPQYRTSQPIKADVLFIHGLMGAAFKTWRQQDSEQAVIEKPM
	EDEDRYTTCWPKTWLAKDCPALRIISVEYDTSLSDWRARCPMERKS
	IAFRSNELLRKLRAAGVGDRPVVWISHSMGGLLVKKMLLEASTKPE
	MSTVINNTRGIIFYSVPHHGSRLAEYSVNIRYLLFPSLEVKELSKDSP
	ALKTLQDDFLEFAKDKNFQVLNFVETLPTYIGSMIKLHVVPVESADL
	GIGDLIPVDVNHLNICKPKKKDAFLYQRTLQFIREALAKDLEN
170	MPAPRAPRALAAAAPASGKAKLTHPGKAILAGGLAGGIEICITFPTE	SLC25A1
	YVKTQLQLDERSHPPRYRGIGDCVRQTVRSHGVLGLYRGLSSLLYG
	SIPKAAVRFGMFEFLSNHMRDAQGRLDSTRGLLCGLGAGVAEAVV
	VVCPMETIKVKFIHDQTSPNPKYRGFFHGVREIVREQGLKGTYQGLT
	ATVLKQGSNQAIRFFVMTSLRNWYRGDNPNKPMNPLITGVFGAIAG
	AASVFGNTPLDVIKTRMQGLEAHKYRNTWDCGLQILKKEGLKAFY
	KGTVPRLGRVCLDVAIVFVIYDEV
	VKLLNKVWKTD
171	MAASMFYGRLVAVATLRNHRPRTAQRAAAQVLGSSGLFNNHGLQ	SUCLA2
	VQQQQQRNLSLHEYMSMELLQEAGVSVPKGYVAKSPDEAYAIAKK
	LGSKDVVIKAQVLAGGRGKGTFESGLKGGVKIVFSPEEAKAVSSQM
	IGKKLFTKQTGEKGRICNQVLVCERKYPRREYYFAITMERSFQGPVL
	IGSSHGGVNIEDVAAESPEAIIKEPIDIEEGIKKEQALQLAQKMGFPPN
	IVESAAENMVKLYSLFLKYDATMIEINPMVEDSDGAVLCMDAKINF
	DSNSAYRQKKIFDLQDWTQEDERDKDAAKANLNYIGLDGNIGCLV
	NGAGLAMATMDIIKLHGGTPANFLDVGGGATVHQVTEAFKLITSDK
	KVLAILVNIFGGIMRCDVIAQGIVMAVKDLEIKIPVVVRLQGTRVDD
	AKALIADSGLKILACDDLDEAARMVVKLSEIVTLAKQAHVDVKFQL
	PI
172	MTATLAAAADIATMVSGSSGLAAARLLSRSFLLPQNGIRHCSYTAS	SUCLG1
	RQHLYVDKNTKIICQGFTGKQGTFHSQQALEYGTKLVGGTTPGKGG
	QTHLGLPVFNTVKEAKEQTGATASVIYVPPPFAAAAINEAIEAEIPLV
	VCITEGIPQQDMVRVKHKLLRQEKTRLIGPNCPGVINPGECKIGIMP
	GHIHKKGRIGIVSRSGTLTYEAVHQTTQVGLGQSLCVGIGGDPFNGT
	DFIDCLEIFLNDSATEGIILIGEIGGNAEENAAEFLKQHNSGPNSKPVV
	SFIAGLTAPPGRRMGHAGAIIAGGKGGAKEKISALQSAGVVVSMSP
	AQLGTTIYKEFEKRKML
173	MPLHVKWPFPAVPPLTWTLASSVVMGLVGTYSCFWTKYMNHLTV	TAZ
	HNREVLYELIEKRGPATPLITVSNHQSCMDDPHLWGILKLRHIWNLK
	LMRWTPAAADICFTKELHSHFFSLGKCVPVCRGAEFFQAENEGKGV
	LDTGRHMPGAGKRREKGDGVYQKGMDFILEKLNHGDWVHIFPEG
	KVNMSSEFLRFKWGIGRLIAECHLNPIILPLWHVGMNDVLPNSPPYF
	PRFGQKITVLIGKPFSALPVLERLRAENKSAVEMRKALTDFIQEEFQ
	HLKTQAEQLHNHLQPGR
174	MTVFFKTLRNHWKKTTAGLCLLTWGGHWLYGKHCDNLLRRAACQ	AGK
	EAQVFGNQLIPPNAQVKKATVFLNPAACKGKARTLFEKNAAPILHL
	SGMDVTIVKTDYEGQAKKLLELMENTDVIIVAGGDGTLQEVVTGV
	LRRTDEATFSKIPIGFIPLGETSSLSHTLFAESGNKVQHITDATLAIVK
	GETVPLDVLQIKGEKEQPVFAMTGLRWGSFRDAGVKVSKYWYLGP
	LKIKAAHFFSTLKEWPQTHQASISYTGPTERPPNEPEETPVQRPSLYR
	RILRRLASYWAQPQDALSQEVSPEVWKDVQLSTIELSITTRNNQLDP
	TSKEDFLNICIEPDTISKGDFITIGSRKVRNPKLHVEGTECLQASQCTL
	LIPEGAGGSFSIDSEEYEAMPVEVKLLPRKLQFFCDPRKREQMLTSPT
	Q
175	MLGSLVLRRKALAPRLLLRLLRSPTLRGHGGASGRNVTTGSLGEPQ	CLPB
	WLRVATGGRPGTSPALFSGRGAATGGRQGGRFDTKCLAAATWGRL
	PGPEETLPGQDSWNGVPSRAGLGMCALAAALVVHCYSKSPSNKDA
	ALLEAARANNMQEVSRLLSEGADVNAKHRLGWTALMVAAINRNN
	SVVQVLLAAGADPNLGDDFSSVYKTAKEQGIHSLEDGGQDGASRHI
	TNQWTSALEFRRWLGLPAGVLITREDDFNNRLNNRASFKGCTALH
	YAVLADDYRTVKELLDGGANPLQRNEMGHTPLDYAREGEVMKLL
	RTSEAKYQEKQRKREAEERRRFPLEQRLKEHIIGQESAIATVGAA
	IRRKENGWYDEEHPLVFLFLGSSGIGKTELAKQTAKYMHKDAKKG
	FIRLDMSEFQERHEVAKFIGSPPGYVGHEEGGQLTKKLKQCPNAVV
	LFDEVDKAHPDVLTIMLQLFDEGRLTDGKGKTIDCKDAIFIMTSNVA
	SDEIAQHALQLRQEALEMSRNRIAENLGDVQISDKITISKNFKENVIR
	PILKAHFRRDEFLGRINEIVYFLPFCHSELIQLVNKELNFWAKRAKQR
	HNITLLWDREVADVLVDGYNVHYGARSIKHEVERRVVNQLAAAYE
	QDLLPGGCTLRITVEDSDKQLLKSPELPSPQAEKRLPKLRLEIIDKDS
	KTRRLDIRAPLHPEKVCNTI
176	MLFLALGSPWAVELPLCGRRTALCAAAALRGPRASVSRASSSSGPS	TMEM70
	GPVAGWSTGPSGAARLLRRPGRAQIPVYWEGYVRFLNTPSDKSEDG
	RLIYTGNMARAVFGVKCFSYSTSLIGLTFLPYIFTQNNAISESVPLPIQ
	IIFYGIMGSFTVITPVLLHFITKGYVIRLYHEATTDTYKAITYNAMLA
	ETSTVFHQNDVKIPDAKHVFTTFYAKTKSLLVNPVLFPNREDYIHLM
	GYDKEEFILYMEETSEEKRHKDDK
177	MLSQVYRCGFQPFNQHLLPWVKCTTVFRSHCIQPSVIRHVRSWSNIP	ALDH18A1
	FITVPLSRTHGKSFAHRSELKHAKRIVVKLGSAVVTRGDECGLALGR
	LASIVEQVSVLQNQGREMMLVTSGAVAFGKQRLRHEILLSQSVRQA
	LHSGQNQLKEMAIPVLEARACAAAGQSGLMALYEAMFTQYSICAA
	QILVTNLDFHDEQKRRNLNGTLHELLRMNIVPIVNTNDAVVPPAEP
	NSDLQGVNVISVKDNDSLAARLAVEMKTDLLIVLSDVEGLFDSPPG
	SDDAKLIDIFYPGDQQSVTFGTKSRVGMGGMEAKVKAALWALQGG
	TSVVIANGTHPKVSGHVITDIVEGKKVGTFFSEVKPAGPTVEQQGE
	MARSGGRMLATLEPEQRAEIIHHLADLLTDQRDEILLANKKDLEEA
	EGRLAAPLLKRLSLSTSKLNSLAIGLRQIAASSQDSVGRVLRRTRIAK
	NLELEQVTVPIGVLLVIFESRPDCLPQVAALAIASGNGLLLKGGKEA
	AHSNRILHLLTQEALSIHGVKEAVQLVNTREEVEDLCRLDKMIDLIIP
	RGSSQLVRDIQKAAKGIPVMGHSEGICHMYVDSEASVDKVTRLVRD
	SKCEYPAACNALETLLIHRDLLRTPLFDQIIDMLRVEQVKIHAGPKF
	ASYLTFSPSEVKSLRTEYGDLELCIEVVDNVQDAIDHIHKYGSSHTD
	VIVTEDENTAEFFLQHVDSACVFWNASTRFSDGYRFGLGAEVGISTS
	RIHARGPVGLEGLLTTKWLLRGKDHVVSDFSEHGSLKYLHENLPIP
	QRNTN
178	MFSKLAHLQRFAVLSRGVHSSVASATSVATKKTVQGPPTSDDIFERE	OAT
	YKYGAHNYHPLPVALERGKGIYLWDVEGRKYFDFLSSYSAVNQGH
	CHPKIVNALKSQVDKLTLTSRAFYNNVLGEYEEYITKLFNYHKVLP
	MNTGVEAGETACKLARKWGYTVKGIQKYKAKIVFAAGNFWGRTL
	SAISSSTDPTSYDGFGPFMPGFDIIPYNDLPALERALQDPNVAAFMVE
	PIQGEAGVVVPDPGYLMGVRELCTRHQVLFIADEIQTGLARTGRWL
	AVDYENVRPDIVLLGKALSGGLYPVSAVLCDDDIMLTIKPGEHGST
	YGGNPLGCRVAIAALEVLEEENLAENADKLGIILRNELMKLPSDVVT
	AVRGKGLLNAIVIKETKDWDAWKVCLRLRDNGLLAKPTHGDIIRFA
	PPLVIKEDELRESIEIINKTILSF
179	MLGRNTWKTSAFSFLVEQMWAPLWSRSMRPGRWCSQRSCAWQTS	CA5A
	NNTLHPLWTVPVSVPGGTRQSPINIQWRDSVYDPQLKPLRVSYEAA
	SCLYIWNTGYLFQVEFDDATEASGISGGPLENHYRLKQFHFHWGAV
	NEGGSEHTVDGHAYPAELHLVHWNSVKYQNYKEAVVGENGLAVI
	GVFLKLGAHHQTLQRLVDILPEIKHKDARAAMRPFDPSTLLPTCWD
	YWTYAGSLTTPPLTESVTWIIQKEPVEVAPSQLSAFRTLLFSALGEEE
	KMMVNNYRPLQPLMNRKVWASFQATNEGTRS
180	MYRYLGEALLLSRAGPAALGSASADSAALLGWARGQPAAAPQPGL	GLUD1
	ALAARRHYSEAVADREDDPNFFKMVEGFFDRGASIVEDKLVEDLRT
	RESEEQKRNRVRGILRIIKPCNHVLSLSFPIRRDDGSWEVIEGYRAQH
	SQHRTPCKGGIRYSTDVSVDEVKALASLMTYKCAVVDVPFGGAKA
	GVKINPKNYTDNELEKITRRFTMELAKKGFIGPGIDVPAPDMSTGER
	EMSWIADTYASTIGHYDINAHACVTGKPISQGGIHGRISATGRGVFH
	GIENFINEASYMSILGMTPGFG
	DKTFVVQGFGNVGLHSMRYLHRFGAKCIAVGESDGSIWNPDGIDPK
	ELEDFKLQHGSILGFPKAKPYEGSILEADCDILIPAASEKQLTKSNAP
	RVKAKIIAEGANGPTTPEADKIFLERNIMVIPDLYLNAGGVTVSYFE
	WLKNLNHVSYGRLTFKYERDSNYHLLMSVQESLERKFGKHGGTIPI
	VPTAEFQDRISGASEKDIVHSGLAYTMERSARQIMRTAMKYNLGLD
	LRTAAYVNAIEKVFKVYNEAGVTFT
181	MTTSASSHLNKGIKQVYMSLPQGEKVQAMYIWIDGTGEGLRCKTR	GLUL
	TLDSEPKCVEELPEWNFDGSSTLQSEGSNSDMYLVPAAMFRDPFRK
	DPNKLVLCEVFKYNRRPAETNLRHTCKRIMDMVSNQHPWFGMEQE
	YTLMGTDGHPFGWPSNGFPGPQGPYYCGVGADRAYGRDIVEAHYR
	ACLYAGVKIAGTNAEVMPAQWEFQIGPCEGISMGDHLWVARFILH
	RVCEDFGVIATFDPKPIPGNWNGAGCHTNFSTKAMREENGLKYIEE
	AIEKLSKRHQYHIRAYDPKGGLDNARRLTGFHETSNINDFSAGVAN
	RSASIRIPRTVGQEKKGYFEDRRPSANCDPFSVTEALIRTCLLNETGD
	EPFQYKN
182	MAVARAALGPLVTGLYDVQAFKFGDFVLKSGLSSPIYIDLRGIVSRP	UMPS
	RLLSQVADILFQTAQNAGISFDTVCGVPYTALPLATVICSTNQIPMLI
	RRKETKDYGTKRLVEGTINPGETCLIIEDVVTSGSSVLETVEVLQKE
	GLKVTDAIVLLDREQGGKDKLQAHGIRLHSVCTLSKMLEILEQQKK
	VDAETVGRVKRFIQENVFVAANHNGSPLSIKEAPKELSFGARAELPR
	IHPVA
	SKLLRLMQKKETNLCLSADVSLARELLQLADALGPSICMLKTHVDI
	LNDFTLDVMKELITLAKCHEFLIFEDRKFADIGNTVKKQYEGGIFKIA
	SWADLVNAHVVPGSGVVKGLQEVGLPLHRGCLLIAEMSSTGSLAT
	GDYTRAAVRMAEEHSEFVVGFISGSRVSMKPEFLHLTPGVQLEAGG
	DNLGQQYNSPQEVIGKRGSDIIIVGRGIISAADRLEAAEMYRKAAWE
	AYLSRLGV
183	MRDYDEVTAFLGEWGPFQRLIFFLLSASIIPNGFTGLSSVFLIATPEHR	SLC22A5
	CRVPDAANLSSAWRNHTVPLRLRDGREVPHSCRRYRLATIANFSAL
	GLEPGRDVDLGQLEQESCLDGWEFSQDVYLSTIVTEWNLVCEDDW
	KAPLTISLFFVGVLLGSFISGQLSDRFGRKNVLFVTMGMQTGFSFLQI
	FSKNFEMFVVLFVLVGMGQISNYVAAFVLGTEILGKSVRIIFSTLGV
	CIFYAFGYMVLPLFAYFIRDWRMLLVALTMPGVLCVALWWFIPESP
	RWLISQGRFEEAEVIIRKAAKANGIVVPSTIFDPSELQDLSSKKQQSH
	NILDLLRTWNIRMVTIMSIMLWMTISVGYFGLSLDTPNLHGDIFVNC
	FLSAMVEVPAYVLAWLLLQYLPRRYSMATALFLGGSVLLFMQLVP
	PDLYYLATVLVMVGKFGVTAAFSMVYVYTAELYPTVVRNMGVGV
	SSTASRLGSILSPYFVYLGAYDRFLPYILMGSLTILTAILTLFLPESFGT
	PLPDTIDQMLRVKGMKHRKTPSHTR
	MLKDGQERPTILKSTAF
184	MAEAHQAVAFQFTVTPDGIDLRLSHEALRQIYLSGLHSWKKKFIRF	CPT1A
	KNGIITGVYPASPSSWLIVVVGVMTTMYAKIDPSLGIIAKINRTLETA
	NCMSSQTKNVVSGVLFGTGLWVALIVTMRYSLKVLLSYHGWMFTE
	HGKMSRATKIWMGMVKIFSGRKPMLYSFQTSLPRLPVPAVKDTVN
	RYLQSVRPLMKEEDFKRMTALAQDFAVGLGPRLQWYLKLKSWWA
	TNYVSDWWEEYIYLRGRGPLMVNSNYYAMDLLYILPTHIQAARAG
	NAIHAILLYRRKLDREEIKPIRLLGSTIPLCSAQWERMFNTSRIPGEET
	DTIQHMRDSKHIVVYHRGRYFKVWLYHDGRLLKPREMEQQMQRIL
	DNTSEPQPGEARLAALTAGDRVPWARCRQAYFGRGKNKQSLDAVE
	KAAFFVTLDETEEGYRSEDPDTSMDSYAKSLLHGRCYDRWFDKSFT
	FVVFKNGKMGLNAEHSWADAPIVAHLWEYVMSIDSLQLGYAEDG
	HCKGDINPNIPYPTRLQWDIPGECQEVIETSLNTANLLANDVDFHSFP
	FVAFGKGIIKKCRTSPDAFVQLALQLAHYKDMGKFCLTYEASMTRL
	FREGRTETVRSCTTESCDFVRAMVDPAQTVEQRLKLFKLASEKHQH
	MYRLAMTGSGIDRHLFCLYVVSKYLAVESPFLKEVLSEPWRLSTSQ
	TPQQQVELFDLENNPEYVSSGGGFGPVADDGYGVSYILVGENLINF
	HISSKFSCPETDSHRFGRHLKEAMTDIITLFGLSSNSKK
185	MVACRAIGILSRFSAFRILRSRGYICRNFTGSSALLTRTHINYGVKGD	HADHA
	VAVVRINSPNSKVNTLSKELHSEFSEVMNEIWASDQIRSAVLISSKPG
	CFIAGADINMLAACKTLQEVTQLSQEAQRIVEKLEKSTKPIVAAING
	SCLGGGLEVAISCQYRIATKDRKTVLGTPEVLLGALPGAGGTQRLP
	KMVGVPAALDMMLTGRSIRADRAKKMGLVDQLVEPLGPGLKPPEE
	RTIEYLEEVAITFAKGLADKKISPKRDKGLVEKLTAYAMTIPFVRQQ
	VYKKVEEKVRKQTKGLYPAPLKIIDVVKTGIEQGSDAGYLCESQKF
	GELVMTKESKALMGLYHGQVLCKKNKFGAPQKDVKHLAILGAGL
	MGAGIAQVSVDKGLKTILKDATLTALDRGQQQVFKGLNDKVKKKA
	LTSFERDSIFSNLTGQLDYQGFEKADMVIEAVFEDLSLKHRVLKEVE
	AVIPDHCIFASNTSALPISEIAAVSKRPEKVIGMHYFSPVDKMQLLEII
	TTEKTSKDTSASAVAVGLKQGKVIIVVK
	DGPGFYTTRCLAPMMSEVIRILQEGVDPKKLDSLTTSFGFPVGAATL
	VDEVGVDVAKHVAEDLGKVFGERFGGGNPELLTQMVSKGFLGRKS
	GKGFYIYQEGVKRKDLNSDMDSILASLKLPPKSEVSSDEDIQFRLVT
	RFVNEAVMCLQEGILATPAEGDIGAVFGLGFPPCLGGPFRFVDLYG
	AQKIVDRLKKYEAAYGKQFTPCQLLADHANSPNKKFYQ
186	MAFVTRQFMRSVSSSSTASASAKKIIVKHVTVIGGGLMGAGIAQVA	HADH
	AATGHTVVLVDQTEDILAKSKKGIEESLRKVAKKKFAENLKAGDEF
	VEKTLSTIATSTDAASVVHSTDLVVEAIVENLKVKNELFKRLDKFAA
	EHTIFASNTSSLQITSIANATTRQDRFAGLHFFNPVPVMKLVEVIKTP
	MTSQKTFESLVDFSKALGKHPVSCKDTPGFIVNRLLVPYLMEAIRLY
	ERGDASKEDIDTAMKLGAGYPMGPFELLDYVGLDTTKFIVDGWHE
	MDAENPLHQPSPSLNKLVAENKFGKKTGEGFYKYK
187	MAAPTLGRLVLTHLLVALFGMGSWAAVNGIWVELPVVVKDLPEG	SLC52A1
	WSLPSYLSVVVALGNLGLLVVTLWRQLAPGKGEQVPIQVVQVLSV
	VGTALLAPLWHHVAPVAGQLHSVAFLTLALVLAMACCTSNVTFLP
	FLSHLPPPFLRSFFLGQGLSALLPCVLALVQGVGRLECPPAPTNGTSG
	PPLDFPERFPASTFFWALTALLVTSAAAFRGLLLLLPSLPSVTTGGSG
	PELQLGSPGAEEEEKEEEEALPLQEPPSQAAGTIPGPDPEAHQLFSAH
	GAFLLGLMAFTSAVTNGVLPSVQSFSCLPYGRLAYHLAVVLGSAAN
	PLACFLAMGVLCRSLAGLVGLSLLGMLFGAYLMALAILSPCPPLVG
	TTAGVVLVVLSWVLCLCVFSYVKVAASSLLHGGGRPALLAAGVAI
	QVGSLLGAGAMFPPTSIYHVFQSRKDCVDPCGP
188	MAAPTPARPVLTHLLVALFGMGSWAAVNGIWVELPVVVKELPEG	SLC52A2
	WSLPSYVSVLVALGNLGLLVVTLWRRLAPGKDEQVPIRVVQVLGM
	VGTALLASLWHHVAPVAGQLHSVAFLALAFVLALACCASNVTFLP
	FLSHLPPRFLRSFFLGQGLSALLPCVLALVQGVGRLECPPAPINGTPG
	PPLDFLERFPASTFFWALTALLVASAAAFQGLLLLLPPPPSVPTGELG
	SGLQVGAPGAEEEVEESSPLQEPPSQAAGTTPGPDPKAYQLLSARSA
	CLLGLLAATNALTNGVLPAVQSFSCLPYGRLAYHLAVVLGSAANPL
	ACFLAMGVLCRSLAGLGGLSLLGVFCGGYLMALAVLSPCPPLVGTS
	AGVVLVVLSWVLCLGVFSYVKVAASSLLHGGGRPALLAAGVAIQV
	GSLLGAVAMFPPTSIYHVFHSRKDCADPCDS
189	MAFLMHLLVCVFGMGSWVTINGLWVELPLLVMELPEGWYLPSYLT	SLC52A3
	VVIQLANIGPLLVTLLHHFRPSCLSEVPIIFTLLGVGTVTCIIFAFLWN
	MTSWVLDGHHSIAFLVLTFFLALVDCTSSVTFLPFMSRLPTYYLTTF
	FVGEGLSGLLPALVALAQGSGLTTCVNVTEISDSVPSPVPTRETDIAQ
	GVPRALVSALPGMEAPLSHLESRYLPAHFSPLVFFLLLSIMMACCLV
	AFFV
	LQRQPRCWEASVEDLLNDQVTLHSIRPREENDLGPAGTVDSSQGQG
	YLEEKAAPCCPAHLAFIYTLVAFVNALTNGMLPSVQTYSCLSYGPV
	AYHLAATLSIVANPLASLVSMFLPNRSLLFLGVLSVLGTCFGGYNM
	AMAVMSPCPLLQGHWGGEVLIVASWVLFSGCLSYVKVMLGVVLR
	DLSRSALLWCGAAVQLGSLLGALLMFPLVNVLRLFSSADFCNLHCP
	A
190	MTILTYPFKNLPTASKWALRFSIRPLSCSSQLRAAPAVQTKTKKTLA	HADHB
	KPNIRNVVVVDGVRTPFLLSGTSYKDLMPHDLARAALTGLLHRTSV
	PKEVVDYIIFGTVIQEVKTSNVAREAALGAGFSDKTPAHTVTMACIS
	ANQAMTTGVGLIASGQCDVIVAGGVELMSDVPIRHSRKMRKLMLD
	LNKAKSMGQRLSLISKFRFNFLAPELPAVSEFSTSETMGHSADRLAA
	AFAVSRLEQDEYALRSHSLAKKAQDEGLLSDVVPFKVPGKDTVTK
	DNGIRPSSLEQMAKLKPAFIKPY
	GTVTAANSSFLTDGASAMLIMAEEKALAMGYKPKAYLRDFMYVSQ
	DPKDQLLLGPTYATPKVLEKAGLTMNDIDAFEFHEAFSGQILANFK
	AMDSDWFAENYMGRKTKVGLPPLEKFNNWGGSLSLGHPFGATGC
	RLVMAAANRLRKEGGQYGLVAACAAGGQGHAMIVEAYPK
191	MLRGRSLSVTSLGGLPQWEVEELPVEELLLFEVAWEVTNKVGGIYT	GYS2
	VIQTKAKTTADEWGENYFLIGPYFEHNMKTQVEQCEPVNDAVRRA
	VDAMNKHGCQVHFGRWLIEGSPYVVLFDIGYSAWNLDRWKGDLW
	EACSVGIPYHDREANDMLIFGSLTAWFLKEVTDHADGKYVVAQFH
	EWQAGIGLILSRARKLPIATIFTTHATLLGRYLCAANIDFYNHLDKFN
	IDKEAGERQIYHRYCMERASVHCAHVFTTVSEITAIEAEHMLKRKP
	DVVTPNGLNVKKFSAVHEFQNLHAMYKARIQDFVRGHFYGHLDFD
	LEKTLFLFIAGRYEFSNKGADIFLESLSRLNFLLRMHKSDITVMVFFI
	MPAKTNNFNVETLKGQAVRKQLWDVAHSVKEKFGKKLYDALLRG
	EIPDLNDILDRDDLTIMKRAIFSTQRQSLPPVTTHNMIDDSTDPILSTI
	RRIGLFNNRTDRVKVILHPEFLSSTSPLLPMDYEEFVRGCHLGVFPSY
	YEPWGYTPAECTVMGIPSVTTNLSGFGCFMQEHVADPTAYGIYIVD
	RRFRSPDDSCNQLTKFLYGFCKQSRRQRIIQRNRTERLSDLLDWRYL
	GRYYQHARHLTLSRAFPDKFHVELTSPPTTEGFKYPRPSSVPPSPSGS
	QASSPQSSDVEDEVEDERYDEEEEAERDRLNIKSPFSLSHVPHGKKK
	LHGEYKN
192	MAKPLTDQEKRRQISIRGIVGVENVAELKKSFNRHLHFTLVKDRNV	PYGL
	ATTRDYYFALAHTVRDHLVGRWIRTQQHYYDKCPKRVYYLSLEFY
	MGRTLQNTMINLGLQNACDEAIYQLGLDIEELEEIEEDAGLGNGGL
	GRLAACFLDSMATLGLAAYGYGIRYEYGIFNQKIRDGWQVEEADD
	WLRYGNPWEKSRPEFMLPVHFYGKVEHTNTGTKWIDTQVVLALPY
	DTPVPGYMNNTVNTMRLWSARAPNDFNLRDFNVGDYIQAVLDRN
	LAENISRVLYPNDNFFEGKELRLKQEYFVVAATLQDIIRRFKASKFG
	STRGAGTVFDAFPDQVAIQLNDTHPALAIPELMRIFVDIEKL
	PWSKAWELTQKTFAYTNHTVLPEALERWPVDLVEKLLPRHLEIIYEI
	NQKHLDRIVALFPKDVDRLRRMSLIEEEGSKRINMAHLCIVGSHAV
	NGVAKIHSDIVKTKVFKDFSELEPDKFQNKTNGITPRRWLLLCNPGL
	AELIAEKIGEDYVKDLSQLTKLHSFLGDDVFLRELAKVKQENKLKFS
	QFLETEYKVKINPSSMFDVQVKRIHEYKRQLLNCLHVITMYNRIKK
	DPKKLFVPRTVIIGGKAAPGYHMAKMIIKLITSVADVVNNDPMVGS
	KLKVIFLENYRVSLAEKVIPATDLSEQISTAGTEASGTGNMKFMLNG
	ALTIGTMDGANVEMAEEAGEENLFIFGMRIDDVAALDKKGYEAKE
	YYEALPELKLVIDQIDNGFFSPKQPDLFKDIINMLFYHDRFKVFADY
	EAYVKCQDKVSQLYMNPKAWNTMVLKNIAASGKFSSDRTIKEYAQ
	NIWNVEPSDLKISLSNESNKVNGN
193	MTEDKVTGTLVFTVITAVLGSFQFGYDIGVINAPQQVIISHYRHVLG	SLC2A2
	VPLDDRKAINNYVINSTDELPTISYSMNPKPTPWAEEETVAAAQLIT
	MLWSLSVSSFAVGGMTASFFGGWLGDTLGRIKAMLVANILSLVGA
	LLMGFSKLGPSHILIIAGRSISGLYCGLISGLVPMYIGEIAPTALRGAL
	GTFHQLAIVTGILISQIIGLEFILGNYDLWHILLGLSGVRAILQSLLLFF
	CPESPRYLYIKLDEEVKAKQSLKRLRGYDDVTKDINEMRKEREEAS
	SEQKVSIIQLFTNSSYRQPILVALMLHVAQQFSGINGIFYYSTSIFQTA
	GISKPVYATIGVGAVNMVFTAVSVFLVEKAGRRSLFLIGMSGMFVC
	AIFMSVGLVLLNKFSWMSYVSMIAIFLFVSFFEIGPGPIPWFMVAEFF
	SQGPRPAALAIAAFSNWTCNFIVALCFQYIADFCGPYVFFLFAGVLL
	AFTLFTFFKVPETKGKSFEEIAAEFQKKSGSAHRPKAAVEMKFLGAT
	ETV
194	MAASCLVLLALCLLLPLLLLGGWKRWRRGRAARHVVAVVLGDVG	ALG1
	RSPRMQYHALSLAMHGFSVTLLGFCNSKPHDELLQNNRIQIVGLTE
	LQSLAVGPRVFQYGVKVVLQAMYLLWKLMWREPGAYIFLQNPPG
	LPSIAVCWFVGCLCGSKLVIDWHNYGYSIMGLVHGPNHPLVLLAK
	WYEKFFGRLSHLNLCVTNAMREDLADNWHIRAVTVYDKPASFFKE
	TPLDLQHRLFMKLGSMHSPFRARSEPEDPVTERSAFTERDAGSGLVT
	RLRERPALLVSSTSWTEDEDFSILLAALEKFEQLTLDGHNLPSLVCVI
	TGKGPLREYYSRLIHQKHFQHIQVCTPWLEAEDYPLLLGSADLGVC
	LHTSSSGLDLPMKVVDMFGCCLPVCAVNFKCLHELVKHEENGLVF
	EDSEELAAQLQMLFSNFPDPAGKLNQFRKNLRESQQLRWDESWVQ
	TVLPLVMDT
195	MAEEQGRERDSVPKPSVLFLHPDLGVGGAERLVLDAALALQARGC	ALG2
	SVKIWTAHYDPGHCFAESRELPVRCAGDWLPRGLGWGGRGAAVC
	AYVRMVFLALYVLFLADEEFDVVVCDQVSACIPVFRLARRRKKILF
	YCHFPDLLLTKRDSFLKRLYRAPIDWIEEYTTGMADCILVNSQFTAA
	VFKETFKSLSHIDPDVLYPSLNVTSFDSVVPEKLDDLVPKGKKFLLL
	SINRYERKKNLTLALEALVQLRGRLTSQDWERVHLIVAGGYDERVL
	ENVEHYQELKKMVQQSDLGQYVTFLRSFSDKQKISLLHSCTCVLYT
	PSNEHFGIVPLEAMYMQCPVIAVNSGGPLESIDHSVTGFLCEPDPVH
	FSEAIEKFIREPSLKATMGLAGRARVKEKFSPEAFTEQLYRYVTKLL
	V
196	MAAGLRKRGRSGSAAQAEGLCKQWLQRAWQERRLLLREPRYTLL	ALG3
	VAACLCLAEVGITFWVIHRVAYTEIDWKAYMAEVEGVINGTYDYT
	QLQGDTGPLVYPAGFVYIFMGLYYATSRGTDIRMAQNIFAVLYLAT
	LLLVFLIYHQTCKVPPFVFFFMCCASYRVHSIFVLRLFNDPVAMVLL
	FLSINLLLAQRWGWGCCFFSLAVSVKMNVLLFAPGLLFLLLTQFGF
	RGALPKLGICAGLQVVLGLPFLLENPSGYLSRSFDLGRQFLFHWTVN
	WRFLPEALFLHRAFHLALLTAHLTL
	LLLFALCRWHRTGESILSLLRDPSKRKVPPQPLTPNQIVSTLFTSNFIG
	ICFSRSLHYQFYVWYFHTLPYLLWAMPARWLTHLLRLLVLGLIELS
	WNTYPSTSCSSAALHICHAVILLQLWLGPQPFPKSTQHSKKAH
197	MEKWYLMTVVVLIGLTVRWTVSLNSYSGAGKPPMFGDYEAQRHW	ALG6
	QEITFNLPVKQWYFNSSDNNLQYWGLDYPPLTAYHSLLCAYVAKFI
	NPDWIALHTSRGYESQAHKLFMRTTVLIADLLIYIPAVVLYCCCLKE
	ISTKKKIANALCILLYPGLILIDYGHFQYNSVSLGFALWGVLGISCDC
	DLLGSLAFCLAINYKQMELYHALPFFCFLLGKCFKKGLKGKGFVLL
	VKLACIVVASFVLCWLPFFTEREQTLQVLRRLFPVDRGLFEDKVANI
	WCSFNVFLKIKDILPRHIQLIMSFCSTFLSLLPACIKLILQPSSKGFKFT
	LVSCALSFFLFSFQVHEKSILLVSLPVCLVLSEIPFMSTWFLLVSTFSM
	LPLLLKDELLMPSVVTTMAFFIACVTSFSIFEKTSEEELQLKSFSISVR
	KYLPCFTFLSRIIQYLFLISVITMVLLTLMTVTLDPPQKLPDLFSVLVC
	FVSCLNFLFFLVYFNIIIMWDSKSGRNQKKIS
198	MAALTIATGTGNWFSALALGVTLLKCLLIPTYHSTDFEVHRNWLAI	ALG8
	THSLPISQWYYEATSEWTLDYPPFFAWFEYILSHVAKYFDQEMLNV
	HNLNYSSSRTLLFQRFSVIFMDVLFVYAVRECCKCIDGKKVGKELTE
	KPKFILSVLLLWNFGLLIVDHIHFQYNGFLFGLMLLSIARLFQKRHM
	EGAFLFAVLLHFKHIYLYVAPAYGVYLLRSYCFTANKPDGSIRWKS
	FSFVRVISLGLVVFLVSALSLGPFLALNQLPQVFSRLFPFKRGLCHAY
	WAPNFWALYNALDKVLSVIGLKLKFLDPNNIPKASMTSGLVQQFQ
	HTVLPSVTPLATLICTLIAILPSIFCLWFKPQGPRGFLRCLTLCALSSF
	MFGWHVHEKAILLAILPMSLLSVGKAGDASIFLILTTTGHYSLFPLLF
	TAPELPIKILLMLLFTIYSISSLKTLFRKEKPLFNWMETFYLLGLGPLE
	VCCEFVFPFTSWKVKYPFIPLLLTSVYCAVGITYAWFKLYVSVLIDS
	AIGKTKKQ
199	MASRGARQRLKGSGASSGDTAPAADKLRELLGSREAGGAEHRTEL	ALG9
	SGNKAGQVWAPEGSTAFKCLLSARLCAALLSNISDCDETFNYWEPT
	HYLIYGEGFQTWEYSPAYAIRSYAYLLLHAWPAAFHARILQTNKILV
	FYFLRCLLAFVSCICELYFYKAVCKKFGLHVSRMMLAFLVLSTGMF
	CSSSAFLPSSFCMYTTLIAMTGWYMDKTSIAVLGVAAGAILGWPFS
	AALGLPIAFDLLVMKHRWKSFFHWSLMALILFLVPVVVIDSYYYGK
	LVIAPLNIVLYNVFTPHGPDLYGT
	EPWYFYLINGFLNFNVAFALALLVLPLTSLMEYLLQRFHVQNLGHP
	YWLTLAPMYIWFIIFFIQPHKEERFLFPVYPLICLCGAVALSALQKCY
	HFVFQRYRLEHYTVTSNWLALGTVFLFGLLSFSRSVALFRGYHGPL
	DLYPEFYRIATDPTIHTVPEGRPVNVCVGKEWYRFPSSFLLPDNWQL
	QFIPSEFRGQLPKPFAEGPLATRIVPTDMNDQNLEEPSRYIDISKCHY
	LVDLDTMRETPREPKYSSNKEEWISLAYRPFLDASRSSKLLRAFYVP
	FLSDQYTVYVNYTILKPRKAKQIRKKSGG
200	MAAGERSWCLCKLLRFFYSLFFPGLIVCGTLCVCLVIVLWGIRLLLQ	ALG11
	RKKKLVSTSKNGKNQMVIAFFHPYCNAGGGGERVLWCALRALQK
	KYPEAVYVVYTGDVNVNGQQILEGAFRRFNIRLIHPVQFVFLRKRY
	LVEDSLYPHFTLLGQSLGSIFLGWEALMQCVPDVYIDSMGYAFTLPL
	FKYIGGCQVGSYVHYPTISTDMLSVVKNQNIGFNNAAFITRNPFLSK
	VKLIYYYLFAHYGLVGSCSDVVMVNSSWTLNHILSLWKVGNCTNI
	VYPPCDVQTFLDIPLHEKKMTPGHLLVSVGQFRPEKNHPLQIRAFAK
	LLNKKMVESPPSLKLVLIGGCRNKDDELRVNQLRRLSEDLGVQEYV
	EFKINIPFDELKNYLSEATIGLHTMWNEHFGIGVVECMAAGTIILAH
	NSGGPKLDIVVPHEGDITGFLAESEEDYAETIAHILSMSAEKRLQIRK
	SARASVSRFSDQEFEVTFLSSVEKLFK
201	MAGKGSSGRRPLLLGLLVAVATVHLVICPYTKVEESFNLQATHDLL	ALG12
	YHWQDLEQYDHLEFPGVVPRTFLGPVVIAVFSSPAVYVLSLLEMSK
	FYSQLIVRGVLGLGVIFGLWTLQKEVRRHFGAMVATMFCWVTAM
	QFHLMFYCTRTLPNVLALPVVLLALAAWLRHEWARFIWLSAFAIIV
	FRVELCLFLGLLLLLALGNRKVSVVRALRHAVPAGILCLGLTVAVD
	SYFWRQLTWPEGKVLWYNTVLNKSSNWGTSPLLWYFYSALPRGL
	GCSLLFIPLGLVDRRTHAPTVLALGFMALYSLLPHKELRFIIYAFPML
	NITAARGCSYLLNNYKKSWLYKAGSLLVIGHLVVNAAYSATALYV
	SHFNYPGGVAMQRLHQLVPPQTDVLLHIDVAAAQTGVSRFLQVNS
	AWRYDKREDVQPGTGMLAYTHILMEAAPGLLALYRDTHRVLASV
	VGTTGVSLNLTQLPPFNVHLQTKLVLLERLPRPS
202	MKCVFVTVGTTSFDDLIACVSAPDSLQKIESLGYNRLILQIGRGTVV	ALG13
	PEPFSTESFTLDVYRYKDSLKEDIQKADLVISHAGAGSCLETLEKGK
	PLVVVINEKLMNNHQLELAKQLHKEGHLFYCTCRVLTCPGQAKSIA
	SAPGKCQDSAALTSTAFSGLDFGLLSGYLHKQALVTATHPTCTLLFP
	SCHAFFPLPLTPTLYKMHKGWKNYCSQKSLNEASMDEYLGSLGLFR
	KLTAKDASCLFRAISEQLFCSQVHHLEIRKACVSYMRENQQTFESYV
	EGSFEKYLERLGDPKESAGQLEIRALSLIYNRDFILYRFPGKPPTYVT
	DNGYEDKILLCYSSSGHYDSVYSKQFQSSAAVCQAVLYEILYKDVF
	VVDEEELKTAIKLFRSGSKKNRNNAVTGSEDAHTDYKSSNQNRME
	EWGACYNAENIPEGYNKGTEETKSPENPSKMPFPYKVLKALDPEIY
	RNVEFDVWLDSRKELQKSDYMEYAGRQYYLGDKCQVCLESEGRY
	YNAHIQEVGNENNSVTVFIEELAEKHVVPLANLKPVTQVMSVPAW
	NAMPSRKGRGYQKMPGGYVPEIVISEMDIKQQKKMFKKIRGKEVY
	M
	TMAYGKGDPLLPPRLQHSMHYGHDPPMHYSQTAGNVMSNEHFHP
	QHPSPRQGRGYGMPRNSSRFINRHNMPGPKVDFYPGPGKRCCQSYD
	NFSYRSRSFRRSHRQMSCVNKESQYGFTPGNGQMPRGLEETITFYE
	VEEGDETAYPTLPNHGGPSTMVPATSGYCVGRRGHSSGKQTLNLEE
	GNGQSENGRYHEEYLYRAEPDYETSGVYSTTASTANLSLQDRKSCS
	MSPQDTVTSYNYPQKMMGNIAAVAASCANNVPAPVLSNGAAANQ
	AISTTSVSSQNAIQPLFVSPPTHGRPVIASPSYPCHSAIPHAGASLPPPP
	PPPPPPPPPPPPPPPPPPPPPPPALDVGETSNLQPPPPLPPPPYSCDPSGS
	DLPQDTKVLQYYFNLGLQCYYHSYWHSMVYVPQMQQQLHVENYP
	VYTEPPLVDQTVPQCYSEVRREDGIQAEASANDTFPNADSSSVPHG
	AVYYPVMSDPYGQPPLPGFDSCLPVVPDYSCVPPWHPVGTAYGGSS
	QIHGAINPGPIGCIAPSPPASHYVPQGM
203	MGSLFRSETMCLAQLFLQSGTAYECLSALGEKGLVQFRDLNQNVSS	ATP6V0A2
	FQRKFVGEVKRCEELERILVYLVQEINRADIPLPEGEASPPAPPLKQV
	LEMQEQLQKLEVELREVTKNKEKLRKNLLELIEYTHMLRVTKTFVK
	RNVEFEPTYEEFPSLESDSLLDYSCMQRLGAKLGFVSGLINQGKVEA
	FEKMLWRVCKGYTIVSYAELDESLEDPETGEVIKWYVFLISFWGEQI
	GHKVKKICDCYHCHVYPYPNTAEERREIQEGLNTRIQDLYTVLHKT
	EDYLRQVLCKAAESVYSRVIQVKKMKAIYHMLNMCSFDVTNKCLI
	AEVWCPEADLQDLRRALEEGSRESGATIPSFMNIIPTKETPPTRIRTN
	KFTEGFQNIVDAYGVGSYREVNPALFTIITFPFLFAVMFGDFGHGFV
	MFLFALLLVLNENHPRLNQSQEIMRMFFNGRYILLLMGLFSVYTGLI
	YNDCFSKSVNLFGSGWNVSAMYSSSHPPAEHKKMVLWNDSVVRH
	NSILQLDPSIPGVFRGPYPLGIDPIWNLATNRLTFLNSFKMKMSVILGI
	IHMTFGVILGIFNHLHFRKKFNIYLVSIPELLFMLCIFGYLIFMIFYKW
	LVFSAETSRVAPSILIEFINMFLFPASKTSGLYTGQEYVQRVLLVVTA
	LSVPVLFLGKPLFLLWLHNGRSCFGVNRSGYTLIRKDSEEEVSLLGS
	QDIEEGNHQVEDGCREMACEEFNFGEILMTQVIHSIEYCLGCISNTA
	SYLRLWALSLAHAQLSDVLWAMLMRVGLRVDTTYGVLLLLPVIAL
	FAVLTIFILLIMEGLSAFLHAIRLHWVEFQNKFYVGAGTKFVPF
	SFSLLSSKFNNDDSVA
204	MRPPACWWLLAPPALLALLTCSLAFGLASEDTKKEVKQSQDLEKS	B3GLCT
	GISRKNDIDLKGIVFVIQSQSNSFHAKRAEQLKKSILKQAADLTQELP
	SVLLLHQLAKQEGAWTILPLLPHFSVTYSRNSSWIFFCEEETRIQIPK
	LLETLRRYDPSKEWFLGKALHDEEATIIHHYAFSENPTVFKYPDFAA
	GWALSIPLVNKLTKRLKSESLKSDFTIDLKHEIALYIWDKGGGPPLTP
	VPEF
	CTNDVDFYCATTFHSFLPLCRKPVKKKDIFVAVKTCKKFHGDRIPIV
	KQTWESQASLIEYYSDYTENSIPTVDLGIPNTDRGHCGKTFAILERFL
	NRSQDKTAWLVIVDDDTLISISRLQHLLSCYDSGEPVFLGERYGYGL
	GTGGYSYITGGGGMVFSREAVRRLLASKCRCYSNDAPDDMVLGMC
	FSGLGIPVTHSPLFHQARPVDYPKDYLSHQVPISFHKHWNIDPVKVY
	FTWLAPSDEDKARQETQKGFREEL
205	MFPRPLTPLAAPNGAEPLGRALRRAPLGRARAGLGGPPLLLPSMLM	CHST14
	FAVIVASSGLLLMIERGILAEMKPLPLHPPGREGTAWRGKAPKPGGL
	SLRAGDADLQVRQDVRNRTLRAVCGQPGMPRDPWDLPVGQRRTL
	LRHILVSDRYRFLYCYVPKVACSNWKRVMKVLAGVLDSVDVRLK
	MDHRSDLVFLADLRPEEIRYRLQHYFKFLFVREPLERLLSAYRNKFG
	EIREYQQRYGAEIVRRYRAGAGPSPAGDDVTFPEFLRYLVDEDPER
	MNEHWMPVYHLCQPCAVHYDFVGSYERLEADANQVLEWVRAPPH
	VRFPARQAWYRPASPESLHYHLCSAPRALLQDVLPKYILDFSLFAYP
	LPNVTKEACQQ
206	MATAATSPALKRLDLRDPAALFETHGAEEIRGLERQVRAEIEHKKE	COG1
	ELRQMVGERYRDLIEAADTIGQMRRCAVGLVDAVKATDQYCARLR
	QAGSAAPRPPRAQQPQQPSQEKFYSMAAQIKLLLEIPEKIWSSMEAS
	QCLHATQLYLLCCHLHSLLQLDSSSSRYSPVLSRFPILIRQVAAASHF
	RSTILHESKMLLKCQGVSDQAVAEALCSIMLLEESSPRQALTDFLLA
	RKATIQKLLNQPHHGAGIKAQICSLVELLATTLKQAHALFYTLPEGL
	LPDPALPCGLLFSTLETITGQHPAGKGTGVLQEEMKLCSWFKHLPAS
	IVEFQPTLRTLAHPISQEYLKDTLQKWIHMCNEDIKNGITNLLMYVK
	SMKGLAGIRDAMWELLTNESTNHSWDVLCRRLLEKPLLFWEDMM
	QQLFLDRLQTLTKEGFDSISSSSKELLVSALQELESSTSNSPSNKHIHF
	EYNMSLFLWSESPNDLPSDAAWVSVANRGQFASSGLSMKAQAISPC
	VQNFCSALDSKLKVKLDDLLAYLPSDD
	SSLPKDVSPTQAKSSAFDRYADAGTVQEMLRTQSVACIKHIVDCIRA
	ELQSIEEGVQGQQDALNSAKLHSVLFMARLCQSLGELCPHLKQCIL
	GKSESSEKPAREFRALRKQGKVKTQEIIPTQAKWQEVKEVLLQQSV
	MGYQVWSSAVVKVLIHGFTQSLLLDDAGSVLATATSWDELEIQEEA
	ESGSSVTSKIRLPAQPSWYVQSFLFSLCQEINRVGGHALPKVTLQEM
	LKSCMVQVVAAYEKLSEEKQIKKEGAFPVTQNRALQLLYDLRYLNI
	VLTAKGDEVKSGRSKPDSRIEK
	VTDHLEALIDPFDLDVFTPHLNSNLHRLVQRTSVLFGLVTGTENQLA
	PRSSTFNSQEPHNILPLASSQIRFGLLPLSMTSTRKAKSTRNIETKAQV
	VPPARSTAGDPTVPGSLFRQLVSEEDNTSAPSLFKLGWLSSMTK
207	MEKSRMNLPKGPDTLCFDKDEFMKEDFDVDHFVSDCRKRVQLEEL	COG2
	RDDLELYYKLLKTAMVELINKDYADFVNLSTNLVGMDKALNQLSV
	PLGQLREEVLSLRSSVSEGIRAVDERMSKQEDIRKKKMCVLRLIQVI
	RSVEKIEKILNSQSSKETSALEASSPLLTGQILERIATEFNQLQFHAVQ
	SKGMPLLDKVRPRIAGITAMLQQSLEGLLLEGLQTSDVDIIRHCLRT
	YATIDKTRDAEALVGQVLVKPYIDEVIIEQFVESHPNGLQVMYNKLL
	EFVPHHCRLLREVTGGAISSEKGNTVPGYDFLVNSVWPQIVQGLEE
	KLPSLFNPGNPDAFHEKYTISMDFVRRLERQCGSQASVKRLRAHPA
	YHSFNKKWNLPVYFQIRFREIAGSLEAALTDVLEDAPAESPYCLLAS
	HRTWSSLRRCWSDEMFLPLLVHRLWRLTLQILARYSVFVNELSLRPI
	SNESPKEIKKPLVTGSKEPSITQGNTEDQGSGPSETKPVVSISRTQLV
	YVVADLDKLQEQLPELLEIIKPKLEMIGFKNFSSISAALEDSQSSFSA
	CVPSLSSKIIQDLSDSCFGFLKSALEVPRLYRRTNKEVPTTASSYVDS
	ALKPLFQLQSGHKDKLKQAIIQQWLEGTLSESTHKYYETVSDVLNS
	VKKMEESLKRLKQARKTTPANPVGPSGGMSDDDKIRLQLALDVEY
	LGEQIQKLGLQASDIKSFSALAELVAAAKDQATAEQP
208	MADLDSPPKLSGVQQPSEGVGGGRCSEISAELIRSLTELQELEAVYE	COG4
	RLCGEEKVVERELDALLEQQNTIESKMVTLHRMGPNLQLIEGDAKQ
	LAGMITFTCNLAENVSSKVRQLDLAKNRLYQAIQRADDILDLKFCM
	DGVQTALRSEDYEQAAAHTHRYLCLDKSVIELSRQGKEGSMIDANL
	KLLQEAEQRLKAIVAEKFAIATKEGDLPQVERFFKIFPLLGLHEEGLR
	KFSEYLCKQVASKAEENLLMVLGTDMSDRRAAVIFADTLTLLFEGI
	ARIVETHQPIVETYYGPGRLYTLIKYLQVECDRQVEKVVDKFIKQRD
	YHQQFRHVQNNLMRNSTTEKIEPRELDPILTEVTLMNARSELYLRFL
	KKRISSDFEVGDSMASEEVKQEHQKCLDKLLNNCLLSCTMQELIGL
	YVTMEEYFMRETVNKAVALDTYEKGQLTSSMVDDVFYIVKKCIGR
	ALSSSSIDCLCAMINLATTELESDFRDVLCNKLRMGFPATTFQDIQR
	GVTSAVNIMHSSLQQGKFDTKGIESTDEAKMSFLVTLNNVEVCSENI
	STLKKTLESDCTKLFSQGIGGEQAQAKFDSCLSDLAAVSNKFRDLLQ
	EGLTELNSTAIKPQVQPWINSFFSVSHNIEEEEFNDYEANDPWVQQFI
	LNLEQQMAEFKASLSPVIYDSLTGLMTSLVAVELEKVVLKSTFNRL
	GGLQFDKELRSLIAYLTTVTTWTIRDKFARLSQMATILNLERVTEILD
	YWGPNSGPLTWRLTPAEVRQVLALRIDFRSEDIKRLRL
209	MGWVGGRRRDSASPPGRSRSAADDINPAPANMEGGGGSVAVAGL	COG5
	GARGSGAAAATVRELLQDGCYSDFLNEDFDVKTYTSQSIHQAVIAE
	QLAKLAQGISQLDRELHLQVVARHEDLLAQATGIESLEGVLQMMQ
	TRIGALQGAVDRIKAKIVEPYNKIVARTAQLARLQVACDLLRRIIRIL
	NLSKRLQGQLQGGSREITKAAQSLNELDYLSQGIDLSGIEVIENDLLF
	IARARLEVENQAKRLLEQGLETQNPTQVGTALQVFYNLGTLKDTITS
	VVDGYCATLEENINSALDIKVLTQPSQSAVRGGPGRSTMPTPGNTA
	ALRASFWTNMEKLMDHIYAVCGQVQHLQKVLAKKRDPVSHICFIE
	EIVKDGQPEIFYTFWNSVTQALSSQFHMATNSSMFLKQAFEGEYPK
	LLRLYNDLWKRLQQYSQHIQGNFNASGTTDLYVDLQHMEDDAQDI
	FIPKKPDYDPEKALKDSLQPYEAAYLSKSLSRLFDPINLVFPPGGRNP
	PSSDELDGIIKTIASELNVAAVDTNLTLAVSKNVAKTIQLYSVKSEQL
	LSTQGDASQVIGPLTEGQRRNVAVVNSLYKLHQSVTKAIHALMENA
	VQPLLTSVGDAIEAIIITMHQEDFSGSLSSSGKPDVPCSLYMKELQGF
	IARVMSDYFKHFECLDFVFDNTEAIAQRAVELFIRHASLIRPLGEGG
	KMRLAADFAQMELAVGPFCRRVSDLGKSYRMLRSFRPLLFQASEH
	VASSPALGDVIPFSIIIQFLFTRAPAELKSPFQRAEWSHTRFSQWLDD
	HPSEKDRLLLIRGALEAYVQSVRSREGKEFAPVYPIMVQLLQKAMS
	ALQ
210	MAEGSGEVVAVSATGAANGLNNGAGGTSATTCNPLSRKLHKILET	COG6
	RLDNDKEMLEALKALSTFFVENSLRTRRNLRGDIERKSLAINEEFVSI
	FKEVKEELESISEDVQAMSNCCQDMTSRLQAAKEQTQDLIVKTTKL
	QSESQKLEIRAQVADAFLSKFQLTSDEMSLLRGTREGPITEDFFKAL
	GRVKQIHNDVKVLLRTNQQTAGLEIMEQMALLQETAYERLYRWAQ
	SECRTLTQESCDVSPVLTQAMEALQDRPVLYKYTLDEFGTARRSTV
	VRGFIDALTRGGPGGTPRPIEMHSHDPLRYVGDMLAWLHQATASE
	KEHLEALLKHVTTQGVEENIQEVVGHITEGVCRPLKVRIEQVIVAEP
	GAVLLYKISNLLKFYHHTISGIVGNSATALLTTIEEMHLLSKKIFFNS
	LSLHASKLMDKVELPPPDLGPSSALNQTLMLLREVLASHDSSVVPL
	DARQADFVQVLSCVLDPLLQMCTVSASNLGTADMATFMVNSLYM
	MKTTLALFEFTDRRLEMLQFQIEAHLDTLINEQASYVLTRVGLSYIY
	NTVQQHKPEQGSLANMPNLDSVTLKAAMVQFDRYLSAPDNLLIPQ
	LNFLLSATVKEQIVKQSTELVCRAYGEVYAAVMNPINEYKDPENIL
	HRSPQQVQTLLS
211	MDFSKFLADDFDVKEWINAAFRAGSKEAASGKADGHAATLVMKL	COG7
	QLFIQEVNHAVEETSHQALQNMPKVLRDVEALKQEASFLKEQMILV
	KEDIKKFEQDTSQSMQVLVEIDQVKSRMQLAAESLQEADKWSTLSA
	DIEETFKTQDIAVISAKLTGMQNSLMMLVDTPDYSEKCVHLEALKN
	RLEALASPQIVAAFTSQAVDQSKVFVKVFTEIDRMPQLLAYYYKCH
	KVQLLAAWQELCQSDLSLDRQLTGLYDALLGAWHTQIQWATQVF
	QKPHEVVMVLLIQTLGALMPSLPSCLSNGVERAGPEQELTRLLEFY
	DATAHFAKGLEMALLPHLHEHNLVKVTELVDAVYDPYKPYQLKY
	GDMEESNLLIQMSAVPLEHGEVIDCVQELSHSVNKLFGLASAAVDR
	CVRFTNGLGTCGLLSALKSLFAKYVSDFTSTLQSIRKKCKLDHIPPNS
	LFQEDWTAFQNSIRIIATCGELLRHCGDFEQQLANRILSTAGKYLSDS
	CSPRSLAGFQESILTDKKNSAKNPWQEYNYLQKDNPAEYASLMEIL
	YTLKEKGSSNHNLLAAPRAALTRLNQQAHQLAFDSVFLRIKQQLLLI
	SKMDSWNTAGIGETLTDELPAFSLTPLEYISNIGQYIMSLPLNLEPFV
	TQEDSALELALHAGKLPFPPEQGDELPELDNMADNWLGSIARATM
	QTYCDAILQIPELSPHSAKQLATDIDYLINVMDALGLQPSRTLQHIVT
	LLKTRPEDYRQVSKGLPRRLATTVATMRSVNY
212	MATAATIPSVATATAAALGEVEDEGLLASLFRDRFPEAQWRERPDV	COG8
	GRYLRELSGSGLERLRREPERLAEERAQLLQQTRDLAFANYKTFIRG
	AECTERIHRLFGDVEASLGRLLDRLPSFQQSCRNFVKEAEEISSNRR
	MNSLTLNRHTEILEILEIPQLMDTCVRNSYYEEALELAAYVRRLERK
	YSSIPVIQGIVNEVRQSMQLMLSQLIQQLRTNIQLPACLRVIGYLRRM
	DVFTEAELRVKFLQARDAWLRSILTAIPNDDPYFHITKTIEASRVHLF
	DIITQYRAIFSDEDPLLPPAMGEHTVNESAIFHGWVLQKVSQFLQVL
	ETDLYRGIGGHLDSLLGQCMYFGLSFSRVGADFRGQLAPVFQRVAI
	STFQKAIQETVEKFQEEMNSYMLISAPAILGTSNMPAAVPATQPGTL
	QPPMVLLDFPPLACFLNNILVAFNDLRLCCPVALAQDVTGALEDAL
	AKVTKIILAFHRAEEAAFSSGEQELFVQFCTVFLEDLVPYLNRCLQV
	LFPPAQIAQTLGIPPTQLSKYGNLGHVNIGAIQEPLAFILPKRETLFTL
	DDQALGPELTAPAPEPPAEEPRLEPAGPACPEGGRAETQAEPPSVGP
213	DRLLQQGSAVFQFRMSANSGLLPASMVMPLLGLVMKERCQTAGNP	DOLK
	FFERFGIVVAATGMAVALFSSVLALGITRPVPTNTCVILGLAGGVIIY
	IMKHSLSVGEVIEVLEVLLIFVYLNMILLYLLPRCFTPGEALLVLGGI
	SFVLNQLIKRSLTLVESQGDPVDFFLLVVVVGMVLMGIFFSTLFVFM
	DSGTWASSIFFHLMTCVLSLGVVLPWLHRLIRRNPLLWLLQFLFQTD
	TRIYLLAYWSLLATLACLVVLYQNAKRSSSESKKHQAPTIARKYFH
	LIVVATYIPGIIFDRPLLYVAATVCLAVFIFLEYVRYFRIKPLGHTLRS
	FLSLFLDERDSGPLILTHIYLLLGMSLPIWLIPRPCTQKGSLGGARAL
	VPYAGVLAVGVGDTVASIFGSTMGEIRWPGTKKTFEGTMTSIFAQII
	SVALILIFDSGVDLNYSYAWILGSISTVSLLEAYTTQIDNLLLPLYLLI
	LLMA
214	MSWIKEGELSLWERFCANIIKAGPMPKHIAFIMDGNRRYAKKCQVE	DHDDS
	RQEGHSQGFNKLAETLRWCLNLGILEVTVYAFSIENFKRSKSEVDGL
	MDLARQKFSRLMEEKEKLQKHGVCIRVLGDLHLLPLDLQELIAQAV
	QATKNYNKCFLNVCFAYTSRHEISNAVREMAWGVEQGLLDPSDISE
	SLLDKCLYTNRSPHPDILIRTSGEVRLSDFLLWQTSHSCLVFQPVLW
	PEYTFWNLFEAILQFQMNHSVLQKARDMYAEERKRQQLERDQATV
	TEQLLREGLQASGDAQLRRTRLHKLSARREERVQGFLQALELKRAD
	WLARLGTASA
215	MWAFSELPMPLLINLIVSLLGFVATVTLIPAFRGHFIAARLCGQDLN	DPAGT1
	KTSRQQIPESQGVISGAVFLIILFCFIPFPFLNCFVKEQCKAFPHHEFV
	ALIGALLAICCMIFLGFADDVLNLRWRHKLLLPTAASLPLLMVYFTN
	FGNTTIVVPKPFRPILGLHLDLGILYYVYMGLLAVFCTNAINILAGIN
	GLEAGQSLVISASIIVFNLVELEGDCRDDHVFSLYFMIPFFFTTLGLL
	YHNWYPSRVFVGDTFCYFAGMTFAVVGILGHFSKTMLLFFMPQVF
	NFLYSLPQLLHIIPCPRHRIPRLNIKTGKLEMSYSKFKTKSLSFLGTFIL
	KVAESLQLVTVHQSETEDGEFTECNNMTLINLLLKVLGPIHERNLTL
	LLLLLQILGSAITFSIRYQLVRLFYDV
216	MASLEVSRSPRRSRRELEVRSPRQNKYSVLLPTYNERENLPLIVWLL	DPM1
	VKSFSESGINYEIIIIDDGSPDGTRDVAEQLEKIYGSDRILLRPREKKL
	GLGTAYIHGMKHATGNYIIIMDADLSHHPKFIPEFIRKQKEGNFDIVS
	GTRYKGNGGVYGWDLKRKIISRGANFLTQILLRPGASDLTGSFRLY
	RKEVLEKLIEKCVSKGYVFQMEMIVRARQLNYTIGEVPISFVDRVY
	GESK
	LGGNEIVSFLKGLLTLFATT
217	MATGTDQVVGLGLVAVSLIIFTYYTAWVILLPFIDSQHVIHKYFLPR	DPM2
	AYAVAIPLAAGLLLLLFVGLFISYVMLKTKRVTKKAQ
218	MTKLAQWLWGLAILGSTWVALTTGALGLELPLSCQEVLWPLPAYL	DPM3
	LVSAGCYALGTVGYRVATFHDCEDAARELQSQIQEARADLARRGL
	RF
219	MESTLGAGIVIAEALQNQLAWLENVWLWITFLGDPKILFLFYFPAAY	G6PC3
	YASRRVGIAVLWISLITEWLNLIFKWFLFGDRPFWWVHESGYYSQA
	PAQVHQFPSSCETGPGSPSGHCMITGAALWPIMTALSSQVATRARSR
	WVRVMPSLAYCTFLLAVGLSRIFILAHFPHQVLAGLITGAVLGWLM
	TPRVPMERELSFYGLTALALMLGTSLIYWTLFTLGLDLSWSISLAFK
	WCERPEWIHVDSRPFASLSRDSGAALGLGIALHSPCYAQVRRAQLG
	NGQKIACLVLAMGLLGPLDWLGHPPQISLFYIFNFLKYTLWPCLVL
	ALVPWAVHMFSAQEAPPIHSS
220	MCGIFAYLNYHVPRTRREILETLIKGLQRLEYRGYDSAGVGFDGGN	GFPT1
	DKDWEANACKIQLIKKKGKVKALDEEVHKQQDMDLDIEFDVHLGI
	AHTRWATHGEPSPVNSHPQRSDKNNEFIVIHNGIITNYKDLKKFLES
	KGYDFESETDTETIAKLVKYMYDNRESQDTSFTTLVERVIQQLEGAF
	ALVFKSVHFPGQAVGTRRGSPLLIGVRSEHKLSTDHIPILYRTARTQI
	GSKFTRWGSQGERGKDKKGSCNLSRVDSTTCLFPVEEKAVEYYFAS
	DASAVIEHTNRVIFLEDDDVAAVVDGRLSIHRIKRTAGDHPGRAVQ
	TLQMELQQIMKGNFSSFMQKEIFEQPESVVNTMRGRVNFDDYTVNL
	GGLKDHIKEIQRCRRLILIACGTSYHAGVATRQVLEELTELPVMVEL
	ASDFLDRNTPVFRDDVCFFLSQSGETADTLMGLRYCKERGALTVGI
	TNTVGSSISRETDCGVHINAGPEIGVASTKAYTSQFVSLVMFALMM
	CDDRISMQERRKEIMLGLKRLPDLIKEVLSMDDEIQKLATELYHQKS
	VLIMGRGYHYATCLEGALKIKEITYMHSEGILAGELKHGPLALVDK
	LMPVIMIIMRDHTYAKCQNALQQVVARQGRPVVICDKEDTETIKNT
	KRTIKVPHSVDCLQGILSVIPLQLLAFHLAVLRGYDVDFPRNLAKSV
	TVE
221	MLKAVILIGGPQKGTRFRPLSFEVPKPLFPVAGVPMIQHHIEACAQV	GMPPA
	PGMQEILLIGFYQPDEPLTQFLEAAQQEFNLPVRYLQEFAPLGTGGG
	LYHFRDQILAGSPEAFFVLNADVCSDFPLSAMLEAHRRQRHPFLLLG
	TTANRTQSLNYGCIVENPQTHEVLHYVEKPSTFISDIINCGIYLFSPEA
	LKPLRDVFQRNQQDGQLEDSPGLWPGAGTIRLEQDVFSALAGQGQI
	YVHL
	TDGIWSQIKSAGSALYASRLYLSRYQDTHPERLAKHTPGGPWIRGN
	VYIHPTAKVAPSAVLGPNVSIGKGVTVGEGVRLRESIVLHGATLQEH
	TCVLHSIVGWGSTVGRWARVEGTPSDPNPNDPRARMDSESLFKDG
	KLLPAITILGCRVRIPAEVLILNSIVLPHKELSRSFTNQIIL
222	MKALILVGGYGTRLRPLTLSTPKPLVDFCNKPILLHQVEALAAAGV	GMPPB
	DHVILAVSYMSQVLEKEMKAQEQRLGIRISMSHEEEPLGTAGPLAL
	ARDLLSETADPFFVLNSDVICDFPFQAMVQFHRHHGQEGSILVTKVE
	EPSKYGVVVCEADTGRIHRFVEKPQVFVSNKINAGMYILSPAVLQRI
	QLQPTSIEKEVFPIMAKEGQLYAMELQGFWMDIGQPKDFLTGMCLF
	LQSLRQKQPERLCSGPGIVGNVLVDPSARIGQNCSIGPNVSLGPGVV
	VEDGVCIRRCTVLRDARIRSHSWLESCIVGWRCRVGQWVRMENVT
	VLGEDVIVNDELYLNGASVLPHKSIGESVPEPRIIM
223	MAARWRFWCVSVTMVVALLIVCDVPSASAQRKKEMVLSEKVSQL	MAGT1
	MEWTNKRPVIRMNGDKFRRLVKAPPRNYSVIVMFTALQLHRQCVV
	CKQADEEFQILANSWRYSSAFTNRIFFAMVDFDEGSDVFQMLNMNS
	APTFINFPAKGKPKRGDTYELQVRGFSAEQIARWIADRTDVNIRVIR
	PPNYAGPLMLGLLLAVIGGLVYLRRSNMEFLFNKTGWAFAALCFVL
	AMTSGQMWNHIRGPPYAHKNPHTGHVNYIHGSSQAQFVAETHIVL
	LFNGGVTLGMVLLCEAATSDMDIGKRKIMCVAGIGLVVLFFSWML
	SIFRSKYHGYPYSFLMS
224	MAACEGRRSGALGSSQSDFLTPPVGGAPWAVATTVVMYPPPPPPPH	MAN1B1
	RDFISVTLSFGENYDNSKSWRRRSCWRKWKQLSRLQRNMILFLLAF
	LLFCGLLFYINLADHWKALAFRLEEEQKMRPEIAGLKPANPPVLPAP
	QKADTDPENLPEISSQKTQRHIQRGPPHLQIRPPSQDLKDGTQEEAT
	KRQEAPVDPRPEGDPQRTVISWRGAVIEPEQGTELPSRRAEVPTKPP
	LPPARTQGTPVHLNYRQKGVIDVFLHAWKGYRKFAWGHDELKPVS
	RSFSEWFGLGLTLIDALDTMWILGLRKEFEEARKWVSKKLHFEKDV
	DVNLFESTIRILGGLLSAYHLSGDSLFLRKAEDFGNRLMPAFRTPSKI
	PYSDVNIGTGVAHPPRWTSDSTVAEVTSIQLEFRELSRLTGDKKFQE
	AVEKVTQHIHGLSGKKDGLVPMFINTHSGLFTHLGVFTLGARADSY
	YEYLLKQWIQGGKQETQLLEDYVEAIEGVRTHLLRHSEPSKLTFVG
	ELAHGRFSAKMDHLVCFLPGTLALGVYHGLPASHMELAQELMETC
	YQMNRQMETGLSPEIVHFNLYPQPGRRDVEVKPADRHNLLRPETVE
	SLFYLYRVTGDRKYQDWGWEILQSFSRFTRVPSGGYSSINNVQDPQ
	KPEPRDKMESFFLGETLKYLFLLFSDDPNLLSLDAYVFNTEAHPLPI
	WTPA
225	MRFRIYKRKVLILTLVVAACGFVLWSSNGRQRKNEALAPPLLDAEP	MGAT2
	ARGAGGRGGDHPSVAVGIRRVSNVSAASLVPAVPQPEADNLTLRY
	RSLVYQLNFDQTLRNVDKAGTWAPRELVLVVQVHNRPEYLRLLLD
	SLRKAQGIDNVLVIFSHDFWSTEINQLIAGVNFCPVLQVFFPFSIQLY
	PNEFPGSDPRDCPRDLPKNAALKLGCINAEYPDSFGHYREAKFSQTK
	HHWWWKLHFVWERVKILRDYAGLILFLEEDHYLAPDFYHVFKKM
	WKLKQQECPECDVLSLGTYSASRSF
	YGMADKVDVKTWKSTEHNMGLALTRNAYQKLIECTDTFCTYDDY
	NWDWTLQYLTVSCLPKFWKVLVPQIPRIFHAGDCGMHHKKTCRPS
	TQSAQIESLLNNNKQYMFPETLTISEKFTVVAISPPRKNGGWGDIRD
	HELCKSYRRLQ
226	MARGERRRRAVPAEGVRTAERAARGGPGRRDGRGGGPRSTAGGV	MOGS
	ALAVVVLSLALGMSGRWVLAWYRARRAVTLHSAPPVLPADSSSPA
	VAPDLFWGTYRPHVYFGMKTRSPKPLLTGLMWAQQGTTPGTPKLR
	HTCEQGDGVGPYGWEFHDGLSFGRQHIQDGALRLTTEFVKRPGGQ
	HGGDWSWRVTVEPQDSGTSALPLVSLFFYVVTDGKEVLLPEVGAK
	GQLKFISGHTSELGDFRFTLLPPTSPGDTAPKYGSYNVFWTSNPGLP
	LLTEMVKSRLNSWFQHRPPGAPPERYLGLPGSLKWEDRGPSGQGQ
	GQFLIQQVTLKIPISIEFVFESGSAQAGGNQALPRLAGSLLTQALESH
	AEGFRERFEKTFQLKEKGLSSGEQVLGQAALSGLLGGIGYFYGQGL
	VLPDIGVEGSEQKVDPALFPPVPLFTAVPSRSFFPRGFLWDEGFHQL
	VVQRWDPSLTREALGHWLGLLNADGWIGREQILGDEARARVPPEF
	LVQRAVHANPPTLLLPVAHMLEVGDPDDLAFLRKALPRLHAWFSW
	LHQSQAGPLPLSYRWRGRDPALPTLLNPKTLPSGLDDYPRASHPSVT
	ERHLDLRCWVALGARVLTRLAEHLGEAEVAAELGPLAASLEAAES
	LDELHWAPELGVFADFGNHTKAVQLKPRPPQGLVRVVGRPQPQLQ
	YVDALGYVSLFPLLLRLLDPTSSRLGPLLDILADSRHLWSPFGLRSL
	AASSSFYGQRNSEHDPPYWRGAVWLNVNYLALGALHHYGHLEGP
	HQARAAKLHGELRANVVGNVWRQYQATGFLWEQYSDRDGRGMG
	CRPFHGWTSLVLLAMAEDY
227	MAAEADGPLKRLLVPILLPEKCYDQLFVQWDLLHVPCLKILLSKGL	MPDU1
	GLGIVAGSLLVKLPQVFKILGAKSAEGLSLQSVMLELVALTGTMVY
	SITNNFPFSSWGEALFLMLQTITICFLVMHYRGQTVKGVAFLACYGL
	VLLVLLSPLTPLTVVTLLQASNVPAVVVGRLLQAATNYHNGHTGQL
	SAITVFLLFGGSLARIFTSIQETGDPLMAGTFVVSSLCNGLIAAQLLF
	YWNAKPPHKQKKAQ
228	MAAPRVFPLSCAVQQYAWGKMGSNSEVARLLASSDPLAQIAEDKP	MPI
	YAELWMGTHPRGDAKILDNRISQKTLSQWIAENQDSLGSKVKDTFN
	GNLPFLFKVLSVETPLSIQAHPNKELAEKLHLQAPQHYPDANHKPE
	MAIALTPFQGLCGFRPVEEIVTFLKKVPEFQFLIGDEAATHLKQTMS
	HDSQAVASSLQSCFSHLMKSEKKVVVEQLNLLVKRISQQAAAGNN
	MEDIFGELLLQLHQQYPGDIGCFAIYFLNLLTLKPGEAMFLEANVPH
	AYLKGDCVECMACSDNTVRAGLTP
	KFIDVPTLCEMLSYTPSSSKDRLFLPTRSQEDPYLSIYDPPVPDFTIMK
	TEVPGSVTEYKVLALDSASILLMVQGTVIASTPTTQTPIPLQRGGVLF
	IGANESVSLKLTEPKDLLIFRACCLL
229	MAAAALGSSSGSASPAVAELCQNTPETFLEASKLLLTYADNILRNPN	NGLY1
	DEKYRSIRIGNTAFSTRLLPVRGAVECLFEMGFEEGETHLIFPKKASV
	EQLQKIRDLIAIERSSRLDGSNKSHKVKSSQQPAASTQLPTTPSSNPS
	GLNQHTRNRQGQSSDPPSASTVAADSAILEVLQSNIQHVLVYENPAL
	QEKALACIPVQELKRKSQEKLSRARKLDKGINISDEDFLLLELLHWF
	KEE
	FFHWVNNVLCSKCGGQTRSRDRSLLPSDDELKWGAKEVEDHYCDA
	CQFSNRFPRYNNPEKLLETRCGRCGEWANCFTLCCRAVGFEARYV
	WDYTDHVWTEVYSPSQQRWLHCDACEDVCDKPLLYEIGWGKKLS
	YVIAFSKDEVVDVTWRYSCKHEEVIARRTKVKEALLRDTINGLNKQ
	RQLFLSENRRKELLQRIIVELVEFISPKTPKPGELGGRISGSVAWRVA
	RGEMGLQRKETLFIPCENEKISKQLHLCYNIVKDRYVRVSNNNQTIS
	GWENGVWKMESIFRKVETDWHMVYLARKEGSSFAYISWKFECGS
	VGLKVDSISIRTSSQTFQTGTVEWKLRSDTAQVELTGDNSLHSYADF
	SGATEVILEAELSRGDGDVAWQHTQLFRQSLNDHEENCLEIIIKFSDL
230	MVKIVTVKTQAYQDQKPGTSGLRKRVKVFQSSANYAENFIQSIISTV	PGM1
	EPAQRQEATLVVGGDGRFYMKEAIQLIARIAAANGIGRLVIGQNGIL
	STPAVSCIIRKIKAIGGIILTASHNPGGPNGDFGIKFNISNGGPAPEAIT
	DKIFQISKTIEEYAVCPDLKVDLGVLGKQQFDLENKFKPFTVEIVDS
	VEAYATMLRSIFDFSALKELLSGPNRLKIRIDAMHGVVGPYVKKILC
	EELGAPANSAVNCVPLEDFGGHHPDPNLTYAADLVETMKSGEHDF
	GAAFDGDGDRNMILGKHGFFVNPSDSVAVIAANIFSIPYFQQTGVRG
	FARSMPTSGALDRVASATKIALYETPTGWKFFGNLMDASKLSLCGE
	ESFGTGSDHIREKDGLWAVLAWLSILATRKQSVEDILKDHWQKYGR
	NFFTRYDYEEVEAEGANKMMKDLEALMFDRSFVGKQFSANDKVY
	TVEKADNFEYSDPVDGSISRNQGLRLIFTDGSRIVFRLSGTGSAGATI
	RLYIDSYEKDVAKINQDPQVMLAPLISIALKVSQLQERTGRTAPTVIT
231	MDLGAITKYSALHAKPNGLILQYGTAGFRTKAEHLDHVMFRMGLL	PGM3
	AVLRSKQTKSTIGVMVTASHNPEEDNGVKLVDPLGEMLAPSWEEH
	ATCLANAEEQDMQRVLIDISEKEAVNLQQDAFVVIGRDTRPSSEKLS
	QSVIDGVTVLGGQFHDYGLLTTPQLHYMVYCRNTGGRYGKATIEG
	YYQKLSKAFVELTKQASCSGDEYRSLKVDCANGIGALKLREMEHY
	FSQGLSVQLFNDGSKGKLNHLCGADFVKSHQKPPQGMEIKSNERCC
	SFDGDADRIVYYYHDADGHFHLIDGDKIATLISSFLKELLVEIGESLN
	IGVVQTAYANGSSTRYLEEVMKVPVYCTKTGVKHLHHKAQEFDIG
	VYFEANGHGTALFSTAVEMKIKQSAEQLEDKKRKAAKMLENIIDLF
	NQAAGDAISDMLVIEAILALKGLTVQQWDALYTDLPNRQLKVQVA
	DRRVISTTDAERQAVTPPGLQEAINDLVKKYKLSRAFVRPSGTEDV
	VRVYAEADSQESADHLAHEVSLAVFQLAGGIGERPQPGF
232	MGSQEVLGHAARLASSGLLLQVLFRLITFVLNAFILRFLSKEIVGVV	RFT1
	NVRLTLLYSTTLFLAREAFRRACLSGGTQRDWSQTLNLLWLTVPLG
	VFWSLFLGWIWLQLLEVPDPNVVPHYATGVVLFGLSAVVELLGEPF
	WVLAQAHMFVKLKVIAESLSVILKSVLTAFLVLWLPHWGLYIFSLA
	QLFYTTVLVLCYVIYFTKLLGSPESTKLQTLPVSRITDLLPNITRNGA
	FINWKEAKLTWSFFKQSFLKQILTEGERYVMTFLNVLNFGDQGVYD
	IVNNLGSLVARLIFQPIEESFYIFFAKVLERGKDATLQKQEDVAVAA
	AVLESLLKLALLAGLTITVFGFAYSQLALDIYGGTMLSSGSGPVLLR
	SYCLYVLLLAINGVTECFTFAAMSKEEVDRYNFVMLALSSSFLVLS
	YLLTRWCGSVGFILANCFNMGIRITQSLCFIHRYYRRSPHRPLAGLH
	LSPVLLGTFALSGGVTAVSEVFLCCEQGWPARLAHIAVGAFCLGAT
	LGTAFLTETKLIHFLRTQLGVPRRTDKMT
233	MATYLEFIQQNEERDGVRFSWNVWPSSRLEATRMVVPLACLLTPLK	SEC23B
	ERPDLPPVQYEPVLCSRPTCKAVLNPLCQVDYRAKLWACNFCFQRN
	QFPPAYGGISEVNQPAELMPQFSTIEYVIQRGAQSPLIFLYVVDTCLE
	EDDLQALKESLQMSLSLLPPDALVGLITFGRMVQVHELSCEGISKSY
	VFRGTKDLTAKQIQDMLGLTKPAMPMQQARPAQPQEHPFASSRFL
	QPVHKIDMNLTDLLGELQRDPWPVTQGKRPLRSTGVALSIAVGLLE
	GTFPNTGARIMLFTGGPPTQGPGMVVGDELKIPIRSWHDIEKDNARF
	MKKATKHYEMLANRTAANGHCIDIYACALDQTGLLEMKCCANLT
	GGYMVMGDSFNTSLFKQTFQRIFTKDFNGDFRMAFGATLDVKTSR
	ELKIAGAIGPCVSLNVKGPCVSENELGVGGTSQWKICGLDPTSTLGI
	YFEVVNQHNTPIPQGGRGAIQFVTHYQHSSTQRRIRVTTIARNWAD
	VQSQLRHIEAAFDQEAAAVLMARLGVFRAESEEGPDVLRWLDRQLI
	RLCQKFGQYNKEDPTSFRLSDSFSLYPQFMFHLRRSPFLQVFNNSPD
	ESSYYRHHFARQDLTQSLIMIQPILYSYSFHGPPEPVLLDSSSILADRI
	LLMDTFFQIVIYLGETIAQWRKAGYQDMPEYENFKHLLQAPLDDAQ
	EILQARFPMPRYINTEHGGSQARFLLSKVNPSQTHNNLYAWGQETG
	APILTDDVSLQVFMDHLKKLAVSSAC
234	MAAPRDNVTLLFKLYCLAVMTLMAAVYTIALRYTRTSDKELYFST	SLC35A1
	TAVCITEVIKLLLSVGILAKETGSLGRFKASLRENVLGSPKELLKLSV
	PSLVYAVQNNMAFLALSNLDAAVYQVTYQLKIPCTALCTVLMLNR
	TLSKLQWVSVFMLCAGVTLVQWKPAQATKVVVEQNPLLGFGAIAI
	AVLCSGFAGVYFEKVLKSSDTSLWVRNIQMYLSGIIVTLAGVYLSD
	GAEIKEKGFFYGYTYYVWFVIFLASVGGLYTSVVVKYTDNIMKGFS
	AAAAIVLSTIASVMLFGLQITLTFALGTLLVCVSIYLYGLPRQDTTSI
	QQGETASKERVIGV
235	MAAVGAGGSTAAPGPGAVSAGALEPGTASAAHRRLKYISLAVLVV	SLC35A2
	QNASLILSIRYARTLPGDRFFATTAVVMAEVLKGLTCLLLLFAQKRG
	NVKHLVLFLHEAVLVQYVDTLKLAVPSLIYTLQNNLQYVAISNLPA
	ATFQVTYQLKILTTALFSVLMLNRSLSRLQWASLLLLFTGVAIVQAQ
	QAGGGGPRPLDQNPGAGLAAVVASCLSSGFAGVYFEKILKGSSGSV
	WLRNLQLGLFGTALGLVGLWWAEGTAVATRGFFFGYTPAVWGVV
	LNQAFGGLLVAVVVKYADNILKGFATSLSIVLSTVASIRLFGFHVDP
	LFALGAGLVIGAVYLYSLPRGAAKAIASASASASGPCVHQQPPGQPP
	PPQLSSHRGDLITEPFLPKLLTKVKGS
236	MNRAPLKRSRILHMALTGASDPSAEAEANGEKPFLLRALQIALVVS	SLC35C1
	LYWVTSISMVFLNKYLLDSPSLRLDTPIFVTFYQCLVTTLLCKGLSA
	LAACCPGAVDFPSLRLDLRVARSVLPLSVVFIGMITFNNLCLKYVGV
	AFYNVGRSLTTVFNVLLSYLLLKQTTSFYALLTCGIIIGGFWLGVDQ
	EGAEGTLSWLGTVFGVLASLCVSLNAIYTTKVLPAVDGSIWRLTFY
	NNVNACILFLPLLLLLGELQALRDFAQLGSAHFWGMMTLGGLFGFA
	IGYVTGLQIKFTSPLTHNVSG
	TAKACAQTVLAVLYYEETKSFLWWTSNMMVLGGSSAYTWVRGW
	EMKKTPEEPSPKDSEKSAMGV
237	MAAMASLGALALLLLSSLSRCSAEACLEPQITPSYYTTSDAVISTET	SSR4
	VFIVEISLTCKNRVQNMALYADVGGKQFPVTRGQDVGRYQVSWSL
	DHKSAHAGTYEVRFFDEESYSLLRKAQRNNEDISIIPPLFTVSVDHR
	GTWNGPWVSTEVLAAAIGLVIYYLAFSAKSHIQA
238	MAPWAEAEHSALNPLRAVWLTLTAAFLLTLLLQLLPPGLLPGCAIF	SRD5A3
	QDLIRYGKTKCGEPSRPAACRAFDVPKRYFSHFYIISVLWNGFLLWC
	LTQSLFLGAPFPSWLHGLLRILGAAQFQGGELALSAFLVLVFLWLHS
	LRRLFECLYVSVFSNVMIHVVQYCFGLVYYVLVGLTVLSQVPMDG
	RNAYITGKNLLMQARWFHILGMMMFIWSSAHQYKCHVILGNLRKN
	KAGVVIHCNHRIPFGDWFEYVSSPNYLAELMIYVSMAVTFGFHNLT
	WWLVVTNVFFNQALSAFLSHQFYKSKFVSYPKHRKAFLPFLF
239	MAAAAPGNGRASAPRLLLLFLVPLLWAPAAVRAGPDEDLSHRNKE	TMEM165
	PPAPAQQLQPQPVAVQGPEPARVEKIFTPAAPVHTNKEDPATQTNL
	GFIHAFVAAISVIIVSELGDKTFFIAAIMAMRYNRLTVLAGAMLALG
	LMTCLSVLFGYATTVIPRVYTYYVSTVLFAIFGIRMLREGLKMSPDE
	GQEELEEVQAELKKKDEEFQRTKLLNGPGDVETGTSITVPQKKWLH
	FISPIFVQALTLTFLAEWGDRSQLTTIVLAAREDPYGVAVGGTVGHC
	LCTGLAVIGGRMIAQKISVRTVTIIGGIVFLAFAFSALFISPDSGF
240	MSSWLGGLGSGLGQSLGQVGGSLASLTGQISNFTKDMLMEGTEEV	TRIP11
	EAELPDSRTKEIEAIHAILRSENERLKKLCTDLEEKHEASEIQIKQQST
	SYRNQLQQKEVEISHLKARQIALQDQLLKLQSAAQSVPSGAGVPAT
	TASSSFAYGISHHPSAFHDDDMDFGDIISSQQEINRLSNEVSRLESEV
	GHWRHIAQTSKAQGTDNSDQSEICKLQNIIKELKQNRSQEIDDHQHE
	MSVLQNAHQQKLTEISRRHREELSDYEERIEELENLLQQGGSGVIET
	DLSKIYEMQKTIQVLQIEKVESTKKMEQLEDKIKDINKKLSSAENDR
	DILRREQEQLNVEKRQIMEECENLKLECSKLQPSAVKQSDTMTEKE
	RILAQSASVEEVFRLQQALSDAENEIMRLSSLNQDNSLAEDNLKLK
	MRIEVLEKEKSLLSQEKEELQMSLLKLNNEYEVIKSTATRDISLDSEL
	HDLRLNLEAKEQELNQSISEKETLIAEIEELDRQNQEATKHMILIKDQ
	LSKQQNEGDSIISKLKQDLNDEKKRVHQLEDDKMDITKELDVQKEK
	LIQSEVALNDLHLTKQKLEDKVENLVDQLNKSQESNVSIQKENLEL
	KEHIRQNEEELSRIRNELMQSLNQDSNSNFKDTLLKEREAEVRNLKQ
	NLSELEQLNENLKKVAFDVKMENEKLVLACEDVRHQLEECLAGNN
	QLSLEKNTIVETLKMEKGEIEAELCWAKKRLLEEANKYEKTIEELSN
	ARNLNTSALQLEHEHLIKLNQKKDMEIAELKKNIEQMDTDHKETKD
	VLSSSLEEQKQLTQLINKKEIFIEKLKERSSKLQEELDKYSQALRKNE
	ILRQTIEEKDRSLGSMKEENNHLQEELERLREEQSRTAPVADPKTLD
	SVTELASEVSQLNTIKEHLEEEIKHHQKIIEDQNQSKMQLLQSLQEQ
	KKEMDEFRYQHEQMNATHTQLFLEKDEEIKSLQKTIEQIKTQLHEER
	QDIQTDNSDIFQETKVQSLNIENGSEKHDLSKAETERLVKGIKERELE
	IKLLNEKNISLTKQIDQLSKDEVGKLTQIIQQKDLEIQALHARISSTSH
	TQDVVYLQQQLQAYAMEREKVFAVLNEKTRENSHLKTEYHKMMD
	IVAAKEAALIKLQDENKKLSTRFESSGQDMFRETIQNLSRIIREKDIEI
	DALSQKCQTLLAVLQTSSTGNEAGGVNSNQFEELLQERDKLKQQV
	KKMEEWKQQVMTTVQNMQHESAQLQEELHQLQAQVLVDSDNNS
	KLQVDYTGLIQSYEQNETKLKNFGQELAQVQHSIGQLCNTKDLLLG
	KLDIISPQLSSASLLTPQSAECLRASKSEVLSESSELLQQELEELRKSL
	QEKDATIRTLQENNHRLSDSIAATSELERKEHEQTDSEIKQLKEKQD
	VLQKLLKEKDLLIKAKSDQLLSSNENFTNKVNENELLRQAVTNLKE
	RILILEMDIGKLKGENEKIVETYRGKETEYQALQETNMKFSMMLRE
	KEFECHSMKEKALAFEQLLKEKEQGKTGELNQLLNAVKSMQEKTV
	VFQQERDQVMLALKQKQMENTALQNEVQRLRDKEFRSNQELERLR
	NHLLESEDSYTREALAAEDREAKLRKKVTVLEEKLVSSSNAMENAS
	HQASVQVESLQEQLNVVSKQRDETALQLSVSQEQVKQYALSLANL
	QMVLEHFQQEEKAMYSAELEKQKQLIAEWKKNAENLEGKVISLQE
	CLDEANAALDSASRLTEQLDVKEEQIEELKRQNELRQEMLDDVQK
	KLMSLANSSEGKVDKVLMRNLFIGHFHTPKNQRHEVLRLMGSILGV
	RREEMEQLFHDDQGGVTRWMTGWLGGGSKSVPNTPLRPNQQSVV
	NSSFSELFVKFLETESHPSIPPPKLSVHDMKPLDSPGRRKRDTNAPES
	FKDTAESRSGRRTDVNPFLAPRSAAVPLINPAGLGPGGPGHLLLKPIS
	DVLPTFTPLPALPDNSAGVVLKDLLKQ
241	MGARGAPSRRRQAGRRLRYLPTGSFPFLLLLLLLCIQLGGGQKKKE	TUSC3
	NLLAEKVEQLMEWSSRRSIFRMNGDKFRKFIKAPPRNYSMIVMFTA
	LQPQRQCSVCRQANEEYQILANSWRYSSAFCNKLFFSMVDYDEGT
	DVFQQLNMNSAPTFMHFPPKGRPKRADTFDLQRIGFAAEQLAKWIA
	DRTDVHIRVFRPPNYSGTIALALLVSLVGGLLYLRRNNLEFIYNKTG
	WAMVSLCIVFAMTSGQMWNHIRGPPYAHKNPHNGQVSYIHGSSQA
	QFVAESHIILVLNAAITMGMVLLNE
	AATSKGDVGKRRIICLVGLGLVVFFFSFLLSIFRSKYHGYPYSDLDFE
242	MVCVLVLAAAAGAVAVFLILRIWVVLRSMDVTPRESLSILVVAGSG	ALG14
	GHTTEILRLLGSLSNAYSPRHYVIADTDEMSANKINSFELDRADRDP
	SNMYTKYYIHRIPRSREVQQSWPSTVFTTLHSMWLSFPLIHRVKPDL
	VLCNGPGTCVPICVSALLLGILGIKKVIIVYVESICRVETLSMSGKILF
	HLSDYFIVQWPALKEKYPKSVYLGRIV
243	MRLREPLLSGSAAMPGASLQRACRLLVAVCALHLGVTLVYYLAGR	B4GALT1
	DLSRLPQLVGVSTPLQGGSNSAAAIGQSSGELRTGGARPPPPLGASS
	QPRPGGDSSPVVDSGPGPASNLTSVPVPHTTALSLPACPEESPLLVGP
	MLIEFNMPVDLELVAKQNPNVKMGGRYAPRDCVSPHKVAIIIPFRN
	RQEHLKYWLYYLHPVLQRQQLDYGIYVINQAGDTIFNRAKLLNVGF
	QEALKDYDYTCFVFSDVDLIPMNDHNAYRCFSQPRHISVAMDKFGF
	SLPYVQYFGGVSALSKQQFLTINGFPNNYWGWGGEDDDIFNRLVFR
	GMSISRPNAVVGRCRMIRHSRDKKNEPNPQRFDRIAHTKETMLSDG
	LNSLTYQVLDVQRYPLYTQITVDIGTPS
244	MGYFRCARAGSFGRRRKMEPSTAARAWALFWLLLPLLGAVCASGP	DDOST
	RTLVLLDNLNVRETHSLFFRSLKDRGFELTFKTADDPSLSLIKYGEFL
	YDNLIIFSPSVEDFGGNINVETISAFIDGGGSVLVAASSDIGDPLRELG
	SECGIEFDEEKTAVIDHHNYDISDLGQHTLIVADTENLLKAPTIVGKS
	SLNPILFRGVGMVADPDNPLVLDILTGSSTSYSFFPDKPITQYPHAVG
	KNTLLIAGLQARNNARVIFSGSLDFFSDSFFNSAVQKAAPGSQRYSQ
	TGNYELAVALSRWVFKEEGVLRVGPVSHHRVGETAPPNAYTVTDL
	VEYSIVIQQLSNGKWVPFDGDDIQLEFVRIDPFVRTFLKKKGGKYSV
	QFKLPDVYGVFQFKVDYNRLGYTHLYSSTQVSVRPLQHTQYERFIP
	SAYPYYASAFSMMLGLFIFSIVFLHMKEKEKSD
245	MTGLYELVWRVLHALLCLHRTLTSWLRVRFGTWNWIWRRCCRAA	NUS1
	SAAVLAPLGFTLRKPPAVGRNRRHHRHPRGGSCLAAAHHRMRWR
	ADGRSLEKLPVHMGLVITEVEQEPSFSDIASLVVWCMAVGISYISVY
	DHQGIFKRNNSRLMDEILKQQQELLGLDCSKYSPEFANSNDKDDQV
	LNCHLAVKVLSPEDGKADIVRAAQDFCQLVAQKQKRPTDLDVDTL
	ASLLSSNGCPDPDLVLKFGPVDSTLGFLPWHIRLTEIVSLPSHLNISYE
	DFFSALRQYAACEQRLGK
246	MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTN	RPN2
	LESAFYSIVGLSSLGAQVPDAKKACTYIRSNLDPSNVDSLFYAAQAS
	QALSGCEISISNETKDLLLAAVSEDSSVTQIYHAVAALSGFGLPLASQ
	EALSALTARLSKEETVLATVQALQTASHLSQQADLRSIVEEIEDLVA
	RLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQ
	LMNAIFSKKNFESLSEAFSVASAAAVLSHNRYHVPVVVVPEGSASD
	THEQAILRLQVTNVLSQPLTQATVKLEHAKSVASRATVLQKTSFTP
	VGDVFELNFMNVKFSSGYYDFLVEVEGDNRYIANTVELRVKISTEV
	GITNVDLSTVDKDQSIAPKTTRVTYPAKAKGTFIADSHQNFALFFQL
	VDVNTGAELTPHQTFVRLHNQKTGQEVVFVAEPDNKNVYKFELDT
	SERKIEFDSASGTYTLYLIIGDATLKNPILWNVADVVIKFPEEEAPST
	VLSQNLFTPKQEIQHLFREPEKRPPTV
	VSNTFTALILSPLLLLFALWIRIGANVSNFTFAPSTIIFHLGHAAMLGL
	MYVYWTQLNMFQTLKYLAILGSVTFLAGNRMLAQQAVKRTAH
247	MTTYLEFIQQNEERDGVRFSWNVWPSSRLEATRMVVPVAALFTPLK	SEC23A
	ERPDLPPIQYEPVLCSRTTCRAVLNPLCQVDYRAKLWACNFCYQRN
	QFPPSYAGISELNQPAELLPQFSSIEYVVLRGPQMPLIFLYVVDTCME
	DEDLQALKESMQMSLSLLPPTALVGLITFGRMVQVHELGCEGISKS
	YVFRGTKDLSAKQLQEMLGLSKVPLTQATRGPQVQQPPPSNRFLQP
	VQKIDMNLTDLLGELQRDPWPVPQGKRPLRSSGVALSIAVGLLECT
	FPNTGARIMMFIGGPATQGPGM
	VVGDELKTPIRSWHDIDKDNAKYVKKGTKHFEALANRAATTGHVI
	DIYACALDQTGLLEMKCCPNLTGGYMVMGDSFNTSLFKQTFQRVF
	TKDMHGQFKMGFGGTLEIKTSREIKISGAIGPCVSLNSKGPCVSENEI
	GTGGTCQWKICGLSPTTTLAIYFEVVNQHNAPIPQGGRGAIQFVTQY
	QHSSGQRRIRVTTIARNWADAQTQIQNIAASFDQEAAAILMARLAIY
	RAETEEGPDVLRWLDRQLIRLCQKFGEYHKDDPSSFRFSETFSLYPQ
	FMFHLRRSSFLQVFNNSPDESSYYRHHFMRQDLTQSLIMIQPILYAY
	SFSGPPEPVLLDSSSILADRILLMDTFFQILIYHGETIAQWRKSGYQD
	MPEYENFRHLLQAPVDDAQEILHSRFPMPRYIDTEHGGSQARFLLSK
	VNPSQTHNNMYAWGQESGAPILTDDVSLQVFMDHLKKLAVSSAA
248	MFANLKYVSLGILVFQTTSLVLTMRYSRTLKEEGPRYLSSTAVVVA	SLC35A3
	ELLKIMACILLVYKDSKCSLRALNRVLHDEILNKPMETLKLAIPSGIY
	TLQNNLLYVALSNLDAATYQVTYQLKILTTALFSVSMLSKKLGVYQ
	WLSLVILMTGVAFVQWPSDSQLDSKELSAGSQFVGLMAVLTACFSS
	GFAGVYFEKILKETKQSVWIRNIQLGFFGSIFGLMGVYIYDGELVSK
	NGFFQGYNRLTWIVVVLQALGGLVIAAVIKYADNILKGFATSLSIILS
	TLISYFWLQDFVPTSVFFLGAILVITATFLYGYDPKPAGNPTKA
249	MGLLVFVRNLLLALCLFLVLGFLYYSAWKLHLLQWEEDSNSVVLS	ST3GAL3
	FDSAGQTLGSEYDRLGFLLNLDSKLPAELATKYANFSEGACKPGYA
	SALMTAIFPRFSKPAPMFLDDSFRKWARIREFVPPFGIKGQDNLIKAI
	LSVTKEYRLTPALDSLRCRRCIIVGNGGVLANKSLGSRIDDYDIVVR
	LNSAPVKGFEKDVGSKTTLRITYPEGAMQRPEQYERDSLFVLAGFK
	WQDFKWLKYIVYKERVSASDGFWKSVATRVPKEPPEIRILNPYFIQE
	AAFTLIGLPFNNGLMGRGNIPTLGSVAVTMALHGCDEVAVAGFGY
	DMSTPNAPLHYYETVRMAAIKESWTHNIQREKEFLRKLVKARVITD
	LSSGI
250	MTKFGFLRLSYEKQDTLLKLLILSMAAVLSFSTRLFAVLRFESVIHEF	STT3A
	DPYFNYRTTRFLAEEGFYKFHNWFDDRAWYPLGRIIGGTIYPGLMIT
	SAAIYHVLHFFHITIDIRNVCVFLAPLFSSFTTIVTYHLTKELKDAGA
	GLLAAAMIAVVPGYISRSVAGSYDNEGIAIFCMLLTYYMWIKAVKT
	GSICWAAKCALAYFYMVSSWGGYVFLINLIPLHVLVLMLTGRFSHR
	IYVAYCTVYCLGTILSMQISFVGFQPVLSSEHMAAFGVFGLCQIHAF
	VDYLRSKLNPQQFEVLFRSVISLVGFVLLTVGALLMLTGKISPWTGR
	FYSLLDPSYAKNNIPIIASVSEHQPTTWSSYYFDLQLLVFMFPVGLYY
	CFSNLSDARIFIIMYGVTSMYFSAVMVRLMLVLAPVMCILSGIGVSQ
	VLSTYMKNLDISRPDKKSKKQQDSTYPIKNEVASGMILVMAFFLITY
	TFHSTWVTSEAYSSPSIVLSARGGDGSRIIFDDFREAYYWLRHNTPE
	DAKVMSWWDYGYQITAMANRTILVDNNTWNNTHISRVGQAMAST
	EEKAYEIMRELDVSYVLVIFGGLTGYSSDDINKFLWMVRIGGSTDT
	GKHIKENDYYTPTGEFRVDREGSPVLLNCLMYKMCYYRFGQVYTE
	AKRPPGFDRVRNAEIGNKDFELDVLEEAYTTEHWLVRIYKVKDLDN
	RGLSRT
251	MAEPSAPESKHKSSLNSSPWSGLMALGNSRHGHHGPGAQCAHKAA	STT3B
	GGAAPPKPAPAGLSGGLSQPAGWQSLLSFTILFLAWLAGFSSRLFAV
	IRFESIIHEFDPWFNYRSTHHLASHGFYEFLNWFDERAWYPLGRIVG
	GTVYPGLMITAGLIHWILNTLNITVHIRDVCVFLAPTFSGLTSISTFLL
	TRELWNQGAGLLAACFIAIVPGYISRSVAGSFDNEGIAIFALQFTYYL
	WVKSVKTGSVFWTMCCCLSYFYMVSAWGGYVFIINLIPLHVFVLLL
	MQRYSKRVYIAYSTFYIVGLILSMQIPFVGFQPIRTSEHMAAAGVFA
	LLQAYAFLQYLRDRLTKQEFQTLFFLGVSLAAGAVFLSVIYLTYTG
	YIAPWSGRFYSLWDTGYAKIHIPIIASVSEHQPTTWVSFFFDLHILVC
	TFPAGLWFCIKNINDERVFVALYAISAVYFAGVMVRLMLTLTPVVC
	MLSAIAFSNVFEHYLGDDMKRENPPVEDSSDEDDKRNQGNLYDKA
	GKVRKHATEQEKTEEGLGPNIKSIVTMLMLMLLMMFAVHCTWVTS
	NAYSSPSVVLASYNHDGTRNILDDFREAYFWLRQNTDEHARVMSW
	WDYGYQIAGMANRTTLVDNNTWNNSHIALVGKAMSSNETAAYKI
	MRTLDVDYVLVIFGGVIGYSGDDINKFLWMVRIAEGEHPKDIRESD
	YFTPQGEFRVDKAGSPTLLNCLMYKMSYYRFGEMQLDFRTPPGFD
	RTRNAEIGNKDIKFKHLEEAFTSEHWLVRIYKVKAPDNRETLDHKP
	RVTNIFPKQKYLSKKTTKRKRGYIKNKLVFKKGKKISKKTV
252	MARKSNLPVLLVPFLLCQALVRCSSPLPLVVNTWPFKNATEAAWR	AGA
	ALASGGSALDAVESGCAMCEREQCDGSVGFGGSPDELGETTLDAMI
	MDGTTMDVGAVGDLRRIKNAIGVARKVLEHTTHTLLVGESATTFA
	QSMGFINEDLSTTASQALHSDWLARNCQPNYWRNVIPDPSKYCGPY
	KPPGILKQDIPIHKETEDDRGHDTIGMVVIHKTGHIAAGTSTNGIKFK
	IHGRVGDSPIPGAGAYADDTAGAAAATGNGDILMRFLPSYQAVEY
	MRRGEDPTIACQKVISRIQKHFPEF
	FGAVICANVTGSYGAACNKLSTFTQFSFMVYNSEKNQPTEEKVDCI
253	MGAPRSLLLALAAGLAVARPPNIVLIFADDLGYGDLGCYGHPSSTTP	ARSA
	NLDQLAAGGLRFTDFYVPVSLCTPSRAALLTGRLPVRMGMYPGVL
	VPSSRGGLPLEEVTVAEVLAARGYLTGMAGKWHLGVGPEGAFLPP
	HQGFHRFLGIPYSHDQGPCQNLTCFPPATPCDGGCDQGLVPIPLLAN
	LSVEAQPPWLPGLEARYMAFAHDLMADAQRQDRPFFLYYASHHTH
	YPQFSGQSFAERSGRGPFGDSLMELDAAVGTLMTAIGDLGLLEETL
	VIFTADNGPETMRMSRGGCSGLLRC
	GKGTTYEGGVREPALAFWPGHIAPGVTHELASSLDLLPTLAALAGA
	PLPNVTLDGFDLSPLLLGTGKSPRQSLFFYPSYPDEVRGVFAVRTGK
	YKAHFFTQGSAHSDTTADPACHASSSLTAHEPPLLYDLSKDPGENY
	NLLGGVAGATPEVLQALKQLQLLKAQLDAAVTFGPSQVARGEDPA
	LQICCHPGCTPRPACCHCPDPHA
254	MGPRGAASLPRGPGPRRLLLPVVLPLLLLLLLAPPGSGAGASRPPHL	ARSB
	VFLLADDLGWNDVGFHGSRIRTPHLDALAAGGVLLDNYYTQPLCT
	PSRSQLLTGRYQIRTGLQHQIIWPCQPSCVPLDEKLLPQLLKEAGYTT
	HMVGKWHLGMYRKECLPTRRGFDTYFGYLLGSEDYYSHERCTLID
	ALNVTRCALDFRDGEEVATGYKNMYSTNIFTKRAIALITNHPPEKPL
	FLYLALQSVHEPLQVPEEYLKPYDFIQDKNRHHYAGMVSLMDEAV
	GNVTAALKSSGLWNNTVFIFSTDNGGQTLAGGNNWPLRGRKWSL
	WEGGVRGVGFVASPLLKQKGVKNRELIHISDWLPTLVKLARGHTN
	GTKPLDGFDVWKTISEGSPSPRIELLHNIDPNFVDSSPCPRNSMAPAK
	DDSSLPEYSAFNTSVHAAIRHGNWKLLTGYPGCGYWFPPPSQYNVS
	EIPSSDPPTKTLWLFDIDRDPEERHDLSREYPHIVTKLLSRLQFYHKH
	SVPVYFPAQDPRCDPKATGVWGPWM
255	MPGRSCVALVLLAAAVSCAVAQHAPPWTEDCRKSTYPPSGPTYRG	ASAH1
	AVPWYTINLDLPPYKRWHELMLDKAPVLKVIVNSLKNMINTFVPSG
	KIMQVVDEKLPGLLGNFPGPFEEEMKGIAAVTDIPLGEIISFNIFYELF
	TICTSIVAEDKKGHLIHGRNMDFGVFLGWNINNDTWVITEQLKPLTV
	NLDFQRNNKTVFKASSFAGYVGMLTGFKPGLFSLTLNERFSINGGY
	LGILEWILGKKDVMWIGFLTRTVLENSTSYEEAKNLLTKTKILAPAY
	FILGGNQSGEGCVITRDRKESLDVYELDAKQGRWYVVQTNYDRWK
	HPFFLDDRRTPAKMCLNRTSQENISFETMYDVLSTKPVLNKLTVYT
	TLIDVTKGQFETYLRDCPDPCIGW
256	MSADSSPLVGSTPTGYGTLTIGTSIDPLSSSVSSVRLSGYCGSPWRVI	ATP13A2
	GYHVVVWMMAGIPLLLFRWKPLWGVRLRLRPCNLAHAETLVIEIR
	DKEDSSWQLFTVQVQTEAIGEGSLEPSPQSQAEDGRSQAAVGAVPE
	GAWKDTAQLHKSEEAVSVGQKRVLRYYLFQGQRYIWIETQQAFYQ
	VSLLDHGRSCDDVHRSRHGLSLQDQMVRKAIYGPNVISIPVKSYPQ
	LLVDEALNPYYGFQAFSIALWLADHYYWYALCIFLISSISICLSLYKT
	RKQSQTLRDMVKLSMRVCVCRPGGEEEWVDSSELVPGDCLVLPQE
	GGLMPCDAALVAGECMVNESSLTGESIPVLKTALPEGLGPYCAETH
	RRHTLFCGTLILQARAYVGPHVLAVVTRTGFCTAKGGLVSSILHPRP
	INFKFYKHSMKFVAALSVLALLGTIYSIFILYRNRVPLNEIVIRALDL
	VTVVVPPALPAAMTVCTLYAQSRLRRQGIFCIHPLRINLGGKLQLVC
	FDKTGTLTEDGLDVMGVVPLKGQAFLPLV
	PEPRRLPVGPLLRALATCHALSRLQDTPVGDPMDLKMVESTGWVL
	EEEPAADSAFGTQVLAVMRPPLWEPQLQAMEEPPVPVSVLHRFPFS
	SALQRMSVVVAWPGATQPEAYVKGSPELVAGLCNPETVPTDFAQM
	LQSYTAAGYRVVALASKPLPTVPSLEAAQQLTRDTVEGDLSLLGLL
	VMRNLLKPQTTPVIQALRRTRIRAVMVTGDNLQTAVTVARGCGMV
	APQEHLHVHATHPERGQPASLEFLPMESPTAVNGVKDPDQAASYTV
	EPDPRSRHLALSGPTFGIIVKHFPKL
	LPKVLVQGTVFARMAPEQKTELVCELQKLQYCVGMCGDGANDCG
	ALKAADVGISLSQAEASVVSPFTSSMASIECVPMVIREGRCSLDTSFS
	VFKYMALYSLTQFISVLILYTINTNLGDLQFLAIDLVITTTVAVLMSR
	TGPALVLGRVRPPGALLSVPVLSSLLLQMVLVTGVQLGGYFLTLAQ
	PWFVPLNRTVAAPDNLPNYENTVVFSLSSFQYLILAAAVSKGAPFRR
	PLYTNVPFLVALALLSSVLVGLVLVPGLLQGPLALRNITDTGFKLLL
	LGLVTLNFVGAFMLESVLDQCLPACLRRLRPKRASKKRFKQLEREL
	AEQPWPPLPAGPLR
257	MGGCAGSRRRFSDSEGEETVPEPRLPLLDHQGAHWKNAVGFWLLG	CLN3
	LCNNFSYVVMLSAAHDILSHKRTSGNQSHVDPGPTPIPHNSSSRFDC
	NSVSTAAVLLADILPTLVIKLLAPLGLHLLPYSPRVLVSGICAAGSFV
	LVAFSHSVGTSLCGVVFASISSGLGEVTFLSLTAFYPRAVISWWSSG
	TGGAGLLGALSYLGLTQAGLSPQQTLLSMLGIPALLLASYFLLLTSP
	EAQDPGGEEEAESAARQPLIRTEAPESKPGSSSSLSLRERWTVFKGL
	LWYIVPLVVVYFAEYFINQGLFELLFFWNTSLSHAQQYRWYQMLY
	QAGVFASRSSLRCCRIRFTWALALLQCLNLVFLLADVWFGFLPSIYL
	VFLIILYEGLLGGAAYVNTFHNIALETSDEHREFAMAATCISDTLGIS
	LSGLLALPLHDFLCQLS
258	MAQEVDTAQGAEMRRGAGAARGRASWCWALALLWLAVVPGWS	CLN5
	RVSGIPSRRHWPVPYKRFDFRPKPDPYCQAKYTFCPTGSPIPVMEGD
	DDIEVFRLQAPVWEFKYGDLLGHLKIMHDAIGFRSTLTGKNYTME
	WYELFQLGNCTFPHLRPEMDAPFWCNQGAACFFEGIDDVHWKENG
	TLVQVATISGNMFNQMAKWVKQDNETGIYYETWNVKASPEKGAE
	TWFDSYDCSKFVLRTFNKLAEFGAEFKNIETNYTRIFLYSGEPTYLG
	NETSVFGPTGNKTLGLAIKRFYYPFKPHLPTKEFLLSLLQIFDAVIVH
	KQFYLFYNFEYWFLPMKFPFIKITYEEIPLPIRNKTLSGL
259	MEATRRRQHLGATGGPGAQLGASFLQARHGSVSADEAARTAPFHL	CLN6
	DLWFYFTLQNWVLDFGRPIAMLVFPLEWFPLNKPSVGDYFHMAYN
	VITPFLLLKLIERSPRTLPRSITYVSIIIFIMGASIHLVGDSVNHRLLFSG
	YQHHLSVRENPIIKNLKPETLIDSFELLYYYDEYLGHCMWYIPFFLIL
	FMYFSGCFTASKAESLIPGPALLLVAPSGLYYWYLVTEGQIFILFIFTF
	FAMLALVLHQKRKRLFLDSNGLFLFSSFALTLLLVALWVAWLWND
	PVLRKKYPGVIYVPEPWAFYTLHVSSRH
260	MNPASDGGTSESIFDLDYASWGIRSTLMVAGFVFYLGVFVVCHQLS	CLN8
	SSLNATYRSLVAREKVFWDLAATRAVFGVQSTAAGLWALLGDPVL
	HADKARGQQNWCWFHITTATGFFCFENVAVHLSNLIFRTFDLFLVI
	HHLFAFLGFLGCLVNLQAGHYLAMTTLLLEMSTPFTCVSWMLLKA
	GWSESLFWKLNQWLMIHMFHCRMVLTYHMWWVCFWHWDGLVS
	SLYLPHLTLFLVGLALLTLIINPYWTHKKTQQLLNPVDWNFAQPEA
	KSRPEGNGQLLRKKRP
261	MIRNWLTIFILFPLKLVEKCESSVSLTVPPVVKLENGSSTNVSLTLRP	CTNS
	PLNATLVITFEITFRSKNITILELPDEVVVPPGVTNSSFQVTSQNVGQL
	TVYLHGNHSNQTGPRIRFLVIRSSAISIINQVIGWIYFVAWSISFYPQV
	IMNWRRKSVIGLSFDFVALNLTGFVAYSVFNIGLLWVPYIKEQFLLK
	YPNGVNPVNSNDVFFSLHAVVLTLIIIVQCCLYERGGQRVSWPAIGF
	LVLAWLFAFVTMIVAAVGVTTWLQFLFCFSYIKLAVTLVKYFPQAY
	MNFYYKSTEGWSIGNVLLDFTGGSFSLLQMFLQSYNNDQWTLIFGD
	PTKFGLGVFSIVFDVVFFIQHFCLYRKRPGYDQLN
262	MIRAAPPPLFLLLLLLLLLVSWASRGEAAPDQDEIQRLPGLAKQPSF	CTSA
	RQYSGYLKGSGSKHLHYWFVESQKDPENSPVVLWLNGGPGCSSLD
	GLLTEHGPFLVQPDGVTLEYNPYSWNLIANVLYLESPAGVGFSYSD
	DKFYATNDTEVAQSNFEALQDFFRLFPEYKNNKLFLTGESYAGIYIP
	TLAVLVMQDPSMNLQGLAVGNGLSSYEQNDNSLVYFAYYHGLLG
	NRLWSSLQTHCCSQNKCNFYDNKDLECVTNLQEVARIVGNSGLNIY
	NLYAPCAGGVPSHFRYEKDTVVVQD
	LGNIFTRLPLKRMWHQALLRSGDKVRMDPPCTNTTAASTYLNNPY
	VRKALNIPEQLPQWDMCNFLVNLQYRRLYRSMNSQYLKLLSSQKY
	QILLYNGDVDMACNFMGDEWFVDSLNQKMEVQRRPWLVKYGDS
	GEQIAGFVKEFSHIAFLTIKGAGHMVPTDKPLAAFTMFSRFLNKQPY
263	MQPSSLLPLALCLLAAPASALVRIPLHKFTSIRRTMSEVGGSVEDLIA	CTSD
	KGPVSKYSQAVPAVTEGPIPEVLKNYMDAQYYGEIGIGTPPQCFTV
	VFDTGSSNLWVPSIHCKLLDIACWIHHKYNSDKSSTYVKNGTSFDIH
	YGSGSLSGYLSQDTVSVPCQSASSASALGGVKVERQVFG
	EATKQPGITFIAAKFDGILGMAYPRISVNNVLPVFDNLMQQKLVDQ
	NIFSFYLSRDPDAQPGGELMLGGTDSKYYKGSLSYLNVTRKAYWQ
	VHLDQVEVASGLTLCKEGCEAIVDTGTSLMVGPVDEVRELQKAIGA
	VPLIQGEYMIPCEKVSTLPAITLKLGGKGYKLSPEDYTLKVSQAGKT
	LCLSGFMGMDIPPPSGPLWILGDVFIGRYYTVFDRDNNRVGFAEAA
	RL
264	MAPWLQLLSLLGLLPGAVAAPAQPRAASFQAWGPPSPELLAPTRFA	CTSF
	LEMFNRGRAAGTRAVLGLVRGRVRRAGQGSLYSLEATLEEPPCND
	PMVCRLPVSKKTLLCSFQVLDELGRHVLLRKDCGPVDTKVPGAGEP
	KSAFTQGSAMISSLSQNHPDNRNETFSSVISLLNEDPLSQDLPVKMA
	SIFKNFVITYNRTYESKEEARWRLSVFVNNMVRAQKIQALDRGTAQ
	YGVTKFSDLTEEEFRTIYLNTLLRKEPGNKMKQAKSVGDLAPPEWD
	WRSKGAVTKVKDQGMCGSCWAFSVTGNVEGQWFLNQGTLLSLSE
	QELLDCDKMDKACMGGLPSNAYSAIKNLGGLETEDDYSYQGHMQ
	SCNFSAEKAKVYINDSVELSQNEQKLAAWLAKRGPISVAINAFGMQ
	FYRHGISRPLRPLCSPWLIDHAVLLVGYGNRSDVPFWAIKNSWGTD
	WGEKGYYYLHRGSGACGVNTMASSAVVD
265	MWGLKVLLLPVVSFALYPEEILDTHWELWKKTHRKQYNNKVDEIS	CTSK
	RRLIWEKNLKYISIHNLEASLGVHTYELAMNHLGDMTSEEVVQKMT
	GLKVPLSHSRSNDTLYIPEWEGRAPDSVDYRKKGYVTPVKNQGQC
	GSCWAFSSVGALEGQLKKKTGKLLNLSPQNLVDCVSENDGCGGGY
	MTNAFQYVQKNRGIDSEDAYPYVGQEESCMYNPTGKAAKCRGYR
	EIPEGNEKALKRAVARVGPVSVAIDASLTSFQFYSKGVYYDESCNSD
	NLNHAVLAVGYGIQKGNKHWIIKNSWGENWGNKGYILMARNKNN
	ACGIANLASFPKM
266	MADQRQRSLSTSGESLYHVLGLDKNATSDDIKKSYRKLALKYHPD	DNAJC5
	KNPDNPEAADKFKEINNAHAILTDATKRNIYDKYGSLGLYVAEQFG
	EENVNTYFVLSSWWAKALFVFCGLLTCCYCCCCLCCCFNCCCGKC
	KPKAPEGEETEFYVSPEDLEAQLQSDEREATDTPIVIQPASATETTQL
	TADSHPSYHTDGFN
267	MRAPGMRSRPAGPALLLLLLFLGAAESVRRAQPPRRYTPDWPSLDS	FUCA1
	RPLPAWFDEAKFGVFIHWGVFSVPAWGSEWFWWHWQGEGRPQYQ
	RFMRDNYPPGFSYADFGPQFTARFFHPEEWADLFQAAGAKYVVLT
	TKHHEGFTNWPSPVSWNWNSKDVGPHRDLVGELGTALRKRNIRYG
	LYHSLLEWFHPLYLLDKKNGFKTQHFVSAKTMPELYDLVNSYKPD
	LIWSDGEWECPDTYWNSTNFLSWLYNDSPVKDEVVVNDRWGQNC
	SCHHGGYYNCEDKFKPQSLPDHKWEMCTSIDKFSWGYRRDMALSD
	VTEESEIISELVQTVSLGGNYLLNIGPTKDGLIVPIFQERLLAVGK
	WLSINGEAIYASKPWRVQWEKNTTSVWYTSKGSAVYAIFLHWPEN
	GVLNLESPITTSTTKITMLGIQGDLKWSTDPDKGLFISLPQLPPSAVP
	AEFAWTIKLTGVK
268	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSP	GAA
	VLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCA
	PDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLE
	NLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDP
	ANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLN
	TTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNR
	DLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPA
	LSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHL
	CRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFN
	KDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLR
	RGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHD
	QVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQA
	ATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRST
	FAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVC
	GFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQ
	AMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWT
	VDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALG
	SLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLT
	TTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIF
	LARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVS
	NFTYSPDTKVLDICVSLLMGEQFLVSWC
269	MAEWLLSASWQRRAKAMTAAAGSAGRAAVPLLLCALLAPGGAYV	GALC
	LDDSDGLGREFDGIGAVSGGGATSRLLVNYPEPYRSQILDYLFKPNF
	GASLHILKVEIGGDGQTTDGTEPSHMHYALDENYFRGYEWWLMKE
	AKKRNPNITLIGLPWSFPGWLGKGFDWPYVNLQLTAYYVVTWIVG
	AKRYHDLDIDYIGIWNERSYNANYIKILRKMLNYQGLQRVKIIASDN
	LWESISASMLLDAELFKVVDVIGAHYPGTHSAKDAKLTGKKLWSSE
	DFSTLNSDMGAGCWGRILNQNYINGYMTSTIAWNLVASYYEQLPY
	GRCGLMTAQEPWSGHYVVESPVWVSAHTTQFTQPGWYYLKTVGH
	LEKGGSYVALTDGLGNLTIIIETMSHKHSKCIRPFLPYFNVSQQFATF
	VLKGSFSEIPELQVWYTKLGKTSERFLFKQLDSLWLLDSDGSFTLSL
	HEDELFTLTTLTTGRKGSYPLPPKSQPFPSTYKDDFNVDYPFFSEAPN
	FADQTGVFEYFTNIEDPGEHHFTLRQVLNQRPITWAADASNTISIIGD
	YNWTNLTIKCDVYIETPDTGGVFIAGRVNKGGILIRSARGIFFWIFAN
	GSYRVTGDLAGWIIYALGRVEVTAKKWYTLTLTIKGHFTSGMLND
	KSLWTDIPVNFPKNGWAAIGTHSFEFAQFDNFLVEATR
270	MAAVVAATRWWQLLLVLSAAGMGASGAPQPPNILLLLMDDMGW	GALNS
	GDLGVYGEPSRETPNLDRMAAEGLLFPNFYSANPLCSPSRAALLTG
	RLPIRNGFYTTNAHARNAYTPQEIVGGIPDSEQLLPELLKKAGYVSKI
	VGKWHLGHRPQFHPLKHGFDEWFGSPNCHFGPYDNKARPNIPVYR
	DWEMVGRYYEEFPINLKTGEANLTQIYLQEALDFIKRQARHHPFFL
	YWAVDATHAPVYASKPFLGTSQRGRYGDAVREIDDSIGKILELLQD
	LHVADNTFVFFTSDNGAALISAPEQGGSNGPFLCGKQTTFEGGMRE
	PALAWWPGHVTAGQVSHQLGSIMDLFTTSLALAGLTPPSDRAIDGL
	NLLPTLLQGRLMDRPIFYYRGDTLMAATLGQHKAHFWTWTNSWE
	NFRQGIDFCPGQNVSGVTTHNLEDHTKLPLIFHLGRDPGERFPLSFAS
	AEYQEALSRITSVVQQHQEALVPAQPQLNVCNWAVMNWAPPGCE
	KLGKCLTPPESIPKKCLWSH
271	MQLRNPELHLGCALALRFLALVSWDIPGARALDNGLARTPTMGWL	GLA
	HWERFMCNLDCQEEPDSCISEKLFMEMAELMVSEGWKDAGYEYL
	CIDDCWMAPQRDSEGRLQADPQRFPHGIRQLANYVHSKGLKLGIYA
	DVGNKTCAGFPGSFGYYDIDAQTFADWGVDLLKFDGCYCDSLENL
	ADGYKHMSLALNRTGRSIVYSCEWPLYMWPFQKPNYTEIRQYCNH
	WRNFADIDDSWKSIKSILDWTSFNQERIVDVAGPGGWNDPDMLVIG
	NFGLSWNQQVTQMALWAIMAAPLFMSNDLRHISPQAKALLQDKD
	VIAINQDPLGKQGYQLRQGDNFEVWERPLSGLAWAVAMINRQEIG
	GPRSYTIAVASLGKGVACNPACFITQLLPVKRKLGFYEWTSRLRSHI
	NPTGTVLLQLENTMQMSLKDLL
272	MPGFLVRILPLLLVLLLLGPTRGLRNATQRMFEIDYSRDSFLKDGQP	GLB1
	FRYISGSIHYSRVPRFYWKDRLLKMKMAGLNAIQTYVPWNFHEPW
	PGQYQFSEDHDVEYFLRLAHELGLLVILRPGPYICAEWEMGGLPAW
	LLEKESILLRSSDPDYLAAVDKWLGVLLPKMKPLLYQNGGPVITVQ
	VENEYGSYFACDFDYLRFLQKRFRHHLGDDVVLFTTDGAHKTFLK
	CGALQGLYTTVDFGTGSNITDAFLSQRKCEPKGPLINSEFYTGWLDH
	WGQPHSTIKTEAVASSLYDILARG
	ASVNLYMFIGGTNFAYWNGANSPYAAQPTSYDYDAPLSEAGDLTE
	KYFALRNIIQKFEKVPEGPIPPSTPKFAYGKVTLEKLKTVGAALDILC
	PSGPIKSLYPLTFIQVKQHYGFVLYRTTLPQDCSNPAPLSSPLNGVHD
	RAYVAVDGIPQGVLERNNVITLNITGKAGATLDLLVENMGRVNYG
	AYINDFKGLVSNLTLSSNILTDWTIFPLDTEDAVRSHLGGWGHRDSG
	HHDEAWAHNSSNYTLPAFYMGNFSIPSGIPDLPQDTFIQFPGWTKGQ
	VWINGFNLGRYWPARGPQLTLFVPQHILMTSAPNTITVLELEWAPC
	SSDDPELCAVTFVDRPVIGSSVTYDHPSKPVEKRLMPPPPQKNKDS
	WLDHV
273	MQSLMQAPLLIALGLLLAAPAQAHLKKPSQLSSFSWDNCDEGKDPA	GM2A
	VIRSLTLEPDPIIVPGNVTLSVMGSTSVPLSSPLKVDLVLEKEVAGLW
	IKIPCTDYIGSCTFEHFCDVLDMLIPTGEPCPEPLRTYGLPCHCPFKEG
	TYSLPKSEFVVPDLELPSWLTTGNYRIESVLSSSGKRLGCIKIAASLK
	GI
274	MLFKLLQRQTYTCLSHRYGLYVCFLGVVVTIVSAFQFGEVVLEWSR	GNPTAB
	DQYHVLFDSYRDNIAGKSFQNRLCLPMPIDVVYTWVNGTDLELLKE
	LQQVREQMEEEQKAMREILGKNTTEPTKKSEKQLECLLTHCIKVPM
	LVLDPALPANITLKDLPSLYPSFHSASDIFNVAKPKNPSTNVSVVVFD
	STKDVEDAHSGLLKGNSRQTVWRGYLTTDKEVPGLVLMQDLAFLS
	GFPPTFKETNQLKTKLPENLSSKVKLLQLYSEASVALLKLNNPKDFQ
	ELNKQTKKNMTIDGKELTISPA
	YLLWDLSAISQSKQDEDISASRFEDNEELRYSLRSIERHAPWVRNIFI
	VTNGQIPSWLNLDNPRVTIVTHQDVFRNLSHLPTFSSPAIESHIHRIEG
	LSQKFIYLNDDVMFGKDVWPDDFYSHSKGQKVYLTWPVPNCAEGC
	PGSWIKDGYCDKACNNSACDWDGGDCSGNSGGSRYIAGGGGTGSI
	GVGQPWQFGGGINSVSYCNQGCANSWLADKFCDQACNVLSCGFD
	AGDCGQDHFHELYKVILLPNQTHYIIPKGECLPYFSFAEVAKRGVEG
	AYSDNPIIRHASIANKWKTIHLIMHSGMNATTIHFNLTFQNTNDEEF
	KMQITVEVDTREGPKLNSTAQKGYENLVSPITLLPEAEILFEDIPKEK
	RFPKFKRHDVNSTRRAQEEVKIPLVNISLLPKDAQLSLNTLDLQLEH
	GDITLKGYNLSKSALLRSFLMNSQHAKIKNQAIITDETNDSLVAPQE
	KQVHKSILPNSLGVSERLQRLTFPAVSVKVNGHDQGQNPPLDLETT
	ARFRVETHTQKTIGGNVTKEKPPSLIVPLESQMTKEKKITGKEKENS
	RMEENAENHIGVTEVLLGRKLQHYTDSYLGFLPWEKKKYFQDLLD
	EEESLKTQLAYFTDSKNTGRQLKDTFADSLRYVNKILNSKFGFTSRK
	VPAHMPHMIDRIVMQELQDMFPEEFDKTSFHKVRHSEDMQFAFSYF
	YYLMSAVQPLNISQVFDEVDTDQSGVLSDREIRTLATRIHELPLSLQ
	DLTGLEHMLINCSKMLPADITQLNNIPPTQESYYDPNLPPVTKSLVT
	NCKPVTDKIHKAYKDKNKYRFEIMGEEEIAFKMIRTNVSHVVGQLD
	DIRKNPRKFVCLNDNIDHNHKDAQTVKAVLRDFYESMFPIPSQFELP
	REYRNRFLHMHELQEWRAYRDKLKFWTHCVLATLIMFTIFSFFAEQ
	LIALKRKIFPRRRIHKEASPNRIRV
275	MAAGLARLLLLLGLSAGGPAPAGAAKMKVVEEPNAFGVNNPFLPQ	GNPTG
	ASRLQAKRDPSPVSGPVHLFRLSGKCFSLVESTYKYEFCPFHNVTQH
	EQTFRWNAYSGILGIWHEWEIANNTFTGMWMRDGDACRSRSRQSK
	VELACGKSNRLAHVSEPSTCVYALTFETPLVCHPHALLVYPTLPEAL
	QRQWDQVEQDLADELITPQGHEKLLRTLFEDAGYLKTPEENEPTQL
	EGGPDSLGFETLENCRKAHKELSKEIKRLKGLLTQHGIPYTRPTETS
	NLEHLGHETPRAKSPEQLRGDPG
	LRGSL
276	MRLLPLAPGRLRRGSPRHLPSCSPALLLLVLGGCLGVFGVAAGTRR	GNS
	PNVVLLLTDDQDEVLGGMTPLKKTKALIGEMGMTFSSAYVPSALC
	CPSRASILTGKYPHNHHVVNNTLEGNCSSKSWQKIQEPNTFPAILRS
	MCGYQTFFAGKYLNEYGAPDAGGLEHVPLGWSYWYALEKNSKYY
	NYTLSINGKARKHGENYSVDYLTDVLANVSLDFLDYKSNFEPFFM
	MIATPAPHSPWTAAPQYQKAFQNVFAPRNKNFNIHGTNKHWLIRQ
	AKTPMTNSSIQFLDNAFRKRWQTLLSVD
	DLVEKLVKRLEFTGELNNTYIFYTSDNGYHTGQFSLPIDKRQLYEFD
	IKVPLLVRGPGIKPNQTSKMLVANIDLGPTILDIAGYDLNKTQMDG
	MSLLPILRGASNLTWRSDVLVEYQGEGRNVTDPTCPSLSPGVSQCFP
	DCVCEDAYNNTYACVRTMSALWNLQYCEFDDQEVFVEVYNLTAD
	PDQITNIAKTIDPELLGKMNYRLMMLQSCSGPTCRTPGVFDPGYRFD
	PRLMFSNRGSVRTRRFSKHLL
277	MWTLVSWVALTAGLVAGTRCPDGQFCPVACCLDPGGASYSCCRPL	GRN
	LDKWPTTLSRHLGGPCQVDAHCSAGHSCIFTVSGTSSCCPFPEAVAC
	GDGHHCCPRGFHCSADGRSCFQRSGNNSVGAIQCPDSQFECPDFST
	CCVMVDGSWGCCPMPQASCCEDRVHCCPHGAFCDLVHTRCITPTG
	THPLAKKLPAQRTNRAVALSSSVMCPDARSRCPDGSTCCELPSGKY
	GCCPMPNATCCSDHLHCCPQDTVCDLIQSKCLSKENATTDLLTKLP
	AHTVGDVKCDMEVSCPDGYTCCRLQSGAWGCCPFTQAVCCEDHIH
	CCPAGFTCDTQKGTCEQGPHQVPWMEKAPAHLSLPDPQALKRDVP
	CDNVSSCPSSDTCCQLTSGEWGCCPIPEAVCCSDHQHCCPQGYTCV
	AEGQCQRGSEIVAGLEKMPARRASLSHPRDIGCDQHTSCPVGQTCC
	PSLGGSWACCQLPHAVCCEDRQHCCPAGYTCNVKARSCEKEVVSA
	QPATFLARSPHVGVKDVECGEGHFCHDNQTCCRDNRQGWACCPY
	RQGVCCADRRHCCPAGFRCAARGTKCLRREAPRWDAPLRDPALRQ
	LL
278	MARGSAVAWAALGPLLWGCALGLQGGMLYPQESPSRECKELDGL	GUSB
	WSFRADFSDNRRRGFEEQWYRRPLWESGPTVDMPVPSSFNDISQD
	WRLRHFVGWVWYEREVILPERWTQDLRTRVVLRIGSAHSYAIVWV
	NGVDTLEHEGGYLPFEADISNLVQVGPLPSRLRITIAINNTLTPTTLPP
	GTIQYLTDTSKYPKGYFVQNTYFDFFNYAGLQRSVLLYTTPTTYIDD
	ITVTTSVEQDSGLVNYQISVKGSNLFKLEVRLLDAENKVVANGTGT
	QGQLKVPGVSLWWPYLMHERPAYL
	YSLEVQLTAQTSLGPVSDFYTLPVGIRTVAVTKSQFLINGKPFYFHG
	VNKHEDADIRGKGFDWPLLVKDFNLLRWLGANAFRTSHYPYAEEV
	MQMCDRYGIVVIDECPGVGLALPQFFNNVSLHHHMQVMEEVVRR
	DKNHPAVVMWSVANEPASHLESAGYYLKMVIAHTKSLDPSRPVTF
	VSNSNYAADKGAPYVDVICLNSYYSWYHDYGHLELIQLQLATQFE
	NWYKKYQKPIIQSEYGAETIAGFHQDPPLMFTEEYQKSLLEQYHLG
	LDQKRRKYVVGELIWNFADFMTEQSPTRVLGNKKGIFTRQRQPKSA
	AFLLRERYWKIANETRYPHSVAKSQCLENSLFT
279	MTSSRLWFSLLLAAAFAGRATALWPWPQNFQTSDQRYVLYPNNFQ	HEXA
	FQYDVSSAAQPGCSVLDEAFQRYRDLLFGSGSWPRPYLTGKRHTLE
	KNVLVVSVVTPGCNQLPTLESVENYTLTINDDQCLLLSETVWGALR
	GLETFSQLVWKSAEGTFFINKTEIEDFPRFPHRGLLLDTSRHYLPLSSI
	LDTLDVMAYNKLNVFHWHLVDDPSFPYESFTFPELMRKGSYNPVT
	HIYTAQDVKEVIEYARLRGIRVLAEFDTPGHTLSWGPGIPGLLTPCY
	SGSEPSGTFGPVNPSLNNTYEFMSTFFLEVSSVFPDFYLHLGGDEVD
	FTCWKSNPEIQDFMRKKGFGEDFKQLESFYIQTLLDIVSSYGKGYVV
	WQEVFDNKVKIQPDTIIQVWREDIPVNYMKELELVTKAGFRALLSA
	PWYLNRISYGPDWKDFYIVEPLAFEGTPEQKALVIGGEACMWGEY
	VDNTNLVPRLWPRAGAVAERLWSNKLTSDLTFAYERLSHFRCELLR
	RGVQAQPLNVGFCEQEFEQT
280	MELCGLGLPRPPMLLALLLATLLAAMLALLTQVALVVQVAEAARA	HEXB
	PSVSAKPGPALWPLPLSVKMTPNLLHLAPENFYISHSPNSTAGPSCTL
	LEEAFRRYHGYIFGFYKWHHEPAEFQAKTQVQQLLVSITLQSECDA
	FPNISSDESYTLLVKEPVAVLKANRVWGALRGLETFSQLVYQDSYG
	TFTINESTIIDSPRFSHRGILIDTSRHYLPVKIILKTLDAMAFNKFNVLH
	WHIVDDQSFPYQSITFPELSNKGSYSLSHVYTPNDVRMVIEYARLRG
	IRVLPEFDTPGHTLSWGKGQKDLLTPCYSRQNKLDSFGPINPTLNTT
	YSFLTTFFKEISEVFPDQFIHLGGDEVEFKCWESNPKIQDFMRQKGF
	GTDFKKLESFYIQKVLDIIATINKGSIVWQEVFDDKAKLAPGTIVEV
	WKDSAYPEELSRVTASGFPVILSAPWYLDLISYGQDWRKYYKVEPL
	DFGGTQKQKQLFIGGEACLWGEYVDATNLTPRLWPRASAVGERLW
	SSKDVRDMDDAYDRLTRHRCRMVERG
	IAAQPLYAGYCNHENM
281	MTGARASAAEQRRAGRSGQARAAERAAGMSGAGRALAALLLAAS	HGSNAT
	VLSAALLAPGGSSGRDAQAAPPRDLDKKRHAELKMDQALLLIHNE
	LLWTNLTVYWKSECCYHCLFQVLVNVPQSPKAGKPSAAAASVSTQ
	HGSILQLNDTLEEKEVCRLEYRFGEFGNYSLLVKNIHNGVSEIACDL
	AVNEDPVDSNLPVSIAFLIGLAVIIVISFLRLLLSLDDFNNWISKAISSR
	ETDRLINSELGSPSRTDPLDGDVQPATWRLSALPPRLRSVDTFRGIAL
	ILMVFVNYGGGKYWYFKHASWNGLTVADLVFPWFVFIMGSSIFLS
	MTSILQRGCSKFRLLGKIAWRSFLLICIGIIIVNPNYCLGPLSWDKVRI
	PGVLQRLGVTYFVVAVLELLFAKPVPEHCASERSCLSLRDITSSWPQ
	WLLILVLEGLWLGLTFLLPVPGCPTGYLGPGGIGDFGKYPNCTGGA
	AGYIDRLLLGDDHLYQHPSSAVLYHTEVAYDPEGILGTINSIVMAFL
	GVQAGKILLYYKARTKDILIRFTAWCC
	ILGLISVALTKVSENEGFIPVNKNLWSLSYVTTLSSFAFFILLVLYPVV
	DVKGLWTGTPFFYPGMNSILVYVGHEVFENYFPFQWKLKDNQSHK
	EHLTQNIVATALWVLIAYILYRKKIFWKI
282	MAAHLLPICALFLTLLDMAQGFRGPLLPNRPFTTVWNANTQWCLE	HYAL1
	RHGVDVDVSVFDVVANPGQTFRGPDMTIFYSSQLGTYPYYTPTGEP
	VFGGLPQNASLIAHLARTFQDILAAIPAPDFSGLAVIDWEAWRPRW
	AFNWDTKDIYRQRSRALVQAQHPDWPAPQVEAVAQDQFQGAARA
	WMAGTLQLGRALRPRGLWGFYGFPDCYNYDFLSPNYTGQCPSGIR
	AQNDQLGWLWGQSRALYPSIYMPAVLEGTGKSQMYVQHRVAEAF
	RVAVAAGDPNLPVLPYVQIFYDTTNHFLPLDELEHSLGESAAQGAA
	GVVLWVSWENTRTKESCQAIKEYMDTTLGPFILNVTSGALLCSQ
	ALCSGHGRCVRRTSHPKALLLLNPASFSIQLTPGGGPLSLRGALSLE
	DQAQMAVEFKCRCYPGWQAPWCERKSMW
283	MPPPRTGRGLLWLGLVLSSVCVALGSETQANSTTDALNVLLIIVDDL	IDS
	RPSLGCYGDKLVRSPNIDQLASHSLLFQNAFAQQAVCAPSRVSFLTG
	RRPDTTRLYDFNSYWRVHAGNFSTIPQYFKENGYVTMSVGKVFHP
	GISSNHTDDSPYSWSFPPYHPSSEKYENTKTCRGPDGELHANLLCPV
	DVLDVPEGTLPDKQSTEQAIQLLEKMKTSASPFFLAVGYHKPHIPFR
	YPKEFQKLYPLENITLAPDPEVPDGLPPVAYNPWMDIRQREDVQAL
	NISVPYGPIPVDFQRKIRQSYFASVSYLDTQVGRLLSALDDLQLANS
	THAFTSDHGWALGEHGEWAKYSNFDVATHVPLIFYVPGRTASLPEA
	GEKLFPYLDPFDSASQLMEPGRQSMDLVELVSLFPTLAGLAGLQVP
	PRCPVPSFHVELCREGKNLLKHFRFRDLEEDPYLPGNPRELIAYSQY
	PRPSDIPQWNSDKPSLKDIKIMGYSIRTIDYRYTVWVGFNPDEFLAN
	FSDIHAGELYFVDSDPLQDHNMYNDSQGGDLFQLLMP
284	MRPLRPRAALLALLASLLAAPPVAPAEAPHLVHVDAARALWPLRRF	IDUA
	WRSTGFCPPLPHSQADQYVLSWDQQLNLAYVGAVPHRGIKQVRTH
	WLLELVTTRGSTGRGLSYNFTHLDGYLDLLRENQLLPGFELMGSAS
	GHFTDFEDKQQVFEWKDLVSSLARRYIGRYGLAHVSKWNFETWNE
	PDHHDFDNVSMTMQGFLNYYDACSEGLRAASPALRLGGPGDSFHT
	PPRSPLSWGLLRHCHDGTNFFTGEAGVRLDYISLHRKGARSSISILEQ
	EKVVAQQIRQLFPKFADTPIYNDEADPLVGWSLPQPWRADVTYAA
	MVVKVIAQHQNLLLANTTSAFPYALLSNDNAFLSYHPHPFAQRTLT
	ARFQVNNTRPPHVQLLRKPVLTAMGLLALLDEEQLWAEVSQAGTV
	LDSNHTVGVLASAHRPQGPADAWRAAVLIYASDDTRAHPNRSVAV
	TLRLRGVPPGPGLVYVTRYLDNGLCSPDGEWRRLGRPVFPTAEQFR
	RMRAAEDPVAAAPRPLPAGGRLTLRPALRLPSLLLVHVCARPEKPP
	GQVTRLRALPLTQGQLVLVWSDEHVGSKCLWTYEIQFSQDGKAYT
	PVSRKPSTFNLFVFSPDTGAVSGSYRVRALDYWARPGPFSDPVPYLE
	VPVPRGPPSPGNP
285	MVVVTGREPDSRRQDGAMSSSDAEDDFLEPATPTATQAGHALPLLP	KCTD7
	QEFPEVVPLNIGGAHFTTRLSTLRCYEDTMLAAMFSGRHYIPTDSEG
	RYFIDRDGTHFGDVLNFLRSGDLPPRERVRAVYKEAQYYAIGPLLE
	QLENMQPLKGEKVRQAFLGLMPYYKDHLERIVEIARLRAVQRKAR
	FAKLKVCVFKEEMPITPYECPLLNSLRFERSESDGQLFEHHCEVDVS
	FGPWEAVADVYDLLHCLVTDLSAQGLTVDHQCIGVCDKHLVNHY
	YCKRPIYEFKITWW
286	MVCFRLFPVPGSGLVLVCLVLGAVRSYALELNLTDSENATCLYAK	LAMP2
	WQMNFTVRYETTNKTYKTVTISDHGTVTYNGSICGDDQNGPKIAV
	QFGPGFSWIANFTKAASTYSIDSVSFSYNTGDNTTFPDAEDKGILTV
	DELLAIRIPLNDLFRCNSLSTLEKNDVVQHYWDVLVQAFVQNGTVS
	TNEFLCDKDKTSTVAPTIHTTVPSPTTTPTPKEKPEAGTYSVNNGND
	TCLLATMGLQLNITQDKVASVININPNTTHSTGSCRSHTALLRLNSS
	TIIKYLDFVFAVKNENRFYLKEVNISMYLVNGSVFSIANNNLSYWDA
	PLGSSYMCNKEQTVSVSGAFQINTFDLRVQPFNVTQGKYSTAQDCS
	ADDDNFLVPIAVGAALAGVLILVLLAYFIGLKHHHAGYEQF
287	MGAYARASGVCARGCLDSAGPWTMSRALRPPLPPLCFFLLLLAAA	MAN2B1
	GARAGGYETCPTVQPNMLNVHLLPHTHDDVGWLKTVDQYFYGIK
	NDIQHAGVQYILDSVISALLADPTRRFIYVEIAFFSRWWHQQTNATQ
	EVVRDLVRQGRLEFANGGWVMNDEAATHYGAIVDQMTLGLRFLE
	DTFGNDGRPRVAWHIDPFGHSREQASLFAQMGFDGFFFGRLDYQD
	KWVRMQKLEMEQVWRASTSLKPPTADLFTGVLPNGYNPPRNLCW
	DVLCVDQPLVEDPRSPEYNAKELVDYFLNVATAQGRYYRTNHTVM
	TMGSDFQYENANMWFKNLDKLIRLVNAQQAKGSSVHVLYSTPAC
	YLWELNKANLTWSVKHDDFFPYADGPHQFWTGYFSSRPALKRYER
	LSYNFLQVCNQLEALVGLAANVGPYGSGDSAPLNEAMAVLQHHD
	AVSGTSRQHVANDYARQLAAGWGPCEVLLSNALARLRGFKDHFTF
	CQQLNISICPLSQTAARFQVIVYNPLGRKVNWMVRLPVSEGVFVVK
	DPNGRTVPSDVVIFPSSDSQAHPPELLFSASLPALGFSTYSVAQVPR
	WKPQARAPQPIPRRSWSPALTIENEHIRATFDPDTGLLMEIMNMNQ
	QLLLPVRQTFFWYNASIGDNESDQASGAYIFRPNQQKPLPVSRWAQI
	HLVKTPLVQEVHQNFSAWCSQVVRLYPGQRHLELEWSVGPIPVGD
	TWGKEVISRFDTPLETKGRFYTDSNGREILERRRDYRPTWKLNQTEP
	VAGNYYPVNTRIYITDGNMQLTVLTDRSQGGSSLRDGSLELMVHRR
	LLKDDGRGVSEPLMENGSGAWVRGRHLVLLDTAQAAAAGHRLLA
	EQEVLAPQVVLAPGGGAAYNLGAPPRTQFSGLRRDLPPSVHLLTLA
	SWGPEMVLLRLEHQFAVGEDSGRNLSAPVTLNLRDLFSTFTITRLQE
	TTLVANQLREAASRLKWTTNTGPTPHQTPYQLDPANITLEPMEIRTF
	LASVQWKEVDG
288	MRLHLLLLLALCGAGTTAAELSYSLRGNWSICNGNGSLELPGAVPG	MANBA
	CVHSALFQQGLIQDSYYRFNDLNYRWVSLDNWTYSKEFKIPFEISK
	WQKVNLILEGVDTVSKILFNEVTIGETDNMFNRYSFDITNVVRDVNS
	IELRFQSAVLYAAQQSKAHTRYQVPPDCPPLVQKGECHVNFVRKEQ
	CSFSWDWGPSFPTQGIWKDVRIEAYNICHLNYFTFSPIYDKSAQEWN
	LEIESTFDVVSSKPVGGQVIVAIPKLQTQQTYSIELQPGKRIVELFVNI
	SKNITVETWWPHGHGNQTGYNMTVLFELDGGLNIEKSAKVYFRTV
	ELIEEPIKGSPGLSFYFKINGFPIFLKGSNWIPADSFQDRVTSELLRLLL
	QSVVDANMNTLRVWGGGIYEQDEFYELCDELGIMVWQDFMFACA
	LYPTDQGFLDSVTAEVAYQIKRLKSHPSIIIWSGNNENEEALMMNW
	YHISFTDRPIYIKDYVTLYVKNIRELVLAGDKSRPFITSSPTNGAETV
	AEAWVSQNPNSNYFGDVHFYDYISDC
	WNWKVFPKARFASEYGYQSWPSFSTLEKVSSTEDWSFNSKFSLHRQ
	HHEGGNKQMLYQAGLHFKLPQSTDPLRTFKDTIYLTQVMQAQCVK
	TETEFYRRSRSEIVDQQGHTMGALYWQLNDIWQAPSWASLEYGGK
	WKMLHYFAQNFFAPLLPVGFENENTFYIYGVSDLHSDYSMTLSVRV
	HTWSSLEPVCSRVTERFVMKGGEAVCLYEEPVSELLRRCGNCTRES
	CVVSFYLSADHELLSPTNYHFLSSPKEAVGLCKAQITAIISQQGDIFV
	FDLETSAVAPFVWLDVGSIPGRFSDNGFLMTEKTRTILFYPWEPTSK
	NELEQSFHVTSLTDIY
289	MTAPAGPRGSETERLLTPNPGYGTQAGPSPAPPTPPEEEDLRRRLKY	MCOLN1
	FFMSPCDKFRAKGRKPCKLMLQVVKILVVTVQLILFGLSNQLAVTF
	REENTIAFRHLFLLGYSDGADDTFAAYTREQLYQAIFHAVDQYLAL
	PDVSLGRYAYVRGGGDPWTNGSGLALCQRYYHRGHVDPANDTFDI
	DPMVVTDCIQVDPPERPPPPPSDDLTLLESSSSYKNLTLKFHKLVNV
	TIHFRLKTINLQSLINNEIPDCYTFSVLITFDNKAHSGRIPISLETQAHI
	QECKHPSVFQHGDNSFRLLFDVVVILTCSLSFLLCARSLLRGFLLQN
	EFVGFMWRQRGRVISLWERLEFVNGWYILLVTSDVLTISGTIMKIGI
	EAKNLASYDVCSILLGTSTLLVWVGVIRYLTFFHNYNILIATLRVALP
	SVMRFCCCVAVIYLGYCFCGWIVLGPYHVKFRSLSMVSECLFSLING
	DDMFVTFAAMQAQQGRSSLVWLFSQLYLYSFISLFIYMVLSLFIALI
	TGAYDTIKHPGGAGAEESELQAYIAQCQDSPTSGKFRRGSGSACSLL
	CCCGRDPSEEHSLLVN
290	MAGLRNESEQEPLLGDTPGSREWDILETEEHYKSRWRSIRILYLTMF	MFSD8
	LSSVGFSVVMMSIWPYLQKIDPTADTSFLGWVIASYSLGQMVASPIF
	GLWSNYRPRKEPLIVSILISVAANCLYAYLHIPASHNKYYMLVARGL
	LGIGAGNVAVVRSYTAGATSLQERTSSMANISMCQALGFILGPVFQ
	TCFTFLGEKGVTWDVIKLQINMYTTPVLLSAFLGILNIILILAILREHR
	VDDS
	GRQCKSINFEEASTDEAQVPQGNIDQVAVVAINVLFFVTLFIFALFET
	IITPLTMDMYAWTQEQAVLYNGIILAALGVEAVVIFLGVKLLSKKIG
	ERAILLGGLIVVWVGFFILLPWGNQFPKIQWEDLHNNSIPNTTFGEIII
	GLWKSPMEDDNERPTGCSIEQAWCLYTPVIHLAQFLTSAVLIGLGYP
	VCNLMSYTLYSKILGPKPQGVYMGWLTASGSGARILGPMFISQVYA
	HWGPRWAFSLVCGIIVLTITLLGVVYKRLIALSVRYGRIQE
291	MLLKTVLLLGHVAQVLMLDNGLLQTPPMGWLAWERFRCNINCDE	NAGA
	DPKNCISEQLFMEMADRMAQDGWRDMGYTYLNIDDCWIGGRDAS
	GRLMPDPKRFPHGIPFLADYVHSLGLKLGIYADMGNFTCMGYPGTT
	LDKVVQDAQTFAEWKVDMLKLDGCFSTPEERAQGYPKMAAALNA
	TGRPIAFSCSWPAYEGGLPPRVNYSLLADICNLWRNYDDIQDSWWS
	VLSILNWFVEHQDILQPVAGPGHWNDPDMLLIGNFGLSLEQSRAQM
	ALWTVLAAPLLMSTDLRTISAQNMDILQNPLMIKINQDPLGIQGRRI
	HKEKSLIEVYMRPLSNKASALVFFSCRTDMPYRYHSSLGQLNFTGS
	VIYEAQDVYSGDIISGLRDETNFTVIINPSGVVMWYLYPIKNLEMSQ
	Q
292	MEAVAVAAAVGVLLLAGAGGAAGDEAREAAAVRALVARLLGPGP	NAGLU
	AADFSVSVERALAAKPGLDTYSLGGGGAARVRVRGSTGVAAAAGL
	HRYLRDFCGCHVAWSGSQLRLPRPLPAVPGELTEATPNRYRYYQN
	VCTQSYSFVWWDWARWEREIDWMALNGINLALAWSGQEAIWQR
	VYLALGLTQAEINEFFTGPAFLAWGRMGNLHTWDGPLPPSWHIKQL
	YLQHRVLDQMRSFGMTPVLPAFAGHVPEAVTRVFPQVNVTKMGS
	WGHFNCSYSCSFLLAPEDPIFPIIGSLFLRELIKEFGTDHIYGADTFNE
	MQPPSSEPSYLAAATTAVYEAMTAVDTEAVWLLQGWLFQHQPQF
	WGPAQIRAVLGAVPRGRLLVLDLFAESQPVYTRTASFQGQPFIWCM
	LHNFGGNHGLFGALEAVNGGPEAARLFPNSTMVGTGMAPEGISQN
	EVVYSLMAELGWRKDPVPDLAAWVTSFAARRYGVSHPDAGAAWR
	LLLRSVYNCSGEACRGHNRSPLVRRPSLQMNTSIWYNRSDVFEAWR
	LLLTSAPSLATSPAFRYDLLDLTRQAVQELVSLYYEEARSAYLSKEL
	ASLLRAGGVLAYELLPALDEVLASDSRFLLGSWLEQARAAAVSEAE
	ADFYEQNSRYQLTLWGPEGNILDYANKQLAGLVANYYTPRWRLFL
	EALVDSVAQGIPFQQHQFDKNVFQLEQAFVLSKQRYPSQPRGDTVD
	LAKKIFLKYYPRWVAGSW
293	MTGERPSTALPDRRWGPRILGFWGGCRVWVFAAIFLLLSLAASWSK	NEU1
	AENDFGLVQPLVTMEQLLWVSGRQIGSVDTFRIPLITATPRGTLLAF
	AEARKMSSSDEGAKFIALRRSMDQGSTWSPTAFIVNDGDVPDGLNL
	GAVVSDVETGVVFLFYSLCAHKAGCQVASTMLVWSKDDGVSWST
	PRNLSLDIGTEVFAPGPGSGIQKQREPRKGRLIVCGHGTLERDGVFC
	LLSDDHGASWRYGSGVSGIPYGQPKQENDFNPDECQPYELPDGSVV
	INARNQNNYHCHCRIVLRSYDACDTLRPRDVTFDPELVDPVVAAGA
	VVTSSGIVFFSNPAHPEFRVNLTLRWSFSNGTSWRKET
	VQLWPGPSGYSSLATLEGSMDGEEQAPQLYVLYEKGRNHYTESISV
	AKISVYGTL
294	MTARGLALGLLLLLLCPAQVFSQSCVWYGECGIAYGDKRYNCEYS	NPC1
	GPPKPLPKDGYDLVQELCPGFFFGNVSLCCDVRQLQTLKDNLQLPL
	QFLSRCPSCFYNLLNLFCELTCSPRQSQFLNVTATEDYVDPVTNQTK
	TNVKELQYYVGQSFANAMYNACRDVEAPSSNDKALGLLCGKDAD
	ACNATNWIEYMFNKDNGQAPFTITPVFSDFPVHGMEPMNNATKGC
	DESVDEVTAPCSCQDCSIVCGPKPQPPPPPAPWTILGLDAMYVIMWI
	TYMAFLLVFFGAFFAVWCYRKRYFVSEYTPIDSNIAFSVNASDKGE
	ASCCDPVSAAFEGCLRRLFTRWGSFCVRNPGCVIFFSLVFITACSSGL
	VFVRVTTNPVDLWSAPSSQARLEKEYFDQHFGPFFRTEQLIIRAPLT
	DKHIYQPYPSGADVPFGPPLDIQILHQVLDLQIAIENITASYDNETVT
	LQDICLAPLSPYNTNCTILSVLNYFQNSHSVLDHKKGDDFFVYADY
	HTHFLYCVRAPASLNDTSLLHDPCLGTFGGPVFPWLVLGGYDDQN
	YNNATALVITFPVNNYYNDTEKLQRAQAWEKEFINFVKNYKNPNL
	TISFTAERSIEDELNRESDSDVFTVVISYAIMFLYISLALGHMKSCRRL
	LVDSKVSLGIAGILIVLSSVACSLGVFSYIGLPLTLIVIEVIPFLVLAVG
	VDNIFILVQAYQRDERLQGETLDQQLGRVLGEVAPSMFLSSFSETVA
	FFLGALSVMPAVHTFSLFAGLAVFIDFLLQITCFV
	SLLGLDIKRQEKNRLDIFCCVRGAEDGTSVQASESCLFRFFKNSYSPL
	LLKDWMRPIVIAIFVGVLSFSIAVLNKVDIGLDQSLSMPDDSYMVDY
	FKSISQYLHAGPPVYFVLEEGHDYTSSKGQNMVCGGMGCNNDSLV
	QQIFNAAQLDNYTRIGFAPSSWIDDYFDWVKPQSSCCRVDNITDQFC
	NASVVDPACVRCRPLTPEGKQRPQGGDFMRFLPMFLSDNPNPKCG
	KGGHAAYSSAVNILLGHGTRVGATYFMTYHTVLQTSADFIDALKK
	ARLIASNVTETMGINGSAYRVFPYSVFYVFYEQYLTIIDDTIFNLGVS
	LGAIFLVTMVLLGCELWSAVIMCATIAMVLVNMFGVMWLWGISLN
	AVSLVNLVMSCGISVEFCSHITRAFTVSMKGSRVERAEEALAHMGS
	SVFSGITLTKFGGIVVLAFAKSQIFQIFYFRMYLAMVLLGATHGLIFL
	PVLLSYIGPSVNKAKSCATEERYKGTERERLLNF
295	MRFLAATFLLLALSTAAQAEPVQFKDCGSVDGVIKEVNVSPCPTQP	NPC2
	CQLSKGQSYSVNVTFTSNIQSKSSKAVVHGILMGVPVPFPIPEPDGC
	KSGINCPIQKDKTYSYLNKLPVKSEYPSIKLVVEWQLQDDKNQSLFC
	WEIPVQIVSHL
296	MSCPVPACCALLLVLGLCRARPRNALLLLADDGGFESGAYNNSAIA	SGSH
	TPHLDALARRSLLFRNAFTSVSSCSPSRASLLTGLPQHQNGMYGLH
	QDVHHFNSFDKVRSLPLLLSQAGVRTGIIGKKHVGPETVYPFDFAYT
	EENGSVLQVGRNITRIKLLVRKFLQTQDDRPFFLYVAFHDPHRCGHS
	QPQYGTFCEKFGNGESGMGRIPDWTPQAYDPLDVLVPYFVPNTPAA
	RADLAAQYTTVGRMDQGVGLVLQELRDAGVLNDTLVIFTSDNGIPF
	PSGRTNLYWPGTAEPLLVSSPE
	HPKRWGQVSEAYVSLLDLTPTILDWFSIPYPSYAIFGSKTIHLTGRSL
	LPALEAEPLWATVFGSQSHHEVTMSYPMRSVQHRHFRLVHNLNFK
	MPFPIDQDFYVSPTFQDLLNRTTAGQPTGWYKDLRHYYYRARWEL
	YDRSRDPHETQNLATDPRFAQLLEMLRDQLAKWQWETHDPWVCA
	PDGVLEEKLSPQCQPLHNEL
297	MASPGCLWLLAVALLPWTCASRALQHLDPPAPLPLVIWHGMGDSC	PPT1
	CNPLSMGAIKKMVEKKIPGIYVLSLEIGKTLMEDVENSFFLNVNSQV
	TTVCQALAKDPKLQQGYNAMGFSQGGQFLRAVAQRCPSPPMINLIS
	VGGQHQGVFGLPRCPGESSHICDFIRKTLNAGAYSKVVQERLVQAE
	YWHDPIKEDVYRNHSIFLADINQERGINESYKKNLMALKKFVMVKF
	LNDSIVDPVDSEWFGFYRSGQAKETIPLQETSLYTQDRLGLKEMDN
	AGQLVFLATEGDHLQLSEEWFYAHIIPFLG
298	MYALFLLASLLGAALAGPVLGLKECTRGSAVWCQNVKTASDCGA	PSAP
	VKHCLQTVWNKPTVKSLPCDICKDVVTAAGDMLKDNATEEEILVY
	LEKTCDWLPKPNMSASCKEIVDSYLPVILDIIKGEMSRPGEVCSALN
	LCESLQKHLAELNHQKQLESNKIPELDMTEVVAPFMANIPLLLYPQ
	DGPRSKPQPKDNGDVCQDCIQMVTDIQTAVRTNSTFVQALVEHVK
	EECDRLGPGMADICKNYISQYSEIAIQMMMHMQPKEICALVGFCDE
	VKEMPMQTLVPAKVASKNVIPALELVEPIKKHEVPAKSDVYCEVCE
	FLVKEVTKLIDNNKTEKEILDAFDKMCSKLPKSLSEECQEVVDTYGS
	SILSILLEEVSPELVCSMLHLCSGTRLPALTVHVTQPKDGGFCEVCK
	KLVGYLDRNLEKNSTKQEILAALEKGCSFLPDPYQKQCDQFVAEYE
	PVLIEILVEVMDPSFVCLKIGACPSAHKPLLGTEKCIWGPSYWCQNT
	ETAAQCNAVEHCKRHVWN
299	MRSPVRDLARNDGEESTDRTPLLPGAPRAEAAPVCCSARYNLAILA	SLC17A5
	FFGFFIVYALRVNLSVALVDMVDSNTTLEDNRTSKACPEHSAPIKVH
	HNQTGKKYQWDAETQGWILGSFFYGYIITQIPGGYVASKIGGKMLL
	GFGILGTAVLTLFTPIAADLGVGPLIVLRALEGLGEGVTFPAMHAM
	WSSWAPPLERSKLLSISYAGAQLGTVISLPLSGIICYYMNWTYVFYF
	FGTIGIFWFLLWIWLVSDTPQKHKRISHYEKEYILSSLRNQLSSQKSV
	PWVPILKSLPLWAIVVAHFSYNWTFYTLLTLLPTYMKEILRFNVQEN
	GFLSSLPYLGSWLCMILSGQAADNLRAKWNFSTLCVRRIFSLIGMIG
	PAVFLVAAGFIGCDYSLAVAFLTISTTLGGFCSSGFSINHLDIAPSYA
	GILLGITNTFATIPGMVGPVIAKSLTPDNTVGEWQTVFYIAAAINVFG
	AIFFTLFAKGEVQNWALNDHHGHRH
300	MPRYGASLRQSCPRSGREQGQDGTAGAPGLLWMGLVLALALALAL	SMPD1
	ALALSDSRVLWAPAEAHPLSPQGHPARLHRIVPRLRDVFGWGNLTC
	PICKGLFTAINLGLKKEPNVARVGSVAIKLCNLLKIAPPAVCQSIVHL
	FEDDMVEVWRRSVLSPSEACGLLLGSTCGHWDIFSSWNISLPTVPKP
	PPKPPSPPAPGAPVSRILFLTDLHWDHDYLEGTDPDCADPLCCRRGS
	GLPPASRPGAGYWGEYSKCDLPLRTLESLLSGLGPAGPFDMVYWT
	GDIPAHDVWHQTRQDQLRALTTVTALVRKFLGPVPVYPAVGNHES
	TPVNSFPPPFIEGNHSSRWLYEAMAKAWEPWLPAEALRTLRIGGFY
	ALSPYPGLRLISLNMNFCSRENFWLLINSTDPAGQLQWLVGELQAA
	EDRGDKVHIIGHIPPGHCLKSWSWNYYRIVARYENTLAAQFFGHTH
	VDEFEVFYDEETLSRPLAVAFLAPSATTYIGLNPGYRVYQIDGNYSG
	SSHVVLDHETYILNLTQANIPGAIPHWQLLYRARETYGLPNTLPTAW
	HNLVYRMRGDMQLFQTFWFLYHKGHPPSEPCGTPCRLATLCAQLS
	ARADSPALCRHLMPDGSLPEAQSLWPRPLFC
301	MAAPALGLVCGRCPELGLVLLLLLLSLLCGAAGSQEAGTGAGAGSL	SUMF1
	AGSCGCGTPQRPGAHGSSAAAHRYSREANAPGPVPGERQLAHSKM
	VPIPAGVFTMGTDDPQIKQDGEAPARRVTIDAFYMDAYEVSNTEFE
	KFVNSTGYLTEAEKFGDSFVFEGMLSEQVKTNIQQAVAAAPWWLP
	VKGANWRHPEGPDSTILHRPDHPVLHVSWNDAVAYCTWAGKRLP
	TEAEWEYSCRGGLHNRLFPWGNKLQPKGQHYANIWQGEFPVTNTG
	EDGFQGTAPVDAFPPNGYGLYNIVGNAWEWTSDWWTVHHSVEET
	LNPKGPPSGKDRVKKGGSYMCHRSYCYRYRCAARSQNTPDSSASN
	LGFRCAADRLPTMD
302	MGLQACLLGLFALILSGKCSYSPEPDQRRTLPPGWVSLGRADPEEEL	TPP1
	SLTFALRQQNVERLSELVQAVSDPSSPQYGKYLTLENVADLVRPSPL
	TLHTVQKWLLAAGAQKCHSVITQDFLTCWLSIRQAELLLPGAEFHH
	YVGGPTETHVVRSPHPYQLPQALAPHVDFVGGLHRFPPTSSLRQRPE
	PQVTGTVGLHLGVTPSVIRKRYNLTSQDVGSGTSNNSQACAQFLEQ
	YFHDSDLAQFMRLFGGNFAHQASVARVVGQQGRGRAGIEASLDVQ
	YLMSAGANISTWVYSSPGRHEG
	QEPFLQWLMLLSNESALPHVHTVSYGDDEDSLSSAYIQRVNTELMK
	AAARGLTLLFASGDSGAGCWSVSGRHQFRPTFPASSPYVTTVGGTS
	FQEPFLITNEIVDYISGGGFSNVFPRPSYQEEAVTKFLSSSPHLPPSSYF
	NASGRAYPDVAALSDGYWVVSNRVPIPWVSGTSASTPVFGGILSLIN
	EHRILSGRPPLGFLNPRLYQQHGAGLFDVTRGCHESCLDEEVEGQGF
	CSGPGWDPVTGWGTPNFPALLKTLLNP
303	MSDKLPYKVADIGLAAWGRKALDIAENEMPGLMRMRERYSASKPL	AHCY
	KGARIAGCLHMTVETAVLIETLVTLGAEVQWSSCNIFSTQDHAAAAI
	AKAGIPVYAWKGETDEEYLWCIEQTLYFKDGPLNMILDDGGDLTN
	LIHTKYPQLLPGIRGISEETTTGVHNLYKMMANGILKVPAINVNDSV
	TKSKFDNLYGCRESLIDGIKRATDVMIAGKVAVVAGYGDVGKGCA
	QALRGFGARVIITEIDPINALQAAMEGYEVTTMDEACQEGNIFVTTT
	GCIDIILGRHFEQMKDDAIVCNIG
	HFDVEIDVKWLNENAVEKVNIKPQVDRYRLKNGRRIILLAEGRLVN
	LGCAMGHPSFVMSNSFTNQVMAQIELWTHPDKYPVGVHFLPKKLD
	EAVAEAHLGKLNVKLTKLTEKQAQYLGMSCDGPFKPDHYRY
304	MVDSVYRTRSLGVAAEGLPDQYADGEAARVWQLYIGDTRSRTAEY	GNMT
	KAWLLGLLRQHGCQRVLDVACGTGVDSIMLVEEGFSVTSVDASDK
	MLKYALKERWNRRHEPAFDKWVIEEANWMTLDKDVPQSAEGGFD
	AVICLGNSFAHLPDCKGDQSEHRLALKNIASMVRAGGLLVIDHRNY
	DHILSTGCAPPGKNIYYKSDLTKDVTTSVLIVNNKAHMVTLDYTVQ
	VPGAGQDGSPGLSKFRLSYYPHCLASFTELLQAAFGGKCQHSVLGD
	FKPYKPGQTYIPCYFIHVLKRTD
305	MNGPVDGLCDHSLSEGVFMFTSESVGEGHPDKICDQISDAVLDAHL	MAT1A
	KQDPNAKVACETVCKTGMVLLCGEITSMAMVDYQRVVRDTIKHIG
	YDDSAKGFDFKTCNVLVALEQQSPDIAQCVHLDRNEEDVGAGDQG
	LMFGYATDETEECMPLTIILAHKLNARMADLRRSGLLPWLRPDSKT
	QVTVQYMQDNGAVIPVRIHTIVISVQHNEDITLEEMRRALKEQVIRA
	VVPAKYLDEDTVYHLQPSGRFVIGGPQGDAGVTGRKIIVDTYGGW
	GAHGGGAFSGKDYTKVDRSAAYAARWVAKSLVKAGLCRRVLVQ
	VSYAIGVAEPLSISIFTYGTSQKTERELLDVVHKNFDLRPGVIVRDLD
	LKKPIYQKTACYGHFGRSEFPWEVPRKLVF
306	MEKGPVRAPAEKPRGARCSNGFPERDPPRPGPSRPAEKPPRPEAKSA	GCH1
	QPADGWKGERPRSEEDNELNLPNLAAAYSSILSSLGENPQRQGLLK
	TPWRAASAMQFFTKGYQETISDVLNDAIFDEDHDEMVIVKDIDMFS
	MCEHHLVPFVGKVHIGYLPNKQVLGLSKLARIVEIYSRRLQVQERL
	TKQIAVAITEALRPAGVGVVVEATHMCMVMRGVQKMNSKTVTST
	MLGVFREDPKTREEFLTLIRS
307	MAGKAHRLSAEERDQLLPNLRAVGWNELEGRDAIFKQFHFKDFNR	PCBD1
	AFGFMTRVALQAEKLDHHPEWFNVYNKVHITLSTHECAGLSERDIN
	LASFIEQVAVSMT
308	MSTEGGGRRCQAQVSRRISFSASHRLYSKFLSDEENLKLFGKCNNP	PTS
	NGHGHNYKVVVTVHGEIDPATGMVMNLADLKKYMEEAIMQPLDH
	KNLDMDVPYFADVVSTTENVAVYIWDNLQKVLPVGVLYKVKVYE
	TDNNIVVYKGE
309	MAAAAAAGEARRVLVYGGRGALGSRCVQAFRARNWWVASVDVV	QDPR
	ENEEASASIIVKMTDSFTEQADQVTAEVGKLLGEEKVDAILCVAGG
	WAGGNAKSKSLFKNCDLMWKQSIWTSTISSHLATKHLKEGGLLTL
	AGAKAALDGTPGMIGYGMAKGAVHQLCQSLAGKNSGMPPGAAAI
	AVLPVTLDTPMNRKSMPEADFSSWTPLEFLVETFHDWITGKNRPSS
	GSLIQVVTTEGRTELTPAYF
310	MEGGLGRAVCLLTGASRGFGRTLAPLLASLLSPGSVLVLSARNDEA	SPR
	LRQLEAELGAERSGLRVVRVPADLGAEAGLQQLLGALRELPRPKGL
	QRLLLINNAGSLGDVSKGFVDLSDSTQVNNYWALNLTSMLCLTSSV
	LKAFPDSPGLNRTVVNISSLCALQPFKGWALYCAGKAARDMLFQV
	LALEEPNVRVLNYAPGPLDTDMQQLARETSVDPDMRKGLQELKAK
	GKLVDCKVSAQKLLSLLEKDEFKSGAHVDFYDK
311	MDAILNYRSEDTEDYYTLLGCDELSSVEQILAEFKVRALECHPDKHP	DNAJC12
	ENPKAVETFQKLQKAKEILTNEESRARYDHWRRSQMSMPFQQWEA
	LNDSVKTSMHWVVRGKKDLMLEESDKTHTTKMENEECNEQRERK
	KEELASTAEKTEQKEPKPLEKSVSPQNSDSSGFADVNGWHLRFRWS
	KDAPSELLRKFRNYEI
312	MLLPAPALRRALLSRPWTGAGLRWKHTSSLKVANEPVLAFTQGSPE	ALDH4A1
	RDALQKALKDLKGRMEAIPCVVGDEEVWTSDVQYQVSPFNHGHK
	VAKFCYADKSLLNKAIEAALAARKEWDLKPIADRAQIFLKAADMLS
	GPRRAEILAKTMVGQGKTVIQAEIDAAAELIDFFRFNAKYAVELEG
	QQPISVPPSTNSTVYRGLEGFVAAISPFNFTAIGGNLAGAPALMGNV
	VLWKPSDTAMLASYAVYRILREAGLPPNIIQFVPADGPLFGDTVTSS
	EHLCGINFTGSVPTFKHLWKQVAQ
	NLDRFHTFPRLAGECGGKNFHFVHRSADVESVVSGTLRSAFEYGGQ
	KCSACSRLYVPHSLWPQIKGRLLEEHSRIKVGDPAEDFGTFFSAVID
	AKSFARIKKWLEHARSSPSLTILAGGKCDDSVGYFVEPCIVESKDPQ
	EPIMKEEIFGPVLSVYVYPDDKYKETLQLVDSTTSYGLTGAVFSQDK
	DVVQEATKVLRNAAGNFYINDKSTGSIVGQQPFGGARASGTNDKP
	GGPHYILRWTSPQVIKETHKPLGDWSYAYMQ
313	MALRRALPALRPCIPRFVQLSTAPASREQPAAGPAAVPGGGSATAV	PRODH
	RPPVPAVDFGNAQEAYRSRRTWELARSLLVLRLCAWPALLARHEQ
	LLYVSRKLLGQRLFNKLMKMTFYGHFVAGEDQESIQPLLRHYRAFG
	VSAILDYGVEEDLSPEEAEHKEMESCTSAAERDGSGTNKRDKQYQA
	HRAFGDRRNGVISARTYFYANEAKCDSHMETFLRCIEASGRVSDDG
	FIAIKLTALGRPQFLLQFSEVLAKWRCFFHQMAVEQGQAGLAAMDT
	KLEVAVLQESVAKLGIASRAEIEDW
	FTAETLGVSGTMDLLDWSSLIDSRTKLSKHLVVPNAQTGQLEPLLSR
	FTEEEELQMTRMLQRMDVLAKKATEMGVRLMVDAEQTYFQPAISR
	LTLEMQRKFNVEKPLIFNTYQCYLKDAYDNVTLDVELARREGWCF
	GAKLVRGAYLAQERARAAEIGYEDPINPTYEATNAMYHRCLDYVL
	EELKHNAKAKVMVASHNEDTVRFALRRMEELGLHPADHQVYFGQ
	LLGMCDQISFPLGQAGYPVYKYVPYGPVMEVLPYLSRRALENSSLM
	KGTHRERQLLWLELLRRLRTGNLFHRPA
314	MTTYSDKGAKPERGRFLHFHSVTFWVGNAKQAASFYCSKMGFEPL	HPD
	AYRGLETGSREVVSHVIKQGKIVFVLSSALNPWNKEMGDHLVKHG
	DGVKDIAFEVEDCDYIVQKARERGAKIMREPWVEQDKFGKVKFAV
	LQTYGDTTHTLVEKMNYIGQFLPGYEAPAFMDPLLPKLPKCSLEMI
	DHIVGNQPDQEMVSASEWYLKNLQFHRFWSVDDTQVHTEYSSLRSI
	VVANYEESIKMPINEPAPGKKKSQIQEYVDYNGGAGVQHIALKTEDI
	ITAIRHLRERGLEFLSVPSTYYKQLREKLKTAKIKVKENIDALEELKI
	LVDYDEKGYLLQIFTKPVQDRPTLFLEVIQRHNHQGFGAGNFNSLF
	KAFEEEQNLRGNLTNMETNGVVPGM
315	MEFSSPSREECPKPLSRVSIMAGSLTGLLLLQAVSWASGARPCIPKSF	GBA
	GYSSVVCVCNATYCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPI
	QANHTGTGLLLTLQPEQKFQKVKGFGGAMTDAAALNILALSPPAQ
	NLLLKSYFSEEGIGYNIIRVPMASCDFSIRTYTYADTPDDFQLHNFSL
	PEEDTKLKIPLIHRALQLAQRPVSLLASPWTSPTWLKTNGAVNGKGS
	LKGQP
	GDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGLLSGYPF
	QCLGFTPEHQRDFIARDLGPTLANSTHHNVRLLMLDDQRLLLPHWA
	KVVLTDPEAAKYVHGIAVHWYLDFLAPAKATLGETHRLFPNTMLF
	ASEACVGSKFWEQSVRLGSWDRGMQYSHSIITNLLYHVVGWTDW
	NLALNPEGGPNWVRNFVDSPIIVDITKDTFYKQPMFYHLGHFSKFIP
	EGSQRVGLVASQKNDLDAVALMHPDGSAVVVVLNRSSKDVPLTIK
	DPAVGFLETISPGYSIHTYLWRRQ
316	MAELKYISGFGNECSSEDPRCPGSLPEGQNNPQVCPYNLYAEQLSGS	HGD
	AFTCPRSTNKRSWLYRILPSVSHKPFESIDEGQVTHNWDEVDPDPNQ
	LRWKPFEIPKASQKKVDFVSGLHTLCGAGDIKSNNGLAIHIFLCNTS
	MENRCFYNSDGDFLIVPQKGNLLIYTEFGKMLVQPNEICVIQRGMRF
	SIDVFEETRGYILEVYGVHFELPDLGPIGANGLANPRDFLIPIAWYED
	RQVPGGYTVINKYQGKLFAAKQDVSPFNVVAWHGNYTPYKYNLK
	NFMVINSVAFDHADPSIFTVLTAKSVRPGVAIADFVIFPPRWGVADK
	TFRPPYYHRNCMSEFMGLIRGHYEAKQGGFLPGGGSLHSTMTPHGP
	DADCFEKASKVKLAPERIADGTMAFMFESSLSLAVTKWGLKASRCL
	DENYHKCWEPLKSHFTPNSRNPAEPN
317	MGVLGRVLLWLQLCALTQAVSKLWVPNTDFDVAANWSQNRTPCA	AMN
	GGAVEFPADKMVSVLVQEGHAVSDMLLPLDGELVLASGAGFGVSD
	VGSHLDCGAGEPAVFRDSDRFSWHDPHLWRSGDEAPGLFFVDAER
	VPCRHDDVFFPPSASFRVGLGPGASPVRVRSISALGRTFTRDEDLAV
	FLASRAGRLRFHGPGALSVGPEDCADPSGCVCGNAEAQPWICAALL
	QPLGGRCPQAACHSALRPQGQCCDLCGAVVLLTHGPAFDLERYRA
	RILDTFLGLPQYHGLQVAVSKVPRSSRLREADTEIQVVLVENGPETG
	GAGRLARALLADVAENGEALGVLEATMRESGAHVWGSSAAGLAG
	GVAAAVLLALLVLLVAPPLLRRAGRLRWRRHEAAAPAGAPLGFRN
	PVFDVTASEELPLPRRLSLVPKAAADSTSHSYFVNPLFAGAEAEA
318	MSGGWMAQVGAWRTGALGLALLLLLGLGLGLEAAASPLSTPTSAQ	CD320
	AAGPSSGSCPPTKFQCRTSGLCVPLTWRCDRDLDCSDGSDEEECRIE
	PCTQKGQCPPPPGLPCPCTGVSDCSGGTDKKLRNCSRLACLAGELR
	CTLSDDCIPLTWRCDGHPDCPDSSDELGCGTNEILPEGDATTMGPPV
	TLESVTSLRNATTMGPPVTLESVPSVGNATSSSAGDQSGSPTAYGVI
	AAAAVLSASLVTATLLLLSWLRAQERLRPLGLLVAMKESLLLSEQK
	TSLP
319	MMNMSLPFLWSLLTLLIFAEVNGEAGELELQRQKRSINLQQPRMAT	CUBN
	ERGNLVFLTGSAQNIEFRTGSLGKIKLNDEDLSECLHQIQKNKEDIIE
	LKGSAIGLPQNISSQIYQLNSKLVDLERKFQGLQQTVDKKVCSSNPC
	QNGGTCLNLHDSFFCICPPQWKGPLCSADVNECEIYSGTPLSCQNGG
	TCVNTMGSYSCHCPPETYGPQCASKYDDCEGGSVARCVHGICEDL
	MREQAGEPKYSCVCDAGWMFSPNSPACTLDRDECSFQPGPCSTLV
	QCFNTQGSFYCGACPTGWQGNGYICEDINECEINNGGCSVAPPVEC
	VNTPGSSHCQACPPGYQGDGRVCTLTDICSVSNGGCHPDASCSSTL
	GSLPLCTCLPGYTGNGYGPNGCVQLSNICLSHPCLNGQCIDTVSGYF
	CKCDSGWTGVNCTENINECLSNPCLNGGTCVDGVDSFSCECTRLWT
	GALCQVPQQVCGESLSGINGSFSYRSPDVGYVHDVNCFWVIKTEMG
	KVLRITFTFFRLESMDNCPHEFLQVYDGDSSSAFQLGRFCGSSLPHE
	LLSSDNALYFHLYSEHLRNGRGFTVRWETQQPECGGILTGPYGSIKS
	PGYPGNYPPGRDCVWIVVTSPDLLVTFTFGTLSLEHHDDCNKDYLEI
	RDGPLYQDPLLGKFCTTFSVPPLQTTGPFARIHFHSDSQISDQGFHIT
	YLTSPSDLRCGGNYTDPEGELFLPELSGPFTHTRQCVYMMKQPQGE
	QIQINFTHVELQCQSDSSQNYIEVRDGETLLGKVCGNGTISHIKSITN
	SVWIRFKIDASVEKASFRAVYQVACGDELTGEGVIRSPFFPNVYPGE
	RTCRWTIHQPQSQVILLNFTVFEIGSSAHCETDYVEIGSSSILGSPENK
	KYCGTDIPSFITSVYNFLYVTFVKSSSTENHGFMAKFSAEDLACGEIL
	TESTGTIQSPGHPNVYPHGINCTWHILVQPNHLIHLMFETFHLEFHY
	NCTNDYLEVYDTDSETSLGRYCGKSIPPSLTSSGNSL
	MLVFVTDSDLAYEGFLINYEAISAATACLQDYTDDLGTFTSPNFPNN
	YPNNWECIYRITVRTGQLIAVHFTNFSLEEAIGNYYTDFLEIRDGGYE
	KSPLLGIFYGSNLPPTIISHSNKLWLKFKSDQIDTRSGFSAYWDGSST
	GCGGNLTTSSGTFISPNYPMPYYHSSECYWWLKSSHGSAFELEFKDF
	HLEHHPNCTLDYLAVYDGPSSNSHLLTQLCGDEKPPLIRSSGDSMFI
	KLR
	TDEGQQGRGFKAEYRQTCENVVIVNQTYGILESIGYPNPYSENQHC
	NWTIRATTGNTVNYTFLAFDLEHHINCSTDYLELYDGPRQMGRYCG
	VDLPPPGSTTSSKLQVLLLTDGVGRREKGFQMQWFVYGCGGELSG
	ATGSFSSPGFPNRYPPNKECIWYIRTDPGSSIQLTIHDFDVEYHSRCN
	FDVLEIYGGPDFHSPRIAQLCTQRSPENPMQVSSTGNELAIRFKTDLS
	INGRGFNASWQAVTGGCGGIFQAPSGEIHSPNYPSPYRSNTDCSWVI
	RVDRNHRVLLNFTDFDLEPQDSCIMAYDGLSSTMSRLARTCGREQL
	ANPIVSSGNSLFLRFQSGPSRQNRGFRAQFRQACGGHILTSSFDTVSS
	PRFPANYPNNQNCSWIIQAQPPLNHITLSFTHFELERSTTCARDFVEIL
	DGGHEDAPLRGRYCGTDMPHPITSFSSALTLRFVSDSSISAGGFHTT
	VTASVSACGGTFYMAEGIFNSPGYPDIYPPNVECVWNIVSSPGNRLQ
	LSFISFQLEDSQDCSRDFVEIREGNATGHLVGRYCGNSFPLNYSSIVG
	HTLWVRFISDGSGSGTGFQATFMKIFGNDNIVGTHGKVASPFWPEN
	YPHNSNYQWTVNVNASHVVHGRILEMDIEEIQNCYYDKLRIYDGPS
	IHARLIGAYCGTQTESFSSTGNSLTFHFYSDSSISGKGFLLEWFAVDA
	PDGVLPTIAPGACGGFLRTGDAPVFLFSPGWPDSYSNRVDCTWLIQ
	APDSTVELNILSLDIESHRTCAYDSLVIRDGDNNLAQQLAVLCGREIP
	GPIRSTGEYMFIRFTSDSSVTRAGFNASFHKSCGGYLHADRGIITSPK
	YPETYPSNLNCSWHVLVQSGLTIAVHFEQPFQIPNGDSSCNQGDYLV
	LRNGPDICSPPLGPPGGNGHFCGSHASSTLFTSDNQMFVQFISDHSNE
	GQGFKIKYEAKSLACGGNVYIHDADSAGYVTSPNHPHNYPPHADCI
	WILAAPPETRIQLQFEDRFDIEVTPNCTSNYLELRDGVDSDAPILSKF
	CGTSLPSSQWSSGEVMYLRFRSDNSPTHVGFKAKYSIAQCGGRVPG
	QSGVVESIGHPTLPYRDNLFCEWHLQGLSGHYLTISFEDFNLQNSSG
	CEKDFVEIWDNHTSGNILGRYCGNTIPDSIDTSSNTAVVRFVTDGSV
	TASGFRLRFESSMEECGGDLQGSIGTFTSPNYPNPNPHGRICEWRITA
	PEGRRITLMFNNLRLATHPSCNNEHVIVFNGIRSNSPQLEKLCSSVNV
	SNEIKSSGNTMKVIFFTDGSRPYGGFTASYTSSEDAVCGGSLPNTPE
	GNFTSPGYDGVRNYSRNLNCEWTLSNPNQGNSSISIHFEDFYLESHQ
	DCQFDVLEFRVGDADGPLMWRLCGPSKPTLPLVIPYSQVWIHFVTN
	ERVEHIGFHAKYSFTDCGGIQIGDSGVITSPNYPNAYDSLTHCSSLLE
	APQGHTITLTFSDFDIEPHTTCAWDSVTVRNGGSPESPIIGQYCGNSN
	PRTIQSGSNQLVVTFNSDHSLQGGGFYATWNTQTLGCGGIFHSDNG
	TIRSPHWPQNFPENSRCSWTAITHKSKHLEISFDNNFLIPSGDGQCQN
	SFVKVWAGTEEVDKALLATGCGNVAPGPVITPSNTFTAVFQSQEAP
	AQGFSASFVSRCGSNFTGPSGYIISPNYPKQYDNNMNCTYVIEANPL
	SVVLLTFVSFHLEARSAVTGSCVNDGVHIIRGYSVMSTPFATVCG
	DEMPAPLTIAGPVLLNFYSNEQITDFGFKFSYRIISCGGVFNFSSGIITS
	PAYSYADYPNDMHCLYTITVSDDKVIELKFSDFDVVPSTSCSHDYL
	AIYDGANTSDPLLGKFCGSKRPPNVKSSNNSMLLVFKTDSFQTAKG
	WKMSFRQTLGPQQGCGGYLTGSNNTFASPDSDSNGMYDKNLNCV
	WIIIAPVNKVIHLTFNTFALEAASTRQRCLYDYVKLYDGDSENANLA
	GTFCGSTVPAPFISSGNFLTVQFISDLTLEREGFNATYTIMDMPCGGT
	YNATWTPQNISSPNSSDPDVPFSICTWVIDSPPHQQVKITVWALQLT
	SQDCTQNYLQLQDSPQGHGNSRFQFCGRNASAVPVFYSSMSTAMVI
	FKSGVVNRNSRMSFTYQIADCNRDYHKAFGNLRSPGWPDNYDNDK
	DCTVTLTAPQNHTISLFFHSLGIENSVECRNDFLEVRNGSNSNSPLLG
	KYCGTLLPNPVFSQNNELYLRFKSDSVTSDRGYEIIWTSSPSGCGGT
	LYGDRGSFTSPGYPGTYPNNTYCEWVLVAPAGRLVTINFYFISIDDP
	GDCVQNYLTLYDGPNASSPSSGPYCGGDTSIAPFVASSNQVFIKFHA
	DYARRPSAFRLTWDS
320	MAWFALYLLSLLWATAGTSTQTQSSCSVPSAQEPLVNGIQVLMENS	GIF
	VTSSAYPNPSILIAMNLAGAYNLKAQKLLTYQLMSSDNNDLTIGQL
	GLTIMALTSSCRDPGDKVSILQRQMENWAPSSPNAEASAFYGPSLAI
	LALCQKNSEATLPIAVRFAKTLLANSSPFNVDTGAMATLALTCMYN
	KIPVGSEEGYRSLFGQVLKDIVEKISMKIKDNGIIGDIYSTGLAMQAL
	SVTPEPSKKEWNCKKTTDMILNEIKQGKFHNPMSIAQILPSLKGKTY
	LDVPQVTCSPDHEVQPTLPSNPGPGPTSASNITVIYTINNQLRGVELL
	FNETINVSVKSGSVLLVVLEEAQRKNPMFKFETTMTSWGLVVSSIN
	NIAENVNHKTYWQFLSGVTPLNEGVADYIPFNHEHITANFTQY
321	MRQSHQLPLVGLLLFSFIPSQLCEICEVSEENYIRLKPLLNTMIQSNY	TCN1
	NRGTSAVNVVLSLKLVGIQIQTLMQKMIQQIKYNVKSRLSDVSSGE
	LALIILALGVCRNAEENLIYDYHLIDKLENKFQAEIENMEAHNGTPL
	TNYYQLSLDVLALCLFNGNYSTAEVVNHFTPENKNYYFGSQFSVDT
	GAMAVLALTCVKKSLINGQIKADEGSLKNISIYTKSLVEKILSEKKE
	NGLIGN
	TFSTGEAMQALFVSSDYYNENDWNCQQTLNTVLTEISQGAFSNPNA
	AAQVLPALMGKTFLDINKDSSCVSASGNFNISADEPITVTPPDSQSYI
	SVNYSVRINETYFTNVTVLNGSVFLSVMEKAQKMNDTIFGFTMEER
	SWGPYITCIQGLCANNNDRTYWELLSGGEPLSQGAGSYVVRNGENL
	EVRWSKY
322	MRHLGAFLFLLGVLGALTEMCEIPEMDSHLVEKLGQHLLPWMDRL	TCN2
	SLEHLNPSIYVGLRLSSLQAGTKEDLYLHSLKLGYQQCLLGSAFSED
	DGDCQGKPSMGQLALYLLALRANCEFVRGHKGDRLVSQLKWFLE
	DEKRAIGHDHKGHPHTSYYQYGLGILALCLHQKRVHDSVVDKLLY
	AVEPFHQGHHSVDTAAMAGLAFTCLKRSNFNPGRRQRITMAIRTVR
	EEILKAQTPEGHFGNVYSTPLALQFLMTSPMRGAELGTACLKARVA
	LLASLQDGAFQNALMISQLLPVLNHKTYIDLIFPDCLAPRVMLEPAA
	ETIPQTQEIISVTLQVLSLLPPYRQSISVLAGSTVEDVLKKAHELGGFT
	YETQASLSGPYLTSVMGKAAGEREFWQLLRDPNTPLLQGIADYRPK
	DGETIELRLVSW
323	MQQKTKLFLQALKYSIPHLGKCMQKQHLNHYNFADHCYNRIKLKK	PREPL
	YHLTKCLQNKPKISELARNIPSRSFSCKDLQPVKQENEKPLPENMDA
	FEKVRTKLETQPQEEYEIINVEVKHGGFVYYQEGCCLVRSKDEEAD
	NDNYEVLFNLEELKLDQPFIDCIRVAPDEKYVAAKIRTEDSEASTCVI
	IKLSDQPVMEASFPNVSSFEWVKDEEDEDVLFYTFQRNLRCHDVYR
	ATFGDNKRNERFYTEKDPSYFVFLYLTKDSRFLTINIMNKTTSEVWL
	IDGLSPWDPPVLIQKRIHGVLYYVEHRDDELYILTNVGEPTEFKLMR
	TAADTPAIMNWDLFFTMKRNTKVIDLDMFKDHCVLFLKHSNLLYV
	NVIGLADDSVRSLKLPPWACGFIMDTNSDPKNCPFQLCSPIRPPKYY
	TYKFAEGKLFEETGHEDPITKTSRVLRLEAKSKDGKLVPMTVFHKT
	DSEDLQKKPLLVHVYGAYGMDLKMNFRPERRVLVDDGWILAYCH
	VRGGGELGLQWHADGRLTKKLNGLADLEACIKTLHGQGFSQPSLT
	TLTAFSAGGVLAGALCNSNPELVRAVTLEAPFLDVLNTMMDTTLPL
	T
	LEELEEWGNPSSDEKHKNYIKRYCPYQNIKPQHYPSIHITAYENDER
	VPLKGIVSYTEKLKEAIAEHAKDTGEGYQTPNIILDIQPGGNHVIEDS
	HKKITAQIKFLYEELGLDSTSVFEDLKKYLKF
324	MAFANLRKVLISDSLDPCCRKILQDGGLQVVEKQNLSKEELIAELQD	PHGDH
	CEGLIVRSATKVTADVINAAEKLQVVGRAGTGVDNVDLEAATRKGI
	LVMNTPNGNSLSAAELTCGMIMCLARQIPQATASMKDGKWERKKF
	MGTELNGKTLGILGLGRIGREVATRMQSFGMKTIGYDPIISPEVSASF
	GVQQLPLEEIWPLCDFITVHTPLLPSTTGLLNDNTFAQCKKGVRVVN
	CARGGIVDEGALLRALQSGQCAGAALDVFTEEPPRDRALVDHENVI
	SCPHLGASTKEAQSRCGEEIA
	VQFVDMVKGKSLTGVVNAQALTSAFSPHTKPWIGLAEALGTLMRA
	WAGSPKGTIQVITQGTSLKNAGNCLSPAVIVGLLKEASKQADVNLV
	NAKLLVKEAGLNVTTSHSPAAPGEQGFGECLLAVALAGAPYQAVG
	LVQGTTPVLQGLNGAVFRPEVPLRRDLPLLLFRTQTSDPAMLPTMIG
	LLAEAGVRLLSYQTSLVSDGETWHVMGISSLLPSLEAWKQHVTEAF
	QFHF
325	MDAPRQVVNFGPGPAKLPHSVLLEIQKELLDYKGVGISVLEMSHRS	PSAT1
	SDFAKIINNTENLVRELLAVPDNYKVIFLQGGGCGQFSAVPLNLIGL
	KAGRCADYVVTGAWSAKAAEEAKKFGTINIVHPKLGSYTKIPDPST
	WNLNPDASYVYYCANETVHGVEFDFIPDVKGAVLVCDMSSNFLSK
	PVDVSKFGVIFAGAQKNVGSAGVTVVIVRDDLLGFALRECPSVLEY
	KVQAGNSSLYNTPPCFSIYVMGLVLEWIKNNGGAAAMEKLSSIKSQ
	TIYEIIDNSQGFYVCPVEPQNRSKMNIPFRIGNAKGDDALEKRFLDK
	ALELNMLSLKGHRSVGGIRASLYNAVTIEDVQKLAAFMKKFLEMH
	QL
326	MVSHSELRKLFYSADAVCFDVDSTVIREEGIDELAKICGVEDAVSE	PSPH
	MTRRAMGGAVPFKAALTERLALIQPSREQVQRLIAEQPPHLTPGIRE
	LVSRLQERNVQVFLISGGFRSIVEHVASKLNIPATNVFANRLKFYFN
	GEYAGFDETQPTAESGGKGKVIKLLKEKFHFKKIIMIGDGATDMEA
	CPPADAFIGFGGNVIRQQVKDNAKWYITDFVELLGELEE
327	MQRAVSVVARLGFRLQAFPPALCRPLSCAQEVLRRTPLYDFHLAHG	AMT
	GKMVAFAGWSLPVQYRDSHTDSHLHTRQHCSLFDVSHMLQTKILG
	SDRVKLMESLVVGDIAELRPNQGTLSLFTNEAGGILDDLIVTNTSEG
	HLYVVSNAGCWEKDLALMQDKVRELQNQGRDVGLEVLDNALLAL
	QGPTAAQVLQAGVADDLRKLPFMTSAVMEVFGVSGCRVTRCGYT
	GEDGVEISVPVAGAVHLATAILKNPEVKLAGLAARDSLRLEAGLCL
	YGNDIDEHTTPVEGSLSWTLGKRRRAAMDFPGAKVIVPQLKGRVQ
	RRRVGLMCEGAPMRAHSPILNMEGTKIGTVTSGCPSPSLKKNVAMG
	YVPCEYSRPGTMLLVEVRRKQQMAVVSKMPFVPTNYYTLK
328	MALRVVRSVRALLCTLRAVPSPAAPCPPRPWQLGVGAVRTLRTGP	GCSH
	ALLSVRKFTEKHEWVTTENGIGTVGISNFAQEALGDVVYCSLPEVG
	TKLNKQDEFGALESVKAASELYSPLSGEVTEINEALAENPGLVNKSC
	YEDGWLIKMTLSNPSELDELMSEEAYEKYIKSIEE
329	MQSCARAWGLRLGRGVGGGRRLAGGSGPCWAPRSRDSSSGGGDS	GLDC
	AAAGASRLLERLLPRHDDFARRHIGPGDKDQREMLQTLGLASIDELI
	EKTVPANIRLKRPLKMEDPVCENEILATLHAISSKNQIWRSYIGMGY
	YNCSVPQTILRNLLENSGWITQYTPYQPEVSQGRLESLLNYQTMVC
	DITGLDMANASLLDEGTAAAEALQLCYRHNKRRKFLVDPRCHPQTI
	AVVQTRAKYTGVLTELKLPCEMDFSGKDVSGVLFQYPDTEGKVED
	FTELVERAHQSGSLACCATDLLALC
	ILRPPGEFGVDIALGSSQRFGVPLGYGGPHAAFFAVRESLVRMMPGR
	MVGVTRDATGKEVYRLALQTREQHIRRDKATSNICTAQALLANMA
	AMFAIYHGSHGLEHIARRVHNATLILSEGLKRAGHQLQHDLFFDTL
	KIQCGCSVKEVLGRAAQRQINFRLFEDGTLGISLDETVNEKDLDDLL
	WIFGCESSAELVAESMGEECRGIPGSVFKRTSPFLTHQVFNSYHSET
	NIVRYMKKLENKDISLVHSMIPLGSCTMKLNSSSELAPITWKEFANI
	HPFVPLDQAQGYQQLFRELEKDLCELTGYDQVCFQPNSGAQGEYA
	GLATIRAYLNQKGEGHRTVCLIPKSAHGTNPASAHMAGMKIQPVEV
	DKYGNIDAVHLKAMVDKHKENLAAIMITYPSTNGVFEENISDVCDL
	IHQHGGQVYLDGANMNAQVGICRPGDFGSDVSHLNLHKTFCIPHG
	GGGPGMGPIGVKKHLAPFLPNHPVISLKRNEDACPVGTVSAAPWGS
	SSILPISWAYIKMMGGKGLKQATETAILNANYMAKRLETHYRILFR
	GARGYVGHEFILDTRPFKKSANIEAVDVAKRLQDYGFHAPTMSWP
	VAGTLMVEPTESEDKAELDRFCDAMISIRQEIADIEEGRIDPRVNPLK
	MSPHSLTCVTSSHWDRPYSREVAAFPLPFVKPENKFWPTIARIDDIY
	GDQHLVCTCPPMEVYESPFSEQKRASS
330	MSLRCGDAARTLGPRVFGRYFCSPVRPLSSLPDKKKELLQNGPDLQ	LIAS
	DFVSGDLADRSTWDEYKGNLKRQKGERLRLPPWLKTEIPMGKNYN
	KLKNTLRNLNLHTVCEEARCPNIGECWGGGEYATATATIMLMGDT
	CTRGCRFCSVKTARNPPPLDASEPYNTAKAIAEWGLDYVVLTSVDR
	DDMPDGGAEHIAKTVSYLKERNPKILVECLTPDFRGDLKAIEKVALS
	GLDVYAHNVETVPELQSKVRDPRANFDQSLRVLKHAKKVQPDVIS
	KTSIMLGLGENDEQVYATMKALREADVDCLTLGQYMQPTRRHLK
	VEEYITPEKFKYWEKVGNELGFHYTASGPLVRSSYKAGEFFL
	KNLVAKRKTKDL
331	MAATARRGWGAAAVAAGLRRRFCHMLKNPYTIKKQPLHQFVQRP	NFU1
	LFPLPAAFYHPVRYMFIQTQDTPNPNSLKFIPGKPVLETRTMDFPTPA
	AAFRSPLARQLFRIEGVKSVFFGPDFITVTKENEELDWNLLKPDIYAT
	IMDFFASGLPLVTEETPSGEAGSEEDDEVVAMIKELLDTRIRPTVQE
	DGGDVIYKGFEDGIVQLKLQGSCTSCPSSIITLKNGIQNMLQFYIPEV
	EGVEQVMDDESDEKEANSP
332	MSGGDTRAAIARPRMAAAHGPVAPSSPEQVTLLPVQRSFFLPPFSGA	SLC6A9
	TPSTSLAESVLKVWHGAYNSGLLPQLMAQHSLAMAQNGAVPSEAT
	KRDQNLKRGNWGNQIEFVLTSVGYAVGLGNVWRFPYLCYRNGGG
	AFMFPYFIMLIFCGIPLFFMELSFGQFASQGCLGVWRISPMFKGVGY
	GMMVVSTYIGIYYNVVICIAFYYFFSSMTHVLPWAYCNNPWNTHD
	CAGVLDASNLTNGSRPAALPSNLSHLLNHSLQRTSPSEEYWRLYVL
	KLSDDIGNFGEVRLPLLGCLGVSWLVVFLCLIRGVKSSGKVVYFTA
	TFPYVVLTILFVRGVTLEGAFDGIMYYLTPQWDKILEAKVWGDAAS
	QIFYSLGCAWGGLITMASYNKFHNNCYRDSVIISITNCATSVYAGFV
	IFSILGFMANHLGVDVSRVADHGPGLAFVAYPEALTLLPISPLWSLL
	FFFMLILLGLGTQFCLLETLVTAIVDEVGNEWILQKKTYVTLGVAVA
	GFLLGIPLTSQAGIYWLLLMDNYAASFSLVVISCIMCVAIMYIYGHR
	NYFQDIQMMLGFPPPLFFQICWRFVSPAIIFFILVFTVIQYQPITYNHY
	QYPGWAVAIGFLMALSSVLCIPLYAMFRLCRTDGDTLLQRLKNATK
	PSRDWGPALLEHRTGRYAPTIAPSPEDGFEVQPLHPDKAQIPIVGSN
	GSSRLQDSRI
333	MEPSSKKLTGRLMLAVGGAVLGSLQFGYNTGVINAPQKVIEEFYNQ	SLC2A1
	TWVHRYGESILPTTLTTLWSLSVAIFSVGGMIGSFSVGLFVNRFGRR
	NSMLMMNLLAFVSAVLMGFSKLGKSFEMLILGRFIIGVYCGLTTGF
	VPMYVGEVSPTALRGALGTLHQLGIVVGILIAQVFGLDSIMGNKDL
	WPLLLSIIFIPALLQCIVLPFCPESPRFLLINRNEENRAKSVLKKLRGT
	ADVTHDLQEMKEESRQMMREKKVTILELFRSPAYRQPILIAVVLQL
	SQQLSGINAVFYYSTSIFEKAGVQQPVYATIGSGIVNTAFTVVSLFVV
	ERAGRRTLHLIGLAGMAGCAILMTIALALLEQLPWMSYLSIVAIFGF
	VAFFEVGPGPIPWFIVAELFSQGPRPAAIAVAGFSNWTSNFIVGMCF
	QYVEQLCGPYVFIIFTVLLVLFFIFTYFKVPETKGRTFDEIASGFRQG
	GASQSDKTPE
	ELFHPLGADSQV
334	MDPSMGVNSVTISVEGMTCNSCVWTIEQQIGKVNGVHHIKVSLEEK	ATP7A
	NATIIYDPKLQTPKTLQEAIDDMGFDAVIHNPDPLPVLTDTLFLTVTA
	SLTLPWDHIQSTLLKTKGVTDIKIYPQKRTVAVTIIPSIVNANQIKELV
	PELSLDTGTLEKKSGACEDHSMAQAGEVVLKMKVEGMTCHSCTST
	IEGKIGKLQGVQRIKVSLDNQEATIVYQPHLISVEEMKKQIEAMGFP
	AFVKKQPKYLKLGAIDVERLKNTPVKSSEGSQQRSPSYTNDSTATFII
	DGMHCKSCVSNIESTLSALQYVSSIVVSLENRSAIVKYNASSVTPESL
	RKAIEAVSPGLYRVSITSEVESTSNSPSSSSLQKIPLNVVSQPLTQETV
	INIDGMTCNSCVQSIEGVISKKPGVKSIRVSLANSNGTVEYDPLLTSP
	ETLRGAIEDMGFDATLSDTNEPLVVIAQPSSEMPLLTSTNEFYTKGM
	TPVQD
	KEEGKNSSKCYIQVTGMTCASCVANIERNLRREEGIYSILVALMAG
	KAEVRYNPAVIQPPMIAEFIRELGFGATVIENADEGDGVLELVVRG
	MTCASCVHKIESSLTKHRGILYCSVALATNKAHIKYDPEIIGPRDIIHT
	IESLGFEASLVKKDRSASHLDHKREIRQWRRSFLVSLFFCIPVMGLMI
	YMMVMDHHFATLHHNQNMSKEEMINLHSSMFLERQILPGLSVMNL
	LSFLLC
	VPVQFFGGWYFYIQAYKALKHKTANMDVLIVLATTIAFAYSLIILLV
	AMYERAKVNPITFFDTPPMLFVFIALGRWLEHIAKGKTSEALAKLIS
	LQATEATIVTLDSDNILLSEEQVDVELVQRGDIIKVVPGGKFPVDGR
	VIEGHSMVDESLITGEAMPVAKKPGSTVIAGSINQNGSLLICATHVG
	ADTTLSQIVKLVEEAQTSKAPIQQFADKLSGYFVPFIVFVSIATLLVW
	IVIG
	FLNFEIVETYFPGYNRSISRTETIIRFAFQASITVLCIACPCSLGLATPT
	AVMVGTGVGAQNGILIKGGEPLEMAHKVKVVVFDKTGTITHGTPV
	VNQVKVLTESNRISHHKILAIVGTAESNSEHPLGTAITKYCKQELDTE
	TLGTCIDFQVVPGCGISCKVTNIEGLLHKNNWNIEDNNIKNASLVQI
	DASNEQSSTSSSMIIDAQISNALNAQQYKVLIGNREWMIRNGLVINN
	DVN
	DFMTEHERKGRTAVLVAVDDELCGLIAIADTVKPEAELAIHILKSMG
	LEVVLMTGDNSKTARSIASQVGITKVFAEVLPSHKVAKVKQLQEEG
	KRVAMVGDGINDSPALAMANVGIAIGTGTDVAIEAADVVLIRNDLL
	DVVASIDLSRKTVKRIRINFVFALIYNLVGIPIAAGVFMPIGLVLQPW
	MGSAAMAASSVSVVLSSLFLKLYRKPTYESYELPARSQIGQKSPSEI
	SVHVGIDDTSRNSPKLGLLDRIVNYSRASINSLLSDKRSLNSVVTSEP
	DKHSLLVGDFREDDDTAL
335	MMRFMLLFSRQGKLRLQKWYLATSDKERKKMVRELMQVVLARKP	AP1S1
	KMCSFLEWRDLKVVYKRYASLYFCCAIEGQDNELITLELIHRYVEL
	LDKYFGSVCELDIIFNFEKAYFILDEFLMGGDVQDTSKKSVLKAIEQ
	ADLLQEEDESPRSVLEEMGLA
336	MKILILGIFLFLCSTPAWAKEKHYYIGIIETTWDYASDHGEKKLISVD	CP
	TEHSNIYLQNGPDRIGRLYKKALYLQYTDETFRTTIEKPVWLGFLGPI
	IKAETGDKVYVHLKNLASRPYTFHSHGITYYKEHEGAIYPDNTTDF
	QRADDKVYPGEQYTYMLLATEEQSPGEGDGNCVTRIYHSHIDAPK
	DIASGLIGPLIICKKDSLDKEKEKHIDREFVVMFSVVDENFSWYLED
	NIKTYC
	SEPEKVDKDNEDFQESNRMYSVNGYTFGSLPGLSMCAEDRVKWYL
	FGMGNEVDVHAAFFHGQALTNKNYRIDTINLFPATLFDAYMVAQN
	PGEWMLSCQNLNHLKAGLQAFFQVQECNKSSSKDNIRGKHVRHYY
	IAAEEIIWNYAPSGIDIFTKENLTAPGSDSAVFFEQGTTRIGGSYKKL
	VYREYTDASFTNRKERGPEEEHLGILGPVIWAEVGDTIRVTFHNKG
	AYPLSIEPIGVRFNKNNEGTYYSPNYNPQSRSVPPSASHVAPTETFTY
	EWTVPKEVGPTNADPVCLAKMYY
	SAVDPTKDIFTGLIGPMKICKKGSLHANGRQKDVDKEFYLFPTVFDE
	NESLLLEDNIRMFTTAPDQVDKEDEDFQESNKMHSMNGFMYGNQP
	GLTMCKGDSVVWYLFSAGNEADVHGIYFSGNTYLWRGERRDTAN
	LFPQTSLTLHMWPDTEGTFNVECLTTDHYTGGMKQKYTVNQCRRQ
	SEDSTFYLGERTYYIAAVEVEWDYSPQREWEKELHHLQEQNVSNAF
	LDKGEFYIGSKYKKVVYRQYTDSTFRVPVERKAEEEHLGILGPQLH
	ADVGDKVKIIFKNMATRPYSIHAHGVQTESSTVTPTLPGETLTYVW
	KIPERSGAGTEDSACIPWAYYSTVDQVKDLYSGLIGPLIVCRRPYLK
	VFNPRRKLEFALLFLVFDENESWYLDDNIKTYSDHPEKVNKDDEEFI
	ESNKMHAINGRMFGNLQGLTMHVGDEVNWYLMGMGNEIDLHTV
	HFHGHSFQYKHRGVYSSDVFDIFPGTYQTLEMFPRTPGIWLLHCHV
	TDHIHAGMETTYTVLQNEDTKSG
337	MSPTISHKDSSRQRRPGNFSHSLDMKSGPLPPGGWDDSHLDSAGRE	SLC33A1
	GDREALLGDTGTGDFLKAPQSFRAELSSILLLLFLYVLQGIPLGLAGS
	IPLILQSKNVSYTDQAFFSFVFWPFSLKLLWAPLVDAVYVKNFGRRK
	SWLVPTQYILGLFMIYLSTQVDRLLGNTDDRTPDVIALTVAFFLFEF
	LAATQDIAVDGWALTMLSRENVGYASTCNSVGQTAGYFLGNVLFL
	ALESADFCNKYLRFQPQPRGIVTLSDFLFFWGTVFLITTTLVALLKK
	ENEVSVVKEETQGITDTYKL
	LFAIIKMPAVLTFCLLILTAKIGFSAADAVTGLKLVEEGVPKEHLALL
	AVPMVPLQIILPLIISKYTAGPQPLNTFYKAMPYRLLLGLEYALLVW
	WTPKVEHQGGFPIYYYIVVLLSYALHQVTVYSMYVSIMAFNAKVS
	DPLIGGTYMTLLNTVSNLGGNWPSTVALWLVDPLTVKECVGASNQ
	NCRTPDAVELCKKLGGSCVTALDGYYVESIICVFIGFGWWFFLGPKF
	KKLQDEGSSSWKCKRNN
338	MSAVCGGAARMLRTPGRHGYAAEFSPYLPGRLACATAQHYGIAGC	PEX7
	GTLLILDPDEAGLRLFRSFDWNDGLFDVTWSENNEHVLITCSGDGSL
	QLWDTAKAAGPLQVYKEHAQEVYSVDWSQTRGEQLVVSGSWDQT
	VKLWDPTVGKSLCTFRGHESIIYSTIWSPHIPGCFASASGDQTLRIWD
	VKAAGVRIVIPAHQAEILSCDWCKYNENLLVTGAVDCSLRGWDLR
	NVRQPVFELLGHTYAIRRVKFSPFHASVLASCSYDFTVRFWNFSKPD
	SLLETVEHHTEFTCGLDFSLQSPTQVADCSWDETIKIYDPACLTIPA
339	MEQLRAAARLQIVLGHLGRPSAGAVVAHPTSGTISSASFHPQQFQY	PHYH
	TLDNNVLTLEQRKFYEENGFLVIKNLVPDADIQRFRNEFEKICRKEV
	KPLGLTVMRDVTISKSEYAPSEKMITKVQDFQEDKELFRYCTLPEIL
	KYVECFTGPNIMAMHTMLINKPPDSGKKTSRHPLHQDLHYFPFRPS
	DLIVCAWTAMEHISRNNGCLVVLPGTHKGSLKPHDYPKWEGGVNK
	MFHGIQDYEENKARVHLVMEKGDTVFFHPLLIHGSGQNKTQGFRK
	AISCHFASADCHYIDVKGTSQENIEKEVVGIAHKFFGAENSVNLKDI
	WMFRARLVKGERTNL
340	MAEAAAAAGGTGLGAGASYGSAADRDRDPDPDRAGRRLRVLSGH	AGPS
	LLGRPREALSTNECKARRAASAATAAPTATPAAQESGTIPKKRQEV
	MKWNGWGYNDSKFIFNKKGQIELTGKRYPLSGMGLPTFKEWIQNT
	LGVNVEHKTTSKASLNPSDTPPSVVNEDFLHDLKETNISYSQEADDR
	VFRAHGHCLHEIFLLREGMFERIPDIVLWPTCHDDVVKIVNLACKY
	NLCIIPIGGGTSVSYGLMCPADETRTIISLDTSQMNRILWVDENNLTA
	HVEAGITGQELERQLKESGYCTGH
	EPDSLEFSTVGGWVSTRASGMKKNIYGNIEDLVVHIKMVTPRGIIEK
	SCQGPRMSTGPDIHHFIMGSEGTLGVITEATIKIRPVPEYQKYGSVAF
	PNFEQGVACLREIAKQRCAPASIRLMDNKQFQFGHALKPQVSSIFTS
	FLDGLKKFYITKFKGFDPNQLSVATLLFEGDREKVLQHEKQVYDIA
	AKFGGLAAGEDNGQRGYLLTYVIAYIRDLALEYYVLGESFETSAPW
	DRVVDLCRNVKERITRECKEKGVQFAPFSTCRVTQTYDAGACIYFY
	FAFNYRGISDPLTVFEQTEAAAREEILANGGSLSHHHGVGKLRKQW
	LKESISDVGFGMLKSVKEYVDPNNIFGNRNLL
341	MESSSSSNSYFSVGPTSPSAVVLLYSKELKKWDEFEDILEERRHVSD	GNPAT
	LKFAMKCYTPLVYKGITPCKPIDIKCSVLNSEEIHYVIKQLSKESLQS
	VDVLREEVSEILDEMSHKLRLGAIRFCAFTLSKVFKQIFSKVCVNEE
	GIQKLQRAIQEHPVVLLPSHRSYIDFLMLSFLLYNYDLPVPVIAAGM
	DFLGMKMVGELLRMSGAFFMRRTFGGNKLYWAVFSEYVKTMLRN
	GYAPVEFFLEGTRSRSAKTLTPKFGLLNIVMEPFFKREVFDTYLVPIS
	ISYDKILEETLYVYELLGVPKPKESTTGLLKARKILSENFGSIHVYFG
	DPVSLRSLAAGRMSRSSYNLVPRYIPQKQSEDMHAFVTEVAYKMEL
	LQIENMVLSPWTLIVAVLLQNRPSMDFDALVEKTLWLKGLTQAFGG
	FLIWPDNKPAEEVVPASILLHSNIASLVKDQVILKVDSGDSEVVDGL
	MLQHITLLMCSAYRNQLLNIFVRPSLVAVALQMTPGFRKEDVYSCF
	RFLRDVFADEFIFLPGNTLKDFEEGCYLLCKSEAIQVTTKDILVTEKG
	NTVLEFLVGLFKPFVESYQIICKYLLSEEEDHFSEEQYLAAVRKFTSQ
	LLDQGTSQCYDVLSSDVQKNALAACVRLGVVEKKKINNNCIFNVN
	EPATTKLEEMLGCKTPIGKPATAKL
342	MPVLSRPRPWRGNTLKRTAVLLALAAYGAHKVYPLVRQCLAPARG	ABCD1
	LQAPAGEPTQEASGVAAAKAGMNRVFLQRLLWLLRLLFPRVLCRE
	TGLLALHSAALVSRTFLSVYVARLDGRLARCIVRKDPRAFGWQLLQ
	WLLIALPATFVNSAIRYLEGQLALSFRSRLVAHAYRLYFSQQTYYRV
	SNMDGRLRNPDQSLTEDVVAFAASVAHLYSNLTKPLLDVAVTSYT
	LLRAARSRGAGTAWPSAIAGLVVFLTANVLRAFSPKFGELVAEEAR
	RKGELRYMHSRVVANSEEIAFYGGHEVELALLQRSYQDLASQINLIL
	LERLWYVMLEQFLMKYVWSASGLLMVAVPIITATGYSESDAEAVK
	KAALEKKEEELVSERTEAFTIARNLLTAAADAIERIMSSYKEVTELA
	GYTARVHEMFQVFEDVQRCHFKRPRELEDAQAGSGTIGRSGVRVE
	GPLKIRGQVVDVEQGIICENIPIVTPSGEVVVASLNIRVEEGMHLLITG
	PNGCGKSSLFRILGGLWPTYGGVLYKPPPQRMFYIPQRPYMSVGSL
	RDQVIYPDSVEDMQRKGYSEQDLEAILDVVHLHHILQREGGWEAM
	CD
	WKDVLSGGEKQRIGMARMFYHRPKYALLDECTSAVSIDVEGKIFQ
	AAKDAGIALLSITHRPSLWKYHTHLLQFDGEGGWKFEKLDSAARLS
	LTEEKQRLEQQLAGIPKMQRRLQELCQILGEAVAPAHVPAPSPQGP
	GGLQGAST
343	MNPDLRRERDSASFNPELLTHILDGSPEKTRRRREIENMILNDPDFQ	ACOX1
	HEDLNFLTRSQRYEVAVRKSAIMVKKMREFGIADPDEIMWFKKLHL
	VNFVEPVGLNYSMFIPTLLNQGTTAQKEKWLLSSKGLQIIGTYAQTE
	MGHGTHLRGLETTATYDPETQEFILNSPTVTSIKWWPGGLGKTSNH
	AIVLAQLITKGKCYGLHAFIVPIREIGTHKPLPGITVGDIGPKFGYDEI
	DNGYLKMDNHRIPRENMLMKYAQVKPDGTYVKPLSNKLTYGTMV
	FVRSFLVGEAARALSKACTIAIRYSAVRHQSEIKPGEPEPQILDFQTQ
	QYKLFPLLATAYAFQFVGAYMKETYHRINEGIGQGDLSELPELHAL
	TAGLKAFTSWTANTGIEACRMACGGHGYSHCSGLPNIYVNFTPSCT
	FEGENTVMMLQTARFLMKSYDQVHSGKLVCGMVSYLNDLPSQRIQ
	PQQVAVWPTMVDINSPESLTEAYKLRAARLVEIAAKNLQKEVIHRK
	SKEVAWNLTSVDLVRASEAHCHYVVVKLFSEKLLKIQDKAIQAVLR
	SLCLLYSLYGISQNAGDFLQGSIMTEPQITQVNQRVKELLTLIRSDAV
	ALVDAFDFQDVTLGSVLGRYDGNVYENLFEWAKNSPLNKAEVHES
	YKHLKSLQSKL
344	MWGSDRLAGAGGGGAAVTVAFTNARDCFLHLPRRLVAQLHLLQN	PEX1
	QAIEVVWSHQPAFLSWVEGRHFSDQGENVAEINRQVGQKLGLSNG
	GQVFLKPCSHVVSCQQVEVEPLSADDWEILELHAVSLEQHLLDQIRI
	VFPKAIFPVWVDQQTYIFIQIVALIPAASYGRLETDTKLLIQPKTRRA
	KENTFSKADAEYKKLHSYGRDQKGMMKELQTKQLQSNTVGITESN
	ENESEIPVDSSSVASLWTMIGSIFSFQSEKKQETSWGLTEINAFKNMQ
	SKVVPLDNIFRVCKSQPPSIYNASATSVFHKHCAIHVFPWDQEYFDV
	EPSFTVTYGKLVKLLSPKQQQSKTKQNVLSPEKEKQMSEPLDQKKI
	RSDHNEEDEKACVLQVVWNGLEELNNAIKYTKNVEVLHLGKVWIP
	DDLRKRLNIEMHAVVRITPVEVTPKIPRSLKLQPRENLPKDISEEDIK
	TVFYSWLQQSTTTMLPLVISEEEFIKLETKDGLKEFSLSIVHSWEKEK
	DKNIFLLSPNLLQKTTIQVLLDPMVKEEN
	SEEIDFILPFLKLSSLGGVNSLGVSSLEHITHSLLGRPLSRQLMSLVAG
	LRNGALLLTGGKGSGKSTLAKAICKEAFDKLDAHVERVDCKALRG
	KRLENIQKTLEVAFSEAVWMQPSVVLLDDLDLIAGLPAVPEHEHSP
	DAVQSQRLAHALNDMIKEFISMGSLVALIATSQSQQSLHPLLVSAQG
	VHIFQCVQHIQPPNQEQRCEILCNVIKNKLDCDINKFTDLDLQHVAK
	ETGGFVARDFTVLVDRAIHSRLSRQSISTREKLVLTTLDFQKALRGF
	LPASLRSVNLHKPRDLGWDKIGGLHEVRQILMDTIQLPAKYPELFA
	NLPIRQRTGILLYGPPGTGKTLLAGVIARESRMNFISVKGPELLSKYI
	GASEQAVRDIFIRAQAAKPCILFFDEFESIAPRRGHDNTGVTDRVVN
	QLLTQLDGVEGLQGVYVLAATSRPDLIDPALLRPGRLDKCVYCPPP
	DQVSRLEILNVLSDSLPLADDVDLQHVASVTDSFTGADLKALLYNA
	QLEALHGMLLSSGLQDGSSSSDSDLSLSSMVFLNHSSGSDDSAGDG
	ECGLDQSLVSLEMSEILPDESKFNMYRLYFGSSYESELGNGTSSDLS
	SQCLSAPSSMTQDLPGVPGKDQLFSQPPVLRTASQEGCQELTQEQR
	DQLRADISIIKGRYRSQSGEDESMNQPGPIKTRLAISQSHLMTALGHT
	RPSISEDDWKNFAELYESFQNPKRRKNQSGTMFRPGQKVTLA
345	MASRKENAKSANRVLRISQLDALELNKALEQLVWSQFTQCFHGFKP	PEX2
	GLLARFEPEVKACLWVFLWRFTIYSKNATVGQSVLNIKYKNDFSPN
	LRYQPPSKNQKIWYAVCTIGGRWLEERCYDLFRNHHLASFGKVKQ
	CVNFVIGLLKLGGLINFLIFLQRGKFATLTERLLGIHSVFCKPQNICEV
	GFEYMNRELLWHGFAEFLIFLLPLINVQKLKAKLSSWCIPLTGAPNS
	DNTLATSGKECALCGEWPTMPHTIGCEHIFCYFCAKSSFLFDVYFTC
	PKCGTEVHSLQPLKSGIEMSEVNAL
346	MLRSVWNFLKRHKKKCIFLGTVLGGVYILGKYGQKKIREIQEREAA	PEX3
	EYIAQARRQYHFESNQRTCNMTVLSMLPTLREALMQQLNSESLTAL
	LKNRPSNKLEIWEDLKIISFTRSTVAVYSTCMLVVLLRVQLNIIGGYI
	YLDNAAVGKNGTTILAPPDVQQQYLSSIQHLLGDGLTELITVIKQAV
	QKVLGSVSLKHSLSLLDLEQKLKEIRNLVEQHKSSSWINKDGSKPLL
	CHYMMPDEETPLAVQACGLSPRDITTIKLLNETRDMLESPDFSTVLN
	TCLNRGFSRLLDNMAEFFRPTEQDLQHGNSMNSLSSVSLPLAKIIPIV
	NGQIHSVCSETPSHFVQDLLTMEQVKDFAANVYEAFSTPQQLEK
347	MAMRELVEAECGGANPLMKLAGHFTQDKALRQEGLRPGPWPPGA	PEX5
	PASEAASKPLGVASEDELVAEFLQDQNAPLVSRAPQTFKMDDLLAE
	MQQIEQSNFRQAPQRAPGVADLALSENWAQEFLAAGDAVDVTQD
	YNETDWSQEFISEVTDPLSVSPARWAEEYLEQSEEKLWLGEPEGTA
	TDRWYDEYHPEEDLQHTASDFVAKVDDPKLANSEFLKFVRQIGEG
	QVSLESGAGSGRAQAEQWAAEFIQQQGTSDAWVDQFTRPVNTSAL
	DMEFERAKSAIESDVDFWDKLQAELEEMAKRDAEAHPWLSDYDDL
	TSATYDKGYQFEEENPLRDHPQPFEEGLRRLQEGDLPNAVLLFEAA
	VQQDPKHMEAWQYLGTTQAENEQELLAISALRRCLELKPDNQTAL
	MALAVSFTNESLQRQACETLRDWLRYTPAYAHLVTPAEEGAGGAG
	LGPSKRILGSLLSDSLFLEVKELFLAAVRLDPTSIDPDVQCGLGVLFN
	LSGEYDKAVDCFTAALSVRPNDYLLWNKLGATLANGNQSEEAVAA
	YRRALELQPGYIRSRYNLGISCINLGAHREAVEHFLEALNMQRKSRG
	PRGEGGAMSENIWSTLRLALSMLGQSDAYGAADARDLSTLLTMFG
	LPQ
348	MALAVLRVLEPFPTETPPLAVLLPPGGPWPAAELGLVLALRPAGESP	PEX6
	AGPALLVAALEGPDAGTEEQGPGPPQLLVSRALLRLLALGSGAWVR
	ARAVRRPPALGWALLGTSLGPGLGPRVGPLLVRRGETLPVPGPRVL
	ETRPALQGLLGPGTRLAVTELRGRARLCPESGDSSRPPPPPVVSSFA
	VSGTVRRLQGVLGGTGDSLGVSRSCLRGLGLFQGEWVWVAQARES
	SNTSQPHLARVQVLEPRWDLSDRLGPGSGPLGEPLADGLALVPATL
	AFNLGCDPLEMGELRIQRYLEGS
	IAPEDKGSCSLLPGPPFARELHIEIVSSPHYSTNGNYDGVLYRHFQIPR
	VVQEGDVLCVPTIGQVEILEGSPEKLPRWREMFFKVKKTVGEAPDG
	PASAYLADTTHTSLYMVGSTLSPVPWLPSEESTLWSSLSPPGLEALV
	SELCAVLKPRLQPGGALLTGTSSVLLRGPPGCGKTTVVAAACSHLG
	LHLLKVPCSSLCAESSGAVETKLQAIFSRARRCRPAVLLLTAVDLLG
	RDRDGLGEDARVMAVLRHLLLNEDPLNSCPPLMVVATTSRAQDLP
	ADVQTAFPHELEVPALSEGQRLSILRALTAHLPLGQEVNLAQLARR
	CAGFVVGDLYALLTHSSRAACTRIKNSGLAGGLTEEDEGELCAAGF
	PLLAEDFGQALEQLQTAHSQAVGAPKIPSVSWHDVGGLQEVKKEIL
	ETIQLPLEHPELLSLGLRRSGLLLHGPPGTGKTLLAKAVATECSLTFL
	SVKGPELINMYVGQSEENVREVFARARAAAPCIIFFDELDSLAPSRG
	RSGDSGGVMDRVVSQLLAELDGLHSTQ
	DVFVIGATNRPDLLDPALLRPGRFDKLVFVGANEDRASQLRVLSAIT
	RKFKLEPSVSLVNVLDCCPPQLTGADLYSLCSDAMTAALKRRVHDL
	EEGLEPGSSALMLTMEDLLQAAARLQPSVSEQELLRYKRIQRKFAA
	C
349	MAPAAASPPEVIRAAQKDEYYRGGLRSAAGGALHSLAGARKWLE	PEX10
	WRKEVELLSDVAYFGLTTLAGYQTLGEEYVSIIQVDPSRIHVPSSLR
	RGVLVTLHAVLPYLLDKALLPLEQELQADPDSGRPLQGSLGPGGRG
	CSGARRWMRHHTATLTEQQRRALLRAVFVLRQGLACLQRLHVAW
	FYIHGVFYHLAKRLTGITYLRVRSLPGEDLRARVSYRLLGVISLLHL
	VLSMGLQLYGFRQRQRARKEWRLHRGLSHRRASLEERAVSRNPLC
	TLCLEERRHPTATPCGHLFCWECITAW
	CSSKAECPLCREKFPPQKLIYLRHYR
350	MAEHGAHFTAASVADDQPSIFEVVAQDSLMTAVRPALQHVVKVLA	PEX12
	ESNPTHYGFLWRWFDEIFTLLDLLLQQHYLSRTSASFSENFYGLKRI
	VMGDTHKSQRLASAGLPKQQLWKSIMFLVLLPYLKVKLEKLVSSL
	REEDEYSIHPPSSRWKRFYRAFLAAYPFVNMAWEGWFLVQQLRYIL
	GKAQHHSPLLRLAGVQLGRLTVQDIQALEHKPAKASMMQQPARSV
	SEKINSALKKAVGGVALSLSTGLSVGVFFLQFLDWWYSSENQETIKS
	LTALPTPPPPVHLDYNSDSPLLPKMKTVCPLCRKTRVNDTVLATSG
	YVFCYRCVFHYVRSHQACPITGYPTEVQHLIKLYSPEN
351	MASQPPPPPKPWETRRIPGAGPGPGPGPTFQSADLGPTLMTRPGQPA	PEX13
	LTRVPPPILPRPSQQTGSSSVNTFRPAYSSFSSGYGAYGNSFYGGYSP
	YSYGYNGLGYNRLRVDDLPPSRFVQQAEESSRGAFQSIESIVHAFAS
	VSMMMDATFSAVYNSFRAVLDVANHFSRLKIHFTKVFSAFALVRTI
	RYLYRRLQRMLGLRRGSENEDLWAESEGTVACLGAEDRAATSAKS
	WPIFLFFAVILGGPYLIWKLLSTHSDEVTDSINWASGEDDHVVARAE
	YDFAAVSEEEISFRAGDMLNLALKEQQPKVRGWLLASLDGQTTGLI
	PANYVKILGKRKGRKTVESSKVSKQQQSFTNPTLTKGATVADSLDE
	QEAAFESVFVETNKVPVAPDSIGKDGEKQDL
352	MASSEQAEQPSQPSSTPGSENVLPREPLIATAVKFLQNSRVRQSPLAT	PEX14
	RRAFLKKKGLTDEEIDMAFQQSGTAADEPSSLGPATQVVPVQPPHLI
	SQPYSPAGSRWRDYGALAIIMAGIAFGFHQLYKKYLLPLILGGREDR
	KQLERMEAGLSELSGSVAQTVTQLQTTLASVQELLIQQQQKIQELA
	HELAAAKATTSTNWILESQNINELKSEINSLKGLLLNRRQFPPSPSAP
	KIPSWQIPVKSPSPSSPAAVNHHSSSDISPVSNESTSSSPGKEGHSPEG
	STVTYHLLGPQEEGEGVVDVKGQVRMEVQGEEEKREDKEDEEDEE
	DDDVSHVDEEDCLGVQREDRRGGDGQINEQVEKLRRPEGASNESE
	RD
353	MEKLRLLGLRYQEYVTRHPAATAQLETAVRGFSYLLAGRFADSHE	PEX16
	LSELVYSASNLLVLLNDGILRKELRKKLPVSLSQQKLLTWLSVLECV
	EVFMEMGAAKVWGEVGRWLVIALVQLAKAVLRMLLLLWFKAGL
	QTSPPIVPLDRETQAQPPDGDHSPGNHEQSYVGKRSNRVVRTLQNT
	PSLHSRHWGAPQQREGRQQQHHEELSATPTPLGLQETIAEFLYIARP
	LLHLLSLGLWGQRSWKPWLLAGVVDVTSLSLLSDRKGLTRRERRE
	LRRRTILLLYYLLRSPFYDRFSEARIL
	FLLQLLADHVPGVGLVTRPLMDYLPTWQKIYFYSWG
354	MAAAEEGCSVGAEADRELEELLESALDDFDKAKPSPAPPSTTTAPD	PEX19
	ASGPQKRSPGDTAKDALFASQEKFFQELFDSELASQATAEFEKAMK
	ELAEEEPHLVEQFQKLSEAAGRVGSDMTSQQEFTSCLKETLSGLAK
	NATDLQNSSMSEEELTKAMEGLGMDEGDGEGNILPIMQSIMQNLLS
	KDVLYPSLKEITEKYPEWLQSHRESLPPEQFEKYQEQHSVMCKICEQ
	FEAETPTDSETTQKARFEMVLDLMQQLQDLGHPPKELAGEMPPGLN
	FDLDALNLSGPPGASGEQCLIM
355	MKSDSSTSAAPLRGLGGPLRSSEPVRAVPARAPAVDLLEEAADLLV	PEX26
	VHLDFRAALETCERAWQSLANHAVAEEPAGTSLEVKCSLCVVGIQ
	ALAEMDRWQEVLSWVLQYYQVPEKLPPKVLELCILLYSKMQEPGA
	VLDVVGAWLQDPANQNLPEYGALAEFHVQRVLLPLGCLSEAEELV
	VGSAAFGEERRLDVLQAIHTARQQQKQEHSGSEEAQKPNLEGSVSH
	KFLSLPMLVRQLWDSAVSHFFSLPFKKSLLAALILCLLVVRFDPASP
	SSLHFLYKLAQLFRWIRKAAFSRLYQ
	LRIRD
356	MALQGISVVELSGLAPGPFCAMVLADFGARVVRVDRPGSRYDVSR	AMACR
	LGRGKRSLVLDLKQPRGAAVLRRLCKRSDVLLEPFRRGVMEKLQL
	GPEILQRENPRLIYARLSGFGQSGSFCRLAGHDINYLALSGVLSKIGR
	SGENPYAPLNLLADFAGGGLMCALGIIMALFDRTRTGKGQVIDANM
	VEGTAYLSSFLWKTQKLSLWEAPRGQNMLDGGAPFYTTYRTADGE
	FMAVGAIEPQFYELLIKGLGLKSDELPNQMSMDDWPEMKKKFADV
	FAEKTKAEWCQIFDGTDACVTPVLTFEEVVHHDHNKERGSFITSEE
	QDVSPRPAPLLLNTPAIPSFKRDPFIGEHTEEILEEFGFSREEIYQLNSD
	KIIESNKVKASL
357	MAQTPAFDKPKVELHVHLDGSIKPETILYYGRRRGIALPANTAEGLL	ADA
	NVIGMDKPLTLPDFLAKFDYYMPAIAGCREAIKRIAYEFVEMKAKE
	GVVYVEVRYSPHLLANSKVEPIPWNQAEGDLTPDEVVALVGQGLQ
	EGERDFGVKARSILCCMRHQPNWSPKVVELCKKYQQQTVVAIDLA
	GDETIPGSSLLPGHVQAYQEAVKSGIHRTVHAGEVGSAEVVKEAVD
	ILKTERLGHGYHTLEDQALYNRLRQENMHFEICPWSSYLTGAWKPD
	TEHAVIRLKNDQANYSLNTDDPLIF
	KSTLDTDYQMTKRDMGFTEEEFKRLNINAAKSSFLPEDEKRELLDL
	LYKAYGMPPSASAGQNL
358	MAAGGDHGSPDSYRSPLASRYASPEMCFVFSDRYKFRTWRQLWL	ADSL
	WLAEAEQTLGLPITDEQIQEMKSNLENIDFKMAAEEEKRLRHDVMA
	HVHTFGHCCPKAAGIIHLGATSCYVGDNTDLIILRNALDLLLPKLAR
	VISRLADFAKERASLPTLGFTHFQPAQLTTVGKRCCLWIQDLCMDL
	QNLKRVRDDLRFRGVKGTTGTQASFLQLFEGDDHKVEQLDKMVTE
	KAGFKRAFIITGQTYTRKVDIEVLSVLASLGASVHKICTDIRLLANLK
	EMEEPFEKQQIGSSAMPYKRNPMRSERCCSLARHLMTLVMDPLQT
	ASVQWFERTLDDSANRRICLAEAFLTADTILNTLQNISEGLVVYPKV
	IERRIRQELPFMATENIIMAMVKAGGSRQDCHEKIRVLSQQAASVVK
	QEGGDNDLIERIQVDAYFSPIHSQLDHLLDPSSFTGRASQQVQRFLEE
	EVYPLLKPYESVMKVKAELCL
359	MNVRIFYSVSQSPHSLLSLLFYCAILESRISATMPLFKLPAEEKQIDD	AMPD1
	AMRNFAEKVFASEVKDEGGRQEISPFDVDEICPISHHEMQAHIFHLE
	TLSTSTEARRKKRFQGRKTVNLSIPLSETSSTKLSHIDEYISSSPTYQT
	VPDFQRVQITGDYASGVTVEDFEIVCKGLYRALCIREKYMQKSFQR
	FPKTPSKYLRNIDGEAWVANESFYPVFTPPVKKGEDPFRTDNLPENL
	GYHLKMKDGVVYVYPNEAAVSKDEPKPLPYPNLDTFLDDMNFLLA
	LIAQGPVKTYTHRRLKFLSSKFQVHQMLNEMDELKELKNNPHRDF
	YNCRKVDTHIHAAACMNQKHLLRFIKKSYQIDADRVVYSTKEKNL
	TLKELFAKLKMHPYDLTVDSLDVHAGRQTFQRFDKFNDKYNPVGA
	SELRDLYLKTDNYINGEYFATIIKEVGADLVEAKYQHAEPRLSIYGR
	SPDEWSKLSSWFVCNRIHCPNMTWMIQVPRIYDVFRSKNFLPHFGK
	MLENIFMPVFEATINPQADPELSVFLKHIT
	GFDSVDDESKHSGHMFSSKSPKPQEWTLEKNPSYTYYAYYMYANI
	MVLNSLRKERGMNTFLFRPHCGEAGALTHLMTAFMIADDISHGLNL
	KKSPVLQYLFFLAQIPIAMSPLSNNSLFLEYAKNPFLDFLQKGLMISL
	STDDPMQFHFTKEPLMEEYAIAAQVFKLSTCDMCEVARNSVLQCGI
	SHEEKVKFLGDNYLEEGPAGNDIRRTNVAQIRMAYRYETWCYELN
	LIAEGLKSTE
360	MATEGMILTNHDHQIRVGVLTVSDSCFRNLAEDRSGINLKDLVQDP	GPHN
	SLLGGTISAYKIVPDEIEEIKETLIDWCDEKELNLILTTGGTGFAPRDV
	TPEATKEVIEREAPGMALAMLMGSLNVTPLGMLSRPVCGIRGKTLII
	NLPGSKKGSQECFQFILPALPHAIDLLRDAIVKVKEVHDELEDLPSPP
	PPLSPPPTTSPHKQTEDKGVQCEEEEEEKKDSGVASTEDSSSSHITAA
	AIAAKIPDSIISRGVQVLPRDTASLSTTPSESPRAQATSRLSTASCPTP
	KVQSRCSSKENILRASHSAVDITKVARRHRMSPFPLTSMDKAFITVL
	EMTPVLGTEIINYRDGMGRVLAQDVYAKDNLPPFPASVKDGYAVR
	AADGPGDRFIIGESQAGEQPTQTVMPGQVMRVTTGAPIPCGADAVV
	QVEDTELIRESDDGTEELEVRILVQARPGQDIRPIGHDIKRGECVLAK
	GTHMGPS
	EIGLLATVGVTEVEVNKFPVVAVMSTGNELLNPEDDLLPGKIRDSN
	RSTLLATIQEHGYPTINLGIVGDNPDDLLNALNEGISRADVIITSGGVS
	MGEKDYLKQVLDIDLHAQIHFGRVFMKPGLPTTFATLDIDGVRKIIF
	ALPGNPVSAVVTCNLFVVPALRKMQGILDPRPTIIKARLSCDVKLDP
	RPEYHRCILTWHHQEPLPWAQSTGNQMSSRLMSMRSANGLLMLPP
	KTEQYVELHKGEVVDVMVIGRL
361	MAGAAAESGRELWTFAGSRDPSAPRLAYGYGPGSLRELRAREFSRL	MOCOS
	AGTVYLDHAGATLFSQSQLESFTSDLMENTYGNPHSQNISSKLTHD
	TVEQVRYRILAHFHTTAEDYTVIFTAGSTAALKLVAEAFPWVSQGP
	ESSGSRFCYLTDSHTSVVGMRNVTMAINVISTPVRPEDLWSAEERSA
	SASNPDCQLPHLFCYPAQSNFSGVRYPLSWIEEVKSGRLHPVSTPGK
	WFVLLDAASYVSTSPLDLSAHQADFVPISFYKIFGFPTGLGALLVHN
	RAAPLLRKTYFGGGTASAYLAGEDFYIPRQSVAQRFEDGTISFLDVI
	ALKHGFDTLERLTGGMENIKQHTFTLAQYTYVALSSLQYPNGAPVV
	RIYSDSEFSSPEVQGPIINFNVLDDKGNIIGYSQVDKMASLYNIHLRT
	GCFCNTGACQRHLGISNEMVRKHFQAGHVCGDNMDLIDGQPTGSV
	RISFGYMSTLDDVQAFLRFIIDTRLHSSGDWPVPQAHADTGETGAPS
	ADSQADVIPAVMGRRSLSPQEDALTGSRVWNNSSTVNAVPVAPPV
	CDVARTQPTPSEKAAGVLEGALGPHVVTNLYLYPIKSCAAFEVTRW
	PVGNQGLLYDRSWMVVNHNGVCLSQKQEPRLCLIQPFIDLRQRIMV
	IKAKGMEPIEVPLEENSERTQIRQSRVCADRVSTYDCGEKISSWLSTF
	FGRPCHLIKQSSNSQRNAKKKHGKDQLPGTMATLSLVNEAQYLLIN
	TSSILELHRQLNTSDENGKEELFSLKDLSLRFRANIIINGKRAFEEEK
	WDEISIGSLRFQVLGPCHRCQMICIDQQTGQRNQHVFQKLSESRETK
	VNFGMYLMHASLDLSSPCFLSVGSQVLPVLKENVEGHDLPASEKHQ
	DVTS
362	MAARPLSRMLRRLLRSSARSCSSGAPVTQPCPGESARAASEEVSRRR	MOCS1
	QFLREHAAPFSAFLTDSFGRQHSYLRISLTEKCNLRCQYCMPEEGVP
	LTPKANLLTTEEILTLARLFVKEGIDKIRLTGGEPLIRPDVVDIVAQLQ
	RLEGLRTIGVTTNGINLARLLPQLQKAGLSAINISLDTLVPAKFEFIVR
	RKGFHKVMEGIHKAIELGYNPVKVNCVVMRGLNEDELLDFAALTE
	GLP
	LDVRFIEYMPFDGNKWNFKKMVSYKEMLDTVRQQWPELEKVPEEE
	SSTAKAFKIPGFQGQISFITSMSEHFCGTCNRLRITADGNLKVCLFGN
	SEVSLRDHLRAGASEQELLRIIGAAVGRKKRQHAGMFSISQMKNRP
	MILIELFLMFPNSPPANPSIFSWDPLHVQGLRPRMSFSSQVATLWKG
	CRVPQTPPLAQQRLGSGSFQRHYTSRADSDANSKCLSPGSWASAAP
	SGPQLTSEQLTHVDSEGRAAMVDVGRKPDTERVAVASAVVLLGPV
	AFKLVQQNQLKKGDALVVAQLAG
	VQAAKVTSQLIPLCHHVALSHIQVQLELDSTRHAVKIQASCRARGPT
	GVEMEALTSAAVAALTLYDMCKAVSRDIVLEEIKLISKTGGQRGDF
	HRA
363	MENGYTYEDYKNTAEWLLSHTKHRPQVAIICGSGLGGLTDKLTQA	PNP
	QIFDYGEIPNFPRSTVPGHAGRLVFGFLNGRACVMMQGRFHMYEG
	YPLWKVTFPVRVFHLLGVDTLVVTNAAGGLNPKFEVGDIMLIRDHI
	NLPGFSGQNPLRGPNDERFGDRFPAMSDAYDRTMRQRALSTWKQM
	GEQRELQEGTYVMVAGPSFETVAECRVLQKLGADAVGMSTVPEVI
	VARHCGLRVFGFSLITNKVIMDYESLEKANHEEVLAAGKQAAQKLE
	QFVSILMASIPLPDKAS
364	MTADKLVFFVNGRKVVEKNADPETTLLAYLRRKLGLSGTKLGCGE	XDH
	GGCGACTVMLSKYDRLQNKIVHFSANACLAPICSLHHVAVTTVEGI
	GSTKTRLHPVQERIAKSHGSQCGFCTPGIVMSMYTLLRNQPEPTMEE
	IENAFQGNLCRCTGYRPILQGFRTFARDGGCCGGDGNNPNCCMNQ
	KKDHSVSLSPSLFKPEEFTPLDPTQEPIFPPELLRLKDTPRKQLRFEGE
	RVTWIQASTLKELLDLKAQHPDAKLVVGNTEIGIEMKFKNMLFPMI
	VCPAWIPELNSVEHGPDGISFGAACPLSIVEKTLVDAVAKLPAQKTE
	VFRGVLEQLRWFAGKQVKSVASVGGNIITASPISDLNPVFMASGAK
	LTLVSRGTRRTVQMDHTFFPGYRKTLLSPEEILLSIEIPYSREGEYFSA
	FKQASRREDDIAKVTSGMRVLFKPGTTEVQELALCYGGMANRTISA
	LKTTQRQLSKLWKEELLQDVCAGLAEELHLPPDAPGGMVDFRCTL
	TLSFFFKFYLTVLQKLGQENLEDKCGKLDPTFASATLLFQKDPPADV
	QLFQEVPKGQSEEDMVGRPLPHLAADMQASGEAVYCDDIPRYENE
	LSLRLVTSTRAHAKIKSIDTSEAKKVPGFVCFISADDVPGSNITGICN
	DETVFAKDKVTCVGHIIGAVVADTPEHTQRAAQGVKITYEELPAIITI
	EDAIKNNSFYGPELKIEKGDLKKGFSEADNVVSGEIYIGGQEHFYLE
	THCTIAVPKGEAGEMELFVSTQNTMKTQSFVAKMLGVPANRIVVR
	VKRMGGGFGGKETRSTVVSTAVALAAYKTGRPVRCMLDRDEDML
	ITGGR
	HPFLARYKVGFMKTGTVVALEVDHFSNVGNTQDLSQSIMERALFH
	MDNCYKIPNIRGTGRLCKTNLPSNTAFRGFGGPQGMLIAECWMSEV
	AVTCGMPAEEVRRKNLYKEGDLTHFNQKLEGFTLPRCWEECLASS
	QYHARKSEVDKFNKENCWKKRGLCIIPTKFGISFTVPFLNQAGALLH
	VYTDGSVLLTHGGTEMGQGLHTKMVQVASRALKIPTSKIYISETST
	NTVPNTSPTAASVSADLNGQAVYAACQTILKRLEPYKKKNPSGSWE
	DWVTAAYMDTVSLSATGFYRTPNLGYSFETNSGNPFHYFSYGVAC
	SEVEIDCLTGDHKNLRTDIVMDVGSSLNPAIDIGQVEGAFVQGLGLF
	TLEELHYSPEGSLHTRGPSTYKIPAFGSIPIEFRVSLLRDCPNKKAIYA
	SKAVGEPPLFLAASIFFAIKDAIRAARAQHTGNNVKELFRLDSPATPE
	KIRNACVDKFTTLCVTGVPENCKPWSVRV
365	MLLLHRAVVLRLQQACRLKSIPSRICIQACSTNDSFQPQRPSLTFSGD	SUOX
	NSSTQGWRVMGTLLGLGAVLAYQDHRCRAAQESTHIYTKEEVSSH
	TSPETGIWVTLGSEVFDVTEFVDLHPGGPSKLMLAAGGPLEPFWAL
	YAVHNQSHVRELLAQYKIGELNPEDKVAPTVETSDPYADDPVRHPA
	LKVNSQRPFNAEPPPELLTENYITPNPIFFTRNHLPVPNLDPDTYRLH
	VVGAPGGQSLSLSLDDLHNFPRYEITVTLQCAGNRRSEMTQVKEVK
	GLEWRTGAISTARWAGARLCDVLAQAGHQLCETEAHVCFEGLDSD
	PTGTAYGASIPLARAMDPEAEVLLAYEMNGQPLPRDHGFPVRVVVP
	GVVGARHVKWLGRVSVQPEESYSHWQRRDYKGFSPSVDWETVDF
	DSAPSIQELPVQSAITEPRDGETVESGEVTIKGYAWSGGGRAVIRVD
	VSLDGGLTWQVAKLDGEEQRPRKAWAWRLWQLKAPVPAGQKEL
	NIVCKAVDDGYNVQPDTVAPIWNLRGVLSNAWHRVHVYVSP
366	MFHLRTCAAKLRPLTASQTVKTFSQNRPAAARTFQQIRCYSAPVAA	OGDH
	EPFLSGTSSNYVEEMYCAWLENPKSVHKSWDIFFRNTNAGAPPGTA
	YQSPLPLSRGSLAAVAHAQSLVEAQPNVDKLVEDHLAVQSLIRAYQ
	IRGHHVAQLDPLGILDADLDSSVPADIISSTDKLGFYGLDESDLDKVF
	HLPTTTFIGGQESALPLREIIRRLEMAYCQHIGVEFMFINDLEQCQWI
	RQKFETPGIMQFTNEEKRTLLARLVRSTRFEEFLQRKWSSEKRFGLE
	GCEVLIPALKTIIDKSSENGVDYVIMGMPHRGRLNVLANVIRKELEQ
	IFCQFDSKLEAADEGSGDVKYHLGMYHRRINRVTDRNITLSLVANP
	SHLEAADPVVMGKTKAEQFYCGDTEGKKVMSILLHGDAAFAGQGI
	VYETFHLSDLPSYTTHGTVHVVVNNQIGFTTDPRMARSSPYPTDVA
	RVVNAPIFHVNSDDPEAVMYVCKVAAEWRSTFHKDVVVDLVCYR
	RNGHNEMDEPMFTQPLMYKQIRKQKPVLQKYAELLVSQGVVNQPE
	YEEEISKYDKICEEAFARSKDEKILHIKHWLDSPWPGFFTLDGQPRS
	MSCPSTGLTEDILTHIGNVASSVPVENFTIHGGLSRILKTRGEMVKNR
	TVDWALAEYMAFGSLLKEGIHIRLSGQDVERGTFSHRHHVLHDQN
	VDKRTCIPMNHLWPNQAPYTVCNSSLSEYGVLGFELGFAMASPNAL
	VLWEAQFGDFHNTAQCIIDQFICPGQAKWVRQNGIVLLLPHGMEG
	MGPEHSSARPERFLQMCNDDPDVLPDLKEANFDINQLYDCNWVVV
	NCSTPGNFFHVLRRQILLPFRKPLIIFTPKSLLRHPEARSSFDEMLPGT
	HFQRVIPEDGPAAQNPENVKRLLFCTGKVYYDLTRERKARDMVGQ
	VAITRIEQLSPFPFDLLLKEVQKYPNAELAWCQEEHKNQGYYDYVK
	PRLRTTISRAKPVWYAGRDPAAAPATGNKKTHLTELQRLLDTAFDL
	DVFKNFS
367	MVGYDPKPDGRNNTKFQVAVAGSVSGLVTRALISPFDVIKIRFQLQ	SLC25A19
	HERLSRSDPSAKYHGILQASRQILQEEGPTAFWKGHVPAQILSIGYG
	AVQFLSFEMLTELVHRGSVYDAREFSVHFVCGGLAACMATLTVHP
	VDVLRTRFAAQGEPKVYNTLRHAVGTMYRSEGPQVFYKGLAPTLI
	AIFPYAGLQFSCYSSLKHLYKWAIPAEGKKNENLQNLLCGSGAGVIS
	KTLTYPLDLFKKRLQVGGFEHARAAFGQVRRYKGLMDCAKQVLQ
	KEGALGFFKGLSPSLLKAALSTGFMF
	FSYEFFCNVFHCMNRTASQR
368	MASATAAAARRGLGRALPLFWRGYQTERGVYGYRPRKPESREPQG	DHTKD1
	ALERPPVDHGLARLVTVYCEHGHKAAKINPLFTGQALLENVPEIQA
	LVQTLQGPFHTAGLLNMGKEEASLEEVLVYLNQIYCGQISIETSQLQ
	SQDEKDWFAKRFEELQKETFTTEERKHLSKLMLESQEFDHFLATKF
	STVKRYGGEGAESMMGFFHELLKMSAYSGITDVIIGMPHRGRLNLL
	TGLLQFPPELMFRKMRGLSEFPENFSATGDVLSHLTSSVDLYFGAHH
	PLHVTMLPNPSHLEAVNPVAVGK
	TRGRQQSRQDGDYSPDNSAQPGDRVICLQVHGDASFCGQGIVPETF
	TLSNLPHFRIGGSVHLIVNNQLGYTTPAERGRSSLYCSDIGKLVGCAI
	IHVNGDSPEEVVRATRLAFEYQRQFRKDVIIDLLCYRQWGHNELDE
	PFYTNPIMYKIIRARKSIPDTYAEHLIAGGLMTQEEVSEIKSSYYAKL
	NDHLNNMAHYRPPALNLQAHWQGLAQPEAQITTWSTGVPLDLLRF
	VGMKSVEVPRELQMHSHLLKTHVQSRMEKMMDGIKLDWATAEAL
	ALGSLLAQGFNVRLSGQDVGRGT
	FSQRHAIVVCQETDDTYIPLNHMDPNQKGFLEVSNSPLSEEAVLGFE
	YGMSIESPKLLPLWEAQFGDFFNGAQIIFDTFISGGEAKWLLQSGIVI
	LLPHGYDGAGPDHSSCRIERFLQMCDSAEEGVDGDTVNMFVVHPT
	TPAQYFHLLRRQMVRNFRKPLIVASPKMLLRLPAAVSTLQEMAPGT
	TFNPVIGDSSVDPKKVKTLVFCSGKHFYSLVKQRESLGAKKHDFAII
	RVEELCPFPLDSLQQEMSKYKHVKDHIWSQEEPQNMGPWSFVSPRF
	EKQLACKLRLVGRPPLPVPAV
	GIGTVHLHQHEDILAKTFA
369	MASALSYVSKFKSFVILFVTPLLLLPLVILMPAKFVRCAYVIILMAIY	SLC13A5
	WCTEVIPLAVTSLMPVLLFPLFQILDSRQVCVQYMKDTNMLFLGGLI
	VAVAVERWNLHKRIALRTLLWVGAKPARLMLGFMGVTALLSMWI
	SNTATTAMMVPIVEAILQQMEATSAATEAGLELVDKGKAKELPGSQ
	VIFEGPTLGQQEDQERKRLCKAMTLCICYAASIGGTATLTGTGPNVV
	LLGQMNELFPDSKDLVNFASWFAFAFPNMLVMLLFAWLWLQFVY
	MRFNFKKSWGCGLESKKNEKAALKVLQEEYRKLGPLSFAEINVLIC
	FFLLVILWFSRDPGFMPGWLTVAWVEGETKYVSDATVAIFVATLLFI
	VPSQKPKFNFRSQTEEERKTPFYPPPLLDWKVTQEKVPWGIVLLLGG
	GFALAKGSEASGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTEC
	TSNVATTTLFLPIFASMSRSIGLNPLYIMLPCTLSASFAFMLPVATPPN
	AIVFTYGHLKVADMVKTGVIMNIIGVFCVFLAVNTWGRAIFDLDHF
	PDWANVTHIET
370	MYRALRLLARSRPLVRAPAAALASAPGLGGAAVPSFWPPNAARMA	FH
	SQNSFRIEYDTFGELKVPNDKYYGAQTVRSTMNFKIGGVTERMPTP
	VIKAFGILKRAAAEVNQDYGLDPKIANAIMKAADEVAEGKLNDHFP
	LVVWQTGSGTQTNMNVNEVISNRAIEMLGGELGSKIPVHPNDHVN
	KSQSSNDTFPTAMHIAAAIEVHEVLLPGLQKLHDALDAKSKEFAQII
	KIGRTHTQDAVPLTLGQEFSGYVQQVKYAMTRIKAAMPRIYELAAG
	GTAVGTGLNTRIGFAEKVAAKVAALTGLPFVTAPNKFEALAAHDA
	LVELSGAMNTTACSLMKIANDIRFLGSGPRSGLGELILPENEPGSSIM
	PGKVNPTQCEAMTMVAAQVMGNHVAVTVGGSNGHFELNVFKPM
	MIKNVLHSARLLGDASVSFTENCVVGIQANTERINKLMNESLMLVT
	ALNPHIGYDKAAKIAKTAHKNGSTLKETAIELGYLTAEQFDEWVKP
	KDMLGPK
371	MWRVCARRAQNVAPWAGLEARWTALQEVPGTPRVTSRSGPAPAR	DLAT
	RNSVTTGYGGVRALCGWTPSSGATPRNRLLLQLLGSPGRRYYSLPP
	HQKVPLPSLSPTMQAGTIARWEKKEGDKINEGDLIAEVETDKATVG
	FESLEECYMAKILVAEGTRDVPIGAIICITVGKPEDIEAFKNYTLDSSA
	APTPQAAPAPTPAATASPPTPSAQAPGSSYPPHMQVLLPALSPTMTM
	GTVQRWEKKVGEKLSEGDLLAEIETDKATIGFEVQEEGYLAKILVPE
	GTRDVPLGTPLCIIVEKEADISAFADYRPTEVTDLKPQVPPPTPPPVA
	AVPPTPQPLAPTPSAPCPATPAGPKGRVFVSPLAKKLAVEKGIDLTQ
	VKGTGPDGRITKKDIDSFVPSKVAPAPAAVVPPTGPGMAPVPTGVFT
	DIPISNIRRVIAQRLMQSKQTIPHYYLSIDVNMGEVLLVRKELNKILE
	GRSKISVNDFIIKASALACLKVPEANSSWMDTVIRQNHVVDVSVAV
	STPAGLITPIVFNAHIKGVETIANDVVSLATKAREGKLQPHEFQGGTF
	TISNLGMFGIKNFSAIINPPQACILAIGASEDKLVPADNEKGFDVASM
	MSVTLSCDHRVVDGAVGAQWLAEFRKYLEKPITMLL
372	MAGALVRKAADYVRSKDFRDYLMSTHFWGPVANWGLPIAAINDM	MPC1
	KKSPEIISGRMTFALCCYSLTFMRFAYKVQPRNWLLFACHATNEVA
	QLIQGGRLIKHEMTKTASA
373	MRKMLAAVSRVLSGASQKPASRVLVASRNFANDATFEIKKCDLHR	PDHA1
	LEEGPPVTTVLTREDGLKYYRMMQTVRRMELKADQLYKQKIIRGF
	CHLCDGQEACCVGLEAGINPTDHLITAYRAHGFTFTRGLSVREILAE
	LTGRKGGCAKGKGGSMHMYAKNFYGGNGIVGAQVPLGAGIALAC
	KYNGKDEVCLTLYGDGAANQGQIFEAYNMAALWKLPCIFICENNR
	YGMGTSVERAAASTDYYKRGDFIPGLRVDGMDILCVREATRFAAA
	YCRSGKGPILMELQTYRYHGHSMSDPGVSYRTREEIQEVRSKSDPIM
	LLKDRMVNSNLASVEELKEIDVEVRKEIEDAAQFATADPEPPLEELG
	YHIYSSDPPFEVRGANQWIKFKSVS
374	MAAVSGLVRRPLREVSGLLKRRFHWTAPAALQVTVRDAINQGMDE	PDHB
	ELERDEKVFLLGEEVAQYDGAYKVSRGLWKKYGDKRIIDTPISEMG
	FAGIAVGAAMAGLRPICEFMTFNFSMQAIDQVINSAAKTYYMSGGL
	QPVPIVFRGPNGASAGVAAQHSQCFAAWYGHCPGLKVVSPWNSED
	AKGLIKSAIRDNNPVVVLENELMYGVPFEFPPEAQSKDFLIPIGKAKI
	ERQGTHITVVSHSRPVGHCLEAAAVLSKEGVECEVINMRTIRPMDM
	ETIEASVMKTNHLVTVEGGWPQFG
	VGAEICARIMEGPAFNFLDAPAVRVTGADVPMPYAKILEDNSIPQVK
	DIIFAIKKTLNI
375	MAASWRLGCDPRLLRYLVGFPGRRSVGLVKGALGWSVSRGANWR	PDHX
	WFHSTQWLRGDPIKILMPSLSPTMEEGNIVKWLKKEGEAVSAGDAL
	CEIETDKAVVTLDASDDGILAKIVVEEGSKNIRLGSLIGLIVEEGEDW
	KHVEIPKDVGPPPPVSKPSEPRPSPEPQISIPVKKEHIPGTLRFRLSPAA
	RNILEKHSLDASQGTATGPRGIFTKEDALKLVQLKQTGKITESRPTP
	APTATPTAPSPLQATAGPSYPRPVIPPVSTPGQPNAVGTFTEIPASNIR
	RVIAKRLTESKSTVPHAYATADCDLGAVLKVRQDLVKDDIKVSVN
	DFIIKAAAVTLKQMPDVNVSWDGEGPKQLPFIDISVAVATDKGLLTP
	IIKDAAAKGIQEIADSVKALSKKARDGKLLPEEYQGGSFSISNLGMF
	GIDEFTAVINPPQACILAVGRFRPVLKLTEDEEGNAKLQQRQLITVT
	MSSDSRVVDDELATRFLKSFKANLENPIRLA
376	MPAPTQLFFPLIRNCELSRIYGTACYCHHKHLCCSSSYIPQSRLRYTP	PDP1
	HPAYATFCRPKENWWQYTQGRRYASTPQKFYLTPPQVNSILKANE
	YSFKVPEFDGKNVSSILGFDSNQLPANAPIEDRRSAATCLQTRGMLL
	GVFDGHAGCACSQAVSERLFYYIAVSLLPHETLLEIENAVESGRALL
	PILQWHKHPNDYFSKEASKLYFNSLRTYWQELIDLNTGESTDIDVKE
	ALINAFKRLDNDISLEAQVGDPNSFLNYLVLRVAFSGATACVAHVD
	GVDLHVANTGDSRAMLGVQEEDGSWSAVTLSNDHNAQNERELER
	LKLEHPKSEAKSVVKQDRLLGLLMPFRAFGDVKFKWSIDLQKRVIE
	SGPDQLNDNEYTKFIPPNYHTPPYLTAEPEVTYHRLRPQDKFLVLAT
	DGLWETMHRQDVVRIVGEYLTGMHHQQPIAVGGYKVTLGQMHGL
	LTERRTKMSSVFEDQNAATHLIRHAVGNNEFGTVDHERLSKMLSLP
	EELARMYRDDITIIVVQFNSHVVGAYQNQE
377	MLEKFCNSTFWNSSFLDSPEADLPLCFEQTVLVWIPLGYLWLLAPW	ABCC2
	QLLHVYKSRTKRSSTTKLYLAKQVFVGFLLILAAIELALVLTEDSGQ
	ATVPAVRYTNPSLYLGTWLLVLLIQYSRQWCVQKNSWFLSLFWILS
	ILCGTFQFQTLIRTLLQGDNSNLAYSCLFFISYGFQILILIFSAFSENNE
	SSNNPSSIASFLSSITYSWYDSIILKGYKRPLTLEDVWEVDEEMKTKT
	LVS
	KFETHMKRELQKARRALQRRQEKSSQQNSGARLPGLNKNQSQSQD
	ALVLEDVEKKKKKSGTKKDVPKSWLMKALFKTFYMVLLKSFLLKL
	VNDIFTFVSPQLLKLLISFASDRDTYLWIGYLCAILLFTAALIQSFCLQ
	CYFQLCFKLGVKVRTAIMASVYKKALTLSNLARKEYTVGETVNLM
	SVDAQKLMDVTNFMHMLWSSVLQIVLSIFFLWRELGPSVLAGVGV
	MVLVIPINAILSTKSKTIQVKNMKNKDKRLKIMNEILSGIKILKYFAW
	EPSFRDQVQNLRKKELKNLLAFS
	QLQCVVIFVFQLTPVLVSVVTFSVYVLVDSNNILDAQKAFTSITLFNI
	LRFPLSMLPMMISSMLQASVSTERLEKYLGGDDLDTSAIRHDCNFD
	KAMQFSEASFTWEHDSEATVRDVNLDIMAGQLVAVIGPVGSGKSSL
	ISAMLGEMENVHGHITIKGTTAYVPQQSWIQNGTIKDNILFGTEFNE
	KRYQQVLEACALLPDLEMLPGGDLAEIGEKGINLSGGQKQRISLAR
	ATYQNLDIYLLDDPLSAVDAHVGKHIFNKVLGPNGLLKGKTRLLVT
	HSMHFLPQVDEIVVLGNGTIV
	EKGSYSALLAKKGEFAKNLKTFLRHTGPEEEATVHDGSEEEDDDYG
	LISSVEEIPEDAASITMRRENSFRRTLSRSSRSNGRHLKSLRNSLKTRN
	VNSLKEDEELVKGQKLIKKEFIETGKVKFSIYLEYLQAIGLFSIFFIILA
	FVMNSVAFIGSNLWLSAWTSDSKIFNSTDYPASQRDMRVGVYGAL
	GLAQGIFVFIAHFWSAFGFVHASNILHKQLLNNILRAPMRFFDTTPT
	GRI
	VNRFAGDISTVDDTLPQSLRSWITCFLGIISTLVMICMATPVFTIIVIPL
	GIIYVSVQMFYVSTSRQLRRLDSVTRSPIYSHFSETVSGLPVIRAFEH
	QQRFLKHNEVRIDTNQKCVFSWITSNRWLAIRLELVGNLTVFFSAL
	MMVIYRDTLSGDTVGFVLSNALNITQTLNWLVRMTSEIETNIVAVE
	RITEYTKVENEAPWVTDKRPPPDWPSKGKIQFNNYQVRYRPELDLV
	LRGI
	TCDIGSMEKIGVVGRTGAGKSSLTNCLFRILEAAGGQIIIDGVDIASIG
	LHDLREKLTIIPQDPILFSGSLRMNLDPFNNYSDEEIWKALELAHLKS
	FVASLQLGLSHEVTEAGGNLSIGQRQLLCLGRALLRKSKILVLDEAT
	AAVDLETDNLIQTTIQNEFAHCTVITIAHRLHTIMDSDKVMVLDNGK
	IIECGSPEELLQIPGPFYFMAKEAGIENVNSTKF
378	MDQNQHLNKTAEAQPSENKKTRYCNGLKMFLAALSLSFIAKTLGAI	SLCO1B1
	IMKSSIIHIERRFEISSSLVGFIDGSFEIGNLLVIVFVSYFGSKLHRPKLI
	GIGCFIMGIGGVLTALPHFFMGYYRYSKETNINSSENSTSTLSTCLIN
	QILSLNRASPEIVGKGCLKESGSYMWIYVFMGNMLRGIGETPIVPLG
	LSYIDDFAKEGHSSLYLGILNAIAMIGPIIGFTLGSLFSKMYVDIGYV
	DLSTIRITPTDSRWVGAWWLNFLVSGLFSHSSIPFFFLPQTPNKPQKE
	RKASLSLHVLETNDEKDQTANLTNQGKNITKNVTGFFQSFKSILTNP
	LYVMFVLLTLLQVSSYIGAFTYVFKYVEQQYGQPSSKANILLGVITIP
	IFASGMFLGGYIIKKFKLNTVGIAKFSCFTAVMSLSFYLLYFFILCEN
	KSVAGLTMTYDGNNPVTSHRDVPLSYCNSDCNCDESQWEPVCGNN
	GITYISPCLAGCKSSSGNKKPIVFYNCSCLEVTGLQNRNYSAHLGEC
	PRDDACTRKFYFFVAIQVLNLFFSALGGTSHVMLIVKIVQPELKSLA
	LGFHSMVIRALGGILAPIYFGALIDTTCIKWSTNNCGTRGSCRTYNST
	SFSRVYLGLSSMLRVSSLVLYIILIYAMKKKYQEKDINASENGSVMD
	EANLESLNKNKHFVPSAGADSETHC
379	MDQHQHLNKTAESASSEKKKTRRCNGFKMFLAALSFSYIAKALGGI	SLCO1B3
	IMKISITQIERRFDISSSLAGLIDGSFEIGNLLVIVFVSYFGSKLHRPKLI
	GIGCLLMGTGSILTSLPHFFMGYYRYSKETHINPSENSTSSLSTCLINQ
	TLSFNGTSPEIVEKDCVKESGSHMWIYVFMGNMLRGIGETPIVPLGIS
	YIDDFAKEGHSSLYLGSLNAIGMIGPVIGFALGSLFAKMYVDIGYV
	DLSTIRITPKDSRWVGAWWLGFLVSGLFSHSSIPFFFLPKNPNKPQKE
	RKISLSLHVLKTNDDRNQTANLTNQGKNVTKNVTGFFQSLKSILTNP
	LYVIFLLLTLLQVSSFIGSFTYVFKYMEQQYGQSASHANFLLGIITIPT
	VATGMFLGGFIIKKFKLSLVGIAKFSFLTSMISFLFQLLYFPLICESKS
	VAGLTLTYDGNNSVASHVDVPLSYCNSECNCDESQWEPVCGNNGI
	TYLSPCLAGCKSSSGIKKHTVFYNCSCVEVTGLQNRNYSAHLGECP
	RDNTCTRKFFIYVAIQVINSLFSATGGTTFILLTVKIVQPELKALAMG
	FQSMVIRTLGGILAPIYFGALIDKTCMKWSTNSCGAQGACRIYNSVF
	FGRVYLGLSIALRFPALVLYIVFIFAMKKKFQGKDTKASDNERKVM
	DEANLEFLNNGEHFVPSAGTDSKTCNLDMQDNAAAN
380	MGEPGQSPSPRSSHGSPPTLSTLTLLLLLCGHAHSQCKILRCNAEYVS	HFE2
	STLSLRGGGSSGALRGGGGGGRGGGVGSGGLCRALRSYALCTRRT
	ARTCRGDLAFHSAVHGIEDLMIQHNCSRQGPTAPPPPRGPALPGAGS
	GLPAPDPCDYEGRFSRLHGRPPGFLHCASFGDPHVRSFHHHFHTCR
	VQGAWPLLDNDFLFVQATSSPMALGANATATRKLTIIFKNMQECID
	QKVYQAEVDNLPVAFEDGSINGGDRPGGSSLSIQTANPGNHVEIQA
	AYIGTTIIIRQTAGQLSFSIKVAEDVAMAFSAEQDLQLCVGGCPPSQR
	LSRSERNRRGAITIDTARRLCKEGLPVEDAYFHSCVFDVLISGDPNFT
	VAAQAALEDARAFLPDLEKLHLFPSDAGVPLSSATLLAPLLSGLFVL
	WLCIQ
381	MHQRHPRARCPPLCVAGILACGFLLGCWGPSHFQQSCLQALEPQAV	ADAMTS13
	SSYLSPGAPLKGRPPSPGFQRQRQRQRRAAGGILHLELLVAVGPDVF
	QAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPEG
	APNITANLTSSLLSVCGWSQTINPEDDTDPGHADLVLYITRFDLELPD
	GNRQVRGVTQLGGACSPTWSCLITEDTGFDLGVTIAHEIGHSFGLEH
	DGAPGSGCGPSGHVMASDGAAPRAGLAWSPCSRRQLLSLLSAGRA
	RCVWDPPRPQPGSAGHPPDAQPGLYYSANEQCRVAFGPKAVACTF
	AREHLDMCQALSCHTDPLDQSSCSRLLVPLLDGTECGVEKWCSKG
	RCRSLVELTPIAAVHGRWSSWGPRSPCSRSCGGGVVTRRRQCNNPR
	PAFGGRACVGADLQAEMCNTQACEKTQLEFMSQQCARTDGQPLRS
	SPGGASFYHWGAAVPHSQGDALCRHMCRAIGESFIMKRGDSFLDG
	TRCMPSGPREDGTLSLCVSGSCRTFGCDGRMDSQQVWDRCQVCGG
	DNSTCSPRKGSFTAGRAREYVTFLTVTPNLTSVYIANHRPLFTHLAV
	RIGGRYVVAGKMSISPNTTYPSLLEDGRVEYRVALTEDRLPRLEEIRI
	WGPLQEDADIQVYRRYGEEYGNLTRPDITFTYFQPKPRQAWVWAA
	VRGPCSVSCGAGLRWVNYSCLDQARKELVETVQCQGSQQPPAWPE
	ACVLEPCPPYWAVGDFGPCSASCGGGLRERPVRCVEAQGSLLKTLP
	PARCRAGAQQPAVALETCNPQPCPARWEVSEPSSCTSAGGAGLALE
	NETCVPGADGLEAPVTEGPGSVDEKLPAPEPCVGMSCPPGWGHLD
	ATSAGEKAPSPWGSIRTGAQAAHVWTPAAGSCSVSCGRGLMELRF
	LCMDSALRVPVQEELCGLASKPGSRREVCQAVPCPARWQYKLAAC
	SVSCGRGVVRRILYCARAHGEDDGEEILLDTQCQGLPRPEPQEACSL
	EPCPPRWKVMSLGPCSASCGLGTARRSVACVQLDQGQDVEVDEAA
	CAALVRPEASVPCLIADCTYRWHVGTWMECSVSCGDGIQRRRDTC
	LGPQAQAPVPADFCQHLPKPVTVRGCWAGPCVGQGTPSLVPHEEA
	AAPGRTTATPAGASLEWSQARGLLFSPAPQPRRLLPGPQENSVQSSA
	CGRQHLEPTGTIDMRGPGQADCAVAIGRPLGEVVTLRVLESSLNCS
	AGDMLLLWGRLTWRKMCRKLLDMTFSSKTNTLVVRQRCGRPGGG
	VLLRYGSQLAPETFYRECDMQLFGPWGEIVSPSLSPATSNAGGCRLF
	INVAPHARIAIHALATNMGAGTEGANASYILIRDTHSLRTTAFHGQQ
	VLYWESESSQAEMEFSEGFLKAQASLRGQYWTLQSWVPEMQDPQS
	WKGKEGT
382	MSRPLSDQEKRKQISVRGLAGVENVTELKKNFNRHLHFTLVKDRN	PYGM
	VATPRDYYFALAHTVRDHLVGRWIRTQQHYYEKDPKRIYYLSLEFY
	MGRTLQNTMVNLALENACDEATYQLGLDMEELEEIEEDAGLGNGG
	LGRLAACFLDSMATLGLAAYGYGIRYEFGIFNQKISGGWQMEEAD
	DWLRYGNPWEKARPEFTLPVHFYGHVEHTSQGAKWVDTQVVLAM
	PYDTPVPGYRNNVVNTMRLWSAKAPNDFNLKDFNVGGYIQAVLD
	RNLAENISRVLYPNDNFFEGKELRLKQEYFVVAATLQDIIRRFKSSK
	FGCRDPVRTNFDAFPDKVAIQLNDTHPSLAIPELMRILVDLERM
	DWDKAWDVTVRTCAYTNHTVLPEALERWPVHLLETLLPRHLQIIYE
	INQRFLNRVAAAFPGDVDRLRRMSLVEEGAVKRINMAHLCIAGSHA
	VNGVARIHSEILKKTIFKDFYELEPHKFQNKTNGITPRRWLVLCNPG
	LAEVIAERIGEDFISDLDQLRKLLSFVDDEAFIRDVAKVKQENKLKF
	AAYLEREYKVHINPNSLFDIQVKRIHEYKRQLLNCLHVITLYNRIKR
	EPNKFFVPRTVMIGGKAAPGYHMAKMIIRLVTAIGDVVNHDPAVG
	DRLRVIFLENYRVSLAEKVIPAADLSEQISTAGTEASGTGNMKFMLN
	GALTIGTMDGANVEMAEEAGEENFFIFGMRVEDVDKLDQRGYNAQ
	EYYDRIPELRQVIEQLSSGFFSPKQPDLFKDIVNMLMHHDRFKVFAD
	YEDYIKCQEKVSALYKNPREWTRMVIRNIATSGKFSSDRTIAQYARE
	IWGVEPSRQRLPAPDEAI
383	MLSFVDTRTLLLLAVTLCLATCQSLQEETVRKGPAGDRGPRGERGP	COL1A2
	PGPPGRDGEDGPTGPPGPPGPPGPPGLGGNFAAQYDGKGVGLGPGP
	MGLMGPRGPPGAAGAPGPQGFQGPAGEPGEPGQTGPAGARGPAGP
	PGKAGEDGHPGKPGRPGERGVVGPQGARGFPGTPGLPGFKGIRGHN
	GLDGLKGQPGAPGVKGEPGAPGENGTPGQTGARGLPGERGRVGAP
	GPAGARGSDGSVGPVGPAGPIGSAGPPGFPGAPGPKGEIGAVGNAG
	PAGPAGPRGEVGLPGLSGPVGPPGNP
	GANGLTGAKGAAGLPGVAGAPGLPGPRGIPGPVGAAGATGARGLV
	GEPGPAGSKGESGNKGEPGSAGPQGPPGPSGEEGKRGPNGEAGSAG
	PPGPPGLRGSPGSRGLPGADGRAGVMGPPGSRGASGPAGVRGPNGD
	AGRPGEPGLMGPRGLPGSPGNIGPAGKEGPVGLPGIDGRPGPIGPAG
	ARGEPGNIGFPGPKGPTGDPGKNGDKGHAGLAGARGAPGPDGNNG
	AQGPPGPQGVQGGKGEQGPPGPPGFQGLPGPSGPAGEVGKPGERGL
	HGEFGLPGPAGPRGERGPPGESGAA
	GPTGPIGSRGPSGPPGPDGNKGEPGVVGAVGTAGPSGPSGLPGERGA
	AGIPGGKGEKGEPGLRGEIGNPGRDGARGAPGAVGAPGPAGATGD
	RGEAGAAGPAGPAGPRGSPGERGEVGPAGPNGFAGPAGAAGQPGA
	KGERGAKGPKGENGVVGPTGPVGAAGPAGPNGPPGPAGSRGDGGP
	PGMTGFPGAAGRTGPPGPSGISGPPGPPGPAGKEGLRGPRGDQGPV
	GRTGEVGAVGPPGFAGEKGPSGEAGTAGPPGTPGPQGLLGAPGILG
	LPGSRGERGLPGVAGAVGEPGPLGIAGPPGARGPPGAVGSPGVNGA
	PGEAGRDGNPGNDGPPGRDGQPGHKGERGYPGNIGPVGAAGAPGP
	HGPVGPAGKHGNRGETGPSGPVGPAGAVGPRGPSGPQGIRGDKGEP
	GEKGPRGLPGLKGHNGLQGLPGIAGHHGDQGAPGSVGPAGPRGPA
	GPSGPAGKDGRTGHPGTVGPAGIRGPQGHQGPAGPPGPPGPPGPPG
	VSGGGYDFGYDGDFYRADQPRSAPSLRPKDYEVDATLKSLNNQIET
	LLTPEGSRKNPARTCRDLRLSHPEWSSGYYWIDPNQGCTMDAIKVY
	CDFSTGETCIRAQPENIPAKNWYRSSKDKKHVWLGETINAGSQFEY
	NVEGVTSKEMATQLAFMRLLANYASQNITYHCKNSIAYMDEETGN
	LKKAVILQGSNDVELVAEGNSRFTYTVLVDGCSKKTNEWGKTIIEY
	KTNKPSRLPFLDIAPLDIGGADQEFFVDIGPVCFK
384	MNNLLCCALVFLDISIKWTTQETFPPKYLHYDEETSHQLLCDKCPPG	TNFRSF11B
	TYLKQHCTAKWKTVCAPCPDHYYTDSWHTSDECLYCSPVCKELQY
	VKQECNRTHNRVCECKEGRYLEIEFCLKHRSCPPGFGVVQAGTPER
	NTVCKRCPDGFFSNETSSKAPCRKHTNCSVFGLLLTQKGNATHDNI
	CSGNSESTQKCGIDVTLCEEAFFRFAVPTKFTPNWLSVLVDNLPGTK
	VNAESVERIKRQHSSQEQTFQLLKLWKHQNKDQDIVKKIIQDIDLCE
	NSVQRHIGHANLTFEQLRSLMESLPGKKVGAEDIEKTIKACKPSDQI
	LKLLSLWRIKNGDQDTLKGLMHALKHSKTYHFPKTVTQSLKKTIRF
	LHSFTMYKLYQKLFLEMIGNQVQSVKISCL
385	MAQQANVGELLAMLDSPMLGVRDDVTAVFKENLNSDRGPMLVNT	TSC1
	LVDYYLETSSQPALHILTTLQEPHDKHLLDRINEYVGKAATRLSILSL
	LGHVIRLQPSWKHKLSQAPLLPSLLKCLKMDTDVVVLTTGVLVLIT
	MLPMIPQSGKQHLLDFFDIFGRLSSWCLKKPGHVAEVYLVHLHASV
	YALFHRLYGMYPCNFVSFLRSHYSMKENLETFEEVVKPMMEHVRI
	HPELVTGSKDHELDPRRWKRLETHDVVIECAKISLDPTEASYEDGYS
	VSHQISARFPHRSADVTTSPYADT
	QNSYGCATSTPYSTSRLMLLNMPGQLPQTLSSPSTRLITEPPQATLW
	SPSMVCGMTTPPTSPGNVPPDLSHPYSKVFGTTAGGKGTPLGTPATS
	PPPAPLCHSDDYVHISLPQATVTPPRKEERMDSARPCLHRQHHLLND
	RGSEEPPGSKGSVTLSDLPGFLGDLASEEDSIEKDKEEAAISRELSEIT
	TAEAEPVVPRGGFDSPFYRDSLPGSQRKTHSAASSSQGASVNPEPLH
	SSL
	DKLGPDTPKQAFTPIDLPCGSADESPAGDRECQTSLETSIFTPSPCKIP
	PPTRVGFGSGQPPPYDHLFEVALPKTAHHFVIRKTEELLKKAKGNTE
	EDGVPSTSPMEVLDRLIQQGADAHSKELNKLPLPSKSVDWTHFGGS
	PPSDEIRTLRDQLLLLHNQLLYERFKRQQHALRNRRLLRKVIKAAAL
	EEHNAAMKDQLKLQEKDIQMWKVSLQKEQARYNQLQEQRDTMVT
	KLHSQIRQLQHDREEFYNQSQELQTKLEDCRNMIAELRIELKKANN
	KVCHTELLLSQVSQKLSNSESVQQQMEFLNRQLLVLGEVNELYLEQ
	LQNKHSDTTKEVEMMKAAYRKELEKNRSHVLQQTQRLDTSQKRIL
	ELESHLAKKDHLLLEQKKYLEDVKLQARGQLQAAESRYEAQKRIT
	QVFELEILDLYGRLEKDGLLKKLEEEKAEAAEAAEERLDCCNDGCS
	DSMVGHNEEASGHNGETKTPRPSSARGSSGSRGGGGSSSSSSELSTP
	EKPPHQRAGPFSSRWETTMGEASASIPTTVGSLPSSKSFLGMKAREL
	FRNKSESQCDEDGMTSSLSESLKTELGKDLGVEAKIPLNLDGPHPSP
	PTPDSVGQLHIMDYNETHHEHS
386	MAKPTSKDSGLKEKFKILLGLGTPRPNPRSAEGKQTEFIITAEILRELS	TSC2
	MECGLNNRIRMIGQICEVAKTKKFEEHAVEALWKAVADLLQPERPL
	EARHAVLALLKAIVQGQGERLGVLRALFFKVIKDYPSNEDLHERLE
	VFKALTDNGRHITYLEEELADFVLQWMDVGLSSEFLLVLVNLVKFN
	SCYLDEYIARMVQMICLLCVRTASSVDIEVSLQVLDAVVCYNCLPA
	ESLPLFIVTLCRTINVKELCEPCWKLMRNLLGTHLGHSAIYNMCHL
	MEDRAYMEDAPLLRGAVFFVGMALWGAHRLYSLRNSPTSVLPSFY
	QAMACPNEVVSYEIVLSITRLIKKYRKELQVVAWDILLNIIERLLQQL
	QTLDSPELRTIVHDLLTTVEELCDQNEFHGSQERYFELVERCADQRP
	ESSLLNLISYRAQSIHPAKDGWIQNLQALMERFFRSESRGAVRIKVL
	DVLSFVLLINRQFYEEELINSVVISQLSHIPEDKDHQVRKLATQLLVD
	LAEGCHTHHFNSLLDIIEKVMARSLSPPPELEERDVAAYSASLEDVK
	TAVLGLLVILQTKLYTLPASHATRVYEMLVSHIQLHYKHSYTLPIAS
	SIRLQAFDFLLLLRADSLHRLGLPNKDGVVRFSPYCVCDYMEPERGS
	E1(KTSGPLSPPTGPPGPAPAGPAVRLGSVPYSLLFRVLLQCLKQESD
	WKVLKLVLGRLPESLRYKVLIFTSPCSVDQLCSALCSMLSGPKTLER
	LRGAPEGFSRTDLHLAVVPVLTALISYHNYL
	DKTKQREMVYCLEQGLIHRCASQCVVALSICSVEMPDIIIKALPVLV
	VKLTHISATASMAVPLLEFLSTLARLPHLYRNFAAEQYASVFAISLP
	YTNPSKFNQYIVCLAHHVIAMWFIRCRLPFRKDFVPFITKGLRSNVL
	LSFDDTPEKDSFRARSTSLNERPKSLRIARPPKQGLNNSPPVKEFKES
	SAAEAFRCRSISVSEHVVRSRIQTSLTSASLGSADENSVAQADDSLK
	NLHL
	ELTETCLDMMARYVFSNFTAVPKRSPVGEFLLAGGRTKTWLVGNK
	LVTVTTSVGTGTRSLLGLDSGELQSGPESSSSPGVHVRQTKEAPAKL
	ESQAGQQVSRGARDRVRSMSGGHGLRVGALDVPASQFLGSATSPG
	PRTAPAAKPEKASAGTRVPVQEKTNLAAYVPLLTQGWAEILVRRPT
	GNTSWLMSLENPLSPFSSDINNMPLQELSNALMAAERFKEHRDTAL
	YKSLSVPAASTAKPPPLPRSNTVASFSSLYQSSCQGQLHRSVSWADS
	AVVMEEGSPGEVPVLVEPPGLEDV
	EAALGMDRRTDAYSRSSSVSSQEEKSLHAEELVGRGIPIERVVSSEG
	GRPSVDLSFQPSQPLSKSSSSPELQTLQDILGDPGDKADVGRLSPEVK
	ARSQSGTLDGESAAWSASGEDSRGQPEGPLPSSSPRSPSGLRPRGYTI
	SDSAPSRRGKRVERDALKSRATASNAEKVPGINPSFVFLQLYHSPFF
	GDESNKPILLPNESQSFERSVQLLDQIPSYDTHKIAVLYVGEGQSNSE
	LA
	ILSNEHGSYRYTEFLTGLGRLIELKDCQPDKVYLGGLDVCGEDGQFT
	YCWHDDIMQAVFHIATLMPTKDVDKHRCDKKRHLGNDFVSIVYND
	SGEDFKLGTIKGQFNFVHVIVTPLDYECNLVSLQCRKDMEGLVDTS
	VAKIVSDRNLPFVARQMALHANMASQVHHSRSNPTDIYPSKWIARL
	RHIKRLRQRICEEAAYSNPSLPLVHPPSHSKAPAQTPAEPTPGYEVG
	QRKRLISSVEDFTEFV
387	MAAKSQPNIPKAKSLDGVTNDRTASQGQWGRAWEVDWFSLASVIF	DHCR7
	LLLFAPFIVYYFIMACDQYSCALTGPVVDIVTGHARLSDIWAKTPPIT
	RKAAQLYTLWVTFQVLLYTSLPDFCHKFLPGYVGGIQEGAVTPAGV
	VNKYQINGLQAWLLTHLLWFANAHLLSWFSPTIIFDNWIPLLWCAN
	ILGYAVSTFAMVKGYFFPTSARDCKFTGNFFYNYMMGIEFNPRIGK
	WFDFKLFFNGRPGIVAWTLINLSFAAKQRELHSHVTNAMVLVNVL
	QAIYVIDFFWNETWYLKTIDICHD
	HFGWYLGWGDCVWLPYLYTLQGLYLVYHPVQLSTPHAVGVLLLG
	LVGYYIFRVANHQKDLFRRTDGRCLIWGRKPKVIECSYTSADGQRH
	HSKLLVSGFWGVARHFNYVGDLMGSLAYCLACGGGHLLPYFYIIY
	MAILLTHRCLRDEHRCASKYGRDWERYTAAVPYRLLPGIF
388	MSLSNKLTLDKLDVKGKRVVMRVDFNVPMKNNQITNNQRIKAAVP	PGK1
	SIKFCLDNGAKSVVLMSHLGRPDGVPMPDKYSLEPVAVELKSLLGK
	DVLFLKDCVGPEVEKACANPAAGSVILLENLRFHVEEEGKGKDASG
	NKVKAEPAKIEAFRASLSKLGDVYVNDAFGTAHRAHSSMVGVNLP
	QKAGGFLMKKELNYFAKALESPERPFLAILGGAKVADKIQLINNML
	DKVNEMIIGGGMAFTFLKVLNNMEIGTSLFDEEGAKIVKDLMSKAE
	KNGVKITLPVDFVTADKFDENAKTGQATVASGIPAGWMGLDCGPE
	SSKKYAEAVTRAKQIVWNGPVGVFEWEAFARGTKALMDEVV
	KATSRGCITIIGGGDTATCCAKWNTEDKVSHVSTGGGASLELLEGK
	VLPGVDALSNI
389	MGTSALWALWLLLALCWAPRESGATGTGRKAKCEPSQFQCTNGR	VLDLR
	CITLLWKCDGDEDCVDGSDEKNCVKKTCAESDFVCNNGQCVPSRW
	KCDGDPDCEDGSDESPEQCHMRTCRIHEISCGAHSTQCIPVSWRCD
	GENDCDSGEDEENCGNITCSPDEFTCSSGRCISRNFVCNGQDDCSDG
	SDELDCAPPTCGAHEFQCSTSSCIPISWVCDDDADCSDQSDESLEQC
	GRQPVIHTKCPASEIQCGSGECIHKKWRCDGDPDCKDGSDEVNCPS
	RTCRPDQFECEDGSCIHGSRQCNGI
	RDCVDGSDEVNCKNVNQCLGPGKFKCRSGECIDISKVCNQEQDCR
	DWSDEPLKECHINECLVNNGGCSHICKDLVIGYECDCAAGFELIDRK
	TCGDIDECQNPGICSQICINLKGGYKCECSRGYQMDLATGVCKAVG
	KEPSLIFTNRRDIRKIGLERKEYIQLVEQLRNTVALDADIAAQKLFW
	ADLSQKAIFSASIDDKVGRHVKMIDNVYNPAAIAVDWVYKTIYWT
	DAASKTISVATLDGTKRKFLFNSDLREPASIAVDPLSGFVYWSDWG
	EPAKIEKAGMNGFDRRPLVTADIQ
	WPNGITLDLIKSRLYWLDSKLHMLSSVDLNGQDRRIVLKSLEFLAHP
	LALTIFEDRVYWIDGENEAVYGANKFTGSELATLVNNLNDAQDIIV
	YHELVQPSGKNWCEEDMENGGCEYLCLPAPQINDHSPKYTCSCPSG
	YNVEENGRDCQSTATTVTYSETKDTNTTEISATSGLVPGGINVTTAV
	SEVSVPPKGTSAAWAILPLLLLVMAAVGGYLMWRNWQHKNMKS
	MNFDNPVYLKTTEEDLSIDIGRHSASVGHTYPAISVVSTDDDLA
390	MEPSSLELPADTVQRIAAELKCHPTDERVALHLDEEDKLRHFRECFY	KYNU
	IPKIQDLPPVDLSLVNKDENAIYFLGNSLGLQPKMVKTYLEEELDKW
	AKIAAYGHEVGKRPWITGDESIVGLMKDIVGANEKEIALMNALTVN
	LHLLMLSFFKPTPKRYKILLEAKAFPSDHYAIESQLQLHGLNIEESMR
	MIKPREGEETLRIEDILEVIEKEGDSIAVILFSGVHFYTGQHFNIPAITK
	AGQAKGCYVGFDLAHAVGNVELYLHDWGVDFACWCSYKYLNAG
	AGGIAGAFIHEKHAHTIKPALVGWFGHELSTRFKMDNKLQLIPGVC
	GFRISNPPILLVCSLHASLEIFKQATMKALRKKSVLLTGYLEYLIKHN
	YGKDKAATKKPVVNIITPSHVEERGCQLTITFSVPNKDVFQELEKRG
	VVCDKRNPNGIRVAPVPLYNSFHDVYKFTNLLTSILDSAETKN
391	MFPGCPRLWVLVVLGTSWVGWGSQGTEAAQLRQFYVAAQGISWS	F5
	YRPEPTNSSLNLSVTSFKKIVYREYEPYFKKEKPQSTISGLLGPTLYA
	EVGDIIKVHFKNKADKPLSIHPQGIRYSKLSEGASYLDHTFPAEKMD
	DAVAPGREYTYEWSISEDSGPTHDDPPCLTHIYYSHENLIEDFNSGLI
	GPLLICKKGTLTEGGTQKTFDKQIVLLFAVFDESKSWSQSSSLMYTV
	NGYVNGTMPDITVCAHDHISWHLLGMSSGPELFSIHFNGQVLEQNH
	HKVSAITLVSATSTTANMTVGPEGKWIISSLTPKHLQAGMQAYIDIK
	NCPKKTRNLKKITREQRRHMKRWEYFIAAEEVIWDYAPVIPANMD
	KKYRSQHLDNFSNQIGKHYKKVMYTQYEDESFTKHTVNPNMKED
	GILGPIIRAQVRDTLKIVFKNMASRPYSIYPHGVTFSPYEDEVNSSFTS
	GRNNTMIRAVQPGETYTYKWNILEFDEPTENDAQCLTRPYYSDVDI
	MRDIASGLIGLLLICKSRSLDRRGIQRAA
	DIEQQAVFAVFDENKSWYLEDNINKFCENPDEVKRDDPKFYESNIM
	STINGYVPESITTLGFCFDDTVQWHFCSVGTQNEILTIHFTGHSFIYG
	KRHEDTLTLFPMRGESVTVTMDNVGTWMLTSMNSSPRSKKLRLKF
	RDVKCIPDDDEDSYEIFEPPESTVMATRKMHDRLEPEDEESDADYD
	YQNRLAAALGIRSFRNSSLNQEEEEFNLTALALENGTEFVSSNTDIIV
	GSNYSSPSNISKFTVNNLAEPQKAPSHQQATTAGSPLRHLIGKNSVL
	NSSTAEHSSPYSEDPIEDPLQPDVTGIRLLSLGAGEFKSQEHAKHKGP
	KVERDQAAKHRFSWMKLLAHKVGRHLSQDTGSPSGMRPWEDLPS
	QDTGSPSRMRPWKDPPSDLLLLKQSNSSKILVGRWHLASEKGSYEII
	QDTDEDTAVNNWLISPQNASRAWGESTPLANKPGKQSGHPKFPRV
	RHKSLQVRQDGGKSRLKKSQFLIKTRKKKKEKHTHHAPLSPRTFHP
	LRSEAYNTFSERRLKHSLVLHKSNETSLPT
	DLNQTLPSMDFGWIASLPDHNQNSSNDTGQASCPPGLYQTVPPEEH
	YQTFPIQDPDQMHSTSDPSHRSSSPELSEMLEYDRSHKSFPTDISQMS
	PSSEHEVWQTVISPDLSQVTLSPELSQTNLSPDLSHTTLSPELIQRNLS
	PALGQMPISPDLSHTTLSPDLSHTTLSLDLSQTNLSPELSQTNLSPAL
	GQMPLSPDLSHTTLSLDFSQTNLSPELSHMTLSPELSQTNLSPALGQ
	MP
	ISPDLSHTTLSLDFSQTNLSPELSQTNLSPALGQMPLSPDPSHTTLSLD
	LSQTNLSPELSQTNLSPDLSEMPLFADLSQIPLTPDLDQMTLSPDLGE
	TDLSPNFGQMSLSPDLSQVTLSPDISDTTLLPDLSQISPPPDLDQIFYP
	SESSQSLLLQEFNESFPYPDLGQMPSPSSPTLNDTFLSKEFNPLVIVGL
	SKDGTDYIEIIPKEEVQSSEDDYAEIDYVPYDDPYKTDVRTNINSSRD
	PDNIAAWYLRSNNGNRRNYYIAAEEISWDYSEFVQRETDIEDSDDIP
	EDTTYKKVVFRKYLDSTFTKRDPRGEYEEHLGILGPIIRAEVDDVIQ
	VRFKNLASRPYSLHAHGLSYEKSSEGKTYEDDSPEWFKEDNAVQPN
	SSYTYVWHATERSGPESPGSACRAWAYYSAVNPEKDIHSGLIGPLLI
	CQKGILHKDSNMPMDMREFVLLFMTFDEKKSWYYEKKSRSSWRLT
	SSEMK
	KSHEFHAINGMIYSLPGLKMYEQEWVRLHLLNIGGSQDIHVVHFHG
	QTLLENGNKQHQLGVWPLLPGSFKTLEMKASKPGWWLLNTEVGE
	NQRAGMQTPFLIMDRDCRMPMGLSTGIISDSQIKASEFLGYWEPRL
	ARLNNGGSYNAWSVEKLAAEFASKPWIQVDMQKEVIITGIQTQGAK
	HYLKSCYTTEFYVAYSSNQINWQIFKGNSTRNVMYFNGNSDASTIK
	ENQFDPPIVARYIRISPTRAYNRPTLRLELQGCEVNGCSTPLGMENG
	KIENKQITASSFKKSWWGDYWEPFR
	ARLNAQGRVNAWQAKANNNKQWLEIDLLKIKKITAIITQGCKSLSS
	EMYVKSYTIHYSEQGVEWKPYRLKSSMVDKIFEGNTNTKGHVKNF
	FNPPIISRFIRVIPKTWNQSIALRLELFGCDIY
392	MGPTSGPSLLLLLLTHLPLALGSPMYSIITPNILRLESEETMVLEAHD	C3
	AQGDVPVTVTVHDFPGKKLVLSSEKTVLTPATNHMGNVTFTIPANR
	EFKSEKGRNKFVTVQATFGTQVVEKVVLVSLQSGYLFIQTDKTIYTP
	GSTVLYRIFTVNHKLLPVGRTVMVNIENPEGIPVKQDSLSSQNQLGV
	LPLSWDIPELVNMGQWKIRAYYENSPQQVFSTEFEVKEYVLPSFEVI
	VEPTEKFYYIYNEKGLEVTITARFLYGKKVEGTAFVIFGIQDGEQRIS
	LPESLKRIPIEDGSGEVVLSRKVLLDGVQNPRAEDLVGKSLYVSATV
	ILHSGSDMVQAERSGIPIVTSPYQIHFTKTPKYFKPGMPFDLMVFVT
	NPDGSPAYRVPVAVQGEDTVQSLTQGDGVAKLSINTHPSQKPLSITV
	RTKKQELSEAEQATRTMQALPYSTVGNSNNYLHLSVLRTELRPGET
	LNVNFLLRMDRAHEAKIRYYTYLIMNKGRLLKAGRQVREPGQDLV
	VLPLSITTDFIPSFRLVAYYTLIGASGQREVVADSVWVDVKDSCVGS
	LVVKSGQSEDRQPVPGQQMTLKIEGDHGARVVLVAVDKGVFVLNK
	KNKLTQSKIWDVVEKADIGCTPGSGKDYAGVFSDAGLTFTSSSGQQ
	TAQRAELQCPQPAARRRRSVQLTEKRMDKVGKYPKELRKCCEDG
	MRENPMRFSCQRRTRFISLGEACKKVFLDCCNYITELRRQHARASH
	LGLARSNLDEDIIAEENIVSRSEFPESWLWNVEDLKEPPKNGISTKLM
	NIFLKDSITTWEILAVSMSDKKGICVADPFEVTVMQDFFIDLRLPYSV
	VRNEQVEIRAVLYNYRQNQELKVRVELLHNPAFCSLATTKRRHQQ
	TVTIPPKSSLSVPYVIVPLKTGLQEVEVKAAVYHHFISDGVRKSLKV
	VPEGIRMNKTVAVRTLDPERLGREGVQKEDIPPADLSDQVPDTESET
	RILLQGTPVAQMTEDAVDAERLKHLIVTPSGCGEQNMIGMTPTVIA
	VHYLDETEQWEKFGLEKRQGALELIKKGYTQQLAFRQPSSAFAAFV
	KRAPSTWLTA
	YVVKVFSLAVNLIAIDSQVLCGAVKWLILEKQKPDGVFQEDAPVIH
	QEMIGGLRNNNEKDMALTAFVLISLQEAKDICEEQVNSLPGSITKAG
	DFLEANYMNLQRSYTVAIAGYALAQMGRLKGPLLNKFLTTAKDKN
	RWEDPGKQLYNVEATSYALLALLQLKDFDFVPPVVRWLNEQRYYG
	GGYGSTQATFMVFQALAQYQKDAPDHQELNLDVSLQLPSRSSKITH
	RIHWESASLLRSEETKENEGFTVTAEGKGQGTLSVVTMYHAKAKD
	QLTCNKFDLKVTIKPAPETEKRPQDAKNTMILEICTRYRGDQDATM
	SILDISMMTGFAPDTDDLKQLANGVDRYISKYELDKAFSDRNTLIIY
	LDKVSHSEDDCLAFKVHQYFNVELIQPGAVKVYAYYNLEESCTRFY
	HPEKEDGKLNKLCRDELCRCAEENCFIQKSDDKVTLEERLDKACEP
	GVDYVYKTRLVKVQLSNDFDEYIMAIEQTIKSGSDEVQVGQQRTFIS
	PIKCREALKLEEKKHYLMWGLSSDFWGEKPNLSYIIGKDTWVEHWP
	EEDECQDEENQKQCQDLGAFTESMVVFGCPN
393	MGPRLSVWLLLLPAALLLHEEHSRAAAKGGCAGSGCGKCDCHGV	COL4A1
	KGQKGERGLPGLQGVIGFPGMQGPEGPQGPPGQKGDTGEPGLPGTK
	GTRGPPGASGYPGNPGLPGIPGQDGPPGPPGIPGCNGTKGERGPLGP
	PGLPGFAGNPGPPGLPGMKGDPGEILGHVPGMLLKGERGFPGIPGTP
	GPPGLPGLQGPVGPPGFTGPPGPPGPPGPPGEKGQMGLSFQGPKGDK
	GDQGVSGPPGVPGQAQVQEKGDFATKGEKGQKGEPGFQGMPGVG
	EKGEPGKPGPRGKPGKDGDKGEKGSPGFPGEPGYPGLIGRQGPQGE
	KGEAGPPGPPGIVIGTGPLGEKGERGYPGTPGPRGEPGPKGFPGLPG
	QPGPPGLPVPGQAGAPGFPGERGEKGDRGFPGTSLPGPSGRDGLPGP
	PGSPGPPGQPGYTNGIVECQPGPPGDQGPPGIPGQPGFIGEIGEKGQK
	GESCLICDIDGYRGPPGPQGPPGEIGFPGQPGAKGDRGLPGRDGVAG
	VPGPQGTPGLIGQPGAKGEPGEFYFDLRLKGDKGDPGFPGQPGMPG
	RAGSPGRDGHPGLPGPKGSPGSVGLKGERGPPGGVGFPGSRGDTGP
	PGPPGYGPAGPIGDKGQAGFPGGPGSPGLPGPKGEPGKIVPLPGPPG
	AEGLPGSPGFPGPQGDRGFPGTPGRPGLPGEKGAVGQPGIGFPGPPG
	PKGVDGLPGDMGPPGTPGRPGFNGLPGNPGVQGQKGEPGVGLPGL
	KGLPGLPGIPGTPGEKGSIGVPGVPGEHGAIGPPGLQGIRGEPGPPGL
	PGSVGSPGVPGIGPPGARGPPGGQGPPGLSGPPGIKGEKGFPGFPGLD
	MPGPKGDKGAQGLPGITGQSGLPGLPGQQGAPGIPGFPGSKGEMGV
	MGTPGQPGSPGPVGAPGLPGEKGDHGFPGSSGPRGDPGLKGDKGD
	VGLPGKPGSMDKVDMGSMKGQKGDQGEKGQIGPIGEKGSRGDPGT
	PGVPGKDGQAGQPGQPGPKGDPGISGTPGAPGLPGPKGSVGGMGLP
	GTPGEKGVPGIPGPQGSPGLPGDKGAKGEKGQAGPPGIGIPGLRGEK
	GDQGIAGFPGSPGEKGEKGSIGIPGMPGSPGLKGSPGSVGYPGSPGLP
	GEKGDKGLPGLDGIPGVKGEAGLPGTPGPTGPAGQKGEPGSDGIPG
	SAGEKGEPGLPGRGFPGFPGAKGDKGSKGEVGFPGLAGSPGIPGSK
	GEQGFMGPPGPQGQPGLPGSPGHATEGPKGDRGPQGQPGLPGLPGP
	MGPPGLPGIDGVKGDKGNPGWPGAPGVPGPKGDPGFQGMPGIGGS
	PGITGSKGDMGPPGVPGFQGPKGLPGLQGIKGDQGDQGVPGAKGLP
	GPPGPPGPYDIIKGEPGLPGPEGPPGLKGLQGLPGPKGQQGVTGLVG
	IPGPPGIPGFDGAPGQKGEMGPAGPTGPRGFPGPPGPDGLPGSMGPP
	GTPSVDHGFLVTRHSQTIDDPQCPSGTKILYHGYSLLYVQGNERAH
	GQDLGTAGSCLRKFSTMPFLFCNINNVCNFASRNDYSYWLSTPEPM
	PMSMAPITGENIRPFISRCAVCEAPAMVMAVHSQTIQIPPCPSGWSSL
	WIGYSFVMHTSAGAEGSGQALASPGSCLEEFRSAPFIECHGRGTCNY
	YANAYSFWLATIERSEMFKKPTPSTLKAGELRTHVSRCQVCMRRT
394	MRLLAKIICLMLWAICVAEDCNELPPRRNTEILTGSWSDQTYPEGTQ	CFH
	AIYKCRPGYRSLGNVIMVCRKGEWVALNPLRKCQKRPCGHPGDTP
	FGTFTLTGGNVFEYGVKAVYTCNEGYQLLGEINYRECDTDGWTNDI
	PICEVVKCLPVTAPENGKIVSSAMEPDREYHFGQAVRFVCNSGYKIE
	GDEEMHCSDDGFWSKEKPKCVEISCKSPDVINGSPISQKIIYKENERF
	QYKCNMGYEYSERGDAVCTESGWRPLPSCEEKSCDNPYIPNGDYSP
	LRIKHRTGDEITYQCRNGFYPATRGNTAKCTSTGWIPAPRCTLKPCD
	YPDIKHGGLYHENMRRPYFPVAVGKYYSYYCDEHFETPSGSYWDH
	IHCTQDGWSPAVPCLRKCYFPYLENGYNQNYGRKFVQGKSIDVAC
	HPGYALPKAQTTVTCMENGWSPTPRCIRVKTCSKSSIDIENGFISESQ
	YTYALKEKAKYQCKLGYVTADGETSGSITCGKDGWSAQPTCIKSC
	DIPVFMNARTKNDFTWFKLNDTLDYECHDGYESNTGSTTGSIVCGY
	NGWSDLPICYERECELPKIDVHLVPDRKKDQYKVGEVLKFSCKPGF
	TIVGPNSVQCYHFGLSPDLPICKEQVQSCGPPPELLNGNVKEKTKEE
	YGHSEVVEYYCNPRFLMKGPNKIQCVDGEWTTLPVCIVEESTCGDI
	PELEHGWAQLSSPPYYYGDSVEFNCSESFTMIGHRSITCIHGVWTQL
	PQCVAIDKLKKCKSSNLIILEEHLKNKKEFDHNSNIRYRCRGKEGWI
	HTVCINGRWDPEVNCSMAQIQLCPPPPQIPNSHNMTTTLNYRDGEK
	VSVLCQENYLIQEGEEITCKDGRWQSIPLCVEKIPCSQPPQIEHGTINS
	SRSSQESYAHGTKLSYTCEGGFRISEENETTCYMGKWSSPPQCEGLP
	CKSPPEISHGVVAHMSDSYQYGEEVTYKCFEGFGIDGPAIAKCLGEK
	WSHPPSCIKTDCLSLPSFENAIPMGEKKDVYKAGEQVTYTCATYYK
	MDGASNVTCINSRWTGRPTCRDTSCVNPPTVQNAYIVSRQMSKYPS
	GERVRYQCRSP
	YEMFGDEEVMCLNGNWTEPPQCKDSTGKCGPPPPIDNGDITSFPLSV
	YAPASSVEYQCQNLYQLEGNKRITCRNGQWSEPPKCLHPCVISREIM
	ENYNIALRWTAKQKLYSRTGESVEFVCKRGYRLSSRSHTLRTTCWD
	GKLEYPTCAKR
395	MEPRPTAPSSGAPGLAGVGETPSAAALAAARVELPGTAVPSVPEDA	SLC12A2
	APASRDGGGVRDEGPAAAGDGLGRPLGPTPSQSRFQVDLVSENAG
	RAAAAAAAAAAAAAAAGAGAGAKQTPADGEASGESEPAKGSEEA
	KGRFRVNFVDPAASSSAEDSLSDAAGVGVDGPNVSFQNGGDTVLSE
	GSSLHSGGGGGSGHHQHYYYDTHTNTYYLRTFGHNTMDAVPRIDH
	YRHTAAQLGEKLLRPSLAELHDELEKEPFEDGFANGEESTPTRDAV
	VTYTAESKGVVKFGWIKGVLVRCMLNIWGVMLFIRLSWIVGQAGI
	GLSVLVIMMATVVTTITGLSTSAIATNGFVRGGGAYYLISRSLGPEF
	GGAIGLIFAFANAVAVAMYVVGFAETVVELLKEHSILMIDEINDIRII
	GAITVVILLGISVAGMEWEAKAQIVLLVILLLAIGDFVIGTFIPLESKK
	PKGFFGYKSEIFNENFGPDFREEETFFSVFAIFFPAATGILAGANISGD
	LADPQSAIPKGTLLAILITTLVYVGIAVSV
	GSCVVRDATGNVNDTIVTELTNCTSAACKLNFDFSSCESSPCSYGL
	MNNFQVMSMVSGFTPLISAGIFSATLSSALASLVSAPKIFQALCKDNI
	YPAFQMFAKGYGKNNEPLRGYILTFLIALGFILIAELNVIAPIISNFFL
	ASYALINFSVFHASLAKSPGWRPAFKYYNMWISLLGAILCCIVMFVI
	NWWAALLTYVIVLGLYIYVTYKKPDVNWGSSTQALTYLNALQHSI
	RLSGVEDHVKNFRPQCLVMTGAPNSRPALLHLVHDFTKNVGLMIC
	GHVHMGPRRQAMKEMSIDQAKYQRWLIKNKMKAFYAPVHADDL
	REGAQYLMQAAGLGRMKPNTLVLGFKKDWLQADMRDVDMYINL
	FHDAFDIQYGVVVIRLKEGLDISHLQGQEELLSSQEKSPGTKDVVVS
	VEYSKKSDLDTSKPLSEKPITHKVEEEDGKTATQPLLKKESKGPIVPL
	NVADQKLLEASTQFQKKQGKNTIDVWWLFDDGGLTLLIPYLLTTK
	KKWKDCKIRVFIGGKINRIDHDRRAMATLLSKFRIDFSDIMVLGDIN
	TKPKKENIIAFEEIIEPYRLHEDDKEQDIADKMKEDEPWRITDNELEL
	YKTKTYRQIRLNELLKEHSSTANIIVMSLPVARKGAVSSALYMAWL
	EALSKDLPPILLVRGNHQSVLTFYS
396	MAASKKAVLGPLVGAVDQGTSSTRFLVFNSKTAELLSHHQVEIKQE	GK
	FPREGWVEQDPKEILHSVYECIEKTCEKLGQLNIDISNIKAIGVSNQR
	ETTVVWDKITGEPLYNAVVWLDLRTQSTVESLSKRIPGNNNFVKSK
	TGLPLSTYFSAVKLRWLLDNVRKVQKAVEEKRALFGTIDSWLIWSL
	TGGVNGGVHCTDVTNASRTMLFNIHSLEWDKQLCEFFGIPMEILPN
	VRSSSEIYGLMKISHSVKAGALEGVPISGCLGDQSAALVGQMCFQIG
	QAKNTYGTGCFLLCNTGHKCVFSDHGLLTTVAYKLGRDKPVYYAL
	EGSVAIAGAVIRWLRDNLGIIKTSEEIEKLAKEVGTSYGCYFVPAFSG
	LYAPYWEPSARGIICGLTQFTNKCHIAFAALEAVCFQTREILDAMNR
	DCGIPLSHLQVDGGMTSNKILMQLQADILYIPVVKPSMPETTALGAA
	MAAGAAEGVGVWSLEPEDLSAVTMERFEPQINAEESEIRYSTWKK
	AVMKSMGWVTTQSPESGDPSIFCSLPLGF
	FIVSSMVMLIGARYISGIP
397	MDVGSKEVLMESPPDYSAAPRGRFGIPCCPVHLKRLLIVVVVVVLIV	SFTPC
	VVIVGALLMGLHMSQKHTEMVLEMSIGAPEAQQRLALSEHLVTTA
	TFSIGSTGLVVYDYQQLLIAYKPAPGTCCYIMKIAPESIPSLEALNRK
	VHNFQMECSLQAKPAVPTSKLGQAEGRDAGSAPSGGDPAFLGMAV
	NTLCGEVPLYYI
398	MEPGRRGAAALLALLCVACALRAGRAQYERYSFRSFPRDELMPLES	CRTAP
	AYRHALDKYSGEHWAESVGYLEISLRLHRLLRDSEAFCHRNCSAAP
	QPEPAAGLASYPELRLFGGLLRRAHCLKRCKQGLPAFRQSQPSREV
	LADFQRREPYKFLQFAYFKANNLPKAIAAAHTFLLKHPDDEMMKR
	NMAYYKSLPGAEDYIKDLETKSYESLFIRAVRAYNGENWRTSITDM
	ELALPDFFKAFYECLAACEGSREIKDFKDFYLSIADHYVEVLECKIQ
	CEENLTPVIGGYPVEKFVATMYHY
	LQFAYYKLNDLKNAAPCAVSYLLFDQNDKVMQQNLVYYQYHRDT
	WGLSDEHFQPRPEAVQFFNVTTLQKELYDFAKENIMDDDEGEVVE
	YVDDLLELEETS
399	MAVRALKLLTTLLAVVAAASQAEVESEAGWGMVTPDLLFAEGTA	P3H1
	AYARGDWPGVVLSMERALRSRAALRALRLRCRTQCAADFPWELDP
	DWSPSPAQASGAAALRDLSFFGGLLRRAACLRRCLGPPAAHSLSEE
	MELEFRKRSPYNYLQVAYFKINKLEKAVAAAHTFFVGNPEHMEMQ
	QNLDYYQTMSGVKEADFKDLETQPHMQEFRLGVRLYSEEQPQEAV
	PHLEAALQEYFVAYEECRALCEGPYDYDGYNYLEYNADLFQAITD
	HYIQVLNCKQNCVTELASHPSREKPFEDFLPSHYNYLQFAYYNIGN
	YTQAVECAKTYLLFFPNDEVMNQNLAYYAAMLGEEHTRSIGPRES
	AKEYRQRSLLEKELLFFAYDVFGIPFVDPDSWTPEEVIPKRLQEKQK
	SERETAVRISQEIGNLMKEIETLVEEKTKESLDVSRLTREGGPLLYEG
	ISLTMNSKLLNGSQRVVMDGVISDHECQELQRLTNVAATSGDGYR
	GQTSPHTPNEKFYGVTVFKALKLGQEGKVPLQSAHLYYNVTEKVR
	RIMESYFRLDTPLYFSYSHLVCRTAIEEVQAERKDDSHPVHVDNCIL
	NAETLVCVKEPPAYTFRDYSAILYLNGDFDGGNFYFTELDAKTVTA
	EVQPQCGRAVGFSSGTENPHGVKAVTRGQRCAIALWFTLDPRHSER
	DRVQADDLVKMLFSPEEMDLSQEQPLDAQQGPPEPAQESLSGSESK
	PKDEL
400	MTLRLLVAALCAGILAEAPRVRAQHRERVTCTRLYAADIVFLLDGS	COL7A1
	SSIGRSNFREVRSFLEGLVLPFSGAASAQGVRFATVQYSDDPRTEFG
	LDALGSGGDVIRAIRELSYKGGNTRTGAAILHVADHVFLPQLARPG
	VPKVCILITDGKSQDLVDTAAQRLKGQGVKLFAVGIKNADPEELKR
	VASQPTSDFFFFVNDFSILRTLLPLVSRRVCTTAGGVPVTRPPDDSTS
	APRDLVLSEPSSQSLRVQWTAASGPVTGYKVQYTPLTGLGQPLPSE
	RQEVNVPAGETSVRLRGLRPLTEYQVTVIALYANSIGEAVSGTARTT
	ALEGPELTIQNTTAHSLLVAWRSVPGATGYRVTWRVLSGGPTQQQE
	LGPGQGSVLLRDLEPGTDYEVTVSTLFGRSVGPATSLMARTDASVE
	QTLRPVILGPTSILLSWNLVPEARGYRLEWRRETGLEPPQKVVLPSD
	VTRYQLDGLQPGTEYRLTLYTLLEGHEVATPATVVPTGPELPVSPVT
	DLQATELPGQRVRVSWSPVPGATQYRII
	VRSTQGVERTLVLPGSQTAFDLDDVQAGLSYTVRVSARVGPREGSA
	SVLTVRREPETPLAVPGLRVVVSDATRVRVAWGPVPGASGFRISWS
	TGSGPESSQTLPPDSTATDITGLQPGTTYQVAVSVLRGREEGPAAVI
	VARTDPLGPVRTVHVTQASSSSVTITWTRVPGATGYRVSWHSAHGP
	EKSQLVSGEATVAELDGLEPDTEYTVHVRAHVAGVDGPPASVVVR
	TAPEPVGRVSRLQILNASSDVLRITWVGVTGATAYRLAWGRSEGGP
	MRHQILPGNTDSAEIRGLEGGVSY
	SVRVTALVGDREGTPVSIVVTTPPEAPPALGTLHVVQRGEHSLRLR
	WEPVPRAQGFLLHWQPEGGQEQSRVLGPELSSYHLDGLEPATQYR
	VRLSVLGPAGEGPSAEVTARTESPRVPSIELRVVDTSIDSVTLAWTP
	VSRASSYILSWRPLRGPGQEVPGSPQTLPGISSSQRVTGLEPGVSYIFS
	LTPVLDGVRGPEASVTQTPVCPRGLADVVFLPHATQDNAHRAEATR
	RVLERLVLALGPLGPQAVQVGLLSYSHRPSPLFPLNGSHDLGIILQRI
	RDMPYMDPSGNNLGTAVVTAHRYMLAPDAPGRRQHVPGVMVLLV
	DEPLRGDIFSPIREAQASGLNVVMLGMAGADPEQLRRLAPGMDSVQ
	TFFAVDDGPSLDQAVSGLATALCQASFTTQPRPEPCPVYCPKGQKG
	EPGEMGLRGQVGPPGDPGLPGRTGAPGPQGPPGSATAKGERGFPGA
	DGRPGSPGRAGNPGTPGAPGLKGSPGLPGPRGDPGERGPRGPKGEP
	GAPGQVIGGEGPGLPGRKGDPGPSGPPGPRGPLGDPGPRGPPGLPGT
	AMKGDKGDRGERGPPGPGEGGIAPGEPGLPGLPGSPGPQGPVGPPG
	KKGEKGDSEDGAPGLPGQPGSPGEQGPRGPPGAIGPKGDRGFPGPL
	GEAGEKGERGPPGPAGSRGLPGVAGRPGAKGPEGPPGPTGRQGEKG
	EPGRPGDPAVVGPAVAGPKGEKGDVGPAGPRGATGVQGERGPPGL
	VLPGDPGPKGDPGDRGPIGLTGRAGPPGDSGPPGEKGDPGRPGPPGP
	VGPRGRDGEVGEKGDEGPPGDPGLPGKAGERGLRGAPGVRGPVGE
	KGDQGDPGEDGRNGSPGSSGPKGDRGEPGPPGPPGRLVDTGPGARE
	KGEPGDRGQEGPRGPKGDPGLPGAPGERGIEGFRGPPGPQGDPGVR
	GPAGEKGDRGPPGLDGRSGLDGKPGAAGPSGPNGAAGKAGDPGRD
	GLPGLRGEQGLPGPSGPPGLPGKPGEDGKPGLNGKNGEPGDPGEDG
	RKGEKGDSGASGREGRDGPKGERGAPGILGPQGPPGLPGPVGPPGQ
	GFPGVPGGTGPKGDRGETGSKGEQGLPGERGLRGEPGSVPNVDRLL
	ETAGIKASALREIVETWDESSGSFLPVPERRRGPKGDSGEQGPPGKE
	GPIGFPGERGLKGDRGDPGPQGPPGLALGERGPPGPSGLAGEPGKPG
	IPGLPGRAGGVGEAGRPGERGERGEKGERGEQGRDGPPGLPGTPGP
	PGPPGPKVSVDEPGPGLSGEQGPPGLKGAKGEPGSNGDQGPKGDRG
	VPGIKGDRGEPGPRGQDGNPGLPGERGMAGPEGKPGLQGPRGPPGP
	VGGHGDPGPPGAPGLAGPAGPQGPSGLKGEPGETGPPGRGLTGPTG
	AVGLPGPPGPSGLVGPQGSPGLPGQVGETGKPGAPGRDGASGKDG
	DRGSPGVPGSP
	GLPGPVGPKGEPGPTGAPGQAVVGLPGAKGEKGAPGGLAGDLVGE
	PGAKGDRGLPGPRGEKGEAGRAGEPGDPGEDGQKGAPGPKGFKGD
	PGVGVPGSPGPPGPPGVKGDLGLPGLPGAPGVVGFPGQTGPRGEMG
	QPGPSGERGLAGPPGREGIPGPLGPPGPPGSVGPPGASGLKGDKGDP
	GVGLPGPRGERGEPGIRGEDGRPGQEGPRGLTGPPGSRGERGEKGD
	VGSAGLKGDKGDSAVILGPPGPRGAKGDMGERGPRGLDGDKGPRG
	DNGDPGDKGSKGEPGDKGSAGLPGLRGLLGPQGQPGAAGIPGDPGS
	PGKDGVPGIRGEKGDVGFMGPRGLKGERGVKGACGLDGEKGDKG
	EAGPPGRPGLAGHKGEMGEPGVPGQSGAPGKEGLIGPKGDRGFDG
	QPGPKGDQGEKGERGTPGIGGFPGPSGNDGSAGPPGPPGSVGPRGPE
	GLQGQKGERGPPGERVVGAPGVPGAPGERGEQGRPGPAGPRGEKG
	EAALTEDDIRGFVRQEMSQHCACQGQFIASGSRPLPSYAADTAGSQ
	LHAVPVLRVSHAEEEERVPPEDDEYSEYSEYSVEEYQDPEAPWDSD
	DPCSLPLDEGSCTAYTLRWYHRAVTGSTEACHPFVYGGCGGNANR
	FGTREACERRCPPRVVQSQGTGTAQD
401	MSIQENISSLQLRSWVSKSQRDLAKSILIGAPGGPAGYLRRASVAQL	PKLR
	TQELGTAFFQQQQLPAAMADTFLEHLCLLDIDSEPVAARSTSIIATIG
	PASRSVERLKEMIKAGMNIARLNFSHGSHEYHAESIANVREAVESFA
	GSPLSYRPVAIALDTKGPEIRTGILQGGPESEVELVKGSQVLVTVDPA
	FRTRGNANTVWVDYPNIVRVVPVGGRIYIDDGLISLVVQKIGPEGLV
	TQVENGGVLGSRKGVNLPGAQVDLPGLSEQDVRDLRFGVEHGVDI
	VFASFVRKASDVAAVRAALGPEGHGIKIISKIENHEGVKRFDEILEVS
	DGIMVARGDLGIEIPAEKVFLAQKMMIGRCNLAGKPVVCATQMLES
	MITKPRPTRAETSDVANAVLDGADCIMLSGETAKGNFPVEAVKMQ
	HAIAREAEAAVYHRQLFEELRRAAPLSRDPTEVTAIGAVEAAFKCC
	AAAIIVLTTTGRSAQLLSRYRPRAAVIAVTRSAQAARQVHLCRGVFP
	LLYREPPEAIWADDVDRRVQFGIESG
	KLRGFLRVGDLVIVVTGWRPGSGYTNIMRVLSIS
402	MSSPVKRQRMESALDQLKQFTTVVADTGDFHAIDEYKPQDATTNP	TALDO1
	SLILAAAQMPAYQELVEEAIAYGRKLGGSQEDQIKNAIDKLFVLFGA
	EILKKIPGRVSTEVDARLSFDKDAMVARARRLIELYKEAGISKDRILI
	KLSSTWEGIQAGKELEEQHGIHCNMTLLFSFAQAVACAEAGVTLISP
	FVGRILDWHVANTDKKSYEPLEDPGVKSVTKIYNYYKKFSYKTIVM
	GASFRNTGEIKALAGCDFLTISPKLLGELLQDNAKLVPVLSAKAAQA
	SDLEKIHLDEKSFRWLHNEDQMAVEKLSDGIRKFAADAVKLERML
	TERMFNAENGK
403	MRLAVGALLVCAVLGLCLAVPDKTVRWCAVSEHEATKCQSFRDH	TF
	MKSVIPSDGPSVACVKKASYLDCIRAIAANEADAVTLDAGLVYDAY
	LAPNNLKPVVAEFYGSKEDPQTFYYAVAVVKKDSGFQMNQLRGK
	KSCHTGLGRSAGWNIPIGLLYCDLPEPRKPLEKAVANFFSGSCAPCA
	DGTDFPQLCQLCPGCGCSTLNQYFGYSGAFKCLKDGAGDVAFVKH
	STIFENLANKADRDQYELLCLDNTRKPVDEYKDCHLAQVPSHTVVA
	RSMGGKEDLIWELLNQAQEHFGKDKSKEFQLFSSPHGKDLLFKDSA
	HGFLKVPPRMDAKMYLGYEYVTAIRNLREGTCPEAPTDECKP
	VKWCALSHHERLKCDEWSVNSVGKIECVSAETTEDCIAKIMNGEA
	DAMSLDGGFVYIAGKCGLVPVLAENYNKSDNCEDTPEAGYFAIAV
	VKKSASDLTWDNLKGKKSCHTAVGRTAGWNIPMGLLYNKINHCRF
	DEFFSEGCAPGSKKDSSLCKLCMGSGLNLCEPNNKEGYYGYTGAFR
	CLVEKGDVAFVKHQTVPQNTGGKNPDPWAKNLNEKDYELLCLDG
	TRKPVEEYANCHLARAPNHAVVTRKDKEACVHKILRQQQHLFGSN
	VTDCSGNFCLFRSETKDLLFRDDTVCLAKLHDRNTYEKYLGEEYVK
	AVGNLRKCSTSSLLEACTFRRP
404	MAPPQVLAFGLLLAAATATFAAAQEECVCENYKLAVNCFVNNNRQ	EPCAM
	CQCTSVGAQNTVICSKLAAKCLVMKAEMNGSKLGRRAKPEGALQN
	NDGLYDPDCDESGLFKAKQCNGTSMCWCVNTAGVRRTDKDTEITC
	SERVRTYWIIIELKHKAREKPYDSKSLRTALQKEITTRYQLDPKFITSI
	LYENNVITIDLVQNSSQKTQNDVDIADVAYYFEKDVKGESLFHSKK
	MDLTVNGEQLDLDPGQTLIYYVDEKAPEFSMQGLKAGVIAVIVVVV
	IAVVAGIVVLVISRKKRMAKYEKA
	EIKEMGEMHRELNA
405	MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPE	VHL
	ELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFD
	GEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPS
	LNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYE
	DLEDHPNVQKDLERLTQERIAHQRMGD
406	MKRVLVLLLAVAFGHALERGRDYEKNKVCKEFSHLGKEDFTSLSL	GC
	VLYSRKFPSGTFEQVSQLVKEVVSLTEACCAEGADPDCYDTRTSAL
	SAKSCESNSPFPVHPGTAECCTKEGLERKLCMAALKHQPQEFPTYV
	EPTNDEICEAFRKDPKEYANQFMWEYSTNYGQAPLSLLVSYTKSYL
	SMVGSCCTSASPTVCFLKERLQLKHLSLLTTLSNRVCSQYAAYGEK
	KSRLSNLIKLAQKVPTADLEDVLPLAEDITNILSKCCESASEDCMAK
	ELPEHTVKLCDNLSTKNSKFEDCCQEKTAMDVFVCTYFMPAAQLPE
	LPDVELPTNKDVCDPGNTKVMDKYTFELSRRTHLPEVFLSKVLEPT
	LKSLGECCDVEDSTTCFNAKGPLLKKELSSFIDKGQELCADYSENTF
	TEYKKKLAERLKAKLPDATPTELAKLVNKHSDFASNCCSINSPPLYC
	DSEIDAELKNIL
407	MPSSVSWGILLLAGLCCLVPVSLAEDPQGDAAQKTDTSHHDQDHPT	SERPINA1
	FNKITPNLAEFAFSLYRQLAHQSNSTNIFFSPVSIATAFAMLSLGTKA
	DTHDEILEGLNFNLTEIPEAQIHEGFQELLRTLNQPDSQLQLTTGNGL
	FLSEGLKLVDKFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVEKG
	TQGKIVDLVKELDRDTVFALVNYIFFKGKWERPFEVKDTEEEDFHV
	DQVTTVKVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNATAIFFLP
	DEGKLQHLENELTHDIITKFLENEDRRSASLHLPKLSITGTYDLKSVL
	GQLGITKVFSNGADLSGVTEEAPLKLSKAVHKAVLTIDEKGTEAAG
	AMFLEAIPMSIPPEVKFNKPFVFLMIEQNTKSPLFMGKVVNPTQK
408	MAAPAEPCAGQGVWNQTEPEPAATSLLSLCFLRTAGVWVPPMYL	ABCC6
	WVLGPIYLLFIHHHGRGYLRMSPLFKAKMVLGFALIVLCTSSVAVA
	LWKIQQGTPEAPEFLIHPTVWLTTMSFAVFLIHTERKKGVQSSGVLF
	GYWLLCFVLPATNAAQQASGAGFQSDPVRHLSTYLCLSLVVAQFV
	LSCLADQPPFFPEDPQQSNPCPETGAAFPSKATFWWVSGLVWRGYR
	RPLRPKDLWSLGRENSSEELVSRLEKEWMRNRSAARRHNKAIAFKR
	KGGSGMKAPETEPFLRQEGSQWRPLL
	KAIWQVFHSTFLLGTLSLIISDVFRFTVPKLLSLFLEFIGDPKPPAWKG
	YLLAVLMFLSACLQTLFEQQNMYRLKVLQMRLRSAITGLVYRKVL
	ALSSGSRKASAVGDVVNLVSVDVQRLTESVLYLNGLWLPLVWIVV
	CFVYLWQLLGPSALTAIAVFLSLLPLNFFISKKRNHHQEEQMRQKDS
	RARLTSSILRNSKTIKFHGWEGAFLDRVLGIRGQELGALRTSGLLFS
	VSLVSFQVSTFLVALVVFAVHTLVAENAMNAEKAFVTLTVLNILNK
	AQAFLPFSIHSLVQARVSFDRLVTFLCLEEVDPGVVDSSSSGSAAGK
	DCITIHSATFAWSQESPPCLHRINLTVPQGCLLAVVGPVGAGKSSLLS
	ALLGELSKVEGFVSIEGAVAYVPQEAWVQNTSVVENVCFGQELDPP
	WLERVLEACALQPDVDSFPEGIHTSIGEQGMNLSGGQKQRLSLARA
	VYRKAAVYLLDDPLAALDAHVGQHVFNQVIGPGGLLQGTTRILVT
	HALHILPQADWIIVLANGAIAEMGSYQELLQRKGALMCLLDQARQP
	GDRGEGETEPGTSTKDPRGTSAGRRPELRRERSIKSVPEKDRTTSEA
	QTEVPLDDPDRAGWPAGKDSIQYGRVKATVHLAYLRAVGTPLCLY
	ALFLFLCQQVASFCRGYWLSLWADDPAVGGQQTQAALRGGIFGLL
	GCLQAIGLFASMAAVLLGGARASRLLFQRLLWDVVRSPISFFERTPI
	GHLLNRFSKETDTVDVDIPDKLRSLLMYAFGLLEVSLVVAVATPLA
	TVAILPLFLLYAGFQSLYVVSSCQLRRLESASYSSVCSHMAETFQGS
	TVVRAF
	RTQAPFVAQNNARVDESQRISFPRLVADRWLAANVELLGNGLVFA
	AATCAVLSKAHLSAGLVGFSVSAALQVTQTLQWVVRNWTDLENSI
	VSVERMQDYAWTPKEAPWRLPTCAAQPPWPQGGQIEFRDFGLRYR
	PELPLAVQGVSFKIHAGEKVGIVGRTGAGKSSLASGLLRLQEAAEG
	GIWIDGVPIAHVGLHTLRSRISIIPQDPILFPGSLRMNLDLLQEHSDEA
	IWAALETVQLKALVASLPGQLQYKCADRGEDLSVGQKQLLCLARA
	LLRKTQILILDEATAAVDPGTELQM
	QAMLGSWFAQCTVLLIAHRLRSVMDCARVLVMDKGQVAESGSPA
	QLLAQKGLFYRLAQESGLV
409	MQIELSTCFFLCLLRFCFSATRRYYLGAVELSWDYMQSDLGELPVD	F8
	ARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGP
	TIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTS
	QREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDL
	VKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSE
	TKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYW
	HVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDL
	GQFLLFCHISSHQHDGMEAYVKVDSCPEPQLRMKNNEEAEDYDD
	DLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWD
	YAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDETFKTR
	EAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYS
	RRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSS
	FVNMERDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDEN
	RSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSV
	CLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGE
	TVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYED
	SYEDISAYLLSKNNAIEPRSFSQNSRHPSTRQKQFNATTIPENDIEKTD
	PWFAHRTPMPKIQNVSSSDLLMLLRQSPTPHGLSLSDLQEAKYETFS
	DDPS
	PGAIDSNNSLSEMTHFRPQLHHSGDMVFTPESGLQLRLNEKLGTTA
	ATELKKLDFKVSSTSNNLISTIPSDNLAAGTDNTSSLGPPSMPVHYDS
	QLDTTLFGKKSSPLTESGGPLSLSEENNDSKLLESGLMNSQESSWGK
	NVSSTESGRLFKGKRAHGPALLTKDNALFKVSISLLKTNKTSNNSAT
	NRKTHIDGPSLLIENSPSVWQNILESDTEFKKVTPLIHDRMLMDKNA
	TALRLNHMSNKTTSSKNMEMVQQKKEGPIPPDAQNPDMSFFKMLF
	LPESARWIQRTHGKNSLNSGQGPSPKQLVSLGPEKSVEGQNFLSEKN
	KVVVGKGEFTKDVGLKEMVFPSSRNLFLTNLDNLHENNTHNQEKK
	IQEEIEKKETLIQENVVLPQIHTVTGTKNFMKNLFLLSTRQNVEGSYD
	GAYAPVLQDFRSNDSTNRTKKHTAHFSKKGEEENLEGLGNQTKQI
	VEKYACTTRISPNTSQQNFVTQRSKRALKQFRLPLEETELEKRIIVDD
	TSTQWSKNMKHLTPSTLTQIDYNEKE
	KGAITQSPLSDCLTRSHSIPQANRSPLPIAKVSSFPSIRPIYLTRVLFQD
	NSSHLPAASYRKKDSGVQESSHFLQGAKKNNLSLAILTLEMTGDQR
	EVGSLGTSATNSVTYKKVENTVLPKPDLPKTSGKVELLPKVHIYQK
	DLFPTETSNGSPGHLDLVEGSLLQGTEGAIKWNEANRPGKVPFLRV
	ATESSAKTPSKLLDPLAWDNHYGTQIPKEEWKSQEKSPEKTAFKKK
	DTILSLNACESNHAIAAINEGQNKPEIEVTWAKQGRTERLCSQNPPV
	LKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPR
	SFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVF
	QEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRP
	YSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKD
	EFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTV
	QEFALFFTIFDETKSWYFTENMERNCRA
	PCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSM
	GSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKA
	GIVVRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITAS
	GQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKT
	QGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDS
	SGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGM
	ESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNP
	KEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQW
	TLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIA
	LRMEVLGCEAQDLY
410	MQRVNMIMAESPGLITICLLGYLLSAECTVFLDHENANKILNRPKRY	F9
	NSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVD
	GDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNG
	RCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQ
	TSKLTRAETVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGED
	AKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITV
	VAGEHNIEETEHTEQKRNVIRII
	PHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKF
	GSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNN
	MFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKG
	KYGIYTKVSRYVNwIKEKTKLT
411	MDPPRPALLALLALPALLLLLLAGARAEEEMLENVSLVCPKDATRF	ApoB
	KHLRKYTYNYEAESSSGVPGTADSRSATRINCKVELEVPQLCSFILK
	TSQCTLKEVYGFNPEGKALLKKTKNSEEFAAAMSRYELKLAIPEGK
	QVFLYPEKDEPTYILNIKRGIISALLVPPETEEAKQVLFLDTVYGNCS
	THFTVKTRKGNVATEISTERDLGQCDRFKPIRTGISPLALIKGMTRPL
	STLIS
	SSQSCQYTLDAKRKHVAEAICKEQHLFLPFSYKNKYGMVAQVTQT
	LKLEDTPKINSRFFGEGTKKMGLAFESTKSTSPPKQAEAVLKTLQEL
	KKLTISEQNIQRANLFNKLVTELRGLSDEAVTSLLPQLIEVSSPITLQA
	LVQCGQPQCSTHILQWLKRVHANPLLIDVVTYLVALIPEPSAQQLRE
	IFNMARDQRSRATLYALSHAVNNYHKTNPTGTQELLDIANYLMEQI
	QDDCTGDEDYTYLILRVIGNMGQTMEQLTPELKSSILKCVQSTKPSL
	MIQKAAIQALRKMEPKDKD
	QEVLLQTFLDDASPGDKRLAAYLMLMRSPSQAINKIVQILPWEQNE
	QVKNFVASHIANILNSEELDIQDLKKLVKEALKESQLPTVMDFRKFS
	RNYQLYKSVSLPSLDPASAKIEGNLIFDPNNYLPKESMLKTTLTAFG
	FASADLIEIGLEGKGFEPTLEALFGKQGFFPDSVNKALYWVNGQVP
	DGVSKVLVDHFGYTKDDKHEQDMVNGIMLSVEKLIKDLKSKEVPE
	ARAYLRILGEELGFASLHDLQLLGKLLLMGARTLQGIPQMIGEVIRK
	GSKNDFFLHYIFMENAFELPTGAGLQLQISSSGVIAPGAKAGVKLEV
	ANMQAELVAKPSVSVEFVTNMGIIIPDFARSGVQMNTNFFHESGLE
	AHVALKAGKLKFIIPSPKRPVKLLSGGNTLHLVSTTKTEVIPPLIENR
	QSWSVCKQVFPGLNYCTSGAYSNASSTDSASYYPLTGDTRLELELR
	PTGEIEQYSVSATYELQREDRALVDTLKFVTQAEGAKQTEATMTFK
	YNRQSMTLSSEVQIPDFDVDLGTILRVN
	DESTEGKTSYRLTLDIQNKKITEVALMGHLSCDTKEERKIKGVISIPR
	LQAEARSEILAHWSPAKLLLQMDSSATAYGSTVSKRVAWHYDEEKI
	EFEWNTGTNVDTKKMTSNFPVDLSDYPKSLHMYANRLLDHRVPQT
	DMTFRHVGSKLIVAMSSWLQKASGSLPYTQTLQDHLNSLKEFNLQ
	NMGLPDFHIPENLFLKSDGRVKYTLNKNSLKIEIPLPFGGKSSRDLK
	MLETVRTPALHFKSVGFHLPSREFQVPTFTIPKLYQLQVPLLGVLDL
	STNVYSNLYNWSASYSGGNTST
	DHFSLRARYHMKADSVVDLLSYNVQGSGETTYDHKNTFTLSYDGS
	LRHKFLDSNIKFSHVEKLGNNPVSKGLLIFDASSSWGPQMSASVHLD
	SKKKQHLFVKEVKIDGQFRVSSFYAKGTYGLSCQRDPNTGRLNGES
	NLRFNSSYLQGTNQITGRYEDGTLSLTSTSDLQSGIIKNTASLKYENY
	ELTLKSDTNGKYKNFATSNKMDMTFSKQNALLRSEYQADYESLRF
	FSLLSGSLNSHGLELNADILGTDKINSGAHKATLRIGQDGISTSATTN
	LKCSLLVLENELNAELGLSGASMKLTTNGRFREHNAKFSLDGKAAL
	TELSLGSAYQAMILGVDSKNIFNFKVSQEGLKLSNDMMGSYAEMK
	FDHTNSLNIAGLSLDFSSKLDNIYSSDKFYKQTVNLQLQPYSLVTTL
	NSDLKYNALDLTNNGKLRLEPLKLHVAGNLKGAYQNNEIKHIYAIS
	SAALSASYKADTVAKVQGVEFSHRLNTDIAGLASAIDMSTNYNSDS
	LHFSNVFRSVMAPFTMTIDAHTNGNGKLALWGEHTGQLYSKFLLK
	AEPLAFTFSHDYKGSTSHHLVSRKSISAALEHKVSALLTPAEQTGTW
	KLKTQFNNNEYSQDLDAYNTKDKIGVELTGRTLADLTLLDSPIKVPL
	LLSEPINIIDALEMRDAVEKPQEFTIVAFVKYDKNQDVHSINLPFFET
	LQEYFERNRQTIIVVLENVQRNLKHINIDQFVRKYRAALGKLPQQA
	NDYLNSFNWERQVSHAKEKLTALTKKYRITENDIQIALDDAKINFNE
	KLSQLQTYMIQFDQYIKDSYDLHDLKIAIANIIDEIIEKLKSLDEHYHI
	RVNLVKTIHDLHLFIENIDFNKSGSSTASWIQNVDTKYQIRIQIQEKL
	QQLKRHIQNIDIQHLAGKLKQHIEAIDVRVLLDQLGTTISFERINDILE
	HVKHFVINLIGDFEVAEKINAFRAKVHELIERYEVDQQIQVLMDKLV
	ELAHQYKLKETIQKLSNVLQQVKIKDYFEKLVGFIDDAVKKLNELSF
	KTFIEDVNKFLDMLIKKLKSFDYHQFVDETNDKIREVTQRLNGEIQA
	LELPQKAEALKLFLEETKATVAVYLESLQDTKITLIINWLQEALSSAS
	LAHMKAKFRETLEDTRDRMYQMDIQQELQRYLSLVGQVYSTLVTY
	ISDWWTLAAKNLTDFAEQYSIQDWAKRMKALVEQGFTVPEIKTILG
	TMPAFEVSLQALQKATFQTPDFIVPLTDLRIPSVQINFKDLKNIKIPSR
	FSTPEFTILNTFHIPSFTIDFVEMKVKIIRTIDQMLNSELQWPVPDIYLR
	DLKVEDIPLARITLPDFRLPEIAIPEFIIPTLNLNDFQVPDLHIPEFQLPH
	ISHTIEVPTFGKLYSILKIQSPLFTLDANADIGNGTTSANEAGIAASITA
	KGESKLEVLNFDFQANAQLSNPKINPLALKESVKFSSKYLRTEHGSE
	MLFFGNAIEGKSNTVASLHTEKNTLELSNGVIVKINNQLTLDSNTKY
	FHKLNIPKLDFSSQADLRNEIKTLLKAGHIAWTSSGKGSWKWACPR
	FSDEGTHESQISFTIEGPLTSFGLSNKINSKHLRVNQNLVYESGSLNFS
	KLEIQSQVDSQHVGHSVLTAKGMALFGEGKAEFTGRHDAHLNGKV
	IGTLKNSLFFSAQPFEITASTNNEGNLKVRFPLRLTGKIDFLNNYALF
	LSPSAQQASWQVSARFNQYKYNQNFSAGNNENIMEAHVGINGE
	ANLDFLNIPLTIPEMRLPYTIITTPPLKDFSLWEKTGLKEFLKTTKQSF
	DLSVKAQYKKNKHRHSITNPLAVLCEFISQSIKSFDRHFEKNRNNAL
	DFVTKSYNETKIKFDKYKAEKSHDELPRTFQIPGYTVPVVNVEVSPF
	TIEMSAFGYVFPKAVSMPSFSILGSDVRVPSYTLILPSLELPVLHVPR
	NLKLSLPDFKELCTISHIFIPAMGNITYDFSFKSSVITLNTNAELFNQS
	DIVAHLLSSSSSVIDALQYKLEGTTRLTRKRGLKLATALSLSNKFVE
	GSHNSTVSLTTKNMEVSVATTTKAQIPILRMNFKQELNGNTKSKPT
	VSSSMEFKYDFNSSMLYSTAKGAVDHKLSLESLTSYFSIESSTKGDV
	KGSVLSREYSGTIASEANTYLNSKSTRSSVKLQGTSKIDDIWNLEVK
	ENFAGEATLQRIYSLWEHSTKNHLQLEGLFFTNGEHTSKATLELSPW
	QMSALV
	QVHASQPSSFHDFPDLGQEVALNANTKNQKIRWKNEVRIHSGSFQS
	QVELSNDQEKAHLDIAGSLEGHLRFLKNIILPVYDKSLWDFLKLDVT
	TSIGRRQHLRVSTAFVYTKNPNGYSFSIPVKVLADKFIIPGLKLNDLN
	SVLVMPTFHVPFTDLQVPSCKLDFREIQIYKKLRTSSFALNLPTLPEV
	KFPEVDVLTKYSQPEDSLIPFFEITVPESQLTVSQFTLPKSVSDGIAAL
	DL
	NAVANKIADFELPTIIVPEQTIEIPSIKFSVPAGIVIPSFQALTARFEVDS
	PVYNATWSASLKNKADYVETVLDSTCSSTVQFLEYELNVLGTHKIE
	DGTLASKTKGTFAHRDFSAEYEEDGKYEGLQEWEGKAHLNIKSPAF
	TDLHLRYQKDKKGISTSAASPAVGTVGMDMDEDDDFSKWNFYYSP
	QSSPDKKLTIFKTELRVRESDEETQIKVNWEEEAASGLLTSLKDNVP
	KATGVLYDYVNKYHWEHTGLTLREVSSKLRRNLQNNAEWVYQGA
	IRQIDDIDVRFQKAASGTTGT
	YQEWKDKAQNLYQELLTQEGQASFQGLKDNVFDGLVRVTQEFHM
	KVKHLIDSLIDFLNFPRFQFPGKPGIYTREELCTMFIREVGTVLSQVY
	SKVHNGSEILFSYFQDLVITLPFELRKHKLIDVISMYRELLKDLSKEA
	QEVFKAIQSLKTTEVLRNLQDLLQFIFQLIEDNIKQLKEMKFTYLINY
	IQDEINTIFSDYIPYVFKLLKENLCLNLHKFNEFIQNELQEASQELQQI
	HQY
	IMALREEYFDPSIVGWTVKYYELEEKIVSLIKNLLVALKDFHSEYIVS
	ASNFTSQLSSQVEQFLHRNIQEYLSILTDPDGKGKEKIAELSATAQEII
	KSQAIATKKIISDYHQQFRYKLQDFSDQLSDYYEKFIAESKRLIDLSI
	QNYHTFLIYITELLKKLQSTTVMNPYMKLAPGELTIIL
412	MGTVSSRRSWWPLPLLLLLLLLLGPAGARAQEDEDGDYEELVLAL	PCSK9
	RSEEDGLAEAPEHGTTATFHRCAKDPWRLPGTYVVVLKEETHLSQS
	ERTARRLQAQAARRGYLTKILHVFHGLLPGFLVKMSGDLLELALKL
	PHVDYIEEDSSVFAQSIPWNLERITPPRYRADEYQPPDGGSLVEVYL
	LDTSIQSDHREIEGRVMVTDFENVPEEDGTRFHRQASKCDSHGTHL
	AGVVSGRDAGVAKGASMRSLRVLNCQGKGTVSGTLIGLEFIRKSQL
	VQPVGPLVVLLPLAGGYSRVLNAA
	CQRLARAGVVLVTAAGNFRDDACLYSPASAPEVITVGATNAQDQP
	VTLGTLGTNFGRCVDLFAPGEDIIGASSDCSTCFVSQSGTSQAAAHV
	AGIAAMMLSAEPELTLAELRQRLIHFSAKDVINEAWFPEDQRVLTPN
	LVAALPPSTHGAGWQLFCRTVWSAHSGPTRMATAVARCAPDEELL
	SCSSFSRSGKRRGERMEAQGGKLVCRAHNAFGGEGVYAIARCCLLP
	QANCSVHTAPPAEASMGTRVHCHQQGHVLTGCSSHWEVEDLGTH
	KPPVLRPRGQPNQCVGHREASIHASCCHAPGLECKVKEHGIPAPQE
	QVTVACEEGWTLTGCSALPGTSHVLGAYAVDNTCVVRSRDVSTTG
	STSEGAVTAVAICCRSRHLAQASQELQ
413	MDALKSAGRALIRSPSLAKQSWGGGGRHRKLPENWTDTRETLLEG	LDLRAP1
	MLFSLKYLGMTLVEQPKGEELSAAAIKRIVATAKASGKKLQKVTLK
	VSPRGIILTDNLTNQLIENVSIYRISYCTADKMHDKVFAYIAQSQHNQ
	SLECHAFLCTKRKMAQAVTLTVAQAFKVAFEFWQVSKEEKEKRDK
	ASQEGGDVLGARQDCTPSLKSLVATGNLLDLEETAKAPLSTVSANT
	TNMDEVPRPQALSGSSVVWELDDGLDEAFSRLAQSRTNPQVLDTG
	LTAQDMHYAQCLSPVDWDKPDSSGTEQDDLFSF
414	MGDLSSLTPGGSMGLQVNRGSQSSLEGAPATAPEPHSLGILHASYSV	ABCG5
	SHRVRPWWDITSCRQQWTRQILKDVSLYVESGQIMCILGSSGSGKT
	TLLDAMSGRLGRAGTFLGEVYVNGRALRREQFQDCFSYVLQSDTL
	LSSLTVRETLHYTALLAIRRGNPGSFQKKVEAVMAELSLSHVADRLI
	GNYSLGGISTGERRRVSIAAQLLQDPKVMLFDEPTTGLDCMTANQI
	VVLLVELARRNRIVVLTIHQPRSELFQLFDKIAILSFGELIFCGTPAEM
	LDFFNDCGYPCPEHSNPFDFYMDLTSVDTQSKEREIETSKRVQMIES
	AYKKSAICHKTLKNIERMKHLKTLPMVPFKTKDSPGVFSKLGVLLR
	RVTRNLVRNKLAVITRLLQNLIMGLFLLFFVLRVRSNVLKGAIQDRV
	GLLYQFVGATPYTGMLNAVNLFPVLRAVSDQESQDGLYQKWQMM
	LAYALHVLPFSVVATMIFSSVCYWTLGLHPEVARFGYFSAALLAPH
	LIGEFLTLVLLGIVQNPNIVNSVVALLSIAGVLVGSGFLRNIQEMPIPF
	KIISYFTFQKYCSEILVVNEFYGLNFTCGSSNVSVTTNPMCAFTQGIQ
	FIEKTCPGATSRFTMNFLILYSFIPALVILGIVVFKIRDHLISR
415	MAGKAAEERGLPKGATPQDTSGLQDRLFSSESDNSLYFTYSGQPNT	ABCG8
	LEVRDLNYQVDLASQVPWFEQLAQFKMPWTSPSCQNSCELGIQNLS
	FKVRSGQMLAIIGSSGCGRASLLDVITGRGHGGKIKSGQIWINGQPSS
	PQLVRKCVAHVRQHNQLLPNLTVRETLAFIAQMRLPRTFSQAQRDK
	RVEDVIAELRLRQCADTRVGNMYVRGLSGGERRRVSIGVQLLWNP
	GILILDEPTSGLDSFTAHNLVKTLSRLAKGNRLVLISLHQPRSDIFRLF
	DLVLLMTSGTPIYLGAAQHMVQYFTAIGYPCPRYSNPADFYVDLTSI
	DRRSREQELATREKAQSLAALFLEKVRDLDDFLWKAETKDLDEDT
	CVESSVTPLDTNCLPSPTKMPGAVQQFTTLIRRQISNDFRDLPTLLIH
	GAEACLMSMTIGFLYFGHGSIQLSFMDTAALLFMIGALIPFNVILDVI
	SKCYSERAMLYYELEDGLYTTGPYFFAKILGELPEHCAYIIIYGMPT
	YWLANLRPGLQPFLLHFLLVWLVVFCCRIMALAAAALLPTFHMASF
	FSNALYNSFYLAGGFMINLSSLWTVPAWISKVSFLRWCFEGLMKIQ
	FSRRTYKMPLGNLTIAVSGDKILSVMELDSYPLYAIYLIVIGLSGGFM
	VLYYVSLRFIKQKPSQDW
416	MGPPGSPWQWVTLLLGLLLPPAAPFWLLNVLFPPHTTPKAELSNHT	LCAT
	RPVILVPGCLGNQLEAKLDKPDVVNWMCYRKTEDFFTIWLDLNMF
	LPLGVDCWIDNTRVVYNRSSGLVSNAPGVQIRVPGFGKTYSVEYLD
	SSKLAGYLHTLVQNLVNNGYVRDETVRAAPYDWRLEPGQQEEYY
	RKLAGLVEEMHAAYGKPVFLIGHSLGCLHLLYFLLRQPQAWKDRFI
	DGFISLGAPWGGSIKPMLVLASGDNQGIPIMSSIKLKEEQRITTTSPW
	MFPSRMAWPEDHVFISTPSFNYTGR
	DFQRFFADLHFEEGWYMWLQSRDLLAGLPAPGVEVYCLYGVGLPT
	PRTYIYDHGFPYTDPVGVLYEDGDDTVATRSTELCGLWQGRQPQPV
	HLLPLHGIQHLNMVFSNLTLEHINAILLGAYRQGPPASPTASPEPPPP
	E
417	MKIATVSVLLPLALCLIQDAASKNEDQEMCHEFQAFMKNGKLFCPQ	SPINK5
	DKKFFQSLDGIMFINKCATCKMILEKEAKSQKRARHLARAPKATAP
	TELNCDDFKKGERDGDFICPDYYEAVCGTDGKTYDNRCALCAENA
	KTGSQIGVKSEGECKSSNPEQDVCSAFRPFVRDGRLGCTRENDPVL
	GPDGKTHGNKCAMCAELFLKEAENAKREGETRIRRNAEKDFCKEY
	EKQVRNGRLFCTRESDPVRGPDGRMHGNKCALCAEIFKQRFSEENS
	KTDQNLGKAEEKTKVKREIVKLCSQYQNQAKNGILFCTRENDPIRG
	PDGKMHGNLCSMCQAYFQAENEEKKKAEARARNKRESGKA
	TSYAELCSEYRKLVRNGKLACTRENDPIQGPDGKVHGNTCSMCEVF
	FQAEEEEKKKKEGKSRNKRQSKSTASFEELCSEYRKSRKNGRLFCT
	RENDPIQGPDGKMHGNTCSMCEAFFQQEERARAKAKREAAKEICSE
	FRDQVRNGTLICTREHNPVRGPDGKMHGNKCAMCASVFKLEEEEK
	KNDKEEKGKVEAEKVKREAVQELCSEYRHYVRNGRLPCTRENDPI
	EGLDGKIHGNTCSMCEAFFQQEAKEKERAEPRAKVKREAEKETCDE
	FRRLLQNGKLFCTRENDPVRGPDGKTHGNKCAMCKAVFQKENEER
	KRKEEEDQRNAAGHGSSGGGGGNTQDECAEYREQMKNGRLS
	CTRESDPVRDADGKSYNNQCTMCKAKLEREAERKNEYSRSRSNGT
	GSESGKDTCDEFRSQMKNGKLICTRESDPVRGPDGKTHGNKCTMC
	KEKLEREAAEKKKKEDEDRSNTGERSNTGERSNDKEDLCREFRSM
	QRNGKLICTRENNPVRGPYGKMHINKCAMCQSIFDREANERKKKD
	EEKSSSKPSNNAKDECSEFRNYIRNNELICPRENDPVHGADGKFYTN
	KCYMCRAVFLTEALERAKLQEKPSHVRASQEEDSPDSFSSLDSEMC
	KDYRVLPRIGYLCPKDLKPVCGDDGQTYNNPCMLCHENLIRQTNTH
	IRSTGKCEESSTPGTTAASMPPSDE
418	MEKNGNNRKLRVCVATCNRADYSKLAPIMFGIKTEPEFFELDVVVL	GNE
	GSHLIDDYGNTYRMIEQDDFDINTRLHTIVRGEDEAAMVESVGLAL
	VKLPDVLNRLKPDIMIVHGDRFDALALATSAALMNIRILHIEGGEVS
	GTIDDSIRHAITKLAHYHVCCTRSAEQHLISMCEDHDRILLAGCPSY
	DKLLSAKNKDYMSIIRMWLGDDVKSKDYIVALQHPVTTDIKHSIKM
	FELTLDALISFNKRTLVLFPNIDAGSKEMVRVMRKKGIEHHPNFRAV
	KHVPFDQFIQLVAHAGCMIGNSSCGVREVGAFGTPVINLGTRQIGRE
	TGENVLHVRDADTQDKILQALHLQFGKQYPCSKIYGDGNAVPRILK
	FLKSIDLQEPLQKKFCFPPVKENISQDIDHILETLSALAVDLGGTNLR
	VAIVSMKGEIVKKYTQFNPKTYEERINLILQMCVEAAAEAVKLNCRI
	LGVGISTGGRVNPREGIVLHSTKLIQEWNSVDLRTPLSDTLHLPVWV
	DNDGNCAALAERKFGQGKGLENFVTL
	ITGTGIGGGIIHQHELIHGSSFCAAELGHLVVSLDGPDCSCGSHGCIE
	AYASGMALQREAKKLHDEDLLLVEGMSVPKDEAVGALHLIQAAKL
	GNAKAQSILRTAGTALGLGVVNILHTMNPSLVILSGVLASHYIHIVK
	DVIRQQALSSVQDVDVVVSDLVDPALLGAASMVLDYTTRRIY
419	DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLL	Anti-CD19 scFv
	IYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLP	(FMC63)
	YTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQS
	LSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSAL
	KSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMD
	YWGQGTSVTVSS
420	DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLL	Anti-CD19 scFv
	IYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLP	(FMC63)
	YTFGGGTKLEITGGGGSGGGGSGGGGSEVKLQESGPGLVAPSQSLS
	VTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIVVGSETTYYNSALKS
	RLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYW
	GQGTSVTVSS
421	ESKYGPPCPPCP	IgG4 Hinge
422	TTTPAPRPPTPAPTIASQPLSLRPE	CD8 Hinge
423	IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP	CD28
424	ACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYC	CD8
425	FWVLVVVGGVLACYSLLVTVAFIIFWV	CD28
426	FWVLVVVGGVLACYSLLVTVAFIIFWV	CD28
427	RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS	CD28
428	KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL	4-1BB
429	RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEM	CD3zeta
	GGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGL
	YQGLSTATKDTYDALHMQALPPR
430	RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEM	CD3zeta
	GGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGL
	YQGLSTATKDTYDALHMQALPPR

Claims

1. A targeted lipid particle, comprising: (a) a lipid bilayer enclosing a lumen,(b) a henipavirus F protein molecule or biologically active portion thereof; and(c) a targeted envelope protein comprising (i) a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and (ii) single domain antibody (sdAb) variable domain, wherein the sdAb variable domain is attached to the C-terminus of the G protein or the biologically active portion thereof and/or wherein the sdAb is attached to the G protein or the biologically active portion thereof via a peptide linker, wherein the sdAb binds to a cell surface molecule of a target cell,wherein the F protein molecule or the biologically active portion thereof and the targeted envelope protein are embedded in the lipid bilayer.

2. The targeted lipid particle of claim 1, wherein the cell surface molecule is a protein, glycan, lipid or low molecular weight molecule.

3. The targeted lipid particle of claim 1, wherein the target cell is selected from the group consisting of tumor-infiltrating lymphocytes, T cells, neoplastic or tumor cells, virus-infected cells, stem cells, central nervous system (CNS) cells, hematopoeietic stem cells (HSCs), liver cells and fully differentiated cells.

4. The targeted lipid particle of claim 1, wherein the target cell is selected from the group consisting of a CD3+ T cell, a CD4+ T cell, a CD8+ T cell, a hepatocyte, a haematopoietic stem cell, a CD34+ haematopoietic stem cell, a CD105+ haematopoietic stem cell, a CD117+ haematopoietic stem cell, a CD105+ endothelial cell, a B cell, a CD20+ B cell, a CD19+ B cell, a cancer cell, a CD133+ cancer cell, an EpCAM+ cancer cell, a CD19+ cancer cell, a Her2/Neu+ cancer cell, a GluA2+ neuron, a GluA4+ neuron, a NKG2D+ natural killer cell, a SLC1A3+ astrocyte, a SLC7A10+ adipocyte, and a CD30+ lung epithelial cell.

5. The targeted lipid particle of claim 1, wherein the single domain antibody binds to an antigen or portion thereof present on a hepatocyte.

6. The targeted lipid particle of claim 1, wherein the cell surface molecule or antigen is selected from the group consisting of ASGR1, ASGR2 and TM4SF.

7. The targeted lipid particle of claim 1, wherein the single domain antibody binds to an antigen or portion thereof present on a T cell.

8. The targeted lipid particle of claim 1, wherein the cell surface molecule or antigen is CD8 or CD4.

9. The targeted lipid particle of claim 1, wherein the cell surface molecule or antigen is low density lipoprotein receptor (LDL-R).

10. A targeted lipid particle, comprising: (a) a lipid bilayer enclosing a lumen,(b) a henipavirus F protein molecule or biologically active portion thereof; and(c) a targeted envelope protein comprising (i) a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and (ii) a binding domain, wherein the binding domain is attached to the C-terminus of the G protein or the biologically active portion thereof, and wherein the binding domain binds a cell surface molecule selected from the group consisting of ASGR1, ASGR2, TM4SF5, CD8, CD4 and low density lipoprotein receptor (LDL-R),wherein the F protein molecule or the biologically active portion thereof and the targeted envelope protein are embedded in the lipid bilayer.

11-12. (canceled)

13. The targeted lipid particle of claim 1, wherein the lipid particle is a lentiviral vector.

14. A lentiviral vector, comprising: (a) a henipavirus F protein molecule or biologically active portion thereof; and(b) a targeted envelope protein comprising (i) a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and (ii) a binding domain, wherein the binding domain is attached to the C-terminus of the G protein or the biologically active portion thereof, and wherein the binding domain binds CD4; and(c) a cargo comprising nucleic acid encoding a chimeric antigen receptor (CAR), wherein the CAR comprises (i) an extracellular antigen binding domain that binds CD19, (ii) a transmembrane domain and (iii) an intracellular signaling region comprising a CD3zeta signaling domain.

15-16. (canceled)

17. A lentiviral vector, comprising: (a) a henipavirus F protein molecule or biologically active portion thereof; and(b) a targeted envelope protein comprising (i) a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and (ii) a binding domain, wherein the binding domain is attached to the C-terminus of the G protein or the biologically active portion thereof, and wherein the binding domain binds a cell surface molecule selected from the group consisting of ASGR1, ASGR2 and TM4SF5.

18-19. (canceled)

20. The lentiviral vector of claim 14, wherein the binding domain is attached to the G protein via a linker.

21. The targeted lipid particle of claim 10, wherein the binding domain is a single domain antibody or is a single chain variable fragment (scFv).

22-23. (canceled)

24. The targeted lipid particle of claim 1, wherein the G protein or the biologically active portion thereof is a wild-type Nipah virus G (NiV-G) protein or a Hendra virus G protein, or is a functionally active variant or biologically active portion thereof.

25-33. (canceled)

34. The targeted lipid particle of claim 1, wherein the mutant NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 16 or an amino acid sequence having at or about 80% sequence identity to SEQ ID NO:16.

35. The targeted lipid particle of claim 1, wherein the F protein or the biologically active portion thereof is a wild-type Nipah virus F (NiV-F) protein or a Hendra virus F protein or is a functionally active variant or biologically active portion thereof.

36-39. (canceled)

40. The targeted lipid particle of claim 1, wherein the NiV-F protein is a biologically active portion thereof that has a 22 amino acid truncation at or near the C-terminus of the wild-type NiV-F protein (SEQ ID NO:2).

41. The targeted lipid particle of claim 1, wherein the NiV-F protein or the biologically active portion has the sequence set forth in SEQ ID NO:23 or an amino acid sequence that is encoded by a sequence of nucleotides encoding a sequence having at or about 80% sequence identity to SEQ ID NO:23.

42. The targeted lipid particle of claim 1, wherein the F protein comprises the sequence set forth in SEQ ID NO:23 and the G protein comprises the sequence set forth in SEQ ID NO:16.

43-48. (canceled)

49. The targeted lipid particle of claim 1, wherein the lipid particle further comprises an exogenous agent.

50-54. (canceled)

55. The targeted lipid particle of claim 10, wherein the membrane protein is a chimeric antigen receptor (CAR).

56. (canceled)

57. The targeted lipid particle of claim 10, wherein the exogenous agent is a nucleic acid comprising a payload gene for correcting a genetic deficiency.

58. A polynucleotide comprising a nucleic acid sequence encoding: (i) a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and (ii) a single domain antibody (sdAb) variable domain, wherein the sdAb variable domain is attached to the C-terminus of the G protein or the biologically active portion thereof; or(i) a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and (ii) a binding domain that binds a cell surface molecule selected from the group consisting of ASGR1, ASGR2, TM4SF5, CD4, CD8, and low density lipoprotein receptor (LDL-R).

59-90. (canceled)

91. A vector comprising the polynucleotide of claim 58.

92. (canceled)

93. A plasmid comprising the polynucleotide of claim 58.

94. (canceled)

95. A cell comprising the vector of claim 91.

96. A method of making a targeted lipid particle comprising a henipavirus F protein molecule or biologically active portion thereof and a targeted envelope protein comprising a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and a single domain antibody (sdAb) variable domain, the method comprising: a) providing a cell that comprises a nucleic acid encoding a henipavirus F protein molecule or biologically active portion thereof and a nucleic acid encoding a targeted envelope protein, the targeted envelope protein comprising a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and a single domain antibody (sdAb) variable domain;b) culturing the cell under conditions that allow for production of a targeted lipid particle, andc) separating, enriching, or purifying the targeted lipid particle from the cell, thereby making the targeted lipid particle.

97. A method of making a pseudotyped lentiviral vector, the method comprising: a) providing a producer cell that comprises a lentiviral viral nucleic acid(s), a nucleic acid encoding a henipavirus F protein molecule or biologically active portion thereof, and a nucleic acid encoding a targeted envelope protein, said targeted envelope protein comprising a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and a single domain antibody;b) culturing the cell under conditions that allow for production of the lentiviral vector, andc) separating, enriching, or purifying the lentiviral vector from the cell, thereby making the pseudotyped lentiviral vector.

98. A method of making a targeted lipid particle comprising a henipavirus F protein molecule or biologically active portion thereof and a targeted envelope protein comprising a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and a binding domain, the method comprising: a) providing a cell that comprises a nucleic acid encoding a henipavirus F protein molecule or biologically active portion thereof and a nucleic acid encoding a targeted envelope protein, the targeted envelope protein comprising a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and binding domain, wherein the binding domain:(i) binds a cell surface molecule selected from the group consisting of ASGR1, ASGR2, and TM4SF5;(ii) binds a cell surface molecule selected from the group consisting of CD4 or CD8; or(iii) binds a cell surface molecule that is low density lipoprotein receptor (LDL-R);b) culturing the cell under conditions that allow for production of a targeted lipid particle, andc) separating, enriching, or purifying the targeted lipid particle from the cell, thereby making the targeted lipid particle,wherein the targeted lipid particle is a pseudotyped lentiviral vector.

99-105. (canceled)

106. A producer cell comprising the polynucleotide of claim 58.

107. The producer cell of claim 106, further comprising nucleic acid encoding a henipavirus F protein or a biologically active portion thereof.

108. (canceled)

109. A producer cell comprising (i) a viral nucleic acid(s) and (ii) nucleic acid encoding a henipavirus F protein molecule or biologically active portion thereof and (iii) a nucleic acid encoding a targeted envelope protein comprising a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and a single domain antibody (sdAb) variable domain.

110-113. (canceled)

114. A producer cell comprising (i) a viral nucleic acid(s) and (ii) nucleic acid encoding a henipavirus F protein molecule or biologically active portion thereof and (iii) a nucleic acid encoding a targeted envelope protein comprising a henipavirus envelope attachment glycoprotein G (G protein) or a biologically active portion thereof and a binding domain, wherein the binding domain: (i) binds a cell surface molecule selected from the group consisting of ASGR1, ASGR2, and TM4SF5;(ii) binds a cell surface molecule selected from the group consisting of CD4 or CD8; or(iii) binds a cell surface molecule that is low density lipoprotein receptor (LDL-R).

115-123. (canceled)

124. A targeted lipid particle produced by the method of claim 96.

125-126. (canceled)

127. A composition comprising a plurality of targeted lipid particles of claim 1.

128-129. (canceled)

130. A method of transducing a cell comprising transducing a cell with a lentiviral vector of claim 13.

131. (canceled)

132. A method of delivering an exogenous agent to a subject, the method comprising administering to the subject the targeted lipid particle of claim 49, wherein the targeted lipid particle comprises the exogenous agent.

133. A method of delivering an exogenous agent to a subject, the method comprising administering to the subject the composition of claim 127, wherein targeted lipid particles of the plurality comprise the exogenous agent.

134. A method of delivering a chimeric antigen receptor (CAR) to a cell, comprising contacting a cell with the lentiviral vector of claim 14, wherein the lentiviral vector comprises a nucleic acid encoding the CAR.

135. A method of delivering a chimeric antigen receptor (CAR) to a cell, comprising contacting a cell with the composition of claim 127 wherein targeted lipid particles of the plurality comprise a nucleic acid encoding the CAR.

136. A method of delivering an exogenous agent to a hepatocyte, comprising contacting a cell with the lentiviral vector of claim 17.

137. A method of delivering an exogenous agent to a hepatocyte, comprising contacting a cell with the composition of claim 127, wherein targeted lipid particles of the plurality comprise an exogenous agent for delivery to the hepatocyte.

138. (canceled)

139. A method of treating a disease or disorder in a subject, the method comprising administering to the subject the composition of claim 127.

140. A method of fusing a mammalian cell to a targeted lipid particle, the method comprising administering to the subject the composition of claim 127.

141. (canceled)